fluorouracil has been researched along with Cancer of Stomach in 3465 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate whether adding aprepitant to palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin) chemotherapy regimens among women with gastrointestinal cancer at higher risk." | 9.41 | Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. ( Fong, WP; Hu, MT; Jin, Y; Li, YH; Luo, HY; Peng, JW; Qiu, MZ; Ren, C; Tan, Q; Wang, DS; Wang, FH; Wang, SB; Wang, ZQ; Zou, QF, 2021) |
| " We hypothesized that sunitinib in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) would be a tolerable and effective regimen in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma." | 9.34 | Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. ( Attwood, K; Boland, PM; Fountzilas, C; Gosain, R; Iyer, R; Khushalani, N; Mukherjee, S; Tan, W, 2020) |
| "5-Fluorouracil (5-FU) and platinum-based perioperative chemotherapy is standard of care for resectable gastric adenocarcinoma (RGA)." | 9.30 | Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST). ( Bachet, JB; Cohen, R; Colin, D; de la Fouchardière, C; Ferraz, JM; Kim, S; Lefevre, M; Louvet, C; Meurisse, A; Svrcek, M; Tournigand, C; Watson, S, 2019) |
| "Apatinib mesylate combined with chemotherapy for the treatment of patients with gastroesophageal junction adenocarcinoma was safe and effective, with improved survival benefit compared with control." | 9.30 | Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma. ( Chen, J; Hua, Z; Lu, B; Lu, C; Qu, C; Sun, Z; Tong, R; Zhang, J, 2019) |
| "Based upon preclinical data showing synergy with mTOR inhibition and platinum chemotherapy, this study explores the safety and tolerability of combining everolimus with mFOLFOX6 for patients with metastatic gastroesophageal adenocarcinoma." | 9.22 | Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma. ( Chao, J; Chung, S; Chung, V; Fakih, MG; Frankel, P; Koehler, S; Lau, SC; Leong, L; Lim, D; Luevanos, E; Ruel, N; Yeon, C, 2016) |
| "Docetaxel, cisplatin, and fluorouracil (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma and is associated with significant toxicity." | 9.20 | Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. ( Capanu, M; Henderson, C; Janjigian, YY; Kelsen, DP; Kemeny, M; Krishnamurthi, S; Mehrotra, B; Ocean, A; Ritch, P; Shah, MA; Shibata, S; Stoller, R; Su, YB, 2015) |
| "This phase II trial aimed to evaluate the efficacy and safety of docetaxel, cisplatin, and fluorouracil (DCF) combination in neoadjuvant setting in patients with locally advanced gastric adenocarcinoma." | 9.19 | Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. ( Abali, H; Bostanci, B; Civelek, B; Oguz, D; Oksuzoglu, B; Ozdemir, N; Vural, M; Yalcin, B; Yalcin, S; Zengin, N, 2014) |
| "To compare epirubicin, cisplatin, and capecitabine (ECX) with fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatments in patients with advanced gastric or esophagogastric junction (EGJ) adenocarcinoma." | 9.19 | Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd ( André, T; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Boucher, E; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Louvet, C; Maillard, E; Nguyen, S; Rebischung, C; Ries, P; Rougier, P; Ychou, M, 2014) |
| " We evaluated the safety, tolerability, and efficacy of the combination capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas." | 9.17 | A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. ( Altomare, I; Arrowood, CC; Bendell, JC; Blobe, GC; Brady, JC; Conkling, P; Cushman, SM; Favaro, J; Hsu, SD; Hurwitz, HI; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Uronis, HE; Zafar, SY, 2013) |
| "To evaluate the safety and tolerability of two different weekly doses of the fully humanized epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab combined with high-dose 5-fluorouracil, leucovorin and cisplatin (PLF) in the first-line treatment of patients with EGFR-positive advanced gastric and esophagogastric adenocarcinomas." | 9.17 | Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. ( Heeger, S; Lüpfert, C; Przyborek, M; Schleucher, N; Trarbach, T; Vanhoefer, U, 2013) |
| "This prospective multicentre phase II trial assessed the feasibility and efficacy of perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in patients with gastro-oesophageal adenocarcinoma." | 9.16 | Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. ( Arnold, D; Bichev, D; Breithaupt, K; Daum, S; Florschütz, A; Gahn, B; Glanemann, M; Hofheinz, RD; Kneba, M; Kretzschmar, A; Mantovani-Löffler, L; Reichardt, P; Schlattmann, P; Schumacher, G; Thuss-Patience, PC, 2012) |
| "Fluorouracil, l-leucovorin and paclitaxel at Level 1 is feasible as first-line treatment for peritoneal disseminated gastric cancer patients with massive ascites or inadequate oral intake." | 9.16 | Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake. ( Fuse, N; Goto, M; Hironaka, S; Iwasa, S; Kusaba, H; Nakajima, TE; Nakayama, N; Nishina, T; Shimada, Y; Taira, K; Takahari, D; Yasui, H, 2012) |
| "Hand-foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy." | 9.16 | Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. ( Aparicio, J; Dueñas, R; Falcó, E; Gómez-Martin, C; Irigoyen, A; Lacasta, A; Llorente, B; López, RL; Muñoz, ML; Pérez, B; Reboredo, M; Regueiro, P; Safont, MJ; Sánchez, A; Sanchez-Viñes, E; Serrano, R, 2012) |
| "Previously untreated patients with metastatic gastroesophageal adenocarcinoma received bevacizumab 10 mg/kg, docetaxel 40 mg/m², fluorouracil 400 mg/m², leucovorin 400 mg/m² on day 1, fluorouracil 1,000 mg/m²/d × 2 days intravenous continuous infusion beginning on day 1, and cisplatin 40 mg/m² on day 3." | 9.15 | Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. ( Capanu, M; Ilson, DH; Jhawer, M; Kelsen, DP; Lefkowitz, RA; Robinson, E; Shah, MA, 2011) |
| "We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia." | 9.14 | A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. ( Drew, PA; Jamieson, GG; Liu, JF; Wu, TC; Zhu, GJ, 2009) |
| "Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours x 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression." | 9.14 | S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. ( Abbruzzese, JL; Blanke, CD; Budd, GT; Chansky, K; Christman, KL; Hundahl, SA; Issell, BF; Macdonald, JS; Van Veldhuizen, PJ, 2010) |
| "Cisplatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile." | 9.14 | Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. ( Ajani, JA; Bodoky, G; Falcon, S; Garin, A; Gorbunova, V; Lang, I; Lichinitser, M; Moiseyenko, V; Rodriguez, W; Vynnychenko, I, 2010) |
| "To assess the efficacy and safety of docetaxel plus oxaliplatin and capecitabine (DOX) in the treatment of advanced gastric adenocarcinoma." | 9.14 | [Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial]. ( Liu, Y; Ma, T; Ye, ZB; Zhang, J; Zhu, ZG, 2010) |
| "The regimen of docetaxel and capecitabine is a well-tolerated, easily administered and active outpatient regimen for advanced gastric and GE adenocarcinoma." | 9.14 | A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. ( Hantel, A; Hwang, J; Javle, M; Khorana, AA; Kiefer, G; Lo, SS; Rajasenan, K; Ramanathan, RK; Schmotzer, A; Shayne, M; Simon, S; Wang, H, 2010) |
| "Patients with histologically confirmed metastatic or locally advanced adenocarcinoma of the stomach or gastroesophageal junction received docetaxel 25 mg/m2 and oxaliplatin 50 mg/m2 on days 1 and 8 with capecitabine 625 mg/m2 twice daily from day 1-14, in 21-day cycles." | 9.14 | Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. ( Aggarwal, S; Goel, G; Jauhri, M; Negi, A, 2010) |
| "We aimed to establish the superiority (or noninferiority if superiority was not achieved) in terms of time to progression (TTP) of irinotecan/5-fluorouracil (IF) over cisplatin/5-fluorouracil (CF) in chemonaive patients with adenocarcinoma of the stomach/esophagogastric junction." | 9.13 | Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. ( Barone, C; Bugat, R; Cisar, L; Dank, M; Goker, E; Peschel, C; Valvere, V; Wang, K; Wenczl, M; Yalcin, S; Zaluski, J, 2008) |
| "Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m(2), leucovorin 200 mg/m(2), and fluorouracil 2600 mg/m(2) as a 24-h infusion in combination with docetaxel 50 mg/m(2) (FLOT) on day 1 every 2 weeks." | 9.13 | Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Clemens, MR; Fritz, M; Hartmann, JT; Hofheinz, R; Homann, N; Jäger, E; Mahlberg, R; Pauligk, C; Probst, S; Rethwisch, V; Seipelt, G; Sievert, M; Stoehlmacher, J, 2008) |
| "Patients with previously untreated advanced adenocarcinoma of the stomach or esophagogastric junction were randomly assigned to receive either fluorouracil 2,600 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2), and oxaliplatin 85 mg/m(2) (FLO) every 2 weeks or fluorouracil 2,000 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2) weekly, and cisplatin 50 mg/m(2) every 2 weeks (FLP)." | 9.13 | Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Bokemeyer, C; Derigs, HG; Grossmann, J; Hartmann, JT; Hegewisch-Becker, S; Hofheinz, R; Hollerbach, S; Homann, N; Jäger, E; Knuth, A; Pauligk, C; Probst, S; Rethwisch, V; Schmalenberg, H; Schuch, G; Seipelt, G; Stoehlmacher, J; Wilhelm, G, 2008) |
| "Previous studies suggest that the combination of docetaxel and capecitabine are worthy of further testing in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction." | 9.12 | Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. ( Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK, 2006) |
| "We investigated 2-weekly intravenous irinotecan combined with oral capecitabine in patients with advanced gastroesophageal adenocarcinoma." | 9.12 | A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. ( Anthoney, DA; Burge, ME; Halstead, F; Jackson, DP; Seymour, MT; Smith, D; Topham, C, 2006) |
| "The aim of this study was to investigate the efficacy and safety of combination chemotherapy with weekly paclitaxel and 5-fluorouracil (5-FU) as first-line treatment in patients with advanced or recurrent gastric carcinoma." | 9.12 | Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma. ( Ando, T; Hirabayashi, N; Kawamura, S; Kobayashi, M; Kojima, H; Kondo, K; Konno, H; Matsuo, K; Miyashita, Y; Morita, S; Musha, N; Nagata, N; Ninomiya, M; Oba, K; Sakamoto, J; Usuki, H, 2007) |
| "Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals." | 9.12 | A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. ( Jang, JS; Jeong, JS; Kim, HJ; Kim, MC; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY; Yoo, HS, 2007) |
| "The aim of this study was to evaluate the activity and safety of 5-fluorouracil (5-FU)/leucovorin (LV) and irinotecan as first- or second-line treatment in patients with advanced gastric adenocarcinoma." | 9.12 | Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma. ( Chrysanthopoulos, C; Gerolymos, MK; Iconomou, G; Kalofonos, HP; Kontogeorgou, E; Koutras, AK; Makatsoris, T; Tsiata, E; Vourli, G, 2007) |
| "Patients with metastatic or locally advanced gastric adenocarcinoma without prior chemotherapy were randomly assigned to receive either ECF (epirubicin 50 mg/m(2) day 1, cisplatin 60 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks) or DF (docetaxel 75 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks)." | 9.11 | Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. ( Dörken, B; Hennesser, D; Kingreen, D; Kretzschmar, A; Micheel, S; Pink, D; Reichardt, P; Repp, M; Scholz, C; Thuss-Patience, PC, 2005) |
| "In this phase II randomized study, untreated patients with confirmed advanced gastric or gastroesophageal adenocarcinoma received either DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2 on day 1, and fluorouracil 750 mg/m2/d as continuous infusion on days 1 to 5) or DC (docetaxel 85 mg/m2 and cisplatin 75 mg/m2 on day 1) every 3 weeks." | 9.11 | Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. ( Ajani, JA; Assadourian, S; Cabral Filho, S; Chao, Y; Fodor, MB; Majlis, A; Moiseyenko, VM; Tjulandin, SA; Van Cutsem, E, 2005) |
| "The purpose of this study was to evaluate the dose-limiting toxicity (DLT) and maximum tolerated dose of capecitabine when used in combination with epirubicin and cisplatin (ECC) in patients with oesophageal or gastric adenocarcinoma." | 9.10 | A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. ( Blackie, R; Evans, TR; Fullarton, GM; McDonald, AC; McInnes, A; Morrison, R; Paul, J; Pentheroudakis, G; Raby, N; Soukop, M, 2002) |
| "We performed combination chemotherapy adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in 11 patients with gastric cancer and 7 with colorectal cancer." | 9.09 | [The effect of combination chemotherapy to adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in patients with gastric or colorectal cancer]. ( Iesato, H; Kamoshita, N; Kato, Y; Morishita, Y; Nagaoka, H; Ohwada, S; Ohya, T; Okabe, T; Takeyoshi, I; Yokomori, T, 2000) |
| " 5-fluorouracil (5-FU), and leucovorin (LCV) was conducted in patients with advanced gastric adenocarcinomas." | 9.09 | A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. ( Benson, AB; Berlin, J; Blanke, CD; Haller, DG; Hsieh, YC; Miller, LL; Mori, M; Rothenberg, ML, 2001) |
| "To reduce the Hickman line-associated morbidity of continuous infusion 5-fluorouracil combined with epirubicin and cisplatin (ECF) and to investigate the need for infusional regimens, we conducted a retrospective study in patients with advanced gastro-oesophageal adenocarcinoma." | 9.09 | Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma. ( Dunlop, DJ; Eatock, MM; Lim, KC; Pentheroudakis, G; Soukop, M, 2001) |
| "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma." | 9.08 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996) |
| " The authors examined whether the administration of 5-fluorouracil (5-FU) enhanced apoptosis of gastric carcinoma cells, and investigated the relationship between apoptosis and the expression of Ki-67 and the Bax gene." | 9.08 | Enhanced induction of apoptosis of human gastric carcinoma cells after preoperative treatment with 5-fluorouracil. ( Itoh, H; Kaibara, N; Kimura, O; Maeta, M; Makino, M; Shirai, H; Sugamura, K, 1997) |
| "A Phase II study was performed to evaluate the activity and toxicity of 5-fluorouracil, leucovorin, Adriamycin, and cisplatin combination chemotherapy (FLAP) in patients with previously untreated advanced gastric and gastroesophageal (GE) junction adenocarcinoma." | 9.08 | A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program ( Armstead, B; Douglass, HO; Haller, DG; Holroyde, C; Meropol, NJ; Mintzer, D; Nuamah, I; Vaughn, DJ, 1997) |
| ") of 5-fluorouracil (5-FU) plus daily low-dose cisplatin (CDDP) was evaluated in 45 patients with advanced and recurrent unresected colorectal, lung, gastric and pancreatic adenocarcinoma." | 9.08 | [Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma]. ( Denno, R; Hiraike, N; Hirata, K; Katsuramaki, T; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Takasaka, H; Yagihashi, A; Yamamitsu, S; Yamashiro, K, 1997) |
| "Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i." | 9.07 | Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach. ( Bajardi, G; Cannata, G; Cipolla, C; Curto, G; Gebbia, V; Latteri, M; Mastrandrea, G; Pischedda, G; Testa, A; Valenza, R, 1994) |
| "A novel sequential administration schedule of PALA (N-phosphonoacetyl-L-aspartate) and thymidine to enhance the cytotoxic effect of 5-fluorouracil (5FU) was tested in 36 patients with advanced gastric cancer and 21 patients with advanced poorly differentiated (anaplastic) colorectal cancer." | 9.06 | A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer. ( Goldberg, RM; Krook, JE; Kugler, JW; Laurie, JA; Moertel, CG; O'Connell, MJ; Pfeifle, DM; Rubin, J; Wieand, HS; Windschitl, HE, 1990) |
| "We report the results of an expanded trial of 5-fluorouracil (5-FU) combined with high-dose folinic acid for treatment of patients with advanced colorectal or advanced gastric adenocarcinoma." | 9.06 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Chollet, P; Fourtillan, JB; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1986) |
| "Thirty-four patients with advanced adenocarcinoma of the gastrointestinal tract have been treated with high-dose 5-fluorouracil modulated by concomitant allopurinol therapy, in combination with either razoxane or adriamycin." | 9.05 | A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract. ( Ashford, RF; Bakowski, M; Evans, M; Hellman, K; Jones, R; Lambert, J; Newton, K; Peters, N; Phillips, R; Smith, BJ, 1983) |
| "5-Fluorouracil (5-Fu) is one of the most commonly prescribed antineoplastic agents against gastric and colorectal cancers." | 8.98 | Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis. ( Meng, F; Wang, Y; Xing, X; Zhang, L; Zhong, D, 2018) |
| "The primary purpose of this study was to explore the short-term efficacy of different cisplatin and fluorouracil-based chemotherapy regimens in the treatment of patients with esophagogastric junctional adenocarcinoma (EGJA) using a network meta-analysis (NMA)." | 8.95 | A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma. ( Hu, JH; Song, DJ; Wang, C; Xie, SP; Xu, ZL, 2017) |
| "This case report describes a patient with cutaneous intestinal metaplasia with invasive adenocarcinoma treated successfully with intralesional fluorouracil." | 8.31 | Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil. ( Dahiya, M; Eilers, D; Joseph, MX; Tao, J; Vaudreuil, A, 2023) |
| "Hyperammonemia is an important adverse event associated with 5-fluorouracil (5FU) from 5FU metabolite accumulation." | 7.96 | Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses. ( Funakoshi, T; Horimatsu, T; Ikeda, A; Imamaki, H; Kataoka, S; Matsubara, T; Muto, M; Nakagawa, S; Nishikawa, Y; Oura, M; Ozaki, Y; Watanabe, N; Yanagita, M; Yonezawa, A, 2020) |
| "5-Fluorouracil (5-FU) is the third most common chemotherapeutic agent for treating solid cancers and the second most common to cause cardiotoxicity." | 7.91 | Acute reversible left ventricular systolic dysfunction associated with 5-fluorouracil therapy: a rare and increasingly recognised cardiotoxicity of a commonly used drug. ( Afonso, L; Ahmed, A; Mishra, T; Shokr, M, 2019) |
| " The present study aimed to investigate the effect of Rosmarinic acid (RA) on chemoresistance to 5-Fu and its molecular mechanism in gastric carcinoma." | 7.91 | Rosmarinic acid reduces the resistance of gastric carcinoma cells to 5-fluorouracil by downregulating FOXO4-targeting miR-6785-5p. ( Chen, DQ; Feng, JF; Li, WB; Liu, HX; Lu, JW; Yu, C, 2019) |
| " Therefore, we examined the effects of flavones against CYR61-overexpressing human gastric adenocarcinoma AGS (AGS-cyr61) cells, which show remarkable resistance to 5-fluorouracil (5-FU), adriamycin (ADR), tamoxifen (TAM), paclitaxel (PAC), and docetaxel (DOC)." | 7.88 | Quercetin Suppresses CYR61-Mediated Multidrug Resistance in Human Gastric Adenocarcinoma AGS Cells. ( Cho, SK; Hyun, HB; Moon, JY, 2018) |
| "The objective of the present study was to evaluate the effect of combination of telmisartan with 5-flourouracil (5-FU) in gastric cancer cachexia induced by administering N-methyl-N'-methyl-N-nitrosoguanidine (MNNG)." | 7.83 | Evaluation of role of telmisartan in combination with 5-fluorouracil in gastric cancer cachexia. ( Patel, BM; Patel, HJ; Sukumaran, S, 2016) |
| "In high risk gastric and gastroesophageal adenocarcinoma, adjuvant radiochemotherapy with 5-fluorouracil bolus became a standard adjuvant treatment, showing significant improvement in overall survival after surgery, although with substantial toxicity." | 7.81 | Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction. ( Candamio-Folgar, S; Lopez-Lopez, R; Martínez-Lago, N; Padin-Iruegas, ME; Vazquez-Rivera, F; Vidal-Insua, Y; Vieito-Villar, M, 2015) |
| "We investigated the synergistic effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor plus radiation therapy, on the proliferation and survival of gastric cancer (GC) and colorectal cancer (CRC) cells." | 7.81 | Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor. ( Kang, WK; Kim, J; Lee, I; Lim, T, 2015) |
| " The aim of this study is to evaluate the efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy in advanced gastric adenocarcinoma patients in China." | 7.80 | Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation. ( Bai, L; Jin, Y; Li, YH; Luo, HY; Qiu, MZ; Ren, C; Wang, DS; Wang, FH; Wang, ZQ; Wei, XL; Xu, RH; Yang, DJ; Zhang, DS; Zhou, YX, 2014) |
| "The aim of the present study was to evaluate the change of thymidine phosphorylase (TP) activity in gastric adenocarcinoma and adjacent tissue upon the intraarterial administration of 5-fluorouracil (5-FU)." | 7.80 | The influence of 5-fluorouracil on activity of thymidine phosphorylase in gastric adenocarcinoma and normal adjacent tissue. ( Dumanskiy, Y; Khomutov, E; Matviyenko, A; Stashkevych, M; Zinkovych, I, 2014) |
| "The efficacy of triple-drug combination regimens such as epirubicin, oxaliplatin and capecitabine (EOX) is superior to standard cisplatin/5-fluorouracil, but considerable toxicity needs to be taken into account in patients with upper gastrointestinal adenocarcinoma." | 7.79 | Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma. ( Asari, R; Ba-Ssalamah, A; Birner, P; Datler, P; Hejna, M; Pluschnig, U; Preusser, M; Schoppmann, SF; Schwameis, K; Zacherl, J, 2013) |
| " This study was to investigate whether downregulation of Bcl-2 expression by small interfering RNA (siRNA) against the Bcl-2 gene would enhance the apoptosis and sensitivity of gastric adenocarcinoma SGC-7901 cell to 5-Fluorouracil." | 7.79 | Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells. ( Liu, H; Liu, Y; Wu, FR; Xia, Q; Yu, DF, 2013) |
| "To evaluate the efficacy and safety of docetaxel plus oxaliplatin and capecitabine (DOX) in the first line treatment of advanced gastric adenocarcinoma." | 7.79 | Efficacy and safety of docetaxel plus oxaliplatin and capecitabine in the first line treatment of advanced gastric adenocarcinoma. ( Liu, Y; Ma, T; Shi, M; Xi, W; Yang, L; Ye, Z; Zhang, J; Zhu, Z, 2013) |
| " In this study, we had investigated the synergistic effects of low dose fluorouracil (5-Fu) and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells and explored the potential mechanisms." | 7.79 | The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells. ( He, J; Huang, M; Huang, Y; Ren, D; Yi, C; Zhao, F; Zhu, H, 2013) |
| "Capecitabine is one of the most effective oral chemotherapeutic drugs for advanced or recurrent colorectal cancer and gastric cancer." | 7.79 | [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy]. ( Amemori, K; Koike, C; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamada, T; Yamagiwa, K, 2013) |
| "The aim of this retrospective study was to evaluate the efficacy and safety of weekly high-dose 5-fluorouracil (5-FU)/folinic acid (FA) as 24-h infusion (AIO regimen) plus irinotecan in patients with histologically proven metastatic gastroesophageal adenocarcinoma (UICC stage IV)." | 7.77 | Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b ( Albrecht, H; Boxberger, F; Busse, D; Golcher, H; Hahn, EG; Hohenberger, W; Janka, R; Konturek, PC; Koucky, K; Männlein, G; Neurath, MF; Ostermeier, N; Reulbach, U; Schildberg, C; Siebler, J; Wein, A; Wolff, K, 2011) |
| "A retrospective analysis was carried out to evaluate toxicity and efficacy of the combination chemotherapy of docetaxel, cisplatin and 5-fluorouracil (DCF) plus granulocyte colony-stimulating factor prophylaxis (G-CSF) in patients with metastatic gastric and gastroesophageal junction adenocarcinoma." | 7.77 | Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: experience at the Medical University of Vienna. ( Ba-Ssalamah, A; Bojic, M; Datler, P; Hejna, M; Maresch, J; Pluschnig, U; Schoppmann, SF; Thallinger, CM; Zacherl, J, 2011) |
| "5-fluoro-uracil (FU) is a common agent in postoperative chemoradiation in gastric adenocarcinoma." | 7.76 | A retrospective comparison of concurrent 5-fluorouracil or oral UFT in postoperative chemoradiation for gastric adenocarcinoma. ( Akboru, H; Bati, Y; Isikli, L; Unsal, M; Yoney, A, 2010) |
| "We performed retrospective study in order to compare oxaliplatin, leucovorin, and fluorouracil (FOLFOX) versus irinotecan, leucovorin, and fluorouracil (FOLFIRI) in recurred or metastatic gastric adenocarcinoma." | 7.76 | [Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma]. ( Jeong, HY; Kang, SH; Kim, JI; Kim, SH; Lee, BS; Moon, HS; Sung, JK, 2010) |
| " To investigate the molecular basis for the effect of TP on the metabolic process and the anticancer effect of 5-fluorouracil (5-FU), human gastric carcinoma AZ521 cells and epidermoid carcinoma KB cells were transfected with TP cDNA, and AZ521/TP and KB/TP were cloned." | 7.76 | The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells. ( Akiyama, S; Che, XF; Furukawa, T; Ikeda, R; Kanekura, T; Kanzaki, T; Mataki, H; Matsushita, S; Minami, K; Miyadera, K; Nishizawa, Y; Tabata, S; Tajitsu, Y; Takeda, Y; Ushiyama, M; Yamada, K; Yamamoto, M, 2010) |
| "A case of gastric endocrine cell carcinoma successfully treated by FU (5-FU/UFT) +irinotecan (CPT-11) adjuvant therapy against recurrent metastases is reported with some discussion." | 7.75 | [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases]. ( Hara, T; Hiramatsu, K; Hosoya, J; Kato, K; Kimura, A; Kojima, T; Machiki, Y; Otsuji, H; Sakuragawa, T; Tanaka, H; Tsuchiya, T; Yoshida, K, 2009) |
| " Here human gastric adenocarcinoma (AGS) cells were treated with lethal dose 10 and 50 (LD(10) and LD(50)), determined by using the MTT assay, of the three drugs, epirubicin, 5-fluorouracil and cisplatin, commonly used in the treatment of patients with gastro-oesophageal cancer." | 7.74 | [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil. ( Park, KG; Smith, TA; Suttie, SA, 2007) |
| "To examine the prevalence of anemia and its impact of hemoglobin (Hgb) levels in predicting outcomes of 5-fluorouracil (FU)-based first-line chemotherapy for patients with advanced gastric cancer (AGC)." | 7.73 | Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. ( Bang, SM; Cho, EK; Jung, CW; Kang, WK; Kim, K; Kim, S; Kim, WS; Lee, J; Lee, JH; Lee, SH; Park, JO; Park, K; Park, SH; Park, YS; Shin, DB, 2006) |
| "Retrospectively, we analysed 23 consecutive patients who were treated with epirubicin, cisplatin and oral capecitabine for inoperable or metastatic oesophagogastric adenocarcinoma during 2002 and 2003." | 7.73 | Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma. ( Boot, H; Corporaal, S; Legdeur, MC; Russel, MG; Smit, WM; van der Palen, J, 2006) |
| "We report a case of diffuse type advanced hepatocellular carcinoma (HCC), which was successfully treated by a combination therapy of interferon-alpha (IFN) and 5-fluorouracil (5-FU)." | 7.72 | [Intrahepatic arterial chemotherapy with 5-fluorouracil and intramuscular interferon-alpha for a patient with diffuse type of hepatocellular carcinoma]. ( Fujiwara, H; Hagiwara, A; Ichikawa, D; Kikuchi, S; Ochiai, T; Okamoto, K; Otsuji, E; Sakakura, C; Sonoyama, T; Ueda, Y; Yamagishi, H, 2004) |
| "We report a case in which weekly paclitaxel (TXL) administration was effective for gastric cancer with malignant ascites." | 7.71 | [Effective weekly paclitaxel administration for gastric cancer with malignant ascites--a case report]. ( Ezaki, T; Ikegami, T; Ishida, T; Itoh, H; Kawaguchi, K; Kido, A; Nose, N; Sasaki, Y; Shimokawa, H, 2002) |
| "At increasing use of high-dose 5-fluorouracil-based chemotherapy for metastatic colorectal and gastric cancer complicated drug-induced colitis is observed more frequently." | 7.71 | [5-Fluorouracil-induced colitis--a review based upon consideration of 6 cases]. ( Hotz, J; Madisch, A; Marquard, F; Stolte, M; Wiedbrauck, F, 2002) |
| "The incidence of nausea and vomiting or anorexia was investigated in 16 outpatients receiving oral antimetabolites such as 5-FU (fluorouracil) as chemotherapy, during a maximum observation period of 28 days." | 7.70 | [Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets]. ( Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T, 2000) |
| "We report a case of double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin." | 7.69 | [A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin]. ( Akiyama, S; Hibi, K; Ito, K; Kasai, Y; Kondo, K; Nonami, T; Takagi, H, 1995) |
| "The purpose of this study was to assess the efficacy of verapamil (20 microM) and hyperthermia (42 degrees C) as modifiers of 5-fluorouracil (5-FU), used at different concentrations, in inhibiting the growth of gastric adenocarcinoma cells." | 7.69 | Antitumour activity of 5-fluorouracil, verapamil and hyperthermia against human gastric adenocarcinoma cell (AGS) in vitro. ( Brenner, RV; Buras, RR; Evans, SR; Nauta, RJ; Shabahang, M; Shchepotin, IB, 1994) |
| "After a loading dose of 4 x 90 mg folinic acid orally, a continuous infusion of 5-fluorouracil 500 mg/sqm/day for 5 days with concommitant folinic acid 6 x 60 mg/day orally, was administered to 29 consecutive patients with metastatic adenocarcinoma of the esophagus or esophagogastric junction area." | 7.69 | 5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group. ( Kok, TC; Splinter, TA; van der Gaast, A, 1996) |
| "The aim of this study was to evaluate the effect of 5-fluorouracil (5-FU) and folinic acid on liver function and bile production in patients with recurrent gastric cancer and jaundice." | 7.69 | Relief of jaundice by 5-fluorouracil and folinic acid in patients with recurrent gastric cancer. ( Akiyama, H; Kajiyama, Y; Kinoshita, Y; Tsurumaru, M; Tsutsumi, K; Udagawa, H, 1996) |
| " UFT (400 mg/day in terms of tegafur) was given preoperatively for 1-6 days in 6 patients with gastric cancer and 13 with colorectal cancer." | 7.68 | [Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT]. ( Inaba, S; Kawai, K; Kondo, Y; Ogino, A; Tsuchiya, K; Ueda, Y; Umeda, T, 1992) |
| "A total of 23 patients with advanced gastric adenocarcinoma were treated with a combination of moderate-dose methotrexate (MDMTX), 250 mg/m2 i." | 7.67 | Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma. ( Dickinson, R; Levi, J; Milliken, S; Presgrave, P; Woods, R, 1989) |
| "We report the results of an expanded trial of 5-fluorouracil (FUra) combined with high-dose folinic acid for treatment of patients with advanced colorectal or gastric adenocarcinoma." | 7.67 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Benavides, M; Chollet, P; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1987) |
| "Advanced gastric cancer is associated with poor survival despite chemotherapy." | 7.30 | Study of Efficacy and Toxicity of Capecitabine Maintenance After Response to Docetaxel, Cisplatin, and 5-Fluracil-Based Chemotherapy in Advanced Carcinoma Stomach. ( Chaudhari, K; Doval, DC; Goel, V; Goyal, P; Koyyala, VPB; Maheshwari, U; Patnaik, N; Talwar, V, 2023) |
| " We aimed to assess the safety, efficacy, biomarkers, and pharmacokinetics of rilotumumab combined with epirubicin, cisplatin, and capecitabine (ECX) in patients with advanced gastric or oesophagogastric junction cancer." | 6.79 | Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. ( Anderson, A; Davidenko, I; Deptala, A; Donehower, RC; Dubey, S; Harrison, M; Iveson, T; Jiang, Y; Lakshmaiah, K; Loh, E; Nirni, S; Oliner, KS; Tang, R; Thomas, A; Tjulandin, S; Zhu, M, 2014) |
| "4%) and renal adverse events (all grades: CS, 18." | 6.78 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013) |
| " Toxic effects were graded according to NCI-CTC version 3." | 6.78 | The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. ( Abdel-Latif, RM; Anter, AH, 2013) |
| "Patients with previously untreated gastric cancer with measurable disease received oxaliplatin (100 mg/m(2), day 1), followed by leucovorin (100 mg/m(2), day 1) and 5-FU (2,400 mg/m(2), days 1-2), which was repeated every 2 weeks." | 6.74 | Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. ( Cho, JY; Choi, SH; Jeung, HC; Lee, SI; Lim, JY; Oh, KJ, 2009) |
| "The quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented." | 6.74 | Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. ( Barone, C; Bugat, R; Curran, D; Dank, M; Goker, E; Peschel, C; Pozzo, C; Valvere, V; Wenczl, M; Yalcin, S; Zaluski, J, 2009) |
| "Thirty-four patients with gastric cancer, 16 after failure of first-line chemotherapy and 18 after failure of at least two prior chemotherapies, were included." | 6.73 | Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study. ( Al-Batran, SE; Bokemeyer, C; Hartmann, JT; Horger, M; Jäger, E; Kanz, L; Königsrainer, A; Meisinger, I; Nehls, O; Pintoffl, JP; Quietzsch, D, 2007) |
| " The purpose of the current study was to determine whether dose intensification of parenteral hydroxyurea in combination with fluorouracil could enhance the response rates of the combination against refractory upper gastrointestinal malignancies." | 6.71 | Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. ( Haynes, H; Kaleya, R; Kaubisch, A; Rozenblit, A; Wadler, S, 2004) |
| "Acute disseminated intravascular coagulation (DIC) is a rare but severe complication of gastric adenocarcinoma." | 6.69 | Successful initial treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation. ( Chang, FY; Chao, Y; Chi, KH; Hung, HC; King, KL; Li, CP; Teng, HC; Yen, SH, 2000) |
| "Chemotherapy pretreated patients with colorectal cancer seem to have a substantial survival benefit with this salvage protocol." | 6.68 | High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer. ( Hausamen, TU; Loeffler, TM, 1996) |
| "Thirty one gastric cancer pts." | 6.67 | [High-dose leucovorin and 5-fluorouracil in advanced gastric and colorectal cancer. High-Dose Leucovorin and 5-FU Study Group]. ( Akazawa, S; Matsuoka, T; Mukaiyama, T; Ogawa, M; Ota, K; Sakai, Y; Sakata, Y; Sasaki, T; Wakui, A; Yoshino, M, 1990) |
| "Some gastric cancer studies have reported that MSI has no apparent impact on prognosis after patients receive 5-FU-based adjuvant chemotherapy." | 6.61 | Predicting the Efficacy of 5-Fluorouracil-Based Adjuvant Chemotherapy in Gastric Cancer by Microsatellite Instability: A Meta-Analysis. ( Ahmad, R; Ma, Z; Ren, D; Shen, G; Wang, Z; Yuan, X; Zhao, F; Zhao, J; Zheng, F, 2019) |
| " This open-label randomized phase II trial (2:1) investigated the efficacy of combining pazopanib with FLO (5-fluorouracil, oxaliplatin) vs FLO alone (internal control arm) as first-line treatment in patients with advanced adenocarcinoma of the stomach and gastroesophageal junction (GEJ)." | 5.51 | Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510. ( Al-Batran, SE; Bartels, P; Breithaupt, K; Gläser, D; Hinke, A; Högner, A; Homann, N; Lorenz, M; Malfertheiner, P; Siveke, JT; Stein, A; Tamm, I; Thuss-Patience, P; Vogel, A, 2022) |
| "The perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin plus docetaxel (FLOT) was recommended by the Chinese Society of Clinical Oncology Guidelines for gastric cancer (2018 edition) for patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (class IIA)." | 5.51 | Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma. ( Jia, SJ; Liu, Q; Song, LY; Wang, C; Zeng, H; Zeng, X, 2022) |
| "Metastatic skin lesions of gastric cancers usually appear as nonspecific, firm, and hyperpigmented nodules." | 5.51 | Appearance of cutaneous melanoma and subcutaneous metastases in metastatic gastric carcinoma undergoing chemotherapy with oral 5-fluorouracil prodrug. ( Covarelli, P; De Giorgi, V; Gori, A; Maida, P; Scarfì, F; Silvestri, F; Trane, L, 2019) |
| "Cardiotoxicity is an important side effect in patients receiving chemotherapy and the application of anthracycline drugs for gastric cancer treatment is uncommon." | 5.51 | Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients. ( Bai, Y; Gao, L; Jin, X; Wu, S, 2019) |
| "All cases of locally advanced gastric cancer treated with the XELOX or DOS regimen were reviewed retrospectively." | 5.48 | Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. ( Cheng, X; Cui, YH; Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, ZB; Sun, YH; Wang, Y, 2018) |
| "Blood examinations showed disseminated intravascular coagulation(DIC)at the end of the second-line chemotherapy." | 5.46 | Successful Treatment with 5-fluorouracil and Levofolinate Calcium in Advanced Gastric Cancer Patient with Disseminated Intravascular Coagulation. ( Kichiraku, T; Kotanagi, H; Kotanagi, K; Kudoh, K; Masuda, A; Miyazawa, H; Munakata, M; Muto, O; Ouchi, S; Sakata, Y; Satoyoshi, R; Sawada, T; Yamagata, K, 2017) |
| "Peritoneal metastasis is common in gastric cancer." | 5.46 | Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready? ( Chan, DY; Chee, CE; Nga, ME; Phua, JN; Shabbir, A; So, JB; Soh, TI; Syn, NL; Yap, R; Yong, WP, 2017) |
| " Oxaliplatin in combination with intravenous 5-FU plus leucovorin (LV; modified [m]FOLFOX6) or capecitabine (XELOX) improves tolerability compared with 5-FU/cisplatin regimen." | 5.42 | Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. ( André, T; Bachet, JB; Chibaudel, B; Cohen, R; de Gramont, A; Hentic, O; Louvet, C; Samalin, E; Soularue, É; Tournigand, C; Zaanan, A, 2015) |
| " A phase I and Ib study of modified oxaliplatin, leucovorin, and fluorouracil (mFOLFOX6) with ADX revealed encouraging antitumor activity in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma." | 5.41 | Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). ( Ajani, JA; Bendell, J; Bhargava, P; Bodoky, G; Cunningham, D; He, J; Shah, MA; Starodub, A; Thai, D; Wainberg, ZA; Yip, D, 2021) |
| "To evaluate whether adding aprepitant to palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin) chemotherapy regimens among women with gastrointestinal cancer at higher risk." | 5.41 | Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. ( Fong, WP; Hu, MT; Jin, Y; Li, YH; Luo, HY; Peng, JW; Qiu, MZ; Ren, C; Tan, Q; Wang, DS; Wang, FH; Wang, SB; Wang, ZQ; Zou, QF, 2021) |
| "Capecitabine is an oral prodrug to 5-fluorouracil and is commonly used in the treatment of advanced breast, colon and stomach cancer." | 5.40 | Capecitabine induced colitis. ( Grin, A; Grover, SC; Maggo, G, 2014) |
| "Capecitabine (CA) is an orally administered fluoropyrimidine carbamate which is preferentially converted to active 5-FU and is one of the agents used instead of FU in such cases." | 5.39 | Can capecitabine be used instead of concurrent bolus 5-FU in postoperative chemoradiotherapy for gastric adenocarcinoma? ( Isikli, L; Yoney, A, 2013) |
| "The most commonly used schedules are 5-FU in combination with CDDP with or without epirubicin (ECF) or docetaxel (TCF) in treatment of MGA patients (pts), independently of HER status." | 5.37 | Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. ( Abbas, F; Adenis, A; Afchain, P; Aparicio, T; Bécouarn, Y; Bouché, O; Desseigne, F; Dorval, E; Edeline, J; Guimbaud, R; Kramar, A; Mitry, E; Romano, O; Samalin, E; Thézenas, S; Ychou, M, 2011) |
| " Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases." | 5.36 | The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. ( Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N, 2010) |
| "Advanced gastric cancer (AGC) rarely presents with disseminated intravascular coagulation (DIC) at the time of diagnosis before treatment with no current standard chemotherapy (CTx) regimen." | 5.36 | Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis. ( Hamaguchi, T; Hirashima, Y; Kato, K; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Yamada, Y, 2010) |
| "Capecitabine is an oral fluoropyrimidine which is transformed to 5-Fluorouracil inside tumor cells, where it achieves high drug concentrations." | 5.36 | Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect? ( Emiliani, A; Losanno, T; Manna, G; Seminara, P, 2010) |
| "He was diagnosed as gastric cancer, lymph node metastases, brain metastases, bone marrow carcinomas, and disseminated intravascular coagulation(DIC)." | 5.35 | [A case of bone marrow carcinosis from gastric cancer that presented hypocalcemia caused by zoledronic acid during the treatment of methotrexate/5-fluorouracil sequential therapy]. ( Ariyama, H; Baba, E; Esaki, T; Fujimoto, C; Hiranuma, S; Murakawa, M; Syoji, T; Tsukasa, K, 2009) |
| " We hypothesized that sunitinib in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) would be a tolerable and effective regimen in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma." | 5.34 | Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. ( Attwood, K; Boland, PM; Fountzilas, C; Gosain, R; Iyer, R; Khushalani, N; Mukherjee, S; Tan, W, 2020) |
| "Using data from the 4-year follow-up results of an open, randomised, phase II study, this patient-based cost-effectiveness analysis compares mFOLFIRI (irinotecan, 5-fluorouracil and leucovorin, the IRI arm) with mFOLFOX7 (oxaliplatin, 5-fluorouracil and leucovorin, the OXA arm) as first-line treatments in patients with locally advanced gastric adenocarcinoma (GC)." | 5.34 | Patient-based cost-effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4-year prospective randomised phase II study. ( Bi, F; Chen, H; Li, Q; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K, 2020) |
| "Endoscopic findings showed Type 3 gastric cancer with pyloric stenosis." | 5.34 | [A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil]. ( Ninomiya, M; Nishizaki, M; Sasaki, H; Takakura, N; Yamada, E, 2007) |
| "Thus, patients with a DPD deficiency are at risk of developing severe 5-FU-associated toxicity." | 5.33 | Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency. ( Baek, JH; Hong, YJ; Kim, DH; Kim, JG; Kim, SN; Lee, KB; Sohn, SK, 2006) |
| "The patient was diagnosed with advanced gastric cancer (type-3) with lymphangitis carcinomatosa of the lung." | 5.32 | [A case of advanced gastric cancer with lymphangitis carcinomatosa of the lung, successfully treated with paclitaxel and TS-1]. ( Kawabata, H; Murata, A; Nakajima, H; Takase, I; Watanabe, T, 2003) |
| "The subjects were 50 advanced gastric cancer patients treated with FP." | 5.31 | Retrospective study of hyponatremia in gastric cancer patients treated with a combination chemotherapy of 5-fluorouracil and cisplatin: a possible warning sign of severe hematological toxicities? ( Boku, N; Muto, M; Nagashima, F; Ohtsu, A; Shinkai, T; Yoshida, S, 2001) |
| "5-Fluorouracil (5-FU) and platinum-based perioperative chemotherapy is standard of care for resectable gastric adenocarcinoma (RGA)." | 5.30 | Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST). ( Bachet, JB; Cohen, R; Colin, D; de la Fouchardière, C; Ferraz, JM; Kim, S; Lefevre, M; Louvet, C; Meurisse, A; Svrcek, M; Tournigand, C; Watson, S, 2019) |
| "Apatinib mesylate combined with chemotherapy for the treatment of patients with gastroesophageal junction adenocarcinoma was safe and effective, with improved survival benefit compared with control." | 5.30 | Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma. ( Chen, J; Hua, Z; Lu, B; Lu, C; Qu, C; Sun, Z; Tong, R; Zhang, J, 2019) |
| "Acute disseminated intravascular coagulation (DIC) is a severe complication of gastric adenocarcinoma, and most of the patients die within 1-3 weeks." | 5.30 | Gastric cancer associated with acute disseminated intravascular coagulation: successful initial treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin. ( Cheng, AL; Yeh, KH, 1998) |
| "5-Fluorouracil is an S-phase-specific, synthetic pyrimidine antimetabolite, which is used as a cytostatic agent for a variety of malignant lesions, either singly or in multidrug regimens." | 5.30 | Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. ( Ahmad, M; Aziz, SA; Iqbal, K; Jalal, S; Mohi-ud-Din, K; Tramboo, NA, 1998) |
| " Of the 66 patients with colorectal carcinoma, 44 had not been previously treated with cytostatics and 22 were resistant to previous chemotherapy with 5-FU given either as a single agent or combined with other drugs." | 5.27 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update. ( Chollet, P; Goldschmidt, E; Machover, D; Mathé, G; Misset, JL; Schwarzenberg, L; Vanden-Bulcke, JM, 1985) |
| "Of the 31 patients with stomach cancer who were evaluable for response and had had no previous chemotherapy, 12 (39%) achieved complete or partial remission." | 5.26 | Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas. ( Bennetts, RW; Heifetz, LJ; Jones, RD; Karlin, DA; Mahal, PS; Stroehlein, JR, 1982) |
| "The AIO-FLOT3 (Arbeitsgemeinschaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prospective, phase 2 trial of 252 patients with resectable or metastatic gastric or gastroesophageal junction adenocarcinoma." | 5.24 | Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. ( Al-Batran, SE; Arnold, D; Bechstein, W; Berkhoff, S; Egger, M; Fischbach, W; Grimm, K; Hartmann, JT; Höffkes, HG; Hofheinz, RD; Homann, N; Illerhaus, G; Jäger, E; Koenigsmann, M; Kraus, TW; Luley, KB; Martens, UM; Mayer, F; Messmann, H; Moehler, M; Mönig, S; Pauligk, C; Post, S; Prasnikar, N; Probst, S; Ronellenfitsch, U; Schmalenberg, H; Stoehlmacher, J, 2017) |
| "Purpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Demonstrated superior survival for patients who received postoperative chemoradiotherapy with bolus fluorouracil (FU) and leucovorin (LV) compared with surgery alone." | 5.24 | Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). ( Alberts, SR; Berg, DJ; Bjarnason, GA; Ciombor, K; Dragovich, T; Enzinger, PC; Fuchs, CS; Goldberg, RM; Gunderson, LL; Haller, DG; Ilson, D; Mamon, HJ; Mayer, RJ; Meyerhardt, J; Niedzwiecki, D; O'Reilly, E; Swanson, RS; Tepper, JE; Venook, AP; Willett, CG; Ye, X, 2017) |
| "Patients with untreated metastatic adenocarcinoma of the stomach, gastroesophageal junction, or distal esophagus received mFOLFOX6 (leucovorin 400 mg/m, fluorouracil 400 mg/m bolus and 2400 mg/m continuous infusion over 46 h, oxaliplatin 85 mg/m) and bevacizumab (10 mg/kg) every 2 weeks until disease progression or intolerance." | 5.24 | Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma. ( Deng, Y; Doddamane, I; Fischbach, NA; Hochster, HS; Karimeddini, D; Kortmansky, JS; Lacy, J; Li, J; Stein, S; Yao, X; Zhang, Y, 2017) |
| "Based upon preclinical data showing synergy with mTOR inhibition and platinum chemotherapy, this study explores the safety and tolerability of combining everolimus with mFOLFOX6 for patients with metastatic gastroesophageal adenocarcinoma." | 5.22 | Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma. ( Chao, J; Chung, S; Chung, V; Fakih, MG; Frankel, P; Koehler, S; Lau, SC; Leong, L; Lim, D; Luevanos, E; Ruel, N; Yeon, C, 2016) |
| "Docetaxel is active in esophagogastric junction (EGJ) adenocarcinoma, and DCF (docetaxel/cisplatin/5-fluorouracil) has shown good results in the neoadjuvant setting." | 5.22 | A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma. ( Al-Fakeeh, A; Al-Ruzug, I; Alcindor, T; Doerksen, T; Ferri, L; Mulla, N; Santos, F, 2016) |
| "Patients more than 18 years of age with gastric adenocarcinoma were randomized 1:1 to capecitabine-cisplatin plus either bevacizumab or placebo." | 5.20 | Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). ( Bu, L; Chen, L; Dai, G; Li, J; Liu, Y; Pan, H; Piao, Y; Qin, S; Shen, L; Shu, Y; Wang, J; Wang, L; Xu, J; Xu, R; Yang, Z; Yu, S, 2015) |
| "The aim of the study was to compare efficacy and safety of first-line palliative chemotherapy with (EOX) epirubicin/oxaliplatin/capecitabine and (mDCF) docetaxel/cisplatin/5FU/leucovorin regimens for untreated advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma." | 5.20 | Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. ( Budzynski, A; Fijorek, K; Konopka, K; Krzemieniecki, K; Lazar, A; Matlok, M; Ochenduszko, S; Pedziwiatr, M; Puskulluoglu, M; Sinczak-Kuta, A; Urbanczyk, K, 2015) |
| "Docetaxel, cisplatin, and fluorouracil (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma and is associated with significant toxicity." | 5.20 | Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. ( Capanu, M; Henderson, C; Janjigian, YY; Kelsen, DP; Kemeny, M; Krishnamurthi, S; Mehrotra, B; Ocean, A; Ritch, P; Shah, MA; Shibata, S; Stoller, R; Su, YB, 2015) |
| "This phase II trial aimed to evaluate the efficacy and safety of docetaxel, cisplatin, and fluorouracil (DCF) combination in neoadjuvant setting in patients with locally advanced gastric adenocarcinoma." | 5.19 | Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. ( Abali, H; Bostanci, B; Civelek, B; Oguz, D; Oksuzoglu, B; Ozdemir, N; Vural, M; Yalcin, B; Yalcin, S; Zengin, N, 2014) |
| "To compare epirubicin, cisplatin, and capecitabine (ECX) with fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatments in patients with advanced gastric or esophagogastric junction (EGJ) adenocarcinoma." | 5.19 | Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd ( André, T; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Boucher, E; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Louvet, C; Maillard, E; Nguyen, S; Rebischung, C; Ries, P; Rougier, P; Ychou, M, 2014) |
| "The incidence of diarrhea during chemotherapy was significantly lower in the S-1 plus lafutidine group than in the group treated with S-1 alone (10% vs." | 5.19 | Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. ( Hanazaki, K; Kitagawa, H; Kobayashi, M; Maeda, H; Munekage, E; Namikawa, T, 2014) |
| " We evaluated the safety, tolerability, and efficacy of the combination capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas." | 5.17 | A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. ( Altomare, I; Arrowood, CC; Bendell, JC; Blobe, GC; Brady, JC; Conkling, P; Cushman, SM; Favaro, J; Hsu, SD; Hurwitz, HI; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Uronis, HE; Zafar, SY, 2013) |
| "To evaluate the safety and tolerability of two different weekly doses of the fully humanized epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab combined with high-dose 5-fluorouracil, leucovorin and cisplatin (PLF) in the first-line treatment of patients with EGFR-positive advanced gastric and esophagogastric adenocarcinomas." | 5.17 | Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. ( Heeger, S; Lüpfert, C; Przyborek, M; Schleucher, N; Trarbach, T; Vanhoefer, U, 2013) |
| "Patients with localized, operable gastric or gastroesophageal adenocarcinoma received two cycles of induction chemotherapy of fluorouracil, docetaxel, and cisplatin (TPF) followed by 45 Gy of radiation and concurrent fluorouracil plus docetaxel then surgery for nonmetastatic patients." | 5.17 | Docetaxel-based preoperative chemoradiation in localized gastric cancer: impact of pathological complete response on patient outcome. ( Abd-Allah, D; El-Shazly, W; Khedr, G; Rostom, Y; Zaghloul, H, 2013) |
| "Patients with metastatic gastric, gastro-oesophageal junction, or distal oesophageal adenocarcinoma were randomized 1:1:1 to CX (cisplatin 80 mg/m(2) IV Q3W; capecitabine 1000 mg/m(2) P." | 5.17 | Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. ( Adewoye, AH; Bampton, CL; Bass, MB; Bodoky, G; Eatock, MM; Nanayakkara, N; Strickland, AH; Sun, YN; Swieboda-Sadlej, A; Tebbutt, NC; Valladares-Ayerbes, M; Van Cutsem, E; Zhong, ZD, 2013) |
| "This prospective multicentre phase II trial assessed the feasibility and efficacy of perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in patients with gastro-oesophageal adenocarcinoma." | 5.16 | Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. ( Arnold, D; Bichev, D; Breithaupt, K; Daum, S; Florschütz, A; Gahn, B; Glanemann, M; Hofheinz, RD; Kneba, M; Kretzschmar, A; Mantovani-Löffler, L; Reichardt, P; Schlattmann, P; Schumacher, G; Thuss-Patience, PC, 2012) |
| "Fluorouracil, l-leucovorin and paclitaxel at Level 1 is feasible as first-line treatment for peritoneal disseminated gastric cancer patients with massive ascites or inadequate oral intake." | 5.16 | Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake. ( Fuse, N; Goto, M; Hironaka, S; Iwasa, S; Kusaba, H; Nakajima, TE; Nakayama, N; Nishina, T; Shimada, Y; Taira, K; Takahari, D; Yasui, H, 2012) |
| "Hand-foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy." | 5.16 | Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. ( Aparicio, J; Dueñas, R; Falcó, E; Gómez-Martin, C; Irigoyen, A; Lacasta, A; Llorente, B; López, RL; Muñoz, ML; Pérez, B; Reboredo, M; Regueiro, P; Safont, MJ; Sánchez, A; Sanchez-Viñes, E; Serrano, R, 2012) |
| "Previously untreated patients with metastatic gastroesophageal adenocarcinoma received bevacizumab 10 mg/kg, docetaxel 40 mg/m², fluorouracil 400 mg/m², leucovorin 400 mg/m² on day 1, fluorouracil 1,000 mg/m²/d × 2 days intravenous continuous infusion beginning on day 1, and cisplatin 40 mg/m² on day 3." | 5.15 | Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. ( Capanu, M; Ilson, DH; Jhawer, M; Kelsen, DP; Lefkowitz, RA; Robinson, E; Shah, MA, 2011) |
| "Eighty patients with gastric adenocarcinoma after curative gastrectomy were randomized to receive a 2-h infusion of leucovorin (LV; 200mg/m(2)/d) followed by a 5-fluorouracil (5-FU) bolus (400mg/m(2)/d) and 22-h infusion (600 mg/m(2)/d) for 2 consecutive days every 2 weeks, either alone or together with oxaliplatin 85 mg/m(2) as a 2-h infusion on day 1 (FOLFOX4 regimen or LV5Fu2 regimen)." | 5.15 | Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma. ( Ba, MC; Cui, SZ; Shi, HJ; Tang, YQ; Zhang, XL, 2011) |
| "In this prospective pilot study, we assessed the efficacy and safety of the FOLFIRI regimen (irinotecan 180 mg/m², leucovorin 200 mg/m² d1 followed by bolus 400 mg/m² 5-fluorouracil (5-FU) and by a 46-h 2400 mg/m² 5-FU infusion, every 2 weeks) in patients with advanced esophageal or junctional adenocarcinoma." | 5.15 | FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study. ( Bourgeois, V; Ferte, C; Hebbar, M; Ladrat, L; Lindet, C; Mariette, C; Peugniez, C; Romano, O; Triboulet, JP, 2011) |
| "Oxaliplatin, irinotecan, and capecitabine given in a novel, weekly schedule does induce responses in advanced gastric and GEJ adenocarcinoma." | 5.14 | A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. ( Brell, JM; Dowlati, A; Ivy, SP; Javle, M; Kantharaj, BN; Krishnamurthi, SS; Pelley, R; Rath, L; Remick, SC; Saltzman, J; Schluchter, MD; Wollner, I, 2009) |
| "The feasibility, safety, and efficacy of planned sequential administration of docetaxel and irinotecan with 5-fluorouracil (5-FU)/leucovorin in advanced upper gastrointestinal adenocarcinoma (UGIA) are unknown." | 5.14 | An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer. ( Berglund, A; Byström, P; Frödin, JE; Glimelius, B; Johansson, B; Letocha, H; Nygren, P; Pedersen, D, 2010) |
| "We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia." | 5.14 | A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. ( Drew, PA; Jamieson, GG; Liu, JF; Wu, TC; Zhu, GJ, 2009) |
| "Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours x 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression." | 5.14 | S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. ( Abbruzzese, JL; Blanke, CD; Budd, GT; Chansky, K; Christman, KL; Hundahl, SA; Issell, BF; Macdonald, JS; Van Veldhuizen, PJ, 2010) |
| " We enrolled patients aged 20-75 years or younger, who had histologically proven gastric adenocarcinoma, and randomly assigned them by minimisation to receive either: a continuous infusion of fluorouracil (800 mg/m(2) per day, on days 1-5) every 4 weeks (n=234); intravenous irinotecan (70 mg/m(2), on days 1 and 15) and cisplatin (80 mg/m(2), on day 1) every 4 weeks (n=236); or oral S-1 (40 mg/m(2), twice a day, on days 1-28) every 6 weeks (n=234)." | 5.14 | Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. ( Boku, N; Doi, T; Fukuda, H; Koizumi, W; Nasu, J; Ohtsu, A; Saito, H; Sawaki, A; Shirao, K; Takiuchi, H; Yamaguchi, K; Yamamoto, S, 2009) |
| "Patients suffering from locally-advanced (T3-4 any N M0 or any T N1-3 M0) gastric carcinoma, staged with endoscopic ultrasound, bone scan, computed tomography, and laparoscopy, were assigned to receive four 21 d/cycles of TCF (docetaxel 75 mg/m(2) day 1, cisplatin 75 mg/m(2) day 1, and fluorouracil 300 mg/m(2) per day for days 1-14), either before (Arm A) or after (Arm B) gastrectomy." | 5.14 | Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. ( Andreoni, B; Biffi, R; Bonomo, G; Chiappa, A; Crosta, C; Fazio, N; Fiori, G; Huber, O; Luca, F; Orsi, F; Roth, A; Schuller, JC; Zampino, MG, 2010) |
| "Cisplatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile." | 5.14 | Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. ( Ajani, JA; Bodoky, G; Falcon, S; Garin, A; Gorbunova, V; Lang, I; Lichinitser, M; Moiseyenko, V; Rodriguez, W; Vynnychenko, I, 2010) |
| "To assess the efficacy and safety of docetaxel plus oxaliplatin and capecitabine (DOX) in the treatment of advanced gastric adenocarcinoma." | 5.14 | [Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial]. ( Liu, Y; Ma, T; Ye, ZB; Zhang, J; Zhu, ZG, 2010) |
| "The regimen of docetaxel and capecitabine is a well-tolerated, easily administered and active outpatient regimen for advanced gastric and GE adenocarcinoma." | 5.14 | A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. ( Hantel, A; Hwang, J; Javle, M; Khorana, AA; Kiefer, G; Lo, SS; Rajasenan, K; Ramanathan, RK; Schmotzer, A; Shayne, M; Simon, S; Wang, H, 2010) |
| "Patients with histologically confirmed metastatic or locally advanced adenocarcinoma of the stomach or gastroesophageal junction received docetaxel 25 mg/m2 and oxaliplatin 50 mg/m2 on days 1 and 8 with capecitabine 625 mg/m2 twice daily from day 1-14, in 21-day cycles." | 5.14 | Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. ( Aggarwal, S; Goel, G; Jauhri, M; Negi, A, 2010) |
| "We aimed to establish the superiority (or noninferiority if superiority was not achieved) in terms of time to progression (TTP) of irinotecan/5-fluorouracil (IF) over cisplatin/5-fluorouracil (CF) in chemonaive patients with adenocarcinoma of the stomach/esophagogastric junction." | 5.13 | Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. ( Barone, C; Bugat, R; Cisar, L; Dank, M; Goker, E; Peschel, C; Valvere, V; Wang, K; Wenczl, M; Yalcin, S; Zaluski, J, 2008) |
| "Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m(2), leucovorin 200 mg/m(2), and fluorouracil 2600 mg/m(2) as a 24-h infusion in combination with docetaxel 50 mg/m(2) (FLOT) on day 1 every 2 weeks." | 5.13 | Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Clemens, MR; Fritz, M; Hartmann, JT; Hofheinz, R; Homann, N; Jäger, E; Mahlberg, R; Pauligk, C; Probst, S; Rethwisch, V; Seipelt, G; Sievert, M; Stoehlmacher, J, 2008) |
| "Patients with previously untreated advanced adenocarcinoma of the stomach or esophagogastric junction were randomly assigned to receive either fluorouracil 2,600 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2), and oxaliplatin 85 mg/m(2) (FLO) every 2 weeks or fluorouracil 2,000 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2) weekly, and cisplatin 50 mg/m(2) every 2 weeks (FLP)." | 5.13 | Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Bokemeyer, C; Derigs, HG; Grossmann, J; Hartmann, JT; Hegewisch-Becker, S; Hofheinz, R; Hollerbach, S; Homann, N; Jäger, E; Knuth, A; Pauligk, C; Probst, S; Rethwisch, V; Schmalenberg, H; Schuch, G; Seipelt, G; Stoehlmacher, J; Wilhelm, G, 2008) |
| "Previous studies suggest that the combination of docetaxel and capecitabine are worthy of further testing in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction." | 5.12 | Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. ( Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK, 2006) |
| "We investigated 2-weekly intravenous irinotecan combined with oral capecitabine in patients with advanced gastroesophageal adenocarcinoma." | 5.12 | A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. ( Anthoney, DA; Burge, ME; Halstead, F; Jackson, DP; Seymour, MT; Smith, D; Topham, C, 2006) |
| "A regimen of epirubicin, cisplatin, and infused fluorouracil (ECF) improves survival among patients with incurable locally advanced or metastatic gastric adenocarcinoma." | 5.12 | Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. ( Allum, WH; Chua, YJ; Cunningham, D; Falk, SJ; Iveson, TJ; Langley, RE; Lofts, FJ; Nicolson, M; Scarffe, JH; Smith, DB; Stenning, SP; Thompson, JN; Van de Velde, CJ; Verma, M; Weeden, S, 2006) |
| "From February, 2001 to September, 2002, the Southwest Oncology Group (SWOG) accrued 65 patients with advanced gastric adenocarcinoma to a phase II trial of weekly 5-FU, leucovorin, and the orally-administered uridine analog PN401." | 5.12 | Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study. ( Abbruzzese, JL; Cobb, PW; Doroshow, JH; Issell, BF; Macdonald, JS; McCoy, S; Patel, T; Yost, KJ, 2006) |
| "After recovery from surgery for adenocarcinoma of the gastroesophageal junction or stomach, all patients were treated with capecitabine monotherapy, 1,000 mg/m2 twice daily for 2 weeks." | 5.12 | A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. ( Bartelink, H; Boot, H; Cats, A; Crosby, TD; Dubbelman, R; Jansen, EP; Saunders, MP; Verheij, M, 2007) |
| "The aim of this study was to investigate the efficacy and safety of combination chemotherapy with weekly paclitaxel and 5-fluorouracil (5-FU) as first-line treatment in patients with advanced or recurrent gastric carcinoma." | 5.12 | Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma. ( Ando, T; Hirabayashi, N; Kawamura, S; Kobayashi, M; Kojima, H; Kondo, K; Konno, H; Matsuo, K; Miyashita, Y; Morita, S; Musha, N; Nagata, N; Ninomiya, M; Oba, K; Sakamoto, J; Usuki, H, 2007) |
| "Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals." | 5.12 | A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. ( Jang, JS; Jeong, JS; Kim, HJ; Kim, MC; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY; Yoo, HS, 2007) |
| "The aim of this study was to evaluate the activity and safety of 5-fluorouracil (5-FU)/leucovorin (LV) and irinotecan as first- or second-line treatment in patients with advanced gastric adenocarcinoma." | 5.12 | Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma. ( Chrysanthopoulos, C; Gerolymos, MK; Iconomou, G; Kalofonos, HP; Kontogeorgou, E; Koutras, AK; Makatsoris, T; Tsiata, E; Vourli, G, 2007) |
| "Patients with proven adenocarcinoma of the stomach were randomised to receive four courses of chemotherapy using 5-Fluorouracil, doxorubicin and methotrexate (FAMTX) prior to surgery or to undergo surgery alone." | 5.11 | Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. ( de Vries, JE; Hartgrink, HH; Kranenbarg, EK; Putter, H; Songun, I; Tesselaar, ME; van de Velde, CJ; van der Bijl, J; van Krieken, JH; Wils, JA, 2004) |
| "To determine the efficacy and safety of a biweekly regimen of leucovorin (LV) plus fluorouracil (FU) alone or in combination with cisplatin or irinotecan in patients with previously untreated metastatic gastric adenocarcinoma and to select the best arm for a phase III study." | 5.11 | Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie ( Arsène, D; Bedenne, L; Bonnetain, F; Bouché, O; Buecher, B; Etienne, PL; Giovannini, M; Guérin-Meyer, V; Kaminsky, MC; Lledo, G; Milan, C; Mitry, E; Paitel, JF; Raoul, JL; Rougier, P; Seitz, JF, 2004) |
| "Patients with metastatic or locally advanced gastric adenocarcinoma without prior chemotherapy were randomly assigned to receive either ECF (epirubicin 50 mg/m(2) day 1, cisplatin 60 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks) or DF (docetaxel 75 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks)." | 5.11 | Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. ( Dörken, B; Hennesser, D; Kingreen, D; Kretzschmar, A; Micheel, S; Pink, D; Reichardt, P; Repp, M; Scholz, C; Thuss-Patience, PC, 2005) |
| "We conducted a phase II study to assess the efficacy and tolerability of irinotecan and cisplatin as salvage chemotherapy in patients with advanced gastric adenocarcinoma, progressing after both 5-fluorouracil (5-FU)- and taxane-containing regimen." | 5.11 | Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. ( Bang, SM; Cho, EK; Choi, EY; Chung, M; Ki Lee, W; Lee, JH; Park, SH; Shin, DB, 2005) |
| "Cumulative gastrointestinal toxicities and neutropenia were the DLTs of docetaxel, capecitabine, and carboplatin." | 5.11 | Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. ( Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY, 2005) |
| "In this phase II randomized study, untreated patients with confirmed advanced gastric or gastroesophageal adenocarcinoma received either DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2 on day 1, and fluorouracil 750 mg/m2/d as continuous infusion on days 1 to 5) or DC (docetaxel 85 mg/m2 and cisplatin 75 mg/m2 on day 1) every 3 weeks." | 5.11 | Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. ( Ajani, JA; Assadourian, S; Cabral Filho, S; Chao, Y; Fodor, MB; Majlis, A; Moiseyenko, VM; Tjulandin, SA; Van Cutsem, E, 2005) |
| "The aim of this study was to compare the longitudinal quality of life (QoL) between LV5FU2-irinotecan and LV5FU2 alone or LV5FU2-cisplatin in a randomized Phase II trial in patients with metastatic gastric adenocarcinoma." | 5.11 | Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology. ( Arveux, P; Bedenne, L; Bonnetain, F; Bouché, O; Conroy, T; Etienne, PL; Giovannini, M; Girault, C; Mitry, E; Raoul, JL; Rougier, P; Seitz, JF, 2005) |
| "The purpose of this study was to evaluate the dose-limiting toxicity (DLT) and maximum tolerated dose of capecitabine when used in combination with epirubicin and cisplatin (ECC) in patients with oesophageal or gastric adenocarcinoma." | 5.10 | A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. ( Blackie, R; Evans, TR; Fullarton, GM; McDonald, AC; McInnes, A; Morrison, R; Paul, J; Pentheroudakis, G; Raby, N; Soukop, M, 2002) |
| "Patients with previously untreated metastatic or unresectable measurable gastric adenocarcinoma received oral capecitabine 1250 mg/m(2) twice daily, days 1-14, and i." | 5.10 | Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. ( Ahn, JH; Chang, HM; Kang, YK; Kim, BS; Kim, TW; Lee, JS; Oh, ST; Yook, JH, 2002) |
| "The aim of this phase II study was to investigate the tolerance and efficacy of a second-line irinotecan/mitomycin C combination in patients with advanced gastric or colorectal cancer, pretreated with 5-fluorouracil." | 5.10 | Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. ( Bamias, A; Papamichael, D; Pavlidis, N; Syrigos, K, 2003) |
| " A total of 26 patients with adenocarcinoma of the stomach were treated with 3D-conformal radiation therapy to a dose of 45 Gy in 25 fractions with concurrent continuous infusional 5-fluorouracil (5-FU)." | 5.10 | Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation. ( Foo, K; Leong, T; Lim Joon, D; Michael, M; Ngan, S; Thomas, R; Thompson, A; Weih, L; Zalcberg, J, 2003) |
| "The aim of this study was to evaluate the toxicity and efficacy of combination chemotherapy with weekly 24-h continuous infusion of 5-fluorouracil (5-FU)/folinic acid, weekly paclitaxel and 3-weekly cisplatin in patients with unresectable, locally advanced or metastatic gastric adenocarcinoma." | 5.10 | Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. ( Baronius, W; Bokemeyer, C; Haag, C; Hartmann, JT; Hempel, V; Honecker, F; Kanz, L; Kollmannsberger, C; Quietzsch, D; Schroeder, M; Spott, C, 2002) |
| "This prospective phase II clinical trial was performed to explore the activity and efficacy of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric adenocarcinoma." | 5.09 | Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. ( Aragao, BC; Cabral, LO; Guimaraes, RC; Murad, AM; Petroianu, A; Scalabrini-Neto, AO, 1999) |
| "We performed combination chemotherapy adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in 11 patients with gastric cancer and 7 with colorectal cancer." | 5.09 | [The effect of combination chemotherapy to adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in patients with gastric or colorectal cancer]. ( Iesato, H; Kamoshita, N; Kato, Y; Morishita, Y; Nagaoka, H; Ohwada, S; Ohya, T; Okabe, T; Takeyoshi, I; Yokomori, T, 2000) |
| "Biweekly intravenous infusions of low-dose cisplatin (CDDP) and 5-fluorouracil (5-FU) were evaluated in 80 patients with advanced or recurrent gastric, colorectal, pancreatic or gallbladder adenocarcinoma." | 5.09 | [Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma]. ( Kamata, T; Kanno, M; Koyasaki, N; Morita, A; Nakamoto, A; Onishi, I; Takeda, T, 2000) |
| "To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel, cisplatin and 24 h continuous infusion of 5-FU/folinic acid in patients (pts) with unresectable, locally advanced or metastatic gastric adenocarcinoma." | 5.09 | A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. ( Baronius, W; Bokemeyer, C; Clemens, M; Haag, C; Hartmann, JT; Hempel, V; Kanz, L; Kollmannsberger, C; Lingenfelser, T; Quietzsch, D; Schroeder, M, 2000) |
| "Patients with stage IIIA or early stage IV gastric adenocarcinoma received neoadjuvant 5-fluorouracil, Leucovorin, Adriamycin, and Cisplatin and underwent gastrectomy or esophagogastrectomy with intraoperative radiotherapy (IORT; 1000 cGY) to the gastric bed and postoperative radiation therapy." | 5.09 | Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma. ( Fisher, SA; Harbison, SP; Henry, DH; Stiller, GD; Weese, JL, 2000) |
| " In this study 137 patients with gastric adenocarcinoma, all with positive nodes, were randomized after curative resection so that 69 received epidoxorubicin (EPI), leucovorin (LV) and 5-fluorouracil (5-FU) on days 1-3 every 3 weeks for 7 months, whereas the remaining 68 did not." | 5.09 | Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. ( Andreoli, F; Boffi, B; Cini, G; Francesconi, D; Mazzanti, R; Medi, F; Mercatelli, A; Moretti, R; Neri, B; Romano, S; Siliani, L; Tarquini, R, 2001) |
| " 5-fluorouracil (5-FU), and leucovorin (LCV) was conducted in patients with advanced gastric adenocarcinomas." | 5.09 | A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. ( Benson, AB; Berlin, J; Blanke, CD; Haller, DG; Hsieh, YC; Miller, LL; Mori, M; Rothenberg, ML, 2001) |
| "To reduce the Hickman line-associated morbidity of continuous infusion 5-fluorouracil combined with epirubicin and cisplatin (ECF) and to investigate the need for infusional regimens, we conducted a retrospective study in patients with advanced gastro-oesophageal adenocarcinoma." | 5.09 | Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma. ( Dunlop, DJ; Eatock, MM; Lim, KC; Pentheroudakis, G; Soukop, M, 2001) |
| "A randomized early phase II study using l-leucovorin (l-LV) and 5-fluorouracil (5-FU) against gastric cancer and colorectal cancer was conducted on a multi-institutional basis in Japan." | 5.08 | [Clinical evaluation of leucovorin and 5-fluorouracil]. ( Sasaki, T, 1995) |
| "We tested the hypothesis that polymerase chain reaction (PCR) quantitation of the enzyme thymidylate synthase (TS) within a primary adenocarcinoma of the stomach, has an inverse relationship to response and survival for patients who receive fluorouracil (5FU)-based chemotherapy." | 5.08 | Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. ( Baranda, J; Cohen, H; Crookes, P; Danenberg, KD; Danenberg, PV; Garcia, Y; Groshen, S; Laine, L; Leichman, CG; Leichman, L; Lenz, HJ; Li, J; Silberman, H, 1996) |
| "After curative resection for gastric adenocarcinoma, 103 patients, all with positive nodes, were randomised so that 48 received adjuvant chemotherapy of epidoxorubicin (EPI) 75 mg m-2 on day 1, leucovorin (LV) 200 mg m-2 on days 1-3 and 5-fluorouracil (5-FU) 450 mg m-2 on days 1-3, every 21 days for 7 months, whereas the remaining 55 did not." | 5.08 | Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. ( Andreoli, F; Borrelli, D; Bruno, L; Cini, G; de Leonardis, V; Fabbroni, S; Intini, C; Neri, B; Pernice, LM; Romano, S; Valeri, A, 1996) |
| "In a randomized Phase II study, the authors evaluated the activity and toxicity of the new cisplatin, doxorubicin, and mitomycin C (PAM) combination, that includes cisplatin (P) instead of 5-fluorouracil as in the 5-fluorouracil, doxorubicin, and mitomycin C (FAM) combination, in patients with advanced gastric carcinoma." | 5.08 | The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research. ( Angelini, F; Cavicchi, F; Cocconi, G; De Lisi, V; Di Costanzo, F; Finardi, C; Gilli, G; Rodinò, C; Soldani, M; Tonato, M, 1996) |
| "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma." | 5.08 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996) |
| " The authors examined whether the administration of 5-fluorouracil (5-FU) enhanced apoptosis of gastric carcinoma cells, and investigated the relationship between apoptosis and the expression of Ki-67 and the Bax gene." | 5.08 | Enhanced induction of apoptosis of human gastric carcinoma cells after preoperative treatment with 5-fluorouracil. ( Itoh, H; Kaibara, N; Kimura, O; Maeta, M; Makino, M; Shirai, H; Sugamura, K, 1997) |
| "Fifty-nine patients with invasive primary gastric adenocarcinoma who were deemed resectable for cure entered a clinical trial that called for 2 cycles of protracted infusion 5-fluorouracil with weekly leucovorin and cisplatin chemotherapy followed by surgery." | 5.08 | Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. ( Baranda, J; Casagrande, Y; Crookes, P; Groshen, S; Laine, L; Leichman, CG; Leichman, L; Silberman, H; Stain, S; Tan, M, 1997) |
| "A Phase II study was performed to evaluate the activity and toxicity of 5-fluorouracil, leucovorin, Adriamycin, and cisplatin combination chemotherapy (FLAP) in patients with previously untreated advanced gastric and gastroesophageal (GE) junction adenocarcinoma." | 5.08 | A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program ( Armstead, B; Douglass, HO; Haller, DG; Holroyde, C; Meropol, NJ; Mintzer, D; Nuamah, I; Vaughn, DJ, 1997) |
| ") of 5-fluorouracil (5-FU) plus daily low-dose cisplatin (CDDP) was evaluated in 45 patients with advanced and recurrent unresected colorectal, lung, gastric and pancreatic adenocarcinoma." | 5.08 | [Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma]. ( Denno, R; Hiraike, N; Hirata, K; Katsuramaki, T; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Takasaka, H; Yagihashi, A; Yamamitsu, S; Yamashiro, K, 1997) |
| "We have previously shown that relative thymidylate synthase (TS) mRNA levels in primary gastric adenocarcinomas treated with fluorouracil (5-FU) and cisplatin are inversely associated with response and survival." | 5.08 | ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. ( Baranda, J; Cohen, H; Crookes, P; Danenberg, KD; Danenberg, PV; Groshen, S; Hayashi, K; Konda, B; Laine, L; Leichman, CG; Leichman, L; Lenz, HJ; Metzger, R; Salonga, D; Silberman, H, 1998) |
| "Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i." | 5.07 | Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach. ( Bajardi, G; Cannata, G; Cipolla, C; Curto, G; Gebbia, V; Latteri, M; Mastrandrea, G; Pischedda, G; Testa, A; Valenza, R, 1994) |
| "The combination of cisplatin, epirubicin, and leucovorin preceding fluorouracil (PELF) includes three novel agents compared with the standard combination of fluorouracil, doxorubicin, and mitomycin (FAM) in the treatment of advanced gastric carcinoma." | 5.07 | Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. ( Algeri, R; Bella, M; Cocconi, G; De Lisi, V; Di Costanzo, F; Luppi, G; Mazzocchi, B; Rodinò, C; Soldani, M; Zironi, S, 1994) |
| "Fourteen patients (group A) with unresectable metastasis to the liver from colorectal cancers (11 patients) and gastric cancers (3 patients) were treated with the combined application of hyperthermia and intra-hepato-arterial (IHA) chemotherapy with cisplatinum and 5-fluorouracil." | 5.07 | A phase II pilot study of the combined application of hyperthermia and intra-hepato-arterial chemotherapy using cisplatinum and 5-fluorouracil. ( Hamazoe, R; Hirooka, Y; Kaibara, N; Maeta, M; Murakami, A, 1991) |
| "This study evaluated combined 5-fluorouracil (5FU) and doxorubicin as postoperative adjuvant chemotherapy for patients who had undergone potentially curative resection of a primary gastric adenocarcinoma." | 5.07 | A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. ( Beart, RW; Foley, JF; Krook, JE; Kugler, JW; Leigh, JE; O'Connell, MJ; Pfeifle, DM; Twito, DI; Wieand, HS, 1991) |
| "A novel sequential administration schedule of PALA (N-phosphonoacetyl-L-aspartate) and thymidine to enhance the cytotoxic effect of 5-fluorouracil (5FU) was tested in 36 patients with advanced gastric cancer and 21 patients with advanced poorly differentiated (anaplastic) colorectal cancer." | 5.06 | A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer. ( Goldberg, RM; Krook, JE; Kugler, JW; Laurie, JA; Moertel, CG; O'Connell, MJ; Pfeifle, DM; Rubin, J; Wieand, HS; Windschitl, HE, 1990) |
| "Fifty patients with locally far progressed or metastasizing gastric carcinoma were treated with 5-fluorouracil, adriamycin and methotrexate using a slight modification of the FAMeth schema." | 5.06 | [The results of a modified FAMeth chemotherapy protocol in metastatic stomach carcinoma]. ( Crone-Münzebrock, W; Garbrecht, M; Henne-Bruns, D; Hossfeld, DK; Kremer, B; Platz, D; Weh, HJ, 1989) |
| "In this prospective randomized study the effect of oral Ftorafur was compared with that of intravenous 5-fluorouracil in patients with advanced adenocarcinoma of the stomach, colon or rectum." | 5.06 | Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum. ( Bjerkeset, T; Fjøsne, HE, 1986) |
| "We report the results of an expanded trial of 5-fluorouracil (5-FU) combined with high-dose folinic acid for treatment of patients with advanced colorectal or advanced gastric adenocarcinoma." | 5.06 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Chollet, P; Fourtillan, JB; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1986) |
| "A multi-institutional cooperative study of patients with locally advanced, recurrent, or metastatic gastric adenocarcinoma who had not previously received chemotherapy was conducted, prospectively randomizing patients to receive either doxorubicin or the three-drug combination, 5-fluorouracil (5-FU), doxorubicin (Adriamycin; Adria Laboratories, Columbus, Ohio), and BCNU (FAB)." | 5.06 | Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. ( Fox, RM; Gill, G; Levi, JA; Tattersall, MH; Thomson, D; Woods, RL, 1986) |
| "Thirty-four patients with advanced adenocarcinoma of the gastrointestinal tract have been treated with high-dose 5-fluorouracil modulated by concomitant allopurinol therapy, in combination with either razoxane or adriamycin." | 5.05 | A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract. ( Ashford, RF; Bakowski, M; Evans, M; Hellman, K; Jones, R; Lambert, J; Newton, K; Peters, N; Phillips, R; Smith, BJ, 1983) |
| "This prospective evaluation of 5-fluorouracil (5-FU) and methyl-CCNU administered in combination to patients with surgery for histologically proved gastric adenocarcinoma is based upon 312 patients randomized between August 1974 and May 1980." | 5.05 | Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report. ( Amadeo, JH; Higgins, GA; Humphrey, EW; Keehn, RJ; Smith, DE, 1983) |
| "Thirty-two evaluable patients with advanced measurable gastric adenocarcinoma were treated with a combination of 5-fluorouracil, adriamycin, and BCNU (FAB)." | 5.05 | 5-fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer. ( Di Lauro, L; Lopez, M; Papaldo, P; Perno, CF, 1984) |
| "Because of biochemical and tissue culture evidence casting doubt on the physiologic relevance of reported synergy afforded by sequential administration of methotrexate (MTX) followed by 5-fluorouracil (5-FU), a randomized controlled clinical trial was conducted in 108 patients with advanced cancer, including 70 with squamous cell carcinoma (SCC) of the head and neck, nine with SCC of other primary sites, 24 with colorectal, and five with gastric adenocarcinomas." | 5.05 | Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration. ( Coates, AS; Fox, RM; Hedley, D; Raghavan, D; Swanson, C; Tattersall, MH, 1984) |
| "Two hundred forty-one patients with unresectable gastric adenocarcinoma were entered, between December 1978 and March 1981, into a prospectively randomized comparison of three chemotherapy regimens to identify therapeutic activity and determine patient tolerability: (1) 5-fluorouracil plus Adriamycin (FA); (2) FA plus methyl-CCNU (FAMe); and (3) FA plus mitomycin C (FAMi)." | 5.05 | Randomized study of combination chemotherapy in unresectable gastric cancer. The Gastrointestinal Tumor Study Group. ( , 1984) |
| "The FAM combination with the simultaneous administration of 5-fluorouracil, doxorubicin, and mitomycin C is considered standard chemotherapy for gastric adenocarcinoma." | 5.05 | Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study. ( Athens, J; Chen, TT; Costanzi, JJ; Haas, C; Heilbrun, LK; McDonald, B; Oishi, N; Panettiere, FJ; Talley, RW, 1984) |
| "In a prospectively randomized trial, patients with advanced locally recurrent or metastatic gastric adenocarcinoma were randomized to receive 5-fluorouracil (5-FU) and methyl-CCNU; 5-FU, Adriamycin (Adria Laboratories, Columbus, Ohio), and methyl-CCNU; 5-FU, Adriamycin, and mitomycin C; or Adriamycin and mitomycin C alone." | 5.05 | An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). ( Douglass, HO; Goudsmit, A; Klaassen, DJ; Lavin, PT; Paul, AR, 1984) |
| "A prospective controlled study of combined chemotherapy with 5-fluorouracil, vinblastine and cyclophosphamide was conducted in 53 patients with radical resection for gastric carcinoma." | 5.05 | Gastric carcinoma treated by chemotherapy after resection: a controlled study. ( Baschet, C; Bernard, PF; Destroyes, JP; Huguier, M; Le Henand, F, 1980) |
| "After en bloc resection of gastric adenocarcinoma, 180 patients were randomized to 2 years of 5-fluorouracil (5-FU) + semustine (MeCCNU) chemotherapy or to observation only." | 5.05 | Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). ( Brunner, KW; Douglass, HO; Engstrom, PF; Lavin, PT, 1985) |
| "30 patients with advanced metastatic gastric adenocarcinoma, having a measurable indicator lesion, were randomized (1:2) to receive (intravenously) either weekly 5-fluorouracil alone (15 mg/kg) or combination treatment with cyclophosphamide (20 mg/kg) given on day 1 and 5-FU (15 mg/kg) given weekly on weeks 2-5, beginning on day 8." | 5.05 | Cyclophosphamide plus 5-FU versus 5-FU alone in advanced gastric carcinoma. ( Bateman, JR; Chlebowski, RT; Glass, A; Silverberg, I; Weiner, JM, 1985) |
| "One hundred ninety-one patients with pathologically confirmed, locally unresectable adenocarcinoma of the stomach (57 patients) and pancreas (91 patients), were randomly allocated to therapy with 5-fluorouracil (5-FU) alone, 600 mg/m2 intravenously (IV) once weekly, or radiation therapy, 4,000 rad, plus adjuvant 5-FU, 600 mg/m2 IV, the first three days of radiotherapy, then follow-up maintenance 5-FU, 600 mg/m2, weekly." | 5.05 | Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. ( Catton, GE; Engstrom, PF; Klaassen, DJ; MacIntyre, JM; Moertel, CG, 1985) |
| "Eighteen previously untreated patients with advanced nonresectable adenocarcinoma of the stomach were treated with a four-drug regimen consisting of 5-fluorouracil, methyl-CCNU, adriamycin, and mitomycin C." | 5.04 | 5-fluorouracil, methyl-CCNU, adriamycin, and mitomycin C in the treatment of advanced gastric cancer. ( Bunn, PA; Cohen, MH; Eddy, JL; Ihde, DC; Minna, JD; Nugent, JL, 1978) |
| "In a prospective, multi-centre, randomized study of 109 patients with metastatic gastro-intestinal adenocarcinomas the response rate, survival time and side-effects of two drug combinations, carmustin +5-fluorouracil and carmustin + ftorafur, were compared (same carmustin dosage in both groups)." | 5.04 | [A prospective multi-centre study of the response of metastatic gastrointestinal tumours (author's transl)]. ( Arnold, H; Drings, P; Geldmacher, J; Hartwich, G; Kredel, L; Mayer, M; Neidhardt, B; Queisser, W; Rösch, W; Schaefer, J; von Oldershausen, HF; Wahrendorf, J, 1979) |
| "Seventy-six patients with advanced gastric adenocarcinoma were studied in a prospecitive, randmoised, controlled trial using vincristine, methotrexate, cyclophosphamide, and 5-fluorouracil in an initiation course and mitomycin-C with 5-fluorouracil as maintenance therapy." | 5.04 | Chemotherapy in advanced gastric cancer: a controlled, prospective, randomised multi-centre study. ( Cocking, JB; Cwynarski, MT; Diffey, BL; Fox, CA; Jackson, GA; Mallinson, CN; Rake, MO; Wass, VJ, 1979) |
| "5-Fluorouracil (5-Fu) is one of the most commonly prescribed antineoplastic agents against gastric and colorectal cancers." | 4.98 | Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis. ( Meng, F; Wang, Y; Xing, X; Zhang, L; Zhong, D, 2018) |
| "The primary purpose of this study was to explore the short-term efficacy of different cisplatin and fluorouracil-based chemotherapy regimens in the treatment of patients with esophagogastric junctional adenocarcinoma (EGJA) using a network meta-analysis (NMA)." | 4.95 | A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma. ( Hu, JH; Song, DJ; Wang, C; Xie, SP; Xu, ZL, 2017) |
| "Thymidylate synthetase is the major target of 5-fluorouracil (5-FU), which is widely used for the treatment of gastric cancer (GC) and colorectal cancer (CRC)." | 4.89 | An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens. ( Fang, JY; Wang, YC; Wang, ZH; Xue, HP, 2013) |
| "We report on a case of a 65-year-old Chinese male with locally advanced gastric adenocarcinoma achieving pathological complete response after neoadjuvant chemotherapy with capecitabine and oxaliplatin (XELOX) regimen." | 4.89 | Histological complete response after neoadjuvant XELOX in advanced gastric carcinoma. ( Chang, SL; Chen, YN; Jiao, ZK; Li, Y; Tan, BB; Tian, Y; Zhang, ZD; Zhao, Q; Zhao, XF, 2013) |
| "We searched PubMed, ASO, ECCO, ESMO, Wanfang database (Chinese), CNKI (Chinese), Weipu database (Chinese) and J-STAGE (Japanese) using combinations of keywords, including 'capecitabine', '5-fluorouracil', 'chemotherapy', 'stomach neoplasms' and 'gastric cancer'." | 4.88 | Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity. ( Ma, Y; Tang, L; Wang, HX; Xu, YC; Zhang, FC, 2012) |
| " In patients with metastatic or locally advanced/recurrent gastric or gastro-oesophageal junction adenocarcinoma, the median time to tumour progression was significantly prolonged with 3-week cycles of intravenous (IV) docetaxel plus cisplatin and fluorouracil (5-fluorouracil) compared with 4-week cycles of IV cisplatin plus IV fluorouracil (5." | 4.84 | Docetaxel: in gastric cancer. ( Deeks, ED; Scott, LJ, 2007) |
| "At this juncture in the development of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), knowledge about the agent's pharmacologic behavior and clinical antitumor activity in less common neoplasms is being elucidated." | 4.79 | Paclitaxel pharmacology and other tumor types. ( Rowinsky, EK, 1997) |
| " Studies show a definite therapeutic advantage for folinic acid/5-fluorouracil (5-FU) regimen compared with single agent 5-FU given intravenously in the management of advanced colorectal cancer." | 4.78 | Clinical trials with 5-fluorouracil, folinic acid and cisplatin in patients with gastrointestinal malignancies. ( Avvento, L; Madajewicz, S, 1990) |
| "There is limited real-world data on the efficacy of 2-weekly cycles of docetaxel, oxaliplatin, leucovorin, and fluorouracil (FLOT) compared to epirubicin, oxaliplatin, and capecitabine (EOX) as perioperative therapy in esophagogastric adenocarcinomas (EGAC)." | 4.31 | Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis. ( Bhandare, M; Bhargava, P; Booma, N; Chaudhari, V; Chaugule, D; Das, S; Kannan, S; Kapoor, A; Mantri, A; Ostwal, V; Ramaswamy, A; Shrikhande, SV; Srinivas, S, 2023) |
| "This case report describes a patient with cutaneous intestinal metaplasia with invasive adenocarcinoma treated successfully with intralesional fluorouracil." | 4.31 | Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil. ( Dahiya, M; Eilers, D; Joseph, MX; Tao, J; Vaudreuil, A, 2023) |
| "We hypothesized that perioperative FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) might be used as an alternative to standard FLOT (docetaxel, 5-fluorouracil, leucovorin, and oxaliplatin) in patients with locally advanced oesogastric adenocarcinomas (OGA), particularly those with frailties." | 4.12 | Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma. ( Adenis, A; Khellaf, L; Mazard, T; Mourregot, A; Portales, F; Quesada, S; Samalin, E; Thezenas, S; Ychou, M, 2022) |
| "Perioperative FLOT (fluorouracil plus leucovorin, oxaliplatin, and docetaxel) chemotherapy is a recent regimen used to treat resectable oesophagogastric (OG) adenocarcinoma, associated with improved overall survival versus earlier chemotherapy strategies." | 4.12 | Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study. ( Allum, WH; Bhogal, RH; Chau, I; Chaudry, A; Cunningham, D; Fribbens, C; Gerlinger, M; Kumar, S; Malietzis, G; Moussa, O; Rao, S; Starling, N; Watkins, D, 2022) |
| "Gastric cancer (GC) with microsatellite instability (MSI) is a less aggressive disease and associated with resistance to 5-fluorouracil (5-FU)-based chemotherapy (CMT)." | 4.12 | Gastric cancer with microsatellite instability displays increased thymidylate synthase expression. ( Cardili, L; Dias, AR; Mello, ES; Moraes, RDR; Nahas, SC; Pereira, MA; Ramos, MFKP; Ribeiro, U; Zilberstein, B, 2022) |
| "Perioperative FLOT (5-fluorouracil, oxaliplatin and docetaxel) has recently become the gold standard treatment for fit patients with operable gastric (GC) or gastroesophageal (GEJ) adenocarcinoma, getting a 5-year overall survival (OS) of 45%, over 23% with surgery alone." | 4.02 | Results of the observational prospective RealFLOT study. ( Antonuzzo, L; Brugia, M; De Vita, F; Di Donato, S; Fancelli, S; Formica, V; Fornaro, L; Giommoni, E; Giovanardi, F; Iachetta, F; Lavacchi, D; Pecora, I; Pillozzi, S; Pompella, L; Pozzo, C; Prisciandaro, M; Puzzoni, M; Romagnani, A; Satolli, MA; Sisani, M; Spallanzani, A; Stragliotto, S; Strippoli, A; Tirino, G, 2021) |
| " In this study we aim to compare the efficacy and toxicity of two regimens FOLFOX (leucoverin, 5-fluorouracil and oxaliplatin) and modified DCF (mDCF) (docetaxel, cisplatin, and 5-fluorouracil) in patients with advanced gastric adenocarcinoma." | 3.96 | Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma. ( Danandeh Mehr, A; Habibzadeh, A; Molaei, M; Pourghasemian, M, 2020) |
| "Hyperammonemia is an important adverse event associated with 5-fluorouracil (5FU) from 5FU metabolite accumulation." | 3.96 | Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses. ( Funakoshi, T; Horimatsu, T; Ikeda, A; Imamaki, H; Kataoka, S; Matsubara, T; Muto, M; Nakagawa, S; Nishikawa, Y; Oura, M; Ozaki, Y; Watanabe, N; Yanagita, M; Yonezawa, A, 2020) |
| "A 63-year-old Japanese male with stomach adenocarcinoma received oral 5-fluorouracil derivative, cisplatin and trastuzumab chemotherapy." | 3.96 | A Japanese Patient with Gastric Cancer and Dihydropyrimidine Dehydrogenase Deficiency Presenting with DPYD Variants. ( Fujiki, S; Hiratsuka, A; Ishiguro, M; Kawai, D; Ogura, K; Okada, H; Takeda, H; Takenaka, R; Tsugeno, H, 2020) |
| "5-Fluorouracil (5-FU) is the third most common chemotherapeutic agent for treating solid cancers and the second most common to cause cardiotoxicity." | 3.91 | Acute reversible left ventricular systolic dysfunction associated with 5-fluorouracil therapy: a rare and increasingly recognised cardiotoxicity of a commonly used drug. ( Afonso, L; Ahmed, A; Mishra, T; Shokr, M, 2019) |
| " The present study aimed to investigate the effect of Rosmarinic acid (RA) on chemoresistance to 5-Fu and its molecular mechanism in gastric carcinoma." | 3.91 | Rosmarinic acid reduces the resistance of gastric carcinoma cells to 5-fluorouracil by downregulating FOXO4-targeting miR-6785-5p. ( Chen, DQ; Feng, JF; Li, WB; Liu, HX; Lu, JW; Yu, C, 2019) |
| " Therefore, we examined the effects of flavones against CYR61-overexpressing human gastric adenocarcinoma AGS (AGS-cyr61) cells, which show remarkable resistance to 5-fluorouracil (5-FU), adriamycin (ADR), tamoxifen (TAM), paclitaxel (PAC), and docetaxel (DOC)." | 3.88 | Quercetin Suppresses CYR61-Mediated Multidrug Resistance in Human Gastric Adenocarcinoma AGS Cells. ( Cho, SK; Hyun, HB; Moon, JY, 2018) |
| "The objective of the present study was to evaluate the effect of combination of telmisartan with 5-flourouracil (5-FU) in gastric cancer cachexia induced by administering N-methyl-N'-methyl-N-nitrosoguanidine (MNNG)." | 3.83 | Evaluation of role of telmisartan in combination with 5-fluorouracil in gastric cancer cachexia. ( Patel, BM; Patel, HJ; Sukumaran, S, 2016) |
| "Perioperative chemotherapy with 5-fluorouracil and cisplatin, with or without epirubicin, improves overall survival in resectable gastroesophageal junction and gastric adenocarcinoma." | 3.83 | Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. ( Afchain, P; Aparicio, T; Artru, P; Bachet, JB; Baumgaertner, I; Benallaoua, M; Boige, V; Boubaya, M; Coriat, R; des Guetz, G; Lecaille, C; Locher, C; Mary, F; Samalin, E; Tougeron, D; Zaanan, A, 2016) |
| " Additionally, functional studies indicated that over-expression of RAD51B promoted cell proliferation, aneuploidy, and drug resistance, while RAD51B knockdown led to G1 arrest and sensitized cells to 5-fluorouracil (5-FU)." | 3.83 | RAD51B as a potential biomarker for early detection and poor prognostic evaluation contributes to tumorigenesis of gastric cancer. ( Chen, X; Cheng, Y; Xi, Y; Yang, B, 2016) |
| "Patients with advanced gastric cancer with malignant ascites were treated with 60mg/m2 paclitaxel, followed by 500 mg/m2 5-FU and 250 mg/m2 l-LV on days 1, 8, and 15." | 3.83 | [Analysis of 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel in Advanced Gastric Cancer]. ( Hoshino, H; Hosoda, Y; Kawada, J; Kim, Y; Nagai, K; Nishino, M; Okano, M; Okuyama, M; Tsujinaka, T, 2016) |
| "To compare the treatment outcomes of concurrent involved-field radiotherapy and XELOX (oxaliplatin and capecitabine) versus XELOX chemotherapy alone in gastric adenocarcinoma patients with locoregional recurrence." | 3.81 | Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence. ( Huang, Y; Li, WH; Li, YQ; Liu, N; Liu, SG; Liu, XB; Liu, YH; Wang, FL; Yu, J; Yuan, ST; Zhang, JD; Zhang, Y, 2015) |
| "The MAGIC/UK Medical Research Council (MRC) trial set the standard of care for treatment of resectable gastric and junctional adenocarcinoma, demonstrating that perioperative chemotherapy with epirubicin, cisplatin and 5-fluorouracil (ECF) confers a survival benefit over surgery alone." | 3.81 | Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery. ( Kalachand, R; King, S; Mongan, AM; Muldoon, C; O'Byrne, K; O'Farrell, NJ; Power, D; Ravi, N; Reynolds, JV, 2015) |
| "Perioperative chemotherapy with epirubicin, cisplatin and 5-fluorouracil (5-FU) (ECF)-like regimens is the European standard for patients with adenocarcinoma of the gastroesophageal junction (GEJ) or gastric body (GaCa) stage UICC II/III (staged according to the Union for International Cancer Control)." | 3.81 | High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma. ( Bichev, D; Breithaupt, K; Daum, S; Dogan, Y; Schmidt, SC; Thuss-Patience, PC; Treese, C; von Winterfeld, M, 2015) |
| "In high risk gastric and gastroesophageal adenocarcinoma, adjuvant radiochemotherapy with 5-fluorouracil bolus became a standard adjuvant treatment, showing significant improvement in overall survival after surgery, although with substantial toxicity." | 3.81 | Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction. ( Candamio-Folgar, S; Lopez-Lopez, R; Martínez-Lago, N; Padin-Iruegas, ME; Vazquez-Rivera, F; Vidal-Insua, Y; Vieito-Villar, M, 2015) |
| "We investigated the synergistic effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor plus radiation therapy, on the proliferation and survival of gastric cancer (GC) and colorectal cancer (CRC) cells." | 3.81 | Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor. ( Kang, WK; Kim, J; Lee, I; Lim, T, 2015) |
| " The aim of this study is to evaluate the efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy in advanced gastric adenocarcinoma patients in China." | 3.80 | Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation. ( Bai, L; Jin, Y; Li, YH; Luo, HY; Qiu, MZ; Ren, C; Wang, DS; Wang, FH; Wang, ZQ; Wei, XL; Xu, RH; Yang, DJ; Zhang, DS; Zhou, YX, 2014) |
| "Current NCCN guidelines recommend epirubicin (E), cisplatin (C), and 5-fluorouracil (F) as a first-line therapeutic approach for operable gastric adenocarcinoma (GC)." | 3.80 | Molecular profiling in gastric cancer: examining potential targets for chemotherapy. ( Christians, KK; Eastwood, D; Gamblin, TC; George, B; Johnston, FM; Miura, JT; Thomas, J; Tsai, S; Turaga, KK, 2014) |
| "The aim of the present study was to evaluate the change of thymidine phosphorylase (TP) activity in gastric adenocarcinoma and adjacent tissue upon the intraarterial administration of 5-fluorouracil (5-FU)." | 3.80 | The influence of 5-fluorouracil on activity of thymidine phosphorylase in gastric adenocarcinoma and normal adjacent tissue. ( Dumanskiy, Y; Khomutov, E; Matviyenko, A; Stashkevych, M; Zinkovych, I, 2014) |
| "The efficacy of triple-drug combination regimens such as epirubicin, oxaliplatin and capecitabine (EOX) is superior to standard cisplatin/5-fluorouracil, but considerable toxicity needs to be taken into account in patients with upper gastrointestinal adenocarcinoma." | 3.79 | Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma. ( Asari, R; Ba-Ssalamah, A; Birner, P; Datler, P; Hejna, M; Pluschnig, U; Preusser, M; Schoppmann, SF; Schwameis, K; Zacherl, J, 2013) |
| " This study was to investigate whether downregulation of Bcl-2 expression by small interfering RNA (siRNA) against the Bcl-2 gene would enhance the apoptosis and sensitivity of gastric adenocarcinoma SGC-7901 cell to 5-Fluorouracil." | 3.79 | Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells. ( Liu, H; Liu, Y; Wu, FR; Xia, Q; Yu, DF, 2013) |
| "To evaluate the efficacy and safety of docetaxel plus oxaliplatin and capecitabine (DOX) in the first line treatment of advanced gastric adenocarcinoma." | 3.79 | Efficacy and safety of docetaxel plus oxaliplatin and capecitabine in the first line treatment of advanced gastric adenocarcinoma. ( Liu, Y; Ma, T; Shi, M; Xi, W; Yang, L; Ye, Z; Zhang, J; Zhu, Z, 2013) |
| " In this study, we had investigated the synergistic effects of low dose fluorouracil (5-Fu) and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells and explored the potential mechanisms." | 3.79 | The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells. ( He, J; Huang, M; Huang, Y; Ren, D; Yi, C; Zhao, F; Zhu, H, 2013) |
| "Capecitabine is one of the most effective oral chemotherapeutic drugs for advanced or recurrent colorectal cancer and gastric cancer." | 3.79 | [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy]. ( Amemori, K; Koike, C; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamada, T; Yamagiwa, K, 2013) |
| "All 92 patients received 5-fluorouracil (5-FU)-based chemotherapy; 40 of the patients had massive ascites, 34 had inadequate oral intake, and the remaining 18 had both conditions." | 3.78 | First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer. ( Hamaguchi, T; Iwasa, S; Kato, K; Nakajima, TE; Nakamura, K; Shimada, Y; Takashima, A; Yamada, Y, 2012) |
| "The aim of this study was to determine the pathological complete remission (pCR) rate, and its relationship to clinical outcome, in patients with adenocarcinoma of the stomach or oesophagogastric junction receiving preoperative 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) every 2 weeks." | 3.78 | Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. ( Al-Batran, SE; Altmannsberger, HM; Atmaca, A; Bruch, HP; Homann, N; Jäger, E; Luley, K; Noack, F; Pauligk, C; Werner Kraus, T, 2012) |
| "The aim of this retrospective study was to evaluate the efficacy and safety of weekly high-dose 5-fluorouracil (5-FU)/folinic acid (FA) as 24-h infusion (AIO regimen) plus irinotecan in patients with histologically proven metastatic gastroesophageal adenocarcinoma (UICC stage IV)." | 3.77 | Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b ( Albrecht, H; Boxberger, F; Busse, D; Golcher, H; Hahn, EG; Hohenberger, W; Janka, R; Konturek, PC; Koucky, K; Männlein, G; Neurath, MF; Ostermeier, N; Reulbach, U; Schildberg, C; Siebler, J; Wein, A; Wolff, K, 2011) |
| "A retrospective analysis was carried out to evaluate toxicity and efficacy of the combination chemotherapy of docetaxel, cisplatin and 5-fluorouracil (DCF) plus granulocyte colony-stimulating factor prophylaxis (G-CSF) in patients with metastatic gastric and gastroesophageal junction adenocarcinoma." | 3.77 | Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: experience at the Medical University of Vienna. ( Ba-Ssalamah, A; Bojic, M; Datler, P; Hejna, M; Maresch, J; Pluschnig, U; Schoppmann, SF; Thallinger, CM; Zacherl, J, 2011) |
| " Perioperative treatment with epirubicin, cisplatin, and 5-fluorouracil combination chemotherapy and surgery is considered the standard treatment of locally advanced gastric adenocarcinoma." | 3.77 | Complete pathologic response with combination oxaliplatin and 5-fluorouracil chemotherapy in an older patient with advanced gastric cancer. ( Amini, A; Sanati, H, 2011) |
| "5-fluorouracil was administered at a daily dose of 450 mg/m2 followed by folinic acid 200 mg/m2 for four consecutive days every four weeks." | 3.77 | Is the combination of 5-fluorouracil and folinic acid effective in advanced gastric carcinoma? Results of a pilot study and review of the literature. ( Briassoulis, E; Klouvas, G; Nicolaides, C; Pavlidis, N, 1994) |
| "Mitomycin has also demonstrated efficacy when given in combination with doxorubicin and in the three-drug regimen FAM (5-fluorouracil/doxorubicin/mitomycin)." | 3.77 | Mitomycin therapy in gastric cancer. ( Macdonald, JS; Schnall, S, 1993) |
| "5-fluoro-uracil (FU) is a common agent in postoperative chemoradiation in gastric adenocarcinoma." | 3.76 | A retrospective comparison of concurrent 5-fluorouracil or oral UFT in postoperative chemoradiation for gastric adenocarcinoma. ( Akboru, H; Bati, Y; Isikli, L; Unsal, M; Yoney, A, 2010) |
| "We performed retrospective study in order to compare oxaliplatin, leucovorin, and fluorouracil (FOLFOX) versus irinotecan, leucovorin, and fluorouracil (FOLFIRI) in recurred or metastatic gastric adenocarcinoma." | 3.76 | [Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma]. ( Jeong, HY; Kang, SH; Kim, JI; Kim, SH; Lee, BS; Moon, HS; Sung, JK, 2010) |
| " In the first phase III study, the ToGA trial, HER2-positive patients with advanced gastroesophageal and gastric adenocarcinoma were randomized to receive 5-fluorouracil/capecitabine and cisplatin either alone or in combination with trastuzumab." | 3.76 | Targeted HER2 treatment in advanced gastric cancer. ( Jørgensen, JT, 2010) |
| "Hand-foot syndrome (HFS), the most common toxicity of capecitabine, is characterized by tingling, numbness, pain, erythema, dryness, rash, swelling, increased pigmentation, and/or pruritus of the palmar and/or plantar surfaces of the hands and/or feet." | 3.76 | Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. ( Abali, H; Disel, U; Gürkut, O; Kaleağasi, H; Mertsoylu, H; Ozyilkan, O; Saif, MW, 2010) |
| "Survival and recurrence patterns of 91 patients with adenocarcinoma of the stomach who had received surgery followed by radiotherapy combined with fluorouracil and leucovorin (n = 5), capecitabine (n = 39), or capecitabine and cisplatin (n = 47) were analyzed and compared with survival and recurrence patterns of 694 patients from the DGCT (D1, n = 369; D2, n = 325)." | 3.76 | Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. ( Bakker, B; Boot, H; Cats, A; Dikken, JL; Hartgrink, HH; Jansen, EP; Kranenbarg, EM; Peeters, KC; Putter, H; van de Velde, CJ; Verheij, M, 2010) |
| " To investigate the molecular basis for the effect of TP on the metabolic process and the anticancer effect of 5-fluorouracil (5-FU), human gastric carcinoma AZ521 cells and epidermoid carcinoma KB cells were transfected with TP cDNA, and AZ521/TP and KB/TP were cloned." | 3.76 | The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells. ( Akiyama, S; Che, XF; Furukawa, T; Ikeda, R; Kanekura, T; Kanzaki, T; Mataki, H; Matsushita, S; Minami, K; Miyadera, K; Nishizawa, Y; Tabata, S; Tajitsu, Y; Takeda, Y; Ushiyama, M; Yamada, K; Yamamoto, M, 2010) |
| "We investigated the efficacy and toxicity of metronomic capecitabine administered at a fixed dose of 1,000 mg daily in three elderly or poor performance status patients with advanced colorectal cancer (CRC) and gastric cancer." | 3.75 | To widen the setting of cancer patients who could benefit from metronomic capecitabine. ( Biasco, G; Brandi, G; Di Cicilia, R; Maleddu, A; Nannini, M; Nobili, E; Pantaleo, MA, 2009) |
| "Conflicting data exist regarding the relevance of high-frequency microsatellite instability (MSI-H) for predicting the prognosis and benefits of 5-fluorouracil (5-FU)-based chemotherapy." | 3.75 | Chemosensitivity and survival in gastric cancer patients with microsatellite instability. ( Ando, K; Kakeji, Y; Maehara, Y; Masuda, T; Morita, M; Ohgaki, K; Oki, E; Yoshida, R; Zhao, Y, 2009) |
| "A case of gastric endocrine cell carcinoma successfully treated by FU (5-FU/UFT) +irinotecan (CPT-11) adjuvant therapy against recurrent metastases is reported with some discussion." | 3.75 | [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases]. ( Hara, T; Hiramatsu, K; Hosoya, J; Kato, K; Kimura, A; Kojima, T; Machiki, Y; Otsuji, H; Sakuragawa, T; Tanaka, H; Tsuchiya, T; Yoshida, K, 2009) |
| "Prior to 1974 gastric cancer was considered refractory to chemotherapy." | 3.75 | The role of anthracyclines in the treatment of gastric cancer. ( Green, M; Muggia, F; Wadler, S, 1985) |
| "For patients with locally advanced gastric cancer, combined-modality therapy has resulted in long-term survival for approximately 15% of cases." | 3.75 | The role of chemotherapy in the management of gastric and pancreatic carcinomas. ( Schein, PS, 1985) |
| "To compare the efficacy and tolerability of the regimen FOLFOX [1eucovorin (LV), 5-fluorouracil (5-Fu) and oxaliplatin] and the regimen PLF (Paclitaxel, leucovorin and 5-Fu) for treatment of advanced gastric adenocarcinoma." | 3.74 | [FOLFOX versus PLF regimen in treatment of advanced gastric adenocarcinoma]. ( Huang, Y; Lin, TY; Rong, J; Xiao, J; Ye, S; Zhai, LZ, 2008) |
| " This article presents the case of a 69-year-old African American man with a gastric adenocarcinoma status post gastrectomy who received 5-fluorouracil (5-FU) plus leucovorin for 5 days, to be followed by radiation plus capecitabine given 5 days per week for 5 weeks, and then 8 weeks of capecitabine monotherapy." | 3.74 | Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity? ( Saif, MW; Sandoval, A, 2008) |
| "Docetaxel, capecitabine and 5-fluorouracil have been shown to be active in the treatment of metastatic gastric adenocarcinoma." | 3.74 | Chemoimmunotherapy in the treatment of metastatic gastric cancer. ( Amiconi, G; Blasio, AD; Candeloro, G; Cesta, A; Necozione, S; Rea, S; Recchia, F; Saggio, G, 2007) |
| " Here human gastric adenocarcinoma (AGS) cells were treated with lethal dose 10 and 50 (LD(10) and LD(50)), determined by using the MTT assay, of the three drugs, epirubicin, 5-fluorouracil and cisplatin, commonly used in the treatment of patients with gastro-oesophageal cancer." | 3.74 | [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil. ( Park, KG; Smith, TA; Suttie, SA, 2007) |
| " Therefore, we analyzed expression and prognostic significance of E2F-1 along with thymidylate synthase (TS) in R(0)-resected gastric adenocarcinoma patients, who underwent adjuvant chemoradiation therapy with 5-fluorouracil (5-FU) and leucovorin." | 3.74 | Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. ( Heo, JS; Kang, WK; Kim, KM; Kim, S; Lee, I; Lee, J; Lim, DH; Lim, HY; Lim, T; Noh, JH; Park, CK; Park, JO; Park, YS; Sohn, TS, 2008) |
| " Retention of ascites, peritoneal dissemination, obstructive jaundice and right hydronephrosis appeared in June, 2003, and we started combination chemotherapy with paclitaxel and 5-fluorouracil." | 3.73 | [A case report of recurrent gastric cancer in which combination chemotherapy with paclitaxel and 5-fluorouracil made for successful biliary stenting and improvement in QOL]. ( Miyade, Y; Ninomiya, M; Ohtani, S; Shimizu, Y; Sugiyama, S, 2005) |
| "To investigate the inhibitive effects of matrine and 5-fluorouracil (5-FU) on the growth of human gastric adenocarcinoma cell line SGC-7901 when transplanted into nude mice and to investigate the bone marrow toxicity of these compounds." | 3.73 | Synergistic effects of matrine and 5-fluorouracil on tumor growth of the implanted gastric cancer in nude mice. ( Fu, H; Hu, MJ; Qiao, MM; Wu, YL; Zeng, H; Zhang, S; Zhang, YP, 2005) |
| "To examine the prevalence of anemia and its impact of hemoglobin (Hgb) levels in predicting outcomes of 5-fluorouracil (FU)-based first-line chemotherapy for patients with advanced gastric cancer (AGC)." | 3.73 | Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. ( Bang, SM; Cho, EK; Jung, CW; Kang, WK; Kim, K; Kim, S; Kim, WS; Lee, J; Lee, JH; Lee, SH; Park, JO; Park, K; Park, SH; Park, YS; Shin, DB, 2006) |
| "We describe our experience with a patient who had undifferentiated gastric carcinoma with extensive lymph node metastasis, including para-aortic lymph-node metastasis, and had a complete response to induction therapy with methotrexate plus 5-fluorouracil (sequential therapy with MTX, 5-FU, and Leucovorin) and secondary treatment with oral TS-1." | 3.73 | [Stage IV gastric cancer patient who underwent palliative gastrectomy showing complete response to induction therapy with methotrexate plus 5-fluorouracil and secondary treatment with oral TS-1]. ( Hiramatsu, K; Mizukami, Y; Momiyama, M; Nagashima, T; Niimi, K; Suzuki, M, 2005) |
| "We report a 37-year-old patient with gastric cancer who suffered two distinct episodes of generalized tonic-clonic seizures during ongoing chemotherapy with cisplatin and 5-fluorouracil." | 3.73 | [Relapsing reversible posterior leukoencephalopathy after chemotherapy with cisplatin and 5-fluorouracil]. ( Aktas, O; Dieste, FJ; Kreitsch, P; Paul, F; Vogel, HP; Zipp, F, 2006) |
| "Retrospectively, we analysed 23 consecutive patients who were treated with epirubicin, cisplatin and oral capecitabine for inoperable or metastatic oesophagogastric adenocarcinoma during 2002 and 2003." | 3.73 | Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma. ( Boot, H; Corporaal, S; Legdeur, MC; Russel, MG; Smit, WM; van der Palen, J, 2006) |
| " In our report, a middle age patient suffering from locally advanced gastric cancer with peritonitis carcinomatosa and ascites was treated with neoadjuvant chemotherapy (DCF: docetaxel, cisplatin, fluorouracil protocol) successfully, as at the restaging examination total tumor regression was found." | 3.73 | [Complete regression after neoadjuvant chemotherapy in locally advanced gastric cancer causing peritonitis carcinomatosa--a case report]. ( Ember, A; Esik, O; Horváth, OP; Kalmár, K; Papp, A; Yousuf, AF, 2006) |
| "To evaluate the therapeutic effects of hydroxycamptothecin (H) combined with leucovorin (L), fluorouracil (F) and cisplatin (P) on advanced cancer of gastric cardia and colorectal cancer." | 3.72 | [The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer]. ( Jin, ML; Li, J; Li, Y; Shen, L; Yang, BQ; Zhang, XD, 2003) |
| " The mean values of 5-fluorouracil (5-FU) concentrations in ascites of the S-1 group at 1-4 h were 414-580 ng/ml (n=5), and those of FT group were 70-87 ng/ml (n=5), with significant differences between the two groups at each observation time." | 3.72 | Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer. ( Hirakawa, K; Nakata, B; Yamagata, S, 2004) |
| "We report a case of diffuse type advanced hepatocellular carcinoma (HCC), which was successfully treated by a combination therapy of interferon-alpha (IFN) and 5-fluorouracil (5-FU)." | 3.72 | [Intrahepatic arterial chemotherapy with 5-fluorouracil and intramuscular interferon-alpha for a patient with diffuse type of hepatocellular carcinoma]. ( Fujiwara, H; Hagiwara, A; Ichikawa, D; Kikuchi, S; Ochiai, T; Okamoto, K; Otsuji, E; Sakakura, C; Sonoyama, T; Ueda, Y; Yamagishi, H, 2004) |
| " To evaluate the therapeutic effectiveness and safety of oxaliplatin combined with 5-fluorouracil and leucovorin on the patients with gastric carcinoma after palliative gastric resection, we analyzed all of the cases of gastric adenocarcinoma undergone palliative gastric resection in our Cancer Center in recent years." | 3.72 | [Palliative surgery combined with oxaliplatin-based chemotherapy in treatment of patients with advanced gastric cancer]. ( Chen, YB; Guan, YX; Li, W; Li, YF; Sun, XW; Xu, DZ; Zhan, YQ, 2004) |
| "We report a case in which weekly paclitaxel (TXL) administration was effective for gastric cancer with malignant ascites." | 3.71 | [Effective weekly paclitaxel administration for gastric cancer with malignant ascites--a case report]. ( Ezaki, T; Ikegami, T; Ishida, T; Itoh, H; Kawaguchi, K; Kido, A; Nose, N; Sasaki, Y; Shimokawa, H, 2002) |
| "We have experienced a case of advanced gastric cancer with para-aortic lymph node metastasis effectively treated by neoadjuvant continuous low dosage 5-fluorouracil and cisplatin (FP regimen)." | 3.71 | Advanced gastric cancer effectively treated by neoadjuvant continuous low-dosage 5-fluorouracil and cisplatin (FP regimen): a case report. ( Aoyagi, K; Koufuji, K; Miyagi, M; Murakami, N; Shirouzu, K; Takeda, J; Yano, S, 2001) |
| "At increasing use of high-dose 5-fluorouracil-based chemotherapy for metastatic colorectal and gastric cancer complicated drug-induced colitis is observed more frequently." | 3.71 | [5-Fluorouracil-induced colitis--a review based upon consideration of 6 cases]. ( Hotz, J; Madisch, A; Marquard, F; Stolte, M; Wiedbrauck, F, 2002) |
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| "The incidence of nausea and vomiting or anorexia was investigated in 16 outpatients receiving oral antimetabolites such as 5-FU (fluorouracil) as chemotherapy, during a maximum observation period of 28 days." | 3.70 | [Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets]. ( Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T, 2000) |
| "Epirubicin, cisplatin and continuous 5-fluorouracil (5-FU) infusion (ECF) has been reported to result in high clinical response rates in advanced gastro-oesophageal adenocarcinoma and is currently the 'gold standard' chemotherapy regimen for this tumour site." | 3.70 | Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma. ( Banerji, U; Geh, JI; Glynne-Jones, R; Harrison, RA; Kwok, QS; Livingstone, JI; Mitchell, IC; Townsend, ER, 2000) |
| "We report a case of double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin." | 3.69 | [A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin]. ( Akiyama, S; Hibi, K; Ito, K; Kasai, Y; Kondo, K; Nonami, T; Takagi, H, 1995) |
| " Here we have examined human gastric/esophageal adenocarcinoma cell lines for p53 mutational status, chemosensitivity to 5-fluorouracil, mitomycin C, and cis-dichlorodiammineplatinum(II), alteration in p53 levels following exposure of cells to these drugs, and the mechanisms involved in regulating p53 levels." | 3.69 | The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. ( Albino, AP; Altorki, NK; Blundell, ML; de Oliveira, AR; Kelsen, DP; Lai, L; Loganzo, F; Maslak, P; Nabeya, Y; Schwartz, GK, 1995) |
| "The purpose of this study was to assess the efficacy of verapamil (20 microM) and hyperthermia (42 degrees C) as modifiers of 5-fluorouracil (5-FU), used at different concentrations, in inhibiting the growth of gastric adenocarcinoma cells." | 3.69 | Antitumour activity of 5-fluorouracil, verapamil and hyperthermia against human gastric adenocarcinoma cell (AGS) in vitro. ( Brenner, RV; Buras, RR; Evans, SR; Nauta, RJ; Shabahang, M; Shchepotin, IB, 1994) |
| "In 62 human gastric carcinomas, the expression of GST pi was immunohistochemically evaluated, and sensitivity to the anticancer drugs, cisplatin (CDDP), doxorubicin (DXR) aclacinomycin A (aclarubicin), (ACR), 5-fluorouracil (5-FU), mitomycin C (MMC) and carboquone (carbazilquinon) (CQ) was examined using the in vitro succinate dehydrogenase inhibition test." | 3.69 | Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin. ( Adachi, Y; Baba, H; Endo, K; Kuwano, M; Maehara, Y; Okuyama, T; Sugimachi, K, 1994) |
| "After a loading dose of 4 x 90 mg folinic acid orally, a continuous infusion of 5-fluorouracil 500 mg/sqm/day for 5 days with concommitant folinic acid 6 x 60 mg/day orally, was administered to 29 consecutive patients with metastatic adenocarcinoma of the esophagus or esophagogastric junction area." | 3.69 | 5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group. ( Kok, TC; Splinter, TA; van der Gaast, A, 1996) |
| " We report on a clinical deterioration, yet near-complete pathological and radiological response to a combination of cisplatin and fluorouracil in a patient with locally-advanced gastric adenocarcinoma." | 3.69 | Paradoxical clinical deterioration despite near-complete pathological response to neoadjuvant chemotherapy for locally advanced gastro-oesophageal adenocarcinoma. ( Crellin, A; Guillou, PJ; Hassan, S; Macadam, R; Reynolds, JV; Sadek, SA; Somers, SS; Windsor, AC, 1995) |
| "The aim of this study was to evaluate the effect of 5-fluorouracil (5-FU) and folinic acid on liver function and bile production in patients with recurrent gastric cancer and jaundice." | 3.69 | Relief of jaundice by 5-fluorouracil and folinic acid in patients with recurrent gastric cancer. ( Akiyama, H; Kajiyama, Y; Kinoshita, Y; Tsurumaru, M; Tsutsumi, K; Udagawa, H, 1996) |
| " In order to evaluate the HDRA with the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide end point for clinical use, chemosensitivity to mitomycin C, doxorubicin, 5-fluorouracil, and cisplatin of 107 advanced gastric and 109 advanced colorectal cancers was determined in vitro in a correlative clinical trial." | 3.69 | Clinical applications of the histoculture drug response assay. ( Furukawa, T; Hoffman, RM; Kubota, T, 1995) |
| "Various factors, including thymidylate synthase, thymidine kinase, 5-fluorouracil phosphorylation and degradation pathways, folate concentrations, and the stability of ternary complex, which influence thymidylate synthase inhibition rate of fluoropyrimidines, were studied in 87 human adenocarcinoma tissues." | 3.68 | Ternary complex formation and reduced folate in surgical specimens of human adenocarcinoma tissues. ( Dohden, K; Ohmura, K; Watanabe, Y, 1993) |
| "Twenty-four patients with advanced or relapsed gastric or colorectal cancer were treated with a combination of 5-fluorouracil (5-FU), leucovorin (LV) and interferon-alpha (IFN-alpha)." | 3.68 | [Treatment of advanced gastric and colorectal cancer with 5-FU, leucovorin and interferon-alpha]. ( Ezaki, K; Hatanaka, T; Hobara, R; Iwase, K; Kawase, K; Nakano, H; Ohara, K; Okamoto, M; Ono, Y; Tsujimura, T, 1993) |
| "Sequential therapy consisting of methotrexate (MTX) and 5-FU was performed together with the administration of heparin and FOY in 10 cases of gastric cancer with disseminated intravascular coagulation (DIC) causing systemic bone metastasis." | 3.68 | [Sequential MTX and 5-FU therapy of gastric cancer with systemic bone metastasis and disseminated intravascular coagulation]. ( Ibuka, T; Imai, K; Ishiwata, J; Kobayashi, T; Monma, K; Ohno, T; Onozawa, Y; Sakaki, N; Sasaki, T; Tabata, I, 1992) |
| " UFT (400 mg/day in terms of tegafur) was given preoperatively for 1-6 days in 6 patients with gastric cancer and 13 with colorectal cancer." | 3.68 | [Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT]. ( Inaba, S; Kawai, K; Kondo, Y; Ogino, A; Tsuchiya, K; Ueda, Y; Umeda, T, 1992) |
| "A 63-year-old male had undergone combination chemotherapy including adriamycin, cisplatin, mitomycin C, 5-fluorouracil and vindesine for six months for double cancer of esophagus and stomach." | 3.68 | [Chemotherapy-associated hemolytic uremic syndrome--a case report]. ( Kanamaru, R; Kikuchi, H, 1992) |
| "Experimental chemotherapy with 5-fluorouracil (5-FU; 60 mg/kg), 1-hexylcarbamoyl-5-fluorouracil (HCFU; 70 mg/kg), 3-(3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl)-1-ethoxym ethyl-5- fluorouracil (BOF-A2; 30 mg/kg) and UFT (20 mg/kg as tegafur with uracil at a molar ratio of 1:4) was performed using human gastric (H-111) and colon (Co-4) carcinoma strains in nude mice." | 3.68 | Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition. ( Abe, O; Arisawa, Y; Fujita, S; Ishibiki, K; Josui, K; Kodaira, S; Kubota, T; Mabuchi, K; Suto, A; Yamamoto, T, 1991) |
| "Bilateral total corneal epithelial erosion and descement folds are reported as toxic side effects of 5-fluorouracil in a patient with end stage carcinoma of the stomach." | 3.68 | Bilateral total corneal epithelial erosion as a side effect of cytotoxic therapy. ( Alhalel, A; Avni, I; Brener, H; Hirsh, A; Weiss, A, 1990) |
| "Eighty-nine patients with advanced gastric carcinoma were treated with a combination chemo-immunotherapy regimen that consisted of active immunotherapy with Vibrio cholerae neuraminidase (VCN) treated autologous tumor cells admixed with BCG and drugs including cyclophosphamide, mitomycin C (MMC) and 5-fluorouracil, followed by long term tegafur (FT) and immunomodulators." | 3.67 | Combination chemoimmunotherapy for advanced gastric carcinoma. ( Akiyoshi, T; Arinaga, S; Kawaguchi, M; Koba, F; Miyazaki, S; Tsuji, H; Wada, T, 1984) |
| "Twenty-two previously untreated patients with advanced gastric adenocarcinoma were treated with a modification of the original 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin C (FAM) combination chemotherapy." | 3.67 | Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin C (modified FAM). ( Cohen, Y; Epelbaum, R; Haim, N; Robinson, E, 1984) |
| "A 68-year-old man was treated with FAM (5-fluorouracil, doxorubicin [Adriamycin], mitomycin-C) for metastic gastric adenocarcinoma." | 3.67 | Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma. ( Kerwin, DM; Smith, FP; Tsou, E; Waldhorn, RE, 1984) |
| "5-Fluorouracil(5-FU)is a widely used antitumor agent for treating patients with adenocarcinoma of gastroenterial tract and breast following intravenous or oral administration." | 3.67 | [5-Fluorouracil concentration in various tissues from cancer patients after oral administration of 5-fluorouracil]. ( Hashimoto, I; Kashi, Y; Mikami, J; Nakamura, T; Nakanishi, Y; Nishidai, H; Sawada, Y; Yoshimoto, M, 1984) |
| " A total of 37 patients with advanced measurable adenocarcinoma of the stomach were treated with Adriamycin, methotrexate, and 5-fluorouracil (AMF)." | 3.67 | Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. ( Abbruzzese, JL; Ajani, JA; Boman, BM; Faintuch, JS; Goudeau, P; Kanojia, MD; Levin, B, 1989) |
| "A total of 23 patients with advanced gastric adenocarcinoma were treated with a combination of moderate-dose methotrexate (MDMTX), 250 mg/m2 i." | 3.67 | Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma. ( Dickinson, R; Levi, J; Milliken, S; Presgrave, P; Woods, R, 1989) |
| " Following our former report in which the combination effects of mitomycin C (MMC) and 5'-deoxy-5-fluorouridine (5'-DFUR) were clarified, combined applications of 4 drugs, vindesine (VDS), methotrexate (MTX), cisplatin (CDDP) and 5'-DFUR against 3 lines of human breast cancer (H-62, H-31, H-71), and one line each of gastric cancer (H-55) and colon cancer (H-110) xenografted into nude mice were evaluated in comparison with CAF (cyclophosphamide, adriamycin and 5-FU) therapy which is commonly used for breast cancer." | 3.67 | [Combination chemotherapy with 3 or 4 drugs on human breast and gastrointestinal cancer xenografts in nude mice (II)]. ( Fujita, F; Fujita, M; Inaba, H; Sakamoto, Y; Shimozuma, K; Taguchi, T, 1987) |
| "A 55-year-old female, in which an unresectable Borrmann II-type gastric cancer (moderately differentiated adenocarcinoma) extending from vicinity of the cardia to the lower portion of the corpus, with direct invasion into the pancreas and extensive lymph node metastases, confirmed by laparotomy, was treated postoperatively by 3 courses of chemotherapy with cisplatinum in combination with mitomycin C and 5-fluorouracil." | 3.67 | Cure of advanced gastric cancer by combined chemotherapy with cisplatinum, mitomycin C, and 5-fluorouracil. ( Azuma, S; Furuta, T; Kawata, R; Ohashi, H; Saji, S; Sakata, K; Shimokawa, K; Suzuki, M; Tanemura, H, 1988) |
| "Between January 1981 and December 1986, 20 patients with adenocarcinoma of the esophagus and gastroesophageal junction were entered into a prospective study involving combined radiation therapy and chemotherapy (5-fluorouracil [5-FU] and mitomycin) as primary management." | 3.67 | Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction. ( Coia, LR; Engstrom, PF; Paul, AR, 1988) |
| "Fourteen patients with advanced gastric adenocarcinoma were treated with continuous 5-fluorouracil (5-FU) infusion, 300 mg/m2/day, through an indwelling central venous catheter; 13 were evaluable for response." | 3.67 | Continuous 5-fluorouracil infusion in advanced gastric carcinoma. ( Anderson, T; Ausman, R; Beatty, P; Chitambar, C; Hansen, R; Moynihan, T; Quebbeman, E; Ritch, P; Vukelich, M, 1988) |
| "We report the results of an expanded trial of 5-fluorouracil (FUra) combined with high-dose folinic acid for treatment of patients with advanced colorectal or gastric adenocarcinoma." | 3.67 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Benavides, M; Chollet, P; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1987) |
| "A 59-year-old man undergoing systemic 5-fluorouracil treatment for metastatic adenocarcinoma of the stomach developed ocular lesions consisting of bilateral conjunctival ulcers and ulcerative blepharitis leading to ankyloblepharon." | 3.67 | Ankyloblepharon associated with systemic 5-fluorouracil treatment. ( Helm, CJ; Insler, MS, 1987) |
| "Twenty-five patients with locally advanced but resectable adenocarcinoma of the stomach were given concomitant postoperative radiotherapy to the tumor bed and chemotherapy with 5-Fluorouracil (5-FU)." | 3.67 | Combined 5-fluorouracil (5-FU) and radiation therapy following resection of locally advanced gastric carcinoma. ( Gez, E; Sulkes, A; Weshler, Z; Yablonsky-Peretz, T, 1986) |
| "The cytotoxic effects of three anticancer drugs, methotrexate (MTX), 5-fluorouracil (5-Fu) and oridonin (Rub A), were investigated using a human gastric adenocarcinoma cell line (MGc80-3) and a human esophageal cancer cell line (CaEs-17) by means of colony-forming assay, dye exclusion test, measurement of incorporation of 3H-thymidine into DNA and examination of mitotic index." | 3.67 | [Comparison of in vitro assays for the cytotoxic effect of anticancer drugs]. ( Li, PY; Li, XT; Lin, C, 1986) |
| "During the past three years we have entered 54 patients with gastric adenocarcinoma into a clinical trial of oral administration of injectable 5-fluorouracil (5-Fu)." | 3.67 | Adjuvant chemotherapy of gastric carcinoma: a pilot study of oral administration of injectable 5-fluorouracil. ( Wu, YF, 1985) |
| "Twenty patients (15 male, 5 female) with nonresectable gastric adenocarcinoma were treated with FAP (5-fluorouracil 300 mg/m2 IV on days 1-5, adriamycin 50 mg/m2 IV on day 1, cisplatin 20 mg/m2 IV on days 1-5)." | 3.67 | Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer. ( Burghouts, JT; Hillen, HF; Hoogendoorn, GJ; Scheerder, H; van Dam, FE; van der Vegt, SG; Wagener, DJ; Wobbes, T; Yap, SH, 1985) |
| "Twenty-seven patients with colorectal adenocarcinoma, (12) non-small cell bronchogenic carcinoma, (11) gastric adenocarcinoma (3), and adenocarcinoma of unknown primary lesion (1) were treated with the combination of thymidine (TdR), 5-fluorouracil (FU), and N-phosphonacetyl-L-aspartic acid (PALA)." | 3.67 | Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study. ( Bedikian, A; Benvenuto, JA; Bodey, GP; Chiuten, DF; Freireich, EJ; Loo, TL; Miller, A; Valdivieso, M, 1985) |
| "In a multicentre trial of adjuvant chemotherapy in gastric adenocarcinoma, a number of patients developed chronic haemolysis and renal failure following long-term treatment with 5-fluorouracil and mitomycin-C." | 3.66 | Intravascular haemolysis and renal impairment after blood transfusion in two patients on long-term 5-fluorouracil and mitomycin-C. ( Brookes, VS; Fielding, JW; Howell, A; Jones, BG; Newman, CE, 1980) |
| "Following gastrectomy for locally advanced adenocarcinomas, three patients developed microangiopathic hemolytic anemia and renal failure shortly after completing courses of adjuvant chemotherapy with mitomycin and 5-FU." | 3.66 | Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema: a chemotherapy-induced syndrome. ( Band, PR; Bettez, P; Giroux, L; Gruber, J; Jolivet, J; Laurin, S, 1983) |
| "Twenty-nine patients with advanced gastric adenocarcinoma were treated with 72-hour continuous intravenous infusion of 5-fluorouracil (30 mg/kg/24 hr) at 2-week intervals." | 3.66 | Chemotherapy of advanced gastric cancer with 72-hour continuous intravenous 5-fluorouracil infusion at 2-week intervals. ( MacDonald, WC; Shah, A, 1983) |
| "Thirty-five patients with advanced-stage metastatic or unresectable gastric adenocarcinoma were given combination chemotherapy consisting of fluorouracil, doxorubicin, and 1,3-bis (2-chlorbethyl)-1-nitrosourea." | 3.66 | Improved combination chemotherapy in advanced gastric cancer. ( Aroney, RS; Dalley, DN; Levi, JA, 1979) |
| "In the present paper a test model was used to examine if human adenocarcinomas of the colon and the stomach are heterogenous as regards the sensitivity to cytosine arabinoside, melphalan, vinblastine sulphate, amethopterin and 5-fluorouracil in vitro." | 3.65 | Heterogeneity of human adenocarcinomas of the colon and the stomach as regards sensitivity to cytostatic drugs. ( Dencker, H; Håkansson, L; Tropé, C, 1975) |
| " 5-Fluorouracil (5 FU) is the first chemotherapeutic agent found to have a significant effect on gastrointestinal adenocarcinoma." | 3.64 | PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER. ( HART, GD, 1964) |
| "We herein investigated the association between early tumor shrinkage (ETS) and depth of response (DpR) and clinical outcomes in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil (bDCF) using data from the JCOG0807, a phase I/II trial of bDCF as first-line chemotherapy for metastatic esophageal cancer." | 3.30 | Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807. ( Chin, K; Doki, Y; Fujitani, K; Fushiki, K; Hironaka, S; Kato, K; Kitagawa, Y; Kojima, T; Kusaba, H; Matsushita, H; Mizusawa, J; Okuno, T; Seki, S; Tomori, A; Tsubosa, Y; Tsushima, T; Ura, T, 2023) |
| " Treatment-related adverse events (TRAEs) occurred more frequently in group A vs." | 3.30 | A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10). ( Choi, IS; Han, HS; Kim, JW; Kim, KH; Kim, MJ; Ko, YH; Koh, SA; Koo, DH; Lee, KW; Lee, SS; Nam, BH; Park, JH; Ryu, MH; Sohn, BS; Zang, DY, 2023) |
| "Advanced gastric cancer is associated with poor survival despite chemotherapy." | 3.30 | Study of Efficacy and Toxicity of Capecitabine Maintenance After Response to Docetaxel, Cisplatin, and 5-Fluracil-Based Chemotherapy in Advanced Carcinoma Stomach. ( Chaudhari, K; Doval, DC; Goel, V; Goyal, P; Koyyala, VPB; Maheshwari, U; Patnaik, N; Talwar, V, 2023) |
| " Currently, no trials have investigated the impact of perioperative immunotherapy in combination with chemotherapy for resectable gastric or GEJ adenocarcinoma." | 3.11 | Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). ( Brachet, PE; Castera-Tellier, M; Clarisse, B; Corbinais, S; Dorbeau, M; Dos Santos, M; Galais, MP; Guilloit, JM; Le Gallic, C; Leconte, A; Lequesne, J; Parzy, A; Poulain, L; Varatharajah, S; Vaur, D; Weiswald, LB, 2022) |
| " All cases of reported adverse events were recorded and analyzed." | 3.11 | Safety and efficacy of the FLOT regimen in the Polish population - an analysis of the prospective trial. ( Jóźwiak, M; Kolasińska-Ćwikła, A; Marcisz-Grzanka, K; Olesiński, T; Pałucki, J; Samsel, R; Sułkowska, U; Wieszczy, P; Winiarek, M; Wyrwicz, LS, 2022) |
| "To assess S-1 and 5-fluorouracil (5-FU)-related adverse events in patients with advanced gastric cancer and provide focused health care approaches to improve patient compliance and quality of survival." | 3.01 | S-1 and 5-Fluorouracil-related adverse events in patients with advanced gastric cancer: A meta-analysis. ( Chu, T; Hu, Q; Ke, J; Xu, J; Zhang, Z, 2023) |
| " Evaluation of pharmacogenomically dosed perioperative gFOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and UGT1A1 genotype-directed irinotecan) to optimize efficacy while limiting toxic effects may have value." | 2.94 | Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. ( Allen, K; Alpert, L; Catenacci, DVT; Chase, L; de Wilton Marsh, R; Ferguson, MK; Gordon, B; Hart, J; Karrison, T; Kindler, HL; Kipping-Johnson, K; Liao, CY; Lomnicki, S; Markevicius, U; Maron, SB; Moore, K; Narula, S; Peterson, B; Polite, BN; Posner, MC; Prachand, VN; Racette, C; Rampurwala, MM; Roggin, KK; Setia, N; Siddiqui, UD; Turaga, K; Xiao, SY, 2020) |
| "Advanced unresectable gastroesophageal cancers continue to confer a dismal patient prognosis." | 2.94 | Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. ( Ajani, JA; Blum Murphy, M; Palmer, M; Rogers, JE; Trail, A; Xiao, L, 2020) |
| "Using taxane-treated gastric cancer patient biopsies, we demonstrated that absence of drug-target engagement was correlated with clinical taxane resistance." | 2.94 | Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer. ( Betel, D; Cleveland, K; Galletti, G; Giannakakou, P; Gjyrezi, A; Powell, S; Shah, MA; Thakkar, PV; Zhang, C; Zhang, J, 2020) |
| "In patients with advanced gastric cancer refractory to chemotherapy, the treatment options are limited." | 2.94 | A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies. ( Ando, M; Honda, K; Kadowaki, S; Kato, K; Komori, A; Kondoh, C; Masuishi, T; Mitani, S; Muro, K; Narita, Y; Oze, I; Tajika, M; Tanaka, T; Taniguchi, H, 2020) |
| " The purpose of this study was to evaluate the pharmacokinetic (PK), bioequivalence, and safety of a newly developed generic formulation of S-1 compared with the branded reference formulation, in Korean gastric cancer patients." | 2.90 | Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients. ( Cho, K; Cho, S; Gwon, MR; Kang, WY; Kim, BK; Kim, JG; Lee, HW; Ohk, B; Seong, SJ; Sung, YK; Yoon, YR, 2019) |
| "The proportion of elderly patients in esophageal cancer is now growing, but there is a lack of evidence in term of treatment standard for this group of patients, which is what we aim to obtain through this prospective phase III study." | 2.90 | A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. ( Chang, X; Chen, J; Deng, L; Ge, X; Han, C; Li, C; Liang, J; Lin, Y; Ni, W; Pang, Q; Sun, X; Wang, L; Wang, P; Wang, W; Wang, X; Xiao, Z; Zhang, W; Zhao, Y; Zhou, Z, 2019) |
| "10-20% of patients with gastric cancer (GC) have HER2+ tumors." | 2.90 | EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction aden ( Caballero, C; Cats, A; Elme, A; Grabsch, HI; Kang, YK; Lordick, F; Marreaud, S; Martens, U; Mauer, M; Moehler, MH; Mueller, L; Rha, SY; Thuss-Patience, P; Tokunaga, M; Wagner, AD, 2019) |
| "PRODIGE 41-BEVANEC is an academic randomized, phase II study designed to evaluate the efficacy of bevacizumab in combination with FOLFIRI after failure of CT1 in unknown primary NEC and GEP-NEC." | 2.87 | Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study. ( Assenat, E; Bouarioua, N; Cadiot, G; Coriat, R; Dahan, L; Dubreuil, O; Elhajbi, F; Ferru, A; Gangloff, A; Granger, V; Hautefeuille, V; Hentic, O; Kurtz, JE; Le Malicot, K; Lepage, C; Lepere, C; Lievre, A; Lombard-Bohas, C; Malka, D; Roquin, G; Scoazec, JY; Smith, D; Walter, T, 2018) |
| "Gastric cancer is common malignancy and exhibits a poor prognosis." | 2.87 | Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial. ( Al-Batran, SE; Galle, PR; Gehrke, N; Goepfert, K; Grimminger, P; Hegewisch-Becker, S; Maderer, A; Möhler, M; Nagel, M; Schattenberg, JM; Schulz, J; Thomaidis, T; Thuss-Patience, PC, 2018) |
| "Lapatinib with ECF/X was well tolerated, but did not show clear activity in patients with metastatic GC." | 2.87 | Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071). ( Atasoy, A; Caballero, C; Freire, J; John, JMM; Lang, I; Lutz, MP; Maderer, A; Mauer, ME; Moehler, M; Roth, A; Schad, A; Thomaidis, T; Van Cutsem, E, 2018) |
| "A total of 52 patients with advanced gastric cancer were enrolled in this study." | 2.84 | Reduction in Peripheral CD19+CD24hCD27+ B Cell Frequency Predicts Favourable Clinical Course in XELOX-Treated Patients with Advanced Gastric Cancer. ( Li, H; Li, W; Liang, L; Liu, T; Song, D; Zhao, N, 2017) |
| "This phase I/II study was designed to determine the maximum tolerated dose of tivantinib in combination with standard dose FOLFOX for the treatment of patients with advanced solid tumors and to evaluate the safety and efficacy of this combination for patients with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach." | 2.84 | A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach. ( Bendell, J; Flores, M; Hemphill, B; Kurkjian, C; Pant, S; Patel, M; Thompson, D, 2017) |
| "Metastatic gastric cancer patients with stable disease or a better response after the completion of first-line chemotherapy were randomized to oral UFT (360mg/m2 × 2 weeks) every 3 weeks until disease progression/intolerable toxicity or to observation (OBS)." | 2.84 | Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study. ( Chen, Z; Guo, W; Huang, M; Li, J; Li, W; Liu, X; Qiu, L; Wang, H; Zhang, W; Zhao, X; Zhu, X, 2017) |
| "Hyperpigmentation is a rare side effect occurring with 5-FU infusions; it has been reported in 2-5% of patients." | 2.82 | Serpentine Supra-venous Hyperpigmentation "Badge of Courage" in Fight Against Cancer: An Brief Review. ( Basu, D; Chaudhary, K; Goel, V; Jain, A; Narayan, S; Redhu, P; Soni, S; Talwar, V, 2022) |
| "Untreated advanced gastric cancer patients randomly received docetaxel and cisplatin at 60 mg/m(2) (day 1) followed by fluorouracil at 600 mg/m(2)/day (days 1-5; mDCF regimen) or cisplatin at 75 mg/m(2) (day 1) followed by fluorouracil at 600 mg/m(2)/day (days 1-5; CF) every 3 weeks." | 2.82 | Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. ( Ba, Y; Bai, Y; Chen, W; Dai, G; Fan, N; Jiao, S; Li, J; Liu, T; Liu, Y; Ma, D; Qin, S; Shen, L; Shu, Y; Wang, J; Xu, J; Xu, R; Zheng, L, 2016) |
| "Patients with stage IB-IIIC gastric cancer (per the AJCC, 7th edition) who had undergone R0 and D2 gastrectomy were recruited." | 2.82 | A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection. ( Bi, F; Cao, D; Gou, H; Li, Q; Li, Z; Liao, Z; Liu, J; Luo, D; Qiu, M; Shen, Y; Wang, X; Xu, F; Yang, Y; Yi, C; Zhao, Y; Zhu, H, 2016) |
| "For 64 patients with advanced gastric cancer, 30 cases were treated with docetaxel, cisplatin, and 5-fluorouracil (DCF group, control group), and 34 cases were treated with paclitaxel liposome and capecitabine (PC group, experimental group)." | 2.82 | Effects of paclitaxel liposome and capecitabine in the treatment of advanced gastric cancer by clinical observation. ( Lu, M; Wang, J; Wang, T, 2016) |
| "In advanced refractory esophagogastric cancer patients, monotherapy with SUN was associated with good tolerability but limited tumor response." | 2.82 | Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. ( Al-Batran, SE; Galle, PR; Gepfner-Tuma, I; Hegewisch-Becker, S; Kanzler, S; Koenig, J; Kullmann, F; Maderer, A; Moehler, M; Otte, M; Rafiyan, MR; Ruessel, J; Schimanski, CC; Schmoll, HJ; Schollenberger, L; Siveke, JT; Thuss-Patience, PC; von Weikersthal, LF; Weißinger, F; Weusmann, J; Wilke, H, 2016) |
| "Trastuzumab has been approved for use in combination with fluoropyrimidine plus cisplatin for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC)." | 2.80 | Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. ( Chung, IJ; Han, HS; Kang, SY; Kang, YK; Kim, JG; Lee, KH; Park, SR; Park, YS; Ryoo, BY; Ryu, MH; Song, EK; Yoo, C, 2015) |
| "A total of 185 patients with gastric cancer and abdominal lymph node metastasis were enrolled and divided into 2 groups: group A received chemotherapy alone (n = 102); group B received HIFU combined with chemotherapy (n = 83)." | 2.80 | Effects of high-intensity focused ultrasound for treatment of abdominal lymph node metastasis from gastric cancer. ( Liu, L; Liu, P; Lu, K; Shu, Y; Wang, J; Wang, R; Zhang, M, 2015) |
| " The safety and dosage of S-1 combined with postoperative radiotherapy have not yet been evaluated." | 2.80 | Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer. ( Bi, F; Cao, D; Chen, Y; Gou, HF; Li, Q; Li, ZP; Liu, JY; Peng, XC; Qiu, M; Shen, YL; Wang, X; Xu, F; Yang, Y; Yi, C; Zhao, YQ, 2015) |
| "In the context of gastric cancer, lymph node target volume delineation for post-operative radiotherapy is currently built on the traditional system of dividing the stomach and 2-D treatment methods." | 2.80 | A new approach to delineating lymph node target volumes for post-operative radiotherapy in gastric cancer: A phase II trial. ( Conghua, X; Haijun, Y; Qiuji, W; Yahua, Z; Yong, H; Yunfeng, Z; Zhengkai, L; Zhenming, F, 2015) |
| " The purpose of this phase I study was to evaluate the safety, pharmacokinetics, and preliminary efficacy of sorafenib in combination with S-1 plus CDDP." | 2.79 | A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer. ( Fuse, N; Hashizume, K; Ito, Y; Kato, K; Kiyota, N; Kuroki, Y; Minami, H; Ohtsu, A; Yamada, Y, 2014) |
| "A phase I trial of first-line vorinostat, an orally bio-available histone deacetylase inhibitor, in combination with capecitabine plus cisplatin (XP) was performed to assess recommend phase II trial dose in patients with advanced gastric cancer." | 2.79 | Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer. ( Kang, YK; Kim, SY; Koo, DH; Lee, CW; Maeng, J; Na, YS; Park, I; Ryoo, BY; Ryu, MH; Yoo, C, 2014) |
| "For resectable gastric cancer, both postoperative chemoradiotherapy and perioperative chemotherapy demonstrate high-level evidence for improved survival in Western populations." | 2.79 | Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308. ( Aparicio, T; Breysacher, G; Chapet, S; Dousset, B; Faroux, R; Jouve, JL; Maillard, E; Martel-Lafay, I; Michel, P; Mornex, F; Nguyen, S; Pere-Verge, D; Pezet, D; Seitz, JF; Sobhani, I, 2014) |
| "Capecitabine monotherapy was continued for patients without disease progression." | 2.79 | The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma. ( Bai, C; Bai, Y; Cheng, Y; Fan, Q; Gong, J; Hu, B; Hu, G; Jiao, S; Liang, J; Liu, Y; Shen, L; Shi, Y; Wang, J; Xu, N; Xu, R; Zhang, F; Zhang, J; Zhang, X; Zheng, L, 2014) |
| " Median values for AUC, Cmax, and Cmin were lower in patients with progressive disease (PD) than other response categories, although the 1." | 2.79 | Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. ( Cosson, VF; Lehle, M; Lum, BL; Ng, VW, 2014) |
| "We evaluated the safety and efficacy of biweekly capecitabine in combination with oxaliplatin in previously untreated patients with locally advanced or metastatic gastric cancer." | 2.79 | A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. ( Bai, LY; Chao, Y; Chen, JS; Hsieh, JS; Li, CP; Su, WC; Su, YC; Tai, CJ; Wu, CC; Yeh, HT; Yeh, KH, 2014) |
| "Capecitabine was administered twice daily on every radiotherapy treatment day in a dose-escalation schedule (mg/m²) of 625 (level I, n = 6), 700 (level II, n = 6), 800 (level III, n = 6), 900 (level IV, n = 0) and 1000 (level V, n = 0)." | 2.79 | Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer. ( Fang, H; Jin, J; Li, YX; Liu, XF; Liu, YP; Ren, H; Song, YW; Wang, SL; Wang, WH; Wang, X; Yu, ZH, 2014) |
| "In advanced gastric cancer (AGC), no globally accepted prognostic scoring system has been developed." | 2.79 | Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. ( Boku, N; Fukase, K; Goto, M; Koizumi, W; Mizusawa, J; Nishina, T; Ohtsu, A; Takahari, D; Takashima, A; Tamura, T; Tsuji, A; Yamada, Y; Yamaguchi, K; Yamazaki, K; Yoshino, T, 2014) |
| " After six chemotherapy cycles, the short-term efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors guidelines and adverse reactions were recorded according to National Cancer Institute Common Toxicity Criteria 2." | 2.79 | Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer. ( Chang, ZW; Dong, L; Han, ZF; Li, J; Lou, XP; Lu, P; Miao, JH, 2014) |
| "Patients who were diagnosed with gastric cancer and PAN involvement (Stations No." | 2.79 | A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. ( Feng, Y; Hou, J; Ji, Y; Li, W; Liu, TS; Qin, XY; Shen, KT; Shen, ZB; Sun, YH; Wang, Y; Yu, YY, 2014) |
| " Predicted Cp [median and 90% prediction interval] was simulated using the population pharmacokinetic model established for other cancers (PPK model) and compared to observed Cp." | 2.79 | Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial. ( Allison, DE; Han, K; Jin, J; Lowe, J; Maia, M; Sersch, MA, 2014) |
| "Gastric cancer is a heterogeneous disease, and the strategy of combining chemotherapy with HH inhibition may only be effective in tumors with high CD44 levels." | 2.79 | CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. ( Cohen, DJ; Janjigian, YY; Kim, TS; Lee, HJ; Park, DJ; Schmidt, B; Thomas, NJ; Yoon, C; Yoon, SS, 2014) |
| "The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer." | 2.79 | Quality of life in the trastuzumab for gastric cancer trial. ( Al-Sakaff, N; Bang, YJ; Chung, HC; Gotovkin, EA; Hamamoto, Y; Hill, J; Kang, YK; Moiseyenko, VM; Ohtsu, A; Satoh, T; Urspruch, A; Van Cutsem, E; Weber, HA, 2014) |
| " We aimed to assess the safety, efficacy, biomarkers, and pharmacokinetics of rilotumumab combined with epirubicin, cisplatin, and capecitabine (ECX) in patients with advanced gastric or oesophagogastric junction cancer." | 2.79 | Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. ( Anderson, A; Davidenko, I; Deptala, A; Donehower, RC; Dubey, S; Harrison, M; Iveson, T; Jiang, Y; Lakshmaiah, K; Loh, E; Nirni, S; Oliner, KS; Tang, R; Thomas, A; Tjulandin, S; Zhu, M, 2014) |
| "Paclitaxel was administered intravenously on day 1 at a dose of 120 mg/m(2), and oral S-1 was administered twice a day from days 1 to 7, followed by a 7-day drug-free interval." | 2.79 | Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study. ( Fang, W; Jiang, H; Mao, C; Qian, J; Xu, N; Zhang, X; Zhao, P; Zheng, Y, 2014) |
| "Advanced gastric cancer (AGC) patients have a poor prognosis." | 2.79 | Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey. ( Kemal, Y; Kut, E; Teker, F; Yilmaz, B; Yucel, I, 2014) |
| "Patients with locally advanced gastric cancer (n = 32) received preoperative chemotherapy under the XELOX (capecitabine plus oxaliplatin) regimen." | 2.79 | Comparison between better and poorly differentiated locally advanced gastric cancer in preoperative chemotherapy: a retrospective, comparative study at a single tertiary care institute. ( Ding, DY; Hou, RZ; Li, YC; Song, B; Sun, LB; Zhao, GJ, 2014) |
| "We consider that our observations in gastric cancer patients in our clinic can be useful in the future randomised trials to point the way to improved outcomes." | 2.79 | Adjuvant radiotherapy for gastric carcinoma: 10 years follow-up of 244 cases from a single institution. ( Coskun-Breuneval, M; Demirkasimoglu, T; Elgin, Y; Guney, Y; Kara, SP; Kucukpilakci, B; Misirlioglu, HC; Ozgen, A; Sanri, E; Ugur, VI, 2014) |
| "Patients with stage II-IIIB gastric cancer who underwent curative D2 gastrectomy were randomly assigned (1:1) after surgery to receive adjuvant chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m(2) twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m(2) on day 1) for 6 months or observation alone." | 2.79 | Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. ( Bang, YJ; Chen, JS; Choi, JH; Chung, HC; Chung, IJ; Ha, S; Ji, J; Kim, HH; Kim, HK; Kim, SW; Lee, JI; Lim, Y; Noh, SH; Park, SR; Shin, DB; Yang, HK; Yu, W, 2014) |
| "To explore the clinical effects of nimotuzumab combined with chemotherapy in the treatment of late gastric cancer." | 2.79 | Clinical study of nimotuzumab combined with chemotherapy in the treatment of late stage gastric cancer. ( Xu, CD, 2014) |
| "To investigate the clinical efficacy and toxic effects of neoadjuvant chemotherapy using docetaxel combined with oxaliplatin and fluorouracil for treating stage III/IV gastric cancer." | 2.79 | Efficacy of docetaxel combined with oxaliplatin and fluorouracil against stage III/IV gastric cancer. ( Huang, H; Li, PH; Lu, MD; Qi, DS; Sun, WJ; Wang, FH; You, T; Yu, YJ; Zhang, Y; Zheng, ZQ, 2014) |
| " Most treatment-related adverse events occurred at similar rates in both treatment arms." | 2.78 | Safety analysis of weekly paclitaxel plus S-1 versus paclitaxel plus 5-fluorouracil/calcium folinate as first-line therapy in advanced gastric cancer: a multicenter open random phase II trial. ( Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX, 2013) |
| "Between 2001 and 2008, 65 consecutive gastric cancer patients received either 3D-CRT (n = 27) or IMRT (n = 38) following tumor resection." | 2.78 | Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. ( Boda-Heggemann, J; Haneder, S; Hochhaus, A; Hofheinz, RD; Lohr, F; Michaely, H; Ronellenfitsch, U; Schneider, V; Weiss, C; Wenz, F; Wertz, H, 2013) |
| "Patients with advanced gastric cancer have a poor prognosis and few efficacious treatment options." | 2.78 | Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. ( Bodoky, G; Celik, I; Chung, HC; Gorbunova, V; Götte, H; Kang, YK; Kurteva, G; Lordick, F; Melezínková, H; Moehler, M; Moiseyenko, VM; Oh, SC; Park, JO; Salman, P; Sawaki, A; Volovat, C, 2013) |
| "59 cases of advanced gastric cancer were enrolled." | 2.78 | Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer. ( Ji, M; Jiang, JT; Li, XD; Wu, CP; Wu, J; Xu, B; Zhang, HY; Zhao, WQ; Zhou, WJ, 2013) |
| " The experimental arm's dosage schedule was paclitaxel 60 mg/m2 (intravenous infusion) on days 1, 8 and 15 and S-1 80-120 mg/d (oral administration) on days 1-14." | 2.78 | A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer. ( Ba, Y; Deng, T; Guo, Z; Hu, C; Huang, D; Meng, J; Wan, H; Wang, M; Xiong, J; Xu, N; Yan, Z; Yao, Y; Yu, Z; Zhang, Y; Zheng, R; Zhuang, Z, 2013) |
| "4%) and renal adverse events (all grades: CS, 18." | 2.78 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013) |
| "To evaluate the efficacy and safety of trastuzumab in combination with chemotherapy versus chemotherapy alone in the first-line treatment of HER-2-positive advanced gastric or gastro-oesophageal junction cancer." | 2.78 | [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport]. ( Feng, FY; Guan, ZZ; Jiao, SC; Jin, YN; Li, J; Pan, LX; Qin, SK; Shen, L; Tao, M; Wang, JJ; Wang, LW; Wang, YJ; Xu, JM; Yu, SY; Zheng, LZ, 2013) |
| "5-fluorouracil continuous infusion for gastric cancer with peritoneal metastasis." | 2.78 | Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). ( Boku, N; Denda, T; Doi, T; Fukuda, H; Goto, M; Hamamoto, Y; Nasu, J; Ohtsu, A; Shirao, K; Takashima, A; Yamada, Y; Yamaguchi, K, 2013) |
| "Eighty-five patients with advanced gastric cancer (stage IIB and IIIC) were randomly divided into two groups: neoadjuvant chemotherapy group (40 cases) and surgery alone group (45 cases)." | 2.78 | [Effects of XELOX regimen as neoadjuvant chemotherapy on radical resection rate and prognosis in patients with advanced gastric cancer]. ( Jiao, ZK; Li, Y; Tan, BB; Tian, Y; Wang, D; Yang, PG; Zhang, ZD; Zhao, Q; Zhao, XF, 2013) |
| " There was no evidence of a pharmacokinetic drug-drug interaction between sunitinib and 5-FU." | 2.78 | A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. ( Bellmunt, J; Gil-Martín, M; Gómez-Martín, C; Khosravan, R; Lechuga, MJ; Lin, X; Montagut, C; Núñez, JA; Puig, M; Salazar, R; Tursi, JM, 2013) |
| " Adverse events were generally mild; the most common grade 3/4 events were neutropenia, anemia, anorexia, and nausea." | 2.78 | Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study. ( Abe, T; Baba, E; Boku, N; Chin, K; Doi, T; Hamamoto, Y; Koizumi, W; Komatsu, Y; Miyata, Y; Nishina, T; Ohtsu, A; Omuro, Y; Saji, S; Sato, A; Satoh, T; Sawaki, A; Takiuchi, H; Tamura, T; Yamada, Y; Yamaguchi, K, 2013) |
| " Toxic effects were graded according to NCI-CTC version 3." | 2.78 | The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. ( Abdel-Latif, RM; Anter, AH, 2013) |
| " However, because of decreased relative dose intensity during treatment, further study is warranted to determine optimal dosage and combination." | 2.77 | A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer. ( Ahn, JY; Chung, HC; Hyung, WJ; Jeung, HC; Lee, SS; Noh, SH; Rha, SY, 2012) |
| "Eligible patients with advanced gastric cancer were treated with capecitabine at a fixed dose 1,000 mg daily (days 1-28 continuously, every 5 weeks) until disease progression or significant toxicity." | 2.77 | Capecitabine "metronomic" chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy. ( He, S; Hong, L; Niu, D; Niu, L; Shen, J, 2012) |
| "pCR was achieved in 67% of squamous cell carcinoma." | 2.77 | Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. ( Balagué, C; Bellmunt, J; Conill, C; Gallego, R; Iglesias, M; Martín-Richard, M; Maurel, J; Momblan, D; Montagut, C; Pera, M; Pétriz, L; Reig, A, 2012) |
| "The primary objective of this Phase I study was to assess the safety and tolerability of the vascular endothelial growth factor signalling inhibitor cediranib in combination with cisplatin plus an oral fluoropyrimidine, in Japanese patients with previously untreated advanced gastric cancer." | 2.77 | Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. ( Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y, 2012) |
| " The CCRT began 28 days after the first cycle of chemotherapy, and chemotherapy was given within the first four and last three days during the CCRT period, at a radiation dosage of 45 Gy/25 f, i." | 2.77 | Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. ( Li, T; Song, Y; Yu, C; Yu, R; Zhu, W, 2012) |
| "To evaluate the pharmacokinetics (PK) of capecitabine and cisplatin, administered in combination with or without trastuzumab, in Japanese patients with HER2-positive advanced gastric cancer (AGC)." | 2.77 | Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer. ( Boku, N; Hamamoto, Y; Ohtsu, A; Omuro, Y; Sasaki, Y; Satoh, T; Tamura, T, 2012) |
| "The Trastuzumab for Gastric Cancer (ToGA) study is the first international trial to include Japanese patients with human epidermal growth factor 2 (HER2) positive advanced/metastatic gastric or gastroesophageal junction cancer." | 2.77 | Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. ( Abe, T; Baba, E; Boku, N; Hamamoto, Y; Hatake, K; Miyata, Y; Nishina, T; Ohashi, Y; Ohtsu, A; Omuro, Y; Sasaki, Y; Satoh, A; Satoh, T; Sawaki, A; Takiuchi, H; Tamura, T; Yamaguchi, K, 2012) |
| "Patients with stage II-IIIB gastric cancer who had had curative D2 gastrectomy were randomly assigned to receive adjuvant chemotherapy of eight 3-week cycles of oral capecitabine (1000 mg/m(2) twice daily on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m(2) on day 1 of each cycle) for 6 months or surgery only." | 2.77 | Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. ( Bang, YJ; Button, P; Cho, JY; Chung, HC; Ji, J; Kim, YH; Kim, YW; Lee, KH; Lee, KW; Mok, YJ; Noh, SH; Noh, SI; Park, YK; Sirzén, F; Yang, HK; Yeh, TS, 2012) |
| " The aim of the study was to compare efficacy and safety, including response rate (RR), progression-free survival (PFS), overall survival, and grade ≥3 adverse events, between patients aged ≥65 years and patients aged <65 years." | 2.77 | Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer. ( Bang, HY; Cho, YH; Hong Lee, M; Kim, SY; Lee, KY; Yoo, MW; Yoon, SY, 2012) |
| "For patients with metastatic gastric cancer, the sequential administration of cisplatin, leucovorin, 5-FU, and docetaxel may be an effective palliative option and offers a far more favorable toxicity profile than the simultaneous use of docetaxel, cisplatin, and 5-FU." | 2.77 | Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study. ( Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, V; D'Emidio, S; Fiorentini, G; Giordani, P; Graziano, F; Luzi Fedeli, S; Rossi, D; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B, 2012) |
| "Systemic chemotherapy for patients with gastric cancer has limited impact on overall survival." | 2.77 | Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution. ( Inal, A; Isikdogan, A; Kaplan, MA; Kucukoner, M, 2012) |
| "Capecitabine is an oral prodrug of flurouracil with broad activity against various malignancies." | 2.77 | Cisplatin with capecitabine: tolerance and activity in a phase I/II study preferentially enrolling patients with gastric cancer. ( Hochster, HS; Levinson, B; Muggia, F; Newman, E; Ryan, T; Wu, J, 2012) |
| "A total of 56 histologically proven gastric cancer patients, who were considered to be stage II or higher with metastatic lymph nodes and with or without distant metastasis (T2-4, N1-3, and M0-1), were treated with a neoadjuvant chemotherapy." | 2.77 | Retrospective analysis of 56 patients with advanced gastric cancer treated with combination of intravenous and intra-arterial intensified neoadjuvant chemotherapy. ( Bao, Y; Cao, JM; Li, GL; Li, JS; Liu, K; Wang, XL; Wu, B; Xu, J, 2012) |
| "Surgical resection of gastric cancer has produced suboptimal survival despite multiple randomized trials that used postoperative chemotherapy or more aggressive surgical procedures." | 2.77 | Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. ( Ajani, JA; Benedetti, JK; Blanke, CD; Estes, NC; Goldman, B; Gunderson, LL; Haller, DG; Hundahl, SA; Jessup, JM; Macdonald, JS; Martenson, JA; Smalley, SR; Stemmermann, GN, 2012) |
| "Despite substantial developments in gastric cancer treatment, the majority of patients relapse after definitive surgery." | 2.77 | Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer. ( Hubert, A; Kadouri, L; Peretz, T; Rivkind, A; Rottenberg, Y; Sonnenblick, A; Vainer, GW; Wygoda, M, 2012) |
| "The highest rates of gastric cancer occur in Eastern Asia." | 2.77 | A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy. ( Chen, JS; Choo, SP; Chu, KM; DelaCruz, C; Kim, YH; Lainas, I; Li, CP; Mukhopadhyay, P; Muro, K; Park, SH; Ryu, MH; Sanchez, T; Yasui, H, 2012) |
| " This prospective phase II study evaluated the activity and toxicity of a modified regimen with lower doses of docetaxel and cisplatin combined with oral capecitabine instead of fluorouracil for patients with advanced gastric cancer." | 2.77 | Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study. ( Dimitroulis, D; Felekouras, E; Griniatsos, J; Karatzas, T; Karavokyros, J; Kontzoglou, K; Mantas, D; Nikiteas, N; Polyzos, A; Polyzos, K; Syrigos, K; Tsavaris, N; Vafiadis, I, 2012) |
| "Additional treatment with aVQ is safe and was associated with improved QoL of gastric cancer patients." | 2.77 | Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study. ( Eisenbraun, J; Huber, R; Kim, BS; Kim, KC; Yook, JH, 2012) |
| "With better access to metastases and certain large or inoperable tumours, we applied two treatment sessions of combined therapy of whole-body hyperthermia and hyperthermic intraperitoneal chemo-perfusion in the treatment group, while patients in the control group were treated with oxaliplatin combined with 5-fluorouracil chemotherapy or Xeloda." | 2.77 | Whole-body hyperthermia combined with hyperthermic intraperitoneal chemotherapy for the treatment of stage IV advanced gastric cancer. ( Chen, X; Dai, C; Zhao, C, 2012) |
| " The purpose of the present study was to update the results of radiotherapy combined with nedaplatin and 5-fluorouracil (5-FU) for postoperative loco-regional recurrent esophageal cancer." | 2.77 | Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study. ( Abe, K; Ishikawa, Y; Jingu, K; Kubozono, M; Matsushita, H; Nemoto, K; Shirata, Y; Sugawara, T; Takahashi, C; Takeda, K; Tanabe, T; Umezawa, R; Yamamoto, T, 2012) |
| "To evaluate the efficacy and safety of weekly paclitaxel combined with S-1 or fluorouracil in the first line treatment of advanced gastric carcinoma." | 2.77 | [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma]. ( Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX, 2012) |
| "IGF-1 was associated with the number of metastases (p = 0." | 2.77 | Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy. ( Camphausen, K; Graves, CA; Kim, HJ; Kim, SH; Kwon, HC; Lee, JH; Lee, S; Oh, SY, 2012) |
| "We evaluated the efficacy and safety of cetuximab in combination with XELOX [XELoda® (capecitabine) and OXaliplatin] in advanced gastric cancer (AGC) patients." | 2.76 | A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. ( Chang, HM; Kang, HJ; Kang, YK; Kim, C; Kim, TW; Lee, JL; Lim, HY; Park, YS; Ryoo, BY; Ryu, MH, 2011) |
| "Chemo-naïve patients with metastatic gastric cancer were enrolled to receive 4 cycles of TCF-dd (docetaxel initially 85 mg/m(2) and cisplatin initially 75 mg/m(2) on day 1 [later modified due to toxicity: 70 and 60 mg/m(2) respectively], l-folinic acid 100 mg/m(2) on days 1 and 2, 5-fluorouracil 400 mg/m(2) bolus and then 600 mg/m(2) as a 22 h continuous infusion on day 1 and 2, every 14 days)." | 2.76 | Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial. ( Brighenti, M; Buti, S; Dalla Chiesa, M; Donati, G; Lazzarelli, S; Passalacqua, R; Rovere, RK; Tomasello, G, 2011) |
| "This study was conducted to determine the optimal dosage of the docetaxel-capecitabine-cisplatin (DXP) regimen and to evaluate its efficacy and safety in patients with advanced gastric cancer." | 2.76 | Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. ( Chang, HM; Kang, YK; Kim, BS; Kim, TW; Oh, ST; Ryu, MH; Yoo, C; Yook, JH, 2011) |
| "A total of 268 patients with stage II gastric cancer underwent D2 resection in our Cancer Center between January 1990 and December 2006 were recruited." | 2.76 | No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer. ( Chen, S; Chen, YB; Feng, XY; Guan, YX; Li, W; Li, YF; Sun, XW; Xu, DZ; Zhan, YQ; Zhou, ZW, 2011) |
| "Patients with Stage II/III gastric cancer after surgery were recruited." | 2.76 | Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen). ( Bi, F; Cao, D; Gou, HF; He, B; Li, Q; Li, ZP; Liao, ZY; Liu, JY; Luo, DY; Qiu, M; Shen, YL; Wang, X; Wang, Y; Xu, F; Yang, Y; Yi, C, 2011) |
| "SOX regimen as neoadjuvant chemotherapy is associated with high efficacy, acceptable adverse effect, and increased rate of D2 lymph nodes dissection and R0 resection." | 2.76 | [Efficacy and safety of SOX regimen as neoadjuvant chemotherapy for advanced gastric cancer]. ( Chen, L; Li, T, 2011) |
| "Everolimus is a novel inhibitor of the mammalian target of rapamycin pathway, which is aberrantly activated in cancer cell." | 2.76 | Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. ( Ahn, HK; Baek, KK; Han, B; Kang, WK; Kim, KM; Lee, DJ; Lee, HY; Lee, J; Lee, SJ; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS, 2011) |
| "To observe and compare the response rate and toxicity of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer." | 2.76 | [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer]. ( Chen, DY; Qi, Q; Zhao, WY, 2011) |
| "Fluorouracil was permitted in patients unable to take oral medications." | 2.76 | Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. ( Kang, YK; Langer, B; Lim, HY; Ohtsu, A; Park, SR; Rha, SY; Sawaki, A; Shah, MA; Starnawski, M; Van Cutsem, E; Wu, J; Yamada, Y, 2011) |
| "To evaluate the safety and efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen (irinotecan plus 5-FU/LV) in the treatment of HER2-positive advanced gastric cancer." | 2.76 | [Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer]. ( Chen, QQ; Gao, XP; Li, W; Pan, SY; Sun, J, 2011) |
| "Current chemotherapy protocols for gastric cancer present high toxicity." | 2.76 | Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: a first-line phase II study. ( Auby, D; Becouarn, Y; Bellera, C; Brunet, R; Cany, L; Dauba, J; Fonck, M; Legoux, JL; Mathoulin-Pélissier, S; Mertens, C; Rainfray, M; Smith, D; Soubeyran, P; Terrebonne, E; Traissac, L, 2011) |
| "The prognosis of patients with advanced gastric cancer (AGC) remains poor, and no single chemotherapy regimen is recognized as a global standard." | 2.76 | Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer. ( He, YJ; Li, YH; Luo, HY; Qiu, MZ; Ruan, DY; Teng, KY; Wang, FH; Wang, ZQ; Xu, RH, 2011) |
| "We evaluated the efficacy and safety of bolus 5-fluorouracil (5-FU) and leucovorin combined with weekly paclitaxel (FLTAX) in advanced gastric cancer (GC) patients." | 2.76 | Phase II study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer. ( Hamaguchi, T; Iwasa, S; Kato, K; Kobayashi, K; Matsubara, J; Nagai, Y; Nakajima, TE; Nakayama, N; Shimada, Y; Takagi, S; Tsuji, A; Yamada, Y; Yoshioka, A, 2011) |
| "To determine the maximum tolerated dose of oblimersen, an antisense oligonucleotide directed to the Bcl-2 mRNA, in combination with cisplatin and 5-flourouracil in patients with advanced gastric and esophageal carcinoma." | 2.75 | A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma. ( Christos, P; Kaubisch, A; Ocean, AJ; Raab, R; Ramirez, M; Sparano, JA; Vinciguerra, V, 2010) |
| "Capecitabine was administered orally bid on days 1-14." | 2.75 | Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer. ( Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Lee, SS; Oh, ST; Ryu, MH; Sym, SJ; Yook, JH, 2010) |
| "Patients with advanced gastric cancer (AGC), clinically unresectable because of local invasion or limited intra-abdominal metastasis in para-aortic lymph nodes and/or the peritoneum based on multidetector row computed tomography, were enrolled." | 2.75 | Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. ( Chang, HM; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Oh, ST; Ryu, MH; Sym, SJ; Yook, JH, 2010) |
| "The prognosis of patients with advanced gastric cancer (AGC) remains poor, and no single chemotherapy regimen is recognized as a global standard." | 2.75 | Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. ( Chen, XQ; Li, FH; Li, YH; Luo, HY; Qiu, MZ; Wang, F; Xu, RH; Zhou, ZW, 2010) |
| "To explore the efficacy, time to disease progression (TTP), overall survival (OS) and toxicity of paclitaxel liposome versus paclitaxel combined with 5-fluorouracil (5-Fu) for patients with advanced gastric cancer." | 2.75 | [Comparison of the therapeutic effects of paclitaxel liposome-5-Fu versus paclitaxel-5-Fu on 67 patients with advanced gastric cancer]. ( Chen, SC; Lu, ZH; Wu, F; Xiong, JP, 2010) |
| "The AI of gastric cancer tissue in Group FC was significantly higher than in the other groups (P < 0." | 2.75 | Prospective randomized trial of short-term neoadjuvant chemotherapy for advanced gastric cancer. ( Hirai, H; Imamoto, H; Imano, M; Itoh, T; Kato, H; Ohyanagi, H; Okuno, K; Peng, YF; Satou, T; Shinkai, M; Shiozaki, H; Sogo, Y; Yasuda, A; Yasuda, T, 2010) |
| "Forty two patients with advanced gastric cancer received neoadjuvant chemotherapy and subsequently 40 patients underwent standardized gastrectomy (2 patients with tumor progression had therapy limited to palliative chemotherapy without surgery)." | 2.75 | [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. ( Alakus, H; Baldus, S; Bollschweiler, E; Brabender, J; Dietlein, M; Hölscher, AH; Metzger, R; Mönig, SP; Schmidt, M; Schneider, PM; Vallböhmer, D, 2010) |
| "Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in combination with chemotherapy for first-line treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer." | 2.75 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. ( Aprile, G; Bang, YJ; Chung, HC; Feyereislova, A; Hill, J; Kang, YK; Kulikov, E; Lehle, M; Lordick, F; Ohtsu, A; Omuro, Y; Rüschoff, J; Satoh, T; Sawaki, A; Shen, L; Van Cutsem, E, 2010) |
| "Seventy-eight patients with cTNM stage III or IV (M0) gastric cancer were enrolled and 39 were randomized into the treatment arm (n=39, paclitaxel combined with FOLFOX4 regimen neoadjuvant chemotherapy every two weeks in each cycle) and control group (n=39)." | 2.75 | [A clinical study of paclitaxel combined with FOLFOX4 regimen as neoadjuvant chemotherapy for advanced gastric cancer]. ( Liu, FR; Ma, FY; Ma, SQ; Qu, JJ; Shi, YR, 2010) |
| "Twenty-one patients with advanced gastric cancer who had failed first-line therapy received irinotecan on days 1 and 8 plus capecitabine on days 1-14 for a 21-day cycle." | 2.75 | [Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases]. ( Dong, CM; Kang, MF; Liu, Y; Luo, MQ, 2010) |
| "Patients with histologically proven gastric cancer and measurable metastatic disease received capecitabine 825 mg/m(2) twice daily (1,650 mg/m(2) per day) on days 1-14 and paclitaxel 175 mg/m(2) by intravenous infusion on day 1 every 3 weeks until disease progression or unacceptable toxicities." | 2.74 | Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. ( Abakar-Mahamat, A; Baize, N; Berthier, F; Caroli-Bosc, FX; Mounier, N, 2009) |
| "This prospective study was conducted with the Korean Cancer Study Group to evaluate the efficacy and safety of cetuximab combined with modified FOLFOX6 (mFOLFOX6) as first-line treatment in recurrent or metastatic gastric cancer and to identify potential predictive biomarkers." | 2.74 | Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. ( Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, MA; Kim, TY; Kim, WH; Lee, KH; Lee, KW; Lee, MH; Lee, NS; Oh, DY; Park, SR; Song, HS, 2009) |
| "Advanced or metastatic gastric cancer, which is one of the most common malignancies in Korea, is difficult to cure by surgery alone and generally requires combination chemotherapy." | 2.74 | Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer. ( Ahn, JS; Jung, JY; Kim, HJ; Kim, I; Kim, JH; Kwon, JH; Lee, JA; Lee, KS; Park, YI; Song, HH; Zang, DY, 2009) |
| "Of these, 50 patients had untreated gastric cancer, and 14 had received previous therapy with nonplatinum-based therapy." | 2.74 | Phase II study of capecitabine plus cisplatin in patients with gastric cancer. ( AL-Ashry, MS; Ebrahim, MA; Salah-Eldin, MA, 2009) |
| "The prognosis of advanced gastric cancer (AGC) is poor." | 2.74 | A phase II trial of epirubicin plus oxaliplatin and fluorouracil as first-line chemotherapy for advanced gastric cancer. ( Qiu, F; Xiang, XJ; Xiong, JP; Yu, F; Zhang, L; Zhao, JG, 2009) |
| "Patients with previously untreated gastric cancer with measurable disease received oxaliplatin (100 mg/m(2), day 1), followed by leucovorin (100 mg/m(2), day 1) and 5-FU (2,400 mg/m(2), days 1-2), which was repeated every 2 weeks." | 2.74 | Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. ( Cho, JY; Choi, SH; Jeung, HC; Lee, SI; Lim, JY; Oh, KJ, 2009) |
| "This oxaliplatin combined with ELF regimen shows good efficacy and acceptable safety in advanced gastric cancer patients." | 2.74 | [Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer]. ( Lou, F; Pan, HM; Zhu, YH, 2009) |
| "The quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented." | 2.74 | Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. ( Barone, C; Bugat, R; Curran, D; Dank, M; Goker, E; Peschel, C; Pozzo, C; Valvere, V; Wenczl, M; Yalcin, S; Zaluski, J, 2009) |
| "Of the 96 patients with gastric cancers, 21 underwent R0 resection and afterward received adjuvant FOLFOX chemotherapy." | 2.74 | [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer]. ( Dai, H; Yan, D, 2009) |
| " This study was to investigate the efficacy and safety of oxaliplatin in combination with capecitabine as first-line chemotherapy for AGC patients." | 2.74 | [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer]. ( Dong, NN; Liu, ZF; Wang, MY; Zhang, Q, 2009) |
| "To investigate the efficiency, time to progression (TTP), overall survival (OS) and toxicity of epirubicin combined with DDP and 5-Fu (PELF regimen) for the treatment of advanced gastric cancer." | 2.74 | [Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer]. ( Li, J; Li, Y; Lu, M; Shen, L; Zhang, XD, 2009) |
| "The standard of care for metastatic gastric cancer (MGC) is systemic chemotherapy which leads to a median survival of 6-15 months." | 2.74 | The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. ( Avital, I; Berger, A; Duffy, A; Giaccone, G; Goldspiel, BR; Kammula, US; Kemp, CD; Kerkar, SP; Kwong, KF; Quezado, M; Rosenberg, SA; Schrump, DS; Steinberg, SM; Toomey, MA; Venkatesan, A; Walker, M, 2009) |
| "To determine the maximum-tolerated dose (MTD) of a 24-h continuous infusion of 5-fluorouracil (5-FU) when administered in combination with a fixed weekly dose of docetaxel and cisplatin in patients with advanced gastric cancer." | 2.74 | Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer. ( Guo, Y; Hong, X; Li, J; Wang, B; Zhang, W, 2009) |
| "This study was designed to determine the efficacy and safety of biweekly oxaliplatin in combination with infusional 5-fluouracil (5-FU) and leucovorin in patients with advanced gastric cancer (AGC)." | 2.73 | Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer. ( Chang, YF; Chao, TY; Chen, PM; Chiou, TJ; Chiu, CF; Chung, CY; Hwang, WS; Lin, SF, 2008) |
| "As prognosis of advanced gastric cancer is still poor, a standard regimen after first-line fluorouracil (FU)-based chemotherapy has not yet been established." | 2.73 | A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial. ( Boku, N; Fukuda, H; Hamaguchi, T; Honma, H; Hyodo, I; Imamura, T; Koizumi, W; Mukai, T; Ohtsu, A; Seki, S; Shirao, K; Yamamichi, N; Yamamoto, S; Yoshida, S, 2008) |
| "The aim of the study was to assess the toxicity and the clinical activity of biweekly oxaliplatin (OXA) in combination with continuous infusional 5-fluorouracil (5-FU) and leucovorin (LV) administered every 2 weeks (modified FOLFOX-4 regimen) in elderly patients with advanced gastric cancer (AGC)." | 2.73 | Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. ( Fu, Z; Guan, F; Guo, QS; Liu, ZF; Wang, MY; Yang, XG; Zhang, XQ, 2008) |
| "Paclitaxel was administered as a 1-h intravenous (i." | 2.73 | A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer. ( Hamaguchi, T; Hirashima, Y; Kato, K; Matsubara, J; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Yamada, Y, 2008) |
| " The FOLFIRI regimen consisted of irinotecan (180 mg/m(2); day 1) combined with leucovorin (200 mg/m(2)), followed by 5-fluorouracil (400 mg/m(2)) as a bolus and 600 mg/m(2) as a 22-h infusion on days 1 and 2 every 2 weeks." | 2.73 | Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. ( Bang, YJ; Im, SA; Kim, DY; Kim, JH; Kim, TY; Lee, JS; Lee, KW; Lim, JH; Oh, DY; Seo, MD; Yi, HG, 2008) |
| "To determine the clinical toxicities and antitumor effects of a chemotherapy regimen of FTQ, a compound preparation of tegafur, the drug prototype of 5-furacil (5-FU), gimeracil (CDHP), a decomposition inhibitor of 5-FU, oteracil potassium, phosphorylation inhibitor of 5-FU, and combined with cisplatin in patients with inoperable locally or metastatic advanced gastric cancer." | 2.73 | [Curative effects of FTQ combined with cisplatin in treatment of advanced gastric cancer: a multicenter study]. ( Dai, GH; Jiao, SC; Li, F; Li, Y; Liu, W; Lu, HS; Niu, RG; Song, SP; Wang, J; Xie, XD; Xu, JM; Yang, JL; Zhang, FC; Zhang, Y; Zhao, H, 2008) |
| "To evaluate the efficacy of r oxaliplatin plus 5-fluorouracil/leucovorin calcium (LV) combined with concurrent radiotherapy in the treatment of local advanced gastric cancer." | 2.73 | [Efficacy of oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy for local advanced gastric cancer]. ( Shao, ZY; Zhang, JD, 2008) |
| "The objective of this study was to evaluate the efficacy and safety of the POF regimen (biweekly 5-fluorouracil/leucovorin combined with paclitaxel and oxaliplatin) as first-line treatment for advanced gastric cancer (AGC)." | 2.73 | A phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as first-line treatment for patients with advanced gastric cancer. ( Chen, L; Fan, NF; Guo, ZQ; Lin, RB; Liu, J; Wang, XJ, 2008) |
| "Capecitabine combined with fractionated cisplatin is highly effective and well tolerated as a first-line treatment for advanced gastric cancer, with comparable results to 5-Fu plus cisplatin combination therapy." | 2.73 | [Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study]. ( Bai, YX; Chen, L; Chen, S; Cheng, Y; Hu, B; Jia, TZ; Jin, ML; Li, J; Liang, J; Shen, L; Shu, YQ; Wan, DS; Wang, BC; Wen, ZZ; Yin, HR; Yu, JR; Zhang, HG; Zhou, Y, 2008) |
| "The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma." | 2.73 | Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). ( Berardi, R; Cascinu, S; Ceccarelli, C; Di Fabio, F; Funaioli, C; Giannetta, L; Giaquinta, S; Longobardi, C; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL; Siena, S, 2007) |
| " The mean area under the curve increased significantly with escalating dosage levels (R = 0." | 2.73 | Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan. ( Hanazaki, K; Kobayashi, M; Kondo, K; Nagata, N; Namikawa, T; Oba, K; Okabayashi, T; Sakamoto, J, 2007) |
| "With poor cure rates in gastric cancer using surgery alone, the safety, efficacy and feasibility of preoperative and postoperative chemotherapy was investigated." | 2.73 | A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group Study 9601. ( Archer, S; Boyer, M; Cullingford, G; Davidson, A; Della-Fiorentina, S; Dhillon, H; Findlay, M; Gebski, V; Goldstein, D; Hargreaves, C; Johnston, P; Richardson, G; Storey, D; Trotter, J; Truskett, P; Yuen, J, 2007) |
| "From January 1998 to January 2003, 400 gastric cancer patients at high risk for recurrence including patients with serosal invasion (stage pT3 N0) and/or lymph node metastasis (stage pT2 or pT3 N1, N2, or N3), were enrolled in a trial of adjuvant chemotherapies; 201 patients were randomly assigned to receive the PELFw regimen, consisting of eight weekly administrations of cisplatin (40 mg/m2), LV (250 mg/m2), epidoxorubicin (35 mg/m2), 5-FU (500 mg/m2), and glutathione (1." | 2.73 | Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. ( Aitini, E; Ardizzoia, A; Arnoldi, E; Barni, S; Barone, C; Beretta, GD; Bertetto, O; Carnaghi, C; Cascinu, S; Cassano, A; Catalano, V; Chiara, S; Cortesi, E; Floriani, I; Foa, P; Frontini, L; Gasparini, G; Giordani, P; Labianca, R; Mansutti, M; Mosconi, S; Nardi, M; Piazza, E; Pozzo, C; Pucci, F; Rabbi, C; Ravaioli, A; Rimassa, L; Rota, S; Santoro, A; Silva, RR; Sobrero, A; Torri, V, 2007) |
| "The aim of the present study was to investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of a 5-fluorouracil derivative (TS-1) in advanced gastric or colorectal carcinoma patients." | 2.73 | Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. ( Fujiwara, T; Harada, M; Homma, S; Ikeda, Y; Ishihara, Y; Itoh, K; Maeda, Y; Mine, T; Sato, Y; Shomura, H; Tanaka, N; Todo, S; Tokunaga, N; Yamada, A, 2007) |
| "Thirty-four patients with gastric cancer, 16 after failure of first-line chemotherapy and 18 after failure of at least two prior chemotherapies, were included." | 2.73 | Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study. ( Al-Batran, SE; Bokemeyer, C; Hartmann, JT; Horger, M; Jäger, E; Kanz, L; Königsrainer, A; Meisinger, I; Nehls, O; Pintoffl, JP; Quietzsch, D, 2007) |
| "In radically resected gastric cancer patients, adjuvant chemotherapy with ELFE regimen does not improve OS over surgery alone." | 2.73 | Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). ( Cartenì, G; Catalano, G; Ciardiello, F; Colucci, G; De Vita, F; Di Martino, N; Galizia, G; Gebbia, V; Giuliani, F; Maiello, E; Manzione, L; Montemurro, F; Orditura, M; Romito, S, 2007) |
| "A total of 145 patients with advanced gastric cancer where randomly assigned to weekly FU 3,000 mg/m2/24 hours (HD-FU), FU 2,600 mg/m2/24 hours plus dl-FA 500 mg/m2 or l-FA 250 mg/m2 (HD-FU/FA), or FU 2000 mg/m2/24 hours plus FA plus biweekly Cis 50 mg/m2, each administered for 6 weeks with a 1-week rest." | 2.73 | Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastroi ( Balleisen, L; Bethe, U; Debois, M; Hegewisch-Becker, S; Jansen, RL; Jeziorski, K; Joossens, E; Lutz, MP; Praet, M; Van Cutsem, E; Vanhoefer, U; Wagener, DJ; Wilke, H; Wils, J, 2007) |
| "5% of the functional volume of both kidneys appears to be safe at a median follow-up of 2 years for a cumulative cisplatin dose of 200 mg/m2 administered before and after simultaneous 5-FU and radiotherapy." | 2.73 | Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer. ( Belka, C; Bokemeyer, C; Budach, W; Hehr, T; Kollmannsberger, C; Welz, S, 2007) |
| "Eight patients had esophageal cancer and 9 had gastric cancer." | 2.73 | A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer. ( Akerman, P; Evans, D; Jean, M; Kennedy, T; Millis, R; Miner, T; Safran, H, 2007) |
| "We hypothesised that gastric cancer outcome could be improved with more effective and intensified postoperative chemoradiotherapy." | 2.73 | Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. ( Bartelink, H; Boot, H; Cats, A; Dubbelman, R; Jansen, EP; Verheij, M, 2007) |
| "Fifty-one patients with T3 or T4 gastric cancer received systemic 5-fluorouracil-based adjuvant chemotherapy, and intratumoral expression of TS and TP in 51 gastric cancer tissue samples was tested by real-time quantitative PCR." | 2.73 | Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. ( Deng, JZ; Hua, D; Huang, ZH; Mao, Y, 2007) |
| "Sixty advanced gastric cancer patients were assigned to two groups randomly, the control group treated with chemotherapy alone and the treated group treated with SQFZI combined chemotherapy." | 2.73 | [Clinical observation on treatment of advanced gastric cancer by combined use of Shenqi Fuzheng injection, docetaxel, flurouracil and calcium folinate]. ( Shi, LR; Wu, AZ; Zhao, JM, 2007) |
| "To assess the therapeutic efficacy and adverse effects of endogenetic field hyperthermia (EFH) in combination with L-OHP /LV / 5-FU in the treatment of advanced gastric cancer." | 2.73 | [Postoperative abdominal endogenic field hyperthermia combined with FOLFOX regimen in the treatment of 68 cases of advanced gastric cancer]. ( Huang, KH; Lin, XG; Liu, TH; Xie, DR, 2007) |
| "To observe the effects and toxicity of docetaxel given once weekly combined with cisplatin and 5-fluororacil in the treatment of advanced gastric cancer (AGC)." | 2.73 | [Weekly dosage of docetaxel combined with cisplatin and 5-fluorouracil in the treatment of advanced gastric cancer]. ( Ye, S; Zhang, AM, 2007) |
| " But given the low efficacy of 5-FU in the dosage we applied in the study, it cannot be recommended as a single treatment for further studies." | 2.73 | Bimonthly 24 h infusion of high-dose 5-fluorouracil vs EAP regimen in patients with advanced gastric cancer. A randomized phase II study. ( Babić, DR; Jelić, SB; Jezdić, SD; Krivokapić, ZV; Micev, MT; Pesko, PM; Popov, IP, 2008) |
| " Patients in the treatment group (34 patients) received chemotherapy of DCF (docetaxel/cisplatin/5-fluorouracil) regimen combined with Chinese herbal medicine, and patients in the control group (32 patients) were treated with chemotherapy of the same regimen alone." | 2.73 | [Clinical observation on treatment of 34 advanced gastric carcinoma patients by chemotherapy of DCF regimen combined with Fuzheng Hewei Decoction]. ( Gao, H; Wang, HB; Wang, HZ, 2007) |
| "Cisplatin (DDP) in large dosage impairs renal functions, while the impact of fractionated low dose DDP on renal functions is unclear." | 2.73 | [Effects of fractionated low dose Cisplatin on renal functions of patients with gastric carcinoma]. ( Jin, ML; Li, J; Li, Y; Shen, L, 2007) |
| "on day 1 every 3 weeks until disease progression or unacceptable toxicities." | 2.73 | A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. ( Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JS; Oh, ST; Ryu, MH; Sohn, HJ; Yook, JH, 2008) |
| "An early detection and treatment of gastric cancer with peritoneal dissemination are rather difficult so that a clinical trial has been neglected." | 2.73 | [Neoadjuvant chemotherapy for gastric cancer with peritoneal dissemination]. ( Doki, Y; Fujiwara, Y; Miyata, H; Monden, M; Nishida, T; Takiguchi, S; Yamazaki, M, 2007) |
| "Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor." | 2.73 | Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. ( Antimi, M; Antonuzzo, L; Arcangeli, A; Banducci, S; Bellini, V; Biagioni, F; Bianchini, D; Bilancia, D; Bisagni, G; Biscottini, B; Boni, C; Bracci, R; Bravi, S; Bruno, L; Cabassi, A; Camera, S; Camisa, R; Canaletti, R; Carboni, M; Carlini, P; Carroccio, R; Cascinu, S; Catalano, G; Catalano, V; Cavalli, C; Cesari, M; Cognetti, F; Contu, A; Corgna, E; Cortesi, E; Croce, E; Dalla Mola, A; De Filippis, S; De Stefanis, M; Di Costanzo, F; Dinota, A; Enzo, MR; Farris, A; Figoli, F; Floriani, I; Foa, P; Fornarini, G; Francavilla, F; Frignano, M; Gasperoni, S; Gilli, G; Giunta, A; Grigniani, F; Ionta, MT; Italia, M; Labianca, R; Lastraioli, E; Leoni, M; Lungarotti, F; Luppi, G; Manzione, L; Masoni, L; Massidda, B; Mela, M; Messerini, L; Monzio Compagnoni, B; Muscogiuri, A; Natalini, G; Nelli, F; Nicolosi, A; Oldani, S; Olgiati, A; Olivetti, A; Orselli, G; Pandolfi, U; Papiani, G; Pazzola, A; Piga, A; Pisani Leretti, A; Porrozzi, S; Recchia, F; Romiti, A; Rondini, E; Rossetti, R; Rovei, R; Saggese, M; Sarobba, MG; Scipioni, L; Strafiuso, G; Tomao, S; Tonato, M; Torri, V; Trignano, M; Zironi, S, 2008) |
| " Seventy-seven patients were randomly assigned to receive paclitaxel 175 mg/m2 or docetaxel 75 mg/m2 on day 1, in combination with 5-FU 500 mg/m2 continuous infusion on days 1-5." | 2.72 | Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. ( Bang, SM; Cho, EK; Chung, M; Han, SH; Lee, JH; Lee, WK; Lee, Y; Park, SH; Shin, DB, 2006) |
| "D2 gastrectomy has improved survival in gastric cancer." | 2.72 | Intraarterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer. ( Dimitriou, T; Fiska, A; Karanikiotis, C; Manolopoulos, VG; Markakidis, SK; Tentes, AA; Tentes, IK, 2006) |
| "Fifty-eight patients with advanced gastric cancer were entered in this phase II study." | 2.72 | Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study. ( Bafaloukos, D; Bamias, A; Fountzilas, G; Janinis, D; Kalofonos, HP; Kosmidis, P; Papakostas, P; Sakantamis, A; Skarlos, D; Tsavdaridis, D; Xiros, N, 2006) |
| " The authors evaluated G17DT vaccination given with cisplatin plus 5-fluorouracil for the treatment gastric adenocarcinoma." | 2.72 | An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. ( Ajani, JA; Baker, J; Eduljee, A; Hecht, JR; Ho, L; Michaeli, D; Oortgiesen, M, 2006) |
| "Histologically diffuse-type gastric cancer is well known to have a poor prognosis and is often complicated with abdominal and pleural effusions." | 2.72 | A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501). ( Koizumi, W; Nakayama, N; Saigenji, K; Sasaki, T; Tanabe, S, 2006) |
| "Advanced gastric cancer patients were randomly assigned to docetaxel 75 mg/m2 and cisplatin 75 mg/m2 (day 1) plus fluorouracil 750 mg/m2/d (days 1 to 5) every 3 weeks or cisplatin 100 mg/m2 (day 1) plus fluorouracil 1,000 mg/m2/d (days 1 to 5) every 4 weeks." | 2.72 | Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. ( Ajani, JA; Boni, C; Chao, Y; Constenla, M; Fodor, M; Majlis, A; Moiseyenko, VM; Risse, ML; Rodrigues, A; Tjulandin, S; Van Cutsem, E; Voznyi, E, 2006) |
| "To evaluate the efficacy and toxicity of oxaliplatin in combination with calcium folinate and fluorouracil (OXA-LV5FU2) regimen as the neoadjuvant chemotherapy in the treatment of patients with advanced gastric cancer." | 2.72 | [Oxaliplatin in combination with calcium folinate and fluorouracil as neoadjuvant chemotherapy in the treatment of advanced gastric cancer]. ( Fang, Y; Li, F; Li, J; Wang, YJ, 2006) |
| "169 patients with radically resected gastric cancer were randomized to receive CPT-11 (180 mg/m2 day 1), leucovorin (100 mg/m2 days 1-2), FU (400-600 mg/m2 days 1-2, q 14; for four cycles; FOLFIRI regimen), followed by docetaxel (85 mg/m2 day 1), cisplatin (75 mg/m2 day 1, q 21; for three cycles; arm A), or MMC (8 mg/m2 days 1-2 as 2-hour infusion, q 42; for four cycles; arm B)." | 2.72 | Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. ( Agostana, B; Aitini, E; Ardizzoia, A; Ardizzoni, A; Bajetta, E; Bochicchio, AM; Bordonaro, R; Botta, M; Buzzoni, R; Cicero, G; Comella, G; Di Bartolomeo, M; Duro, M; Fagnani, D; Ferrario, E; Gevorgyan, A; Katia, D; Kildani, B; Mantovani, G; Mariani, L; Marini, G; Massidda, B; Mozzana, R; Oliani, C; Palazzo, S; Pinotti, G; Reguzzoni, G; Schieppati, G; Villa, E; Zilembo, N, 2006) |
| "A total of 280 patients with advanced gastric cancer were randomly allocated and analyzed for survival, response, and toxicity." | 2.71 | Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). ( Boku, N; Fukuda, H; Hyodo, I; Ikeda, N; Miyata, Y; Ohtsu, A; Saito, H; Shimada, Y; Shirao, K; Yamamichi, N; Yamamoto, S; Yoshida, S, 2003) |
| "Metastatic gastric cancer is usually treated with cisplatin- and 5-FU-based chemotherapy regimens." | 2.71 | Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion. ( Dörken, B; Krenn, V; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC, 2003) |
| "Capecitabine was suggested to be safe and effective in the treatment of advanced or recurrent gastric cancer." | 2.71 | A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. ( Koizumi, W; Saigenji, K; Sakata, Y; Taguchi, T; Terashima, M; Ujiie, S, 2003) |
| " With these findings in mind, we recently devised a new dosing regimen for the drug, by which the drug is administered for 2-week periods separated by 1-week drug-free intervals (the 2-week regimen)." | 2.71 | A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. ( Hayashi, T; Iijima, S; Kato, T; Kikkawa, N; Kimura, Y; Kurokawa, E; Naoi, Y; Tanigawa, T; Yamamoto, H, 2003) |
| "Patients with gastric cancer staged IB to IV(M0) were treated with chemoradiotherapy after curative resection with extensive (D2) lymph node dissection." | 2.71 | Postoperative chemoradiotherapy for gastric cancer. ( Choi, SH; Heo, JS; Im, YH; Jung, CW; Kang, WK; Kim, DY; Kim, K; Kim, S; Kim, WS; Kim, YI; Lee, KW; Lee, MH; Lim, DH; Noh, JH; Park, CH; Park, CK; Park, JO; Park, K; Park, SH; Sohn, TS, 2003) |
| "Only 1-year metastasis in the WCA group was 15." | 2.71 | [Clinical study on post-operative metastasis prevention of progressive stage of gastric cancer by weichang'an]. ( Shen, KP; Yang, JK; Zhen, J, 2003) |
| "Patients with locally advanced gastric cancer (cT3, cT4, N+, M0) have a dismal prognosis, despite complete resection." | 2.71 | Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. ( Becker, K; Busch, R; Dittler, HJ; Fink, U; Helmberger, H; Kollmannsberger, C; Ott, K; Sendler, A; Siewert, JR, 2003) |
| "The time to disease progression and the median survival time were 5." | 2.71 | A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. ( Beretta, GD; Cascinu, S; Catalano, V; Graziano, F; Labianca, R; Lai, V; Mosconi, S; Santini, D; Testa, E; Tonini, G, 2003) |
| "5-FU/irinotecan is a valuable regimen for second-line treatment in 5-FU/platinum-resistant O-G carcinoma." | 2.71 | Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. ( Assersohn, L; Brown, G; Cunningham, D; Hill, ME; Norman, AR; Oates, J; Ward, C; Waters, JS, 2004) |
| "Forty-eight patients with advanced gastric cancer were divided into treatment group (L-OHP+LV+5-FU+VP-16) and control group(DDP+LV+5-FU+VP-16) using non-randomized method." | 2.71 | [Clinical results of advanced gastric cancer patients treated with oxaliplatin-containing regimen]. ( Jiang, Q; Ju, AP; Xu, GH; Zhang, WM; Zheng, YT, 2003) |
| " The purpose of the current study was to determine whether dose intensification of parenteral hydroxyurea in combination with fluorouracil could enhance the response rates of the combination against refractory upper gastrointestinal malignancies." | 2.71 | Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. ( Haynes, H; Kaleya, R; Kaubisch, A; Rozenblit, A; Wadler, S, 2004) |
| " We decided on a recommended dose of cisplatin of 4 mg/m(2)/day because the dosage was one level under the maximum-tolerated dose." | 2.71 | Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902). ( Hirakawa, K; Hirata, K; Mitachi, Y; Nakata, B; Shirasaka, T; Tsuji, A; Yamamitsu, S, 2004) |
| "Mitomycin C (MMC) in combination with infusional 5-fluorouracil (FU) plus folinic acid (FA) is an effective treatment for metastatic gastrointestinal cancer." | 2.71 | Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer. ( Gnad, U; Hartmann, JT; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Saussele, S; Weisser, A; Willer, A, 2004) |
| "To evaluate the efficacy of postoperative intraperitoneal hyperthermic chemoperfusion (IHCP) combined with intravenous chemotherapy for advanced gastric cancer." | 2.71 | [Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients]. ( Lu, JF; Lu, WD; Shen, D; Xu, M; Zuo, Y, 2004) |
| "Capecitabine (Xeloda) is a novel, oral, selectively tumor-activated fluoropyrimidine with proven activity in the treatment of advanced colorectal cancer." | 2.71 | A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. ( Cho, JY; Choi, SH; Chung, HC; Han, JY; Hong, YS; Kang, JH; Lee, KS; Lee, SI; Noh, SH; Park, JN; Song, SY, 2004) |
| "Despite curative resection, 50%-90% of gastric cancer patients die of disease relapse." | 2.71 | Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. ( Czupryna, A; Kulig, J; Popiela, T; Szczepanik, AM; Zembala, M, 2004) |
| "Mitomycin C (MMC) in combination with infusional 5-fluorouracil (5-FU) is a well-tolerated active combination therapy for advanced gastric cancer." | 2.71 | Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial. ( Gnad-Vogt, SU; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Willeke, F; Willer, A, 2005) |
| "A total of 156 gastric cancer patients were randomized into 3 groups, and underwent the combined therapy (treatment group 1), intraoperative chemotherapy (treatment group 2), and peritoneal lavage with distilled water (control group), respectively." | 2.71 | [Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer]. ( Bi, JW; Fang, GE; Hua, JD; Nie, MM; Shen, XJ; Wei, G; Xue, XC, 2005) |
| "Patients with advanced or recurrent gastric cancer were treated with escalating doses of weekly paclitaxel as a 60 min intravenous (i." | 2.71 | Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer. ( Araki, K; Hirabayashi, N; Kataoka, M; Kobayashi, M; Kojima, H; Kondo, K; Matsui, T; Miyashita, Y; Nakao, A; Nakazato, H; Sakamoto, J; Takiyama, W, 2005) |
| "Published data suggests that docetaxel combined with 5-fluorouracil (5-FU) may have synergistic activity in treating advanced gastric cancer." | 2.71 | Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer. ( Bang, SM; Cho, EK; Chung, M; Lee, JH; Lee, WK; Park, SH; Shin, DB, 2005) |
| "Patients presenting with T3-4 or N+ gastric cancer received two cycles of cisplatin 100 mg/m2 d1, 5FU 800 mg/m2 d1-4, and Leucovorin 60 mg twice daily d1-4; one cycle before and one concomitantly with hyperfractionated RT (median dose, 38." | 2.71 | Neoadjuvant radiochemotherapy for locally advanced gastric cancer: long-term results of a phase I trial. ( Allal, AS; Bründler, MA; de Peyer, R; Huber, O; Morel, P; Roth, AD; Zwahlen, D, 2005) |
| "Standard chemotherapy for advanced gastric cancer remains undefined." | 2.71 | [A randomized controlled trail of taxol-based combination regimens for advanced gastric cancer]. ( Cai, XC; Chen, Q; Chen, YG; Fan, NF; Guo, ZQ; Lu, X; Ouyang, XN; Wu, XA; Xu, S; Yang, JW; Zhang, YH, 2005) |
| "Heptaplatin is a newly developed platinum derivative which has been reported to be less toxic than cisplatin." | 2.70 | Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. ( Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002) |
| "Febrile neutropenia was observed in 10% of patients and 2." | 2.70 | Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. ( Campos, B; Carrete, N; Constenla, M; Garcia-Arroyo, R; Lorenzo, I; Palacios, P, 2002) |
| " 5-FU dosage was fixed at 1,600 mg/m2 while docetaxel was evaluated at weekly 1-hour infusion dosages of 30, 40 and 50 mg/m2 to determine the MTD." | 2.70 | A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer. ( Chang, JY; Chen, LT; Chung, TR; Jan, CM; Liu, JM; Liu, TW; Shiah, HS; Whang-Peng, J; Wu, CW, 2002) |
| "Forty-two gastric cancer patients at T(3)II-T(4)III( B) stages and 96 patients with colorectal cancer at B to D stages admitted from January 1996 to October 1998 were randomly divided into control group (group I, 65 cases) receiving intraperitoneal thermochemotherapy, and group II (73 cases) receiving both intraperitoneal thermochemotherapy and intraperitoneal IL-2 immunotherapy." | 2.70 | Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection. ( Fu, QG; Guo, RX; Meng, FD; Shen, XD, 2002) |
| "At present, only few animal experiment has been reported about the pharmacokinetic of peritoneal chemotherapy." | 2.70 | [Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer]. ( Li, ZJ; Lin, AD; Qu, MW; Sun, HY; Wang, FJ; Wang, JY, 2002) |
| "Patients with stage II and III gastric cancer aged between 15 and 70 years, after curative resection, with adequate liver, renal, and cardiac function were included in the study." | 2.70 | Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study. ( Argon, A; Aydiner, A; Aykan, NF; Basaran, M; Bugra, D; Saip, P; Sakar, B; Tas, F; Topuz, E; Uygun, K, 2002) |
| "Music therapy combined with anti-tumor drugs, including chemotherapy and Chinese drugs, was given to 162 tumor patients according to syndrome differentiation to observe the change of self-rating depression scale (SDS), self-rating anxiety scale (SAS), minnesota multiphasic personality inventory (MMPI), Hamilton rating scale for depression (HAMD) and T lymphocyte subsets (immuno-histochemical assay), NK cell anti-tumor activity (NAG method), etc." | 2.70 | [Clinical observation of music therapy combined with anti-tumor drugs in treating 116 cases of tumor patients]. ( Cai, GR; Jiao, LP; Li, PW, 2001) |
| "Fatigue was a frequent side-effect during both PELF and docetaxel chemotherapy." | 2.70 | A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. ( Baldelli, AM; Barni, S; Casaretti, R; Cascinu, S; Catalano, G; Catalano, V; Comella, G; Frontini, L; Graziano, F; Labianca, R, 2001) |
| " Full administration of the planned dosage of the combined drugs is recommendable as opposed to early termination of the chemotherapy in gastric carcinoma." | 2.70 | Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute. ( Chung, HC; Jeung, HC; Kim, BS; Min, JS; Noh, SH; Rha, SY, 2001) |
| " A phase II study of sequential high-dose methotrexate and fluorouracil, combined with doxorubicin, as a neoadjuvant chemotherapy was conducted in an attempt to evaluate the efficacy of this regimen in improving the survival of patients with scirrhous gastric cancer." | 2.70 | Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer. ( Boku, N; Inoue, K; Kinoshita, T; Konishi, M; Nakagouri, T; Ohtsu, A; Ono, M; Sugitou, M; Takahashi, S; Yoshida, S, 2001) |
| "Fifteen patients with advanced gastric cancer undergoing palliative chemotherapy with etoposide, leucovorin and 5-fluorouracil (ELF) received for 10 days (beginning 3 days before chemotherapy) daily i." | 2.70 | Polysaccharides isolated from Echinacea purpurea herba cell cultures to counteract undesired effects of chemotherapy--a pilot study. ( Clemm, C; Draczynski, T; Linde, K; Melchart, D; Saller, R; Wagner, H; Weber, B; Weidenhammer, W; Worku, F, 2002) |
| "We treated 60 patients with advanced gastric cancer with 120 mg/m2 etoposide, 300 mg/m2 folinic acid, and 500 mg/m2 5-FU, on d 1-3." | 2.70 | Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting: efficacy of therapy and value of serum tumor markers. ( Rudi, J; Schulze-Bergkamen, H; Stremmel, W; Teufel, A; Zuna, I, 2002) |
| " To clarify the pharmacokinetic differences according to the administration schedules of cisplatin, we compared three different administration schedules of cisplatin such as single short-term infusion, daily short-term infusion and daily continuous infusion in combination with 5-fluorouracil." | 2.69 | Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. ( Ikeda, K; Ishida, K; Iwaya, T; Kawamura, H; Koeda, K; Maesawa, C; Saito, K; Sato, N; Takagane, A; Takiyama, I; Terashima, M; Yoshinari, H, 1998) |
| "Patients with advanced gastric cancer unresponsive or progressing after PELF chemotherapy (5-fluorouracil, leucovorin, cisplatin and epidoxorubicin) received paclitaxel at the dose of 225 mg/m2 every 3 weeks, over 3 h infusion." | 2.69 | Phase II study of paclitaxel in pretreated advanced gastric cancer. ( Cardarelli, N; Cascinu, S; Catalano, G; Giordani, P; Graziano, F; Marcellini, M; Menichetti, ET, 1998) |
| "For patients with unresectable gastric cancer registered between July 1994 and September 1995, the following dosage regimen was examined: a drip infusion of cisplatin (CDDP) at 7 mg/m2/day for 5 consecutive days and 2-day withdrawal a week for 3 weeks with concomitant sustained drip infusion of 5-FU at 300 mg/m2/day for 21 days." | 2.69 | [A cooperative study on concomitant with low-dose divided administration of cisplatin (CDDP) and sustained drip infusion of 5-fluorouracil (5-FU) for unresectable advanced gastric cancer. Osaka Cisplatin Gastric Cancer Study Group]. ( Ishida, T; Iwanaga, T; Katsu, K; Kobayashi, K; Narahara, H; Okajima, K; Okuno, M; Otani, T; Sowa, M; Taguchi, T; Takami, M; Yamamoto, H; Yasutake, K; Yasutomi, M, 1998) |
| "Patients with advanced and recurrent gastric cancer were treated with this regimen as early phase II trial and its efficacy and toxicity were assessed." | 2.69 | Phase II study of 5-fluorouracil, pirarubicin and low-dose consecutive administration of cisplatin for advanced and recurrent gastric cancer. ( Inada, T; Kikuyama, S; Miyakita, M; Ogata, Y, 1998) |
| "Thirty-six advanced or metastatic gastric cancer and chemotherapy-naïve patients with measurable or evaluable diseases were scheduled to receive intravenous etoposide 100 mg/m2/day on days 2-4, LV 300 mg/m2/day intravenously and 5-FU 500 mg/m2/day intravenously on days 1-5, every 4 weeks." | 2.69 | Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer. ( Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1998) |
| " Five episodes of grade 3 or 4 stomatitis were observed and caused dosage modifications of MTX and 5-FU." | 2.69 | Biochemical modulation of 5-fluorouracil by methotrexate in patients with advanced gastric carcinoma. ( Barbieri, MR; Dominguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Machiavelli, MR; Ortiz, EH; Pérez, JE; Rodriguez, R; Romero Acuña, JM; Romero Acuña, LA; Romero, AO; Vallejo, CT, 1998) |
| "Two hundred forty-eight gastric cancer patients thought to have resectable cancer were randomized intraoperatively to receive EPIC with mitomycin C on postoperative day 1 and 5-fluorouracil on postoperative days 2 to 5 versus surgery only." | 2.69 | Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer. ( Averbach, A; Chang, D; Sugarbaker, PH; Whang, I; Yu, W, 1998) |
| "Twenty-eight patients with advanced gastric cancer were treated with the simultaneous continuous intravenous (i." | 2.69 | Treatment of advanced gastric cancer with 5-fluorouracil and cisplatin in combination with dipyridamole. ( Baba, H; Emi, Y; Kohnoe, S; Maehara, Y; Sugimachi, K; Takahashi, I, 1998) |
| "The role of chemotherapy in metastatic gastric cancer (MGC) is predominantly palliative, therefore regimens with mild toxicity and acceptable activity should be preferred." | 2.69 | Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. ( Adamo, V; Altavilla, G; Ferraro, G; Laudani, A; Maisano, R; Pergolizzi, S; Scimone, A; Zanghì, M, 1999) |
| "The cases with esophageal cancer, stomach cancer, pancreatic cancer, hepatocellular carcinoma or colonic cancer co-existing with their inoperable lesion(s) were considered in this chemotherapy." | 2.69 | [Biochemical modulation of 5-FU--effect of low dose CDDP]. ( Denno, R; Hirata, K; Kimura, H; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Tsuji, A; Yamamitsu, S, 1999) |
| "Thirty-four patients with gastric cancer in stage II and III were enrolled, after curative resection, in a pilot study to assess the feasibility and the impact on relapse of a double modulation of 5-Fluorouracil (5FU) by Methotrexate (MTX) and 1-Leucovorin (LFA) as adjuvant chemotherapy." | 2.69 | A pilot study of adjuvant chemotherapy with double modulation of 5-fluorouracil by methotrexate and leucovorin in gastric cancer patients. ( Auriemma, A; Catalano, G; De Vita, F; Infusino, S; Orditura, M, 1999) |
| "5-fluorouracil (5-FU) has been widely used for the treatment of gastrointestinal cancers." | 2.69 | [Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers]. ( Horimi, T; Morita, S; Shirasaka, T; Takahashi, I; Takasaki, M; Tsuji, A, 1999) |
| "Early gastric cancer or cardia carcinoma were excluded." | 2.69 | Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). ( de Vries, JE; Hermans, J; Keizer, HJ; Klementschitsch, P; Songun, I; van de Velde, CJ; van der Bijl, J; van Krieken, JH; Wils, JA, 1999) |
| " Pharmacodynamic studies were performed to assess drug effects on levels of deoxyuridine triphosphate (dUTP) and thymidine triphosphate (TTP) pools in peripheral-blood mononuclear cells (PBMCs) before and 6 hours after treatment using a highly sensitive DNA polymerase assay." | 2.69 | Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract. ( Berkenblit, R; Damle, S; Haynes, H; Kaleya, R; Ladner, RD; Murgo, A; Schechner, R; Wadler, S, 1999) |
| "Combination chemotherapy with multiple drugs (FLMP therapy), in which the drugs were determined based on biochemical modulation and the dosing schedule was established in accordance with the circadian rhythms of the human body, was performed in cases of advanced recurrent gastric cancer." | 2.69 | [Effect of combination chemotherapy with multiple drugs (FLMP therapy) based on the circadian rhythms of the human body in advanced recurrent gastric cancer]. ( Iesato, H; Kamoshita, N; Kato, Y; Nagaoka, H; Okabe, T; Yokomori, T, 1999) |
| "Five patients, two with gastric cancer and three with colorectal cancer, who had metastatic tumor nodules in their livers were studied dynamically in vivo after 5-FU injection." | 2.69 | Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy. ( Presant, CA; Shani, J; Waluch, V; Weitz, I; Wiseman, CL; Wolf, W, 2000) |
| "S-1 is effective against advanced gastric cancer." | 2.69 | Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. ( Hasegawa, K; Koizumi, W; Kurihara, M; Nakano, S, 2000) |
| "Acute disseminated intravascular coagulation (DIC) is a rare but severe complication of gastric adenocarcinoma." | 2.69 | Successful initial treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation. ( Chang, FY; Chao, Y; Chi, KH; Hung, HC; King, KL; Li, CP; Teng, HC; Yen, SH, 2000) |
| "For advanced irresectible gastric cancer, sequential high-dose methotrexate and 5-fluorouracil (both on day 1) combined with adriamycin on day 15 (FAMTX regimen), cycled every 28 days, is a fairly effective but toxic treatment, with a high incidence of neutropenic fever, dose reductions and dose delays." | 2.69 | Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study. ( Boot, H; Craanen, M; Gerritsen, WR; Swart, M; Taal, BG; Westermann, AM, 2000) |
| "This study was performed to investigate the activity and safety of high dose 5-fluorouracil (5-FU) given as a weekly 24-hour infusion in combination with folinic acid plus mitomycin C in patients with advanced gastric cancer." | 2.69 | Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer. ( Benter, T; Dörken, B; Hohenberger, P; Köhne, CH; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC, 2000) |
| "To assess the clinical effect and safety of Shenqi Fuzheng Injection (SQFZI) combined with chemotherapy in treating malignant tumor of digestive tract." | 2.69 | [Clinical study on Shenqi Fuzheng injection combined with chemotherapy in treating malignant tumor of digestive tract]. ( Wang, J; Xin, M; Zhou, C, 1998) |
| "To assess the effect and mechanism of composite Xiansu Capsule (CXSC) combined with chemotherapy in treating gastric carcinoma of mid-late stage." | 2.69 | [Clinical study on treatment of mid-late stage gastric carcinoma by composite xiansu capsule combined with chemotherapy]. ( Hua, B; Wang, A, 1999) |
| "To assess the clinical effect of Shenqi Fuzheng Injection (SQFZI) combined with chemotherapy in treating gastric cancer." | 2.69 | [Clinical study on effect of shenqi fuzheng injection combined with chemotherapy in treating gastric cancer]. ( Liu, B; Wang, J; Zhou, K, 1999) |
| "To evaluate the efficacy of intra-arterial chemotherapy combined with hyperthermia for metastatic liver cancer, our cooperative study group carried out a randomized clinical trial comparing intra-arterial chemotherapy alone and intra-arterial chemotherapy combined with hyperthermia." | 2.68 | [A prospective randomized clinical trial comparing intra-arterial chemotherapy alone and when combined with hyperthermia for metastatic liver cancer]. ( Hiraoka, M; Itani, K; Kondo, M; Miura, K; Noguchi, M; Tanaka, Y; Watanabe, N; Yoshikawa, T, 1995) |
| "40813) on adjuvant chemotherapy in gastric cancer, results obtained after administration of the FAM2 regimen (fluorouracil [5-FU], doxorubicin, and mitomycin) were compared with results obtained after surgery alone to assess the effect of this regimen on overall survival, time to progression, and disease-free interval." | 2.68 | Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. ( Buyse, M; Dos Santos, JG; Duez, N; Fiorentino, M; Labianca, R; Lise, M; Marchet, A; Nitti, D; Rougier, P; Sahmoud, T, 1995) |
| "Fourteen advanced gastric cancer patients allocated to RT and Control group randomly and received each amino acid as protein source for 7 days TPN with 5-FU administration." | 2.68 | [Clinical evaluation of anticancer effect of methionine-depleting total parenteral nutrition with 5-fluorouracil and/or mitomycin C]. ( Endo, M; Goseki, N; Kando, F; Maruyama, M; Nagai, K; Shimoju, K; Wada, Y, 1995) |
| " These results show that AO-90 in combination with MF therapy is efficacious in the treatment of patients with gastric cancer." | 2.68 | [A controlled study of AO-90, a methionine-free intravenous amino acid solution, in combination with 5-fluorouracil and mitomycin C in advanced gastric cancer patients (internal medicine group evaluation)]. ( Akazawa, S; Kitamura, S; Kosaki, G; Kurihara, M; Nakano, S; Ohtani, T; Sasaki, T; Takahashi, H; Tokunaga, K, 1995) |
| "Fourteen preoperative advanced gastric cancer patients were divided randomly into two groups." | 2.68 | Synergistic effect of methionine-depleting total parenteral nutrition with 5-fluorouracil on human gastric cancer: a randomized, prospective clinical trial. ( Endo, M; Goseki, N; Kando, F; Koike, M; Maruyama, M; Shimojyu, K; Takahashi, H; Yamazaki, S, 1995) |
| " l-LV was administered intravenously by a 2-hour infusion at a dosage of 250 mg/m2 and 5-FU at a dosage of 600 mg/m2, intravenously via bolus one hour after administration of l-LV had been started." | 2.68 | [A cooperative late phase II trial of l-leucovorin and 5-fluorouracil in the treatment of advanced gastric cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Hirabayashi, N; Kurihara, M; Nakano, S; Ohno, T; Ohta, J; Ohtani, T; Taguchi, T; Takeda, S; Yonemura, Y, 1995) |
| "Forty-eight patients with unresectable gastric cancer were enrolled for a randomized trial of FP (n = 24) vs FEP (n = 24) combination chemotherapy with respect to their effects on survival period." | 2.68 | [Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy]. ( Horiuchi, Y; Ina, K; Iwase, H; Kaneko, H; Kuroiwa, A; Kusugami, K; Morise, K; Oka, Y; Shinoda, M; Suga, S, 1995) |
| "Stomatitis was seen more in arm B and C than in arm A." | 2.68 | [A randomized early phase II study of l-leucovorin and 5-fluorouracil in gastric cancer. l-Leucovorin and 5-FU Study Group]. ( Akazawa, S; Konishi, T; Kumai, K; Kurihara, M; Ogawa, M; Ogawa, N; Ota, K; Sasaki, T; Taguchi, T; Tominaga, T, 1995) |
| "The prognosis in gastric cancer has been almost unchanged for the last 20 years." | 2.68 | Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens. ( Angelsen, V; Norum, J, 1995) |
| "We identified patients with gastric cancer at high risk for recurrence before therapy using endoscopic ultrasonography (EUS)." | 2.68 | Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. ( Botet, J; Brennan, M; Gerdes, H; Huang, Y; Karpeh, M; Kelsen, D; Klimstra, D; Lauers, G; Lightdale, C; Quan, V; Saltz, L; Schwartz, G, 1996) |
| "Seventy gastric cancer patients were treated after surgery with one of the following regimens; 5-FU 10 mg/kg/24 hrs c." | 2.68 | [Administration and dosage of fluorouracil (5-FU) continuous i.v. infusion in patients with non-curative resected/non-resected gastric cancer]. ( Hori, A; Isogai, M; Kawai, M; Kubota, T; Maeda, A; Yamada, T; Yamaguchi, A; Yamaguchi, R, 1996) |
| "To evaluate the efficacy of adjuvant immunochemotherapy, especially the long-term administration of HCFU to patients with noncuratively resected and unresected gastric cancer, a randomized controlled study was conducted by 16 institutions in Hokkaido." | 2.68 | [Randomized controlled study on adjuvant immunochemotherapy with carmofur (HCFU) for noncuratively resected and unresected gastric cancer]. ( Fujisawa, J; Kondo, Y; Miyakawa, K; Nakanishi, Y; Nishimura, A; Oku, T; Osawa, S; Shiroto, H; Uchino, J, 1996) |
| "One hundred and three cases of advanced gastric cancer were randomly allocated into Group A (Me-CCNU, 5-Fu and ADM) and Group B (ACNU, 5-Fu and ADM)." | 2.68 | [ACNU and methyl-CCNU in combination chemotherapy for advanced gastric cancer: a randomized comparative study. Shanghai ACNU Collaborative Study Group]. ( Li, D; Xiao, S; Zhang, D, 1996) |
| "Fifty-one patients with advanced gastric cancer who received PDC (30 with 5-fluorouracil peroral administration and the other 21 with intravenous administration of 5-fluorouracil and cisplatin) were studied." | 2.68 | Histopathological response to preoperative chemotherapy including 5-fluorouracil additionally assessed by immunocytochemical and pharmacologic parameters in patients with advanced gastric cancer. ( Kumada, K; Nakamura, T; Nakano, H; Namatame, K; Sakai, H; Suzuki, T; Takahashi, H, 1996) |
| "The liver metastases of gastric cancer without unresectable primary tumors and hepatectomy were divided into two groups, 16 HAIC cases (11 synchronous, 5 metachronous metastases) and 23 systemic chemotherapeutic cases (10 synchronous, 13 metachronous metastases)." | 2.68 | [Evaluation of hepatic arterial infusion chemotherapy for gastric cancer]. ( Kawai, H; Kawasaki, S; Maruyama, S; Morisue, S; Morokoshi, Y; Otani, J; Soda, M; Suga, M; Uemura, T; Yamamoto, M; Yoshizane, K, 1996) |
| "Paclitaxel was administrated as a 3 h infusion of 175 mg/m2 at days 1 and 22, 5-FU 2000 mg/m2 i." | 2.68 | A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. ( Bokemeyer, C; Clemens, MR; Forkmann, L; Hartmann, JT; Kanz, L; Kollmannsberger, C; Lampe, CS; Quietzsch, D, 1997) |
| "5-fluorouracil was given at a dose of 1000 mg/m2 for 5 consecutive days and cisplatin was given on day 2 at a dose of 100 mg/m2." | 2.68 | The French experience with infusional 5-FU in gastric and pancreatic cancer. ( Ducreux, M; Rougier, P, 1996) |
| "Chemotherapy pretreated patients with colorectal cancer seem to have a substantial survival benefit with this salvage protocol." | 2.68 | High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer. ( Hausamen, TU; Loeffler, TM, 1996) |
| "Paclitaxel 175 mg/m2 was given intravenously over 3 hours on days 1 and 22; folinic acid 500 mg/m2 given intravenously over 2 hours followed by 5-FU 2,000 mg/m2 given intravenously over 24 hours was administered on days 1, 8, 15, 22, 29, and 36." | 2.68 | Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. ( Bokemeyer, C; Clemens, MR; Forkmann, L; Hartmann, JT; Kanz, L; Lampe, CS; Quietzsch, D, 1997) |
| "After en bloc resection of gastric cancer without gross or microscopic evidence of residual disease from April 1991 to December 1992, 100 patients were randomized to 6 months of 5-fluorouracil 1,000 mg/m2/day administered as continuous infusion for 5 days, cisplatin 60 mg/m2/day as intravenous infusion for 1 day with or without levamisole (50 mg every eight hours P." | 2.68 | A randomized trial comparing cisplatin plus 5-fluorouracil with or without levamisole in operable gastric cancer. ( Ahn, MJ; Choi, JS; Kim, JC; Kim, SH; Kim, SK; Kim, SW; Kim, WG; Lee, JH; Lee, JS; Lee, KH; Lee, MS; Park, KC; Suh, CW; Zang, DY, 1997) |
| "We studied how gastric cancer tissues and cells changed as a result of preoperative chemotherapy." | 2.68 | [Influence of preoperative on gastric cancer tissues and cells]. ( Chen, Z; Li, G; Liu, F, 1997) |
| "61 cases of the gastric cancers have been treated with Replenishing Qi and Invigorating Spleen (RQIS) combined with chemotherapy." | 2.67 | [Clinical and experimental study in treating gastric cancer with replenishing qi and invigorating spleen oral liquid combined with chemotherapy]. ( Chen, CH; Sun, GZ; Wang, GM, 1994) |
| "Recurrence of gastric cancer or colon cancer was observed in some patients who received 5-fluorouracil (5-FU) high-dose continuous Methotrexate (MTX)-Leucovorin (LV) therapy (FML therapy) previously." | 2.67 | [Usefulness of 5-FU high-dose continuous therapy at home in patients with recurrent gastric and colon cancer]. ( Fujihara, T; Inokuchi, T; Kawano, K; Kimoto, K; Mori, F; Tamura, Y; Yoshioka, Y, 1994) |
| "A phase II study of protracted infusional 5-fluorouracil (5FU) combined with cisplatin (CDDP) was conducted in patients with advanced gastric carcinoma." | 2.67 | Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). ( Kurihara, M; Morise, K; Ohtsu, A; Saito, H; Seki, S; Shimada, Y; Yoshida, S, 1994) |
| "The overall survival in patients with gastric cancer is low, even among those undergoing resection." | 2.67 | The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. ( Allum, WH; Dunn, JA; Hallissey, MT; Ward, LC, 1994) |
| " Drug concentrations in both peritoneal and plasma compartments followed a first-order model with similar half-life value of 1." | 2.67 | Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma. ( Dobbie, JW; el Eini, DI; Kerr, DJ; McArdle, CS; O'Gorman, P; Vinké, BJ; Warren, H; Watson, D; Wotherspoon, HA, 1994) |
| "19 advanced gastric cancer (AGC) patients were divided into the following groups: group A (n = 7): in addition to their oral intake, received a PNS for 5 days, which yielded 117 Kj." | 2.67 | [Effects of preoperative parenteral nutritional support with chemotherapy on tumor cell kinetics in gastric cancer patients]. ( Cao, WX; Xiao, HB; Yin, HR, 1994) |
| "Eighteen patients with gastric cancer with peritoneal metastasis were treated with methotrexate/5-fluorouracil sequential therapy." | 2.67 | [Methotrexate/5-fluorouracil therapy in gastric cancer with peritoneal metastasis]. ( Akiyama, T; Kiriyama, M; Kita, I; Kosaka, T; Nakano, Y; Saito, H; Sejima, T; Sugaya, J; Takano, Y; Tomita, F, 1994) |
| " They were randomly assigned to receive one of the three drug combination regimens or to 5-FU alone administered by rapid injection in 5-day course." | 2.67 | Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. ( Cullinan, SA; Krook, JE; Mailliard, JA; Moertel, CG; O'Connell, MJ; Poon, MA; Tschetter, LK; Wieand, HS, 1994) |
| "Seventy patients with advanced gastric cancer were randomised to receive fluorouracil (500 mg/m2 days 1-5 every three weeks) or epirubicin (100 mg/m2 every three weeks), with doses escalating to a maximum dose of 700 mg/m2 of fluorouracil or 140 mg/m2 of epirubicin." | 2.67 | Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study. ( Amadori, D; Bliss, JM; Chilvers, CE; Coombes, RC; Ferreira, EP; Fountzilas, G; Medi, F; Rauschecker, H; Vannozzi, G; Vassilopoulos, P, 1994) |
| "A total of 23 advanced gastric cancer patients older than 65 years received 500 mg/m2 5-fluorouracil i." | 2.67 | Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study. ( Cascinu, S; Catalano, G; Fedeli, A, 1994) |
| "Leukocytopenia was more severe in group B." | 2.67 | [Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy] ( Ito, T; Komatsu, Y; Moriya, N; Ogasawara, H; Saito, S; Sakata, Y; Sugimoto, N; Tamura, Y; Tsushima, K; Yamada, Y, 1994) |
| " The recommended dosage schedule with this technique is cisplatin 25 mg/m2 and FU 750 mg total dose IP with FU 500 mg/m2 as a continuous 24-hour infusion daily for days 1 to 4." | 2.67 | Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. ( Atiq, OT; Brennan, M; Kelsen, DP; Lin, S; Niedzwiecki, D; Saltz, L; Shiu, MH; Tong, W; Toomasi, F; Trochanowski, B, 1993) |
| "Patients with advanced gastric cancer were randomized to receive modified FAMTX treatment or supportive measures only (control group)." | 2.67 | Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. ( Murad, AM; Petroianu, A; Rausch, M; Rocha, PR; Rodrigues, MA; Santiago, FF, 1993) |
| "Results of 6589 gastric cancer operations at the Department of Surgery, Seoul National University Hospital, from 1970 to 1990 were reported." | 2.67 | Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. ( Kim, JP; Kwon, OJ; Oh, ST; Yang, HK, 1992) |
| "A clinical trial for patients with gastric cancer amenable to curative resection was undertaken to determine feasibility and response to preoperative systemic chemotherapy followed by postoperative intraperitoneal (IP) chemotherapy." | 2.67 | Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. ( Kiyabu, M; Laine, L; Leichman, CG; Leichman, L; Muggia, FM; Radin, R; Ray, M; Silberman, H; Spears, CP; Stain, S, 1992) |
| "Stomatitis was observed in 44/78 (56%) courses." | 2.67 | A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions. ( Alberti, D; Arzoomanian, RZ; Bailey, H; Grem, JL; Spriggs, DR; Tombes, MB; Tutsch, KD; Wilding, G, 1992) |
| "Twenty five patients with gastric cancer were randomly divided into five groups, and 5-FU (250 mg) was given with or without AT-II intraoperatively." | 2.67 | [5-FU concentration in the tissue of gastric cancer, and evaluation of cancer chemotherapy with angiotensin-II]. ( Takahashi, N, 1991) |
| "Treatment of gastric cancer still presents a challenge in cancer chemotherapy." | 2.67 | Evaluation of two consecutive regimens in advanced gastric cancer. ( Crivellari, D; Figoli, F; Frustaci, S; Galligioni, E; Lo Re, G; Monfardini, S; Saracchini, S; Sorio, R; Talamini, R; Tumolo, S, 1991) |
| "Twenty patients with metastatic gastric cancer were treated with methotrexate (MTX, M), 100 to 160 mg/m2 at 0 h, and, in sequence, 5-fluorouracil (FU, F), 600 to 1000 mg/m2 at 4 h; leucovorin (LV, L), 200 mg/m2 at 18 h, then 20 mg/m2 every 6 h x 12; 5-fluorouracil, 600 mg/m2 at 19 h; and high-dose cisplatin (DDP, P), 100 mg/m2 at 20 h." | 2.67 | Folate biochemical modulation regimen for the treatment of gastric cancer. ( Bruckner, HW; Chesser, MR; Mandeli, J; Wong, H, 1991) |
| " The adverse effects related to the DP infusion were flushing, headache, nausea and upper abdominal discomfort, all of a low grade." | 2.67 | Dipyridamole combination chemotherapy can be used safely in treating gastric cancer patients. ( Emi, Y; Kohnoe, S; Kusumoto, T; Maehara, Y; Sakaguchi, Y; Sugimachi, K, 1991) |
| "A total of 848 patients with gastric cancer underwent curative resection were eligible." | 2.67 | [Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supp ( Ichihashi, H; Imaizumi, M; Kamei, H; Kondo, T, 1990) |
| "Thirty one gastric cancer pts." | 2.67 | [High-dose leucovorin and 5-fluorouracil in advanced gastric and colorectal cancer. High-Dose Leucovorin and 5-FU Study Group]. ( Akazawa, S; Matsuoka, T; Mukaiyama, T; Ogawa, M; Ota, K; Sakai, Y; Sakata, Y; Sasaki, T; Wakui, A; Yoshino, M, 1990) |
| "158 cases of late gastric carcinoma (11 males and 47 females, age 30-70 years) were treated postoperatively with TCM prescriptions of strengthening the patient's resistance and dispelling the invading evil in combination with chemotherapy." | 2.67 | [Treatment of operated late gastric carcinoma with prescription of strengthening the patient's resistance and dispelling the invading evil in combination with chemotherapy: follow-up study of 158 patients and experimental study in animals]. ( Wang, GT, 1990) |
| "BACKGROUND Gastric cancer metastasis to the appendix is a rare condition that might present with symptoms of acute appendicitis or remain asymptomatic and be diagnosed incidentally." | 2.66 | Missed Gastric Cancer Metastasis to the Appendix: Case Report and Literature Review. ( Aburahmah, M; Alhadid, D; Almana, H; AlShammari, A, 2020) |
| "Survival for patients with advanced gastric cancer (GC) remains poor." | 2.66 | Maintenance treatment in advanced HER2-negative gastric cancer. ( Deng, R; Jia, Y; Kong, F; Liao, D; Xie, H; Yao, Y; Zuo, J, 2020) |
| "Until now advanced gastric cancer has been generally treated with the FAM chemotherapy protocol." | 2.66 | An EORTC gastrointestinal (GI) group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancer. ( Bleiberg, H; Buyse, M; Duez, N; Klein, HO; Wils, J, 1989) |
| " The LT 5-FU was given at a dosage of 750 mg/m2 every 2 weeks for 18 months or until progression." | 2.66 | Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC. ( Bleiberg, H; Buyse, M; Dalesio, O; Gerard, A; Gignoux, M; Goffin, JC; Michel, J; Pector, JC; Roussel, A; Samana, G, 1989) |
| "A total of 48 patients with gastric cancer were randomly assigned to receive either endoscopic injections of OK-432 plus systemic treatment with intravenously administered 5-fluorouracil and intradermally injected OK-432 (group A) or systemic therapy alone (group B)." | 2.66 | Clinical efficacy of endoscopic injections of OK-432 in the treatment of gastric cancer. ( Nakazawa, S; Okamura, S; Yamao, K; Yoshino, J, 1988) |
| "The cumulative survival rate of 166 gastric cancer patients after noncurative resection and nonresection treated by combination therapy using carmofur (HCFU), mitomycin C (MMC) and immunopotentiators was investigated." | 2.66 | [A randomized controlled trial of immunochemotherapy using carmofur (HCFU), mitomycin C and immunopotentiators in advanced gastric cancer following noncurative resection and nonresection]. ( Nakanishi, Y, 1986) |
| "Fifty of 80 cases had advanced gastric cancer, 30 had pancreatic cancer or other cancers, such as colon cancer, and biliary tract cancer." | 2.66 | [Controlled study of MQF-OK therapy with FT and with UFT on various advanced gastrointestinal cancers. Hirosaki Cooperative Study Group of Cancer Chemotherapy]. ( Baba, T; Furukohori, N; Itoh, T; Kawata, K; Kimura, T; Munakata, A; Saitoh, S; Sakata, Y; Suzuki, H; Tamura, Y, 1988) |
| "In rectosigmoid cancer the group on 5-FU included 26 patients who showed a response rate of 19% (5/26)." | 2.66 | Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer. ( Kolarić, K; Potrebica, V; Stanovnik, M, 1986) |
| "Ten of the gastric cancer patients (29%) had partial responses." | 2.66 | Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach. ( Ahmed, S; Alvarez, CA; Cazap, EL; Estevez, RA; Gisselbrecht, C; Hannois, A; Lagarde, C; Schein, PS; Smith, FP; Woolley, PV, 1986) |
| "Kondo) in Japan." | 2.65 | [Cooperative studies on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer]. ( Ichihashi, H; Imaizumi, M; Kamei, H; Kondo, T, 1984) |
| "This finding was clinically applied to cancer chemotherapy for enhancing drug delivery to tumor tissue selectively." | 2.65 | [Clinical studies on induced hypertension chemotherapy based on functional characteristics of microcirculation of tumor vessels]. ( Sato, H; Wakui, A, 1984) |
| " The optimal dosage was considered to be between 17 mg/kg and 24 mg/kg." | 2.65 | [Joint clinical Phase II study of SF-SP]. ( Hanatani, Y; Sato, H; Sato, T, 1984) |
| " Then, it was followed by long-term administration of tegafur (FT) and immunomodulators." | 2.65 | A trial of adjuvant combination chemoimmunotherapy for stage III carcinoma of stomach. ( Akiyoshi, T; Arinaga, S; Kawaguchi, M; Koba, F; Miyazaki, S; Tsuji, H; Wada, T, 1984) |
| " In patients who underwent of curative resection, the long-term administration of Ftorafur alone tended to prevent recurrence postoperatively, especially within the first two postoperative years." | 2.65 | [A randomized study on the long-term adjuvant chemotherapy with ftorafur and mitomycin C for gastric cancer: the second study (III)]. ( Abe, O; Akiyama, H; Hattori, T; Inokuchi, K; Inoue, K; Kikuchi, K; Kondo, T; Muto, T; Nakajima, T; Taguchi, T, 1984) |
| "A group of 243 patients with gastric cancer was subjected to a prospective randomized trial of adjuvant chemotherapy after curative gastrectomy." | 2.65 | Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. ( Kajitani, T; Kuno, K; Nakajima, T; Takagi, K; Takahashi, T, 1984) |
| "Gastric cancer is the most chemotherapy-responsive adenocarcinoma of the major gastrointestinal sites." | 2.65 | Current management of advanced and locally unresectable gastric carcinoma. ( Ahlgren, JD; Schein, PS; Smith, FP; Woolley, PV, 1982) |
| "Levamisole group was treated with Mitomycin C (day 0, 20 mg, day 1, 10 mg, one shot i." | 2.65 | [Effect of levamisole in postoperative adjuvant immunochemotherapy of stomach cancer--randomized controlled study of MMC-tegafur combination therapy with or without levamisole. 1]. ( Abe, O; Fujimoto, S; Furue, H; Furusawa, M; Hashimoto, I; Hattori, T; Inokuchi, K; Itoh, I; Koga, S; Kondo, T; Niimoto, M; Ogawa, N; Ohya, M; Orita, K; Sugiyama, Y; Tamada, R; Toda, T, 1982) |
| "The levamisole group was treated with Mitomycin C, 5-FU and levamisole." | 2.65 | [Effect of levamisole in postoperative adjuvant immunochemotherapy of stomach cancer--randomized controlled study of MMC-5-FU combination therapy with or without levamisole. 1]. ( Furue, H; Furusawa, M; Hattori, T; Hioki, K; Hirano, M; Inokuchi, K; Itoh, I; Iwanaga, T; Izuo, M; Kondo, T; Kosaki, G; Miura, K; Niimoto, M; Ogawa, N; Orita, K; Taguchi, T; Takemiya, S; Tamada, R; Tomita, M; Tsuji, H; Yura, J, 1982) |
| " Furthermore, the survival was elevated in proportion to the increase of total dosage of futraful." | 2.65 | [Effect of postoperative long-term chemotherapy of stomach cancer using mitomycin C and futraful--the secondary study (1)]. ( Abe, O; Akiyama, H; Hattori, T; Hayasaka, A; Inokuchi, K; Inoue, K; Ito, I; Kasai, Y; Kikuchi, K; Kondo, T; Muto, T; Nakajima, T; Sugie, S; Taguchi, T, 1982) |
| "Combinations of active agents in gastric cancer hold promise as effective surgical adjuvant therapy." | 2.65 | Adjuvant chemotherapy in colon and gastric cancer. ( Haller, DG; Kisner, DL; Macdonald, JS, 1982) |
| "In a prospective randomized study, 53 patients with advanced gastric cancer previously untreated by chemotherapy were randomly assigned to treatment with 5-FU alone or combined with mitomycin and cytarabine (MFC)." | 2.65 | Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. ( Cocconi, G; DeLisi, V; Di Blasio, B, 1982) |
| "Studies on non-curative stomach cancer patients treated with the same dose schedule gave encouraging results." | 2.64 | Protracted oral chemotherapy with fluorinated pyrimidines as an adjuvant to surgical treatment for stomach cancer. ( Akao, T; Fujimoto, S; Itoh, B; Koshizuka, I; Koyano, K, 1977) |
| "originates in the stomach." | 2.64 | Gastric cancer: current status of treatment. ( Carter, SK; Comis, RL, 1977) |
| "Some gastric cancer studies have reported that MSI has no apparent impact on prognosis after patients receive 5-FU-based adjuvant chemotherapy." | 2.61 | Predicting the Efficacy of 5-Fluorouracil-Based Adjuvant Chemotherapy in Gastric Cancer by Microsatellite Instability: A Meta-Analysis. ( Ahmad, R; Ma, Z; Ren, D; Shen, G; Wang, Z; Yuan, X; Zhao, F; Zhao, J; Zheng, F, 2019) |
| "According to the Trastuzumab for Gastric Cancer (ToGA) study, trastuzumab plus cisplatin and capecitabine/5-fluorouracil (5-FU) is standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced oesophagogastric cancer." | 2.58 | Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis. ( Creemers, A; de Waal, L; Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH, 2018) |
| "The optimal Chinese herbal injections (CHIs) combined with XELOX regimen for patients with gastric cancer remains elusive." | 2.58 | Which are the best Chinese herbal injections combined with XELOX regimen for gastric cancer?: A PRISMA-compliant network meta-analysis. ( Duan, X; Liu, S; Wang, K; Wu, J; Zhang, B; Zhang, D, 2018) |
| "Gastric cancer has a fatality-to-case ratio of 0." | 2.55 | The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction. ( Amlashi, FG; Blum Murphy, M; Bozkurt, M, 2017) |
| "Gastric cancer is the fifth most common cancer worldwide." | 2.55 | Chemotherapy for advanced gastric cancer. ( Grothe, W; Ho, J; Moehler, M; Syn, NL; Tai, BC; Unverzagt, S; Wagner, AD; Yong, WP, 2017) |
| "Approximately 20% of patients with cancer of the stomach or gastro-oesophageal junction (GOJ) present with resectable disease." | 2.55 | The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. ( Cartwright, E; Cunningham, D, 2017) |
| " In Japan, S-1 in combination with cisplatin is the recommended first-line treatment in patients with gastric cancer." | 2.55 | New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin. ( Heinemann, V; Lorenzen, S; Mahlberg, R; Möhler, M; Pfeiffer, P; Thuss-Patience, P, 2017) |
| " The objective of this systematic review was to evaluate overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and grade (G) greater than or equal to 3 adverse event of mDCF chemotherapy in this setting." | 2.55 | Modified schedules of DCF chemotherapy for advanced gastric cancer: a systematic review of efficacy and toxicity. ( Barni, S; Ghidini, M; Passalacqua, R; Petrelli, F; Tomasello, G, 2017) |
| "Studies in gastric cancer patients treated with S-1 investigating the expression variations of 5-fluorouracil metabolic enzymes were included after having been identified systematically." | 2.53 | High/positive expression of 5-fluorouracil metabolic enzymes predicts better response to S-1 in patients with gastric cancer: a meta-analysis. ( Wang, D; Wang, X; Yu, X, 2016) |
| "In the West, where esophageal cancer occurs more frequently than gastric cancer, a phase III trial (the CROSS trial) demonstrated the efficacy of preoperative chemoradiotherapy using carboplatin plus paclitaxel for patients with esophageal or EGJ cancer." | 2.52 | [Adjuvant treatment for esophagogastric junction cancer]. ( Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M, 2015) |
| "More than half of radically resected gastric cancer patients relapse locally or with distant metastases, or receive the diagnosis of gastric cancer when tumor is disseminated; therefore, median survival rarely exceeds 12 mo, and 5-years survival is less than 10%." | 2.50 | Treatment of gastric cancer. ( Andreozzi, F; Ciardiello, F; De Vita, F; Fabozzi, A; Galizia, G; Gambardella, V; Laterza, MM; Lieto, E; Mabilia, A; Orditura, M; Savastano, B; Sforza, V; Ventriglia, J, 2014) |
| "Despite advances in the treatment of gastric cancer, it remains the world's second highest cause of cancer death." | 2.50 | Treatment options in patients with metastatic gastric cancer: current status and future perspectives. ( Bilici, A, 2014) |
| "A 48-year-old man with colorectal cancer and right inguinal lymph node metastasis had previously undergone radiotherapy and chemotherapy (uracil/tegafur/leucovorin) after a colostomy in another hospital before being referred to us." | 2.50 | [Disappearance of a gastric lesion following modified FOLFOX6 chemotherapy in a patient with metastatic colorectal cancer: a case report and literature review]. ( Aihara, T; Fukuda, S; Iino, C; Mikami, T; Sakamoto, J; Sawaya, M; Tanaka, M; Tono, H; Yamagata, R; Yoshida, K, 2014) |
| "We conducted a meta-analysis to compare oral S-1 and infusional 5-fluorouracil (5-FU) to determine which agent was more efficacious and less toxic in combination with PTX." | 2.50 | The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus 5-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials. ( Chen, X; Gao, P; Liu, H; Lu, X; Song, Y; Sun, J; Wang, Z; Xu, H; Zhang, N, 2014) |
| "Locally advanced, marginally resectable gastric cancer with poor prognosis, such as large type 3 or 4 tumors, para-aortic and/or bulky nodal disease, and serosa-positive gastric cancer, is the main target of neoadjuvant chemotherapy." | 2.49 | Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East. ( Fujitani, K, 2013) |
| "Stomach cancer is still one of the most prevalent malignancies and is the main cause of cancer deaths worldwide." | 2.48 | Second-line chemotherapy for advanced gastric cancer in Korea. ( Baek, SK; Cho, KS; Jeong, JH; Kim, SY; Yoon, HJ, 2012) |
| " This rare but potentially fatal side effect has neither identified risk factors nor established treatment guideline." | 2.48 | Oxaliplatin-induced lung toxicity. Case report and review of the literature. ( Abeni, C; Bertocchi, P; Prochilo, T; Zaniboni, A, 2012) |
| "Studies that included patients with metastases at enrollment were excluded." | 2.48 | Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis. ( Cai, XH; Ge, L; Lei, C; Wang, HJ; Yin, D; Zhang, GQ; Zhu, JF, 2012) |
| "Gastric cancer is the fourth most common malignancy worldwide with Japan, Korea, Taiwan, China, Mongolia and many countries in South America and eastern Europe, as well as parts of the Middle East, contributing to the majority of cases." | 2.47 | A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. ( Ajani, JA; Blum, M; Suzuki, A, 2011) |
| "So far, the only curative treatment for gastric cancer is surgery." | 2.46 | Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer. ( Farhat, FS; Ghosn, MG; Kattan, J, 2010) |
| "From a global perspective, gastric cancer including cancer of the esophago-gastric junction is the fourth most common malignant tumor and the second-most common cause of cancer-related death." | 2.46 | [Diagnosis and treatment of gastric cancer]. ( Ebert, M; Grenacher, L; Lordick, F; Moehler, M; Röcken, C; Schumacher, G, 2010) |
| "Capecitabine is an oral prodrug of 5-fluorouracil (5-FU)." | 2.46 | Capecitabine for the treatment of advanced gastric cancer. ( Eastwood, A; Norman, G; Peura, P; Rice, S; Sculpher, M; Soares, M; Suh, D; Wright, K, 2010) |
| "Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug." | 2.45 | The role of capecitabine in the management of tumors of the digestive system. ( Gennatas, C; Gennatas, S; Michalaki, V, 2009) |
| "It has been demonstrated that gastric cancer mesenchymal stem cells (GC-MSCs) can promote the progression, metastasis, and chemoresistance of GC through various mechanisms, but the effect of GC-MSCs on GC during chemotherapy is still unknown." | 2.44 | Chemotherapeutic Drugs Endow Gastric Cancer Mesenchymal Stem Cells with Stronger Tumor-Promoting Ability. ( Chen, Z; Cui, L; Huang, C; Shen, B; Shen, J; Wang, M; Zhao, Y; Zhu, M; Zhu, W, 2024) |
| "The prognosis for advanced gastric cancer patients treated with multimodal therapy after surgery remains discouraging." | 2.44 | Stem cell landscape aids in tumor microenvironment identification and selection of therapeutic agents in gastric cancer. ( Che, G; Chen, Y; Ding, Y; He, C; Teng, F; Teng, L; Wang, H; Yang, Y; Zhang, J; Zhou, D; Zhou, Z, 2024) |
| "Approximately 84% of patients with gastric cancer will have advanced disease and median survival of these patients without chemotherapy is only 3-4 months." | 2.44 | Chemotherapy of advanced gastric cancer. ( López-Brea, MF; Rivera, F; Vega-Villegas, ME, 2007) |
| "Gemcitabine is a well-tolerated anti-tumour drug with broad-spectrum activity." | 2.44 | [Gemcitabine and digestive carcinomas]. ( André, T; Blanchard, P; Huguet, F, 2007) |
| " Dosing of S-1 is different between Western and Asian populations due to differences in metabolism by CYP2A6." | 2.44 | Medical treatment for advanced gastroesophageal adenocarcinoma. ( Ajani, JA; Cen, P, 2007) |
| "Capecitabine is an orally-active fluoropyrimidine, which is selectively metabolised to fluorouracil in tumour cells." | 2.44 | Capecitabine in advanced gastric cancer. ( Chau, I; Cunningham, D; Okines, A, 2007) |
| "Colorectal cancers have been the first cancers to benefit from an efficient anti-angiogenic treatment, represented by bevacizumab, which has been approved for first-line metastatic treatment in combination with reference chemotherapies and which is under study in the adjuvant setting." | 2.44 | [Angiogenesis targeting in gastro-intestinal cancers]. ( Meric, JB, 2007) |
| "UFT (tegafur-uracil) has similar efficacy to continuous infusion 5-FU with improved tolerability and is more convenient for patients." | 2.44 | The role of UFT in advanced gastric cancer. ( Aykan, NF; Idelevich, E, 2008) |
| "Gastric cancer is the second most common cause of cancer death worldwide." | 2.43 | Experience with docetaxel in the treatment of gastric cancer. ( Philip, PA, 2005) |
| "If almost all colorectal cancers (CRC) correspond to the same histopathological type (adenocarcinoma), molecular biology allowed the identification of two different molecular mechanisms of colorectal carcinogenesis: chromosomal instability characterized by recurrent allelic losses on chromosomes 17, 5, 18, 8 and 22 that contribute to the inactivation of tumor suppressor genes, and genetic instability characterized by the instability of microsatellite loci due to an alteration of DNA mismatch repair leading to the accumulation of mutations in genes involved in the control of cell cycle and apoptosis." | 2.43 | [Molecular biology in clinical cancer research: the example of digestive cancers]. ( Laurent-Puig, P; Lièvre, A, 2005) |
| "Gastric cancer is often diagnosed in locally advanced or metastatic stages and, therefore, of poor prognosis." | 2.43 | The emerging role of oxaliplatin in the treatment of gastric cancer. ( Meriggi, F; Zaniboni, A, 2005) |
| "The incidence of gastric cancer in Europe is declining but the prognosis after curatively intended surgery remains dismal." | 2.43 | [Efficacy of current adjuvant and neoadjuvant therapeutic concepts in gastric cancer?]. ( Kretzschmar, A; Schlag, PM, 2006) |
| "Because patients with advanced gastric cancers have less than 50% chance of cure after R0 resection, the need for an adjuvant treatment to eradicate residual microscopic disease is clear." | 2.43 | A review of adjuvant therapy for resected primary gastric cancer with an update on Taegu's phase III trial with intraperitoneal chemotherapy. ( Yu, W, 2006) |
| "Capecitabine is a novel, orally administered fluoropyrimidine carbamate that has been approved for adjuvant treatment in patients with Stage III colon cancer, first-line metastatic colorectal cancer, and metastatic breast cancer, both as a single agent (for patients who are resistant to paclitaxel and anthracyclines) and in combination with docetaxel (after failure on anthracycline-based therapy)." | 2.43 | Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. ( Ajani, J, 2006) |
| "Recent advances in the management of gastric cancer, especially in the arena of chemotherapy, are paving the way for optimization of treatment that maximizes effectiveness while minimizing toxicity." | 2.43 | Determinants of chemosensitivity in gastric cancer. ( Lenz, HJ; Park, DJ, 2006) |
| "Treatment of localized gastric cancer relies primarily on surgical intervention, although growing evidence suggests that the addition of chemoradiation may improve disease-free intervals and overall survival." | 2.43 | Molecular markers for gastric adenocarcinoma: an update. ( Anderson, C; Kim, J; Nijagal, A, 2006) |
| "Formerly the treatment of gastrointestinal cancers was exclusively surgical." | 2.43 | [Progress in the treatment of gastrointestinal cancers due to introduction of neoadjuvant concept]. ( Cseke, L; Esik, O; Horváth Ors, P; Kalmár, K; Papp, A; Yousuf, AF, 2006) |
| "In advanced pancreatic cancer, oxaliplatin has been found to be clinically effective in phase II trials in which it was combined with either 5-fluorouracil (5-FU) or gemcitabine, the current standard chemotherapy for this disease." | 2.42 | The role of oxaliplatin in the management of upper gastrointestinal tract malignancies. ( Scheithauer, W; Van Cutsem, E, 2003) |
| "In untreated metastatic gastric cancer, median survival is 3-4 months." | 2.42 | Current treatments and future perspectives in colorectal and gastric cancer. ( Van Cutsem, E; Wilke, HJ, 2003) |
| "Capecitabine is an oral 5-fluorouracil (5-FU) prodrug that is more convenient than using infusional 5-FU, appears to have a similar therapeutic profile, and can be combined with daily irradiation." | 2.42 | COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas. ( Rich, TA; Shepard, R, 2003) |
| "The potential place of docetaxel in gastric cancer is not restricted to metastatic disease and the same three-therapy with TCF is currently under evaluation as a neoadjuvant or adjuvant treatment in resectable lesions." | 2.42 | [Docetaxel and gastric cancer]. ( Boige, V; Ducreux, M; Roth, A, 2004) |
| "Untreated metastatic gastric cancer is associated with a median survival of only 3-4 months, but this can be increased to 8-10 months, associated with improved quality of life, with combination chemotherapy." | 2.42 | Systemic treatment of gastric cancer. ( Cunningham, D; Dickson, JL, 2004) |
| "In the treatment of gastric cancer R0 surgical resection is the only hope for cure." | 2.41 | [Neoadjuvant chemotherapy in advanced stomach cancer--a case of complete response]. ( Cseke, L; Horváth, OP; Kalmár, K; Káposztás, Z, 2002) |
| "Because of the low chemosensitivity of gastric cancer to conventionally available agents, several approaches were investigated to design "order made" treatments using chemosensitivity tests, including the histoculture drug response assay (HDRA) which was useful in evaluating the appropriate cancer chemotherapy for the patients with Stage III/IV gastric cancer." | 2.41 | [Recent advance in gastric cancer chemotherapy]. ( Kubota, T, 2000) |
| "Metastatic gastric cancer is a relatively chemosensitive disease." | 2.41 | Developments in the treatment of gastric cancer in Europe. ( Köhne, CH; Wilke, HJ; Wils, JA, 2000) |
| " The dosage and administration is referred to the weekly method developed at RPMI." | 2.41 | [Levofolinate and fluorouracil combination therapy]. ( Murakami, M; Takeuchi, S, 2001) |
| "A case of AFP producing early gastric cancer successfully treated with a small dose of CDDP and 5-FU therapy administered intermittedly is reported with a review of the literature." | 2.41 | [A case of AFP producing early gastric cancer successfully treated with small dose CDDP and 5-FU (PF) therapy]. ( Aoki, T; Fujimitsu, Y; Koyanagi, Y; Moritani, M; Niido, T; Shinohara, M; Tsuchida, A, 2001) |
| "Most patients diagnosed with gastric cancer in the United States and the Western World will either present with advanced disease or have recurrence after surgery, requiring discussions of chemotherapy." | 2.41 | Chemotherapy options for gastric cancer. ( Fuchs, CS; Meyerhardt, JA, 2002) |
| "In addition, the PHREG analysis in 1453 gastric cancer patients showed that MF therapy (mitomycin C i." | 2.40 | Selection of adjuvant chemotherapy for gastric cancer using objective criteria. ( Nishiyama, M; Toge, T, 1997) |
| "Paclitaxel was well tolerated." | 2.40 | Treatment of patients with upper gastrointestinal carcinomas. ( Ajani, JA, 1997) |
| "The recurrence rate of resected gastric cancer with curative intent was around 20%." | 2.40 | [Treatment of recurrent gastric cancer]. ( Sakata, Y; Tsushima, K, 1998) |
| "Capecitabine was converted to 5'-DFUR by either human carboxyestelase or cytidine deaminase, which were mainly localized in human liver." | 2.40 | [Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine]. ( Saeki, T; Takashima, S, 1999) |
| "Both gastric and pancreatic cancer remain leading causes of cancer death in the United States and worldwide." | 2.40 | Adjuvant/neoadjuvant chemoradiation for gastric and pancreatic cancer. ( Leach, SD; Lowy, AM, 1999) |
| "Chemotherapy for gastric cancer should be evaluated with survival advantages or rate of long-term survivors in future studies." | 2.39 | [Recent advances in chemotherapy for advanced gastric cancer: from the standpoint of survival advantages]. ( Miyata, Y; Ohtsu, A; Shimada, Y; Yoshida, S, 1995) |
| "For Dukes' C colon cancer, postoperative adjuvant chemotherapy with a combination of fluorouracil and levamisole is now recommended as standard therapy." | 2.39 | Adjuvant postoperative therapy of gastrointestinal malignancies. ( Ilson, DH; Kelsen, DP, 1994) |
| "Work has been done in gastric cancer, pancreatic cancer, and colon and rectal cancer, all of which demonstrate an advantage in certain clinical situations for combined-modality therapy." | 2.38 | Combined radiotherapy and chemotherapy in the treatment of gastrointestinal malignancies. ( Tepper, JE, 1992) |
| "However, in gastric cancer, 5-FU/FA and 5-FU/IFN seem to induce higher complete and overall remission rates in advanced gastric cancer compared with 5-FU alone." | 2.38 | Biochemical modulation of 5-fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer. ( Achterrath, W; Fink, U; Harstrick, A; Knipp, H; Köhne-Wömpner, CH; Meyer, HJ; Preusser, P; Schmoll, HJ; Stahl, M; Wilke, H, 1992) |
| " It is expected that the dose intensity may clear dose-response relationships which are sometimes obscure in cancer chemotherapy because dose reduction or treatment delay caused by adverse effects." | 2.38 | [Dose intensity in cancer chemotherapy in gastric cancer]. ( Ishibiki, K; Kumai, K, 1990) |
| "Thirty one patients with diagnosis of Gastric Cancer were admitted in this study." | 2.38 | [Combined chemotherapy with the FEM protocol in advanced gastric cancer]. ( Casanova, L; Celis, J; Montalbetti, J; Nuñez, J; Otero, J; Payet, C; Salazar, F; Sánchez, J; Solidoro, A; Vallejos, C, 1989) |
| " To date, a lot of phase II studies have been conducted, but there are many distance in each clinical data concerning response rate and side effect by the difference between their clinical methods with respect to the interval between methotrexate and 5-fluorouracil, or the dosage of each drugs." | 2.37 | [Current studies of sequential methotrexate and 5-fluorouracil treatment in cancer chemotherapy]. ( Murakami, M; Ota, K, 1988) |
| "For example, the role of cisplatin in gastric cancer has not been completely defined." | 2.37 | Chemotherapy of advanced gastric cancer: present status, future prospects. ( Gohmann, JJ; Macdonald, JS, 1988) |
| "Fluorouracil has been used for a long time, remission rates reported range from 0% to 80%." | 2.36 | [Chemotherapy of gastrointestinal tumors (review of the literature)]. ( Mayr, AC, 1978) |
| "Interestingly, patients with gastroesophageal cancer benefitted more from this therapy." | 1.91 | Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort. ( Brossart, P; Feldmann, G; Gonzalez-Carmona, MA; Jafari, A; Kalff, JC; Köksal, M; Lingohr, P; Mahn, R; Mańczak, A; Möhring, C; Monin, MB; Sadeghlar, F; Sarria, GR; Sommer, N; Strassburg, CP; Timotheou, A; Toma, M; Zhou, T, 2023) |
| "We prospectively included patients with gastric cancer who underwent radical gastrectomy between March 14, 2017 and September 30, 2021." | 1.91 | Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy. ( Dong, Q; Gao, L; Li, E; Li, Z; Liu, Z; Ma, J; Ren, D; Shen, G; Wang, M; Xie, Q; Zhao, F; Zhao, J; Zhao, Y, 2023) |
| "In locally advanced gastric cancer (GC), FLOT represents the standard perioperative regimen and combination with immunotherapy is under investigation." | 1.91 | Dynamic Profiling of the Immune Tumor Microenvironment in Locally Advanced Gastric Cancer Treated with Perioperative Chemotherapy. ( Belluomini, MA; Catanese, S; Cremolini, C; Fontanini, G; Fornaro, L; Giannini, R; Giordano, M; Lencioni, M; Masi, G; Massa, V; Pallabazzer, G; Pecora, I; Salani, F; Santi, S; Ugolini, C; Vasile, E; Vivaldi, C, 2023) |
| "The migration and invasion of gastric cancer cells were significantly inhibited by 10 mg/L auramycin G, which was consistent with the down-regulation of the VEGFR2-VEGFA-pPI3K-pAkt-pErk1 and VEGFR3-VEGFC-pPI3K-pAkt-pmTOR proteins." | 1.91 | Anthracycline chemicals with anthracyclinone structure exert antitumor effects by inhibiting angiogenesis and lymphangiogenesis in a xenografted gastric tumor model. ( Du, W; Jia, C; Jiang, H; Li, C; Li, H; Wang, Y, 2023) |
| "Based on cancer-related deaths, stomach cancer is ranked fifth, and first among Hispanics." | 1.91 | β-Glucan-Mediated Oral Codelivery of 5FU and Bcl2 siRNA Attenuates Stomach Cancer. ( Afrin, H; Boland, T; Esquivel, SV; Kumar, R; Nurunnabi, M; Oporeza, B; Rahman, MF; Zahid, MI, 2023) |
| "Gastric carcinoma is a frequently detected malignancy worldwide, while its mainstream drugs usually result in some adverse reactions, including immunosuppression." | 1.91 | The Antitumor Potential of λ-Carrageenan Oligosaccharides on Gastric Carcinoma by Immunomodulation. ( Chen, H; Chen, J; Tang, M; Wang, F; Wu, W; Zhai, L, 2023) |
| "Poorly cohesive cells-gastric cancer (PCC-GC) represents distinct features within the GC spectrum." | 1.91 | Clinical implications and chemo-sensitivity of adjuvant chemotherapy in patients with poorly cohesive cells-gastric cancer. ( Baek, JH; Cho, M; Kang, BW; Kang, H; Kim, JG; Kwon, OK; Park, JY; Park, KB; Seo, AN, 2023) |
| "Sarcopenia was present in 38 patients (50." | 1.91 | Association between Pre-Treatment Biological Indicators and Compliance to Neoadjuvant/Perioperative Chemotherapy in Operable Gastric Cancer. ( Bianchini, D; Esposito, L; Foca, F; Frassineti, GL; Gallio, C; Molinari, C; Montanari, D; Monti, M; Morgagni, P; Passardi, A; Prochowski Iamurri, A; Ruscelli, S; Vittimberga, G, 2023) |
| " This work aimed to investigate the clinical efficacy of intraperitoneal perfusion of fluorouracil and cisplatin combined with intravenous chemotherapy for the treatment of peritoneal metastasis in GC." | 1.91 | Clinical effectiveness of fluorouracil and cisplatin intraperitoneal perfusion combined with intravenous chemotherapy for peritoneal metastasis in gastric cancer. ( Chen, SY; Li, XQ; Mao, QC; Xiong, XH; Yang, JW, 2023) |
| "More importantly, the anti-gastric cancer activity of the active compound was confirmed in MGC-803 xenograft nude mice in vivo." | 1.72 | Isolation, synthesis and bioactivity evaluation of isoquinoline alkaloids from Corydalis hendersonii Hemsl. against gastric cancer in vitro and in vivo. ( Deng, XM; Jiang, K; Li, QE; Li, Z; Liu, D; Liu, LY; Luo, T; Shi, T; Wang, Z; Wen, HX; Zhang, HH, 2022) |
| "Furthermore, compound a21-2 inhibits gastric cancer cells proliferation and cell colony formation." | 1.72 | Design, synthesis and antitumour activity of novel 5(6)-amino-benzimidazolequinones containing a fused morpholine. ( Huang, H; Liu, FW; Meng, Y; Wang, C; Wang, H; Yang, J; Zhao, Y; Zhu, C, 2022) |
| "Primary CAFs and NFs were cultured from gastric cancer specimens, and their variant expression was analyzed by RNA-sequencing." | 1.72 | CAF promotes chemoresistance through NRP2 in gastric cancer. ( Chen, G; Chen, S; Hu, J; Liu, Y; Ma, Y; Wang, J; Wang, P; Yan, S; Yang, Y; Zhu, J, 2022) |
| "Because recurrent gastric cancer is often a progressive condition, post-treatment might be promptly transferred to the other posterior regimen without 5-FU as required." | 1.72 | [Hyperammonemic encephalopathy after treatment with modified FOLFOX6 regimen for recurrent gastric cancer:a case report]. ( Hirano, S; Ichinokawa, M; Kumagai, K; Kuwabara, S; Matsumoto, J; Murakawa, K; Ono, K; Takeuchi, Y; Wada, H, 2022) |
| "Gastric cancer is still the fifth most common malignant tumor in the world and has the fourth highest mortality rate in the world." | 1.72 | Experimental Research on the Antitumor Effect of Human Gastric Cancer Cells Transplanted in Nude Mice Based on Deep Learning Combined with Spleen-Invigorating Chinese Medicine. ( Ai, K; Yuan, D; Zheng, J, 2022) |
| " Furthermore, UA exhibited tumor-suppressing index (TSI) score of 90% over a 6-week treatment term when used for single dosing in xenograft tumor model." | 1.72 | Ursolic acid silences CYP19A1/aromatase to suppress gastric cancer growth. ( Chang, N; Chang, WC; Chen, GY; Cheng, WC; Li, CC; Ma, WL; Su, YT; Wu, YC; Yang, JC; Yu, Y, 2022) |
| "TCGA gastric cancer data (n = 436) were analyzed, and mutation sites detected in 16 GC patients in this study were in agreement with TCGA cohort with some exceptions." | 1.72 | Comparative analysis of cancer gene mutations using targeted sequencing in matched primary and recurrent gastric cancers after chemotherapy. ( Cho, MS; Cho, SY; Huh, YJ; Lee, JH; Lee, KE, 2022) |
| "5-Fluorouracil (5-FU) is widely used in gastric cancer treatment, yet 5-FU resistance remains an important clinical challenge." | 1.72 | Long noncoding RNA OVAAL enhances nucleotide synthesis through pyruvate carboxylase to promote 5-fluorouracil resistance in gastric cancer. ( Han, FH; Hu, H; Huang, J; Luo, ML; Tan, JN; Yang, B; Zhang, W; Zhong, GY; Zhou, SN, 2022) |
| "To improve the early detection of gastric cancer (GC), there is a growing need for novel and efficient biomarkers." | 1.72 | Plasma thioredoxin reductase: a potential diagnostic biomarker for gastric cancer. ( Hu, Y; Tang, C; Wei, X; Yuwen, D; Zhang, J; Zhang, W; Zhu, X; Zhu, Y, 2022) |
| "Several clinical trials are underway in gastric cancer, but the autophagy mechanism of Nab-PTX on gastric cancer is still unclear." | 1.72 | Albumin Paclitaxel Compared with 5-Penfluorouracil, Lobaplatin, and Albumin Paclitaxel Combined with 5-Penfluorouracil in the Treatment of Human Gastric Cancer Cell AGS Line Autophagy and Apoptosis. ( Cheng, X; Mahendra Upadhyay, A; Nie, W; Wang, Q; Wang, Y; Yan, Z; Yang, F; Zhang, M, 2022) |
| "However, the role of CD96 in the gastric cancer (GC) microenvironment remains fragmentary." | 1.72 | Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer. ( Fang, H; Gu, Y; He, H; Li, H; Li, R; Lin, C; Liu, H; Wang, J; Xu, C; Yu, K; Zhang, H, 2022) |
| "The prognosis of gastric cancer in an advanced stage remains poor." | 1.72 | No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer. ( Ding, SK; Ren, JS; Tian, YT; Wang, BZ; Wu, M; Wu, YZ; Xie, YB; Xue, LY; Yang, L; Zheng, XH, 2022) |
| "Owing to its high recurrence rate, gastric cancer (GC) is the leading cause of tumor-related deaths worldwide." | 1.72 | Synergistic Effects of the Combinational Use of Escitalopram Oxalate and 5-Fluorouracil on the Inhibition of Gastric Cancer SNU-1 Cells. ( Chen, VC; Hsu, TC; Huang, JY; McIntyre, RS; Tzang, BS, 2022) |
| "However, its clinical significance in gastric cancer (GC) remains largely unknown." | 1.62 | Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer. ( Cao, Y; Fang, H; Fei, Y; Gu, Y; He, H; Li, H; Li, R; Lin, C; Liu, H; Wang, J; Xia, S; Xu, J; Zhang, H; Zhang, W, 2021) |
| "We report a case of advanced gastric cancer that was successfully treated with mFOLFOX6 therapy." | 1.62 | [A Case of Advanced Gastric Cancer Successfully Treated with mFOLFOX6 Therapy]. ( Fukada, A; Hashimoto, Y; Hirose, H; Kawada, J; Kidogami, S; Kishimoto, T; Mizuno, M; Mokutani, Y; Murotani, M; Nagano, S; Nakano, M; Sasaki, Y; Tamura, S; Yoneda, N; Yoshioka, S, 2021) |
| "The study focused on the dual-source computed tomography (CT) images segmented by the decision tree algorithm, to explore the efficacy of docetaxel combined with fluorouracil therapy on gastric patients undergoing chemotherapy." | 1.62 | Intelligent Algorithm-Based CT Imaging for Evaluation of Efficacy of Docetaxel Combined with Fluorouracil on Patients with Gastric Cancer. ( Chen, Q; Ding, R; Wang, X; Wang, Z, 2021) |
| "Traditional Chinese medicine injections (TCMJs) combined with FOLFOX4 regimen could achieve favorable effects in the treatment of gastric cancer." | 1.62 | Efficacy and safety of traditional Chinese medicine injections combined with FOLFOX4 regimen for gastric cancer: A protocol for systematic review and network meta-analysis. ( Du, X; Jiang, L; Ouyang, J; Zhang, Y, 2021) |
| "Stomach cancer is the 4th most common cancer diagnosed worldwide." | 1.62 | Bioactive compounds from Lactarius deterrimus interfere with the invasive potential of gastric cancer cells. ( Czyż, J; Krakowska, A; Król, K; Krzysiek-Mączka, G; Muszyńska, B; Pudełek, M; Ryszawy, D; Sułkowska-Ziaja, K; Wierdak, M, 2021) |
| "Cisatracurium besilate treatment restrained the proliferation and promoted the apoptosis of AGS cells." | 1.62 | Cisatracurium besilate enhances the TRAIL-induced apoptosis of gastric cancer cells via p53 signaling. ( Liu, Y; Wu, Y; Yuan, J; Zhou, Q, 2021) |
| "The clinical management of gastric cancer still remains challenge due to its poor response to chemotherapy." | 1.62 | Inhibition of β-glucosidase overcomes gastric cancer chemoresistance through inducing lysosomal dysfunction. ( Li, Z; Shan, C; Tong, X; Xu, D, 2021) |
| "The AGS gastric cancer cell line were pretreated with three different sub-toxic concentration of metformin and then treated with various concentrations of 5-FU and docetaxel." | 1.62 | Efficacy of Metformin and Chemotherapeutic Agents on the Inhibition of Colony Formation and Shh/Gli1 Pathway: Metformin/Docetaxel Versus Metformin/5-Fluorouracil. ( Fatehi-Agdam, M; Jeddi, F; Najafzadeh, N; Panahizadeh, R; Vatankhah, MA, 2021) |
| "Therefore, we examined five gastric cancer cell lines and isolated gastric oncospheres from three gastric cancer cell lines." | 1.62 | SNAIL regulates gastric carcinogenesis through CCN3 and NEFL. ( Chen, R; Masuo, K; Seno, H; Sugiyama, A; Takaishi, S; Yogo, A; Yokoyama, S; Yoshizawa, A, 2021) |
| "However, the mechanisms underlying gastric cancer (GC) resistance to chemotherapy are still unclear." | 1.62 | LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM. ( Li, W; Wang, H; Xu, L; Yang, S; Yao, X; Yu, J; Zhang, F; Zhao, L, 2021) |
| "Alopecia was observed in 60% of patients." | 1.62 | Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases. ( Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A, 2021) |
| "However, gastric cancer cells are usually insensitive to TRAIL so reducing this drug resistance may improve the treatment of gastric cancer." | 1.62 | 5-Fluorouracil enhances the chemosensitivity of gastric cancer to TRAIL via inhibition of the MAPK pathway. ( Guo, J; Li, H; Liang, Z; Liu, S; Lv, J; Ma, Y; Qi, W; Qiu, W; Wang, S; Wang, Y, 2021) |
| "To compare the chemoradiotherapy for esophageal cancer followed by surgery study (CROSS) and continuous infusion 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) protocols administered in distal esophageal and gastroesophageal junction (GEJ) tumors in terms of effectiveness and toxicity." | 1.62 | CROSS or FLOT in Distal Esophageal and Gastroesophageal Cancer. ( Ates, O; Cakmak Oksuzoglu, OB; Karadag, I; Karakaya, S, 2021) |
| "Key Words: FLOT, Gastric cancer, Ki-67, Platelet lymphocyte ratio." | 1.62 | Predictive Significance of Ki-67 and Platelet Lymphocyte Ratio in Patients with Gastric Cancer Receiving Neoadjuvant FLOT Chemotherapy. ( Demirag, G; Sullu, Y; Yilmaz, A; Yilmaz, H, 2021) |
| "SNU620/5FU, a gastric cancer cell harboring resistance to 5FU, showed much higher lactate production and expression of glycolysis-related enzymes, such as lactate dehydrogenase A (LDHA), than those of the parent SNU620 cells." | 1.62 | Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil. ( Bae, SJ; Ha, KT; Han, JH; Jang, SB; Kim, HJ; Kim, M; Lee, IK; Ryu, D, 2021) |
| "In this study we subjected the gastric cancer cell line AGS to chronic exposure of 5-fluorouracil, cisplatin or paclitaxel, thus selecting cell subpopulations showing resistance to the different drugs." | 1.62 | Enhanced Vasculogenic Capacity Induced by 5-Fluorouracil Chemoresistance in a Gastric Cancer Cell Line. ( Andreucci, E; Barbato, G; Biagioni, A; Cianchi, F; Coratti, F; Giovannelli, L; Magnelli, L; Papucci, L; Peri, S; Schiavone, N; Staderini, F; Versienti, G, 2021) |
| "However, their roles in gastric cancer (GC) remain poorly characterized." | 1.62 | Distinctive Prognostic Value and Cellular Functions of Osteopontin Splice Variants in Human Gastric Cancer. ( Cui, Y; Hao, C; Ji, J; Jia, S; Jiang, WG; Lane, J, 2021) |
| "Of the 881 gastric cancer patients, 88 (10." | 1.56 | Prognostic value of mismatch repair deficiency in patients with advanced gastric cancer, treated by surgery and adjuvant 5-fluorouracil and leucovorin chemoradiotherapy. ( An, JY; Bae, JM; Byeon, SJ; Choi, MG; Kim, KM; Kim, S; Kim, SM; Lee, J; Lee, JH; Sohn, TS, 2020) |
| "Epstein-Barr virus (EBV)-associated gastric cancer (GC) is associated with a high degree of DNA methylation." | 1.56 | Methylation of drug resistance-related genes in chemotherapy-sensitive Epstein-Barr virus-associated gastric cancer. ( Akashi, K; Ariyama, H; Baba, E; Isobe, T; Ito, M; Komoda, M; Kusaba, H; Kuwayama, M; Momosaki, S; Nakano, M; Oda, Y; Ohmura, H; Okada, C; Okumura, Y; Tanishima, S; Tsuchihashi, K; Uchino, K; Yamada, Y; Yamaguchi, K, 2020) |
| "Advanced gastric cancer was affected by the interaction the among modules with three functions, namely cell migration, angiogenesis, and the immune response, all of which are related to metastasis." | 1.56 | Gene regulatory network analysis with drug sensitivity reveals synergistic effects of combinatory chemotherapy in gastric cancer. ( Jung, M; Lee, JH; Lim, SG; Park, YR, 2020) |
| "We used 6 human gastric cancer cell lines (SNU-1, SNU-5, SNU-16, NCI-N87, KATO- III and AGS), and demonstrated the chemosensitivity of APEX1 and Jagged-1 through the MTT assay and immunoblotting." | 1.56 | Clinical Significance of Jagged-1 Activated by APEX1 as a Chemoresistance Factor in Advanced Gastric Cancer. ( Kim, GB; Kim, HB; Lee, HJ; Lim, HJ; Park, JH; Park, SG, 2020) |
| "The expression of sCLU in gastric cancer tissues was detected by RT-PCR assays." | 1.56 | Overexpression of secretory clusterin (sCLU) induces chemotherapy resistance in human gastric cancer cells by targeting miR-195-5p. ( Guo, D; Li, P; Mu, L; Yang, F; Zhang, M, 2020) |
| "Among patients with esophageal cancer who received treatment with curative intention, cisplatin-fluorouracil was associated with better survival compared to carboplatin-fluorouracil, while patients with gastroesophageal junction cancer who were treated with cisplatin-fluorouracil had worse survival compared to fluorouracil-oxaliplatin." | 1.56 | Survival of esophageal and gastric cancer patients with adjuvant and palliative chemotherapy-a retrospective analysis of a register-based patient cohort. ( Ebrahim, F; Ekheden, I; Henriksson, R; Ólafsdóttir, H; Raaschou, P; Wettermark, B; Ye, W, 2020) |
| "FOLFOX therapy has been used for gastric cancer in Japan since 2017." | 1.56 | [Clinical Efficacy of mFOLFOX6 for Advanced Gastric Cancer]. ( Cho, H; Funasaka, C; Kanemasa, Y; Omuro, Y; Shimoyama, T, 2020) |
| "One of the most common treatment for gastric cancer is chemotherapy, however, multiple drug resistance (MDR) induce the therapeutic effect which result in the failure of anticancer therapy." | 1.56 | Reversal Effect of Dihydromyricetin on Multiple Drug Resistance in SGC7901/5-FU Cells. ( Dong, T; Huang, M; Jiang, M; Lv, J; Wu, M; Xu, L; Xue, M, 2020) |
| "The prognosis of patients with advanced gastric cancer remains unsatisfactory, highlighting the need for improved therapeutic strategies." | 1.56 | FLOT Neoadjuvant Chemotherapy Followed by Laparoscopic D2 Gastrectomy in the Treatment of Locally Resectable Advanced Gastric Cancer. ( Cao, D; Du, T; Jiang, X; Li, H; Song, C; Sun, Q; Yan, D; Yang, Y; Yuan, B; Zhang, S, 2020) |
| " Thirty-three percent of patients experienced immune-related adverse events in the Good group, and 18% in the Poor group." | 1.56 | Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses. ( Kimura, S; Kuriona, Y; Mastumoto, Y; Matsumoto, T; Miura, K; Okazaki, U; Takatani, M; Tsuduki, T; Watanabe, T; Yamamoto, Y, 2020) |
| "Patient-derived gastric cancer was established in nude mice from the patient' s surgical tumor specimen." | 1.56 | A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy. ( Bouvet, M; Higuchi, T; Hoffman, RM; Kawaguchi, K; Nishino, H; Park, JH; Sugisawa, N; Tashiro, Y; Unno, M; Yamamoto, J, 2020) |
| "Gastric cancer is a common malignancy worldwide." | 1.56 | DJ-1 is involved in the multidrug resistance of SGC7901 gastric cancer cells through PTEN/PI3K/Akt/Nrf2 pathway. ( Chen, H; Deng, Y; Duan, G; Li, X; Liu, H; Ma, Z; Qiu, L; Xiao, L; Xu, X; Zhao, LE; Zhu, Z, 2020) |
| "Gastric cancer is one of the most common cancers in Asia, and recently, various cases of resistance to fluorouracil treatment have been reported." | 1.56 | M2 Macrophages Mediate the Resistance of Gastric Adenocarcinoma Cells to 5-Fluorouracil through the Expression of Integrin ( Kim, GD; Ngabire, D; Niyonizigiye, I; Patil, MP; Seo, YB; Seong, YA, 2020) |
| "Gastric cancer is the third leading cause of cancer-related death worldwide, with half of patients developing metastasis within 5 years after curative treatment." | 1.51 | Glycoengineered nanoparticles enhance the delivery of 5-fluoroucil and paclitaxel to gastric cancer cells of high metastatic potential. ( Barros, A; Fernandes, E; Ferreira, D; Ferreira, JA; Freitas, R; Martins, G; Palmeira, C; Peixoto, A; Relvas-Santos, M; Santos, LL; Sarmento, B, 2019) |
| "Metastatic skin lesions of gastric cancers usually appear as nonspecific, firm, and hyperpigmented nodules." | 1.51 | Appearance of cutaneous melanoma and subcutaneous metastases in metastatic gastric carcinoma undergoing chemotherapy with oral 5-fluorouracil prodrug. ( Covarelli, P; De Giorgi, V; Gori, A; Maida, P; Scarfì, F; Silvestri, F; Trane, L, 2019) |
| "In Brazil, patients with gastric cancer have not been systematically followed-up and evaluated, thus data regarding patterns of care and outcomes are scarce or missing." | 1.51 | Treatment Patterns Among Patients with Metastatic and/or Unresectable Gastric Cancer in Brazil. ( Beato, CAM; de Alencar Camara Vieira, FM; de Iracema Gomes Cubero, D; de Souza Victorino, APO; Julian, GS; Minowa, E; Novick, D, 2019) |
| "To investigate the efficacy of paclitaxel combined with a leucovorin and 5-fluorouracil regimen (PLF regimen; q2w) as neoadjuvant chemotherapy (NCT) for advanced gastric cancer." | 1.51 | Retrospective study on efficacy of a paclitaxel combined with a leucovorin and fluorouracil regimen for advanced gastric cancer. ( Chen, Q; Lin, X; Shi, C; Wang, X; Yang, B, 2019) |
| "From our established gastric cancer database, patients with pathological stage II and III gastric cancer who received adjuvant chemotherapy after D2 gastrectomy at Zhongshan Hospital of Fudan University were analyzed." | 1.51 | The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study. ( Cheng, X; Cui, Y; Ji, Y; Jiang, H; Li, W; Liu, F; Liu, TS; Shen, Z; Sun, Y; Tang, C; Wang, X; Wang, Y; Yu, S; Yu, Y, 2019) |
| "Organoids were derived from resected gastric cancer tumors (huTGOs) or normal stomach tissue collected from sleeve gastrectomies (huFGOs)." | 1.51 | An Organoid-Based Preclinical Model of Human Gastric Cancer. ( Ahmad, S; Biesiada, J; Chakrabarti, J; Chang, J; Hawkins, J; Helmrath, M; Holokai, L; Mahe, M; Medvedovic, M; Nowacki, LM; Shroyer, N; Steele, NG; Sundaram, N; Wang, J; Zavros, Y, 2019) |
| " No statistical differences were observed in treatment-related adverse events, hospital admissions, or further treatment lines between age groups." | 1.51 | Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. ( Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E, 2019) |
| "Hyperlipidemia is associated with metastasis in patients with gastric cancer (GC)." | 1.51 | 25-HC decreases the sensitivity of human gastric cancer cells to 5-fluorouracil and promotes cells invasion via the TLR2/NF-κB signaling pathway. ( Chen, W; Rao, C; Wang, S; Yao, Y; Zheng, G, 2019) |
| "Gastric cancer is one of the most common and deadly malignancies worldwide." | 1.51 | Extract of ( Bu, BG; Cui, XL; Li, KJ; Liu, XD; Ren, HX; Wang, L; Zhang, YJ, 2019) |
| "Cardiotoxicity is an important side effect in patients receiving chemotherapy and the application of anthracycline drugs for gastric cancer treatment is uncommon." | 1.51 | Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients. ( Bai, Y; Gao, L; Jin, X; Wu, S, 2019) |
| "Patients with advanced gastric cancer and severe peritoneal metastasis were included if they had massive ascites and/or inadequate oral intake requiring intravenous nutritional support." | 1.51 | Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. ( Arai, H; Boku, N; Fukuda, N; Hironaka, S; Iwasa, S; Kawahira, M; Masuishi, T; Minashi, K; Muro, K; Nakajima, TE; Takahari, D; Yasui, H, 2019) |
| "Adjuvant chemotherapy for gastric cancer, particularly stage III, improves survival after curative D2 gastrectomy." | 1.51 | Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer. ( Bae, WK; Cho, SH; Chung, IJ; Hwang, EC; Hwang, JE; Jeong, O; Kim, H; Park, YK; Ryu, SY; Shim, HJ, 2019) |
| "Gastric cancer is the fourth most common malignancy and the third leading cause of cancer-related deaths worldwide." | 1.48 | Downregulation of MicroRNA-147 Inhibits Cell Proliferation and Increases the Chemosensitivity of Gastric Cancer Cells to 5-Fluorouracil by Directly Targeting PTEN. ( Jun, M; Niu, W; Shen, J; Zhang, H, 2018) |
| "Gastric cancer is an important killer disease, and its therapy methods still need improvement." | 1.48 | A novel design of HA-coated nanoparticles co-encapsulating plasmid METase and 5-Fu shows enhanced application in targeting gastric cancer stem cells. ( Xin, L; Yang, W; Zhang, H, 2018) |
| "Gastric cancer is a malignancy that starts from the cells in the stomach with relatively low overall survival rate." | 1.48 | GSDME mediates caspase-3-dependent pyroptosis in gastric cancer. ( Han, X; Li, D; Sun, X; Wang, G; Wang, Y; Yin, B, 2018) |
| " We evaluated an optimized anti-tumor protocol comprising 5-fluorouracil (5-FU) combined with cisplatin (CDDP) and mitomycin C (MMC) in vitro for clinical use of HIPEC." | 1.48 | 5-fluorouracil combined with cisplatin and mitomycin C as an optimized regimen for hyperthermic intraperitoneal chemotherapy in gastric cancer. ( Kaida, S; Miyake, T; Murata, S; Naitoh, H; Shimizu, T; Takebayashi, K; Tani, M; Tani, T; Yamaguchi, T; Yamamoto, H, 2018) |
| "Patients with metastatic gastric cancer have a poor prognosis (5-year survival of less than 10%)." | 1.48 | Predictors of heterogeneity in the first-line treatment of patients with advanced/metastatic gastric cancer in the U.S. ( Abrams, T; Fuchs, C; Hess, LM; Liepa, AM; Schelman, W; Zhu, YE, 2018) |
| "After curative resection of gastric cancer with D2 lymph node dissection, postoperative adjuvant chemotherapy with S-1 or capecitabine plus oxaliplatin (XELOX) is considered to be standard therapy in Eastern countries." | 1.48 | Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study. ( Chae, H; Kim, HI; Kim, IH; Kim, MC; Kwon, IK; Lee, CM; Lee, HH; Lee, SI; Min, JS; Park, SS, 2018) |
| "To observe changes in the growth of fluorescence-labelled tumour cells in nude mice using small animal in vivo imaging technology and to compare the anti-tumour effects of the administration of bevacizumab monoclonal antibodies combined with chemotherapy at different time sequences." | 1.48 | Effect of bevacizumab combined with chemotherapy at different sequences in the gastric-cancer-bearing nude mice. ( Chang, L; Liu, W; Liu, Y; Lv, Y; Song, L; Zhang, X, 2018) |
| "Palbociclib is a specific inhibitor of CDK4/6 and has been shown to provide a survival benefit in hormone receptor-positive advanced breast cancer." | 1.48 | Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. ( Bang, YJ; Im, SA; Kim, JE; Kim, JW; Kim, S; Kim, TY; Kim, YJ; Lee, KH; Lim, JM; Min, A; Oh, DY, 2018) |
| "Here, we studied its role in gastric cancer (GC)." | 1.48 | HSP70/HSP90-Organizing Protein Contributes to Gastric Cancer Progression in an Autocrine Fashion and Predicts Poor Survival in Gastric Cancer. ( Cai, S; Chen, J; Chen, M; He, X; He, Y; Huang, L; Li, J; Liang, W; Lin, Y; Peng, S; Xu, L; Zeng, Z; Zhai, E; Zhang, N; Zhang, Q, 2018) |
| "Gastric cancer is the most common gastrointestinal malignancy and the leading cause of cancer-related deaths in East Asia." | 1.48 | Autophagy regulates chemoresistance of gastric cancer stem cells via the Notch signaling pathway. ( -Y-Xie, D; Chen, H; Li, LQ; Pan, D; Zhang, SW; Zheng, XL, 2018) |
| "All cases of locally advanced gastric cancer treated with the XELOX or DOS regimen were reviewed retrospectively." | 1.48 | Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. ( Cheng, X; Cui, YH; Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, ZB; Sun, YH; Wang, Y, 2018) |
| "Human AGS gastric cancer cells were used in this study." | 1.48 | Effect of 5-fluorouracil on excision repair cross-complementing 1 expression and consequent cytotoxicity regulation in human gastric cancer cells. ( Chang, SF; Chen, CN; Huang, WS; Lee, KC; Liu, JL; Tung, SY, 2018) |
| "Corosolic acid treatment significantly reduced cell viability while compound c reversed corosolic acid‑induced cell growth inhibition." | 1.48 | Corosolic acid reduces 5‑FU chemoresistance in human gastric cancer cells by activating AMPK. ( Cha, EY; Kim, S; Lee, JS; Lee, MS; Park, JB; Sul, JY, 2018) |
| "A total of 591 gastric cancer patients who had radical gastrectomy were recruited." | 1.48 | Association of Antioxidative Enzymes Polymorphisms with Efficacy of Platin and Fluorouracil-Based Adjuvant Therapy in Gastric Cancer. ( Du, M; Gong, W; Gu, D; Tan, Y; Wang, M; Wen, J; Xu, Z; Zhai, Y; Zhang, H; Zhao, W, 2018) |
| "During gastric cancer (GC) progression, increased extracellular matrix (ECM) deposition, notably collagen type I, correlates with an overall increase in expression of the mesenchymal phenotype." | 1.48 | Increased extracellular matrix density disrupts E-cadherin/β-catenin complex in gastric cancer cells. ( Cheong, JH; Jang, M; Kim, P; Koh, I; Lee, JE; Lim, JY, 2018) |
| " We compared tolerability and efficacy of the two different chemotherapy regimens; 5-FU/leucovorin (LV) versus cisplatin with capecitabine (XP) combined with radiotherapy (RT) in the adjuvant therapy of the lymph node positive locally advanced gastric cancer." | 1.48 | Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer. ( Bilici, A; Erkol, B; Figen, M; Surmelioglu, A; Tilki, M; Ustaalioglu, BBO; Uyar, S, 2018) |
| "The human gastric cancer cell line MKN28 was transfected with pRc/CMV plasmids encoding human CD44 or CD44v9, which were used for in vitro and in vivo experiments." | 1.48 | Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression. ( Hirata, K; Kanai, T; Matsuzaki, J; Miyoshi, S; Mori, H; Saya, H; Suzuki, H; Tsugawa, H, 2018) |
| "Although diagnosis and treatment of gastric cancer have improved, the prognosis of patients remains poor." | 1.46 | Calycosin Enhances Some Chemotherapeutic Drugs Inhibition of Akt Signaling Pathway in Gastric Cells. ( Guo, Y; Li, N; Li, Y; Qin, X; Wu, Y; Yang, Y; Zhou, L, 2017) |
| "Patients with pT3-4 or node-positive gastric cancer after gastrectomy with D2 lymphadenectomy between 2000 and 2013 were included." | 1.46 | Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer. ( Huang, ZP; Li, GX; Wang, F; Wang, ZX; Xu, RH; Zhou, ZW, 2017) |
| "The effects of gankyrin on gastric cancer growth, proliferation, and chemosensitivity were determined." | 1.46 | Gankyrin promotes the proliferation of gastric cancer and is associated with chemosensitivity. ( Li, WH; Sun, D; Xin, Y; Zeng, YC; Zhao, J, 2017) |
| "5-Fluorouracil (5-FU) has been identified as one of the standard first-line chemotherapy drugs for locally advanced or metastatic gastric cancer." | 1.46 | Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells. ( Cao, G; Gao, Q; Sun, X; Xing, Y; Zhang, D; Zhang, L, 2017) |
| " Four patients experienced grade 1 or 2 adverse events." | 1.46 | Feasibility and safety of hyperthermic intraperitoneal chemotherapy using 5-fluorouracil combined with cisplatin and mitomycin C in patients undergoing gastrectomy for advanced gastric cancer. ( Kaida, S; Murata, S; Naitoh, H; Naka, S; Shimizu, T; Shiomi, H; Tani, M; Tani, T; Yamaguchi, T; Yamamoto, H, 2017) |
| "Most patients with advanced gastric cancer eventually succumb to the disease despite the fact that some patients respond initially to chemotherapy." | 1.46 | The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer. ( Gu, D; Liu, B; Xie, J; Yu, B; Zhang, X, 2017) |
| "Positive expression of MGMT in gastric cancer was identified as an independent, favorable prognostic factor." | 1.46 | Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer. ( Cao, Y; He, H; Li, H; Li, R; Lin, C; Liu, H; Wu, S; Xu, J; Zhang, H; Zhang, W, 2017) |
| "Blood examinations showed disseminated intravascular coagulation(DIC)at the end of the second-line chemotherapy." | 1.46 | Successful Treatment with 5-fluorouracil and Levofolinate Calcium in Advanced Gastric Cancer Patient with Disseminated Intravascular Coagulation. ( Kichiraku, T; Kotanagi, H; Kotanagi, K; Kudoh, K; Masuda, A; Miyazawa, H; Munakata, M; Muto, O; Ouchi, S; Sakata, Y; Satoyoshi, R; Sawada, T; Yamagata, K, 2017) |
| "Two human gastric cancer cell lines (AGS and SGC-7901) were xenografted into zebrafish embryos, their sensitivity to 5-FU were tested both in vitro and in vivo." | 1.46 | Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer. ( He, MF; Li, CY; Shen, LZ; Tan, AM; Wei, P; Wu, JQ; Zhai, J, 2017) |
| "Recurrence of gastric cancer after 10 years of surgical resection is highly rare." | 1.46 | [Gastric Cancer Recurrence in 12 Years after Surgical Resection]. ( Chang, HK; Kim, JH; Ku, KH; Kwon, HJ; Park, JG; Park, SJ, 2017) |
| "The microsatellite-instable gastric cancer subtype, because of its supposed high antigenic potential, is a promising candidate for immunotherapy." | 1.46 | Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. ( Andrikou, K; Bianconi, M; Bittoni, A; Bracci, R; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Maccaroni, E; Mandolesi, A; Scarpelli, M; Scartozzi, M, 2017) |
| "This study investigated the inhibitory effects of bevacizumab monoclonal antibodies in combination with chemotherapy in different time sequences on a human gastric cancer cell line (MGC-803)." | 1.46 | Inhibitory effects of bevacizumab monoclonal antibodies in combination with chemotherapy in different time sequences on a human gastric carcinoma cell line. ( Chang, L; Li, Q; Liu, W; Liu, Y; Lv, Y; Song, L; Zhang, X; Zhou, X, 2017) |
| "Methods Twenty-one patients with gastric cancer (including sixteen with advanced/recurrent gastric cancer and five with poor general condition) underwent chemo-radiotherapy, for whom the therapeutic efficacy, toxicity and survival period were analysed." | 1.46 | Usefulness of chemoradiotherapy for inoperable gastric cancer. ( Hoya, Y; Mitsumori, N; Nakayoshi, T; Okamoto, T; Sekine, H; Taki, T; Watanabe, A; Yanaga, K, 2017) |
| "In cultured gastric cancer cells, loss of TGM1 expression inhibited cell proliferation and promoted apoptosis, as well increased gastric cancer cell sensitivity to chemotherapeutic drugs and reducing stemness." | 1.46 | Tissue transglutaminase-1 promotes stemness and chemoresistance in gastric cancer cells by regulating Wnt/β-catenin signaling. ( Chen, Z; Huang, H; Ni, X, 2017) |
| "107 gastro-esophageal cancer patients were retrospectively analyzed." | 1.46 | Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer. ( Borro, M; Botticelli, A; Cerbelli, B; Gentile, G; Lionetto, L; Marchetti, L; Marchetti, P; Mazzotti, E; Mazzuca, F; Onesti, EC; Romiti, A; Simmaco, M, 2017) |
| "CXCR1 in gastric cancer was identified as an independent adverse prognostic factor." | 1.46 | CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients. ( Cao, Y; He, H; Li, H; Li, R; Lin, C; Liu, H; Wu, S; Xu, J; Zhang, H; Zhang, W, 2017) |
| "Peritoneal metastasis is common in gastric cancer." | 1.46 | Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready? ( Chan, DY; Chee, CE; Nga, ME; Phua, JN; Shabbir, A; So, JB; Soh, TI; Syn, NL; Yap, R; Yong, WP, 2017) |
| "Distinct metastasis accounts for the leading cause of mortality among patients with gastric cancer." | 1.46 | Traditional Chinese medicine Jianpi Bushen therapy suppresses the onset of pre-metastatic niche in a murine model of spontaneous lung metastasis. ( Wu, J; Xu, Q; Zhou, Y; Zhu, X, 2017) |
| "Patients with pathological stage II/III gastric cancer undergoing LG with D2 lymphadenectomy (LG group: n = 74) were matched 1:1 with patients selected from 214 similar patients undergoing OG (OG group: n = 74), identically matching gender, age, pathological stage, and type of gastrectomy, and comparing AC initiation timing between the two groups." | 1.46 | Timing of initiation of adjuvant chemotherapy for gastric cancer: A case-matched comparison study of laparoscopic vs. open surgery. ( Kaito, A; Kinoshita, T; Nishida, T; Shibasaki, H; Shitara, K, 2017) |
| "PTBP3 mRNA levels in human gastric cancer and adjuvant non-tumour tissues were detected." | 1.46 | Inhibition of polypyrimidine tract-binding protein 3 induces apoptosis and cell cycle arrest, and enhances the cytotoxicity of 5- fluorouracil in gastric cancer cells. ( Li, J; Liang, X; Lin, S; Liu, J; Qi, Y; Qiu, C; Shi, H; Yang, L; Zhao, A, 2017) |
| "For patients with operable esophagogastric cancer, peri-operative chemotherapy confers a significant overall survival benefit compared to surgery alone, however only 30-40% of patients demonstrate histopathological response." | 1.46 | The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery. ( Bowman, CR; Dorrington, MS; Kaye, P; Madhusudan, S; Mumtaz, E; Pang, V; Parsons, SL; Reece-Smith, AM; Saunders, JH; Soomro, I, 2017) |
| "Therapies for patients with scirrhous gastric cancer remain ineffective." | 1.46 | Effects of 5-fluorouracil, adriamycin and irinotecan on HSC-39, a human scirrhous gastric cancer cell line. ( Amano, F; Kanai-Mori, A; Koike, A; Morishige, Y; Tamaki, R; Yanagihara, K, 2017) |
| "AFP-PGC patients had more liver metastases than non-AFP-PGC patients (p < 0." | 1.46 | The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma. ( Bozkaya, Y; Demirci, NS; Doğan, M; Erdem, GU; Yazıcı, O; Zengin, N, 2017) |
| "The correlation was confirmed in gastric cancer cell lines, analyzed further by gene overexpression and silencing analysis, a cell invasion assay, and a chemosensitivity test." | 1.43 | Inverse association between Bmi-1 and RKIP affecting clinical outcome of gastric cancer and revealing the potential molecular mechanisms underlying tumor metastasis and chemotherapy resistance. ( Chen, J; Chen, S; Chen, Y; Huang, K; Li, H; Li, J; Lian, G; Ou, G; Yang, K; Zeng, L, 2016) |
| "SGC-7901 gastric cancer cell line was treated with 5-fluorouracil (5-FU) or/and autophagy inhibitor bafilomycin A1." | 1.43 | Inhibition of autophagy by bafilomycin A1 promotes chemosensitivity of gastric cancer cells. ( Chen, H; Li, LQ; Pan, D; Xie, WJ; Zhang, L, 2016) |
| "We conducted a prospective pharmacokinetic study to develop an S-1 dosage formula based on renal function." | 1.43 | Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study. ( Boku, N; Booka, E; Gomi, D; Hamamoto, Y; Ichiyama, T; Imamura, CK; Kawakubo, H; Kitagawa, Y; Mizukami, T; Soejima, K; Takahashi, T; Takeuchi, H; Tanigawara, Y; Tateishi, K, 2016) |
| "For patients with liver metastases from gastric cancer (LMGC), combination chemotherapy with fluoropyrimidines and platinum agents has been recognized as standard treatment." | 1.43 | Hepatic arterial infusion chemotherapy using fluorouracil, epirubicin, and mitomycin C for patients with liver metastases from gastric cancer after treatment failure of systemic S-1 plus cisplatin. ( Ohi, H; Ozaki, T; Seki, H; Yabusaki, H, 2016) |
| "Metastatic and refractory gastric cancer (GC) are associated with a poor prognosis; therefore, the identification of prognostic factors and chemosensitivity markers is extremely important." | 1.43 | Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients. ( Altan, B; Asao, T; Bai, T; Bao, P; Hara, K; Ide, M; Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Nishiyama, M; Ogata, K; Oyama, T; Suzuki, M; Toyomasu, Y; Yokobori, T, 2016) |
| "The study included 127 gastric cancer patients, who underwent preoperative or postoperative chemoradiotherapy." | 1.43 | Radiation-induced injury of the exocrine pancreas after chemoradiotherapy for gastric cancer. ( Maslyk, B; Polanowski, P; Tukiendorf, A; Wydmanski, J, 2016) |
| "Advanced gastric cancer patients with PALM can obtain a survival benefit from neoadjuvant chemotherapy, subsequent surgery and radiotherapy." | 1.43 | A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis. ( He, Q; Li, G; Li, Y; Ma, L, 2016) |
| "Photoimmunotherapy (PIT) is a novel type of molecular optical imaging-guided cancer phototherapy based on a monoclonal antibody conjugated to a photosensitizer, IR700, in combination with near-infrared (NIR) light." | 1.43 | Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms. ( Arihiro, S; Ito, K; Kobayashi, H; Matsuoka, M; Mitsunaga, M; Saruta, M; Tajiri, H, 2016) |
| "Co-treatment with lupeol and 5-Fu induced apoptosis through up-regulating the expressions of Bax and p53 and down-regulating the expressions of survivin and Bcl-2." | 1.43 | Lupeol enhances inhibitory effect of 5-fluorouracil on human gastric carcinoma cells. ( Bi, T; Dai, W; Gao, Q; Liu, Y; Qian, L; Shen, G; Wang, G, 2016) |
| "RanBPM expression in human gastric cancer tissue samples was analyzed using real-time polymerase chain reaction." | 1.43 | Reduced RanBPM Expression Is Associated with Distant Metastasis in Gastric Cancer and Chemoresistance. ( Feng, YI; Gao, X; Ji, J; Ji, KE; Jia, Y; Jiang, WG; Satherley, LK; Shao, S; Sun, PH; Ye, L, 2016) |
| "We established a 5-FU-resistant gastric cancer cell subline, and we evaluated its HCCR expression." | 1.43 | Targeting HCCR expression resensitizes gastric cancer cells to chemotherapy via down-regulating the activation of STAT3. ( Chen, GW; Jiang, Y; Liu, XZ; Liu, YC; Pan, YS; Qiao, SK; Wang, PY; Wang, X; Zhang, JL; Zhu, J, 2016) |
| "Gastroscopy revealed that the gastric cancer had disappeared." | 1.43 | [A Case of Double Cancer of Initially Unresectable Sigmoid Colon Cancer and Advanced Gastric Cancer Treated with Curative Resection after mFOLFOX6 Therapy]. ( Aoki, K; Endo, M; Ikenaga, S; Mitsuhashi, Y; Miura, T; Shibasaki, I; Suto, A; Tomiura, S; Yoshikawa, T, 2016) |
| "Patients with unresectable gastric cancer may obtain a survival benefit from preoperative chemotherapy via intra-arterial and intravenous administration and subsequent surgery." | 1.43 | Application of FLEEOX Preoperative Chemotherapy via Intra-arterial and Intravenous Administration in Treatment of Unresectable Locally Advanced Gastric Cancer. ( He, Q; Ji, X; Li, G; Li, Y; Ma, L, 2016) |
| "The aim of this study is to discuss the curative effect of introperitoneal hyperthermic perfusion chemotherapy(IHPC) combined with systemic neoadjuvant chemotherapy on the gastric cancer patients with peritoneal carcinomatosis." | 1.43 | [Study of introperitoneal hyperthermic perfusion chemotherapy combined with systemic neoadjuvent chemotherapy in treatment of gastric cancer patients with peritoneal carcinomatosis]. ( Chen, Y; Guo, Y; Suo, J; Wang, D; Xing, Y; Zhang, Y, 2016) |
| "To determine the function of WEE1 in gastric cancer cells, we determined that WEE1 ablation decreased the proliferation, migration, and invasion, while overexpression of WEE1 increased these effects in gastric cancer cells." | 1.43 | Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer. ( Cho, Y; Chun, KH; Kang, H; Kim, HY; Kim, SJ; Song, J; Yim, YS, 2016) |
| "Importantly, in a preclinical gastric cancer xenograft mouse model, drug co-treatments led to increased mouse survival as well as a synergistic reduction in tumor size and the inhibition of tumor angiogenesis." | 1.43 | Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer. ( Chen, J; Chen, Z; Guo, J; Liu, M; Pang, X; Wang, J, 2016) |
| "Gastric cancer is considered the fourth most common cancer and second most common cause of cancerrelated mortalities worldwide." | 1.43 | Oxaliplatin, 5Fluorouracil and Leucovorin (FOLFOX4) as First Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer. ( Esmaeilpour, K; Haghighi, S; Kasbkar, H; Yasaei, M, 2016) |
| "The incidence of young-age gastric cancer (GC) is increasing worldwide, but clinical behavior of young-age GC patients is not well established." | 1.43 | Clinical characteristics of young-age onset gastric cancer in Korea. ( Kim, IH; Lee, J; Lee, MA; Roh, SY, 2016) |
| "Since gastric cancer (GC) cells exhibited higher grades of SHP-2 encoded by PTPN11 than normal cells, it would be intriguing to explore whether PTPN11 single nucleotide polymorphisms (SNPs) would influence chemotherapy effectiveness and GC prognosis among a Chinese population." | 1.43 | Chemotherapy Effectiveness and Prognosis of Gastric Cancer Influenced by PTPN11 Polymorphisms. ( Chen, C; Chen, G; Jiang, D; Li, J; Lin, C; Lin, X; Shao, M; Tian, H; Wang, L; Zhuo, C, 2016) |
| "We herein describe a case of gastric cancer during pregnancy." | 1.43 | Laparoscopic Gastrectomy Followed by Chemotherapy for Advanced Gastric Cancer Diagnosed During Pregnancy: A Case Report. ( Chin, HM; Jo, YS; Jun, KH; Jung, JH; Kim, EY, 2016) |
| "A total of 337 patients with resected gastric cancer treated at Zhongnan Hospital of Wuhan University from 2004 to 2012 were retrospectively analyzed." | 1.43 | D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy. ( Dai, J; Gong, J; Peng, J; Qin, Y; Wei, Y; Xie, C; Xiong, B; Zhong, Y; Zhou, F; Zhou, Y, 2016) |
| "Febrile neutropenia was not reported." | 1.43 | Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. ( Caparello, C; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Petrini, I; Vasile, E; Vivaldi, C, 2016) |
| "5-Fluorouracil (5-FU) has been a mainstay of chemotherapy for gastric cancer." | 1.43 | The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer. ( Matsuhashi, N; Matsui, S; Okumura, N; Osada, S; Sasaki, Y; Takahashi, T; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yawata, K; Yoshida, K, 2016) |
| "The prognosis of gastric cancer remains poor due to clinical drug resistance." | 1.43 | Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species. ( Cai, A; Chen, G; Chen, L; Cui, J; Liang, W; Wei, B; Wu, X; Xi, H; Yu, J; Zhang, K; Zhao, X, 2016) |
| "Sarcopenia is a significant predictor of DLT in oesophago-gastric cancer patients undergoing neo-adjuvant chemotherapy." | 1.42 | Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. ( Brammer, K; Catton, JA; James, EJ; Parsons, SL; Randhawa, N; Tan, BH; Welch, NT, 2015) |
| "A total of 175 gastric cancer patients who received R0 gastrectomy with standard lymph node dissection were enrolled." | 1.42 | Clinicopathological significance of nuclear factor (erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer. ( Arigami, T; Ishigami, S; Kawasaki, Y; Kijima, Y; Kita, Y; Maemura, K; Nakajo, A; Natsugoe, S; Nishizono, Y; Okumura, H; Uchikado, Y; Uenosono, Y; Yanagita, S, 2015) |
| " Oxaliplatin in combination with intravenous 5-FU plus leucovorin (LV; modified [m]FOLFOX6) or capecitabine (XELOX) improves tolerability compared with 5-FU/cisplatin regimen." | 1.42 | Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. ( André, T; Bachet, JB; Chibaudel, B; Cohen, R; de Gramont, A; Hentic, O; Louvet, C; Samalin, E; Soularue, É; Tournigand, C; Zaanan, A, 2015) |
| "For further investigation, the human gastric cancer cell line SGC7901 was subjected to different glucose concentrations and the aforementioned proteins were detected using reverse transcription-quantitative polymerase chain reaction and western blot analysis." | 1.42 | High glucose promotes gastric cancer chemoresistance in vivo and in vitro. ( Che, XM; Chen, R; Fan, L; Li, L; Zhao, M; Zhao, W, 2015) |
| "In a gastric cancer xenograft model, administration of IH alone (1 mg/kg body weight, i." | 1.42 | Isorhamnetin augments the anti-tumor effect of capecitabine through the negative regulation of NF-κB signaling cascade in gastric cancer. ( Ahn, KS; Alharbi, SA; Arfuso, F; Chinnathambi, A; Kumar, AP; Li, F; Manu, KA; Ramachandran, L; Sethi, G; Shanmugam, MK; Siveen, KS; Zayed, ME, 2015) |
| "Signet ring cell gastric cancer (SRCGC) has very poor prognosis worldwide, and studying its molecular characteristics is urgent for improving the outcome." | 1.42 | Establishment and characterization of GCSR1, a multi-drug resistant signet ring cell gastric cancer cell line. ( Cao, J; Feng, JG; Gu, LH; He, KF; Jin, KT; Li, GL; Qian, LJ; Su, XY; Teng, LS; Wang, HH; Xu, X; Xu, ZZ; Zhang, J; Zhou, Q, 2015) |
| "To explore the sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 (COX-2) expression in cancer tissue." | 1.42 | Sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 expression. ( Qiu, ZQ; Qiu, ZR, 2015) |
| "Patients with gastric cancer who undergo diagnostic laparoscopy, preoperative chemoradiation, and gastrectomy have a high frequency of obtaining an R0 resection and excellent OS rates." | 1.42 | Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. ( Ajani, J; Badgwell, B; Blum, M; Chiang, YJ; Das, P; Estrella, J; Fournier, K; Mansfield, P; Matamoros, A, 2015) |
| "Tissue samples of gastric cancer and adjacent normal gastric mucosa from patients with or without obesity were performed immunohistochemical staining for P-glycoprotein." | 1.42 | The impact of insulin on chemotherapeutic sensitivity to 5-fluorouracil in gastric cancer cell lines SGC7901, MKN45 and MKN28. ( Guanglin, Q; Jin, W; Junsong, L; Liang, L; Rui, C; Shicai, H; Shuai, C; Shufeng, W; Wei, Z; Xiangming, C; Zexing, W, 2015) |
| "Human gastric cancer cell line BGC823 (BGC823 cells) was used for the testing of in vitro cytotoxicity assays." | 1.42 | Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy. ( Chen, MM; Chen, YW; Qu, CY; Shen, F; Xu, LM; Zhou, M, 2015) |
| "Current medication for gastric cancer patients has a low success rate and the patients develop rapid tolerance to these drugs." | 1.42 | Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer. ( Choi, IJ; Chun, KH; Kim, SJ; Lee, HW; Song, J, 2015) |
| "Most gastric cancer patients are asymptomatic until the advanced stages, for which current therapeutic treatments are suboptimal." | 1.42 | Alpha 7-nicotinic acetylcholine receptor mediates the sensitivity of gastric cancer cells to 5-fluorouracil. ( Chang, YJ; Chen, CL; Chen, WY; Cheng, WL; Huang, CY; Huang, MT; Hung, CS; Liu, YN; Tai, CJ, 2015) |
| "From January 2008 to December 2013, 107 gastric cancer patients with synchronous liver metastasis attending the four participating centers were enrolled in this multicenter, ambispective, controlled cohort study." | 1.42 | Comparison of Therapeutic Efficacy between Gastrectomy with Transarterial Chemoembolization Plus Systemic Chemotherapy and Systemic Chemotherapy Alone in Gastric Cancer with Synchronous Liver Metastasis. ( Chen, L; Cheng, HD; Cui, JX; Li, JY; Liu, SF; Lu, CR; Shen, WS; Xi, HQ, 2015) |
| "The human gastric cancer BGC-823 cells were infected with Cx43-IRES2-EGFP recombinant adenovirus vector." | 1.42 | Infection by Cx43 adenovirus increased chemotherapy sensitivity in human gastric cancer BGC-823 cells: not involving in induction of cell apoptosis. ( Hu, X; Li, Y; Liu, D; Liu, W; Shi, G; Sun, X; Wang, T; Wu, J; Yue, X; Zhang, X; Zhao, Y; Zhou, H, 2015) |
| "Berberine was more effective in inhibiting survivin expression as compared to other herbal agents." | 1.42 | Berberine and Curcumin Target Survivin and STAT3 in Gastric Cancer Cells and Synergize Actions of Standard Chemotherapeutic 5-Fluorouracil. ( Bharti, AC; Dwivedi, M; Mahata, S; Mehrotra, R; Misra, SP; Misra, V; Pandey, A; Tripathi, SC; Vishnoi, K, 2015) |
| "Transfection of miR-125b sensitizes gastric cancer cells to 5-FU-induced apoptosis." | 1.42 | miR-125b Suppresses Proliferation and Invasion by Targeting MCL1 in Gastric Cancer. ( He, X; Liu, F; Lv, X; Peng, Y; Wu, S; Xie, L; Zhang, Z; Zhu, Y, 2015) |
| "The clinicopathological data of 110 gastric cancer patients who developed recurrence or second primary malignancies after radical gastrectomy and adjuvant chemotherapy with FOLFOX4 regimen or docetaxel plus FOLFOX4 regimen were analyzed retrospectively." | 1.42 | [Characteristics of recurrence in patients with gastric cancer after radical gastrectomy and adjuvant chemotherapy]. ( Du, C; Guo, C; Wang, J; Xu, Q; Zhou, A, 2015) |
| "A total of 101 gastric cancer multidrug resistant cases and 100 controls were genotyped with sequence-specific primed PCR (SSP-PCR)." | 1.42 | Genetic Variation in the ABCB1 Gene May Lead to mRNA Level Chabge: Application to Gastric Cancer Cases. ( Alizadeh, S; Fakharai, H; Golalipour, M; Jahangirerad, A; Khandozi, SR; Mansoori, M; Shahbazi, M, 2015) |
| "The long-term outcomes of advanced gastric cancer (AGC) patients treated with S-1 plus cisplatin (SP) combination chemotherapy remain unclear." | 1.40 | Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment. ( Ando, M; Kadowaki, S; Komori, A; Kondo, C; Muro, K; Narita, Y; Nitta, S; Takahari, D; Taniguchi, H; Ura, T; Yamaguchi, K, 2014) |
| "Embelin reduced gastric cancer cell viability, induced apoptosis, and enhanced 5-FU antitumor activity in gastric cancer cells." | 1.40 | Anti-tumor activity of the X-linked inhibitor of apoptosis (XIAP) inhibitor embelin in gastric cancer cells. ( Gao, L; Kharbuja, P; Li, W; Sun, YB; Suo, J; Wang, DG; Ye, F; Zhang, DY, 2014) |
| "Whether simvastatin can sensitize the gastric cancer to the antitumor effects of capecitabine in vitro and in vivo was investigated." | 1.40 | Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products. ( Ahn, KS; Chen, L; Kumar, AP; Li, F; Manu, KA; Sethi, G; Shanmugam, MK; Siveen, KS, 2014) |
| "Knockdown of DAP3 was conducted in gastric cancer cell lines to investigate its impact on cell growth, migration, adhesion and invasion." | 1.40 | Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy. ( Hargest, R; Ji, J; Ji, K; Jia, Y; Jiang, WG; Ye, L; Zhang, L, 2014) |
| "In this study, we investigated whether gastric cancer with hypoxia-induced resistance to 5-fluorouracil (5-FU) could be re-sensitized following treatment with low-dose dichloroacetate (DCA), an inhibitor of the glycolytic pathway." | 1.40 | Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism. ( Cho, YK; Ham, IH; Han, SU; Hur, H; Kim, YB; Lee, G; Lee, JY; Shim, W; Xuan, Y; Yun, J, 2014) |
| "Treatment of gastric cancer cells with genistein reduced its chemoresistance to 5-Fu (fluorouracil) and ciplatin." | 1.40 | Genistein-inhibited cancer stem cell-like properties and reduced chemoresistance of gastric cancer. ( Huang, W; Huang, Z; Luo, Q; Wan, C, 2014) |
| "A total of 100 gastric cancer patients who received curative D2 gastrectomy were enrolled in this study and were randomly assigned to either XELOX group (oral capecitabine combined with intravenous oxaliplatin chemotherapy) or the control group (surgery alone)." | 1.40 | [Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): Chinese subgroup analysis]. ( He, Y; Huang, C; Ji, J; Liang, H; Liu, Y; Shi, Y; Sun, Y; Wu, A; Yan, M; Ye, Y; Zhan, Y, 2014) |
| "Three gastric cancer cell lines therein KATO-III(, SGC7901 and MKN45 were sorted by immunomagnetic beads cell sorting method." | 1.40 | [Relationship between CD133 and chemoresistance in human gastric cancer and its associated mechanism]. ( Cai, C; Jiang, B; Wang, S; Wu, J; Yu, J; Zhu, Y, 2014) |
| "On treatment with PI103 or Ku-0063794, only the PIK3CA mutant cells displayed increased resistance in LG conditions." | 1.40 | Increased drug resistance is associated with reduced glucose levels and an enhanced glycolysis phenotype. ( Beloueche-Babari, M; Bhattacharya, B; Kamal Mustapa, N; Koh, KX; Loh, J; Low, SH; Soh, C; Soong, R, 2014) |
| "Basaloid squamous cell carcinoma (BSCC) is a high-grade variant of squamous cell carcinoma usually localized in the aerodigestive tract, with a poor prognosis." | 1.40 | Basaloid squamous cell carcinoma: a rare tumor at the esophagogastric junction and an unexpected durable complete response to FOLFOX-4. ( Attademo, L; Camera, L; Carlomagno, C; Cella, CA; D'Armiento, M; De Stefano, A; Feliciano, S; Guadagno, E; Lordick, F; Matano, E; Moretto, R; Raimondo, L, 2014) |
| "In this study, the gastric cancer cell line HGC-27 was used and capsaicin used as a chemosensitizer and 5-flourouracil (5-FU) was used as chemotherapeutic." | 1.40 | Capsaicin inhibits cell proliferation by cytochrome c release in gastric cancer cells. ( Alpay, M; Cakir, DU; Kismali, G; Kosova, F; Meral, O; Pekcan, M; Sel, T; Yigit, S, 2014) |
| "Diffuse-type gastric cancer patients (n = 22) demonstrated higher OPRT expression levels than intestinal-type(n = 10) ones (2." | 1.40 | [Correlated analysis of 5 fluorouracil metabolic enzymes with tumor response after SOX regimen neoadjuvant chemotherapy in advanced gastric cancer]. ( Chen, L; Feng, D; Guo, X; Li, T; Li, Z; Liang, M; Peng, Z; Teng, D; Wang, H; Wu, X; Yuan, J, 2014) |
| "Axitinib alone could inhibit cell proliferation and retard tumor growth through inducing cell cycle arrest at G2/M phase, cell senescence, cell apoptosis, and antiangiogenesis in vitro and in vivo." | 1.40 | Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo. ( Gao, J; Ge, S; He, Q; Li, Y; Peng, Z; Shen, L; Wang, T, 2014) |
| "Gastric cancer is a common malignant tumor." | 1.40 | Inhibitory effects of 3-bromopyruvate on human gastric cancer implant tumors in nude mice. ( Cao, W; Lu, YF; Xian, SL; Zhang, XD, 2014) |
| "2." | 1.40 | p16 Methylation is associated with chemosensitivity to fluorouracil in patients with advanced gastric cancer. ( Deng, D; Gao, J; Gu, L; Li, Y; Shen, L; Wang, M; Zhou, J, 2014) |
| "MELK expression levels in human gastric cancer were determined by quantitative-PCR and immunohistochemistry." | 1.40 | Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway. ( Du, T; Li, C; Li, H; Li, J; Liu, B; Qu, Y; Su, L; Yan, M; Zhou, Q; Zhu, Z, 2014) |
| "Secondary surgery of metastasized gastric cancer may be justified in selected cases without progression under induction chemotherapy." | 1.40 | Secondary gastrectomy for stage IV gastroesophageal adenocarcinoma after induction-chemotherapy. ( Friess, HM; Novotny, AR; Reim, D; Schuhmacher, C, 2014) |
| "We present a case of recurrent gastric cancer in which stable disease status was achieved for four months due to treatment with capecitabine/cisplatin (CDDP)after the failure of multiple anticancer drugs including S-1/CDDP." | 1.40 | [A case of S-1/CDDP-resistant recurrent gastric cancer responsive to capecitabine/CDDP]. ( Sakamoto, K; Sakashita, K; Sawada, R; Sunami, T; Tauchi, J; Yukimoto, K, 2014) |
| "Capecitabine is an oral prodrug to 5-fluorouracil and is commonly used in the treatment of advanced breast, colon and stomach cancer." | 1.40 | Capecitabine induced colitis. ( Grin, A; Grover, SC; Maggo, G, 2014) |
| "Three and five years survival of gastric cancer patients subjected to adjuvant chemoradiotherapy was 53 and 41% respectively." | 1.40 | [Adjuvant chemoradiotherapy in advanced gastric cancer: experience in 168 patients]. ( Isa O, N; López V, H; Russo N, M, 2014) |
| "Data of 124 patients with advanced gastric cancer undergoing radical operation in Tianjin Medical University Cancer Institute and Hospital from January 2007 to January 2009 were analyzed retrospectively." | 1.40 | [Clinical observation of abdominal regional fluorouracil implants in advanced gastric cancer patients during operation]. ( Cui, J; Deng, J; Jiang, N; Liang, H; Liu, H; Wang, X; Wu, L, 2014) |
| "To evaluate the efficacy and safety of autologous cytokine-induced killer (CIK) cell t combined with XELOX regimen in treatment of senile advanced gastric cancer." | 1.40 | [Clinical study of autologous cytokine-induced killer cells combined with XELOX regimen in the treatment of senile advanced gastric cancer]. ( Bai, B; Cui, Y; Kuang, S; Wen, Y, 2014) |
| "Metastatic gastric cancer patients who progressed on modified DCF regimens were included." | 1.40 | Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and ci ( Aksoy, S; Benekli, M; Ekinci, AS; Günaydın, Y; Oksuzoglu, B; Özatlı, T; Ozdemir, N; Sendur, MA; Yazıcı, O; Yazılıtaş, D; Zengin, N, 2014) |
| " R0 resection, survival, and adverse events were compared." | 1.40 | Neoadjuvant chemotherapy with FOLFOX4 regimen to treat advanced gastric cancer improves survival without increasing adverse events: a retrospective cohort study from a Chinese center. ( Li, Y; Sun, Z; Yang, GF; Zhu, RJ, 2014) |
| "Radiotherapy (RT) planning of gastric cancer is important because of the low radiation tolerance of surrounding critical organs." | 1.40 | Comparison of 2-dimensional and 3-dimensional conformal treatment plans in gastric cancer radiotherapy. ( Adas, YG; Aktas, C; Akyurek, S; Andrieu, MN; Atakul, T; Dirican, B; Ergocen, S; Gokce, SC; Hicsonmez, A; Yilmaz, S, 2014) |
| "We report a case of gastric cancer with peritoneal dissemination that was successfully treated with low-dose S-1 or capecitabine chemotherapy over a 5-year period." | 1.40 | [A case of gastric cancer with peritoneal dissemination successfully treated with low-dose S-1 or capecitabine chemotherapy for five years]. ( Hara, Y; Minami, Y; Nakamura, T; Ueda, S, 2014) |
| "The study included 405 gastric cancer patients who underwent curative gastrectomy with D2 lymph node dissection and received adjuvant therapy between January 2008 and July 2009." | 1.40 | Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. ( Bae, JM; Choi, MG; Kang, WK; Kim, S; Lee, J; Lee, JH; Lee, SJ; Lim, DH; Lim, HY; Park, JO; Park, SH; Park, YS; Sohn, TS, 2014) |
| "Docetaxel and cisplatin in combination with fluorouracil (DCF) regimen is accepted to be one of the standard regimens in the treatment of advanced gastric cancer." | 1.40 | Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer. ( Bilici, A; Demir, N; Dikilitas, M; Oven Ustaalioglu, BB; Selcukbiricik, F; Yildiz, O, 2014) |
| " Short-term efficacy and adverse reactions were observed." | 1.40 | [Safety and efficacy of intraperitoneal hyperthermic perfusion chemotherapy following laparoscopic palliative resection for gastric cancer patients with peritoneal metastasis]. ( Chen, T; Hu, Y; Li, G; Mou, T; Xia, W; Yu, J, 2014) |
| "A 77-year-old woman was diagnosed with gastric cancer complicated by multiple liver metastases and peritoneal dissemination." | 1.40 | [Gastric cancer with liver metastasis and peritoneal dissemination treated with conversion surgery to achieve r0 resection after capecitabine, cisplatin, and trastuzumab chemotherapy-a case report]. ( Choda, Y; Harano, M; Idani, H; Kanazawa, T; Matsukawa, H; Ninomiya, M; Ojima, Y; Okajima, M; Sato, D; Shiozaki, S; Tokumoto, N, 2014) |
| "Gastric samples from patients with gastric cancer were further analyzed for levels of a specifically downregulated lncRNA (termed as LEIGC)." | 1.40 | LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. ( Chen, J; Chen, Z; Gao, S; Han, Y; Huang, J; Wu, D; Wu, P; Ye, J, 2014) |
| "Two patients presented with brain metastases, while one demonstrated lymphangitic spread to lungs." | 1.40 | A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. ( Calkins, SM; Cinar, P; Kelley, RK; Venook, AP, 2014) |
| " Therefore, we aimed to assess the clinical effect of XELOX neoadjuvant chemotherapy on AGC when combined with laparoscopic surgery." | 1.40 | Treatment of locally advanced gastric cancer with the XELOX program of neoadjuvantchemotherapy combined with laparoscopic surgery: the experience in China. ( Huang, CM; Li, P; Lin, JX; Lu, J; Wang, JB; Xie, JW; Zheng, CH, 2014) |
| "Metastatic gastric cancer is uncommon, and metastasis of colorectal cancer to the stomach is extremely rare." | 1.40 | [A case of metastatic gastric cancer originating from transverse colon cancer]. ( Doi, S; Kan, K; Maruyama, H; Murata, K; Nakaguchi, K; Nakano, K; Nushijima, Y; Okamura, S; Sugimoto, K, 2014) |
| "A 62-year-old man presented with type 3 gastric cancer (tub1, HER2 positive) in the cardia, with 10-cm direct invasion into the lower esophagus, and extensive lymph node metastasis (Virchow and paraaortic nodes)." | 1.40 | [A case of HER2-positive advanced gastric cancer with extensive lymph node metastasis treated via chemotherapy with a trastuzumab-containing regimen followed by conversion surgery]. ( Asaoka, T; Fujitani, K; Fukuda, Y; Haraguchi, N; Hirao, M; Ikeda, M; Miyake, M; Miyamoto, A; Nakamori, S; Nishikawa, K; Omiya, H; Sekimoto, M; Takami, K; Tsujinaka, T; Yamamoto, K, 2014) |
| "Six months after surgery, recurrence was detected in the para-aortic lymph node." | 1.40 | [A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy]. ( Egawa, T; Ito, Y; Kemmochi, T; Mihara, K; Nagashima, A; Nishiya, S; Yamashiro, N, 2014) |
| "The patient has had no recurrence of gastric cancer for 18 months after the initial operation." | 1.40 | [A case of early gastric cancer completely responding to adjuvant chemotherapy for advanced colon cancer]. ( Hanyu, T; Ichikawa, H; Ishikawa, T; Kameyama, H; Kobayashi, T; Kosugi, S; Koyama, Y; Minagawa, M; Nakano, M; Sakata, J; Shimada, Y; Tanaka, R; Wakai, T, 2014) |
| "In patients with metastatic gastric cancer, the prognosis is poor with a median overall survival of 11 months since curative treatments are excluded; however, this case illustrated that a personalized treatment with chemotherapy and surgery can allow a curative strategy in selected patients with HER2-negative advanced gastric cancer." | 1.40 | Advanced gastric cancer with liver and lymph node metastases successfully resected after induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil. ( Anselmi, E; Banchini, F; Bodini, FC; Capelli, P; Cavanna, L; Michieletti, E; Stroppa, EM; Zangrandi, A, 2014) |
| "The aim is to evaluate the preliminary efficacy and side effects of paclitaxel, 5-fluorouracil, and leucovorin intravenous chemotherapy in combination with cisplatin hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) as postoperative adjuvant therapy for patients of locally advanced gastric cancer (GC) at high risk for recurrence after curative resection." | 1.40 | Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer. ( Chen, S; Deng, Q; Jing, S; Li, J; Li, X; Ma, S; Tang, R; Wu, K; Wu, Z; Zheng, Z, 2014) |
| "To investigate the efficacy and safety of PCF chemotherapy combined with surgery in the treatment of late-stage gastric cancer." | 1.40 | PCF Chemotherapy Combined with Surgical Treatment of Late Gastric Cancer. ( Cheng, X; Dong, R; Du, Y; Huang, L; Wang, B; Xu, Z; Yang, L; Yu, P; Zhou, Y, 2014) |
| " During HIPEC in Colliseum technique Oxaliplatin was given in a dosage of 200 mg/m2 and Docetaxel in a dosage of 80 mg/m2." | 1.40 | Systemic Chemotherapy using FLOT - Regimen Combined with Cytoreductive Surgery plus HIPEC for Treatment of Peritoneal Metastasized Gastric Cancer. . ( Hotopp, T; Müller, H; Tofeili, A; Wutke, K, 2014) |
| "In all, 48 advanced gastric cancer patients were recruited from June 2007 to December 2010 after providing their written, informed consent." | 1.40 | Endoscopic ultrasound in restaging and predicting pathological response for advanced gastric cancer patients after neoadjuvant chemotherapy. ( Guo, T; Li, XY; Lu, XH; Wu, DS; Wu, X; Yang, AM; Yao, F; Zhong, DR, 2014) |
| "Nobiletin is a typical polymethoxyl flavone from citrus fruits that has anticancer properties, but the molecular mechanism of its inhibitory effects on the growth of p53-mutated SNU-16 human gastric cancer cells has not been explored." | 1.39 | Nobiletin induces apoptosis and potentiates the effects of the anticancer drug 5-fluorouracil in p53-mutated SNU-16 human gastric cancer cells. ( Ahn, KS; Cho, M; Cho, SK; Moon, JY, 2013) |
| "Subcutaneous injections of CD44+ gastric cancer cells conferred tumorigenicity in SCID mice." | 1.39 | Identification of CD44+ cancer stem cells in human gastric cancer. ( Chen, M; Chen, W; Cheung, WL; Chow, A; Chu, C; Lam, S; Lau, T; Li, Y; Ng, L; Nie, Y; Pang, R; Wong, BC; Zhang, X, 2013) |
| "A 5‑fluorouracil (5‑Fu)‑induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5‑Fu." | 1.39 | microRNA expression profiling in multidrug resistance of the 5‑Fu‑induced SGC‑7901 human gastric cancer cell line. ( Chen, Z; Gu, X; Jiang, J; Li, Z; Wang, Y; Xiang, J, 2013) |
| "However, the effect of TIIA on gastric cancer cells remains unknown." | 1.39 | Tanshinone IIA reverses the malignant phenotype of SGC7901 gastric cancer cells. ( Cao, FL; Li, NY; Li, YP; Liu, YQ; Lv, CL; Xu, M, 2013) |
| "A total of 128 patients with gastric cancer who underwent gastrectomy, followed by adjuvant chemotherapy consisting of epirubicin, cisplatin or oxaliplatin, leucovorin, and 5-fluorouracil, according to a defined schedule, were divided into three groups according to the number of chemotherapy cycles: Group I (<6 cycles); Group II (6 cycles); and Group III (>6 cycles)." | 1.39 | Impact of adjuvant chemotherapy cycles on prognosis of resectable stomach cancer: a retrospective analysis. ( Bai, Y; Gao, J; Gong, YF; Jiang, B; Liu, F; Yuan, HH; Zhang, WJ; Zhang, WY, 2013) |
| "Our data suggested that gastric cancer patients harboring ERCC1‑118 C/C and XRCC1‑399 A/G or A/A genotypes may benefit from receiving OXA‑based adjuvant chemotherapy, and carrying at least one variant XRCC1 Arg399Gln or GSTP1 Ile105Val allele may contribute to the occurrence of adverse drug effects associated with OXA‑based chemotherapy." | 1.39 | Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy. ( Ling, Y; Liu, YP; Pan, YD; Qi, QF; Wang, MH; Zhang, CS; Zhang, YP; Zhu, CT, 2013) |
| "To investigate the sensitivity of gastric cancer stem cells (GCSCs) to 5-fluorouracil (5-FU), and to explore the cytological mechanism of drug-resistance of gastric cancer." | 1.39 | [Isolation of gastric cancer stem cells based on colony morphology and detection of their sensitivity to 5-fluorouracil]. ( Xu, GF; Zhang, JD; Zhao, HB; Zhou, ZH, 2013) |
| "Almost all gastric cancers are adenocarcinomas, which have considerable heterogeneity among patients." | 1.39 | Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. ( Boussioutas, A; Chua, C; Das, K; Deng, N; Feng, Z; Flotow, H; Goh, LK; Guan, YK; Ivanova, T; Lee, M; Lei, Z; Lim, TK; Manesh, S; Ngo, A; Ooi, CH; Pattison, S; Rozen, SG; So, JB; Tan, E; Tan, IB; Tan, P; Teh, BT; Wu, J; Zhang, S; Zouridis, H, 2013) |
| "Patients with advanced gastric cancer receiving chemotherapy were retrospectively collected, and divided into two groups." | 1.39 | Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer. ( Huang, XE; Qian, YD; Wang, L; Xiang, J; Xu, HQ; Xu, X, 2013) |
| "Survival of the 5-FU-resistant gastric cancer cell line, SNU-620-5FU/1000, was not significantly reduced even by a high dose of 5-FU treatment." | 1.39 | Cannabinoid receptor agonist as an alternative drug in 5-fluorouracil-resistant gastric cancer cells. ( Choi, MG; Park, H; Park, JM; Xian, XS, 2013) |
| "Like capecitabine, tegafur is a metabolic precursor of fluorouracil." | 1.39 | Tegafur + gimeracil + oteracil. Just another fluorouracil precursor. ( , 2013) |
| "Here, we present a case of recurrent gastric cancer during S-1 adjuvant therapy that showed partial response to CDDP + capecitabine therapy." | 1.39 | [A case of mediastinal lymph node gastric cancer recurrence during S-1 adjuvant therapy successfully treated with cisplatin + capecitabine as second-line chemotherapy]. ( Ebata, T; Fukaya, M; Hirata, A; Igami, T; Itatsu, K; Nagino, M; Sugawara, G; Tsunoda, N; Uehara, K; Usui, H; Yokoyama, Y; Yoshioka, Y, 2013) |
| "Because the gastric cancer was HER2-positive, she was treated with trastuzumab plus capecitabine plus cisplatin(XP)chemotherapy as third-line treatment." | 1.39 | [A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment]. ( Fuyuki, A; Hata, Y; Kanoshima, K; Kuriyama, H; Kuwabara, H; Matsuura, T; Murata, Y; Taniguchi, R; Tomeno, W; Uchiyama, T, 2013) |
| "A cisplatin-resistant gastric cancer cell line with stable downregulation of CDX2 was established." | 1.39 | Reversal of multidrug resistance in gastric cancer cells by CDX2 downregulation. ( Kong, FB; Lian, C; Luo, W; Wang, XT; Wei, WY; Xiao, Q; Xie, YB; Yan, LH; Yang, J, 2013) |
| "Between 2005 and 2009, 71 gastric cancer patients who underwent D2 lymph node dissection and had pTanyN3M0 stage (according to AJCC 6th edition) were identified." | 1.39 | Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients? ( Asoglu, O; Aykan, F; Ekenel, M; Gural, Z; Keskin, S; Kilic, L; Kizir, A; Ordu, C; Sen, F; Yildiz, I, 2013) |
| "In two gastric cancer cell lines without Reprimo methylation, we observed faint or weak Reprimo expression under normal conditions and high expression under DNA-damaging conditions." | 1.39 | DNA damage-inducible gene, reprimo functions as a tumor suppressor and is suppressed by promoter methylation in gastric cancer. ( Mondal, A; Nishimiya, H; Ooki, A; Watanabe, M; Yamaguchi, K; Yamashita, K, 2013) |
| "Clinical data of 311 node-negative gastric cancer patients who underwent potentially curative gastrectomy with more than 15 lymph nodes resected, from January 2002 to December 2006, were analyzed retrospectively." | 1.39 | Effects of extended lymphadenectomy and postoperative chemotherapy on node-negative gastric cancer. ( Deng, JY; Liang, H; Wang, XN; Xue, Q; Zhang, RP, 2013) |
| "Preincubation of gastric cancer cells with IFN-α enhanced 5'-DFUR-induced apoptosis via IFN-α-mediated upregulation of TP." | 1.39 | Interferon-α enhances 5'-deoxy-5-fluorouridine-induced apoptosis by ERK-dependant upregulation of thymidine phosphorylase. ( Fan, Y; Hou, K; Li, C; Liu, Y; Qu, X; Xu, L; Zhang, Y; Zheng, H; Zhu, Y, 2013) |
| "Gastric cancer is one of the major public health problems." | 1.39 | Lentivirus-mediated shRNA targeting of cyclin D1 enhances the chemosensitivity of human gastric cancer to 5-fluorouracil. ( Choi, YK; Heo, SH; Jeong, DG; Jeong, ES; Lee, KS; Seo, JH, 2013) |
| "MKN45, a gastric cancer cell line, was treated with each single agent alone or a combination of FGF19, PD and 5-Fu." | 1.39 | Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer. ( Hu, S; Shi, YQ; Wang, GJ; Wen, JG; Ye, YW; Zhang, XF; Zhao, CL; Zhou, Y; Zong, H, 2013) |
| "Gastric cancer is one of the most common human cancers and ranks the second in the global cancer-related mortality." | 1.39 | High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients. ( Feng, J; Gao, J; Han, Y; Huang, H; Qu, L; Shen, L; Shou, C; Zhu, L, 2013) |
| "Capecitabine (CA) is an orally administered fluoropyrimidine carbamate which is preferentially converted to active 5-FU and is one of the agents used instead of FU in such cases." | 1.39 | Can capecitabine be used instead of concurrent bolus 5-FU in postoperative chemoradiotherapy for gastric adenocarcinoma? ( Isikli, L; Yoney, A, 2013) |
| "However, the role of Nrf2 in gastric cancer (GC) remains incompletely understood." | 1.39 | Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer. ( Feng, XS; Gao, SG; Hu, XF; Peng, XQ; Wang, XS; Yang, YT; Yao, J, 2013) |
| "We analysed 111 patients with advanced gastric cancer treated at the University Hospital Heidelberg (51) and the private oncology practice Bottrop/Dorsten (60) between 2001 and 2011, comparing the outcome of patients with first-line chemotherapy and those who received second-line chemotherapy." | 1.39 | Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients. ( Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W, 2013) |
| "Chemosensitivity of the gastric cancer cells varied; the rates of inhibition of cells exposed to HCPT, CDDP and 5-FU were significantly higher than that of cells exposed to ADM and MMC (p < 0." | 1.39 | The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer. ( Cao, R; Chen, X; Geng, M; Li, P; Wang, L, 2013) |
| "The role of second-line therapy in gastric cancer patients mostly stemmed from clinical trials with monochemotherapy carried out in Asian countries." | 1.39 | FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. ( Amodio, A; Barba, M; Belli, F; Boggia, S; Di Lauro, L; Fattoruso, S; Giannarelli, D; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Vici, P, 2013) |
| "5-Fluorouracil (5-FU) is an essential component of anticancer chemotherapy against gastric cancer." | 1.39 | Cbl-b enhances sensitivity to 5-fluorouracil via EGFR- and mitochondria-mediated pathways in gastric cancer cells. ( Feng, D; Liu, J; Liu, Y; Ma, Y; Qu, J; Qu, X; Xu, L; Zhang, Y, 2013) |
| "A 70-year-old man with advanced gastric cancer was treated with neoadjuvant chemotherapy consisting of S-1 plus cisplatin( CDDP)." | 1.39 | [Recurrent gastric cancer treated with fourth-line chemotherapy consisting of capecitabine and cisplatin leading to partial response]. ( Doi, T; Hoshi, M; Iijima, S; Ikeda, K; Kikkawa, N; Kurokawa, E; Makari, Y; Oshima, S, 2013) |
| "Gastric and colorectal cancers are among the most common cancers worldwide and cause serious cancer mortality." | 1.39 | Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers. ( He, C; Hu, X; Huang, X; Kuang, Y; Li, L; Mo, L; Rong, R; Shi, Q; Shu, X; Su, X; Sui, X; Tao, Q, 2013) |
| "Liver metastasis and peritonitis carcinomatosa were found in 20 (43 %) and 18 (39 %) of the 46 cases, respectively." | 1.39 | Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC). ( Aydogan, F; Aykan, F; Disci, R; Ekenel, M; Keskin, S; Kilic, L; Saglam, S; Sakar, B; Sen, F; Yıldız, I, 2013) |
| "Median age at gastric cancer diagnosis was 48." | 1.39 | Chemosensitivity in ovarian metastases from gastric cancer: a case series. ( Berger, A; Brieau, B; Dubreuil, O; Landi, B; Lepère, C; Markoutsaki, T; Rougier, P; Roussel, H; Taieb, J; Trouilloud, I; Vaillant, JN; Zaanan, A, 2013) |
| " We evaluated the antitumor effect of a c-Src/Abl kinase inhibitor, saracatinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer cell lines and a NCI-N87 xenograft model." | 1.39 | Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. ( Bang, YJ; Elvin, P; Han, SW; Im, SA; Kim, HP; Kim, TY; Min, A; Nam, HJ; Oh, DY; Song, SH; Yoon, YK, 2013) |
| "Synchronous gastric and pancreatic cancers represent a very rare association." | 1.39 | Double pancreatic and gastric adenocarcinomas: a rare association. ( Cuenod, CA; Dubreuil, O; Fabre, M; Kourie, HR; Landi, B; Markoutsaki, N; Palazzo, L; Rahmi, G; Rougier, P; Roussel, H; Taieb, J; Van der Stiegel, M, 2013) |
| "However, the function of ASCL2 in gastric cancer (GC) is poorly understood." | 1.39 | Aberrant upregulation of ASCL2 by promoter demethylation promotes the growth and resistance to 5-fluorouracil of gastric cancer cells. ( Baek, SJ; Kim, SY; Kim, YS; Kwon, OH; Noh, SM; Park, JL; Song, KS, 2013) |
| "Small metabolites in gastric cancer cells and 5-FU-resistant cells were measured by liquid chromatography-mass spectrometry." | 1.39 | Metabolomic analysis of dynamic response and drug resistance of gastric cancer cells to 5-fluorouracil. ( Hihara, J; Masujima, T; Miyata, Y; Okada, M; Sasada, S; Tsutani, Y; Tsuyama, N, 2013) |
| "A total of five advanced gastric cancer patients were treated." | 1.39 | [Efficacy of capecitabine/cisplatin chemotherapy after failure of all conventional therapies in patients with advanced gastric cancer]. ( Aono, T; Deguchi, K; Deguchi, T; Fukui, A; Fushimi, H; Higashi, S; Iwase, K; Kawada, J; Matsuda, C; Nishikawa, K; Nomura, M; Takagi, M; Tamagawa, H; Tanaka, Y; Umeda, S; Yoshida, H, 2013) |
| " However, the value of FAK combined with JWA for GC patients as a biomarker has not been studied." | 1.39 | High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients. ( Chen, Y; He, S; Li, A; Qiang, F; Røe, OD; Tan, Y; Wang, S; Wu, X; Xia, X; Zhang, J; Zhou, J; Zhou, Y, 2013) |
| "To investigate the efficacy and safety of chemotherapy combined with intraperitoneal perfusion of cytokine-induced killer (CIK) cells for advanced gastric cancer patients with ascites." | 1.39 | [A pilot study of chemotherapy combined with intraperitoneal perfusion of cytokine-induced killer cells for advanced gastric cancer patients with ascites]. ( Chen, Y; Feng, Y; Li, Q; Liu, TS; Wang, ZM; Zhuang, RY, 2013) |
| "Oral formulations of 5-fluorouracil (5-FU) with enhanced bioavailability were developed using microemulsion as a drug carrier system." | 1.38 | Development and evaluation of novel microemulsion based oral formulations of 5-fluorouracil using non-everted rat intestine sac model. ( Maheshwari, M, 2012) |
| "MSI status in gastric cancer is not itself a prognostic indicator." | 1.38 | Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. ( An, JY; Cheong, JH; Hyung, WJ; Kim, H; Noh, SH, 2012) |
| "Clinicopathological data of 257 cM1 gastric cancer patients who underwent an operation at Seoul National University Hospital from January 1999 to December 2004 were reviewed." | 1.38 | The value of palliative gastrectomy in gastric cancer with distant metastasis. ( Chang, YR; Han, DS; Kim, SH; Kim, WH; Kong, SH; Lee, HJ; Yang, HK, 2012) |
| "In pN0 gastric cancers, prognostic factors differed significantly between early stage and advanced stage." | 1.38 | Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with node-negative gastric cancer. ( Kang, WM; Ma, ZQ; Wang, J; Yu, JC, 2012) |
| "PI103 and 5-FU was synergistic in 3/5 gastric cancer cell lines tested." | 1.38 | Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells. ( Akram, M; Balasubramanian, I; Bhattacharya, B; Koh, KX; Soong, R; Tam, KK; Yee, MQ, 2012) |
| "However, its role for advanced gastric cancer remains unclear." | 1.38 | Laparoscopic gastrectomy for patients with advanced gastric cancer produces oncologic outcomes similar to those for open resection. ( Conrad, T; Jacks, L; Kassam, Z; Khalili, I; MacKay, HJ; MacLellan, SJ; Okrainec, A; Ringash, J, 2012) |
| "Whether γ-tocotrienol can sensitize gastric cancer to capecitabine in vitro and in a xenograft mouse model was investigated." | 1.38 | First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway. ( Fong, CW; Kumar, AP; Li, F; Manu, KA; Ramachandran, L; Sethi, G; Shanmugam, MK; Tan, P, 2012) |
| "5-Fluorouracil (5-FU) plays an important role in the chemotherapy of advanced gastric cancer." | 1.38 | EBP50 gene transfection promotes 5-fluorouracil-induced apoptosis in gastric cancer cells through Bax- and Bcl-2-triggered mitochondrial pathways. ( Dong, WG; Fang, C; Guo, XF; Ji, MY; Lei, XF; Liu, M; Lv, XG; Wang, J, 2012) |
| "One 67 gastric cancer patients with cT2-4 or TanyN1-3M0 between January 2006 and December 2007 were included." | 1.38 | Apoptosis index correlates with chemotherapy efficacy and predicts the survival of patients with gastric cancer. ( Dong, B; Du, H; Ji, J; Jia, Y; Liu, Y; Tang, L; Wu, A; Yuan, P, 2012) |
| "We investigated 20 patients with gastric cancer who were treated with oral fluorouracil anti-cancer drugs as adjuvant chemotherapy." | 1.38 | Plasma diamine oxidase activity is a useful biomarker for evaluating gastrointestinal tract toxicities during chemotherapy with oral fluorouracil anti-cancer drugs in patients with gastric cancer. ( Fukudome, I; Hanazaki, K; Kitagawa, H; Kobayashi, M; Namikawa, T; Okabayashi, T, 2012) |
| "Synergistic interaction on human gastric cancer BGC-823 cells and MKN-28 cells was evaluated using the combination index (CI) method." | 1.38 | Enhancement of anticancer efficacy of chemotherapeutics by gambogic acid against gastric cancer cells. ( Li, XL; Liu, BR; Qian, XP; Wang, TT; Wei, J; Yu, LX; Zou, ZY, 2012) |
| "HER2-positive gastric cancer seems to confer poorer prognosis, particularly in patients without diffuse-type tumor, treated with modified FOLFOX-6." | 1.38 | The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. ( Bang, YJ; Cha, Y; Han, SW; Im, SA; Keam, B; Kim, JW; Kim, M; Kim, MA; Kim, TY; Kim, WH; Lee, KH; Oh, DY, 2012) |
| "In nude mice bearing human gastric cancer, the recombinant adenovirus vector was injected directly into the tumor followed by an intraperitoneal injection of GCV and/or 5-FC." | 1.38 | Adenovirus-mediated double suicide gene selectively kills gastric cancer cells. ( Li, JS; Luo, XR; Miao, L; Niu, Y, 2012) |
| " Pharmacokinetic studies of BIIB036 in tumor-bearing mice revealed a half-life of approximately three days suggesting twice a week dosing would be necessary to maintain efficacy." | 1.38 | The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models. ( Joseph, IB; Kelly, R; Michaelson, JS; Wortham, K; Yang, L; Zhang, X, 2012) |
| "Fourteen patients with advanced gastric cancer refractory to 5-fluorouracil, irinotecan, cisplatin and taxanes were included in the study." | 1.38 | Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study. ( Boku, N; Doyama, H; Fukutomi, A; Machida, N; Onozawa, Y; Taniguchi, H; Todaka, A; Tsuji, K; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2012) |
| "One hundred and twenty-eight advanced gastric cancer patients receiving first-line paclitaxel plus capecitabine in Peking University Cancer Hospital from December 2006 to October 2010 were enrolled in the study." | 1.38 | Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine. ( Gao, J; Li, Y; Lu, Z; Shen, L; Yu, J, 2012) |
| "To study the effect of the sphingosine kinase 1 (SphK1) inhibitor N,N-dimethylsphingosine (DMS) in combination with chemotherapeutic drugs (DDP, 5-Fu, MMC) on the proliferation of gastric cancer cells (SGC7901) in vitro, and to evaluate whether SphK1 inhibitors could be used as synergetic agents in chemotherapy." | 1.38 | [Antitumor effect of sphingosine kinase 1 inhibitor in combination with chemotherapy on SGC7901 gastric cancer cells in vitro]. ( Hu, CY; Lan, KH; Lu, Q; Tang, W; Wang, SF; Yin, GJ, 2012) |
| "She had both advanced ascending colon cancer with multiple liver metastasis(cStage IV: cT3N1H3)and early gastric cancer(cStage 0: cTisN0M0)." | 1.38 | [The chemotherapy with mFOLFOX6 for advanced colon cancer was effective for gastric cancer - a case report]. ( Asakage, M; Muto, Y; Shimoishi, K; Yamada, Y, 2012) |
| "Cyclin L2 was transfected into human gastric cancer cell line BCG823 and expressed with a mammalian expression vector pcDNA3." | 1.38 | Overexpression of cyclin L2 inhibits growth and enhances chemosensitivity in human gastric cancer cells. ( Ba, Y; Bai, M; Deng, T; Huang, DZ; Li, HL; Wang, X; Zhou, LK, 2012) |
| " Toxicity was mild; most adverse events were grade I or II and involved no severe infections or deaths." | 1.38 | Efficacy and safety of neoadjuvant chemotherapy with modified FOLFOX7 regimen on the treatment of advanced gastric cancer. ( Cai, J; Chen, RX; Meng, H; Wang, KL; Wang, Y; Wu, GC; Zhang, J; Zhang, ZT, 2012) |
| "A total of 31 patients with advanced gastric cancer was included." | 1.38 | The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer. ( Bilici, A; Ercan, S; Gumus, M; Orcun, A; Seker, M; Ustaalioglu, BB; Yilmaz, BE, 2012) |
| "Irinotecan was given as a combined regimen for median 6 cycles (range, 3-12) and as a single agent for median 3 cycles (range, 1-10)." | 1.38 | Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer. ( Akyol, M; Bayoglu, IV; Can, A; Demir, L; Dirican, A; Erten, C; Kucukzeybek, Y; Medeni, M; Somali, I; Tarhan, MO, 2012) |
| " FOLFIRI regimen is safe and effective in the second-line treatment of AGC patients pre-treated with cisplatin and taxanes." | 1.38 | The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens. ( Alkis, N; Arpacı, E; Benekli, M; Berk, V; Bilici, A; Budakoglu, B; Buyukberber, S; Coskun, U; Dane, F; Demirci, U; Gumus, M; Inal, A; Isıkdogan, A; Kaya, AO; Ozkan, M; Yumuk, F, 2012) |
| "Here, we present a case of recurrent gastric cancer that showed a partial response resulting in 6 months of progres-sion-free survival, thanks to capecitabine/CDDP after the failure of multiple anticancer drugs such as S-1/CDDP." | 1.38 | [A case of recurrent gastric cancer showing partial response to capecitabine/CDDP after treatment with S-1/CDDP]. ( Adachi, T; Goto, A; Itoh, M; Kanno, S; Kondo, Y; Mitsuhashi, K; Shinomura, Y; Suzuki, T; Wakasugi, H; Yabana, T, 2012) |
| "The majority of patients with gastric cancer in developing countries present with advanced disease." | 1.38 | Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study. ( Guven, M; Inal, A; Işikdogan, A; Kaplan, MA; Kuçukoner, M; Nas, N; Urakci, Z; Yunce, M, 2012) |
| " Blood samples for pharmacokinetic analysis were collected on the seventh day of treatment." | 1.38 | An immunoassay method for the pharmacokinetics of 5-fluorouracil in patients with gastric cancer administered adjuvant chemotherapy. ( Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Nakamura, M; Nakashima, H; Oka, Y; Okumura, H; Tsutsumi, K, 2012) |
| "A 71 years old Italian man had type 3 gastric cancer of the greater curvature." | 1.38 | Local recurrence of gastric cancer after total gastrectomy: an unusual presentation. ( Amato, B; Cardin, F; Lorenzetti, R; Martella, B; Militello, C; Terranova, C, 2012) |
| "The HER2-positive rate of gastric cancer tends to be high for a well-differentiated adenocarcinoma." | 1.38 | [A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy]. ( Hamamoto, Y; Nishi, T; Onodera, K; Uemoto, J; Warita, E; Yamanaka, Y, 2012) |
| "To observe efficacy and side effects, as well as the impact on quality of life, of Kanglaite® (Coix Seed Oil) injections combined with chemotherapy in the treatment of advanced gastric cancer patiensts." | 1.38 | Clinical safety and efficacy of Kanglaite® (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer. ( Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; Xiang, J; Xu, X; Ye, LH; Zhan, YP, 2012) |
| " The pharmacokinetic parameters of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil after single oral administration were as follows: (2,207 +/- 545), (220." | 1.38 | [Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer]. ( Chu, Y; Ding, L; Liu, HY; Yu, Y; Zhu, H, 2012) |
| " An increase in adverse events associated with systemic chemotherapy is shown in elderly patients, but it remains controversial whether they should receive the same chemotherapy used for younger patients." | 1.38 | A retrospective study of the safety and efficacy of a first-line treatment with modified FOLFOX-4 in unresectable advanced or recurrent gastric cancer patients. ( Hou, MF; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, DC; Wu, IC; Yeh, YS, 2012) |
| "Forty-three patients with gastric cancer treated with neoadjuvant chemotherapy followed by curative resection between September 2011 and February 2012 were analyzed." | 1.38 | Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy. ( Ang, J; Cao, CH; Chen, L; Hu, L; Huang, LN; Huang, PT; Wu, JX; Zheng, YX, 2012) |
| "Gastric cancer is the third most common cancer worldwide and the second leading cause of cancer deaths." | 1.37 | Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer. ( Abou-Alfa, GK; Al-Olayan, A; Kelsen, D; Lowery, M; Naghy, M; Power, D; Saliba, T; Shah, MA; Shamseddine, A; Smyth, E, 2011) |
| "We studied 26 gastric cancer patients with lymph node metastasis who underwent gastric resection at the Korea University Guro Hospital from Feb 2007 to July 2008." | 1.37 | Metastatic lymph node targeted chemosensitivity test for gastric cancer. ( Jang, YJ; Kim, CS; Kim, JH; Kim, SJ; Mok, YJ; Park, SH; Park, SS, 2011) |
| "An endoscopy showed a mild, transient ischemic colitis." | 1.37 | Ischemic colitis after capecitabine plus cisplatin treatment in advanced gastric cancer. ( Benekli, M; Buyukberber, S; Cetin, B; Coskun, U; Güzel, E; Sentürk, S, 2011) |
| "In patients with Stage III-IV (M0) gastric cancer, adjuvant 5-fluorouracil/cisplatin chemotherapy was tolerable, but did not seem to confer survival advantage." | 1.37 | Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study. ( Bang, YJ; Choe, KJ; Heo, DS; Im, SA; Kim, DW; Kim, JS; Kim, MA; Kim, NK; Kim, TM; Kim, TY; Kim, WH; Lee, KU; Lee, SH; Oh, DY; Yang, HK, 2011) |
| "Four gastric cancer cell lines with wild-type p53 (wt p53) and three with mutant-type p53 (mt p53) were analyzed for MDM2 and MDM4 expression by immunoblotting, and for their gene amplification by quantitative real-time PCR." | 1.37 | Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. ( Abei, M; Endo, S; Fukuda, K; Hirai, S; Hyodo, I; Moriwaki, T; Nakagawa, I; Suzuki, H; Yamato, K, 2011) |
| "High local failure rates in gastric cancer have been reported of up to 70%." | 1.37 | Post-operative radiochemotherapy in patients with gastric cancer: one department's experience of 56 patients. ( Fijuth, J; Gottwald, L; Jesien-Lewandowicz, E; Rychter, A; Serbiak, B; Spych, M, 2011) |
| "Metabolic imaging of gastric cancer is limited due to the 30% of primary tumors that are not (18)F-fluorodeoxyglucose (FDG) avid." | 1.37 | Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. ( Becker, K; Buck, AK; Ebert, MP; Herrmann, K; Krause, BJ; Langer, R; Lordick, F; Ott, K; Peschel, C; Schuster, T; Schwaiger, M; Siewert, JR; Wester, HJ; Wieder, HA; Wilhelm, D; zum Büschenfelde, CM, 2011) |
| "In Chinese advanced gastric cancer, Thymidine Phosphorylase positive & β-tubulin III negative might predict response and prognosis to capecitabine plus paclitaxel chemotherapy." | 1.37 | Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. ( Gao, J; Li, YY; Lu, M; Shen, L; Yu, JW, 2011) |
| "Prognosis of metastatic gastric cancer is poor and median survival is between 3 and 5 months." | 1.37 | Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer. ( Abali, H; Aksoy, S; Budakoglu, B; Kos, FT; Odabaş, H; Oksuzoglu, B; Ozdemir, N; Uncu, D; Zengin, N, 2011) |
| "Gastric cancer is the second most common cause of cancer deaths worldwide and due to its poor prognosis, it is important that specific biomarkers are identified to enable its early detection." | 1.37 | Identification of 14-3-3β in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker. ( Chang, KJ; Chen, CN; Chuang, KN; Huang, HC; Juan, HF; Lai, HS; Lee, PH; Lin, CC; Tseng, CW; Yang, JC, 2011) |
| "The most commonly used schedules are 5-FU in combination with CDDP with or without epirubicin (ECF) or docetaxel (TCF) in treatment of MGA patients (pts), independently of HER status." | 1.37 | Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. ( Abbas, F; Adenis, A; Afchain, P; Aparicio, T; Bécouarn, Y; Bouché, O; Desseigne, F; Dorval, E; Edeline, J; Guimbaud, R; Kramar, A; Mitry, E; Romano, O; Samalin, E; Thézenas, S; Ychou, M, 2011) |
| "Brain MRI revealed a subdural hematoma, and he was transferred to the Department of Neurosurgery of our hospital." | 1.37 | [A case of gastric cancer accompanied by disseminated carcinomatosis of bone marrow with DIC, and subdural hematoma successfully treated with sequential methotrexate and 5-fluorouracil therapy]. ( Dairaku, N; Iwahashi, S; Maejima, R; Narisawa, A; Shimada, N; Yamagiwa, T, 2011) |
| "Patients with gastric cancer receiving adjuvant chemotherapy after radical resection from January 2004 to December 2008 were included." | 1.37 | [Adjuvant chemotherapy for gastric cancer: more drugs do not mean better efficacy]. ( Cui, YH; Li, W; Liu, TS; Shen, KT; Shen, ZB; Sun, YH; Wang, ZM; Yu, YY, 2011) |
| "CR to CRT for the esophageal cancer and CR to chemotherapy for the gastric cancer were achieved." | 1.37 | Complete response to chemoradiotherapy in a patient with synchronous double gastric and esophageal cancer. ( Fujii, M; Funada, T; Kaiga, T; Kanamori, N; Kochi, M; Mihara, Y; Takayama, T; Tamegai, H; Watanabe, M; Yoshida, N, 2011) |
| "The expression of Nampt and its role in gastric cancer remain largely unknown." | 1.37 | Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil. ( Bi, TQ; Che, XM; Li, HJ; Liao, XH; Long, HL; Zhang, DJ; Zhao, W, 2011) |
| "This study employed gastric cancer cells and patient tissues in attempts to elucidate how and why this mutation in galectin-3 (gal-3H(64)) enhances cancer progression, compared to wild type galectin-3 (gal-3P(64))." | 1.37 | Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of β-catenin in gastric cancer. ( Cheong, TC; Choi, IJ; Chun, KH; Kim, SJ; Lee, YS; Park, SH; Shin, JY, 2011) |
| "For patients with HER2-overexpressing gastric cancer, there is an improved prognosis with additional trastuzumab to chemotherapy with a platinum compound and a fluoropyrimidin in first-line therapy." | 1.37 | Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T). ( Dumke, K; Krüger, M; Reymond, M; Weissinger, F, 2011) |
| "Salinomycin is a novel identified cancer stem cells (CSCs) killer." | 1.37 | Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer. ( Cai, Q; Chen, XH; Gu, QL; Ji, J; Li, JF; Liu, BY; Yu, YY; Zhang, JN; Zhi, QM; Zhu, ZG, 2011) |
| "At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders." | 1.37 | miRNA signature associated with outcome of gastric cancer patients following chemotherapy. ( Aprelikova, O; Choi, IJ; Green, JE; Kim, CH; Kim, HK; Kim, J; Lee, ET; Munroe, DJ; Rettig, RL, 2011) |
| "A total of 107 patients with advanced gastric cancer treated in our hospital from December 2005 to November 2008 were included in this retrospective analysis." | 1.37 | [HER-2 expression in advanced gastric cancer and its correlation with clinical features, outcome and prognosis]. ( Ge, FJ; Li, SS; Lin, L; Liu, JZ; Liu, LJ; Wang, Y; Xu, JM; Zhao, CH, 2011) |
| " Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases." | 1.36 | The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. ( Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N, 2010) |
| "Advanced gastric cancer (AGC) rarely presents with disseminated intravascular coagulation (DIC) at the time of diagnosis before treatment with no current standard chemotherapy (CTx) regimen." | 1.36 | Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis. ( Hamaguchi, T; Hirashima, Y; Kato, K; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Yamada, Y, 2010) |
| "Patients with histologically proven gastric cancer and measurable metastatic disease received docetaxel 75 mg/m(2) as a 1-h intravenous infusion on day 1, and oral etoposide 50 mg/m(2) once daily on days 1-5, every 3 weeks until disease progression or unacceptable toxicities." | 1.36 | Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens. ( Alici, S; Benekli, M; Buyukberber, S; Camci, C; Coskun, U; Dane, F; Gumus, M; Kalender, ME; Kaya, AO; Ozturk, B; Sevinc, A; Uncu, D; Yaman, E; Yildiz, R, 2010) |
| " We examined the administration sequence of combining 5FU with MMC to maximize toxicity against a human gastric cancer cell line, and then investigated the possible molecular mechanisms underlying the observed toxic effects." | 1.36 | Toxicity against gastric cancer cells by combined treatment with 5-fluorouracil and mitomycin c: implication in oxidative stress. ( Alpers, DH; Hara, A; Hirayama, R; Kaai, K; Kohno, S; Komoda, T; Matsunaga, T; Tsuji, Y, 2010) |
| "We established 2 HIF-1alpha knockdown gastric cancer cell lines in order to clarify the role of HIF-1alpha in chemo-resistance against 5-FU." | 1.36 | HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy. ( Hashiguchi, K; Hiraki, M; Kai, K; Kitajima, Y; Miyazaki, K; Nakamura, J; Noshiro, H, 2010) |
| "We hypothesized that the sensitivity of gastric cancer to 5-FU treatment might be related to the rate of glucose transport (GLUT), and investigated the expressions of GLUT1, 2, 3, and 4 in two different gastric cancer cells (SNU-216, moderately differentiated gastric adenocarcinoma; and SNU-668, signet ring cell gastric carcinoma)." | 1.36 | Differential effects of 5-fluorouracil on glucose transport and expressions of glucose transporter proteins in gastric cancer cells. ( Baik, HH; Cho, HY; Ha, E; Ha, TK; Hur, SJ; Kim, YH; Kwon, SJ; Suh, SI; Won, HJ, 2010) |
| " During the S-1 treatment,serious adverse events such as neutropenia were not observed; however, decreases in hemoglobin level were observed (grade 3)." | 1.36 | Safety, efficacy and pharmacokinetics of S-1 in a hemodialysis patient with advanced gastric cancer. ( Arimori, K; Hanada, N; Hidaka, H; Hidaka, M; Kawaguchi, H; Kawano, Y; Nakamura, C; Tomiyama, N, 2010) |
| "In patients with advanced gastric and esophageal cancer who were not candidates for every-3-week DCF, a weekly formulation of DCF demonstrated modest activity with minimal hematologic toxicity, suggesting that weekly DCF is a reasonable treatment option for such patients." | 1.36 | Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. ( Abbruzzese, JL; Ajani, J; Ho, L; Jhamb, J; Kazmi, SM; Lin, E; Overman, MJ; Phan, A; Yao, JC, 2010) |
| "The BGC-823 gastric cancer cell line was incubated for 48 h with 0." | 1.36 | Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells. ( Chen, XM; Huang, ZG; Wang, ZR; Zhang, DW; Zhang, X; Zhu, FS, 2010) |
| "The gastric cancer was complicated by malignant pericardial effusion and pleural effusion as well as metastasis to the peripheral lymph nodes and bones." | 1.36 | A case with cardiac tamponade as the first sign of primary gastric signet-ring cell carcinoma treated with combination therapy. ( Qin, YW; Xu, RL; Zhang, BL; Zheng, X, 2010) |
| "Capecitabine is an oral fluoropyrimidine which is transformed to 5-Fluorouracil inside tumor cells, where it achieves high drug concentrations." | 1.36 | Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect? ( Emiliani, A; Losanno, T; Manna, G; Seminara, P, 2010) |
| "Patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemotherapy were investigated." | 1.36 | Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. ( Jiang, T; Li, QF; Liang, J; Liu, KW; Lv, HY; Yao, RY, 2010) |
| "Adjuvant chemo-radiation for gastric cancer is a standard at our institution and has resulted in few relapses and an interesting median survival." | 1.36 | Adjuvant chemo-radiation for gastric adenocarcinoma: an institutional experience. ( Aftimos, PG; Chahine, GY; El Helou, JA; Ghosn, MG; Nasr, DI; Nasr, EA; Nasr, FL; Noun, RJ, 2010) |
| "A close inspection showed progressive stomach cancer with lymph node metastasis." | 1.36 | [A case of gastric carcinoma with lung and liver metastasis successfully treated by mFOLFOX6]. ( Ishida, T; Iwasaki, T; Kanemitsu, K; Okuda, T; Tanaka, K; Toyokawa, A, 2010) |
| "5-Fluorouracil (5-FU) is a key systemic chemotherapy drug and widely use in the treatment of solid tumors." | 1.36 | Wogonin potentiates the antitumor effects of low dose 5-fluorouracil against gastric cancer through induction of apoptosis by down-regulation of NF-kappaB and regulation of its metabolism. ( Guo, QL; Hu, R; Qiang, L; Rong, JJ; Wang, J; You, QD; Zhao, L; Zhao, Q; Zou, MJ, 2010) |
| " Our study investigated the effects and mechanisms of trastuzumab in combination with 5-Fluorouracil (5-Fu) or cisplatin (DDP) on gastric cancer cell lines." | 1.36 | The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-Fluorouracil or cisplatin on gastric cancer cell lines. ( Chen, W; Li, XL; Song, ST; Xu, JM; Yi, SQ; Zhang, Y, 2010) |
| "All patients with gastric cancers who received adjuvant treatment at the National Cancer Centre Singapore between 1996 and 2006 were reviewed." | 1.36 | Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. ( Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Tham, CK; Toh, HC; Wang, ML, 2010) |
| "As EBV-associated gastric cancer has unique features that are different from EBV (-) gastric cancer, EBV is considered to have a key role in gastric carcinogenesis." | 1.36 | LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells. ( Chae, HS; Kang, JH; Kim, JO; Lee, SK; Shin, JY, 2010) |
| "Inactivation of HIF-1alpha in gastric cancer cells resulted in robust elevation of chemosensitivity." | 1.36 | Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. ( Cramer, T; Dame, C; Detjen, K; Haugstetter, A; Rohwer, N; Schmitt, CA; Wiedenmann, B, 2010) |
| "Two patients with advanced gastric cancer and metastatic pancreatic cancer who received 5-fluorouracil-based chemotherapy presented with acute mental change and hyperammonemia." | 1.36 | Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity. ( Kim, SR; Lee, J; Lee, SY; Park, CH; Park, JO; Park, S, 2010) |
| "Thirty-eight advanced gastric cancer patients who received XELOX regimen during 2004-2009 were analyzed retrospectively." | 1.36 | [Oxaliplatin plus capecitabine for advanced gastric cancer: report of 38 cases]. ( Bai, CM; Guan, M; Zhang, L; Zhao, L, 2010) |
| "To compare the efficacy, time to disease progression (TTP), overall survival (OS) and toxicity of FOLFOX6 and TLF regimens for advanced gastric cancer." | 1.36 | [Therapeutic effects of FOLFOX6 versus TLF regimen as the first line chemotherapy for advanced gastric cancer]. ( Deng, YM; Li, LL; Xian, HB; Yu, HB, 2010) |
| "Eighty five patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemotherapy were investigated." | 1.36 | [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy]. ( Jiang, J; Jiang, T; Li, QF; Liang, J; Lü, HY; Song, SA; Sun, YY; Yao, RY, 2010) |
| "The response rate of Irinotecan for gastric cancer is reported to be 18." | 1.36 | [Effects of irinotecan and 5-FU combination therapy in gastric cancer--is combination therapy synergic?]. ( Furukawa, K; Kanazawa, Y; Mamada, Y; Uchida, E; Yamada, T; Yokoi, K, 2010) |
| "Median survival time following recurrence was 287 days in cohort A, 451 days in B and 547 days in C, with a significant difference between A and C (p = 0." | 1.36 | Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer. ( Fujitani, K; Hasegawa, H; Hirao, M; Kurokawa, Y; Mita, E; Nakazuru, S; Tsujinaka, T, 2010) |
| "It is important to understand that gastric cancer diagnosed poorly differentiated adenocarcinoma pathologically sometimes occurs duodenal invasion and obstructive jaundice." | 1.36 | [A case of duodenal invasion due to recurrent gastric cancer with obstructive jaundice treated by chemotherapy]. ( Fukuda, S; Hiraki, S; Kawaoka, T; Matsukuma, S; Nagashima, A, 2010) |
| "Globally, gastric cancer is the second most common cause of cancer-related death." | 1.35 | Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents? ( Barone, C; Pozzo, C, 2008) |
| "One-hundred and sixteen patients with gastric cancer were treated with 5-FU-based adjuvant chemotherapy." | 1.35 | The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population. ( Hua, D; Huang, ZH; Li, LH, 2009) |
| "Twenty-five gastric cancer patients, 2 at the stage II, 17 at the stage III, and 6 at the stage IV received the FOLFOX regimen after surgery: intravenous infusion of oxaliplatin 85 mg/m2 for 2 h on day 1, intravenous infusion of leucovorin 200 mg/m2 for 2 h on days 1-2, and intravenous bolus injection of 5-fluorouracil (5-FU) 400 mg/m2 on days 1-2, and continuous infusion of 5-FU 600 mg/m2 for 22 h on days 1-2; and this regimen was repeated every 2 weeks." | 1.35 | [Post-operative adjuvant treatment with oxaliplatin, fluorouracil, and leucovorin for local advanced gastric cancer]. ( Bai, CM; Chen, SC; Li, XY; Zhao, L, 2008) |
| "Although the prognosis of gastric cancer with carcinomatous peritonitis is poor, we here reported a patient with StageIV gastric cancer who markedly responded to FT therapy, which made surgical resection possible with the anticipation of extended survival." | 1.35 | [A case of long survival in Stage IV gastric carcinoma responding to combination treatment with paclitaxel and 5- fluorouracil followed by surgical resection]. ( Harano, M; Masumura, K; Ninomiya, M; Nishizaki, M; Ohno, S; Takakura, N; Takata, S, 2008) |
| "Endoscopy revealed gastric cancer with pyloric stenosis and MRI showed multiple metastasis of thoracic vertebral body." | 1.35 | [A case of gastric cancer accompanied by disseminated carcinomatosis of bone marrow with DIC recovered by sequential therapy consisting of MTX and 5-FU]. ( Akazai, Y; Kimura, T; Seita, M; Takahata, T; Yasuda, K, 2008) |
| "The toxic effects of S-1 can lead to discontinuation of treatment." | 1.35 | Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo. ( Arai, W; Haruta, H; Hirashima, Y; Hosoya, Y; Hyodo, M; Kurashina, K; Nagai, H; Saito, S; Sakuma, K; Shirasaka, T; Yasuda, Y; Yokoyama, T; Zuiki, T, 2008) |
| "Recently, standard therapies for either gastric cancer or colorectal cancer have been established through the development of multidrug systemic chemotherapy and the appearance of molecular targeting drugs." | 1.35 | [Hepatic artery infusion chemotherapy to three liver metastasis cases in which systemic chemotherapy was impossible or ineffective]. ( Ando, K; Emi, Y; Endo, K; Kakeji, Y; Maehara, Y; Morita, M; Oki, E; Saeki, H; Sugiyama, M, 2008) |
| "The levels of specific cytokines in 60 gastric cancer patients were detected by flow cytometry before and after chemotherapy with FOLFOX4." | 1.35 | [Pre- and post-chemotherapy expressions of Th1 and Th2 type cytokines and their clinical significance in gastric cancer patients]. ( Gao, J; Han, CZ; Liu, XL; Qiao, LJ, 2008) |
| "He was diagnosed as gastric cancer, lymph node metastases, brain metastases, bone marrow carcinomas, and disseminated intravascular coagulation(DIC)." | 1.35 | [A case of bone marrow carcinosis from gastric cancer that presented hypocalcemia caused by zoledronic acid during the treatment of methotrexate/5-fluorouracil sequential therapy]. ( Ariyama, H; Baba, E; Esaki, T; Fujimoto, C; Hiranuma, S; Murakawa, M; Syoji, T; Tsukasa, K, 2009) |
| "Forty patients with gastric cancer received neoadjuvant chemotherapy." | 1.35 | Survivin expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis. ( Baldus, S; Bollschweiler, E; Brabender, J; Drebber, U; Hölscher, AH; Metzger, R; Mönig, S; Schneider, PM; Vallböhmer, D; Warnecke-Eberz, U, 2009) |
| "Because treatment of advanced gastric cancer (AGC) patients after failure with first-line chemotherapy remains controversial, we performed this retrospective analysis based on the data obtained from 1455 patients registered in a first-line treatment cohort with respect to receiving or not receiving subsequent chemotherapy." | 1.35 | A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. ( Chang, MH; Ji, SH; Jun, HJ; Kang, WK; Kim, HS; Kim, KH; Lee, J; Lim, DH; Lim, HY; Park, JO; Park, MJ; Park, SH; Park, YS; Uhm, JE; Yi, SY, 2009) |
| "Depth of tumor invasion, lymph node metastasis, and differentiation were noted to be significantly correlated with the expression of this antigen in gastric carcinoma." | 1.35 | Serum 3'-sulfo-Lea indication of gastric cancer metastasis. ( Bao, WQ; Guo, L; Sheng, WQ; Wu, LH; Wu, XZ; Zhang, HL; Zheng, J, 2009) |
| "Sixty consecutive patients treated for gastric cancer either with 3D-CRT (n = 27) and IMRT (n = 33) were evaluated." | 1.35 | Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer. ( Boda-Heggemann, J; Hermes, P; Hieber, U; Hochhaus, A; Hofheinz, RD; Lohr, F; Mai, SK; Massner, B; Mennemeyer, P; Post, S; Weiss, C; Wenz, F; Wertz, H, 2009) |
| "Metastatic gastric cancer remains an incurable disease, with a relative 5-year survival rate of 7%-27%." | 1.35 | New perspectives in the treatment of advanced or metastatic gastric cancer. ( Ferrara, D; Manzione, L; Rosati, G, 2009) |
| "1236G>A), which was observed five- out of eight-times in patients with severe adverse effects." | 1.35 | Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. ( Aebi, S; Amstutz, U; Farese, S; Largiadèr, CR, 2009) |
| "104 patients with advanced gastric cancers were treated with capecitabine-based chemotherapy regimens from Sept." | 1.35 | [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer]. ( Li, J; Li, Y; Lu, M; Shen, L; Xiao, Y; Zhang, J; Zhang, XD, 2009) |
| "A 75-year-old man was diagnosed with gastric cancer (UL post c0- II c (c T1N0) and M-less ctype II (cT2N0)) and rectal cancer (Rb ctype II (cT2N1) with multiple lung metastases (M1)." | 1.35 | [A case of advanced gastric and rectal cancer (double cancer) successfully treated with mFOLFOX6 therapy]. ( Furuta, A; Hatsugai, K; Ishibashi, S; Ishii, T; Kaneda, I; Masuoka, H; Ohara, M; Sarashina, H; Sekine, Y; Shoji, M; Watanabe, G, 2009) |
| "The inhibition rate of gastric cancer by 5-FU (29." | 1.35 | [Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer]. ( Chen, G; Fu, LW; Keshari, RP; Liang, YJ; Yuan, SQ; Zhang, LY; Zhou, ZW, 2009) |
| "Epirubicin has been widely used for chemotherapeutic treatment of gastric cancer; however, intrinsic and acquired chemoresistance remains an obstacle to successful management." | 1.35 | Identification of GAS1 as an epirubicin resistance-related gene in human gastric cancer cells with a partially randomized small interfering RNA library. ( Fan, D; Gang, Y; He, L; Jin, H; Li, T; Liu, Z; Pan, Y; Qiao, T; Tie, J; Wang, H; Xia, L; Yao, L; Zhang, Y; Zhao, L, 2009) |
| "Capecitabine regimens were compared with 5-fluorouracil (5-FU) and other chemotherapy regimens, and were stratified by treatment setting." | 1.35 | Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. ( Saif, MW; Shi, N; Zelt, S, 2009) |
| " The pan-caspase inhibitor, zVAD-fmk, inhibits apoptosis induced in combination with 5FU and mTOR inhibitor." | 1.35 | Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. ( Doi, Y; Hirakawa, K; Kaizaki, R; Matsuzaki, T; Ohira, M; Sawada, T; Yashiro, M; Yasuda, K, 2009) |
| "Although peritoneal dissemination of gastric cancer is common and often causes deterioration of the patient's condition and quality of life (QOL), these patients are usually excluded from clinical trials." | 1.35 | Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination. ( Boku, N; Fukutomi, A; Hironaka, S; Imazawa, M; Kojima, T; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H, 2009) |
| "We experienced this AFP-producing gastric cancer in which CR was possible by FLEP." | 1.35 | [Complete remission with FLEP chemotherapy for multiple liver metastasis from alpha-fetoprotein-producing gastric cancer--report of a case]. ( Fujii, M; Funada, T; Kaiga, T; Kanamori, N; Kochi, M; Takahashi, T; Takayama, T, 2009) |
| "Capecitabine is an oral fluoropyrimidine designed to mimic a continuous infusion of 5-FU, and its use can prevent the need for cumbersome intravenous catheters and hospitalization of patients." | 1.35 | ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer. ( Kang, YK; Ryu, MH, 2009) |
| "We thought a gastric cancer patient with liver metastasis who didn't have an uncontrollable other organ metastasis was a good target for this regimen." | 1.35 | [Evaluation of hepatic arterial infusion chemotherapy for liver metastasis from gastric cancer]. ( Kawahira, H; Matsubara, H; Nabeya, Y; Natsume, T; Ohira, G; Ota, T; Saito, H; Sato, A; Shuto, K, 2009) |
| "A clinical finding was Stage IV gastric cancer of poorly differentiated adenocarcinoma." | 1.35 | [A case of long-term survival of unresectable-advanced gastric cancer due to chemotherapy]. ( Akabane, H; Hanamoto, T; Kita, K; Kuji, M; Miyagi, H; Nakano, S; Oikawa, F; Shomura, H; Takahashi, M; Yanagida, N, 2009) |
| " Radiation therapy combined with nedaplatin and 5-FU is a safe and effective method for treating cT4 advanced esophageal cancer." | 1.35 | [A case of stage IV advanced esophageal cancer with a long term survival by radiation therapy combined with nedaplatin and 5-FU chemotherapy]. ( Dan, N; Hirakawa, K; Kubo, N; Morimoto, J; Muguruma, K; Nishiguchi, Y; Oohira, M; Sawada, T; Tanaka, H; Yamashita, Y; Yashiro, M, 2009) |
| "Although triweekly administration of paclitaxel is approved for gastric cancer in Japan, currently, the drug is often delivered with a weekly schedule because of the equivalent efficacy and lesser toxicity of this dosing schedule as compared with the triweekly administration schedule." | 1.35 | Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin. ( Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Onozawa, Y; Sakamoto, T; Shimoyama, R; Taku, K; Todaka, A; Tomita, H; Tsushima, T; Yamazaki, K; Yasui, H, 2009) |
| "Capecitabine was administered at a fixed dose of 2000 mg daily without interruptions." | 1.35 | Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors. ( Battistelli, S; Civitelli, S; Fiaschi, AI; Francini, E; Francini, G; Lorenzi, M; Marsili, S; Pascucci, A; Petrioli, R; Roviello, F; Tanzini, G, 2008) |
| "Fifty-eight advanced gastric cancer patients with previous chemotherapy were enrolled into the study." | 1.35 | The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma. ( Akbulut, H; Boruban, MC; Buyukcelik, A; Demirkazik, A; Icli, F; Onur, H; Sencan, O; Senler, FC; Yalcin, B, 2008) |
| " There was no toxic death, but 1 patient had long-term complications." | 1.35 | The toxicity and outcomes of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected high-risk gastric cancer: results of a single institute. ( Avraham, R; Ayala, H; Luna, K; Marc, W; Tamar, S; Yakir, R, 2008) |
| "Sixty-two patients with advanced gastric cancer previously treated were eligible for the study." | 1.35 | Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis. ( Choi, CW; Choi, IK; Choi, YS; Kim, BS; Kim, DS; Kim, JS; Kim, SJ; Kim, YH; Oh, SC; Park, KH; Seo, HY; Seo, JH; Shin, SW; Sung, HJ, 2009) |
| "Patients with potentially resectable gastric cancer treated with preoperative CRT are found to be ineligible for surgery principally because of peritoneal progression." | 1.35 | Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. ( Ajani, JA; Badgwell, BD; Crane, CH; Das, P; Delclos, ME; Janjan, NA; Kim, MM; Krishnan, S; Mansfield, PF; Maru, D; Phan, AT, 2008) |
| "The lower differentiated gastric cancer cells were more sensitive than the higher ones." | 1.35 | [Anti-tumor effect of chemotherapeutic drugs on human gastric cancer cells in vitro and the relationship with Bcl-2 expression]. ( Cao, YC; Fu, ZJ; Geng, M; Tai, YH; Yin, YC, 2008) |
| "Selective targeting of gastric cancer cells with the activated beta-catenin pathway may be a novel and effective therapy in gastric cancer." | 1.34 | Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway. ( Arber, N; Dvory-Sobol, H; Kazanov, D; Liberman, E; Sagiv, E, 2007) |
| "In Epstein-Barr virus-associated gastric cancer, Epstein-Barr virus is found in virtually all tumor cells, but rarely in normal epithelial cells, thus implying that Epstein-Barr virus-targeting therapies are likely to be an effective treatment strategy." | 1.34 | Ganciclovir augments the lytic induction and apoptosis induced by chemotherapeutic agents in an Epstein-Barr virus-infected gastric carcinoma cell line. ( Ho Kim, W; Ji Jung, E; Lan Lee, B; Mie Lee, Y; Soo Chang, M, 2007) |
| "The most common metastatic sites from gastric cancer are the liver, intra-abdominal lymph nodes, ovary and peritoneal cavity." | 1.34 | Cutaneous metastasis resembling acute dermatitis in patient with advanced gastric cancer. ( Chang, HM; Jung, JY; Kang, YK; Kim, TW; Koo, DH; Lee, JL; Lee, JS; Ryu, MH; Song, JH; Song, JS; Yook, JH, 2007) |
| "Of the 223 patients, 32 had distant metastases but palliative gastrectomy (resected metastatic), 82 had recurrent disease after previous curative gastrectomy (recurrent), and 109 had distant metastases without gastrectomy (initially metastatic)." | 1.34 | Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. ( Chang, HM; Kang, HJ; Kang, YK; Kim, TW; Kim, WK; Lee, JL; Lee, JS; Lee, SS; Ryu, MH, 2007) |
| "Gastric cancer is often diagnosed in advanced stage (AGC) and in elderly patients." | 1.34 | FOLFOX-4 regimen as fist-line chemotherapy in elderly patients with advanced gastric cancer: a safety study. ( Azzarello, D; Costarella, S; Del Medico, P; Falzea, A; Giannicola, R; Maisano, R; Nardi, M; Raffaele, M; Zavettieri, M, 2007) |
| "Among the patients with T3/T4 gastric cancer, postoperative oral fluorouracil treatment was effective in those who were pAkt-positive." | 1.34 | Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy. ( Ikeguchi, M; Katano, K; Murakami, D; Osaki, T; Saito, H; Tatebe, S; Tsujitani, S, 2007) |
| "Three human gastric cancer cell lines were exposed to 5-fluorouracil or cisplatin in vitro." | 1.34 | Predictive value of GADD153, p21 and c-Jun for chemotherapy response in gastric cancer. ( Akatsu, T; Akatsu, Y; Kitagawa, Y; Kitajima, M; Kubota, T; Kumai, K; Otani, Y; Saikawa, Y; Yoshida, M, 2007) |
| "Liver metastases are the most common cause of death in gastric ECs, and their control is very important for improving the poor prognosis associated with the disease." | 1.34 | A successful treatment for metastatic liver tumors from endocrine carcinoma of the stomach. ( Fujiyama, Y; Nishimura, M, 2007) |
| "50 patients diagnosed as advanced gastric cancer were administered continuous infusion of 5-FU (300 mg/m(2)/day, x 14 days) and intermittent infusion of CDDP (3 mg/m(2)/day, day 1-5 and 8-12) before surgery." | 1.34 | [Pathological evaluation of neoadjuvant chemotherapy with low-dose FP therapy for advanced gastric cancer]. ( Koda, K; Miyazaki, M; Oda, K; Seike, K; Takano, S; Takiguchi, N, 2007) |
| "Chemosensitivity of the mouse gastric cancer cells to 6 chemotherapeutic drugs was investigated using MTT assay before the 6 drugs were applied in mice with implanted tumors." | 1.34 | [Drug sensitivity test and drug-resistance gene assessment for chemotherapy planning for tumors derived from high-passage mouse gastric cancer cells: therapeutic effect observation in mice]. ( Jia, HS; Sun, T; Zhang, JR, 2007) |
| " Pharmacokinetic parameters of 5-FU in the serum were as follows: Cmax, 159 ." | 1.34 | [Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients]. ( Fuchimoto, M; Fujikura, H; Hato, S; Higashida, M; Hirabayashi, Y; Hirai, T; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K, 2007) |
| "Endoscopic findings showed Type 3 gastric cancer with pyloric stenosis." | 1.34 | [A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil]. ( Ninomiya, M; Nishizaki, M; Sasaki, H; Takakura, N; Yamada, E, 2007) |
| "A multiple-unit-type oral floating dosage form (FDF) of 5-fluorouracil (5-FU) was developed to prolong gastric residence time, target stomach cancer, and increase drug bioavailability." | 1.34 | Stomach-specific drug delivery of 5-fluorouracil using floating alginate beads. ( Aggarwal, N; Gupta, N, 2007) |
| "After 10 years, second primary cancer (seven cases) became as important an issue as recurrence of primary gastric cancer (six cases)." | 1.34 | Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. ( Chung, HC; Jeung, HC; Kim, BS; Moon, YW; Noh, SH; Rha, SY; Roh, JK; Yoo, NC, 2007) |
| "Paclitaxel also has a high response rate for undifferentiated-type adenocarcinoma, and can be expected to show high efficacy for peritoneal dissemination." | 1.34 | [Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint]. ( Ae, T; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Nakatani, K; Saigenji, K; Sasaki, T; Tanabe, S, 2007) |
| "To study the effects of two specific cyclooxygenase inhibitors (SCI), rofecoxib and celecoxib, combined with chemotherapeutic drugs 5-Fu, DDP and VP-16 on gastric cancer cell line BGC-823, and to evaluate whether specific cyclooxygenase inhibitors can be used as a synergetic agent in chemotherapy." | 1.34 | [Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro]. ( Chen, XM; Feng, JX; Wang, YJ; Zhang, X; Zhu, FS, 2007) |
| "In human colorectal cancer model CXF280, antitumor activity of the combination at two-thirds of the maximum tolerated dose (MTD) was superior to that of each monotherapy at MTD." | 1.34 | Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts. ( Kondoh, K; Mori, K; Sawada, N, 2007) |
| " From March 2002, we started to treat patients with advanced gastric cancer (stage IV) with a new regimen; intermittent dosage of 5-FU (-->S-1), CDDP and paclitaxel utilizing the difference of cell cycle between normal and cancer cells (intermittent FP ." | 1.34 | [The third report from Sapporo Tsukisamu Hospital--chemotherapy for patients with advanced gastric cancer (peritoneal dissemination, peritonitis carcinomatosa)]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamaguchi, K; Yamamitsu, S, 2007) |
| "Using this method, the 17 gastric cancer biopsy specimens, before undergoing S-1 based neoadjuvant chemotherapy, were assessed in order to determine the expression levels of the thymidylate synthase (TS), orotate phosphoribosyltransferase (OPRT) and dihydropyrimidine dehydrogenase (DPD) which determines S-1 efficacy." | 1.34 | Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases i ( Hiraki, M; Kai, K; Kitajima, Y; Miyazaki, K; Nakafusa, Y; Satoh, S; Tanaka, M; Tokunaga, O, 2007) |
| "Surgical treatments for early gastric cancer, such as endoscopic procedures, are currently performed as standard therapy." | 1.34 | [The fourth report from Sapporo Tsukisamu Hospital - chemotherapy and its regimen as second choice for patients with early gastric cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamaguchi, K; Yamamitsu, S, 2007) |
| "We experienced two cases of advanced gastric cancer effectively treated by sequential therapy of docetaxel and paclitaxel." | 1.34 | [Two cases of advanced gastric cancer in which paclitaxel proved effective after resistance to docetaxel]. ( Abe, S; Honda, K; Kondo, H; Makino, K; Mizushima, T; Oura, K; Sumiyoshi, T; Tamura, F; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N, 2007) |
| "S-1 has a potent antitumor effect on gastric cancer, even in 5-FU-refractory cases." | 1.34 | Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism. ( Arakawa, T; Fujiwara, Y; Higuchi, K; Kuwamura, H; Oshitani, N; Sasaki, E; Tominaga, K; Watanabe, T, 2007) |
| "In one matched gastric cancer sample pair, the serial analysis of gene expression (SAGE) experiment was conducted to compare the gene expression profiles between cancerous and adjacent tissues." | 1.34 | Upregulated expression of S100A6 in human gastric cancer. ( Dong, H; Gao, HJ; Han, JS; Jiang, CL; Wu, JX; Wu, YL; Xiao, HS; Yang, YQ; Zhang, LJ; Zhang, QH; Zhu, ZG, 2007) |
| "A 55-year-old man with advanced gastric cancer underwent total gastrectomy (T3N0M0, stage II , por, sig) in the USA." | 1.34 | [A case of recurrent gastric cancer with peritoneal dissemination--prolonging life and good QOL by chemotherapy with combined use of paclitaxel]. ( Akiyama, J; Hayashi, Y; Iwashita, R; Kobayakawa, M; Masaki, N; Nagaoki, Y; Nagata, N; Nozaki, Y; Oshima, T; Sako, A; Sakurai, T; Tamegai, Y; Uemura, N; Umeda, N; Watanabe, M; Yago, Y, 2007) |
| "AI of human gastric cancer xenografts in nude mice was significantly increased to (9." | 1.34 | [Difference of gene expression profile in human gastric cancer grafted onto nude mice treated with WCA]. ( Gu, Y; Li, T; Tang, LD; Yang, JK; You, SF; Zhao, AG; Zhao, HL, 2007) |
| "Patients with stage IV gastric cancer, according to the American Joint Committee on Cancer or with relapsed disease and functional capacity 0-2 of the South West Oncology Group, were included." | 1.34 | [Treatment of advanced gastric cancer with oxaliplatin plus 5-fluorouracil/ leucovorin (FOLFOX-4 chemotherapy)]. ( Alvarez, M; Galindo, H; Garrido, M; Madrid, J; Melgoza, G; Nervi, B; Orellana, E; Sánchez, C, 2007) |
| "Fresh samples of gastric cancer obtained from operation room were prepared to single-cell suspension (3 x 10(5) to 5 x 10(5) cells ml(-1)) and were separately exposed to taxol (TAX), cisplatin (CDDP), 5-fluorouracil (5-Fu), adriamycin (ADM), mitomycin (MMC) for 48 hours." | 1.34 | [Anti-tumor effects of chemotherapeutic drugs on human gastric cancer cells in vitro and the relationship with expression of hTERT mRNA]. ( Cao, YC; Fu, ZJ; Geng, M; Tai, YH; Wang, XY; Yin, YC, 2007) |
| "3%), no toxic death, and only one grade 3 neutropenia (4." | 1.33 | Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients. ( Artru, P; Atlan, D; Bouché, O; Dahan, L; Lledo, G; Mitry, E; Nguyen, T; Richard, K; Ries, P; Rougier, P; Seitz, JF, 2005) |
| "The therapeutic efficacy of G207, a replication-competent herpes simplex virus, for malignancies is increased when combined with certain chemotherapies, but the mechanism is unclear and the interaction between G207 and surgical resection has not been extensively studied." | 1.33 | Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. ( Cohen, JB; Glorioso, JC; Kuroki, S; Nakano, K; Tanaka, M; Todo, T; Yamaguchi, K; Zhao, G, 2005) |
| "The side effect of anticancer agents such as nausea and vomiting frequently interrupt chemotherapy." | 1.33 | [Effect of steroid on antiemetic for side effect of anticancer chemotherapy]. ( Matsumoto, T; Mikami, T; Momokawa, K; Nakamura, Y; Sakayauchi, T; Sasaki, T; Watanabe, T, 2005) |
| "Expressions of GST-pi and P-gp in gastric cancer tissues were detected by immunohistochemistry." | 1.33 | [Antitumor effects of chemotherapeutic drugs on fresh human gastric cancer cells and their relationships to expressions of P-glycoprotein and glutathione S transferase-pi]. ( Ji, J; Ji, YB; Lin, YZ; Liu, BY; Yuan, F; Zhang, J; Zhu, ZG, 2005) |
| " We conducted an analysis to evaluate the efficacy and feasibility of modified pharmacokinetic modulating chemotherapy, for gastric cancer patients with peritoneal dissemination." | 1.33 | [Modified pharmacokinetic modulating chemotherapy for progressive gastric cancer accompanied by peritoneal dissemination]. ( Ishikawa, T; Kamimura, T; Mizuno, K; Ohta, H; Seki, K; Togashi, T; Watanabe, K; Yoshida, T, 2005) |
| " Furthermore, she was administered tegafur/uracil (400 mg/day) 5 days weekly for pharmacokinetic modulating chemotherapy (PMC)." | 1.33 | [A case of advanced gastric cancer with bone metastasis and severe DIC responding to hypertensive subselective chemotherapy with pharmacokinetic modulating chemotherapy]. ( Ishikawa, T; Kamimura, T; Mizuno, K; Ohta, H; Seki, K; Togashi, T; Watanabe, K; Yoshida, T, 2005) |
| "The human scirrhous gastric cancer cell lines OCUM-2D or OCUM-2M, and human gastric fibroblasts (NF-21) were cultured in the absence or presence of JTE-522 at various concentrations." | 1.33 | Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells. ( Hirakawa, K; Nakazawa, K; Tendo, M; Yamada, N; Yashiro, M, 2005) |
| "Sensitivity of two gastric cancer cell lines to anti-cancer drugs, 5-fluorouracil (5-FU) and/or cisplatinum (CDDP), was evaluated by use of either flow cytometric analysis (FACS) or morphological observation in terms of induction of apoptosis." | 1.33 | The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs. ( Matsuhashi, N; Matsuo, A; Saio, M; Saji, S; Sugiyama, Y, 2005) |
| "The lymph node status of 73 resectable gastric cancer patients was analyzed preoperatively by computed tomography (CT), ultrasonography and magnetic resonance, and the OPRT activity of collected tumor tissue was measured." | 1.33 | Impact of orotate phosphoribosyl transferase activity as a predictor of lymph node metastasis in gastric cancer. ( Futagawa, S; Kitajima, M; Nishimura, K; Noguchi, H; Ochiai, T; Okada, T; Ouchi, M; Sugitani, M; Takahashi, Y; Tsuruoka, Y; Yamada, M, 2005) |
| "The role of second-line chemotherapy in gastric cancer is not yet established." | 1.33 | Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy. ( Köster, W; Müller, C; Stahl, M; Wilke, H, 2005) |
| "Paclitaxel was administered at a dose of 80 mg/m(2), 3 times every 4 weeks." | 1.33 | [Feasibility study of weekly paclitaxel as second-line chemotherapy against 5-FU-refractory gastric carcinoma]. ( Ito, S; Kodera, Y; Mochizuki, Y; Yamamura, Y, 2005) |
| "2 patients with advanced gastric cancer repeatedly received 5-FU/cisplatin combination chemotherapy." | 1.33 | Pharmacogenetics of extraordinary responses to 5-FU/cisplatin chemotherapy in advanced gastric cancer -- report of 2 cases. ( Al-Batran, SE; Goekkurt, E; Hossfeld, DK; Stoehlmacher, J; Wolschke, C, 2005) |
| " As adverse effects of the following systemic chemotherapy, three patients had grade 3 anemia and one had grade 3 leukopenia." | 1.33 | [Safety and efficacy of hypotonic CDDP intraperitoneal administration for gastric cancer with peritoneal dissemination]. ( Bamba, T; Hanyu, T; Hatakeyama, K; Ishikawa, T; Kanda, T; Kosugi, S; Makino, S; Ohashi, M; Sakamoto, K; Tanabe, T; Yajima, K, 2005) |
| " In the total gastrectomy cases the post-operative tmax of both 5-FU and CDHP was shorter than the pre-operative tmax, and no significant differences were observed between the pre- and post-operative AUC0-8 h values." | 1.33 | Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1. ( Kamano, T; Kawai, K; Kitajima, M; Ochiai, T; Sakamoto, K; Shirasaka, T; Tsuruoka, Y; Watabe, S, 2006) |
| "Cyclin D1 ASODN could increase the chemosensitivity to 5-FU, MTX, CDDP in cells." | 1.33 | Cyclin D1 antisense oligodexoyneucleotides inhibits growth and enhances chemosensitivity in gastric carcinoma cells. ( Chen, JH; Han, GX; Shuai, XM; Wang, GB, 2006) |
| "Adjuvant CRT for gastric cancer, even with conformal RT, is associated with significant toxicity." | 1.33 | Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases. ( Brierley, J; Cummings, B; Kassam, Z; Kim, J; Knox, JJ; Lockwood, G; Moore, M; O'brien, C; Oza, A; Ringash, J; Siu, L; Swallow, C; Wong, R, 2006) |
| "Thus, patients with a DPD deficiency are at risk of developing severe 5-FU-associated toxicity." | 1.33 | Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency. ( Baek, JH; Hong, YJ; Kim, DH; Kim, JG; Kim, SN; Lee, KB; Sohn, SK, 2006) |
| "Seven patients with gastric cancer were treated with IMRT." | 1.33 | Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. ( Chmura, SJ; Farrey, K; Garofalo, MC; Heimann, R; Jani, AB; Milano, MT; Rash, C, 2006) |
| "The response of gastric cancer with peritoneal dissemination to systemic chemotherapy may be negatively affected by poor drug delivery due to the blood-peritoneal barrier." | 1.33 | Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer. ( Hatori, S; Imada, T; Kunisaki, C; Oshima, T; Yamada, R, 2006) |
| "Most pulmonary metastases of hepatic cancer were hypervascular and the lipiodol deposited well in the nodules; during the follow-up, the nodules shrunk significantly and kept stable." | 1.33 | [Blood supply of pulmonary metastases and its clinical significance]. ( Chen, YX; Jiang, GM; Tian, F; Zhao, JW, 2006) |
| "Human gastric cancer cell lines, OCUM-8 and MKN-74, and 5 anticancer drugs, 5-fluorouracil (5-FU), paclitaxel (PTX), oxaliplatin (OXA), irinotecan (SN38) and gemcitabine (GEM) were used." | 1.33 | Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. ( Hirakawa, K; Ren, J; Yashiro, M; Zhang, X, 2006) |
| "Twenty-five chemonaive patients with AGC have been treated with FOLFIRI regimen consisting of irinotecan 180 mg/m(2) over 30 min on day 1 combined with leucovorin 200 mg/m(2) over 2 h followed by 5-fluorouracil 400 mg/m(2) as bolus and 600 mg/m(2) as a 22-hour infusion on day 1 and 2." | 1.33 | Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy. ( Alacacioglu, A; Oztop, I; Somali, I; Tarhan, O; Yaren, A; Yilmaz, U, 2006) |
| "The growth and metastasis of human gastric cancer implanted in SCID mice were significantly inhibited in SU6668 group and combined group, especially in combined group." | 1.33 | [Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice]. ( Jiang, XT; Tao, HQ; Zou, SC, 2006) |
| "In all, 10 patients with gastric cancer received PVI of 5-FU at a dose of 250 mg/m2/day for 5 days." | 1.33 | [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil]. ( Yamada, Y, 2006) |
| "In this study, five gastric cancer cell lines were used." | 1.33 | Transplatin, a cisplatin trans-isomer, may enhance the anticancer effect of 5-fluorouracil. ( Hirakawa, K; Kanehara, I; Nakata, B; Shirasaka, T; Yamagata, S, 2006) |
| "The failure to treat gastric cancer is often due to the recurrence or dismal metastasis of cancer and the poor response to traditional chemotherapeutic or radiotherapeutic regimens." | 1.33 | [Effect of vascular endothelial growth factor antibody Avastin on angiogenesis of human gastric cancer growing orthotopically in nude mice]. ( Wang, B; Wang, N; Wang, YJ, 2006) |
| " This study was to explore the relationship between activity of DPD and concentration of 5-FU, and their correlation to adverse events among advanced gastric cancer patients treated with the same regimen containing 5-FU continuous infusion." | 1.33 | [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients]. ( Cao, Y; Dong, QM; Jiang, WQ; Li, H; Li, S; Peng, RJ; Shi, YX; Yuan, ZY; Zhou, ZM, 2006) |
| "To study the effect of 5-fluorouracil-FU in combination with astragalus membranaceus(AM) on amino acid metabolism in mice model of gastric carcinoma induced by 3-methylcholanthrene(MC)." | 1.33 | [Effect of 5-fluorouracil in combination with Astragalus membranaceus on amino acid metabolism in mice model of gastric carcinoma]. ( Liang, XY; Qi, F; Wang, PZ; Zhang, ZX; Zhou, DJ; Zhu, LW, 2006) |
| "Type IV advanced gastric cancer was diagnosed on upper gastrointestinal endoscopy." | 1.33 | [A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor]. ( Higuchi, K; Kobayashi, N; Koizumi, W; Mitomi, H; Nakatani, K; Nakayama, N; Nishimura, K; Saigenji, K; Sasaki, T; Shimoda, T; Tanabe, S, 2006) |
| " Only the initial 1 course was administered with 5-FU (500 mg/body) as an inpatient, and further courses were performed as an outpatient with no severe adverse events." | 1.33 | A case report--The marked response to gemcitabine combined with irinotecan and low-dose cisplatin chemotherapy for advanced gastric cancer with multiple liver metastases. ( Fujiwara, T; Gochi, A; Kagawa, S; Tanaka, N; Teraishi, F; Uno, F, 2006) |
| "Human gastric cancer cells (MKN-45) were injected into the peritoneal cavity of nude mice." | 1.32 | Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil. ( Fujiwara, Y; Monden, M; Mori, T; Takiguchi, S; Tamura, S; Yano, M; Yasuda, T, 2003) |
| "Human gastric cancer SNU 484 cells express mutant p16, which migrates slower than the wild-type p16." | 1.32 | Exogenous wild-type p16INK4A gene induces delayed cell proliferation and promotes chemosensitivity through decreased pRB and increased E2F-1 expressions. ( Baek, WK; Cho, JW; Jeong, YW; Kim, KS; Lee, JC; Oh, JY; Park, JC; Suh, MH; Suh, SI, 2003) |
| "Thirty-five gastric cancer specimens surgically resected at our institute between 1998 and 1999 were studied for quantification of expression of 6300 genes by means of oligonucleotide microarray methods, and the results were evaluated in comparison with the chemoresistance of the specimens, which was determined by MTT (tetrazolium-based 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay." | 1.32 | Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray. ( Abe, S; Furukawa, T; Hasegawa, H; Kitajima, M; Kubota, T; Kumai, K; Nakayama, H; Okabe, H; Otani, Y; Saikawa, Y; Suganuma, K; Watanabe, M, 2003) |
| "The patient was diagnosed with advanced gastric cancer (type-3) with lymphangitis carcinomatosa of the lung." | 1.32 | [A case of advanced gastric cancer with lymphangitis carcinomatosa of the lung, successfully treated with paclitaxel and TS-1]. ( Kawabata, H; Murata, A; Nakajima, H; Takase, I; Watanabe, T, 2003) |
| " This study was designed to evaluate the efficacy and the toxicity of paclitaxel combined with semimonthly 5-FU/Leucovorin for the AGC patients." | 1.32 | [Preliminary report of semimonthly 5-fluorouracil/leucovorin combined with paclitaxel in treatment of advanced gastric cancer (AGC)]. ( He, YJ; Hu, PL; Li, YH; Liu, DG; Liu, MZ; Qian, SY; Qiu, HJ; Teng, XY; Tian, WH; Xiang, XJ; Xu, RH; Zhang, B; Zhou, NN; Zhou, ZM, 2003) |
| " Furthermore, he was administered tegafur/uracil (400 mg/day) 5 days weekly as pharmacokinetic modulating chemotherapy (PMC)." | 1.32 | [A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy]. ( Baba, Y; Hayashi, S; Ishikawa, T; Kamimura, T; Nomura, K; Oota, H; Yoshida, T, 2003) |
| "Case 1 A 40-year-old female with gastric cancer located in the MULE area underwent total gastrectomy with D3 lymph node dissection on June 2, 1989." | 1.32 | [Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection]. ( Arai, K; Horiguchi, S; Iwasaki, Y; Katayanagi, S; Matsumoto, H; Miyamoto, H; Nishioka, K; Takahashi, K; Yamaguchi, T, 2003) |
| "We report a case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP." | 1.32 | [A case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP]. ( Akiyama, N; Arai, F; Funakoshi, K; Inayoshi, J; Kato, T; Motoyama, H; Tasaki, A, 2003) |
| " Pharmacokinetic modulating chemotherapy (PMC), a combination of infused 5-fluorouracil and oral uracil-tegafur, has been proven to be highly effective for the treatment of colorectal carcinoma." | 1.32 | Modified pharmacokinetic modulating chemotherapy using 5-fluorouracil, UFT, and taxotere (docetaxel) for advanced gastric cancer. ( Kobayashi, M; Konishi, N; Kusunoki, M; Mohri, Y; Ohmori, Y; Tanaka, K; Tonouchi, H, 2003) |
| "Only surgical resection offers cure in gastric cancer." | 1.32 | [Neoadjuvant chemotherapy for locally advanced gastric cancer]. ( Cseke, L; Horváth, G; Kalmár, K; Káposztás, Z; Varga, E, 2003) |
| "We compared expression profiles from gastric cancer endoscopic biopsy specimens obtained at a chemosensitive state (partial remission after 5-FU/cisplatin) with those obtained at a refractory state (disease progression), using Affymetrix oligonucleotide microarray technology (U133A)." | 1.32 | DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer. ( Bae, JM; Choi, IJ; Chun, JH; Kang, HC; Kim, E; Kim, HK; Kim, HS; Kim, IH; Kim, IJ; Kim, JH; Lee, JS; Park, IS; Park, JG; Park, JH, 2004) |
| "Endoscope and CT scan revealed type 3 gastric cancer with paraaortic lymph nodal metastasis." | 1.32 | [A case of advanced gastric cancer with DIC treated by sequential MTX and 5-FU]. ( Fujita, K; Gotoh, M; Hirata, I; Hongo, H; Katsu, K; Kawabe, S; Ohta, S; Takiuchi, H, 2004) |
| "Thirty-six patients with advanced gastric cancer underwent (99m)Tc-MIBI scintigraphy before chemotherapy." | 1.32 | Usefulness of 99mTc-sestamibi scintigraphy in suggesting the therapeutic effect of chemotherapy against gastric cancer. ( Iwata, S; Kanai, M; Kawata, K; Sasada, T; Takabayashi, A; Yamamoto, N, 2004) |
| "Scirrhous gastric cancer is resistant to chemotherapy in comparison to other types of gastric cancers, and cancer cell-stromal fibroblast interactions play an important role in progression of scirrhous gastric cancer." | 1.32 | Sensitivity of scirrhous gastric cancer to 5-fluorouracil and the role of cancer cell-stromal fibroblast interaction. ( Matsuda, S; Nakajima, K; Okita, Y, 2004) |
| " The alternate-day dosage of pyrimidine fluoride anticancer drugs could reduce their adverse effects without compromising their effects." | 1.32 | Alternate-day oral therapy with TS-1 for advanced gastric cancer. ( Arai, W; Hirashima, Y; Hosoya, Y; Hyodo, M; Nagai, H; Shirasaka, T; Yasuda, Y; Yokoyama, T, 2004) |
| " Pharmacokinetic studies after administration of S-1 revealed high and prolonged plasma 5-FU levels." | 1.32 | S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study. ( Ajani, JA; Itoh, N; Itoi, H; Shirasaka, T; Ueda, Y; Yamagishi, H; Yamashita, T, 2004) |
| "NCI-N87 and AGS human gastric cancer cells were studied." | 1.32 | Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer. ( Brank, A; Camp, ER; Hochwald, SN; Li, J; MacKay, SL; Minnich, DJ; Moldawer, LL, 2004) |
| " Our hypothesis was that a relatively short and high dosage of TAS-102 results in an additional mechanism of FTD incorporation into DNA other than thymidylate synthase (TS) inhibition." | 1.32 | A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. ( Emura, T; Fukushima, M; Ohshimo, H; Suzuki, N; Yamaguchi, M, 2004) |
| "87 micromol/L) in human serum of subjects receiving chronic administration of a commonly recommended dose (8 g/day), curcumin may be useful for the treatment of gastric carcinoma, especially in conjunction with 5-FU." | 1.32 | Curcumin inhibits the growth of AGS human gastric carcinoma cells in vitro and shows synergism with 5-fluorouracil. ( Jung, KO; Kim, HJ; Koo, JY; Park, KY, 2004) |
| " S-1 has safe and potent antitumor effects in patients with gastric cancer via these respective functions." | 1.32 | Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis. ( Arakawa, T; Fujiwara, Y; Hamaguchi, M; Higuchi, K; Matsumoto, T; Okazaki, H; Oshitani, N; Sasaki, E; Shiba, M; Suto, R; Tanigawa, T; Tominaga, K; Watanabe, T, 2004) |
| "AFP-producing gastric cancer was identified as an independent prognostic factor." | 1.32 | FLEP chemotherapy for alpha-fetoprotein-producing gastric cancer. ( Fujii, M; Kaiga, T; Kasakura, Y; Kobayashi, M; Kochi, M; Morishita, Y; Takahashi, T; Takayama, T, 2004) |
| "The prognosis of gastric cancer with liver metastasis is very poor." | 1.32 | [Gastric cancer with liver metastasis effectively treated by intra-hepatic arterial infusion]. ( Aoyagi, K; Imaizumi, T; Koufuji, K; Miyagi, M; Shirouzu, K; Takeda, J; Yano, S, 2004) |
| "Docetaxel will be a key drug for the gastric cancer." | 1.32 | [A case report of the 8 year survivor--unresectable liver metastases from advanced gastric cancer (Stage IV) were completely responsive, after 4 years from a total sequential gastrectomy, combining docetaxel treatment to regress the recurrence]. ( Handa, R; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Naoi, Y; Ohshima, S; Tsujie, M; Yamamoto, H, 2004) |
| "Case 1: A 67-year-old male with gastric cancer." | 1.32 | [Three successful case reports of advanced gastric cancer with chemotherapy]. ( Fukunaga, K; Kawai, M; Kotobuki, T; Niinobu, T; Taniguchi, H; Yamamoto, M, 2004) |
| "We performed radio-frequency ablation (RFA) therapy combined with intra-arterial chemotherapy for a 71-year old female gastric cancer patient with liver metastasis." | 1.32 | [A case of gastric cancer patient with liver metastasis treated by radiofrequency ablation therapy combined with intra-arterial chemotherapy]. ( Imaizumi, H; Kamei, K; Kosaka, T; Nakano, Y; Takashima, S; Ueno, K; Usami, K, 2004) |
| "Twenty patients with advanced gastric cancer received biweekly regimen of CF/5-FU/PTX (200 mg/m(2) of CF, intravenous infusion for 2 h, day 1; 500 mg/m(2) of 5-FU, intravenous injection, day 1; 1 500 mg/m(2) of 5-FU, intravenous infusion for 46 h, day 1, 2; 90 mg/m(2) of PTX, intravenous infusion for 3 h,day 1)." | 1.32 | [Biweekly regimen of high dose of leucovorin, 5-fluorouracil, and paclitaxel for patients with advanced gastric cancer]. ( Feng, JF; Lu, JW; Sun, XF, 2004) |
| "Ninety-six gastric cancer patients were divided into four groups: Co 5-Fu i." | 1.32 | [Drug distribution in gastric cancer and adjacent tissues by preoperative intraperitoneal chemotherapy with Co-fluorouracil liposome]. ( DU, WL; Fan, LQ; Jiao, ZK; Li, QJ; Li, Y; Liu, BW; Song, ZC; Wang, MX; Yang, JQ; Zhang, ZD; Zhao, Q, 2004) |
| "Twenty-four patients with advanced gastric cancer who had been treated by multiple chemotherapy regimens presenting poor responses were allotted." | 1.32 | [Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer]. ( Chen, YX; He, ZM; Mei, JF; Qian, J; Qin, SK; Shao, ZJ, 2004) |
| "p53 wild- and mutant-type gastric and colon cancer cell lines were treated by 5FU alone, TRAIL alone, and a combination of 5FU and TRAIL, and cell viability after each treatment was determined by MTT assay." | 1.31 | Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro. ( Kaminishi, M; Kusada, O; Mochizuki, Y; Shimoyama, S, 2002) |
| "The prognosis for gastric cancer patients who undergo noncurative resection is extremely poor." | 1.31 | Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer. ( Doki, Y; Fujiwara, Y; Inoue, M; Monden, M; Shiozaki, H; Tamura, S; Tsujinaka, T; Yano, M; Yasuda, T, 2002) |
| "This report shows a case of advanced gastric cancer that responded to low-dose 5-FU plus CDDP." | 1.31 | [A case of advanced gastric cancer responding to combination chemotherapy with low-dose 5-FU plus CDDP]. ( Baba, H; Endo, K; Ikeda, Y; Ishio, T; Kawamoto, K; Kohnoe, S; Okamura, T; Toh, Y; Yamamoto, M, 2002) |
| "We report a case of inoperable gastric cancer with multiple liver metastases, which responded significantly to the short-term administration of TS-1 following intravenous FMP therapy." | 1.31 | [Gastric cancer with multiple liver metastases, which responded significantly to oral administration of TS-1 following intravenous FMP therapy under hospitalization]. ( Chinzei, T; Okada, Y; Tasaka, K; Tomofuji, Y, 2002) |
| "Six patients with gastric cancer, stage IIIA to IV, received intraabdominal cisplatin (CDDP) at laporotomy." | 1.31 | [Postoperative adjuvant immunochemotherapy using Lentinan for advanced gastric carcinoma patients with metastasis in the regional lymph nodes and serosal invasion]. ( Kagawa, R; Nakayama, N; Sakata, S; Tada, M; Yamaguchi, T, 2002) |
| "We have experienced a case of long-term survival after treatment with low dosage 5-fluorouracil (5-FU) and cisplatin (FP regimen)." | 1.31 | A long-term survival case of gastric cancer treated by continuous low-dosage 5-fluorouracil and cisplatin: a case report. ( Aoyagi, K; Koga, A; Koufuji, K; Miyagi, M; Murakami, N; Shirouzu, K; Takeda, J; Yano, S, 2002) |
| "She had type 3 advanced stomach cancer that was judged to have caused complete stricture of the pylorus, and to be inoperable." | 1.31 | [A case of pyloric or antral malignant stenosis treated with arterial infusion chemotherapy and palliative therapy--self-expandable metal stents through gastrostomy]. ( Maruyama, M; Nagahama, T; Tokairin, Y, 2002) |
| "Nude mouse xenografts of 5 human gastric cancer cell lines and 85 clinical samples were used as the specimens in this study." | 1.31 | Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR. ( Abe, K; Fujiwara, H; Fukushima, M; Irinoda, T; Kashiwaba, M; Maesawa, C; Oyama, K; Saito, K; Takagane, A; Takahashi, M; Takechi, T; Terashima, M, 2002) |
| "Twenty-four patients with gastric cancers who underwent the intraoperative systemic chemotherapy were taken as controls." | 1.31 | [Clinical comparison between intraoperative local arterial infusion chemotherapy and systemic venous chemotherapy of gastric cancer]. ( Chen, D; Lai, Y; Peng, B; Xiao, Q; Zhang, S, 2001) |
| "112 cases of fresh human gastric cancer samples were obtained for drug sensitivity testing using MTT." | 1.31 | [Study on the chemosensitivity test of human gastric cancer using the MTT assay]. ( Chen, J; Chen, Z; Hu, J; Mao, Y; Yan, L; Zou, L, 2001) |
| " Although various dosage regimens of FP therapy have been investigated, there has been a certain limit to the response rate achieved by this therapy, and new protocols have been explored." | 1.31 | [Two cases of recurrent gastric cancer for which combination chemotherapy with pirarubicin, cis-platinum and 5-fluorouracil were markedly effective]. ( Ashizawa, T; Katsumata, K; Koyanagi, Y; Majima, T; Mori, M; Murohashi, T; Nagashima, K; Sumi, T; Takahashi, S; Yamamoto, K; Yamashita, S, 2000) |
| "Forty-one patients with advanced gastric cancer gave informed consent and were enrolled in the study." | 1.31 | Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. ( Fukushima, M; Ishikawa, Y; Kitajima, M; Kubota, T; Kumai, K; Okabe, H; Otani, Y; Takechi, T; Teramoto, T; Watanabe, M, 2000) |
| "A nationwide questionnaire survey was carried out on low-dose cisplatin-5-FU therapy for solid malignant tumors (mostly stomach and colon cancer) regarding its antitumor as well as adverse effects." | 1.31 | [Current status of "low-dose cisplatin-5-FU therapy" for solid tumors (2nd report)--from a nationwide questionnaire on its adverse effects]. ( Hirata, K; Nakazato, H; Nishiyama, M; Saji, S; Sowa, M; Toge, T; Yamamitsu, S, 2000) |
| "5-fluorouracil (5-FU) was given 200 mg/day for 26 days orally." | 1.31 | [A case of AFP-producing gastric cancer after curative operation effectively treated with chemotherapies including hepatic arterial infusion therapy]. ( Nashimoto, A; Tanaka, O; Yabusaki, H, 2000) |
| "In patients with T3 gastric cancer who were treated with curative gastrectomy, however, FU-based chemotherapy did not affect survival of either patients with TS-positive tumors or with TS-negative tumors." | 1.31 | Expression of thymidylate synthase in relation to survival and chemosensitivity in gastric cancer patients. ( Gomyo, Y; Hirooka, Y; Kaibara, N; Konishi, I; Matsumoto, S; Oka, S; Suzuki, K; Tsujitani, S, 2000) |
| "In stage 3 gastric cancer, the overall survival rates following surgery was significantly (p < 0." | 1.31 | Postsurgical sequential methotrexate, fluorouracil, and leucovorin for stages 3 and 4 gastric carcinoma: A preliminary study. ( Kitaoka, A; Ohsumi, K; Tokuka, A; Tokunaga, Y; Yagi, T, 2000) |
| "We conclude that 24-h exposure of gastric cancer cells to low concentration of 5-FU resulted in better suppression of free TS, a higher degree of S-phase blockade, and enhanced cytotoxicity compared to 30-min exposure to high concentration of 5-FU." | 1.31 | Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil. ( Cheng, AL; Hsu, CH; Ma, IF; Wang, TM; Yeh, KH; Yeh, SH, 2000) |
| "For both of the two patients with pancreatic cancer, although they were responsive to the therapy, there was no prolongation of survival." | 1.31 | [Hepatic arterial infusion chemotherapy for unresectable liver metastasis of gastrointestinal cancers]. ( Hirakawa, K; Nishino, H; Ohira, M; Shimizu, S; Tamamori, Y; Tanaka, H; Yamada, N, 2000) |
| "We treated a case of unresectable gastric cancer in which peritoneal lavage cytology and the primary tumor responded to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection." | 1.31 | [A case of stage IV gastric cancer responding to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection]. ( Hattori, T; Hirano, K; Kase, H; Kobayashi, K; Ogawa, M; Teramoto, T; Tokura, N; Washizawa, N, 2000) |
| "5-Fluorouracil and cisplatin were administered intraperitoneally on postoperative days 1-4, and this was repeated at 4-week intervals." | 1.31 | Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer. ( Chung, HC; Min, JS; Noh, SH; Roh, JK; Shin, DW; Yoo, CH, 2001) |
| " Based on in vitro study showing that the introduction of bax gene enhanced the sensitivity to anticancer drugs, we examined whether the intratumoral administration of bax gene could enhance the anti-tumor effect in combination with anticancer drugs in gastric cancer." | 1.31 | Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer. ( Kim, R; Minami, K; Nishimoto, N; Toge, T, 2001) |
| "A total of 18 patients (13: colon cancer, 5: gastric cancer) with multiple liver metastases (H3) underwent hepatic arterial infusion chemotherapy (HAI) using an implanted arterial port with portable syringe pumps in our outpatient clinic." | 1.31 | [Outcomes of home anti-cancer chemotherapy--estimation of hepatic arterial infusion chemotherapy for patients with multiple liver metastases]. ( Fukunaga, M; Goda, F; Maeba, T; Maeta, H; Mihara, T; Mori, S; Ohkawa, M; Okada, H; Okano, K; Senda, S; Uchida, Y; Usuki, H; Wakabayashi, H, 2000) |
| "We have experienced a case of advanced gastric cancer with liver metastasis effectively treated by intra-hepatic arterial infusion of 5-fluorouracil (5-FU), mitomycin C (MMC) and peroral administration of 5-FU." | 1.31 | Advanced gastric cancer with liver metastasis effectively treated by intra-hepatic arterial infusion of 5-FU, MMC and peroral administration of 5-FU: a case report. ( Aoyagi, K; Koufuji, K; Murakami, N; Shirouzu, K; Takeda, J; Terasaki, Y; Yamasaki, Y; Yano, S, 2000) |
| "As an outpatient without recurrence he has received oral administration of uracil plus tegafur." | 1.31 | [A patient with obstructive jaundice due to recurrence after gastric cancer surgery responding remarkably to FLP combination therapy]. ( Kawahara, M; Nashimoto, A; Yabusaki, H, 2001) |
| "Final diagnosis stated a multilocular metastasising gastric cancer with infiltration of bone, peritoneum and dura and signet-cell infiltration of the bone marrow." | 1.31 | [Hemorrhagic diathesis as initial symptom of stomach carcinoma]. ( Dempke, W; Kellner, O; Schmoll, HJ; von Poblozki, A; Wolf, HH, 2000) |
| "In other two groups (gastric and colorectal cancer patients) side effects of chemotherapy caused relatively less QL deterioration." | 1.31 | Quality of life in cancer patients treated by chemotherapy. ( Herman, ZS; Machalski, M; Scieszka, M; Zielinski, M, 2000) |
| "A 77-year-old man who had advanced gastric cancer with multiple liver metastases was treated by combined chemotherapy with 5-fluorouracil and low-dose cisplatin for 1 and half courses (1 course = 4 weeks)." | 1.31 | [A case of advanced gastric cancer complicated with liver metastases responding remarkably to combined chemotherapy with 5-fluorouracil and low-dose cisplatin, with UFT and low-dose cisplatin for maintenance on an outpatient basis]. ( Ikeda, S; Iwamoto, M; Nagata, S; Niiya, F; Shirouzu, K, 2001) |
| "Preoperative chemoradiotherapy for gastric cancer can be delivered safely and is well tolerated." | 1.31 | A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. ( Ajani, JA; Feig, BW; Janjan, N; Lowy, AM; Mansfield, PF; Pisters, PW; Rich, TA, 2001) |
| "Deficiency of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in 5-fluorouracil (5-FU) catabolism, has been linked to toxic side effects of 5-FU." | 1.31 | Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. ( Behnke, D; Häusler, P; Höffken, K; Raida, M; Schwabe, W; Van Gennip, AH; Van Kuilenburg, AB, 2001) |
| "The subjects were 50 advanced gastric cancer patients treated with FP." | 1.31 | Retrospective study of hyponatremia in gastric cancer patients treated with a combination chemotherapy of 5-fluorouracil and cisplatin: a possible warning sign of severe hematological toxicities? ( Boku, N; Muto, M; Nagashima, F; Ohtsu, A; Shinkai, T; Yoshida, S, 2001) |
| " Thirty-one patients with superficial oesophageal or gastric cardiac carcinomas, who refused or were unsuitable for surgery, received endoscopic Nd:YAG laser therapy combined with local injection of chemotherapeutic drugs 5-fluorouracil and mitomycin." | 1.31 | Endoscopic Nd:YAG laser therapy combined with local chemotherapy of superficial carcinomas of the oesophagus and gastric cardia. ( Huang, T; Jia, J; Wang, Y; Zhou, C, 2001) |
| "Most gastric cancer patients with peritoneal dissemination have been excluded from clinical studies because they usually have no measurable lesions." | 1.31 | Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study. ( Boku, N; Hironaka, S; Mera, K; Muto, M; Nagashima, F; Ohtsu, A; Sano, Y; Tahara, M; Tajiri, H; Yoshida, M; Yoshida, S, 2001) |
| "We experienced a case of recurrent gastric cancer with a long-term survival." | 1.31 | [Dormant chemotherapy by low-dose FP and low-dose UFT-E in recurrent gastric cancer with long-term survival--a case report]. ( Koyama, S; Shimoda, S; Takeda, N; Tanaka, N; Tsukahara, A; Yajima, K, 2002) |
| " We report three cases of advanced gastric cancer treated using TS-1 in combination with a low-dose of cisplatinum (CDDP) that well responded." | 1.31 | [Three cases of advanced gastric cancer treated by TS-1 in combination with low-dose cisplatinum]. ( Gomi, T; Kanaya, S; Katayama, T; Momoi, H; Ohtoshi, M; Tamaki, N; Wada, Y, 2002) |
| "Since metastases to the liver, left adrenal gland, and Douglas' pouch were detected in addition to ascites and bilateral hydronephrosis, the tumor was judged unresectable and systemic chemotherapy with TS-1 was begun." | 1.31 | [A case in which TS-1, an orally-administered 5-FU chemotherapeutic agent, showed marked effectiveness against scirrhous type gastric cancer with multiple organ metastases]. ( Araki, S; Asakura, R; Itou, A; Kobayashi, K; Naganuma, J; Teruya, M; Yanagida, O, 2002) |
| "We report three patients with recurrent gastric cancer responding to TS-1 therapy after combination chemotherapy with 5-fluorouracil, mitomycin C and cisplatin." | 1.31 | [Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin]. ( Hayashi, K; Iijima, S; Koyama, Y; Miyazawa, K; Morikawa, A; Murakami, M; Okabe, R; Ozaki, K; Sugiyama, A; Suzuki, A, 2002) |
| "Advanced gastric cancer was found in 12 cases (operation performed in 9 cases and 7 cases resectable) and recurrent in 5 cases." | 1.30 | [Clinical analysis of adjuvant chemotherapy using 5-fluorouracil, leucovorin and cis-diamminedichloroplatinum for patients with advanced and recurrent gastric cancer]. ( Katsumata, K; Kohno, M; Koyanagi, Y; Moriwaki, R; Ohno, M; Shibata, K; Tadatomo, H; Yamamoto, K; Yamashita, S, 1997) |
| "5-Fluorouracil was administered at an initial daily dose of 125 mg/m2, with dose escalation planned in 25-mg increments, depending on patient tolerance." | 1.30 | Pilot study of continuous-infusion 5-fluorouracil, oral leucovorin, and upper-abdominal radiation therapy in patients with locally advanced residual or recurrent upper gastrointestinal or extrapelvic colon cancer. ( Burch, PA; Garton, GR; Kugler, JW; Martenson, JA; Pitot, HC; Santala, RG; Schroeder, G; Stella, PJ; Swaminathan, R; Wright, K, 1997) |
| "Though treatment of recurrent gastric cancer with liver metastasis is often ineffective, this case suggests that a combination therapy of cisplatin and carmofur might be effective." | 1.30 | [A case of recurrent gastric cancer with liver metastasis responding to combination chemotherapy with cisplatin and carmofur]. ( Inomata, Y; Inoue, K; Kuroda, T; Mizutani, H; Sakuyama, T; Tadaoka, N; Takahashi, N; Yamada, T; Yoshinaga, K, 1997) |
| "We reported two cases of advanced gastric cancer effectively treated with chemotherapy of 5-fluorouracil (5-FU), cisplatin (CDDP) and cytarabine (Ara-C), 5-FU (300-350 mg/body) was given by continuous intravenous infusion." | 1.30 | [Two cases of advanced gastric cancer effectively treated with chemotherapy of 5-fluorouracil, cisplatin and cytarabine]. ( Hizawa, Y; Itoh, J; Munakata, A; Saitoh, S; Satoh, T; Tamura, Y; Tsushima, K; Yamada, Y, 1997) |
| "Endoscopic study revealed an advanced gastric cancer in the upper body of her stomach." | 1.30 | [A case of advanced gastric cancer with carcinomatosa peritonitis effectively treated by 5-FU and low-dose CDDP therapy]. ( Kunii, Y; Saito, E; Sakakibara, N; Tsuchiya, S; Wada, G; Yamasaki, T, 1997) |
| "About one-third of patients with gastric cancer are unresectable at the time of diagnosis." | 1.30 | Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. ( Cho, JY; Chung, HC; Kim, BS; Kim, CB; Kim, JH; Min, JS; Noh, SH; Park, JO; Rha, SY; Roh, JK; You, NC, 1997) |
| "Thirteen patients with advanced gastric cancer treated by palliative radiotherapy were retrospectively analyzed." | 1.30 | [Radiation therapy for advanced gastric cancer]. ( Akiyama, T; Kita, I; Kosaka, T; Nakano, Y; Ooguchi, M; Saito, H; Sejima, T; Sugaya, J; Takashima, S; Tamamura, H; Tomita, F, 1997) |
| "A 57-year-old man suffering from gastric cancer with esophageal invasion and liver and paraaortic lymph nodes metastases was treated with continuous 5-FU injection and intra-hepatic arterial infusion of low-dose cisplatin following non-curative surgery." | 1.30 | [A case of far-advanced gastric cancer treated with continuous 5-fluorouracil injection and intrahepatic arterial infusion of low-dose cisplatin]. ( Oka, M; Ueno, T, 1997) |
| "We reported a case of advanced gastric cancer with multiple bone metastasis successfully treated by both methotrexate (MTX) and 5-fluorouracil (5-FU) sequential therapy, and endoscopic intratumoral injection of 5-fluorouracil." | 1.30 | [A case of advanced gastric cancer with multiple bone metastasis successfully treated by both methotrexate and 5-fluorouracil sequential therapy, and endoscopic intratumoral injection of 5-fluorouracil]. ( Kamei, M; Kawabata, H; Matsuda, K; Nishioka, M; Sasahara, K; Uchida, Y, 1998) |
| "A 69-year-old male patient with gastric cancer complaining severe jaundice was readmitted for the purpose of chemotherapy." | 1.30 | [A case of unresectable advanced gastric cancer with severe obstructive jaundice responding to combined chemotherapy with 5-fluorouracil and low-dose cisplatin]. ( Hoshiko, M; Iwamoto, M; Kawabata, S; Shirouzu, K; Takeda, J; Yasumoto, K, 1998) |
| "Acute disseminated intravascular coagulation (DIC) is a severe complication of gastric adenocarcinoma, and most of the patients die within 1-3 weeks." | 1.30 | Gastric cancer associated with acute disseminated intravascular coagulation: successful initial treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin. ( Cheng, AL; Yeh, KH, 1998) |
| "An advanced gastric cancer patient with T3N1M0 successfully underwent a curatively total gastrectomy combined with distal pancreatectomy and lymphnode dissection following ELF-P combined chemotherapy." | 1.30 | [Advanced gastric cancer curatively resected following combined neoadjuvant chemotherapy--report of a case]. ( Kamiyama, H; Kawashima, K; Koike, N; Morishita, Y; Ogawa, T; Ohwada, S; Sato, Y; Takeyoshi, I, 1998) |
| "Of 125 cases of advanced gastric cancer, 41 cases received intraarterial chemotherapy (A group) and the rest were given systemic infusion (S group)." | 1.30 | [Evaluation of intra-arterial infusion chemotherapy for advanced gastric cancer]. ( Akiyama, T; Kita, I; Kosaka, T; Nakano, Y; Saito, H; Sugaya, J; Takashima, S; Tomita, F; Ueshige, N, 1998) |
| "Many cases with metastatic hepatic cancer have a poor prognosis because of the appearance of extrahepatic lesions in spite of the fact that a partial response can be obtained by hepatic arterial infusion chemotherapy." | 1.30 | [Appearance of extrahepatic lesions in the superior lip and orbit of a patient with liver metastases of gastric cancer following partial response by hepatic arterial infusion chemotherapy]. ( Hasegawa, K; Ichikawa, T; Kawai, S; Kirihara, M; Kume, S; Maruo, H; Tominaga, S, 1998) |
| " Pharmacokinetic parameters were calculated using a two-compartment open model." | 1.30 | [Pharmacokinetic analysis of low-dose intra-peritoneal cis-platinum administration]. ( Abe, K; Araya, M; Ikeda, K; Irinoda, T; Nakaya, T; Nishizuka, S; Oyama, K; Saito, K; Sasaki, N; Takagane, A; Terashima, M; Yonezawa, H, 1998) |
| "Fluorouracil was given p." | 1.30 | [Report of case who survived more than five years after repeated intraperitoneal chemotherapy with cisplatin and 5-fluorouracil for treatment of macroscopically negative but microscopically positive peritoneal dissemination of gastric cancer]. ( Furukawa, H; Hiratsuka, M; Imaoka, S; Ishikawa, O; Kabuto, T; Kameyama, M; Murata, K; Nakano, H; Ohigashi, H; Sasaki, Y; Yasuda, T, 1998) |
| "The patient was diagnosed to have gastric cancer (T3 N3 M0 P3, Stage IV b)." | 1.30 | [Low-dose CDDP and continuous 5-FU treatment of advanced gastric cancer with peritoneal dissemination: a case with long disease-free survival]. ( Horimi, T; Morita, S; Takahashi, I; Takamatsu, M; Takasaki, M; Tsuji, A, 1998) |
| "Nocturnal infusion of 5-fluorouracil (5-FU) combined with pamidronate was performed in a 62-year-old male gastric cancer patient with multiple bone metastasis." | 1.30 | [A case of gastric cancer with multiple bone metastasis treated by nocturnal 5-fluorouracil infusion combined with pamidronate]. ( Fukano, S; Furuya, Y; Kinugasa, T; Kohno, N; Maekawa, Y; Sekimoto, K; Toyokawa, A, 1998) |
| "32 patients with advanced gastric cancer were treated with oral etoposide (100 mg), leucovorin (3 x 100 mg), and tegafur (3 x 200 mg) over 14-21 days for a maximum of six cycles." | 1.30 | Treatment of advanced gastric cancer with oral etoposide, leucovorin and tegafur: experience with an oral modification of the etoposide, leucovorin and 5-fluorouracil (ELF) regimen. ( Brodowicz, T; Fiebiger, WC; Hejna, MH; Kornek, GV; Miholic, J; Raderer, M; Scheithauer, W; Valencak, JB; Weinlaender, G, 1998) |
| "5-Fluorouracil is an S-phase-specific, synthetic pyrimidine antimetabolite, which is used as a cytostatic agent for a variety of malignant lesions, either singly or in multidrug regimens." | 1.30 | Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. ( Ahmad, M; Aziz, SA; Iqbal, K; Jalal, S; Mohi-ud-Din, K; Tramboo, NA, 1998) |
| "Advanced gastric, colon and esophageal cancers (n = 21) were treated with 5-FU (250 mg) modulated by CDDP (5 mg)." | 1.30 | [Treatment with 5-FU modulated by low-dose CDDP for advanced cancers and recurrent cases of metastasis]. ( Hisano, H; Kida, H; Nomura, M; Shibasaki, S; Shinkai, K; Yano, H, 1999) |
| "A patient with advanced gastric cancer was treated with combined administration of CPT-11 CDDP and 5-FU before operation." | 1.30 | [A case of advanced gastric cancer successfully treated by neoadjuvant chemotherapy with CPT-11, CDDP and 5-FU]. ( Fukuda, S; Kume, S; Nagamoto, N; Okamura, K; Sakaguchi, T; Tanabe, D, 1999) |
| "Twenty-one paired pharmacokinetic studies were completed on patients with colorectal, gastric, and hepatocellular cancer, utilizing positron emission tomography (PET), which allowed the acquisition of tumor, normal tissue, and plasma pharmacokinetic data and tumor blood flow (TBF) measurements." | 1.30 | Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. ( Brady, F; Brown, G; Harte, RJ; Jones, T; Luthra, SJ; Matthews, JC; O'Reilly, SM; Osman, S; Price, PM; Tilsley, DW, 1999) |
| "A human stomach cancer cell line with acquired resistance to 5-fluorouracil (5-FU), NUGC-3/5FU/ L, has been found to possess reduced ability to convert 5-FU into active metabolites." | 1.30 | Circumvention of 5-fluorouracil resistance in human stomach cancer cells by uracil phosphoribosyltransferase gene transduction. ( Hamada, H; Inaba, M; Sadata, A; Sawada, H, 1999) |
| "Mitomycin C (20 mg) was injected through out the induced hypertension (1." | 1.30 | [A case of liver metastases from gastric cancer responding to induced hypertensive chemotherapy with angiotensin II]. ( Arai, K; Iwasaki, Y; Kitamura, M; Nakajima, Y, 1999) |
| "Mitomycin C was injected for 10 minutes via implanted port, whose tip was located in the hepatic artery, when the mean systolic blood pressure rose to 50 percent above the level in the untreated state by intravenous administration of angiotensin II." | 1.30 | [Efficacy and problems of hepatic arterial chemotherapy with angiotensin II for liver metastasis from gastric cancer]. ( Arai, K; Iwasaki, Y; Ohashi, M; Takahashi, T, 1999) |
| "Acanthosis nigricans is an uncommon skin condition characterized by hyperkeratosis and skin hyperpigmentation." | 1.30 | Malignant acanthosis nigricans: potential role of chemotherapy. ( Anderson, SH; Hudson-Peacock, M; Muller, AF, 1999) |
| "Lung metastasis in mice bearing subcutaneous tumors was significantly inhibited by HCFU at doses of 100-150 mg kg(-1) day(-1) without severe toxic side-effects, when orally administered three times per week either from week 4 or week 6 to 9 weeks after implantation." | 1.30 | Induction of apoptosis in metastatic foci from human gastric cancer xenografts in nude mice and reduction of circulating tumor cells in blood by 5-FU and 1-hexylcarbamoyl-5-fluorouracil. ( Abe, A; Inada, K; Nakanishi, H; Tatematsu, M; Tsukamoto, T; Yasui, K, 1999) |
| "In contrast, in group B, 9 had tubular adenocarcinomas (well or moderately differentiated) and 3 non-solid or diffuse-type poorly differentiated adenocarcinomas and there was only one solid-type tumor." | 1.30 | Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy. ( Ishihara, S; Kato, Y; Kitagawa, T; Nakajima, T; Ninomiya, Y; Yanagisawa, A, 1999) |
| "We performed pharmacokinetic modulating chemotherapy (PMC) postoperatively in patients with advanced gastric cancer and examined its antitumor and the side effects." | 1.30 | [PMC (pharmacokinetic modulating chemotherapy) for advanced gastric cancer]. ( Fujiwara, Y; Itoh, R; Kusunoki, M; Nakagawa, K; Nakao, K; Yamamura, T, 1999) |
| "We analyzed 26 patients with advanced gastric cancer in whom at least one of the tumor markers CEA, CA19-9 and CA125 was elevated before systemic chemotherapy with regard to the relationship between the change in serum tumor marker level and response assessment by imaging studies throughout the treatment course." | 1.30 | Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. ( Handa, T; Kai, S; Kazami, A; Koizumi, K; Maruyama, M; Takemoto, N; Yamao, T, 1999) |
| "A case of far advanced gastric cancer with multiple liver metastasis (H3) was treated with transarterial intermittent chemotherapy (5-FU: 250 mg/week, Farmorubicin: 10 mg/4 weeks, MMC: 4 mg/2 weeks) and intradermal administration of low molecular lipopolysaccharide (LPSp) extracted from Pantoea agglomerans." | 1.29 | [A case report of far advanced gastric cancer with multiple liver metastasis (H3) treated with transarterial intermittent chemotherapy and intradermal administration of low molecular lipopolysaccharide (LPSp) extracted from Pantoea agglomerans]. ( Fukuma, E; Goto, S; Imai, I; Ishiyama, J; Kano, N; Kasugai, H; Kera, J; Miyajima, N; Takeuchi, S; Yamakawa, T, 1995) |
| "The response of gastric cancer to intravenous application of low-dose CDDP plus 5-fluorouracil (FP) was assessed by changes in DNA indices (DIs) and PCNA labeling indices (LIs) by flow cytometry, and by the thymidylate synthetase inhibition rate (TSIR)." | 1.29 | [Effect of low dose CDDP/5-fluorouracil therapy on PCNA labeling index and TS inhibition rate of gastric cancer]. ( Akiyama, T; Kiriyama, M; Kita, I; Kosaka, T; Nakano, Y; Saito, H; Sugaya, J; Takano, Y; Tomita, F; Yoshida, S, 1995) |
| "Three gastric, three colon and three breast cancer patients were administered 300 mg/m2 FUra continuously for 10 h per day from 2100 h to 0700 h for more than 20 consecutive days." | 1.29 | Serum concentrations of 5-fluorouracil achieved with nocturnal constant-rate infusion in patients with disseminated cancer. ( Furuya, Y; Kohno, N; Saitoh, Y; Yamamoto, K; Yamamoto, M, 1995) |
| "5-Fluorouracil (5-FU) is an antimetabolite frequently used in the treatment of cancer." | 1.29 | Dermatological toxicity from chemotherapy containing 5-fluorouracil. ( Campanella, GA; Carrieri, G; Colucci, G; Leo, S; Tatulli, C; Taveri, R, 1994) |
| "The other five patients with advanced stomach cancer who could not have so good nutrition were receiving home parental nutrition (HPN, 1,200 kcal/day) and continuous or intermittent 5-FU infusion (250-500 mg/body/day) using Lentinan at the same time." | 1.29 | [Home infusion chemotherapy in patients with relapsed or recurred stomach and colorectal cancer]. ( Chibai, M; Inomata, Y; Isshi, K; Nakamura, Y; Sakuyama, T; Shimono, S; Tadaoka, N; Takahashi, N; Takamura, S; Yamada, T, 1994) |
| "We reported a case of gastric cancer with peritoneal dissemination, which was successfully treated by neoadjuvant chemotherapy and partial gastrectomy." | 1.29 | [Case report of long-term survivor of advanced gastric cancer associated with peritoneal dissemination successfully treated with cancer chemotherapy]. ( Ikeda, K; Shibata, N; Tamai, M, 1995) |
| "A 75-year-old man with gastric cancer having multiple liver metastases was given intraarterial infusion therapy with sequential low-dose MTX (30 mg/body) and 5-FU (1,000 mg/body) for metastatic liver tumors one month after the primary gastric tumor was resected." | 1.29 | [A case report: multiple liver metastasis from gastric cancer responding to intraarterial infusion of sequential low-dose MTX and 5-FU]. ( Hamanaka, Y; Hazama, S; Oka, M; Suzuki, T; Tangoku, A; Tsurumi, M, 1994) |
| "FLP therapy for advanced or recurrent stomach cancer in outpatients was expected to improve the QOL." | 1.29 | [Effects of combination chemotherapy using 5-FU, leucovorin, and CDDP (FLP therapy) for noncurative resected or recurrent stomach cancer in outpatients]. ( Kobayashi, O; Motohashi, H; Okada, K; Okugawa, T; Onodera, S; Rino, Y; Sairenji, M, 1994) |
| "A 67-year-old man with advanced gastric cancer with multiple liver metastases was treated by a new combination chemotherapy using 5-FU, THP and MMC (FTM)." | 1.29 | [A case of advanced gastric cancer with multiple liver metastases showing marked response to new combination chemotherapy using 5-FU, THP and MMC (FTM)]. ( Kusano, F; Maekawa, N; Sakai, Y; Sasaki, N; Tajiri, K; Tazawa, J; Yamamoto, C, 1994) |
| "We described a case of advanced gastric cancer with multiple liver metastases, who was placed on neoadjuvant chemotherapy using CDDP and 5-FU (FP therapy) with a marked reduction in tumor load." | 1.29 | [Successful neoadjuvant chemotherapy in a patient with advanced gastric cancer with multiple liver metastases]. ( Igarashi, S; Kurosu, Y; Mori, K; Niki, M; Nishimura, G; Oohara, M; Osada, H; Takamoto, Y; Tsuzuki, H; Ueda, H, 1994) |
| "Three cases of postoperative gastric cancer with peritoneal dissemination were treated by combined administration of CDDP, 5-FU and Lentinan." | 1.29 | [Postoperative immunochemotherapy for gastric carcinoma with peritoneal dissemination--the effects with the combination of CDDP, 5-FU and lentinan]. ( Mio, H; Terabe, K, 1994) |
| "The second patient had advanced gastric cancer with carcinomatosis." | 1.29 | [Nocturnal infusion of 5-fluorouracil in advanced digestive tract cancer--two case reports]. ( Furuya, Y; Hamabe, Y; Ku, Y; Nakamura, T; Saitoh, Y; Yamamoto, K, 1994) |
| "A 51-year-old female with inoperable gastric cancer and with infiltration of pancreatic tail diagnosed by abdominal CT was treated with leucovorin (LV) and 5-fluorouracil (5-FU)." | 1.29 | [Efficacy of the treatment of gastric cancer as neo-adjuvant chemotherapy of 48 hour continuous intravenous infusion of 5-fluorouracil (5-FU) with leucovorin (LV)]. ( Inamura, Y; Kanemitsu, T; Koike, A; Kojima, T; Matsumoto, K; Miwa, M; Nagata, H; Naruse, T; Ohiwa, Y; Suzumura, K, 1993) |
| "An advanced gastric cancer patient with multiple retroperitoneal lymph node metastases and bone metastases was treated with sequential MTX and 5-FU." | 1.29 | [A case of nonresectable gastric cancer treated by sequential methotrexate and 5-fluorouracil]. ( Anai, H; Furuyama, M; Ikejiri, K; Maekawa, S; Muranaka, T; Saku, M; Takeo, S; Yakabe, S, 1994) |
| "A case of Borrmann type 4 gastric cancer responding to sequential methotrexate and 5-fluorouracil combined with cis-diamminedichloroplatinum (CDDP) is reported." | 1.29 | [A case of Borrmann type 4 gastric cancer responding to sequential methotrexate and 5-fluorouracil combined with CDDP]. ( Hayashi, H; Iwashita, R; Miyauchi, H; Miyoshi, H; Mochizuki, R; Nakagohri, T; Takeuchi, H; Tsunoda, Y; Ueda, K, 1994) |
| "The frequency of multiple early gastric cancer occurring in patients who had not received chemotherapy was 11." | 1.29 | The significance of preoperative chemotherapy for early gastric carcinoma. ( Kumagai, K; Masuo, K; Nishida, Y; Yasui, A; Yoshitoshi, A, 1993) |
| " The appropriate dosage of six well-known antitumor drugs [mitomycin C (MMC), cyclophosphamide (CPA), nimustine hydrochloride 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU), cis-platinum (II) diaminodichloride (CDDP), adriamycin (ADM) and 5-fluorouracil (5-FU)] in human tumor-bearing nude mice was determined based on the maximum tolerance dose of the drug." | 1.29 | A standardized method of using nude mice for the in vivo screening of antitumor drugs for human tumors. ( Abe, O; Hattori, T; Imaizumi, M; Kitano, M; Kondo, T; Taguchi, T; Wakui, A, 1993) |
| "Nine gastric cancer patients with simultaneous liver metastases were given intermittent transarterial administration of chemotherapeutics (adriamycin, mitomycin C or 5-fluorouracil) and biological response modifiers (BRM; OK-432 and interleukin (IL) -2) after gastrectomy." | 1.29 | [Immunological effects of locoregional immunochemotherapy for liver metastases of gastric cancer]. ( Azuma, S; Furuta, T; Kato, M; Kida, H; Kunieda, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H; Umemoto, T, 1993) |
| " The Cmax of 5-FU in serum was lowest in group B." | 1.29 | [Pharmacokinetics following intraperitoneal sequential administration of cisplatin and fluorouracil for gastric cancer]. ( Furukawa, H; Hiratsuka, M; Ishikawa, O; Iwanaga, T; Kabuto, T; Kameyama, M; Masutani, S; Nakamori, S; Ohigashi, H; Sasaki, Y, 1993) |
| "Forty gastric cancer patients and 29 colorectal cancer patients were treated by subselective intraarterial infusion chemotherapy." | 1.29 | [Evaluation of subselective intraarterial infusion chemotherapy in far advanced gastric and colorectal cancer]. ( Fujimoto, T; Kitada, M; Murotani, M; Okumura, Y; Saito, M; Shibata, T; Takada, T; Takami, M; Tsukahara, Y; Watanabe, Y, 1993) |
| "Fourteen patients with advanced gastric cancer were treated with EAP-F therapy." | 1.29 | [Etoposide, doxorubicin, cisplatin and 5-FU (EAP-F) therapy of advanced gastric cancer--its antitumor effect and evaluation of quality of life]. ( Inada, T; Kano, Y; Ogata, Y; Suda, K, 1993) |
| "Recently, in the treatment of gastric cancer this biochemical modulation has been introduced into clinical practice and has also achieved good antitumor activity." | 1.29 | [Clinical effect and characteristics of low dose leucovorin and high dose 5-FU therapy in patients with recurrent gastric cancer--a new method of biochemical modulation]. ( Akiyama, H; Kajiyama, Y; Matsuda, M; Ono, Y; Suzuki, M; Tsurumaru, M; Udagawa, H; Watanabe, G, 1993) |
| "To evaluate the effect of the oral fluoropyrimidines, tegafur and uracil (UFT) and 5-fluorouracil (5-FU), a pharmacodynamic analysis was conducted using a nude mouse system and patients." | 1.29 | A pharmacodynamic and pharmacokinetic study of fluoropyrimidines in a nude mouse system and in postoperative patients with gastric cancer. ( Hishinuma, S; Ikeda, T; Inada, T; Kotake, K; Koyama, Y; Kubota, T; Ogata, Y; Ozawa, I; Shimizu, H, 1993) |
| "A 59-year-old woman with advanced gastric cancer was treated with continuous 5-fluorouracil infusion for thirty-five days." | 1.29 | Continuous 5-fluorouracil infusion causing acute gastric mucosal lesions. ( Kano, Y; Sasagawa, M; Seki, T; Suda, K, 1993) |
| "As 5-fluorouracil (5-FU) has been known to show clinically antitumor effects against both breast and stomach carcinomas." | 1.29 | [Effect of medroxyprogesterone acetate on the anticellular activity of 5-fluorouracil against human breast and stomach cancer cells]. ( Gomi, K; Horiuchi, R; Ishida, H; Okabe, M, 1993) |
| "Tegafur or UFT was administrated orally to patients with gastric or colorectal cancers after surgery for at least a year." | 1.29 | [Evaluation of long-term administration of oral anti-cancer agent]. ( Sakakibara, N; Watanabe, H, 1993) |
| "An experience with an advanced gastric cancer patient with metastases to bilateral breasts, uterus, abdominal lymph nodes, bilateral axillary and supraclavicular lymph nodes, and bone marrow, responded extremely well to an FAP combined chemotherapy as reported here." | 1.29 | [A case of advanced gastric cancer responding to an FAP (5-FU, ADM, platinum compounds) combined chemotherapy]. ( Azuma, T; Doihara, H; Kirihara, Y; Miyahara, E; Ohashi, R; Sakamoto, N; Soga, H; Takiyama, W; Tanada, M; Yokoyama, N, 1993) |
| "This metastatic model of human stomach cancer shows that locally growing and metastatic tumors may have different chemosensitivities, and provides the opportunity to test both with various treatment regimens." | 1.29 | Differential chemosensitivity of local and metastatic human gastric cancer after orthotopic transplantation of histologically intact tumor tissue in nude mice. ( Furukawa, T; Hoffman, RM; Kitajima, M; Kubota, T; Kuo, TH; Watanabe, M, 1993) |
| "In a 63-year-old male patient with gastric cancer having multiple liver metastases, the metastatic lesions responded well to postoperative staggered intraarterial infusion therapy with MTX and 5-FU." | 1.29 | [A case report: multiple liver metastasis of gastric cancer responding to intraarterial infusion of MTX and 5-FU]. ( Adachi, A; Nakano, Y; Ota, Y; Shirafuji, T; Yamaguchi, H; Yoshida, K, 1993) |
| "The patient was a 44-year-old male with gastric cancer accompanied by pancreatic invasion and metastasis to the periaortic lymph nodes." | 1.29 | [A patient with stage IV gastric cancer responding to combination chemotherapy with 5-FU, leucovorin and CDDP]. ( Kobayashi, O; Motohashi, H; Okada, K; Okugawa, T; Rino, Y; Sairenji, M, 1993) |
| "A 41-year-old woman diagnosed as gastric cancer with peritoneal dissemination was admitted for operation." | 1.29 | [A case of unresectable gastric cancer responding to combined therapy with intraperitoneal cisplatinum administration and continuous intravenous infusion of 5-fluorouracil]. ( Fukuda, I; Kishimoto, S; Kokufu, I; Miyake, Y, 1995) |
| "Mitomycin C 26 mg was given intravenously on the day of operation and 5-fluorouracil (5-FU) 150 mg/day orally since postoperative 14th day as adjuvant chemotherapy." | 1.29 | [A case of advanced gastric cancer with liver metastasis with no recurrence and long survival]. ( Kajiura, Y; Kondo, Y; Mitomi, T; Miyaji, M; Nakamura, K; Ogoshi, K; Tajima, T, 1996) |
| "We described a case of advanced gastric cancer accompanied by metastasis to the periaortic lymph node." | 1.29 | [Successful neoadjuvant chemotherapy in a patient with advanced gastric cancer with periaortic lymph node metastasis]. ( Horiuchi, H; Hyodo, S; Kakegawa, T; Nozoe, Y; Sasatomi, T; Takeuchi, K; Tanaka, T, 1996) |
| "In 56 patients with a 3d stage gastric cancer regional intraarterial chemotherapy with 5-fluorouracil was used pre- and postoperatively." | 1.29 | [The combined treatment of locally disseminated stomach cancer with intra-arterial regional chemotherapy]. ( Makarkin, NA; Tikhonov, VI; Tuzikov, SA; Zyrianov, BN, 1996) |
| "The chemosensitivity of various head and neck cancers was investigated with the 5-day rapid thymidine incorporation assay in soft agar culture." | 1.28 | Chemosensitivity of head and neck cancer with the rapid thymidine incorporation assay and its clinical application. ( Fujieda, S; Ohtsubo, T; Saito, H; Tanigawa, N, 1992) |
| "Highly purified fresh human gastric cancer cells could be obtained from 43 solid tumours and eight malignant ascites for the MTT assay." | 1.28 | Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay. ( Hotta, T; Iwahashi, M; Iwakura, S; Noguchi, K; Tamai, M; Tani, M; Tanimura, H; Tsunoda, T; Yamaue, H, 1992) |
| "A 60-year-old woman with gastric cancer had undergone partial gastrectomy in September 1989." | 1.28 | Complete disappearance of metastatic abdominal tumors from gastric cancer after treatment with irsogladine maleate. ( Hosokawa, T; Kajiwara, T; Ogawa, K; Otani, Y, 1992) |
| "Eighty-one cases of advanced gastric cancer, who had been treated by intra-arterial infusion chemotherapy, were examined for complications related to catheter indwelling." | 1.28 | [Complications related to catheter indwelling in intra-arterial infusion chemotherapy from the standpoint of the route of cannulation]. ( Arai, K; Kitamura, M; Miyashita, K, 1992) |
| "All the five patients in this study had gastric cancer with metastases and recurrent lesions in the liver or lymph node, or localized or with peritoneal spread." | 1.28 | [Evaluation of loco-regional cancer chemotherapy with assistance of home parenteral nutrition]. ( Hamano, K; Imai, S; Kirita, T; Mabuchi, G; Oishi, H; Seshimo, A; Yamada, Y; Yoneyama, K, 1992) |
| " Pharmaceutical dosage was set at approximately 30% of the increased life span (ILS) for Meth-A." | 1.28 | [Experimental study of the treatment of carcinomatous peritonitis in gastric cancer]. ( Arai, K; Kitamura, M; Miyashita, K, 1992) |
| " A marked pharmacokinetic advantage was observed when 5-FU and CDDP were administered." | 1.28 | [Large volume intraperitoneal chemotherapy as treatment for the peritoneal carcinomatosis from gastric cancer]. ( Ito, A; Ito, K; Kodera, Y; Kondo, K; Kuzuya, T; Nagai, S; Nakahara, H; Satta, T; Takagi, H; Yamauchi, M, 1992) |
| "Intra-abdominal panniculitis can result in mass lesions in the mesentery and omentum." | 1.28 | Intra-abdominal panniculitis can mimic recurrent stomach carcinoma. ( Cunningham, D; Husband, JE; MacVicar, D; Menzies-Gow, N; Taylor, R, 1992) |
| "A clone of human gastric cancer cells (AGS-6) and the parental line (AGS-P) from which it was isolated were used in cell survival studies to determine whether pretreatment for 24, 48 or 72h with alpha-difluoromethylornithine (DFMO, 5mM) would increase the cell's sensitivity to 5-Fluorouracil (5FU), Adriamycin (Adria), 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU), or Bleomycin (Bleo)." | 1.28 | Schedule dependent potentiation of antitumor drug effects by alpha-difluoromethylornithine in human gastric carcinoma cells in vitro. ( Barranco, SC; Ford, PJ; Ho, BY; Koester, SK; Reumont, KJ; Townsend, CM, 1990) |
| "Fifty patients with advanced gastric cancer underwent chemotherapy in accordance with the FAMTX protocol." | 1.28 | [Initial results of combined surgical-medical therapy for metastatic cancer of the stomach]. ( Henne-Bruns, D; Kremer, B; Weh, HJ, 1990) |
| "A group of 20 patients with gastric cancer, refractory to or with no change after two or three cycles of carboplatin were treated with etoposide/folinic acid/5-fluorouracil (ELF)." | 1.28 | Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. ( Achterrath, W; Harstrick, A; Meyer, HJ; Preusser, P; Schmoll, HJ; Seeber, S; Stahl, M; Wilke, H, 1991) |
| "A care system for cancer bearing patients at a highly advanced stage should be informed by a better quality of life based on a life style of the patients and their families." | 1.28 | [Nutritional support for cancer bearing patients]. ( Yamada, S, 1991) |
| "Ten patients with non-resectable gastric cancer were subjected to a neo-adjuvant chemotherapy (FLEP therapy), consisting of 4 drugs (leucovorin and 5-FU i." | 1.28 | [Evaluation of effective neo-adjuvant chemotherapy (FLEP therapy) in the treatment of advanced gastric cancer]. ( Ishihara, S; Mizuno, S; Nakajima, T; Nishi, M; Ohashi, Y; Ohta, K; Okumura, S; Toyoda, S; Tsuchiya, S, 1991) |
| "(3) In hepatic metastasis of breast cancer, arterial infusion therapy was more effective, and the survival period was prolonged significantly." | 1.28 | [Loco-regional cancer therapy for hepatic metastasis]. ( Aogi, K; Jinushi, K; Sawamura, A; Toge, T, 1991) |
| "Feasibility of utilizing human gastric cancers as first transplant generation xenografts in nude mice for determining tumor sensitivity to chemotherapeutic agents was demonstrated by applying subrenal capsule (SRC) assay." | 1.28 | Subrenal capsule assay using nude mice as a predictor of the response of the gastric cancer to chemotherapy. ( Akiyama, S; Ito, A; Ito, K; Kondo, K; Satta, T; Takagi, H; Watanabe, T; Yamauchi, M, 1991) |
| "Etoposide was found to be most effective against gastric carcinoma in this test." | 1.28 | [Chemosensitivity test for gastric cancer by in vitro MTT assay]. ( Endo, Y; Kimura, H; Kinoshita, K; Miyazaki, I; Ninomiya, I; Ohyama, S; Sasaki, T; Tanaka, M; Tugawa, K; Yonemura, Y, 1991) |
| "A 55-year-old woman with gastric cancer underwent laparotomy and was found to have an unresectable tumor characterized by S3 (invasion of the pancreas), N3, P0 and H0." | 1.28 | [A long-term survival case of advanced gastric cancer undergoing radical gastrectomy by second-look operation after successful chemotherapy (CDDP, MMC, 5-FU)]. ( Azuma, S; Furuta, T; Kawata, R; Kunieda, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H; Tanemura, H; Umemoto, T, 1991) |
| "5-fluorouracil (5-FU) was administered by arterial continuous infusion, adriamycin (ADM) and mitomycin C (MMC) by bolus infusion in the hospital, and continuous arterial 5-FU infusion and ADM low dose intermittent bolus infusion chemotherapy (AF therapy) was used for outpatients." | 1.28 | [Intraperitoneal administration of cis-platin with arterial infusion chemotherapy of advanced and recurrent gastric cancer]. ( Niitsu, Y; Saito, K; Sato, M; Takagane, A; Terashima, M; Yokkaichi, H, 1991) |
| "5-fluorouracil (5-FU) was orally administered before surgical operation to two groups of patients, one treated at 300 mg for 7 days and the other treated at 400 mg for 5 days, to examine the change of TSIR in gastric patients." | 1.28 | [Evaluation of pre-operative 5-fluorouracil treatment of the patients with gastric cancer--alteration of the inhibition rate of thymidilate synthetase by dose difference]. ( Iwai, H; Koh, Y; Nakamura, T; Nakano, H; Namatame, K; Sasaki, E; Shimada, K; Suzuki, K, 1991) |
| "Forty-four patients with advanced gastric cancer were treated with a combination including 5-fluorouracil, 4-epi-doxorubicin and mitomycin C." | 1.28 | Open phase II with 5-fluorouracil, 4-epi-doxorubicin and mitomycin C (FEM) in advanced gastric cancer. ( Kolarić, K; Luetić, J; Roth, A; Zupanc, D, 1990) |
| "One hundred and thirty-seven cases of stomach cancer given fluoropyrimidines (UFT: 66 cases, Tegafur: 58 cases, 5-FU: 13 cases) after gastrectomy as the adjuvant chemotherapy were examined as to appearance of macrocytic anemia." | 1.28 | [Macrocytic anemia as a possible adverse effect of fluoropyrimidines]. ( Arai, K; Awane, Y; Kitamura, M; Miyashita, K, 1990) |
| "The cases were comprised of 9 gastric cancers, 6 colorectal cancers, 1 appendiceal carcinoma, and 1 malignant tumor of retroperitoneum, all of which were observed to have peritoneal dissemination during surgical operations." | 1.28 | [Evaluation of intraperitoneal cancer chemotherapy using an implantable reservoir in patients with peritonitis carcinomatosa]. ( Katsuki, Y; Nishimura, A; Tsuji, Y; Yasuda, T, 1990) |
| "In case of breast cancer, it was 10 times higher than normal tissue." | 1.28 | [A study on pre-operative administration of 5'-DFUR in carcinomas of the gastric, breast, thyroid and colon]. ( Adachi, I; Douden, K; Hayashi, H; Hikishima, H; Iwa, T; Munemoto, Y; Okada, Y; Omura, K; Watanabe, Y, 1990) |
| "This study observed the effect of chemotherapy combined with Chinese herbs and western drugs on white blood cell count in 31 patients with gastric cancer." | 1.28 | [Clinical effect of chemotherapy combined with Chinese herbs and western drugs on leukocytes of gastric cancer patients]. ( Chen, JZ, 1990) |
| "The prognosis of unresectable advanced gastric cancer is extremely poor." | 1.28 | Locally advanced unresectable gastric cancer successfully resected after neoadjuvant chemotherapy with FADE regimen. ( Chung, HC; Kim, BS; Lee, JT; Lee, KB; Lee, SI; Min, JS; Park, YJ; Roh, JK, 1990) |
| "Fourteen patients with stage IV gastric cancer who underwent absolutely non-curative gastrectomy, received 5-FU infusion postoperatively." | 1.28 | [Efficacy of a 48-hour infusion of 5-fluorouracil in patients with stage IV gastric cancer after palliative gastrectomy]. ( Inamura, Y; Kanemitsu, T; Kato, K; Koike, A; Kojima, T; Matsumoto, K; Naruse, T; Saegusa, J; Suzumura, K; Yamamoto, S, 1990) |
| "5-Fluorouracil (5-FU) was administered by arterial continuous infusion, Adriamycin (ADM) and mitomycin C (MMC) were given by bolus infusion in the hospital, and continuous arterial 5-FU infusion and ADM low-dose intermittent bolus infusion chemotherapy (AF therapy) were used for outpatients at home." | 1.28 | [Long-term arterial infusion chemotherapy in advanced and recurrent gastric cancer patients at home and an interesting autopsy case]. ( Saito, K; Sato, M; Takagane, A; Terashima, M, 1990) |
| "In patients with gastric cancer, depending on location of a tumor, the left gastric or right gastroepiploic artery was catheterized via a puncture of the femoral artery, the course of polychemotherapy with fluorouracil and adriablastin was carried out, then the operative treatment was performed." | 1.28 | [Preoperative superselective intra-arterial polychemotherapy in combined treatment of gastric stomach]. ( Chernyĭ, VA; Eremenko, VN; Galakhin, KA; Iugrinov, OG; Shchepotin, IB; Tofan, AV, 1990) |
| "Forty-one patients with advanced gastric cancer underwent gastrectomy and the correlation between tissue uptake of the adjuvant drug and the prognosis were studied." | 1.28 | The uptake of anticancer drugs by tumor tissues and lymph node and the effectiveness of postoperative adjuvant chemotherapy on survival time. ( Arima, S; Futami, K; Shimura, H; Toriya, H, 1989) |
| "In 14 gastric cancer and 15 colonic cancer cases, to which UFT 400 mg/day and OK-432 2KE 2/W were administered orally and intra-muscularly for 2 weeks preoperatively until surgical treatment, intratumor 5-fluorouracil (5-FU) concentration was measured and compared with that of patients who given UFT 400 mg/day orally for 2 weeks (15 gastric cancer and 15 colonic cancer cases)." | 1.28 | [Influence of OK-432 on intratumor 5-fluorouracil concentration in cases given UFT]. ( Hosoi, H; Kitagawa, M; Sinmyo, K; Susaki, H; Suwa, H; Yamaguchi, K, 1989) |
| "Tegafur (FT) is a masked compound of 5-fluorouracil (5-FU) and supposed to be activated in the liver." | 1.28 | [Anti-tumor effect of fluoropyrimidines on human tumor cell lines transplanted in nude mice with CCl4-induced liver dysfunction]. ( Imai, S; Nio, Y; Ohgaki, K; Shiraishi, T; Tobe, T, 1989) |
| "Fifty-five gastric cancer patients with liver metastasis received arterial infusion chemotherapy." | 1.28 | [Arterial infusion chemotherapy in patients with gastric cancer in liver metastasis and long-term survival after treatment]. ( Arai, K; Kitamura, M; Kosaki, G; Miyashita, K, 1989) |
| " The dosage was 250 mg/day for 5-FU continuously, 10 mg/week for MMC and 5 KE/week for OK-432, respectively." | 1.28 | [Three cases of effective hepatic arterial infusion with OK-432, mitomycin C and 5-fluorouracil in liver metastasis from gastric cancer]. ( Hamada, H; Mori, N; Nakajima, I; Nakamura, T; Nakamura, Y; Tanaka, A; Wada, T; Yasutomi, M, 1989) |
| " The median dosage of FAM agents delivered to nonresponders was reduced." | 1.28 | 5-Fluorouracil, doxorubicin (adriamycin) and mitomycin-C (FAM) in advanced gastric cancer: observations on response, patient characteristics, myelosuppression and delivered dosage. ( Biran, H; Biran, S; Sulkes, A, 1989) |
| "Fifty-two non-resectable and recurrent cancer patients with prior treatment, were entered in this study; 1 esophageal, 33 gastric, 1 duodenal, 4 colorectal, 2 pancreatic, 2 bile duct, and 9 breast cancer." | 1.28 | [Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients]. ( Hattori, T; Jinushi, K; Kim, R; Niimoto, M; Saeki, K; Saeki, T; Toi, M; Yanagawa, E; Yoshinaka, K, 1989) |
| "Overall median survival was 352 days in colon cancer and 449 days in gastric cancer." | 1.28 | [A 5-FU, ADR, MMC combined hepatic arterial infusion therapy in non-resectable liver metastases from colon and gastric cancer]. ( Arai, Y; Endo, T; Kido, C; Miyake, Y; Sakamoto, K, 1989) |
| "5-fluorouracil (5-FU) was administered by arterial continuous infusion, and adriamycin (ADM) and mitomycin C (MMC) by bolus infusion." | 1.28 | [Clinical effectiveness of arterial infusion chemotherapy in advanced and recurrent gastric cancer]. ( Odaka, Y; Oikawa, K; Saito, K; Sato, M; Takagane, A; Terashima, M, 1989) |
| "Six patients with hepatocellular carcinoma (HCC) and 9 patients with metastatic liver carcinoma (MLC) (4 with stomach cancer, 4 with pancreas cancer and 1 with colon cancer) were treated with rapid hepatic artery infusion of adriamycin." | 1.27 | [Intraarterial Adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma]. ( Hino, I; Kimura, I; Kuroda, S; Numoto, A; Ohnoshi, T; Takahashi, M; Tsuji, M; Ueoka, H, 1984) |
| "Two cases of gastric cancer were treated with immunochemotherapy using Tegafur and Schizophyllan." | 1.27 | [Immunochemotherapy with tegafur and schizophyllan for stomach cancer--report of 2 cases]. ( Abe, T; Fuse, Y; Nishida, K; Takino, T; Yokota, S; Yoshida, J, 1983) |
| "We found that this conversion in human tumors was catalyzed not by uridine phosphorylase but by thymidine phosphorylase." | 1.27 | [5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues]. ( Hara, Y, 1984) |
| "One partial remission out of 7 cases of stomach cancer was obtained, and its duration was 40 weeks." | 1.27 | [Clinical trial on the effect of tegafur (SF-SP)]. ( Akazawa, S; Futatsuki, K; Hattori, M; Ishibashi, I; Kanda, Y; Sendai, H; Shimada, S, 1984) |
| "Thirty patients with advanced gastric cancer were treated with a combination chemotherapy consisting of adriamycin 20-30 mg/m2 iv day 1 q3wks, mitomycin C 2." | 1.27 | [Combination chemotherapy of advanced gastric cancer with adriamycin, mitomycin C, and ftorafur]. ( Ezaki, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Miyamoto, H; Nakada, H; Ogawa, M; Okada, Y; Usui, N, 1983) |
| " Determination of 5-FU concentrations in blood, normal and tumor tissues following a long term administration of Tegafur was performed." | 1.27 | [Enzymatic conversion of tegafur in human tumor tissue]. ( Hara, Y; Kono, A; Sugata, S; Tanaka, M, 1983) |
| "Advanced gastric cancer cases (42 cases) undergone gastrectomy were studied on the correlation between tissue uptakes and prognosis." | 1.27 | [Study on the correlation between tissue uptake of anticancer agents and prognosis -- with special reference to Tegafur]. ( Arima, S; Futami, K; Jyozaki, H; Kinashi, M; Shigeta, M; Shimura, H, 1983) |
| "FT and 5-FU fractions in cancer tissues were found to be higher than those of the patients receiving only 800 mg of Tegafur fine granules as previously reported." | 1.27 | [UFT concentration in various tissues from cancer patients]. ( Bekki, E; Hashimoto, I; Kasai, Y; Mikami, J; Nakamura, T; Nakanishi, Y; Nishi, H; Nishindai, H; Sawada, Y; Yoshimoto, M, 1983) |
| "In the inoperable Borrmann type 4 Gastric cancer, which is to be used as a synonym of gastric scirrhus clinically, it is regrettable but effect is hardly expected from radiotherapy or immunotherapy, and the treatment relies entirely on chemotherapy." | 1.27 | [Chemotherapy of unresectable Borrmann's type IV stomach cancer]. ( Izumi, T; Kurihara, M; Maruyama, T; Miyasaka, K; Sasaki, Y, 1983) |
| "CR was observed in one case of breast cancer, and PR in 29 cases." | 1.27 | [Cooperative phase II study of spansule tegafur (SF-SP)]. ( Taguchi, T, 1984) |
| "We studied 161 gastric cancer patients with P0, H(+) and 51 colorectal cancer patients with P0, H(+) from among cancer patients of the digestive organs and obtained the following conclusions." | 1.27 | [Basic and clinical studies on metastatic cancer--with special reference of multidisciplinary treatment of gastric and colorectal cancer patients with hepatic metastasis]. ( Hanaoka, A; Isono, K; Kimura, M; Koide, Y; Okuyama, K; Onoda, S; Ryu, M; Satoh, H; Tohnosu, N; Yamamoto, Y, 1983) |
| "An 80-yr-old man with advanced gastric cancer was admitted on September 10, 1982." | 1.27 | A case of gastric cancer achieving a complete response by chemotherapy. ( Yoshikawa, K, 1984) |
| "Eighty-four patients with advanced gastric cancer treated in four centres in Scotland between June 1980 and December 1982 were reviewed following treatment with 5-fluorouracil, adriamycin and mitomycin-C (FAM)." | 1.27 | Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C. ( Allan, SG; Calman, KC; Carter, DC; Cunningham, D; Hutcheon, AW; Kaye, SB; McArdle, CS; Sangster, G; Smyth, JF; Soukop, M, 1984) |
| " Although the dosage of the anticancer chemotherapy was quite small, this treatment may have promoted the regression of the tumor in conjunction with activated antitumor immunity of the host." | 1.27 | [A case of advanced gastric cancer which disappeared histopathologically after short-time chemotherapy]. ( Furuta, K; Hara, K; Kiyomitsu, Y; Nakazaki, S; Shinoda, M; Watanabe, K; Yajima, K; Yasuda, S; Yokoyama, T, 1984) |
| " Paradoxical dose-response relationships for cytostatic agents or radiation in vitro point to artifacts." | 1.27 | Chemosensitivity testing of human neoplasms using the soft agar colony assay. ( Flentje, D; Schlag, P, 1984) |
| "Twenty-one patients with advanced gastric cancer were treated with a combination chemotherapy of adriamycin and 5-fluorouracil (AF)." | 1.27 | [Co-administration of adriamycin and 5-fluorouracil for the treatment of advanced stomach cancer]. ( Ezaki, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Miyamoto, H; Nakada, H; Ogawa, M; Usui, N, 1983) |
| "However, against colo-rectal and stomach cancer, the response rate was only 25% (2/8) and 28." | 1.27 | [Chemotherapy and total body hyperthermia]. ( Kato, N; Yamanaka, N, 1985) |
| "The ability of human gastric cancer clones to recover from potentially lethal damage was studied." | 1.27 | Loss in cell killing effectiveness of anticancer drugs in human gastric cancer clones due to recovery from potentially lethal damage in vitro. ( Barranco, SC; Townsend, CM, 1986) |
| "Investigations were made on 76 cases of scirrhous carcinoma of the stomach in the care of our department, and the treatment methods in these cases were as follows: 1) Lymph node dissection: Lymphadenectomy of over R2 is performed." | 1.27 | [Treatment methods for scirrhous carcinoma of the stomach--with special reference to total gastrectomy and chemotherapy in early postoperative period]. ( Hamakubo, S; Higashino, K; Nabeya, K; Nyumura, T, 1988) |
| "For the response of advanced gastric cancer to chemotherapy in the National Cancer Center Hospital, the combined use of UFT and Mitomycin C gave the highest rate, 46%." | 1.27 | Radiation therapy for advanced gastric cancer. ( Akine, Y; Egawa, S; Hijikata, J; Kajiura, Y; Kitagawa, T; Ogino, T; Tsukiyama, I; Yamashita, K, 1988) |
| "She died from general metastasis seven months after the radical mastectomy in spite of adjuvant immunochemotherapy." | 1.27 | [A case of bilateral metastatic breast carcinoma from gastric carcinoma]. ( Hanamura, N; Iida, F; Kasuga, Y; Katsuyama, T; Oota, H; Senga, O; Tsuchiya, S, 1986) |
| "Moreover, human pancreatic cancer cells were completely eliminated after incubation with 5-fluorouracil (0." | 1.27 | [Combined effect of interferons alpha, beta and gamma on tumor growth in vitro]. ( Kimoto, Y, 1986) |
| " However, increase in tegafur dosage volume did not correlate with 5-FU levels." | 1.27 | [5-FU concentration in the blood and tissue of patients with gastric and colorectal cancer after administration of UFT or tegafur]. ( Arima, S; Futami, K; Kinashi, M; Shigeta, M; Shimura, H, 1986) |
| "A 55-year-old woman with gastric cancer underwent laparotomy and was found to have an unresectable tumor at the MC region, characterized by S3 (invasion into the pancreas), N3, P0, H0, Borrmann-II and moderately differentiated tubular adenocarcinoma." | 1.27 | [Successful treatment of advanced gastric cancer by combined cisplatinum, mitomycin C and 5-FU administration. A case report]. ( Ando, T; Azuma, S; Furuta, T; Kawata, R; Ohashi, H; Saji, S; Shimokawa, K; Suzuki, M; Tanemura, H; Tsuya, H, 1987) |
| "Five-fluorouracil was measured by GC-MF method and FT-207 was also done by HPLC method." | 1.27 | [The effect of tegafur suppository and glutathione in patients with gastric and colonic cancer with special reference to the histopathological anticancer effect]. ( Fukuzumi, N; Ikeda, Y; Kaga, F; Kitajima, M; Kiuchi, T; Okada, N, 1987) |
| "A 65-year-old man with gastric cancer showing multiple liver metastases was treated with recombinant interferon-gamma (KW-2202) and 5-fluorouracil (5-FU)." | 1.27 | [A case of gastric cancer with multiple liver metastases responding to combination therapy of recombinant interferon-gamma (KW-2202) and 5-FU]. ( Hisatsugu, T; Katano, M; Kitajima, Y; Sato, S; Uchida, Y; Yamamoto, H, 1987) |
| "Twenty patients with advanced gastric cancer were treated with FAP." | 1.27 | [Combination chemotherapy of 5-fluorouracil (5-FU), adriamycin (ADM), cis-diamminedichloroplatinum (II) (CDDP) and mitomycin C (MMC) (FAP.MMC) in advanced gastric cancer]. ( Horikoshi, N; Imajo, K; Inoue, K; Ito, Y; Mukaiyama, T; Nagamine, D; Ogawa, M; Ozeki, H; Shinagawa, K, 1988) |
| "Forty-one patients with advanced gastric cancer underwent gastrectomy, and the correlation between tissue uptake of the adjuvant drug and the prognosis were studied." | 1.27 | [Uptake of anticancer drugs by target organs and the usefulness of adjuvant chemotherapy]. ( Arima, S; Futami, K; Sakaida, R; Shigeta, M; Shinohara, T; Tateishi, S; Yoshimura, S, 1988) |
| "Fifteen patients with stomach cancer and colorectal cancer were orally administered 600 mg of UFT before operation and the concentration of tegafur, 5-fluorouracil (5-FU) and uracil in the tissues and serum were measured by chemical assay." | 1.27 | [The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT]. ( Kikuchi, K; Kunii, Y; Mori, Y; Nitta, A; Saitou, T; Takahashi, N, 1988) |
| "A 75-year-old man with gastric cancer metastatic to the liver was treated by combined administration of Tegafur (800 mg/body/day), 5-fluorouracil (300 mg/body/day) and Mitomycin C (hepatic arterial infusion of 20 mg/body and intravenous infusion of 8 mg/body)." | 1.27 | [Complete response in a case of unresectable gastric cancer with a combination of tegafur, 5-fluorouracil and mitomycin C]. ( Ito, T; Nehashi, Y; Sasaki, J; Sasaki, Y, 1988) |
| "The sensitivity of human gastric cancer tissue to 5-fluorouracil (5-FU) and its analogues 1-(2-tetrahydrofuryl)-5-fluorouracil (FT), UFT and 1-hexylcarbamoyl-5-fluorouracil (HCFU) was determined, using the in vivo subrenal capsule (SRC) assay." | 1.27 | UFT is more antineoplastic against gastric carcinoma than 5-fluorouracil, 1-(2-tetrahydrofuryl)-5-fluorouracil and 1-hexylcarbamoyl-5-fluorouracil. ( Anai, H; Kusumoto, H; Kusumoto, T; Maehara, Y; Sugimachi, K, 1988) |
| "Fluorodeoxyuridylate (FdUMP) was assayed by isotope dilution of [3H]FdUMP binding to bacterial TS; free and total TS was determined by [3H]FdUMP binding; and deoxyuridylate (dUMP) was assayed by conversion to [14C]thymidylate." | 1.27 | Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. ( Berne, M; Bernstein, L; Frösing, R; Gustavsson, BG; Hayes, AA; Spears, CP, 1988) |
| "In analysing the anticancer effects of TBHT according to cancer site, a high efficacy was observed in patients with their main tumor in the lung, liver and lymph nodes." | 1.27 | [Clinical results and problems of total-body thermochemotherapy]. ( Hamazoe, R; Inoue, Y; Ishiguro, M; Koga, S; Maeta, M; Murakami, A; Sawata, T; Shimizu, N; Shimizu, T, 1988) |
| "Sixty-one patients with advanced gastric cancer who had received preoperative 5-FU dry syrup administration and who had also undergone curative resection between 1976 and 1982, in addition to postoperative chemotherapy (more than 20 mg MMC, 5,000 mg 5-FU), (Group A) were admitted to the present study." | 1.27 | [End result of preoperative adjuvant chemotherapy with oral 5-FU dry syrup in gastric cancer]. ( Izuo, M; Miyamoto, Y; Takeshita, M, 1988) |
| "We treated 24 patients with gastric cancer for whom no surgery was indicated because of serious complications or patient's refusal." | 1.27 | [The significance of endoscopic treatment of early gastric cancer]. ( Maeda, C; Muto, T; Nashimoto, A; Sasaki, K, 1988) |
| "In patients with colorectal cancer metastatic to the liver, partial response (PR) rates in Regimens I and II were 38% and 62%, respectively." | 1.27 | Intra-hepato-arterial chemotherapy with CDDP and 5-FU for metastases to the liver from colorectal and gastric cancers. ( Hamazoe, R; Ishiguro, M; Koga, S; Maeta, M; Murakami, A; Sawada, T; Shimizu, N, 1988) |
| "In summary, in this phase II study on gastric cancer, although the response was limited with A, the relatively high response rate of 40." | 1.27 | [Biochemical modulation with sequential methotrexate (MTX)-5-fluorouracil (5-FU) treatment]. ( Murakami, M; Ota, K, 1987) |
| "The therapy of advanced stomach cancer is used to exemplify the clinicians' thoughts when confronted with the decision of adapting a standard treatment for a particular disease." | 1.27 | [Medical decision in clinical oncology: the example of drug therapy of gastric cancer in the advanced stage during the last decade]. ( Kenis, Y, 1987) |
| "In most cases of metastatic gastric cancer, treatment with cytostatic drugs seems to be justified." | 1.27 | [Chemotherapy of metastatic gastric cancer--x-ray follow-up]. ( Hofmann-Preiss, K; Theobaldy, S; Walter, M, 1987) |
| "In the colorectal cancer group, the response rate for Regimen A was 28." | 1.27 | [Sequential methotrexate-5-fluorouracil (MTX-5-FU) treatment of patients with advanced gastric and colorectal cancer. Sequential Methotrexate-5-FU Study Group]. ( Akazawa, S; Futatsuki, K; Kanamaru, R; Miyazaki, T; Murakami, M; Niitsu, Y; Ota, K; Sakai, Y; Wakui, A; Yokoyama, M, 1987) |
| " The possible mechanisms of these toxic effects, as well as the drug interactions are briefly discussed." | 1.27 | Cardiotoxicity during chemotherapy for advanced gastroenteric tumors. ( Bisol, A; Ferrante, F; Fiori, G; Galeone, M; Raina, A, 1987) |
| "4 of the 23 completed cases with stomach cancer were judged as PR, and the response rate was 19." | 1.27 | [Phase II study of 590-S (1-phthalidyl-5-fluorouracil) in patients with gastrointestinal cancer. Tokyo Cancer Chemotherapy Cooperative Group]. ( Furue, H; Nakatsu, T; Takahashi, H, 1987) |
| "A 51-year-old man with recurrent gastric cancer was treated by combined administration of Cisplatin and Carmofur." | 1.27 | [A case of recurrent gastric cancer successfully treated with a combination of cisplatin and carmofur]. ( Abe, S; Akazawa, S; Fujiki, T; Futatsuki, K; Kanda, Y; Kuwatsuru, R; Saifuku, K; Yamamoto, K; Yoon, S; Yoshida, K, 1987) |
| " The preclinical pharmacokinetic studies revealed a steep increase and rapid decrease of 590-S and activated 5-FU in the blood compared with those of other fluorinated pyrimidines." | 1.27 | [Pharmacokinetic studies of a new fluorinated pyrimidine, 590-S (PH-FU), in human patients]. ( , 1986) |
| "The dominant location of metastasis was the liver in 21 pts (48." | 1.27 | Chemotherapy of advanced gastric cancer: a study of 43 consecutive cases treated with fluorouracil, adriamycin and mitomycin C (FAM). ( Amadori, D; Amadori, M; Biserni, R; Bonaguri, C; Faedi, M; Gentilini, P; Ravaioli, A; Ridolfi, R, 1986) |
| "In a phase II multicenter trial, 71 patients with advanced measurable gastric cancer were registered to receive sequential high-dose methotrexate (MTX) and 5-fluorouracil (5-FU) combined with Adriamycin (A [Adria Laboratories, Columbus, OH])." | 1.27 | An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. ( Bleiberg, H; Blijham, G; Dalesio, O; Duez, N; Mulder, N; Planting, A; Splinter, T; Wils, J, 1986) |
| " Of the 66 patients with colorectal carcinoma, 44 had not been previously treated with cytostatics and 22 were resistant to previous chemotherapy with 5-FU given either as a single agent or combined with other drugs." | 1.27 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update. ( Chollet, P; Goldschmidt, E; Machover, D; Mathé, G; Misset, JL; Schwarzenberg, L; Vanden-Bulcke, JM, 1985) |
| "Preoperative cancer chemotherapy for gastric cancer was reviewed with special emphasis on histologic findings and survival." | 1.27 | [Preoperative cancer chemotherapy for gastric cancer]. ( Endoh, F; Fujimoto, S; Kawata, S; Kurihara, M; Miyazaki, M; Ohta, M; Shimura, T; Sugasawa, H; Takahashi, O; Udagawa, I, 1985) |
| "At present hyperthermia shows great promise when combined with other modalities." | 1.27 | [Clinical application of local hyperthermia combined with antineoplastic agents]. ( Ishiwata, J; Iwamoto, S; Koike, M; Maeda, Y; Masuda, T; Sasaki, T; Takeshita, Y; Tanaka, Y, 1985) |
| "Advanced gastric cancer patients were continuously infused with 5-FU at a dose of 500 mg/day under TPN." | 1.27 | [Continuous venous infusion of 5-fluorouracil (5-FU) under total parenteral nutrition (TPN) in advanced gastric cancer]. ( Kido, Y; Kokunai, I; Miyamoto, T; Mori, T; Ogawa, M; Ogawa, Y; Shiozaki, H; Tane, S; Watase, M, 1985) |
| "Twenty-one patients were treated with sequential doses of MTX and 5-FU so as to be classified by MTX dosage into an intermediate MTX-dose group and a high MTX-dose group." | 1.27 | [Therapeutic effect of sequential doses of methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced gastric cancer: comparison of intermediate-dose MTX with high-dose MTX]. ( Akazawa, S; Futatsuki, K; Honda, T; Kanda, Y; Kitagawa, H; Nakagawa, T; Nakajima, T; Suda, Y; Yoshida, S, 1985) |
| "In group A for gastric cancer and in group C for colon cancer, the histological response was stronger at the edge of the cancer than at its surface." | 1.27 | [Preoperative treatment with 5-fluorouracil (5-FU) in gastric and colorectal cancer]. ( Hashizume, Y; Hirano, M; Iwa, T; Kawaura, Y; Ohmura, K; Sakatoku, M; Takayama, K; Yamada, T, 1985) |
| "In 161 cases of gastric cancer with liver metastasis but without peritoneal dissemination, evaluations were executed to find effective treatment." | 1.27 | Evaluation of treatment for gastric cancer with liver metastasis. ( Isono, K; Juan, IK; Koide, Y; Ochiai, T; Okuyama, K; Onoda, S; Satoh, H; Yamamoto, Y, 1985) |
| "For stage I and II gastric cancer, radical gastrectomy and postoperative immunotherapy for 3 months would be the best treatment." | 1.27 | Immunochemosurgery for gastric cancer. ( Kim, JP, 1985) |
| "In a total of 45 patients with gastric cancer, tumor tissue level of 5-fluorouracil (5-FU) was determined at 2, 4, 6, 8, and 12 hours following the oral administration of drug, using a resected stomach specimen as material." | 1.26 | Studies on the designing of chemotherapy for gastric cancer in man, based on the tumor tissue concentration of anticancer agents. ( Isobe, K; Iwase, H; Kimura, K; Kuwabara, T; Sato, A; Suga, S; Takada, T; Yokoyama, Y; Yoshida, Y, 1982) |
| "UFT was given to two patients with carcinoid tumor of the stomach and the effect of the drug was evaluated." | 1.26 | [Two cases of carcinoid tumor of the stomach which responded to oral administration of UFT]. ( Hirota, T; Okazaki, N; Tajiri, H; Yamaguchi, H; Yoshida, S; Yoshimori, M, 1982) |
| "A total of 58 cases with inoperable advanced gastric carcinomas were treated by radiotherapy combined with tegafur, and the result was analyzed mainly from the aspects of life expectancies and some prognostic factors." | 1.26 | [Radiotherapy combined with tegafur for inoperable advanced gastric cancer]. ( Asakawa, H; Matsumoto, K; Otawa, H; Yamada, S, 1982) |
| "Thirty patients with gastric cancer were clinically studied by rectal administration of FT-207 suppository at a dose of 1500mg per day as a preoperative adjuvant chemotherapy." | 1.26 | [Evaluation of pre-operative chemotherapy using FT-207 suppositories combined with glutathione--with special reference to histopathological antitumor effect]. ( Fukuzumi, N; Ikeda, Y; Kaga, F; Kitajima, M; Seki, M; Sohma, S; Yagita, A, 1982) |
| " Conclusion ACNU has a strong antitumor activity and may be more effective if combined with antimetabolite agent, such as 5FU." | 1.26 | [Physiological effects and antitumor efficiency of ACNU in postoperative patients with stomach cancer--an evaluation of the treatment combined with FT-207 or 5-FU dry syrup]. ( Inuo, T; Kaneko, H; Ohashi, A; Sekizawa, Y; Tsuchiya, S, 1982) |
| "Fifteen cases with advanced cancer were treated with UFD-1 (mixture of FD-1 and uracil under molar ratio of 1: 20) in a daily dose of 300 mg of FD-1." | 1.26 | [Clinical experiences with UFD-1]. ( Furue, H, 1982) |
| "Forty patients with gastric cancer and 30 patients with colon cancer were administered FT-207 prior to the operation." | 1.26 | [Tissue concentration of 5-FU following pre-operative administration of FT-207]. ( Fukao, K; Ishikawa, A; Iwasaki, Y; Nagoshi, K; Okamura, T; Orii, K; Ozaki, A; Sarashina, H; Takase, Y; Takeshima, T; Todoroki, T, 1982) |
| "The levels of anticancer drugs in tissue were measured by bioassay method in 28 patients with gastrointestinal cancer, who were treated with intravenous administration of 500 mg of 5-FU combined with ANG-II during surgery." | 1.26 | [Clinical studies of cancer chemotherapy combined with angiotensin-II (ANG-II)]. ( Kanno, H; Kikuchi, K; Kunii, Y; Takahashi, N, 1982) |
| "Of the 31 patients with stomach cancer who were evaluable for response and had had no previous chemotherapy, 12 (39%) achieved complete or partial remission." | 1.26 | Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas. ( Bennetts, RW; Heifetz, LJ; Jones, RD; Karlin, DA; Mahal, PS; Stroehlein, JR, 1982) |
| "For the diffuse invasive type of gastric cancer, the changes in the X-ray finding such as stiffness and poor elasticity of gastric wall and malignant relief were also taken into consideration for the judgement." | 1.26 | [Evaluation of the therapeutic effect of HCFU (1-hexylcarbamoyl-5-fluorouracil) on non-resectable stomach cancer]. ( Chin, F; Hirasawa, H; Isono, K; Kimura, M; Kouzu, T; Okuyama, K; Onoda, S; Ryu, M; Sato, H; Satoh, H; Tounosu, N; Yamamoto, Y, 1982) |
| " Twelve (33%) of the 36 patients reported adverse effects: gastrointestinal symptoms in 8, CNS symptoms in 3, and others in 1." | 1.26 | [TAC-278. A new 5-FU derivative, by the oral route for its efficacy and safety in 36 patients with advanced cancers]. ( Arimori, S; Furue, H; Ikenaga, M; Iketa, T; Komita, T; Nagao, T; Ohki, S; Satoh, H; Watanabe, K; Yamamoto, S, 1982) |
| "In the chemotherapy for gastric cancer, the most sensitive anticancer agent against individual tumors should be prescribed." | 1.26 | Sensitivity of anticancer agents of human gastric cancers transplanted into nude mice. ( Hattori, T; Nishimawari, K; Nosoh, Y; Tani, T, 1981) |
| "Seven gastric cancer patients were treated in this manner, and 4 gastric cancer patients treated with 5-FU alone to serve as the control." | 1.26 | The effect of oral administration of amphotericin B on the incorporation of 5-fluorouracil into human gastric cancer tissue. ( Nakazawa, I; Ouchi, E; Ouchi, K; Wagai, K, 1981) |
| "After confirming the presence of gastric cancer, 1-n-hexylcarbamoyl-5-fluorouracil (HCFU), a derivative of 5-fluorouracil, was given to the dogs orally as capsules at a daily dose of 5 or 10 mg/kg body weight." | 1.26 | Chemotherapeutic study on canine gastric cancer induced by N-ethyl-N'-nitro-N-nitrosoguanidine. ( Aoyagi, M; Hirashima, T; Hirota, T; Kawachi, T; Matsukura, N; Sugimura, T; Takasugi, T; Uchida, E; Ushio, K; Yoshida, S, 1980) |
| "Less than 20% of advanced colorectal cancers respond to chemotherapy." | 1.26 | Chemotherapy for gastrointestinal malignancy. ( Balint, JA; Van der Veer, LD, 1980) |
| " The protocol comprises the administration of large-dose of Mitomycin-C (20+10) mg just after gastrectomy and the long-term administration of PSK, FT-207 or (PSK+FT-207)." | 1.26 | Post-operative long-term adjuvant immunochemotherapy with mitomycin-C, PSK and FT-207 in gastric cancer patients. ( Hattori, T; Koh, T; Nakano, A; Niimoto, M; Nishimawari, K; Oride, M; Takiyama, W, 1979) |
| "Fifteen patients with advanced gastric cancer were treated with the combination of Ftorafur, Adriamycin and mitomycin-C (FAM II)." | 1.26 | A phase II trial of ftorafur: adriamycin and mitomycin-C (FAM II) in advanced gastric adenocarcinoma. ( Haller, DG; Hoth, DF; MacDonald, JS; Rosenoff, S; Schein, PS; Smythe, T; Woolley, PV, 1979) |
| "Up to date of the total number of gastric cancer patients, who referred to the polyclinic, only 13% were found to be curable, 27%--may be treated without any guarantee of success, while 60% of patients were incurable." | 1.26 | [Chemotherapy of stomach cancer in an oncology office]. ( Gusarov, IuP, 1979) |
| "In additional 13 cases with gastric cancer, the active 5-FU concentrations in the regional lymph nodes were determined." | 1.26 | Histological evaluation of the effect of 5-FU emulsion on lymph node metastasis of stomach cancer. ( Cho, K; Fujita, Y; Majima, S; Morisawa, K; Nakao, E; Nishioka, B; Takahashi, T; Ueda, T; Watanabe, S, 1978) |
| "The therapy of cancer of the colon still remains unsatisfactory: the rate of remissions could be increased, but survival remains unaltered." | 1.26 | [Current state of therapy for gastrointestinal tumors]. ( Hartmann, D; Obrecht, JP, 1978) |
| "A series of 156 patients with gastric cancer during a 15-year period were reviewed retrospectively to determine the effectiveness of combined surgery and adjuvant chemotherapy." | 1.26 | The treatment of gastric cancer with combined surgical resection and chemotherapy. ( Cruz, AB; Franz, JL, 1977) |
| "Although advanced gastrointestinal cancer is the most commonplace problem encountered by the medical oncologist, this group of diseases has proved exceedingly resistant to past chemotherapy efforts." | 1.25 | Clinical management of advanced gastrointestinal cancer. ( Moertel, CG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 679 (19.60) | 18.7374 |
| 1990's | 607 (17.52) | 18.2507 |
| 2000's | 896 (25.86) | 29.6817 |
| 2010's | 1051 (30.33) | 24.3611 |
| 2020's | 232 (6.70) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, XH | 1 |
| Liu, HF | 1 |
| Chen, J | 19 |
| Yang, Y | 12 |
| Song, BA | 1 |
| Bai, LS | 1 |
| Liu, JX | 1 |
| Zhu, HL | 2 |
| Qi, XB | 1 |
| Zheng, QZ | 1 |
| Zhang, XM | 1 |
| Xu, Y | 8 |
| Cheng, K | 1 |
| Jiao, QC | 1 |
| Shen, QK | 1 |
| Liu, CF | 1 |
| Zhang, HJ | 1 |
| Tian, YS | 1 |
| Quan, ZS | 1 |
| Zhao, TQ | 1 |
| Zhao, YD | 1 |
| Liu, XY | 1 |
| Li, ZH | 1 |
| Wang, B | 13 |
| Zhang, XH | 3 |
| Cao, YQ | 1 |
| Ma, LY | 2 |
| Liu, HM | 6 |
| Zhao, JW | 2 |
| Wu, ZH | 1 |
| Guo, JW | 1 |
| Huang, MJ | 1 |
| You, YZ | 1 |
| Huang, LH | 1 |
| Gao, QL | 2 |
| Wu, BW | 3 |
| Li, D | 5 |
| Shi, L | 2 |
| Zhu, T | 3 |
| Lou, JF | 1 |
| Jin, CY | 2 |
| Zhang, YB | 4 |
| Zhang, SY | 6 |
| Song, J | 5 |
| Cui, XX | 2 |
| Wang, SH | 2 |
| Jin, CJ | 1 |
| Wang, SY | 1 |
| Fu, DJ | 1 |
| Li, YC | 2 |
| Wang, S | 19 |
| Ma, XB | 1 |
| Yuan, XH | 2 |
| Yu, B | 6 |
| Xu, YC | 3 |
| Xu, HW | 3 |
| Jia, S | 2 |
| Liu, M | 7 |
| Li, X | 19 |
| Meng, X | 1 |
| Wu, X | 16 |
| Yu, L | 4 |
| Wang, M | 13 |
| Hikita, K | 1 |
| Yamakage, Y | 1 |
| Okunaga, H | 1 |
| Motoyama, Y | 1 |
| Matsuyama, H | 1 |
| Matsuoka, K | 2 |
| Murata, T | 2 |
| Nakayoshi, T | 2 |
| Oda, A | 1 |
| Kato, K | 18 |
| Tanaka, H | 11 |
| Asao, N | 1 |
| Dan, S | 1 |
| Kaneda, N | 1 |
| Liu, Y | 35 |
| Yuan, XY | 1 |
| Liu, WB | 2 |
| Li, YR | 1 |
| Yu, GX | 1 |
| Tian, XY | 1 |
| Fu, XJ | 1 |
| Zhang, QH | 2 |
| Li, XJ | 1 |
| Wang, SQ | 2 |
| Chen, XB | 1 |
| Ma, YH | 1 |
| Ma, WT | 1 |
| Zhou, ZK | 1 |
| Huang, X | 4 |
| Jiang, XR | 1 |
| Du, KJ | 1 |
| Sun, MZ | 1 |
| Zhang, H | 28 |
| Fang, H | 6 |
| Zhao, Y | 14 |
| Zhu, HM | 1 |
| Liu, HX | 2 |
| Chen, P | 2 |
| Liu, YQ | 4 |
| Luo, T | 1 |
| Li, Z | 18 |
| Deng, XM | 1 |
| Jiang, K | 2 |
| Liu, D | 5 |
| Zhang, HH | 1 |
| Shi, T | 1 |
| Liu, LY | 1 |
| Wen, HX | 1 |
| Li, QE | 1 |
| Wang, Z | 10 |
| Wang, H | 15 |
| Meng, Y | 1 |
| Yang, J | 9 |
| Huang, H | 7 |
| Zhu, C | 1 |
| Wang, C | 12 |
| Liu, FW | 1 |
| Huff, S | 1 |
| Kummetha, IR | 1 |
| Zhang, L | 22 |
| Wang, L | 20 |
| Bray, W | 1 |
| Yin, J | 7 |
| Kelley, V | 1 |
| Wang, Y | 27 |
| Rana, TM | 1 |
| Cordova-Delgado, M | 1 |
| Bravo, ML | 1 |
| Cumsille, E | 1 |
| Hill, CN | 1 |
| Muñoz-Medel, M | 1 |
| Pinto, MP | 1 |
| Retamal, IN | 1 |
| Lavanderos, MA | 1 |
| Miquel, JF | 1 |
| Rodriguez-Fernandez, M | 1 |
| Liao, Y | 3 |
| Corvalán, AH | 1 |
| Armisén, R | 1 |
| Garrido, M | 3 |
| Quiñones, LA | 1 |
| Owen, GI | 1 |
| Xia, S | 1 |
| Gu, Y | 8 |
| Fei, Y | 2 |
| Cao, Y | 10 |
| Wang, J | 39 |
| Lin, C | 10 |
| Li, H | 22 |
| He, H | 8 |
| Xu, J | 18 |
| Li, R | 11 |
| Liu, H | 22 |
| Zhang, W | 16 |
| Giommoni, E | 1 |
| Lavacchi, D | 1 |
| Tirino, G | 2 |
| Fornaro, L | 6 |
| Iachetta, F | 1 |
| Pozzo, C | 8 |
| Satolli, MA | 1 |
| Spallanzani, A | 1 |
| Puzzoni, M | 1 |
| Stragliotto, S | 2 |
| Sisani, M | 1 |
| Formica, V | 1 |
| Giovanardi, F | 1 |
| Strippoli, A | 2 |
| Prisciandaro, M | 2 |
| Di Donato, S | 2 |
| Pompella, L | 2 |
| Pecora, I | 2 |
| Romagnani, A | 1 |
| Fancelli, S | 1 |
| Brugia, M | 1 |
| Pillozzi, S | 1 |
| De Vita, F | 9 |
| Antonuzzo, L | 4 |
| Arai, H | 4 |
| Inoue, E | 1 |
| Yamaguchi, K | 26 |
| Boku, N | 32 |
| Hara, H | 2 |
| Nishina, T | 10 |
| Tsuda, M | 2 |
| Shitara, K | 10 |
| Shinozaki, K | 2 |
| Nakamura, S | 3 |
| Hyodo, I | 14 |
| Muro, K | 17 |
| Sasako, M | 9 |
| Terashima, M | 16 |
| Nakajima, TE | 10 |
| Kawada, J | 4 |
| Mizuno, M | 1 |
| Fukada, A | 1 |
| Nakano, M | 4 |
| Murotani, M | 2 |
| Nagano, S | 1 |
| Yoneda, N | 1 |
| Kidogami, S | 1 |
| Mokutani, Y | 1 |
| Kishimoto, T | 3 |
| Hashimoto, Y | 1 |
| Hirose, H | 2 |
| Yoshioka, S | 1 |
| Tamura, S | 6 |
| Sasaki, Y | 13 |
| Chen, Q | 6 |
| Wang, X | 29 |
| Ding, R | 1 |
| Zhang, Y | 29 |
| Jiang, L | 5 |
| Ouyang, J | 1 |
| Du, X | 1 |
| Högner, A | 1 |
| Al-Batran, SE | 25 |
| Siveke, JT | 2 |
| Lorenz, M | 1 |
| Bartels, P | 1 |
| Breithaupt, K | 4 |
| Malfertheiner, P | 1 |
| Homann, N | 11 |
| Stein, A | 3 |
| Gläser, D | 1 |
| Tamm, I | 1 |
| Hinke, A | 2 |
| Vogel, A | 1 |
| Thuss-Patience, P | 6 |
| Król, K | 1 |
| Pudełek, M | 1 |
| Krzysiek-Mączka, G | 1 |
| Wierdak, M | 1 |
| Muszyńska, B | 1 |
| Sułkowska-Ziaja, K | 1 |
| Krakowska, A | 1 |
| Ryszawy, D | 1 |
| Czyż, J | 1 |
| Ma, Y | 8 |
| Yan, S | 1 |
| Wang, P | 8 |
| Hu, J | 6 |
| Chen, S | 9 |
| Zhu, J | 6 |
| Chen, G | 7 |
| Zhou, Q | 3 |
| Yuan, J | 4 |
| Wu, Y | 7 |
| Guo, L | 2 |
| Liu, C | 3 |
| Ren, W | 1 |
| Rogers, JE | 2 |
| Trail, A | 2 |
| Ajani, JA | 38 |
| Quesada, S | 1 |
| Samalin, E | 9 |
| Thezenas, S | 2 |
| Khellaf, L | 1 |
| Mourregot, A | 2 |
| Portales, F | 2 |
| Mazard, T | 3 |
| Ychou, M | 12 |
| Adenis, A | 6 |
| Kuwabara, S | 1 |
| Murakawa, K | 1 |
| Kumagai, K | 5 |
| Takeuchi, Y | 2 |
| Wada, H | 1 |
| Ichinokawa, M | 1 |
| Matsumoto, J | 1 |
| Ono, K | 4 |
| Hirano, S | 1 |
| Moore, JL | 1 |
| Kumar, S | 2 |
| Santaolalla, A | 1 |
| Patel, PH | 1 |
| Kapiris, M | 1 |
| Van Hemelrijck, M | 1 |
| Maisey, N | 2 |
| Hill, M | 6 |
| Lagergren, J | 1 |
| Gossage, JA | 2 |
| Kelly, M | 1 |
| Chaudry, A | 2 |
| Allum, WH | 9 |
| Baker, CR | 1 |
| Cunningham, D | 51 |
| Davies, AR | 1 |
| Cheong, JH | 7 |
| Wang, SC | 1 |
| Park, S | 3 |
| Porembka, MR | 1 |
| Christie, AL | 1 |
| Kim, H | 9 |
| Kim, HS | 14 |
| Zhu, H | 5 |
| Hyung, WJ | 7 |
| Noh, SH | 23 |
| Hu, B | 3 |
| Hong, C | 1 |
| Karalis, JD | 1 |
| Kim, IH | 4 |
| Lee, SH | 12 |
| Hwang, TH | 1 |
| He, L | 2 |
| Chen, H | 10 |
| Qi, Q | 3 |
| Wu, N | 1 |
| Chen, M | 6 |
| Feng, Q | 1 |
| Dong, B | 3 |
| Jin, R | 1 |
| Ai, K | 1 |
| Yuan, D | 1 |
| Zheng, J | 4 |
| Moussa, O | 1 |
| Bhogal, RH | 1 |
| Malietzis, G | 1 |
| Fribbens, C | 1 |
| Starling, N | 8 |
| Gerlinger, M | 1 |
| Watkins, D | 2 |
| Chau, I | 10 |
| Rao, S | 8 |
| Yu, J | 18 |
| Gao, Y | 4 |
| Chen, L | 23 |
| Wu, D | 3 |
| Shen, Q | 2 |
| Zhao, Z | 2 |
| Liu, W | 12 |
| Yang, H | 4 |
| Zhang, Q | 9 |
| Hu, P | 1 |
| Zheng, Z | 6 |
| Xu, Z | 6 |
| Yan, Z | 5 |
| Jin, M | 3 |
| Liu, X | 15 |
| Zhu, K | 3 |
| Shou, C | 3 |
| Wu, JQ | 2 |
| Fan, RY | 1 |
| Zhai, J | 3 |
| Li, CY | 2 |
| Wei, P | 2 |
| Shen, LZ | 2 |
| He, MF | 2 |
| Huang, XE | 3 |
| Rosati, G | 7 |
| Cella, CA | 2 |
| Cavanna, L | 3 |
| Codecà, C | 1 |
| Mosconi, S | 4 |
| Luchena, G | 1 |
| Silvestris, N | 3 |
| Bernardini, I | 1 |
| Casaretti, R | 5 |
| Zoratto, F | 1 |
| Amoroso, D | 1 |
| Ciarlo, A | 1 |
| Barni, S | 8 |
| Cascinu, S | 24 |
| Davite, C | 1 |
| Di Sanzo, A | 1 |
| Casolaro, A | 1 |
| Bilancia, D | 3 |
| Labianca, R | 14 |
| Zhou, F | 2 |
| Ding, W | 2 |
| Mao, Q | 1 |
| Jiang, X | 4 |
| Zhao, X | 10 |
| Xu, W | 5 |
| Huang, J | 8 |
| Zhong, L | 3 |
| Sun, X | 7 |
| Aktürk Esen, S | 1 |
| Ergun, Y | 1 |
| Erol, C | 1 |
| Arikan, R | 1 |
| Er, MM | 1 |
| Atci, MM | 2 |
| Topçu, A | 1 |
| Uçar, G | 1 |
| Akagündüz, B | 2 |
| Aykan, MB | 1 |
| Özen, M | 1 |
| Baytemur, NK | 1 |
| Özçelik, M | 1 |
| Şahin, E | 1 |
| Güven, D | 1 |
| Menekşe, S | 1 |
| Ak, N | 1 |
| Teker, F | 2 |
| Kut, E | 2 |
| Şakalar, T | 1 |
| Alan, Ö | 1 |
| Kaçan, T | 1 |
| Turhal, NS | 1 |
| Kiliçkap, S | 1 |
| Türker, S | 1 |
| Şendur, MAN | 1 |
| Köstek, O | 2 |
| Karaağaç, M | 1 |
| Sakin, A | 1 |
| Türk, HM | 2 |
| Çağlayan, D | 1 |
| Cihan, Ş | 1 |
| Açikgöz, Y | 1 |
| Uncu, D | 7 |
| Ouyang, S | 1 |
| Lou, L | 1 |
| Huang, Q | 2 |
| Zhang, Z | 15 |
| Mo, J | 1 |
| Li, M | 10 |
| Lu, J | 4 |
| Chu, Y | 3 |
| Lin, Z | 2 |
| Yue, P | 1 |
| Turkson, J | 1 |
| Liu, P | 9 |
| Zhang, X | 29 |
| Janjigian, YY | 6 |
| Van Cutsem, E | 18 |
| Wainberg, Z | 2 |
| Molena, D | 1 |
| Marcovitz, M | 1 |
| Ruscica, D | 1 |
| Robbins, SH | 1 |
| Negro, A | 1 |
| Tabernero, J | 3 |
| Ma, WL | 2 |
| Chang, N | 2 |
| Yu, Y | 6 |
| Su, YT | 1 |
| Chen, GY | 1 |
| Cheng, WC | 2 |
| Wu, YC | 1 |
| Li, CC | 1 |
| Chang, WC | 3 |
| Yang, JC | 3 |
| Dos Santos, M | 1 |
| Lequesne, J | 1 |
| Leconte, A | 1 |
| Corbinais, S | 1 |
| Parzy, A | 1 |
| Guilloit, JM | 2 |
| Varatharajah, S | 1 |
| Brachet, PE | 1 |
| Dorbeau, M | 1 |
| Vaur, D | 1 |
| Weiswald, LB | 1 |
| Poulain, L | 1 |
| Le Gallic, C | 1 |
| Castera-Tellier, M | 1 |
| Galais, MP | 1 |
| Clarisse, B | 1 |
| Ham, IH | 4 |
| Lee, D | 2 |
| Woo, J | 1 |
| Kim, TH | 3 |
| Jeong, HY | 4 |
| Oh, HJ | 2 |
| Choi, KS | 2 |
| Kim, TM | 3 |
| Hur, H | 4 |
| Huh, YJ | 1 |
| Cho, SY | 2 |
| Cho, MS | 1 |
| Lee, KE | 2 |
| Lee, JH | 28 |
| Tan, JN | 1 |
| Zhou, SN | 1 |
| Yang, B | 4 |
| Zhong, GY | 1 |
| Hu, H | 1 |
| Han, FH | 1 |
| Luo, ML | 1 |
| Pereira, MA | 1 |
| Dias, AR | 1 |
| Ramos, MFKP | 1 |
| Cardili, L | 1 |
| Moraes, RDR | 1 |
| Zilberstein, B | 1 |
| Nahas, SC | 1 |
| Mello, ES | 1 |
| Ribeiro, U | 1 |
| Zhu, Y | 6 |
| Hu, Y | 8 |
| Zhu, X | 12 |
| Zhang, J | 29 |
| Yuwen, D | 1 |
| Wei, X | 4 |
| Tang, C | 2 |
| Zhou, M | 3 |
| Dong, J | 2 |
| Ye, W | 2 |
| Huang, K | 2 |
| Pan, Y | 7 |
| Cen, J | 1 |
| Liang, Y | 5 |
| Shu, G | 1 |
| Ye, S | 4 |
| Lu, X | 5 |
| Cheng, X | 6 |
| Yang, F | 4 |
| Nie, W | 1 |
| Mahendra Upadhyay, A | 1 |
| Zhang, M | 3 |
| Wang, Q | 8 |
| Möhring, C | 2 |
| Timotheou, A | 2 |
| Mańczak, A | 2 |
| Sadeghlar, F | 2 |
| Zhou, T | 3 |
| Mahn, R | 2 |
| Bartels, A | 1 |
| Monin, M | 1 |
| Toma, M | 2 |
| Feldmann, G | 2 |
| Brossart, P | 2 |
| Köksal, M | 2 |
| Sarria, GR | 2 |
| Giordano, FA | 1 |
| Lingohr, P | 2 |
| Jafari, A | 2 |
| Kalff, JC | 2 |
| Strassburg, CP | 2 |
| Gonzalez-Carmona, MA | 2 |
| Zhao, L | 13 |
| Hollebecque, A | 1 |
| Kepp, O | 1 |
| Zitvogel, L | 1 |
| Kroemer, G | 1 |
| Huang, W | 5 |
| Han, Z | 2 |
| Sun, Z | 4 |
| Feng, H | 1 |
| Yuan, Q | 1 |
| Chen, C | 4 |
| Yu, S | 4 |
| Li, G | 12 |
| Jiang, Y | 6 |
| Xu, C | 3 |
| Yu, K | 3 |
| Zhang, P | 5 |
| Qin, J | 3 |
| Ti, G | 1 |
| Guo, Z | 5 |
| Li, L | 6 |
| Lv, Y | 3 |
| Guo, R | 1 |
| Chen, Y | 22 |
| Meng, D | 1 |
| Li, F | 7 |
| Ahn, MS | 4 |
| Choi, YW | 2 |
| Kang, SY | 5 |
| Choi, JH | 6 |
| Lee, HW | 8 |
| Park, M | 1 |
| Okuda, Y | 1 |
| Mikame, Y | 1 |
| Sato, R | 1 |
| Shinada, M | 1 |
| Saito, T | 9 |
| Kezuka, C | 1 |
| Wakamori, M | 1 |
| Aoki, R | 1 |
| Kano, S | 1 |
| Sanbe, R | 1 |
| Otsuka, Y | 1 |
| Nakazawa, T | 1 |
| Yamaguchi, H | 3 |
| Imai, Y | 2 |
| Arjmandi, K | 1 |
| Ameli, F | 1 |
| Salahshourifar, I | 1 |
| Esfandbod, M | 1 |
| Irani, S | 1 |
| Dong, S | 1 |
| Zhang, S | 8 |
| Zhao, P | 2 |
| Lin, G | 1 |
| Ma, X | 2 |
| Zou, C | 1 |
| Aliabadi, P | 1 |
| Sadri, M | 1 |
| Siri, G | 1 |
| Ebrahimzadeh, F | 1 |
| Yazdani, Y | 1 |
| Gusarov, AM | 1 |
| Kharkouei, SA | 1 |
| Asadi, F | 1 |
| Adili, A | 1 |
| Mardi, A | 1 |
| Mohammadi, H | 1 |
| Cao, T | 1 |
| Hui, J | 1 |
| Zhou, Y | 15 |
| Han, S | 1 |
| Ramaswamy, A | 1 |
| Bhargava, P | 2 |
| Srinivas, S | 1 |
| Kannan, S | 1 |
| Bhandare, M | 1 |
| Chaudhari, V | 1 |
| Mantri, A | 1 |
| Kapoor, A | 1 |
| Das, S | 1 |
| Booma, N | 1 |
| Chaugule, D | 1 |
| Shrikhande, SV | 1 |
| Ostwal, V | 1 |
| An, J | 1 |
| Yang, L | 13 |
| He, Y | 9 |
| Xie, H | 2 |
| Tao, Y | 1 |
| Li, W | 23 |
| Yan, Y | 4 |
| An, L | 1 |
| Ji, D | 3 |
| Su, Z | 2 |
| Sheng, J | 1 |
| Wu, YZ | 1 |
| Wu, M | 3 |
| Zheng, XH | 1 |
| Wang, BZ | 2 |
| Xue, LY | 1 |
| Ding, SK | 1 |
| Ren, JS | 1 |
| Tian, YT | 3 |
| Xie, YB | 2 |
| Tang, JL | 1 |
| Zhang, B | 12 |
| Xu, JP | 1 |
| Qi, L | 1 |
| Xin, D | 1 |
| Li, Y | 48 |
| Xiaohui, Z | 2 |
| Shanshan, L | 1 |
| Taiyuan, C | 1 |
| Ge, D | 1 |
| Hongen, Y | 1 |
| Lishuo, S | 1 |
| Xiaoru, L | 1 |
| Wanjia, H | 1 |
| Jian, X | 1 |
| Wang, T | 6 |
| Li, C | 13 |
| Shen, L | 29 |
| Marcisz-Grzanka, K | 1 |
| Winiarek, M | 1 |
| Pałucki, J | 1 |
| Wieszczy, P | 1 |
| Olesiński, T | 1 |
| Jóźwiak, M | 1 |
| Samsel, R | 1 |
| Sułkowska, U | 1 |
| Kolasińska-Ćwikła, A | 1 |
| Wyrwicz, LS | 1 |
| Zeng, H | 3 |
| Song, LY | 1 |
| Jia, SJ | 1 |
| Zeng, X | 2 |
| Liu, Q | 4 |
| Mariani, A | 3 |
| Zaanan, A | 9 |
| Glehen, O | 3 |
| Karoui, M | 3 |
| Tao, J | 3 |
| Joseph, MX | 3 |
| Vaudreuil, A | 3 |
| Dahiya, M | 3 |
| Eilers, D | 3 |
| Gürler, F | 4 |
| Güven, DC | 4 |
| Aydemir, E | 3 |
| Sütçüoğlu, O | 4 |
| İnci, BK | 3 |
| Arık, Z | 4 |
| Yalçın, Ş | 7 |
| Özdemir, N | 9 |
| Özet, A | 5 |
| Yazıcı, O | 8 |
| Lu, Y | 7 |
| Jin, Z | 4 |
| Hou, J | 6 |
| Yu, Z | 10 |
| Yao, L | 4 |
| Pan, T | 3 |
| Chang, X | 4 |
| Li, J | 52 |
| Yan, M | 8 |
| Yan, C | 5 |
| Zhu, Z | 13 |
| Liu, B | 15 |
| Su, L | 5 |
| Ura, T | 13 |
| Hironaka, S | 10 |
| Tsubosa, Y | 3 |
| Mizusawa, J | 8 |
| Tsushima, T | 7 |
| Fushiki, K | 3 |
| Chin, K | 9 |
| Tomori, A | 3 |
| Okuno, T | 3 |
| Matsushita, H | 4 |
| Kojima, T | 12 |
| Doki, Y | 13 |
| Kusaba, H | 6 |
| Fujitani, K | 10 |
| Seki, S | 6 |
| Kitagawa, Y | 7 |
| Narayan, S | 3 |
| Talwar, V | 4 |
| Redhu, P | 3 |
| Goel, V | 4 |
| Jain, A | 5 |
| Soni, S | 3 |
| Chaudhary, K | 3 |
| Basu, D | 3 |
| Park, H | 6 |
| Imoto, S | 3 |
| Miyano, S | 3 |
| Wang, MQ | 2 |
| Chen, YR | 2 |
| Zhan, JR | 2 |
| Suo, DQ | 2 |
| Wang, JJ | 5 |
| Ma, YZ | 2 |
| Guan, XY | 2 |
| Zhu, SL | 2 |
| Chen, VC | 1 |
| Huang, JY | 1 |
| Tzang, BS | 1 |
| Hsu, TC | 1 |
| McIntyre, RS | 1 |
| Chia, DKA | 1 |
| Sundar, R | 1 |
| Kim, G | 1 |
| Ang, JJ | 1 |
| Shabbir, A | 2 |
| So, JBY | 1 |
| Yong, WP | 4 |
| Kim, NH | 3 |
| Park, JH | 10 |
| Koo, DH | 6 |
| Jung, YS | 2 |
| Yang, JY | 2 |
| Lee, HY | 6 |
| Miyake, M | 2 |
| Miyake, K | 1 |
| Han, Q | 2 |
| Igarashi, K | 3 |
| Kawaguchi, K | 4 |
| Barangi, M | 1 |
| Kiyuna, T | 1 |
| Sugisawa, N | 2 |
| Higuchi, T | 3 |
| Oshiro, H | 1 |
| Razmjooei, S | 1 |
| Bouvet, M | 3 |
| Endo, I | 1 |
| Hoffman, RM | 5 |
| Chen, MC | 1 |
| Su, HY | 1 |
| Su, YH | 1 |
| Huang, KH | 4 |
| Fang, WL | 1 |
| Lin, CW | 1 |
| Chen, MH | 4 |
| Chao, Y | 10 |
| Lo, SS | 4 |
| Fen-Yau Li, A | 1 |
| Wu, CW | 6 |
| Li, YT | 1 |
| Chang, WH | 1 |
| Sisic, L | 2 |
| Crnovrsanin, N | 1 |
| Nienhueser, H | 1 |
| Jung, JO | 1 |
| Schiefer, S | 1 |
| Haag, GM | 2 |
| Bruckner, T | 2 |
| Schneider, M | 1 |
| Müller-Stich, BP | 1 |
| Büchler, MW | 2 |
| Schmidt, T | 2 |
| Sinnamon, AJ | 1 |
| Savoldy, M | 1 |
| Mehta, R | 2 |
| Dineen, SP | 2 |
| Peña, LR | 1 |
| Lauwers, GY | 1 |
| Pimiento, JM | 2 |
| Goetze, TO | 1 |
| Hofheinz, RD | 16 |
| Gaiser, T | 2 |
| Schmalenberg, H | 6 |
| Strumberg, D | 2 |
| Goekkurt, E | 6 |
| Angermeier, S | 1 |
| Zander, T | 1 |
| Kopp, HG | 1 |
| Pink, D | 3 |
| Siegler, G | 1 |
| Schenk, M | 2 |
| Galizia, G | 6 |
| Maiello, E | 4 |
| Bechstein, WO | 1 |
| Elshafei, M | 1 |
| Loose, M | 1 |
| Sookthai, D | 1 |
| Brulin, T | 1 |
| Pauligk, C | 11 |
| Monin, MB | 1 |
| Sommer, N | 1 |
| Hingorani, M | 1 |
| Goody, R | 1 |
| Bozas, G | 1 |
| Zahid, K | 2 |
| Mitton, DJ | 1 |
| Jain, P | 2 |
| Wong, V | 1 |
| Roy, R | 1 |
| Yu, T | 1 |
| Sun, J | 6 |
| Zeng, Z | 2 |
| Liu, Z | 10 |
| Ma, M | 1 |
| Kang, W | 3 |
| Zhao, F | 3 |
| Li, E | 2 |
| Shen, G | 3 |
| Dong, Q | 1 |
| Ren, D | 4 |
| Ma, J | 3 |
| Xie, Q | 1 |
| Gao, L | 4 |
| Zhao, J | 5 |
| Gao, X | 4 |
| Zhang, N | 7 |
| Han, W | 1 |
| Liu, K | 3 |
| Yan, J | 6 |
| Niu, P | 1 |
| Wang, W | 8 |
| Ji, G | 1 |
| Zhao, Q | 12 |
| Shang, L | 1 |
| Liang, H | 4 |
| Wu, K | 7 |
| Deng, J | 3 |
| Nie, Y | 6 |
| Weng, S | 1 |
| Xu, H | 2 |
| Ren, Y | 1 |
| Zhou, Z | 6 |
| Xing, Z | 2 |
| Han, X | 3 |
| Zheng, Y | 5 |
| Chen, W | 8 |
| Lin, Y | 5 |
| Guo, J | 6 |
| Ye, G | 1 |
| Wong, TL | 1 |
| Loh, JJ | 1 |
| Lu, S | 2 |
| Yan, HHN | 1 |
| Siu, HC | 1 |
| Xi, R | 1 |
| Chan, D | 1 |
| Kam, MJF | 1 |
| Zhou, L | 6 |
| Tong, M | 2 |
| Copland, JA | 1 |
| Yun, JP | 1 |
| Leung, SY | 1 |
| Ma, S | 4 |
| Lee, KW | 13 |
| Zang, DY | 7 |
| Ryu, MH | 23 |
| Han, HS | 4 |
| Kim, KH | 5 |
| Kim, MJ | 4 |
| Koh, SA | 1 |
| Lee, SS | 6 |
| Ko, YH | 2 |
| Sohn, BS | 1 |
| Kim, JW | 10 |
| Nam, BH | 4 |
| Choi, IS | 7 |
| Li, K | 7 |
| Sun, S | 5 |
| Liang, W | 3 |
| Xu, X | 8 |
| Chang, Z | 1 |
| Maheshwari, U | 1 |
| Goyal, P | 1 |
| Patnaik, N | 1 |
| Koyyala, VPB | 1 |
| Chaudhari, K | 1 |
| Doval, DC | 1 |
| Khan, SU | 1 |
| Yang, C | 2 |
| Tong, Q | 1 |
| Shariff, B | 1 |
| Ugolini, C | 1 |
| Giannini, R | 1 |
| Giordano, M | 1 |
| Vivaldi, C | 2 |
| Lencioni, M | 3 |
| Santi, S | 1 |
| Massa, V | 1 |
| Pallabazzer, G | 1 |
| Catanese, S | 1 |
| Salani, F | 1 |
| Belluomini, MA | 1 |
| Vasile, E | 5 |
| Cremolini, C | 1 |
| Fontanini, G | 1 |
| Masi, G | 4 |
| Jia, C | 1 |
| Du, W | 1 |
| Jiang, H | 4 |
| Afrin, H | 1 |
| Esquivel, SV | 1 |
| Kumar, R | 3 |
| Zahid, MI | 1 |
| Oporeza, B | 1 |
| Rahman, MF | 1 |
| Boland, T | 1 |
| Nurunnabi, M | 1 |
| Duzkopru, Y | 1 |
| Cilbir, E | 1 |
| Imamoglu, GI | 1 |
| Dogan, O | 1 |
| Eren, T | 2 |
| Tang, M | 1 |
| Zhai, L | 1 |
| Wang, F | 10 |
| Wu, W | 4 |
| Zheng, H | 4 |
| Gu, AM | 1 |
| Lin, J | 2 |
| Ding, X | 1 |
| Baek, JH | 6 |
| Kang, BW | 3 |
| Kang, H | 2 |
| Cho, M | 2 |
| Kwon, OK | 2 |
| Park, JY | 3 |
| Park, KB | 1 |
| Seo, AN | 1 |
| Kim, JG | 9 |
| Takahari, D | 14 |
| Nakayama, I | 2 |
| du Rusquec, P | 1 |
| Guimbaud, R | 5 |
| Le Malicot, K | 4 |
| Gornet, JM | 4 |
| Nguyen, S | 4 |
| Lecomte, T | 3 |
| Khemissa-Akouz, F | 1 |
| Perrier, H | 1 |
| Bouché, O | 13 |
| Paoletti, X | 1 |
| Le Tourneau, C | 1 |
| Andreucci, E | 2 |
| Biagioni, A | 2 |
| Peri, S | 2 |
| Versienti, G | 2 |
| Cianchi, F | 2 |
| Staderini, F | 2 |
| Supuran, CT | 1 |
| Olivo, E | 1 |
| Pasqualini, E | 1 |
| Messerini, L | 2 |
| Massi, D | 1 |
| Lulli, M | 1 |
| Ruzzolini, J | 1 |
| Peppicelli, S | 1 |
| Bianchini, F | 1 |
| Schiavone, N | 2 |
| Calorini, L | 1 |
| Magnelli, L | 2 |
| Papucci, L | 2 |
| Hu, Q | 2 |
| Ke, J | 1 |
| Chu, T | 1 |
| Monti, M | 1 |
| Prochowski Iamurri, A | 1 |
| Bianchini, D | 2 |
| Gallio, C | 1 |
| Esposito, L | 1 |
| Montanari, D | 1 |
| Ruscelli, S | 1 |
| Molinari, C | 1 |
| Foca, F | 1 |
| Passardi, A | 1 |
| Vittimberga, G | 1 |
| Morgagni, P | 1 |
| Frassineti, GL | 1 |
| Ye, H | 1 |
| Shi, W | 1 |
| Zhao, H | 4 |
| Qin, L | 1 |
| Cai, W | 1 |
| Guan, J | 1 |
| Zhou, H | 5 |
| Sun, H | 1 |
| Jiao, Z | 1 |
| Huang, Z | 2 |
| Luo, Y | 4 |
| Zhou, C | 3 |
| Cai, C | 3 |
| Xiong, XH | 1 |
| Mao, QC | 1 |
| Yang, JW | 2 |
| Chen, SY | 2 |
| Li, XQ | 1 |
| Maeng, CH | 1 |
| Kim, M | 5 |
| Shen, J | 7 |
| Huang, C | 2 |
| Cui, L | 1 |
| Zhu, M | 3 |
| Chen, Z | 21 |
| Zhu, W | 5 |
| Shen, B | 1 |
| Tasnim, S | 1 |
| Sudarshan, M | 2 |
| He, C | 2 |
| Ding, Y | 3 |
| Che, G | 1 |
| Teng, F | 1 |
| Zhou, D | 1 |
| Teng, L | 1 |
| Liu, J | 17 |
| Chen, X | 9 |
| Shang, D | 1 |
| Kimura, Y | 9 |
| Kawakami, K | 4 |
| Nakamura, M | 7 |
| Yokokawa, T | 1 |
| Shimizu, H | 5 |
| Kobayashi, K | 12 |
| Aoyama, T | 2 |
| Suzuki, W | 1 |
| Hatori, M | 1 |
| Suzuki, K | 7 |
| Ogura, M | 2 |
| Wakatsuki, T | 1 |
| Yamaguchi, M | 5 |
| Fernandes, E | 1 |
| Ferreira, D | 1 |
| Peixoto, A | 1 |
| Freitas, R | 1 |
| Relvas-Santos, M | 1 |
| Palmeira, C | 1 |
| Martins, G | 1 |
| Barros, A | 1 |
| Santos, LL | 1 |
| Sarmento, B | 1 |
| Ferreira, JA | 1 |
| Mao, C | 2 |
| Kim, SM | 2 |
| An, JY | 6 |
| Byeon, SJ | 1 |
| Lee, J | 26 |
| Kim, KM | 7 |
| Choi, MG | 6 |
| Sohn, TS | 10 |
| Bae, JM | 10 |
| Kim, S | 18 |
| Mishra, T | 1 |
| Shokr, M | 1 |
| Ahmed, A | 1 |
| Afonso, L | 1 |
| Wu, DC | 2 |
| Chung, WM | 1 |
| Lei, FJ | 1 |
| Liu, CJ | 1 |
| Wu, IC | 3 |
| Lai, HC | 1 |
| Wu, C | 2 |
| Yu, XY | 1 |
| Liang, C | 1 |
| Liu, SB | 1 |
| Ding, H | 3 |
| Xue, T | 1 |
| Song, D | 2 |
| Lei, Z | 2 |
| Amin, HM | 1 |
| Song, YH | 1 |
| Zhou, J | 14 |
| Seong, SJ | 1 |
| Kang, WY | 1 |
| Ohk, B | 1 |
| Gwon, MR | 1 |
| Kim, BK | 1 |
| Cho, S | 1 |
| Cho, K | 3 |
| Sung, YK | 1 |
| Yoon, YR | 1 |
| Otta-Oshiro, RJ | 1 |
| Lista-Mateos, F | 1 |
| Encinas-García, S | 1 |
| Morales-García, S | 1 |
| Núñez-Mora, C | 1 |
| De Giorgi, V | 1 |
| Scarfì, F | 1 |
| Trane, L | 1 |
| Silvestri, F | 1 |
| Maida, P | 1 |
| Gori, A | 1 |
| Covarelli, P | 1 |
| Ohmura, H | 1 |
| Ito, M | 3 |
| Uchino, K | 1 |
| Okada, C | 1 |
| Tanishima, S | 1 |
| Yamada, Y | 25 |
| Momosaki, S | 1 |
| Komoda, M | 1 |
| Kuwayama, M | 1 |
| Okumura, Y | 3 |
| Tsuchihashi, K | 1 |
| Isobe, T | 1 |
| Ariyama, H | 3 |
| Oda, Y | 2 |
| Akashi, K | 1 |
| Baba, E | 6 |
| Mukherjee, S | 1 |
| Fountzilas, C | 1 |
| Boland, PM | 1 |
| Gosain, R | 1 |
| Attwood, K | 1 |
| Tan, W | 1 |
| Khushalani, N | 1 |
| Iyer, R | 1 |
| Iqbal, S | 2 |
| McDonough, S | 1 |
| Lenz, HJ | 6 |
| Ilson, D | 3 |
| Burtness, B | 1 |
| Nangia, CS | 1 |
| Barzi, A | 1 |
| Schneider, CJ | 1 |
| Liu, JJ | 1 |
| Dotan, E | 1 |
| Guthrie, KA | 1 |
| Hochster, HS | 3 |
| Wen, F | 3 |
| Zhou, K | 2 |
| Li, Q | 13 |
| Bi, F | 5 |
| Brown, J | 1 |
| Liepa, AM | 2 |
| Bapat, B | 1 |
| Madhwani, S | 1 |
| Lorenzen, S | 13 |
| García-Foncillas, J | 2 |
| Candrilli, SD | 1 |
| Kaye, JA | 1 |
| Alhadid, D | 1 |
| AlShammari, A | 1 |
| Almana, H | 1 |
| Aburahmah, M | 1 |
| Nishiguchi, Y | 2 |
| Oue, N | 3 |
| Fujiwara-Tani, R | 1 |
| Sasaki, T | 34 |
| Ohmori, H | 1 |
| Kishi, S | 1 |
| Mori, S | 4 |
| Mori, T | 8 |
| Ikeda, N | 3 |
| Matsumoto, S | 4 |
| Wakatsuki, K | 2 |
| Yasui, W | 5 |
| Sho, M | 1 |
| Kuniyasu, H | 2 |
| Roviello, G | 6 |
| Roviello, F | 4 |
| Mini, E | 2 |
| Wen, L | 1 |
| Yang, S | 6 |
| Li, P | 7 |
| Chen, R | 3 |
| Kaspo, B | 1 |
| Fan, H | 1 |
| Kawakami, R | 1 |
| Mashima, T | 1 |
| Kawata, N | 1 |
| Migita, T | 1 |
| Sano, T | 5 |
| Mizunuma, N | 2 |
| Seimiya, H | 1 |
| Archid, R | 2 |
| Zieker, D | 2 |
| Weinreich, FJ | 1 |
| Hönes, F | 1 |
| Königsrainer, A | 4 |
| Quintanilla-Martínez, L | 1 |
| Reymond, MA | 1 |
| Solass, W | 1 |
| Zhong, S | 1 |
| Tong, Y | 1 |
| Feng, G | 1 |
| Zhou, X | 5 |
| Huang, G | 1 |
| Guan, G | 1 |
| Zhao, D | 1 |
| Sakamoto, T | 5 |
| Katayama, H | 2 |
| Ganschow, P | 1 |
| Hofmann, L | 1 |
| Stintzing, S | 1 |
| Heinemann, V | 4 |
| Angele, M | 1 |
| Werner, J | 1 |
| Schulz, C | 1 |
| Catenacci, DVT | 1 |
| Chase, L | 1 |
| Lomnicki, S | 1 |
| Karrison, T | 1 |
| de Wilton Marsh, R | 1 |
| Rampurwala, MM | 1 |
| Narula, S | 1 |
| Alpert, L | 1 |
| Setia, N | 1 |
| Xiao, SY | 1 |
| Hart, J | 1 |
| Siddiqui, UD | 1 |
| Peterson, B | 1 |
| Moore, K | 1 |
| Kipping-Johnson, K | 1 |
| Markevicius, U | 1 |
| Gordon, B | 1 |
| Allen, K | 1 |
| Racette, C | 1 |
| Maron, SB | 1 |
| Liao, CY | 1 |
| Polite, BN | 1 |
| Kindler, HL | 1 |
| Turaga, K | 1 |
| Prachand, VN | 1 |
| Roggin, KK | 1 |
| Ferguson, MK | 1 |
| Posner, MC | 1 |
| Maruta, M | 1 |
| Miyoshi, T | 3 |
| Matsuo, N | 1 |
| Yamashina, T | 1 |
| Irie, K | 1 |
| Tsuruta, M | 1 |
| Tsukada, H | 1 |
| Tsuruyama, M | 1 |
| Nagano, M | 1 |
| Hiraki, Y | 1 |
| Nishibeppu, K | 1 |
| Komatsu, S | 1 |
| Imamura, T | 3 |
| Kiuchi, J | 1 |
| Arita, T | 1 |
| Kosuga, T | 1 |
| Konishi, H | 1 |
| Kubota, T | 20 |
| Shiozaki, A | 1 |
| Fujiwara, H | 8 |
| Okamoto, K | 2 |
| Otsuji, E | 2 |
| Xiao, F | 1 |
| Ouyang, B | 1 |
| Zou, J | 2 |
| Yi, L | 2 |
| Yan, H | 2 |
| Xiao, L | 3 |
| Blum Murphy, M | 2 |
| Palmer, M | 1 |
| Gockel, I | 1 |
| Lordick, F | 30 |
| Park, YR | 1 |
| Jung, M | 2 |
| Lim, SG | 1 |
| Zhao, M | 2 |
| Hou, Y | 1 |
| Du, YE | 1 |
| Qin, Y | 2 |
| Peng, M | 1 |
| Liu, S | 5 |
| Wan, X | 2 |
| Qiao, Y | 1 |
| Cui, X | 1 |
| Teng, Y | 1 |
| Di Bartolomeo, M | 4 |
| Morano, F | 1 |
| Raimondi, A | 1 |
| Miceli, R | 1 |
| Corallo, S | 1 |
| Tamborini, E | 1 |
| Perrone, F | 1 |
| Antista, M | 1 |
| Niger, M | 1 |
| Pellegrinelli, A | 1 |
| Randon, G | 1 |
| Pagani, F | 1 |
| Martinetti, A | 2 |
| Fucà, G | 1 |
| Pietrantonio, F | 1 |
| Kim, HB | 2 |
| Lee, HJ | 9 |
| Kim, GB | 1 |
| Lim, HJ | 1 |
| Park, SG | 2 |
| Mu, L | 1 |
| Guo, D | 2 |
| Galletti, G | 1 |
| Zhang, C | 4 |
| Gjyrezi, A | 1 |
| Cleveland, K | 1 |
| Powell, S | 1 |
| Thakkar, PV | 1 |
| Betel, D | 1 |
| Shah, MA | 12 |
| Giannakakou, P | 1 |
| Lin, JP | 1 |
| Zhao, YJ | 1 |
| He, QL | 1 |
| Hao, HK | 1 |
| Zou, BB | 1 |
| Jiang, LX | 1 |
| Lin, W | 1 |
| Zhou, YB | 2 |
| Zhao, G | 4 |
| Xue, FQ | 1 |
| Li, SL | 1 |
| Fu, WH | 1 |
| Li, YX | 2 |
| Zhou, XJ | 1 |
| Zhu, ZG | 8 |
| Chen, JP | 4 |
| Xu, ZK | 1 |
| Cai, LH | 1 |
| Li, HL | 2 |
| Xie, JW | 2 |
| Huang, CM | 3 |
| Lin, JX | 2 |
| Zheng, CH | 2 |
| Ekheden, I | 1 |
| Ebrahim, F | 1 |
| Ólafsdóttir, H | 1 |
| Raaschou, P | 1 |
| Wettermark, B | 1 |
| Henriksson, R | 1 |
| Mitani, S | 2 |
| Kadowaki, S | 5 |
| Komori, A | 4 |
| Kondoh, C | 2 |
| Oze, I | 1 |
| Masuishi, T | 3 |
| Honda, K | 4 |
| Narita, Y | 5 |
| Taniguchi, H | 11 |
| Ando, M | 5 |
| Tanaka, T | 19 |
| Tajika, M | 6 |
| Funasaka, C | 2 |
| Kanemasa, Y | 1 |
| Shimoyama, T | 1 |
| Cho, H | 4 |
| Omuro, Y | 7 |
| Jiang, M | 1 |
| Dong, T | 1 |
| Xu, L | 8 |
| Lv, J | 2 |
| Xue, M | 1 |
| Huang, M | 7 |
| Jin, RU | 1 |
| Wang-Gillam, A | 2 |
| Suresh, R | 1 |
| Rigden, C | 1 |
| Amin, M | 1 |
| Tan, BR | 2 |
| Pedersen, KS | 1 |
| Lim, KH | 3 |
| Trikalinos, NA | 1 |
| Acharya, A | 1 |
| Copsey, ML | 1 |
| Navo, KA | 1 |
| Morton, AE | 1 |
| Gao, F | 2 |
| Lockhart, AC | 2 |
| Tintelnot, J | 1 |
| Binder, M | 1 |
| Knorrenschild, JR | 1 |
| Kretzschmar, A | 8 |
| Ettrich, T | 1 |
| Lindig, U | 1 |
| Jacobasch, L | 1 |
| Hegewisch-Becker, S | 8 |
| Nilsson, S | 1 |
| Bokemeyer, C | 11 |
| Xu, D | 1 |
| Tong, X | 1 |
| Shan, C | 1 |
| Luo, D | 2 |
| Xiong, Y | 1 |
| Yi, F | 1 |
| Ding, J | 2 |
| Wei, Y | 3 |
| Lv, K | 2 |
| He, X | 6 |
| Jin, K | 2 |
| Yao, Y | 5 |
| Deng, R | 1 |
| Liao, D | 1 |
| Zuo, J | 2 |
| Jia, Y | 5 |
| Kong, F | 1 |
| Yan, D | 3 |
| Sun, Q | 4 |
| Du, T | 2 |
| Cao, D | 4 |
| Yuan, B | 1 |
| Song, C | 2 |
| Tang, H | 5 |
| Shu, P | 2 |
| Liao, P | 1 |
| Song, K | 1 |
| Wang, K | 6 |
| Xie, S | 1 |
| Mcleod, HL | 3 |
| Matsumoto, T | 6 |
| Yamamoto, Y | 12 |
| Kuriona, Y | 1 |
| Okazaki, U | 1 |
| Kimura, S | 1 |
| Miura, K | 3 |
| Tsuduki, T | 1 |
| Watanabe, T | 9 |
| Mastumoto, Y | 1 |
| Takatani, M | 1 |
| Kim, DJ | 1 |
| Jeena, MT | 1 |
| Kim, OH | 1 |
| Hong, HE | 1 |
| Seo, H | 1 |
| Ryu, JH | 1 |
| Kim, SJ | 8 |
| Pourghasemian, M | 1 |
| Danandeh Mehr, A | 1 |
| Molaei, M | 1 |
| Habibzadeh, A | 1 |
| Yang, Z | 9 |
| Pu, X | 1 |
| He, S | 5 |
| Xue, YF | 1 |
| Xue, D | 2 |
| Yao, B | 1 |
| Hu, CG | 1 |
| Wang, XY | 3 |
| Zhou, YC | 1 |
| Liu, YY | 1 |
| Wang, YX | 1 |
| Chen, DD | 1 |
| Fan, Y | 2 |
| Fatehi-Agdam, M | 1 |
| Vatankhah, MA | 1 |
| Panahizadeh, R | 1 |
| Jeddi, F | 1 |
| Najafzadeh, N | 2 |
| Nishino, H | 4 |
| Yamamoto, J | 1 |
| Tashiro, Y | 1 |
| Unno, M | 1 |
| Niu, R | 1 |
| Xiang, Y | 2 |
| Feng, B | 4 |
| Ozaki, Y | 1 |
| Imamaki, H | 1 |
| Ikeda, A | 1 |
| Oura, M | 1 |
| Nakagawa, S | 3 |
| Funakoshi, T | 1 |
| Kataoka, S | 1 |
| Nishikawa, Y | 1 |
| Horimatsu, T | 1 |
| Yonezawa, A | 1 |
| Matsubara, T | 2 |
| Yanagita, M | 1 |
| Muto, M | 3 |
| Watanabe, N | 2 |
| Ukai, S | 1 |
| Honma, R | 1 |
| Sakamoto, N | 2 |
| Pham, QT | 1 |
| Harada, K | 3 |
| Takashima, T | 2 |
| Taniyama, D | 1 |
| Asai, R | 1 |
| Fukada, K | 1 |
| Naka, K | 1 |
| Tanabe, K | 6 |
| Ohdan, H | 1 |
| Jiang, DM | 1 |
| Sim, HW | 1 |
| Espin-Garcia, O | 1 |
| Chan, BA | 1 |
| Natori, A | 1 |
| Lim, CH | 1 |
| Moignard, S | 1 |
| Chen, EX | 1 |
| Liu, G | 1 |
| Darling, G | 3 |
| Swallow, CJ | 1 |
| Brar, S | 1 |
| Brierley, J | 3 |
| Ringash, J | 4 |
| Wong, R | 7 |
| Kim, J | 7 |
| Rogalla, P | 1 |
| Hafezi-Bakhtiari, S | 1 |
| Knox, JJ | 2 |
| Jang, RW | 1 |
| Elimova, E | 2 |
| He, J | 5 |
| Xie, J | 4 |
| Xia, J | 1 |
| Shi, Y | 6 |
| Qiu, L | 4 |
| Ma, Z | 2 |
| Deng, Y | 3 |
| Duan, G | 1 |
| Zhao, LE | 1 |
| Hu, X | 4 |
| Li, N | 5 |
| Ge, F | 1 |
| Jiang, J | 7 |
| Yao, J | 3 |
| Huang, D | 2 |
| Yang, Q | 3 |
| Moehler, M | 14 |
| Dvorkin, M | 1 |
| Özgüroğlu, M | 2 |
| Muntean, AS | 1 |
| Lonardi, S | 1 |
| Nechaeva, M | 1 |
| Bragagnoli, AC | 1 |
| Coşkun, HS | 1 |
| Cubillo Gracian, A | 1 |
| Takano, T | 1 |
| Safran, H | 4 |
| Vaccaro, GM | 1 |
| Wainberg, ZA | 4 |
| Silver, MR | 1 |
| Xiong, H | 2 |
| Hong, J | 2 |
| Taieb, J | 6 |
| Bang, YJ | 27 |
| Pei, S | 1 |
| Xiao, Y | 2 |
| Sah, BK | 1 |
| Yuan, F | 3 |
| Ma, T | 6 |
| Shi, M | 6 |
| Xu, G | 1 |
| Wu, YL | 4 |
| Xu, R | 6 |
| Zhang, JB | 1 |
| Ming, H | 1 |
| Park, SH | 28 |
| Lim, DH | 9 |
| Kim, ST | 5 |
| Kang, JH | 10 |
| Oh, SY | 16 |
| Hwang, IG | 3 |
| Ji, JH | 1 |
| Shin, DB | 16 |
| Yu, JI | 1 |
| Hong, JY | 2 |
| Park, JO | 22 |
| Park, YS | 23 |
| Lim, HY | 19 |
| Kang, WK | 24 |
| Ngabire, D | 1 |
| Niyonizigiye, I | 1 |
| Patil, MP | 1 |
| Seong, YA | 1 |
| Seo, YB | 1 |
| Kim, GD | 1 |
| Masuo, K | 3 |
| Yogo, A | 1 |
| Yokoyama, S | 2 |
| Sugiyama, A | 2 |
| Seno, H | 1 |
| Yoshizawa, A | 1 |
| Takaishi, S | 1 |
| Evrard, C | 1 |
| Louvet, C | 8 |
| Hajbi, FE | 1 |
| Fiore, FD | 1 |
| Malicot, KL | 1 |
| Aparicio, T | 8 |
| Laurent-Puig, P | 2 |
| Bibeau, F | 2 |
| Lièvre, A | 3 |
| Sokol, H | 1 |
| Chibaudel, B | 2 |
| Desrame, J | 1 |
| Pierre, S | 1 |
| Gonzalez, D | 3 |
| Lepage, C | 4 |
| Tougeron, D | 4 |
| Ishiguro, M | 3 |
| Takenaka, R | 1 |
| Ogura, K | 1 |
| Hiratsuka, A | 1 |
| Takeda, H | 2 |
| Kawai, D | 1 |
| Tsugeno, H | 1 |
| Fujiki, S | 1 |
| Okada, H | 2 |
| Zhang, F | 5 |
| Yao, X | 6 |
| Tao, S | 1 |
| Gu, J | 3 |
| Zheng, L | 6 |
| Ben Nasr, S | 2 |
| Zribi, A | 1 |
| Ben Hassen, M | 1 |
| Doghri, Y | 1 |
| Ben Abdallah, I | 1 |
| Trigui, E | 1 |
| Fendri, S | 1 |
| Ayari, J | 1 |
| Balti, M | 1 |
| Haddaoui, A | 1 |
| Runkel, M | 1 |
| Verst, R | 1 |
| Spiegelberg, J | 1 |
| Fichtner-Feigl, S | 1 |
| Hoeppner, J | 2 |
| Glatz, T | 2 |
| Huang, T | 2 |
| Wong, CC | 1 |
| Chan, RCK | 1 |
| Dong, Y | 1 |
| Wu, F | 3 |
| Wu, WKK | 1 |
| Chan, MWY | 1 |
| Cheng, ASL | 1 |
| Wong, N | 2 |
| Lo, KW | 1 |
| To, KF | 1 |
| Liang, Z | 1 |
| Qi, W | 1 |
| Qiu, W | 1 |
| Stocker, G | 3 |
| Thieme, R | 1 |
| Bodoky, G | 6 |
| Starodub, A | 1 |
| Yip, D | 2 |
| Bendell, J | 2 |
| Thai, D | 1 |
| Ma, L | 5 |
| Cai, Z | 2 |
| Li, S | 4 |
| Fingerhut, A | 2 |
| Zang, L | 2 |
| Zheng, M | 1 |
| He, Z | 1 |
| Chen, D | 4 |
| Wu, J | 20 |
| Sui, C | 1 |
| Deng, X | 2 |
| Shi, J | 2 |
| Rajabnejad, A | 1 |
| Vaida, F | 1 |
| Valasek, M | 1 |
| Razzaque, S | 1 |
| Fanta, P | 1 |
| Horgan, S | 1 |
| Lowy, AM | 4 |
| Kelly, KJ | 1 |
| Karadag, I | 1 |
| Karakaya, S | 1 |
| Ates, O | 1 |
| Cakmak Oksuzoglu, OB | 1 |
| Sato, M | 5 |
| Imanishi, M | 2 |
| Sugaya, A | 2 |
| Hirose, M | 2 |
| Endo, S | 5 |
| Moriwaki, T | 3 |
| Yamato, K | 3 |
| Onitilo, AA | 1 |
| Stankowski-Drengler, TJ | 1 |
| Shiyanbola, O | 1 |
| Engel, J | 1 |
| Tanimu, S | 1 |
| Fagbemi, SO | 1 |
| Li, YH | 10 |
| Rinninella, E | 1 |
| Cintoni, M | 1 |
| Raoul, P | 1 |
| Vivolo, R | 1 |
| Di Salvatore, M | 1 |
| Genco, E | 1 |
| Manfredi, R | 1 |
| Bria, E | 1 |
| Tortora, G | 1 |
| Gasbarrini, A | 1 |
| Mele, MC | 1 |
| Zhang, LY | 2 |
| Ma, JJ | 1 |
| Hong, HJ | 1 |
| Lu, AG | 1 |
| He, ZR | 1 |
| Jiang, TY | 1 |
| Zheng, MH | 1 |
| Wang, DS | 3 |
| Hu, MT | 1 |
| Wang, ZQ | 5 |
| Ren, C | 4 |
| Qiu, MZ | 8 |
| Luo, HY | 7 |
| Jin, Y | 4 |
| Fong, WP | 1 |
| Wang, SB | 1 |
| Peng, JW | 2 |
| Zou, QF | 1 |
| Tan, Q | 1 |
| Wang, FH | 6 |
| Ishii, T | 2 |
| Suzuki, A | 3 |
| Kuwata, T | 1 |
| Hisamitsu, S | 1 |
| Hashimoto, H | 2 |
| Ohara, Y | 1 |
| Yanagihara, K | 2 |
| Mitsunaga, S | 1 |
| Yoshino, T | 5 |
| Kinoshita, T | 6 |
| Ochiai, A | 2 |
| Ishii, G | 1 |
| Guo, S | 1 |
| Yue, T | 1 |
| Fuchs, CS | 4 |
| Bhagia, P | 1 |
| Adelberg, D | 1 |
| Qin, SK | 3 |
| Hadoux, J | 1 |
| Afchain, P | 3 |
| Walter, T | 2 |
| Hautefeuille, V | 2 |
| Monterymard, C | 1 |
| Lorgis, V | 1 |
| Thuillier, F | 1 |
| Baudin, E | 1 |
| Scoazec, JY | 2 |
| Desgrippes, R | 1 |
| Yilmaz, H | 1 |
| Demirag, G | 1 |
| Sullu, Y | 1 |
| Yilmaz, A | 1 |
| Han, JH | 4 |
| Kim, HJ | 21 |
| Jang, SB | 1 |
| Bae, SJ | 1 |
| Lee, IK | 1 |
| Ryu, D | 1 |
| Ha, KT | 1 |
| Allen, CJ | 1 |
| Pointer, DT | 1 |
| Blumenthaler, AN | 1 |
| Mehta, RJ | 1 |
| Hoffe, SE | 1 |
| Minsky, BD | 1 |
| Smith, GL | 1 |
| Blum, M | 3 |
| Mansfield, PF | 7 |
| Ikoma, N | 2 |
| Das, P | 4 |
| Ajani, J | 7 |
| Fleming, JB | 1 |
| Badgwell, BD | 3 |
| Patel, JN | 1 |
| Jiang, C | 1 |
| Owzar, K | 1 |
| Mulkey, F | 1 |
| Luzum, JA | 1 |
| Mamon, HJ | 2 |
| Haller, DG | 8 |
| Dragovich, T | 2 |
| Alberts, SR | 4 |
| Bjarnason, G | 1 |
| Willet, CG | 1 |
| Niedzwiecki, D | 4 |
| Enzinger, P | 1 |
| Ratain, MJ | 1 |
| Fuchs, C | 2 |
| Long, Q | 1 |
| Zhuang, K | 2 |
| Han, K | 3 |
| Guo, H | 5 |
| Wu, HC | 1 |
| Lin, WL | 1 |
| Lin, CL | 1 |
| Lin, CY | 3 |
| Chen, SW | 1 |
| Chen, YX | 4 |
| Chen, CH | 2 |
| Lee, SW | 2 |
| Chen, SH | 1 |
| Tsao, CJ | 1 |
| Huang, WT | 1 |
| Guo, HR | 1 |
| İlhan, A | 1 |
| Turhan, O | 1 |
| Kurt İnci, B | 1 |
| Yildiz, F | 1 |
| Öksüzoğlu, B | 5 |
| Demir, M | 1 |
| Barbato, G | 1 |
| Giovannelli, L | 1 |
| Coratti, F | 1 |
| Shu, C | 2 |
| Wang, R | 3 |
| Wen, H | 1 |
| Tian, Z | 1 |
| Gou, G | 2 |
| Hao, C | 1 |
| Cui, Y | 4 |
| Lane, J | 1 |
| Ji, J | 14 |
| Jiang, WG | 3 |
| Zhu, CH | 1 |
| Peng, SQ | 1 |
| Cui, LL | 1 |
| Cao, W | 3 |
| Zhang, LS | 2 |
| Zhao, ZM | 1 |
| Jia, L | 1 |
| Zhang, TF | 1 |
| Guo, JB | 1 |
| Pang, C | 1 |
| Na, D | 1 |
| Chae, J | 1 |
| Lee, A | 1 |
| Min, S | 1 |
| Kang, J | 1 |
| Choi, J | 2 |
| Lee, W | 2 |
| Shin, D | 1 |
| Min, A | 3 |
| Kim, YJ | 8 |
| Lee, KH | 13 |
| Kim, TY | 20 |
| Suh, YS | 1 |
| Kong, SH | 2 |
| Kim, WH | 9 |
| Im, SA | 16 |
| Yang, HK | 9 |
| Lee, C | 3 |
| Kim, JI | 3 |
| Nakazawa, N | 1 |
| Sohda, M | 1 |
| Ide, M | 2 |
| Shimoda, Y | 1 |
| Ubukata, Y | 1 |
| Kuriyama, K | 1 |
| Hara, K | 3 |
| Sano, A | 1 |
| Sakai, M | 2 |
| Yokobori, T | 2 |
| Ogawa, H | 1 |
| Oyama, T | 2 |
| Shirabe, K | 1 |
| Saeki, H | 4 |
| Sędłak, K | 1 |
| Rawicz-Pruszyński, K | 1 |
| Mlak, R | 1 |
| Gęca, K | 1 |
| Skórzewska, M | 1 |
| Pelc, Z | 1 |
| Małecka-Massalska, T | 1 |
| Polkowski, WP | 1 |
| Peng, Y | 3 |
| Feng, X | 1 |
| Seeruttun, SR | 1 |
| Cheng, Z | 3 |
| Grieb, BC | 1 |
| Agarwal, R | 1 |
| Dai, X | 2 |
| Jin, F | 2 |
| Qian, Y | 2 |
| Xiong, F | 2 |
| Chang, NA | 1 |
| Sun, YU | 1 |
| Leong, T | 4 |
| Smithers, BM | 2 |
| Haustermans, K | 2 |
| Michael, M | 4 |
| Gebski, V | 5 |
| Miller, D | 2 |
| Zalcberg, J | 4 |
| Boussioutas, A | 4 |
| Findlay, M | 4 |
| O'Connell, RL | 1 |
| Verghis, J | 1 |
| Willis, D | 2 |
| Kron, T | 1 |
| Crain, M | 1 |
| Murray, WK | 1 |
| Swallow, C | 4 |
| Simes, J | 2 |
| Yang, YJ | 1 |
| Qi, SN | 1 |
| Shi, RY | 1 |
| Wang, LS | 1 |
| Yuan, HQ | 1 |
| Jing, YX | 1 |
| Guo, Y | 5 |
| Qin, X | 1 |
| Hou, YC | 1 |
| Fang, JY | 2 |
| Bozkurt, M | 2 |
| Amlashi, FG | 1 |
| Liang, L | 2 |
| Zhao, N | 2 |
| Liu, T | 6 |
| Park, SB | 1 |
| Song, SY | 3 |
| Illerhaus, G | 2 |
| Martens, UM | 1 |
| Stoehlmacher, J | 6 |
| Luley, KB | 1 |
| Prasnikar, N | 1 |
| Egger, M | 1 |
| Probst, S | 3 |
| Messmann, H | 1 |
| Fischbach, W | 1 |
| Hartmann, JT | 16 |
| Mayer, F | 1 |
| Höffkes, HG | 1 |
| Koenigsmann, M | 1 |
| Arnold, D | 3 |
| Kraus, TW | 1 |
| Grimm, K | 1 |
| Berkhoff, S | 1 |
| Post, S | 4 |
| Jäger, E | 11 |
| Bechstein, W | 1 |
| Ronellenfitsch, U | 2 |
| Mönig, S | 2 |
| Wang, ZX | 3 |
| Li, GX | 3 |
| Zhou, ZW | 6 |
| Huang, ZP | 1 |
| Xu, RH | 11 |
| Pernot, S | 3 |
| Badoual, C | 1 |
| Terme, M | 1 |
| Castan, F | 1 |
| Cazes, A | 1 |
| Bennouna, J | 1 |
| Francois, E | 2 |
| Ghiringhelli, F | 1 |
| De La Fouchardiere, C | 2 |
| Bachet, JB | 4 |
| Borg, C | 2 |
| Ducreux, M | 7 |
| Marcheteau, E | 1 |
| Stanbury, T | 1 |
| Gourgou, S | 1 |
| Malka, D | 2 |
| Hsu, JT | 1 |
| Hsu, CS | 1 |
| Le, PH | 1 |
| Chen, TC | 1 |
| Chou, WC | 1 |
| Yeh, TS | 2 |
| Xu, GY | 1 |
| Tang, XJ | 1 |
| Moon, JH | 1 |
| Fujiwara, Y | 17 |
| Hirao, M | 4 |
| Imamura, H | 3 |
| Fujita, J | 1 |
| Takiguchi, S | 11 |
| Yano, M | 8 |
| Mori, M | 12 |
| Xing, X | 2 |
| Meng, F | 1 |
| Zhong, D | 2 |
| Zeng, YC | 1 |
| Sun, D | 1 |
| Li, WH | 2 |
| Xin, Y | 1 |
| Pant, S | 1 |
| Patel, M | 1 |
| Kurkjian, C | 1 |
| Hemphill, B | 1 |
| Flores, M | 1 |
| Thompson, D | 1 |
| Li, T | 10 |
| Xi, S | 1 |
| Wen, Y | 2 |
| Huang, L | 6 |
| Xiao, C | 1 |
| Qi, X | 1 |
| Cai, S | 2 |
| Sobhani, N | 1 |
| Generali, D | 1 |
| Gong, YC | 1 |
| Ren, GL | 1 |
| Zhao, HP | 1 |
| Chen, JB | 1 |
| Li, YP | 2 |
| Yu, HH | 1 |
| Xing, Y | 2 |
| Gao, Q | 2 |
| Zhang, D | 5 |
| Cao, G | 2 |
| Murata, S | 2 |
| Yamamoto, H | 11 |
| Naitoh, H | 2 |
| Yamaguchi, T | 12 |
| Kaida, S | 2 |
| Shimizu, T | 7 |
| Shiomi, H | 1 |
| Naka, S | 2 |
| Tani, T | 5 |
| Tani, M | 4 |
| Jin, J | 3 |
| Lv, H | 1 |
| Chen, K | 1 |
| Han, J | 2 |
| Feng, J | 5 |
| Yu, H | 3 |
| Su, D | 2 |
| Ying, L | 1 |
| Ter Veer, E | 3 |
| Ngai, LL | 2 |
| Valkenhoef, GV | 1 |
| Mohammad, NH | 1 |
| Anderegg, MCJ | 1 |
| van Oijen, MGH | 3 |
| van Laarhoven, HWM | 3 |
| Hirsch, D | 1 |
| Gu, D | 3 |
| Wagner, AD | 5 |
| Syn, NL | 2 |
| Grothe, W | 4 |
| Tai, BC | 1 |
| Ho, J | 1 |
| Unverzagt, S | 2 |
| Sun, Y | 10 |
| Cheng, Y | 5 |
| Hasiqi, MG | 1 |
| Qin, XZ | 1 |
| Tang, XY | 1 |
| Chen, JN | 1 |
| Wang, HY | 2 |
| Gao, A | 1 |
| Zang, M | 1 |
| Hu, L | 2 |
| Cao, S | 1 |
| Fan, Z | 2 |
| Pang, L | 1 |
| Gu, Q | 1 |
| Wu, S | 6 |
| Mazzone, M | 1 |
| Finisguerra, V | 1 |
| Prenen, H | 2 |
| Abramov, M | 1 |
| Bondarenko, I | 1 |
| Shparyk, Y | 1 |
| Gorbunova, V | 5 |
| Hontsa, A | 1 |
| Otchenash, N | 1 |
| Alsina, M | 3 |
| Lazarev, S | 1 |
| Feliu, J | 4 |
| Elme, A | 2 |
| Esko, V | 1 |
| Abdalla, K | 1 |
| Verma, U | 1 |
| Benedetti, F | 1 |
| Mizuguchi, H | 1 |
| Makris, L | 1 |
| Gao, Z | 3 |
| Erdem, GU | 3 |
| Bozkaya, Y | 3 |
| Ozdemir, NY | 4 |
| Demirci, NS | 3 |
| Zengin, N | 8 |
| Noble, F | 2 |
| Lloyd, MA | 1 |
| Turkington, R | 1 |
| Griffiths, E | 1 |
| O'Donovan, M | 1 |
| O'Neill, JR | 1 |
| Mercer, S | 1 |
| Parsons, SL | 6 |
| Fitzgerald, RC | 1 |
| Underwood, TJ | 2 |
| Niu, W | 1 |
| Jun, M | 1 |
| Song, DJ | 1 |
| Xu, ZL | 1 |
| Xie, SP | 1 |
| Hu, JH | 1 |
| Lu, L | 2 |
| Li, ZJ | 2 |
| Li, LF | 1 |
| Li, MX | 1 |
| Xiao, ZG | 1 |
| Wang, JH | 2 |
| Cho, CH | 1 |
| Tepper, JE | 2 |
| Ye, X | 1 |
| Swanson, RS | 1 |
| Enzinger, PC | 2 |
| Bjarnason, GA | 2 |
| Willett, CG | 1 |
| Gunderson, LL | 6 |
| Goldberg, RM | 2 |
| Venook, AP | 2 |
| O'Reilly, E | 1 |
| Ciombor, K | 1 |
| Berg, DJ | 1 |
| Meyerhardt, J | 1 |
| Mayer, RJ | 1 |
| Yang, W | 6 |
| Xin, L | 1 |
| Laterza, MM | 2 |
| Petrillo, A | 1 |
| Pappalardo, A | 1 |
| Orditura, M | 7 |
| Troiani, T | 1 |
| Ciardiello, F | 5 |
| Di Martino, N | 3 |
| Kanazawa, Y | 3 |
| Yamada, T | 11 |
| Fujita, I | 1 |
| Kakinuma, D | 1 |
| Matsuno, K | 1 |
| Shimoda, T | 3 |
| Ko, K | 1 |
| Kato, S | 2 |
| Matsutani, T | 3 |
| Hagiwara, N | 1 |
| Nomura, T | 2 |
| Uchida, E | 6 |
| Muto, O | 2 |
| Munakata, M | 1 |
| Yamagata, K | 1 |
| Masuda, A | 1 |
| Kotanagi, K | 2 |
| Kichiraku, T | 2 |
| Satoyoshi, R | 1 |
| Kudoh, K | 1 |
| Sawada, T | 8 |
| Miyazawa, H | 1 |
| Ouchi, S | 2 |
| Kotanagi, H | 2 |
| Sakata, Y | 17 |
| Sun, L | 3 |
| Wu, Z | 3 |
| Kawasaki, K | 2 |
| Takeuchi, D | 1 |
| Kaneko, T | 2 |
| Miura, S | 3 |
| Kamiya, J | 1 |
| Miyahara, Y | 1 |
| Yoshimura, K | 1 |
| Ogata, A | 1 |
| Tan, AM | 1 |
| Cartwright, E | 1 |
| Ina, K | 3 |
| Furuta, R | 2 |
| Yin, B | 1 |
| Wang, G | 3 |
| Kondo, M | 3 |
| Sugiyama, K | 9 |
| Mishima, H | 4 |
| Cloyd, J | 1 |
| Agnes, A | 1 |
| Rodriguez-Bigas, M | 1 |
| You, YN | 1 |
| Radyk, MD | 1 |
| Burclaff, J | 1 |
| Willet, SG | 1 |
| Mills, JC | 1 |
| Hentic, O | 2 |
| Lombard-Bohas, C | 1 |
| Smith, D | 6 |
| Ferru, A | 1 |
| Assenat, E | 1 |
| Cadiot, G | 1 |
| Kurtz, JE | 1 |
| Dahan, L | 5 |
| Dubreuil, O | 3 |
| Lepere, C | 3 |
| Gangloff, A | 1 |
| Elhajbi, F | 1 |
| Coriat, R | 3 |
| Roquin, G | 1 |
| Bouarioua, N | 1 |
| Granger, V | 1 |
| Takebayashi, K | 1 |
| Miyake, T | 1 |
| Ku, KH | 1 |
| Park, SJ | 2 |
| Kim, JH | 23 |
| Kwon, HJ | 2 |
| Chang, HK | 2 |
| Park, JG | 4 |
| Hyun, HB | 1 |
| Moon, JY | 2 |
| Cho, SK | 2 |
| Abrams, T | 1 |
| Hess, LM | 1 |
| Zhu, YE | 1 |
| Schelman, W | 1 |
| Wang, D | 9 |
| Ye, F | 3 |
| Zhang, DY | 3 |
| Suo, J | 3 |
| Han, Y | 7 |
| Peng, Z | 3 |
| Park, SS | 3 |
| Lee, CM | 1 |
| Kim, MC | 8 |
| Kwon, IK | 1 |
| Min, JS | 12 |
| Kim, HI | 1 |
| Lee, HH | 1 |
| Lee, SI | 6 |
| Chae, H | 1 |
| Creemers, A | 1 |
| de Waal, L | 1 |
| Chu, NS | 1 |
| Chen, LT | 8 |
| Chin, YY | 1 |
| Bian, W | 1 |
| Feng, W | 1 |
| He, XX | 1 |
| Huang, CK | 1 |
| Xie, BS | 1 |
| Nagel, M | 1 |
| Schulz, J | 1 |
| Maderer, A | 4 |
| Goepfert, K | 1 |
| Gehrke, N | 1 |
| Thomaidis, T | 3 |
| Thuss-Patience, PC | 10 |
| Grimminger, P | 1 |
| Galle, PR | 7 |
| Möhler, M | 3 |
| Schattenberg, JM | 1 |
| Duan, X | 1 |
| Sezer, S | 1 |
| Antonoff, M | 1 |
| Jaramillo, S | 1 |
| Sagebiel, T | 1 |
| Murphy, MB | 1 |
| Song, L | 2 |
| Chang, L | 2 |
| Guo, XF | 3 |
| Liu, JP | 1 |
| Ma, SQ | 2 |
| Sun, WD | 1 |
| Pei, G | 1 |
| Luo, M | 1 |
| Ni, X | 2 |
| Chao, X | 1 |
| Ayidu, A | 1 |
| Abudureyimu, A | 1 |
| Yin, Y | 2 |
| Shen, C | 2 |
| Yin, X | 3 |
| Kim, JE | 4 |
| Lim, JM | 1 |
| Oh, DY | 14 |
| Xin, J | 2 |
| Xin, B | 1 |
| Yao, C | 1 |
| Petrioli, R | 6 |
| Nardone, V | 1 |
| Rosellini, P | 2 |
| Multari, AG | 2 |
| Conca, R | 2 |
| Aieta, M | 2 |
| Zhai, E | 1 |
| Peng, S | 1 |
| Choi, M | 1 |
| Suh, KJ | 2 |
| Lee, JY | 4 |
| Kang, B | 2 |
| Kim, SH | 22 |
| Lee, JO | 3 |
| Bang, SM | 9 |
| Lee, JS | 26 |
| Cortellini, A | 1 |
| Cannita, K | 1 |
| Parisi, A | 1 |
| Venditti, O | 1 |
| Lanfiuti Baldi, P | 1 |
| De Berardis, B | 1 |
| Vicentini, R | 1 |
| Vicentini, V | 1 |
| Verna, L | 1 |
| Porzio, G | 1 |
| Ficorella, C | 1 |
| Li, LQ | 3 |
| Pan, D | 3 |
| Zhang, SW | 2 |
| -Y-Xie, D | 1 |
| Zheng, XL | 2 |
| Xie, DY | 1 |
| Wu, DM | 1 |
| Hong, XW | 1 |
| Wang, LL | 2 |
| Cui, XF | 1 |
| Chen, GQ | 1 |
| Zheng, YL | 2 |
| Cui, YH | 2 |
| Ji, Y | 4 |
| Sun, YH | 4 |
| Shen, ZB | 4 |
| Liu, FL | 2 |
| Liu, TS | 7 |
| Nie, H | 1 |
| Mu, J | 1 |
| Knödler, M | 1 |
| Körfer, J | 1 |
| Kunzmann, V | 1 |
| Trojan, J | 1 |
| Daum, S | 4 |
| Kullmann, F | 3 |
| Schroll, S | 1 |
| Behringer, D | 1 |
| Stahl, M | 14 |
| Hacker, U | 1 |
| Ibach, S | 1 |
| Lindhofer, H | 1 |
| Liu, JL | 2 |
| Huang, WS | 1 |
| Lee, KC | 1 |
| Tung, SY | 1 |
| Chen, CN | 2 |
| Chang, SF | 1 |
| Park, JB | 2 |
| Lee, MS | 3 |
| Cha, EY | 2 |
| Sul, JY | 2 |
| de Alencar Camara Vieira, FM | 1 |
| de Souza Victorino, APO | 1 |
| de Iracema Gomes Cubero, D | 1 |
| Beato, CAM | 1 |
| Minowa, E | 1 |
| Julian, GS | 1 |
| Novick, D | 1 |
| Mondaca, S | 2 |
| Margolis, M | 1 |
| Sanchez-Vega, F | 1 |
| Jonsson, P | 1 |
| Riches, JC | 1 |
| Ku, GY | 3 |
| Hechtman, JF | 1 |
| Tuvy, Y | 1 |
| Berger, MF | 1 |
| Kelsen, DP | 9 |
| Ilson, DH | 8 |
| Goldberg, Z | 1 |
| Epstein, AS | 1 |
| Desai, A | 1 |
| Chung, V | 2 |
| Chou, JF | 1 |
| Capanu, M | 3 |
| Solit, DB | 1 |
| Schultz, N | 1 |
| Schad, A | 2 |
| Atasoy, A | 1 |
| Mauer, ME | 1 |
| Caballero, C | 2 |
| John, JMM | 1 |
| Lang, I | 2 |
| Freire, J | 1 |
| Lutz, MP | 2 |
| Roth, A | 6 |
| Zhao, W | 3 |
| Du, M | 1 |
| Gong, W | 5 |
| Tan, Y | 4 |
| Wen, J | 4 |
| Zhai, Y | 1 |
| Jiang, ZC | 1 |
| Chi, Y | 2 |
| Jang, M | 1 |
| Koh, I | 1 |
| Lee, JE | 3 |
| Lim, JY | 3 |
| Kim, P | 1 |
| Shi, C | 1 |
| Lin, X | 6 |
| Fan, B | 1 |
| Guo, Q | 1 |
| Ustaalioglu, BBO | 1 |
| Bilici, A | 7 |
| Tilki, M | 1 |
| Surmelioglu, A | 1 |
| Erkol, B | 1 |
| Figen, M | 1 |
| Uyar, S | 1 |
| Athauda, A | 1 |
| Mohammed, K | 1 |
| Tait, D | 1 |
| Aitken, K | 1 |
| Mori, R | 2 |
| Yoshida, K | 22 |
| Futamura, M | 2 |
| Suetsugu, T | 1 |
| Shizu, K | 1 |
| Tanahashi, T | 3 |
| Tanaka, Y | 10 |
| Matsuhashi, N | 4 |
| Touchefeu, Y | 1 |
| Barbier, E | 1 |
| Cohen, R | 3 |
| Azzedine, A | 2 |
| Etienne, PL | 4 |
| Phelip, JM | 1 |
| Hammel, P | 2 |
| Chapelle, N | 1 |
| Sefrioui, D | 1 |
| Mineur, L | 1 |
| Tang, J | 1 |
| Bu, Y | 1 |
| Miyoshi, S | 1 |
| Tsugawa, H | 1 |
| Matsuzaki, J | 1 |
| Hirata, K | 12 |
| Mori, H | 1 |
| Saya, H | 1 |
| Kanai, T | 1 |
| Suzuki, H | 10 |
| Shen, Z | 1 |
| Liu, F | 8 |
| Zhang, XQ | 3 |
| Yu, LT | 1 |
| Du, P | 1 |
| Yin, TQ | 1 |
| Zhang, ZY | 1 |
| Li, YJ | 1 |
| Luo, C | 2 |
| Yoon, SS | 2 |
| Strong, VE | 1 |
| Greally, M | 1 |
| Natori, Y | 1 |
| Que, WC | 1 |
| Huang, YF | 1 |
| Lin, XY | 1 |
| Lan, YQ | 1 |
| Gao, XY | 1 |
| Wang, XL | 2 |
| Wu, RP | 1 |
| Du, B | 1 |
| Huang, XB | 1 |
| Qiu, HQ | 1 |
| Zhong, DT | 1 |
| Steele, NG | 1 |
| Chakrabarti, J | 1 |
| Biesiada, J | 1 |
| Holokai, L | 1 |
| Chang, J | 1 |
| Nowacki, LM | 1 |
| Hawkins, J | 1 |
| Mahe, M | 1 |
| Sundaram, N | 1 |
| Shroyer, N | 1 |
| Medvedovic, M | 1 |
| Helmrath, M | 1 |
| Ahmad, S | 1 |
| Zavros, Y | 1 |
| Watson, S | 1 |
| Tournigand, C | 2 |
| Ferraz, JM | 1 |
| Lefevre, M | 1 |
| Colin, D | 1 |
| Svrcek, M | 1 |
| Meurisse, A | 1 |
| Yukami, H | 1 |
| Terazawa, T | 1 |
| Goto, M | 8 |
| Aoki, M | 1 |
| Asaishi, K | 1 |
| Kuwakado, S | 1 |
| Kii, T | 1 |
| Higuchi, K | 8 |
| Yu, C | 2 |
| Chen, DQ | 1 |
| Li, WB | 1 |
| Lu, JW | 6 |
| Feng, JF | 7 |
| Fanotto, V | 1 |
| Bordonaro, R | 2 |
| Rimassa, L | 2 |
| Santini, D | 6 |
| Tomasello, G | 4 |
| Leone, F | 1 |
| Scartozzi, M | 4 |
| Giampieri, R | 2 |
| Nichetti, F | 1 |
| Cinieri, S | 1 |
| Avallone, A | 1 |
| Pellegrino, A | 1 |
| Melisi, D | 1 |
| Gerratana, L | 1 |
| Aprile, G | 2 |
| Kim, JL | 1 |
| Lee, DH | 2 |
| Jeong, S | 1 |
| Kim, BR | 1 |
| Na, YJ | 1 |
| Jo, MJ | 1 |
| Jeong, YA | 1 |
| Oh, SC | 6 |
| Kang, YK | 37 |
| Ng, M | 1 |
| Chung, HC | 26 |
| Gendreau, S | 1 |
| Chan, WY | 1 |
| Xu, N | 8 |
| Maslyar, D | 1 |
| Meng, R | 1 |
| Lee, H | 1 |
| Min, BH | 1 |
| Kim, JJ | 1 |
| Jeong, WK | 1 |
| Choi, DI | 1 |
| Seo, SW | 1 |
| Rao, C | 1 |
| Zheng, G | 2 |
| Paganini, G | 1 |
| Chiriacò, G | 1 |
| He, W | 1 |
| Liang, B | 1 |
| Yao, Z | 2 |
| Wu, Q | 5 |
| Liao, W | 2 |
| Yuan, X | 3 |
| Zheng, F | 1 |
| Ahmad, R | 1 |
| Song, N | 1 |
| Han, M | 1 |
| Guo, LH | 1 |
| Jihui, J | 1 |
| Kim, C | 4 |
| Chon, HJ | 1 |
| Nam, CM | 1 |
| Rha, SY | 21 |
| Cleary, JM | 1 |
| Horick, NK | 1 |
| McCleary, NJ | 1 |
| Abrams, TA | 1 |
| Yurgelun, MB | 1 |
| Azzoli, CG | 1 |
| Rubinson, DA | 1 |
| Brooks, GA | 1 |
| Chan, JA | 1 |
| Blaszkowsky, LS | 1 |
| Clark, JW | 1 |
| Goyal, L | 1 |
| Meyerhardt, JA | 2 |
| Ng, K | 1 |
| Schrag, D | 2 |
| Savarese, DMF | 1 |
| Graham, C | 1 |
| Fitzpatrick, B | 1 |
| Gibb, KA | 1 |
| Boucher, Y | 1 |
| Duda, DG | 1 |
| Jain, RK | 1 |
| Liu, L | 4 |
| Xie, X | 1 |
| Xia, L | 3 |
| Meng, J | 2 |
| He, D | 1 |
| Rivera, F | 4 |
| Romero, C | 1 |
| Jimenez-Fonseca, P | 1 |
| Izquierdo-Manuel, M | 1 |
| Salud, A | 1 |
| Martínez, E | 1 |
| Jorge, M | 1 |
| Arrazubi, V | 1 |
| Méndez, JC | 1 |
| García-Alfonso, P | 2 |
| Reboredo, M | 3 |
| Barriuso, J | 3 |
| Muñoz-Unceta, N | 1 |
| Jimeno, R | 1 |
| López, C | 2 |
| Jin, H | 2 |
| Bae, CA | 1 |
| Jeon, SM | 1 |
| Son, SY | 1 |
| Han, SU | 6 |
| Brekken, RA | 1 |
| Lu, B | 2 |
| Lu, C | 2 |
| Qu, C | 1 |
| Hua, Z | 1 |
| Tong, R | 1 |
| Yasui, H | 10 |
| Kawakami, T | 1 |
| Kashiwagi, H | 1 |
| Mori, K | 5 |
| Omae, K | 1 |
| Kasai, J | 1 |
| Yoshisue, K | 1 |
| Kawahira, M | 2 |
| Machida, N | 3 |
| Fukutomi, A | 5 |
| Han, C | 3 |
| Pang, Q | 1 |
| Ge, X | 1 |
| Ni, W | 1 |
| Liang, J | 9 |
| Deng, L | 1 |
| Xiao, Z | 1 |
| Cui, XL | 1 |
| Li, KJ | 1 |
| Ren, HX | 1 |
| Zhang, YJ | 1 |
| Liu, XD | 1 |
| Bu, BG | 1 |
| Yeh, YS | 2 |
| Chen, YT | 1 |
| Tsai, HL | 2 |
| Huang, CW | 1 |
| Ma, CJ | 2 |
| Su, WC | 3 |
| Huang, MY | 1 |
| Hu, HM | 1 |
| Lu, CY | 2 |
| Wang, JY | 4 |
| Zhou, R | 1 |
| Catenacci, DV | 1 |
| Tesfaye, A | 1 |
| Tejani, M | 1 |
| Cheung, E | 1 |
| Eisenberg, P | 1 |
| Scott, AJ | 1 |
| Eng, C | 1 |
| Hnatyszyn, J | 1 |
| Marina, N | 1 |
| Powers, J | 1 |
| Hou, G | 2 |
| Jagric, T | 1 |
| Ilijevec, B | 1 |
| Velenik, V | 2 |
| Ocvirk, J | 2 |
| Potrc, S | 1 |
| Pei, Q | 1 |
| Pei, X | 1 |
| Wang, CQ | 1 |
| Jingyue, S | 1 |
| Xiao, W | 1 |
| Juanmin, Z | 1 |
| Wei, L | 1 |
| Daoming, L | 1 |
| Hong, X | 3 |
| Grabsch, HI | 2 |
| Mauer, M | 1 |
| Marreaud, S | 1 |
| Mueller, L | 1 |
| Moehler, MH | 1 |
| Martens, U | 1 |
| Cats, A | 8 |
| Tokunaga, M | 2 |
| Wu, B | 3 |
| Ma, N | 1 |
| Zhao, S | 1 |
| Mochizuki, Y | 4 |
| Harada, H | 1 |
| Oyama, J | 1 |
| Sakamoto, K | 12 |
| Michi, Y | 1 |
| Kuroshima, T | 1 |
| Kugimoto, T | 1 |
| Zhuang, J | 1 |
| Huang, Y | 7 |
| Zheng, W | 2 |
| Zhu, G | 1 |
| Ye, J | 3 |
| Jin, X | 4 |
| Bai, Y | 7 |
| Ben Kridis, W | 1 |
| Marrekchi, G | 1 |
| Mzali, R | 1 |
| Daoud, J | 1 |
| Khanfir, A | 1 |
| Iwasa, S | 6 |
| Minashi, K | 1 |
| Fukuda, N | 1 |
| Hwang, JE | 2 |
| Shim, HJ | 3 |
| Bae, WK | 2 |
| Hwang, EC | 2 |
| Jeong, O | 2 |
| Ryu, SY | 1 |
| Park, YK | 3 |
| Cho, SH | 6 |
| Chung, IJ | 7 |
| Aznab, M | 1 |
| Maleksabet, D | 1 |
| Khazaei, S | 1 |
| Khazaei, M | 1 |
| Rezaei, M | 1 |
| Nam, HJ | 2 |
| Kim, HP | 3 |
| Han, SW | 8 |
| Cabau, M | 1 |
| Luc, G | 1 |
| Terrebonne, E | 2 |
| Belleanne, G | 1 |
| Vendrely, V | 1 |
| Sa Cunha, A | 1 |
| Collet, D | 1 |
| Rong, H | 1 |
| Li, PF | 1 |
| Geng, M | 5 |
| Cao, YC | 3 |
| Yin, YC | 3 |
| Deng, T | 4 |
| Xiong, JP | 7 |
| Zhuang, ZX | 2 |
| Wan, HP | 2 |
| Huang, DZ | 3 |
| Zheng, RS | 2 |
| Guo, ZQ | 5 |
| Hu, CH | 2 |
| Wang, ML | 3 |
| Yu, ZH | 3 |
| Meng, JC | 2 |
| Ba, Y | 5 |
| Nishikawa, S | 1 |
| Konno, M | 1 |
| Hamabe, A | 1 |
| Hasegawa, S | 3 |
| Kano, Y | 3 |
| Ohta, K | 7 |
| Fukusumi, T | 1 |
| Sakai, D | 1 |
| Kudo, T | 2 |
| Haraguchi, N | 3 |
| Satoh, T | 8 |
| Ishii, H | 2 |
| Ahn, KS | 3 |
| Tsukada, T | 1 |
| Fushida, S | 3 |
| Harada, S | 1 |
| Terai, S | 1 |
| Yagi, Y | 2 |
| Kinoshita, J | 1 |
| Oyama, K | 8 |
| Tajima, H | 1 |
| Ninomiya, I | 3 |
| Fujimura, T | 4 |
| Ohta, T | 4 |
| Kripp, M | 3 |
| Rosowski, J | 1 |
| Migita, K | 1 |
| Takayama, T | 9 |
| Saeki, K | 3 |
| Enomoto, K | 1 |
| Kurumatani, N | 1 |
| Nakajima, Y | 2 |
| Wei, WY | 2 |
| Wang, XT | 2 |
| Chu, C | 1 |
| Cheung, WL | 1 |
| Ng, L | 1 |
| Lam, S | 1 |
| Chow, A | 1 |
| Lau, T | 1 |
| Wong, BC | 1 |
| Pang, R | 1 |
| Pluschnig, U | 2 |
| Schoppmann, SF | 2 |
| Preusser, M | 1 |
| Datler, P | 2 |
| Asari, R | 1 |
| Ba-Ssalamah, A | 2 |
| Schwameis, K | 1 |
| Birner, P | 1 |
| Zacherl, J | 2 |
| Hejna, M | 3 |
| Uronis, HE | 1 |
| Bendell, JC | 2 |
| Altomare, I | 1 |
| Blobe, GC | 1 |
| Hsu, SD | 1 |
| Morse, MA | 1 |
| Pang, H | 1 |
| Zafar, SY | 1 |
| Conkling, P | 1 |
| Favaro, J | 1 |
| Arrowood, CC | 1 |
| Cushman, SM | 1 |
| Meadows, KL | 1 |
| Brady, JC | 1 |
| Nixon, AB | 1 |
| Hurwitz, HI | 1 |
| Xie, L | 3 |
| Su, X | 2 |
| Tang, L | 6 |
| Gao, B | 1 |
| Shen, D | 2 |
| Gavine, PR | 1 |
| Kilgour, E | 1 |
| Ji, Q | 1 |
| Nakamura, A | 1 |
| Nakajima, G | 1 |
| Okuyama, R | 1 |
| Kuramochi, H | 1 |
| Kondoh, Y | 1 |
| Kanemura, T | 1 |
| Takechi, T | 6 |
| Yamamoto, M | 14 |
| Hayashi, K | 4 |
| Gordon, MA | 1 |
| Gundacker, HM | 1 |
| Benedetti, J | 2 |
| Macdonald, JS | 20 |
| Baranda, JC | 1 |
| Levin, WJ | 1 |
| Blanke, CD | 4 |
| Elatre, W | 1 |
| Weng, P | 1 |
| Zhou, JY | 1 |
| Press, MF | 1 |
| Gu, X | 2 |
| Xiang, J | 3 |
| Kiyota, N | 2 |
| Fuse, N | 2 |
| Minami, H | 2 |
| Hashizume, K | 1 |
| Kuroki, Y | 1 |
| Ito, Y | 5 |
| Ohtsu, A | 32 |
| Xu, M | 2 |
| Cao, FL | 1 |
| Li, NY | 1 |
| Lv, CL | 1 |
| Zhang, WY | 1 |
| Zhang, WJ | 2 |
| Yuan, HH | 1 |
| Gao, J | 10 |
| Gong, YF | 1 |
| Jiang, B | 4 |
| Alici, S | 2 |
| Buyukberber, S | 6 |
| Alkis, N | 4 |
| Benekli, M | 6 |
| Ozkan, M | 3 |
| Demirci, U | 2 |
| Karaca, H | 1 |
| Arpaci, E | 4 |
| Gumus, M | 5 |
| Altunbas, M | 1 |
| Dane, F | 6 |
| Qu, JJ | 2 |
| Shi, YR | 2 |
| Hao, FY | 1 |
| Mayahara, H | 1 |
| Jiang, CP | 1 |
| Wu, BH | 1 |
| Wang, BQ | 1 |
| Fu, MY | 1 |
| Yang, M | 2 |
| Boda-Heggemann, J | 2 |
| Weiss, C | 2 |
| Schneider, V | 1 |
| Haneder, S | 1 |
| Michaely, H | 1 |
| Wertz, H | 2 |
| Hochhaus, A | 7 |
| Wenz, F | 3 |
| Lohr, F | 2 |
| Saridaki, Z | 1 |
| Lambrodimou, G | 1 |
| Kachris, S | 1 |
| Makrantonakis, P | 1 |
| Boukovinas, I | 1 |
| Polyzos, A | 2 |
| Anagnostopoulos, A | 1 |
| Athanasiadis, A | 1 |
| Stoltidis, D | 1 |
| Georgoulias, V | 1 |
| Souglakos, J | 1 |
| Shang, Y | 4 |
| Fan, D | 7 |
| Scheithauer, W | 3 |
| Costa, FP | 1 |
| Gumz, B | 1 |
| Pasche, B | 1 |
| Haller, B | 1 |
| Schuster, T | 4 |
| Luley, K | 2 |
| Bichev, D | 4 |
| Schumacher, G | 3 |
| Chen, XL | 1 |
| Chen, XZ | 3 |
| Liao, YB | 1 |
| Yang, K | 3 |
| Hu, JK | 3 |
| Chen, ZX | 3 |
| Zhou, ZG | 2 |
| Waddell, T | 1 |
| Okines, AF | 6 |
| Frances, A | 1 |
| Okines, C | 1 |
| Wotherspoon, A | 6 |
| Saffery, C | 2 |
| Middleton, G | 4 |
| Wadsley, J | 1 |
| Ferry, D | 3 |
| Mansoor, W | 1 |
| Crosby, T | 1 |
| Coxon, F | 4 |
| Waters, J | 2 |
| Iveson, T | 9 |
| Falk, S | 3 |
| Slater, S | 2 |
| Peckitt, C | 3 |
| Barbachano, Y | 1 |
| Salman, P | 1 |
| Kurteva, G | 1 |
| Volovat, C | 1 |
| Moiseyenko, VM | 6 |
| Sawaki, A | 10 |
| Celik, I | 2 |
| Götte, H | 1 |
| Melezínková, H | 1 |
| Song, MQ | 1 |
| Lin, HZ | 1 |
| Hao, LH | 1 |
| Jiang, XJ | 1 |
| Li, ZY | 4 |
| Manikhas, GM | 2 |
| Zhukova, NV | 1 |
| Polysalov, VN | 1 |
| Veriasova, NN | 1 |
| Dolgikh, SD | 1 |
| Gapbarov, ACh | 1 |
| Liu, YP | 4 |
| Ling, Y | 2 |
| Qi, QF | 1 |
| Zhang, YP | 3 |
| Zhang, CS | 1 |
| Zhu, CT | 1 |
| Wang, MH | 1 |
| Pan, YD | 1 |
| Qiang, L | 2 |
| Yanping, L | 1 |
| Zonghai, H | 1 |
| Fei, C | 1 |
| Jinlong, Y | 1 |
| Zhou, ZH | 1 |
| Zhang, JD | 4 |
| Xu, GF | 1 |
| Zhao, HB | 1 |
| Yuan, ST | 1 |
| Wang, FL | 1 |
| Liu, N | 4 |
| Liu, YH | 2 |
| Liu, SG | 1 |
| Li, YQ | 2 |
| Liu, XB | 1 |
| Doganci, S | 1 |
| Kadan, M | 1 |
| Kaya, E | 1 |
| Erol, G | 1 |
| Gunay, C | 1 |
| Demirkilic, U | 1 |
| Song, X | 2 |
| Tian, J | 1 |
| Cao, F | 2 |
| Yin, L | 1 |
| Du, Z | 1 |
| Tang, R | 3 |
| Wang, YC | 1 |
| Xue, HP | 1 |
| Wang, ZH | 3 |
| Khanna, A | 1 |
| Reece-Smith, AM | 2 |
| Cunnell, M | 1 |
| Madhusudan, S | 4 |
| Thomas, A | 2 |
| Bowrey, DJ | 1 |
| Yu, DF | 1 |
| Wu, FR | 1 |
| Xia, Q | 1 |
| Tan, IB | 3 |
| Das, K | 1 |
| Deng, N | 2 |
| Zouridis, H | 1 |
| Pattison, S | 1 |
| Chua, C | 1 |
| Feng, Z | 1 |
| Guan, YK | 1 |
| Ooi, CH | 2 |
| Ivanova, T | 2 |
| Lee, M | 1 |
| Ngo, A | 1 |
| Manesh, S | 1 |
| Tan, E | 1 |
| Teh, BT | 1 |
| So, JB | 2 |
| Goh, LK | 1 |
| Lim, TK | 1 |
| Flotow, H | 1 |
| Tan, P | 3 |
| Rozen, SG | 1 |
| Chongqing, T | 1 |
| Liubao, P | 1 |
| Jianhe, L | 1 |
| Xiaomin, W | 1 |
| Gannong, C | 1 |
| Siying, W | 1 |
| Lihui, O | 1 |
| Ziying, Z | 1 |
| Yoo, C | 3 |
| Na, YS | 1 |
| Ryoo, BY | 10 |
| Lee, CW | 1 |
| Maeng, J | 1 |
| Kim, SY | 13 |
| Park, I | 1 |
| Gao, M | 2 |
| Cai, Y | 1 |
| Fei, Z | 1 |
| Xu, HQ | 1 |
| Qian, YD | 1 |
| Mitry, E | 5 |
| Dalban, C | 1 |
| Seitz, JF | 7 |
| Turki, H | 1 |
| Vaillant, JN | 2 |
| Landi, B | 3 |
| Rougier, P | 20 |
| Wei, ZW | 1 |
| He, YL | 2 |
| Schwarz, RE | 1 |
| Smith, DD | 1 |
| Xia, GK | 1 |
| Zhang, CH | 1 |
| Xian, XS | 1 |
| Park, JM | 2 |
| Piessen, G | 1 |
| Messager, M | 2 |
| Robb, WB | 1 |
| Di Fiore, F | 1 |
| Guilbert, M | 1 |
| Moreau, M | 1 |
| Christophe, V | 1 |
| Mariette, C | 3 |
| Yue, G | 2 |
| Wei, J | 6 |
| Qian, X | 4 |
| Zou, Z | 3 |
| Guan, W | 3 |
| Ji, M | 2 |
| Xu, B | 1 |
| Jiang, JT | 2 |
| Li, XD | 1 |
| Zhao, WQ | 1 |
| Zhang, HY | 1 |
| Zhou, WJ | 1 |
| Wu, CP | 2 |
| Jiang, ZM | 1 |
| Zhang, YD | 1 |
| Zhou, SW | 1 |
| Xie, DR | 2 |
| Xiong, J | 3 |
| Zhuang, Z | 1 |
| Wan, H | 1 |
| Zheng, R | 1 |
| Hu, C | 1 |
| Trusilova, EV | 1 |
| Besova, NS | 2 |
| Bagrova, SG | 1 |
| Gorbunova, VA | 2 |
| Stilidi, IS | 1 |
| Nered, SN | 1 |
| Takahashi, H | 14 |
| Kaniwa, N | 2 |
| Saito, Y | 4 |
| Sai, K | 2 |
| Hamaguchi, T | 10 |
| Shirao, K | 18 |
| Shimada, Y | 20 |
| Matsumura, Y | 4 |
| Takahashi, A | 3 |
| Odaka, Y | 3 |
| Okuyama, M | 4 |
| Sawada, J | 2 |
| Sakamoto, H | 4 |
| Yoshida, T | 11 |
| Cai, H | 3 |
| Tan, X | 1 |
| Chang, W | 1 |
| Ahn, JS | 3 |
| Jeon, JR | 1 |
| Yoo, HS | 2 |
| Park, TK | 1 |
| Park, CK | 6 |
| Sinn, DH | 1 |
| Paik, SW | 1 |
| Hirata, A | 1 |
| Itatsu, K | 1 |
| Fukaya, M | 1 |
| Ebata, T | 1 |
| Yokoyama, Y | 7 |
| Tsunoda, N | 1 |
| Igami, T | 1 |
| Sugawara, G | 1 |
| Uehara, K | 1 |
| Yoshioka, Y | 2 |
| Usui, H | 1 |
| Nagino, M | 1 |
| Jiao, XL | 1 |
| Liu, ZK | 1 |
| Zhang, MS | 1 |
| Niu, M | 1 |
| Katayama, K | 2 |
| Nishino, T | 1 |
| Takahashi, Y | 8 |
| Okitsu, H | 1 |
| Okitsu, N | 1 |
| Murata, Y | 1 |
| Matsuura, T | 1 |
| Kanoshima, K | 1 |
| Kuwabara, H | 1 |
| Fuyuki, A | 1 |
| Tomeno, W | 1 |
| Taniguchi, R | 1 |
| Uchiyama, T | 1 |
| Kuriyama, H | 1 |
| Hata, Y | 2 |
| Zhong, J | 1 |
| Yan, LH | 1 |
| Lian, C | 2 |
| Kong, FB | 1 |
| Luo, W | 1 |
| Xiao, Q | 3 |
| Lee, S | 10 |
| Kilic, L | 2 |
| Ordu, C | 1 |
| Ekenel, M | 2 |
| Yildiz, I | 2 |
| Keskin, S | 2 |
| Sen, F | 2 |
| Gural, Z | 1 |
| Asoglu, O | 2 |
| Kizir, A | 2 |
| Aykan, F | 3 |
| Chen, SS | 1 |
| Yang, XC | 1 |
| Chi, F | 1 |
| Yu, WZ | 1 |
| Wang, ZB | 1 |
| Ning, FL | 2 |
| Yu, ZS | 1 |
| Hao, YZ | 1 |
| Li, ML | 1 |
| Geng, DZ | 1 |
| Liu, LH | 1 |
| Dong, XJ | 1 |
| Peng, XZ | 1 |
| Ji, CX | 1 |
| Denda, T | 3 |
| Tsuji, A | 8 |
| Hamamoto, Y | 10 |
| Konishi, K | 7 |
| Tsuji, Y | 10 |
| Amagai, K | 2 |
| Ohkawa, S | 1 |
| Fujita, Y | 7 |
| Nishisaki, H | 2 |
| Kawai, H | 6 |
| Takashima, A | 8 |
| Nakamura, K | 10 |
| Turner, ES | 1 |
| Turner, JR | 1 |
| Bilir, C | 1 |
| Engin, H | 1 |
| Bakkal, BH | 1 |
| Ilikhan, SU | 1 |
| Malkoç, D | 1 |
| Ren, G | 2 |
| An, Y | 2 |
| Buyse, M | 7 |
| Lichinitser, M | 3 |
| Douillard, JY | 2 |
| Zaucha, R | 1 |
| Carrato, A | 3 |
| Moiseyenko, V | 4 |
| Jeong, SH | 5 |
| Park, JS | 6 |
| Lee, KJ | 2 |
| Cho, YK | 5 |
| Lee, SY | 5 |
| Weng, Y | 1 |
| Fei, B | 1 |
| Chi, AL | 1 |
| Cai, M | 1 |
| Baek, SK | 2 |
| Zhu, AK | 1 |
| Xia, JZ | 1 |
| Jin, HC | 1 |
| Zuo, JB | 1 |
| Shan, T | 2 |
| Stenholm, L | 1 |
| Stoehlmacher-Williams, J | 1 |
| Heussen, N | 1 |
| Akin, S | 1 |
| Lehmann, S | 1 |
| Senff, T | 1 |
| Ehninger, G | 2 |
| Kramer, M | 2 |
| You, T | 3 |
| Wang, WM | 1 |
| Zheng, ZQ | 2 |
| Ooki, A | 1 |
| Yamashita, K | 3 |
| Mondal, A | 1 |
| Nishimiya, H | 1 |
| Watanabe, M | 11 |
| Xu, JM | 5 |
| Feng, FY | 2 |
| Jiao, SC | 2 |
| Wang, LW | 1 |
| Guan, ZZ | 2 |
| Yu, SY | 2 |
| Wang, YJ | 4 |
| Jin, YN | 1 |
| Tao, M | 1 |
| Zheng, LZ | 1 |
| Pan, LX | 3 |
| Nitta, S | 1 |
| Kondo, C | 4 |
| Diaz-Nieto, R | 1 |
| Orti-Rodríguez, R | 1 |
| Winslet, M | 1 |
| Lee, SJ | 5 |
| Do, IG | 1 |
| Jung, SH | 3 |
| Yim, DS | 2 |
| Doi, T | 7 |
| Nasu, J | 2 |
| Fukuda, H | 5 |
| Fukamachi, H | 1 |
| Seol, HS | 1 |
| Shimada, S | 3 |
| Baba, K | 2 |
| Inokuchi, M | 1 |
| Kawachi, H | 1 |
| Yook, JH | 11 |
| Eishi, Y | 1 |
| Kojima, K | 1 |
| Jang, SJ | 1 |
| Yuasa, Y | 2 |
| Xue, Q | 1 |
| Wang, XN | 1 |
| Deng, JY | 1 |
| Zhang, RP | 1 |
| Seufferlein, T | 3 |
| Reinacher-Schick, A | 1 |
| Geissler, M | 2 |
| Schmoll, HJ | 7 |
| Hou, K | 1 |
| Qu, X | 2 |
| Wang, SL | 2 |
| Yu, JW | 2 |
| Lu, RQ | 1 |
| Wu, JG | 1 |
| Ni, XC | 1 |
| Jiang, BJ | 1 |
| Martin-Richard, M | 2 |
| Gallego, R | 2 |
| Pericay, C | 1 |
| Garcia Foncillas, J | 1 |
| Queralt, B | 1 |
| Casado, E | 1 |
| Iranzo, V | 1 |
| Juez, I | 1 |
| Visa, L | 1 |
| Saigi, E | 1 |
| Barnadas, A | 1 |
| Garcia-Albeniz, X | 1 |
| Maurel, J | 2 |
| Popa, EC | 1 |
| Yuan, Y | 4 |
| Yao, S | 2 |
| Park, SR | 13 |
| Park, YI | 4 |
| Khosravan, R | 2 |
| Roh, EJ | 1 |
| Valota, O | 1 |
| Lechuga, MJ | 2 |
| Seo, JH | 5 |
| Jeong, ES | 1 |
| Lee, KS | 8 |
| Heo, SH | 1 |
| Jeong, DG | 1 |
| Choi, YK | 1 |
| Ko, JH | 1 |
| Hsieh, CI | 1 |
| Chou, CY | 1 |
| Wang, KH | 1 |
| Badakhshi, H | 1 |
| Gruen, A | 1 |
| Graf, R | 1 |
| Boehmer, D | 1 |
| Budach, V | 1 |
| Ye, YW | 1 |
| Hu, S | 2 |
| Shi, YQ | 1 |
| Zhang, XF | 1 |
| Zhao, CL | 1 |
| Wang, GJ | 1 |
| Wen, JG | 1 |
| Zong, H | 1 |
| Zhu, L | 2 |
| Qu, L | 2 |
| Wang, DG | 1 |
| Sun, YB | 1 |
| Kharbuja, P | 1 |
| Ye, Z | 2 |
| Xi, W | 2 |
| Mirza, A | 1 |
| Pritchard, S | 1 |
| Welch, I | 1 |
| Yoney, A | 2 |
| Isikli, L | 2 |
| Hu, XF | 1 |
| Gao, SG | 1 |
| Wang, XS | 1 |
| Peng, XQ | 1 |
| Yang, YT | 1 |
| Feng, XS | 1 |
| Ueda, S | 2 |
| Tsumura, T | 2 |
| Sugimoto, N | 3 |
| Shimodaira, H | 1 |
| Tokunaga, S | 1 |
| Esaki, T | 2 |
| Nagase, M | 1 |
| Morita, S | 9 |
| Okamoto, I | 2 |
| Elsing, C | 1 |
| Herrmann, C | 1 |
| Hannig, CV | 1 |
| Stremmel, W | 2 |
| Jäger, D | 3 |
| Herrmann, T | 1 |
| Ueda, A | 1 |
| Hosokawa, A | 1 |
| Ogawa, K | 2 |
| Yoshita, H | 1 |
| Mihara, H | 1 |
| Ando, T | 3 |
| Kajiura, S | 1 |
| Fujinami, H | 1 |
| Nishikawa, J | 1 |
| Minemura, M | 1 |
| Terada, M | 1 |
| Kobayashi, T | 10 |
| Horikawa, N | 1 |
| Yabushita, K | 2 |
| Note, M | 1 |
| Sugiyama, T | 1 |
| Manu, KA | 3 |
| Shanmugam, MK | 3 |
| Siveen, KS | 2 |
| Kumar, AP | 3 |
| Sethi, G | 3 |
| Le Naourès, C | 1 |
| Capovilla, M | 1 |
| Curtis, NJ | 1 |
| Bailey, IS | 1 |
| Kelly, JJ | 1 |
| Byrne, JP | 1 |
| Wu, H | 3 |
| Xu, JB | 1 |
| Cai, SR | 1 |
| Ma, JP | 1 |
| Chen, CQ | 1 |
| Zhan, WH | 1 |
| Ji, SQ | 1 |
| Hua, YW | 1 |
| Liguigli, W | 1 |
| Poli, R | 1 |
| Lazzarelli, S | 2 |
| Brighenti, M | 2 |
| Negri, F | 1 |
| Curti, A | 1 |
| Martinotti, M | 1 |
| Olivetti, L | 1 |
| Rovatti, M | 1 |
| Donati, G | 2 |
| Passalacqua, R | 3 |
| Ye, L | 2 |
| Ji, K | 1 |
| Hargest, R | 1 |
| Stiekema, J | 1 |
| Trip, AK | 2 |
| Jansen, EP | 6 |
| Boot, H | 11 |
| Ponz, OB | 1 |
| Verheij, M | 7 |
| van Sandick, JW | 2 |
| Di Lauro, L | 5 |
| Vici, P | 3 |
| Belli, F | 2 |
| Tomao, S | 2 |
| Fattoruso, SI | 1 |
| Arena, MG | 1 |
| Pizzuti, L | 2 |
| Giannarelli, D | 2 |
| Paoletti, G | 2 |
| Barba, M | 2 |
| Sergi, D | 2 |
| Maugeri-Saccà, M | 2 |
| Lu, ZM | 1 |
| Luo, TH | 1 |
| Nie, MM | 2 |
| Fang, GE | 2 |
| Xue, XC | 2 |
| Wei, G | 2 |
| Ke, CW | 1 |
| Bi, JW | 2 |
| Yi, C | 4 |
| Cao, R | 1 |
| Fattoruso, S | 1 |
| Amodio, A | 1 |
| Boggia, S | 1 |
| Kwon, OH | 2 |
| Kim, YS | 5 |
| Tan, C | 1 |
| Peng, L | 2 |
| Luo, X | 1 |
| Xuan, Y | 2 |
| Yun, J | 3 |
| Shim, W | 3 |
| Kim, YB | 2 |
| Lee, G | 3 |
| He, MM | 3 |
| Wu, WJ | 1 |
| Zhang, DS | 4 |
| Zeng, ZL | 2 |
| Feng, D | 3 |
| Qu, J | 1 |
| Mellors, NJ | 1 |
| Tan, BB | 4 |
| Tian, Y | 4 |
| Jiao, ZK | 3 |
| Zhao, XF | 2 |
| Zhang, ZD | 4 |
| Yang, PG | 2 |
| Qu, JL | 1 |
| Qu, XJ | 3 |
| Zhu, ZT | 1 |
| Zhou, LZ | 1 |
| Teng, YE | 1 |
| Jin, B | 1 |
| Zhao, MF | 1 |
| Yu, P | 4 |
| Deguchi, K | 2 |
| Nishikawa, K | 6 |
| Iwase, K | 4 |
| Aono, T | 2 |
| Yoshida, H | 3 |
| Nomura, M | 7 |
| Tamagawa, H | 3 |
| Matsuda, C | 2 |
| Deguchi, T | 2 |
| Higashi, S | 3 |
| Noguchi, Y | 4 |
| Takagi, M | 3 |
| Fukui, A | 2 |
| Makari, Y | 1 |
| Iijima, S | 5 |
| Hoshi, M | 5 |
| Oshima, S | 2 |
| Ikeda, K | 7 |
| Kurokawa, E | 3 |
| Kikkawa, N | 5 |
| Iwasaki, Y | 18 |
| Yajima, K | 4 |
| Oohinata, R | 1 |
| Yuu, K | 1 |
| Iwanaga, T | 10 |
| Karasawa, K | 1 |
| Maeda, Y | 14 |
| Noda, S | 1 |
| Kashiwagi, S | 1 |
| Kawajiri, H | 1 |
| Onoda, N | 5 |
| Hirakawa, K | 16 |
| Palacio, S | 1 |
| Loaiza-Bonilla, A | 1 |
| Kittaneh, M | 1 |
| Kyriakopoulos, C | 1 |
| Ochoa, RE | 1 |
| Escobar, M | 1 |
| Arango, B | 1 |
| Restrepo, MH | 1 |
| Merchan, JR | 1 |
| Rocha Lima, CM | 1 |
| Hosein, PJ | 1 |
| Baroudi, O | 1 |
| Baroudi, T | 1 |
| Omrane, I | 1 |
| Moussa, A | 1 |
| Mezlini, A | 2 |
| Ayari, H | 1 |
| Guermazi, S | 1 |
| Bahloul, A | 1 |
| Bouzaienne, H | 1 |
| Uhrhammer, N | 1 |
| Bignon, YJ | 1 |
| El-Gaaied, AB | 1 |
| Bougatef, K | 1 |
| Michel, P | 2 |
| Breysacher, G | 1 |
| Mornex, F | 1 |
| Pere-Verge, D | 1 |
| Martel-Lafay, I | 1 |
| Faroux, R | 1 |
| Chapet, S | 1 |
| Sobhani, I | 1 |
| Pezet, D | 2 |
| Dousset, B | 1 |
| Jouve, JL | 1 |
| Maillard, E | 2 |
| Chen, FW | 1 |
| Egbert, BM | 1 |
| Swetter, SM | 1 |
| Sarin, KY | 1 |
| Yao, Q | 1 |
| Tang, G | 1 |
| Chu, PK | 1 |
| Gong, J | 4 |
| Fan, Q | 1 |
| Jiao, S | 3 |
| Bai, C | 2 |
| Hu, G | 1 |
| Ruf, C | 1 |
| Thomusch, O | 1 |
| Goos, M | 1 |
| Makowiec, F | 2 |
| Ruf, G | 1 |
| Fan, LQ | 3 |
| Wei, XL | 1 |
| Zhou, YX | 1 |
| Bai, L | 2 |
| Yang, DJ | 1 |
| Zhang, XT | 3 |
| Chu, YP | 1 |
| Gong, JF | 3 |
| Cosson, VF | 1 |
| Ng, VW | 1 |
| Lehle, M | 2 |
| Lum, BL | 1 |
| Shi, Z | 1 |
| Dong, A | 1 |
| He, F | 1 |
| Guo, T | 2 |
| Ji, H | 1 |
| Hsieh, JS | 1 |
| Yeh, HT | 1 |
| Su, YC | 1 |
| Wu, CC | 1 |
| Chen, JS | 6 |
| Tai, CJ | 2 |
| Bai, LY | 1 |
| Yeh, KH | 8 |
| Li, CP | 4 |
| Lu, M | 7 |
| Lu, ZH | 4 |
| Wang, XC | 1 |
| Miranda, MB | 1 |
| Gencer, D | 1 |
| Merx, K | 1 |
| Pan, H | 2 |
| Dai, G | 2 |
| Qin, S | 2 |
| Shu, Y | 6 |
| Bu, L | 2 |
| Piao, Y | 1 |
| Wan, C | 1 |
| Luo, Q | 2 |
| Ren, H | 4 |
| Wang, WH | 1 |
| Song, YW | 1 |
| Liu, XF | 2 |
| Zhan, Y | 1 |
| Ye, Y | 4 |
| Wu, A | 4 |
| Endo, F | 2 |
| Nishizuka, SS | 2 |
| Kume, K | 2 |
| Ishida, K | 5 |
| Katagiri, H | 2 |
| Sato, K | 2 |
| Iwaya, T | 3 |
| Koeda, K | 4 |
| Wakabayashi, G | 2 |
| Sforza, V | 1 |
| Gambardella, V | 1 |
| Fabozzi, A | 1 |
| Andreozzi, F | 1 |
| Ventriglia, J | 1 |
| Savastano, B | 1 |
| Mabilia, A | 1 |
| Lieto, E | 4 |
| Bhattacharya, B | 2 |
| Low, SH | 1 |
| Soh, C | 1 |
| Kamal Mustapa, N | 1 |
| Beloueche-Babari, M | 1 |
| Koh, KX | 2 |
| Loh, J | 1 |
| Soong, R | 2 |
| Carlomagno, C | 4 |
| Moretto, R | 1 |
| De Stefano, A | 1 |
| Raimondo, L | 1 |
| D'Armiento, M | 1 |
| Camera, L | 1 |
| Guadagno, E | 1 |
| Attademo, L | 1 |
| Feliciano, S | 1 |
| Matano, E | 3 |
| Yu, JK | 1 |
| Fang, XF | 1 |
| Shen, H | 2 |
| Gubanski, M | 2 |
| Glimelius, B | 4 |
| Lind, PA | 3 |
| Deng, D | 2 |
| Yamazaki, K | 6 |
| Koizumi, W | 20 |
| Fukase, K | 1 |
| Tamura, T | 5 |
| Meral, O | 1 |
| Alpay, M | 1 |
| Kismali, G | 1 |
| Kosova, F | 1 |
| Cakir, DU | 1 |
| Pekcan, M | 1 |
| Yigit, S | 1 |
| Sel, T | 1 |
| Deng, W | 2 |
| Wang, QW | 1 |
| Yamagiwa, K | 1 |
| Shigematsu, T | 1 |
| Takeda, K | 5 |
| Shirai, M | 1 |
| Amemori, K | 1 |
| Sunda, K | 1 |
| Koike, C | 1 |
| Kesavan, M | 1 |
| Claringbold, PG | 1 |
| Turner, JH | 1 |
| Dong, L | 2 |
| Lou, XP | 1 |
| Miao, JH | 1 |
| Lu, P | 1 |
| Chang, ZW | 1 |
| Han, ZF | 1 |
| Liang, M | 1 |
| Guo, X | 2 |
| Teng, D | 1 |
| Bajetta, E | 3 |
| Floriani, I | 3 |
| Falcone, A | 5 |
| Di Costanzo, F | 8 |
| Comella, G | 3 |
| Amadori, D | 5 |
| Pinto, C | 3 |
| Nitti, D | 5 |
| Daniele, B | 2 |
| Poli, D | 1 |
| Santoro, A | 2 |
| Boni, C | 6 |
| Pinotti, G | 2 |
| Bidoli, P | 1 |
| Landi, L | 1 |
| Ravaioli, A | 4 |
| Cantore, M | 1 |
| Di Fabio, F | 3 |
| Aitini, E | 3 |
| Marchet, A | 4 |
| Tian, ZH | 1 |
| Qu, LK | 1 |
| Shou, CC | 1 |
| Yu, YY | 6 |
| Feng, Y | 3 |
| Shen, KT | 3 |
| Qin, XY | 1 |
| Duan, Y | 2 |
| Ding, Q | 2 |
| Weng, H | 1 |
| Bao, R | 1 |
| Rau, B | 1 |
| Qian, Z | 1 |
| Shao, Q | 1 |
| Xie, Y | 1 |
| He, Q | 4 |
| Ge, S | 1 |
| Costa, C | 1 |
| Sanchez, JJ | 2 |
| Gimenez-Capitan, A | 1 |
| Rosell, R | 2 |
| Xian, SL | 1 |
| Zhang, XD | 6 |
| Lu, YF | 1 |
| Gu, L | 1 |
| Chung, HY | 1 |
| Yu, W | 7 |
| Miura, JT | 1 |
| Johnston, FM | 1 |
| Thomas, J | 2 |
| George, B | 1 |
| Eastwood, D | 1 |
| Tsai, S | 1 |
| Christians, KK | 1 |
| Turaga, KK | 1 |
| Gamblin, TC | 1 |
| Li, DH | 1 |
| Pan, ZK | 1 |
| An, HX | 1 |
| Wu, JX | 3 |
| Mongan, AM | 1 |
| Kalachand, R | 1 |
| King, S | 1 |
| O'Farrell, NJ | 1 |
| Power, D | 2 |
| Ravi, N | 1 |
| Muldoon, C | 1 |
| O'Byrne, K | 1 |
| Reynolds, JV | 2 |
| Guo, Mg | 2 |
| Zheng, Q | 3 |
| zhong Di, J | 1 |
| Qu, Y | 1 |
| Novotny, AR | 1 |
| Reim, D | 1 |
| Friess, HM | 1 |
| Schuhmacher, C | 3 |
| Sunami, T | 1 |
| Tauchi, J | 1 |
| Sakashita, K | 1 |
| Yukimoto, K | 2 |
| Sawada, R | 1 |
| Maia, M | 1 |
| Lowe, J | 1 |
| Sersch, MA | 1 |
| Allison, DE | 1 |
| Maggo, G | 1 |
| Grover, SC | 1 |
| Grin, A | 1 |
| Yoon, C | 2 |
| Park, DJ | 2 |
| Schmidt, B | 1 |
| Thomas, NJ | 1 |
| Kim, TS | 1 |
| Cohen, DJ | 2 |
| Gotovkin, EA | 1 |
| Al-Sakaff, N | 1 |
| Urspruch, A | 1 |
| Hill, J | 2 |
| Weber, HA | 1 |
| Isa O, N | 1 |
| Russo N, M | 1 |
| López V, H | 1 |
| Tassone, P | 1 |
| Yu, R | 2 |
| Szado, T | 1 |
| Garg, A | 1 |
| Lin, R | 1 |
| Fan, N | 2 |
| Wu, G | 1 |
| Donehower, RC | 1 |
| Davidenko, I | 1 |
| Tjulandin, S | 4 |
| Deptala, A | 1 |
| Harrison, M | 2 |
| Nirni, S | 1 |
| Lakshmaiah, K | 1 |
| Anderson, A | 1 |
| Dubey, S | 1 |
| Oliner, KS | 1 |
| Loh, E | 1 |
| Castro-Rojas, C | 1 |
| Ortiz-Lópezj, R | 1 |
| Rojas-Martínez, A | 1 |
| Kany, J | 1 |
| Steinmetz, K | 2 |
| Hofheinz, R | 4 |
| Wang, JC | 1 |
| Tian, JH | 1 |
| Ge, L | 2 |
| Gan, YH | 1 |
| Yang, KH | 1 |
| Shen, YC | 1 |
| Yen, CJ | 2 |
| Hsu, C | 2 |
| Lin, YL | 1 |
| Lin, ZZ | 1 |
| Cheng, AL | 7 |
| Lu, Z | 3 |
| Alcindor, T | 4 |
| Ades, S | 3 |
| Aloraini, A | 1 |
| van Huyse, M | 1 |
| Asselah, J | 1 |
| David, M | 1 |
| Frechette, D | 1 |
| Brisson, S | 1 |
| Thirlwell, M | 1 |
| Ferri, L | 2 |
| Lv, F | 2 |
| Peng, W | 3 |
| Cao, J | 5 |
| Guo, W | 5 |
| Fang, W | 1 |
| Qian, J | 3 |
| Rudloff, U | 1 |
| Langan, RC | 1 |
| Mullinax, JE | 1 |
| Beane, JD | 1 |
| Steinberg, SM | 2 |
| Beresnev, T | 1 |
| Webb, CC | 1 |
| Walker, M | 2 |
| Toomey, MA | 2 |
| Schrump, D | 1 |
| Pandalai, P | 1 |
| Stojadinovic, A | 1 |
| Avital, I | 2 |
| Cui, J | 3 |
| Jiang, N | 1 |
| Wu, L | 2 |
| Bai, B | 1 |
| Kuang, S | 1 |
| Sun, DS | 1 |
| Jeon, EK | 1 |
| Won, HS | 1 |
| Park, JC | 3 |
| Shim, BY | 1 |
| Park, SY | 3 |
| Hong, YS | 6 |
| Kim, HK | 11 |
| Sendur, MA | 1 |
| Özatlı, T | 1 |
| Aksoy, S | 5 |
| Ekinci, AS | 2 |
| Yazılıtaş, D | 1 |
| Günaydın, Y | 1 |
| Zhu, RJ | 1 |
| Yang, GF | 1 |
| Kortmansky, JS | 1 |
| Fischbach, NA | 1 |
| Stein, S | 1 |
| Doddamane, I | 1 |
| Karimeddini, D | 1 |
| Lacy, J | 1 |
| Yilmaz, B | 1 |
| Kemal, Y | 1 |
| Yucel, I | 1 |
| Velut, G | 1 |
| Mary, F | 2 |
| Wind, P | 2 |
| Sun, JQ | 1 |
| Yin, C | 1 |
| Liu, TF | 1 |
| Chen, LH | 1 |
| Kaytan Saglam, E | 1 |
| Yucel, S | 1 |
| Balik, E | 1 |
| Saglam, S | 2 |
| Yamaner, S | 1 |
| Bugra, D | 2 |
| Oral, EN | 1 |
| Kapran, Y | 1 |
| Sakar, B | 3 |
| Akyuz, A | 1 |
| Gulluoglu, M | 1 |
| Hu, M | 1 |
| Maskey, N | 1 |
| Peng, C | 1 |
| Yang, G | 1 |
| Ahn, HS | 1 |
| Son, YG | 1 |
| Kim, HH | 2 |
| Sun, LB | 1 |
| Zhao, GJ | 1 |
| Ding, DY | 1 |
| Song, B | 1 |
| Hou, RZ | 1 |
| Lee, SC | 2 |
| Park, KW | 3 |
| Lee, HR | 3 |
| Adas, YG | 1 |
| Andrieu, MN | 1 |
| Hicsonmez, A | 1 |
| Atakul, T | 1 |
| Dirican, B | 1 |
| Aktas, C | 1 |
| Yilmaz, S | 1 |
| Akyurek, S | 1 |
| Gokce, SC | 1 |
| Ergocen, S | 1 |
| Ahlgren, J | 1 |
| Patel, N | 1 |
| Simmens, S | 1 |
| Akin, E | 1 |
| Bishop, C | 1 |
| Kirkel, D | 1 |
| Siegel, P | 1 |
| Schuck, S | 1 |
| Guebre-Xabiher, H | 1 |
| Siegel, R | 1 |
| Lu, R | 1 |
| Dong, CX | 1 |
| Fu, JF | 1 |
| Ye, XY | 1 |
| Li, XF | 1 |
| Zhong, X | 1 |
| Goff, LW | 1 |
| Thakkar, N | 1 |
| Du, L | 1 |
| Chan, E | 1 |
| Cardin, DB | 1 |
| Berlin, JD | 1 |
| Zehnbauer, B | 1 |
| Fournier, C | 1 |
| Picus, J | 1 |
| Abali, H | 5 |
| Vural, M | 1 |
| Civelek, B | 1 |
| Oguz, D | 1 |
| Bostanci, B | 1 |
| Yalcin, B | 2 |
| Nijkamp, J | 1 |
| van Tinteren, H | 1 |
| Tsurushima, M | 1 |
| Kawara, H | 1 |
| Mitani, T | 1 |
| Tokuyama, Y | 1 |
| Uchiyama, K | 1 |
| Shimizu, Y | 6 |
| Minami, Y | 1 |
| Hara, Y | 7 |
| Nakamura, T | 16 |
| Iino, C | 1 |
| Mikami, T | 2 |
| Sawaya, M | 1 |
| Aihara, T | 1 |
| Yamagata, R | 1 |
| Sakamoto, J | 17 |
| Tono, H | 1 |
| Tanaka, M | 11 |
| Fukuda, S | 5 |
| Ries, P | 3 |
| André, T | 5 |
| Boucher, E | 1 |
| Rebischung, C | 1 |
| Bedenne, L | 5 |
| Fan, YL | 1 |
| Fan, BY | 1 |
| Di, HX | 1 |
| Meng, XY | 1 |
| Ling, N | 1 |
| Du, Y | 2 |
| Yu, Q | 1 |
| Dong, R | 2 |
| Bai, Z | 1 |
| Chen, B | 1 |
| Yan, F | 2 |
| Jiang, Z | 3 |
| Zhong, Y | 2 |
| Cheng, L | 1 |
| Tong, N | 2 |
| Chen, F | 1 |
| Zhuang, M | 1 |
| Zhong, C | 1 |
| Peng, J | 4 |
| Iwasaki, W | 1 |
| Kikkawa, M | 1 |
| Larsen, AC | 1 |
| Holländer, C | 1 |
| Duval, L | 1 |
| Schønnemann, K | 1 |
| Achiam, M | 1 |
| Pfeiffer, P | 6 |
| Yilmaz, MK | 1 |
| Thorlacius-Ussing, O | 1 |
| Bæksgaard, L | 1 |
| Ladekarl, M | 1 |
| Sun, XE | 1 |
| Liu, WD | 1 |
| Feng, YG | 1 |
| Zhang, HM | 1 |
| Shi, LH | 1 |
| Sun, XN | 1 |
| Gao, ZX | 2 |
| el Aziz, LM | 1 |
| Selcukbiricik, F | 1 |
| Demir, N | 1 |
| Oven Ustaalioglu, BB | 1 |
| Dikilitas, M | 1 |
| Yildiz, O | 1 |
| Misirlioglu, HC | 1 |
| Coskun-Breuneval, M | 1 |
| Kucukpilakci, B | 1 |
| Ugur, VI | 1 |
| Elgin, Y | 1 |
| Demirkasimoglu, T | 1 |
| Kara, SP | 1 |
| Ozgen, A | 1 |
| Sanri, E | 1 |
| Guney, Y | 1 |
| Bhardwaj, P | 1 |
| Chaurasia, D | 1 |
| Singh, R | 1 |
| Swarup, A | 1 |
| Zhu, BS | 1 |
| Sun, JL | 1 |
| Wu, YY | 1 |
| Xing, CG | 1 |
| Massuti, B | 3 |
| Reichardt, P | 7 |
| Pimentel, FL | 1 |
| Cohn, A | 1 |
| Follana, P | 1 |
| Clemens, M | 3 |
| Zaniboni, A | 8 |
| Richards, DA | 1 |
| Ecstein-Fraisse, E | 1 |
| Hitier, S | 1 |
| Xia, W | 1 |
| Mou, T | 1 |
| Chen, T | 2 |
| Cao, Q | 1 |
| Yang, ZR | 1 |
| Lei, XF | 2 |
| Lv, XG | 2 |
| Dong, WG | 2 |
| Choda, Y | 2 |
| Ninomiya, M | 9 |
| Kanazawa, T | 2 |
| Sato, D | 1 |
| Tokumoto, N | 1 |
| Harano, M | 4 |
| Matsukawa, H | 2 |
| Ojima, Y | 2 |
| Idani, H | 1 |
| Shiozaki, S | 2 |
| Okajima, M | 1 |
| Gao, P | 3 |
| Song, Y | 3 |
| Nishida, T | 6 |
| Kim, SW | 2 |
| Lee, JI | 1 |
| Lim, Y | 1 |
| Ha, S | 1 |
| Choi, H | 2 |
| Lee, SK | 3 |
| Salcedo, M | 1 |
| Sastre, J | 1 |
| Martínez Galán, J | 1 |
| Valladares-Ayerbes, M | 3 |
| Serrano, R | 2 |
| García de Paredes, ML | 1 |
| Manzano, JL | 1 |
| Galán, M | 1 |
| Yuste Izquierdo, AL | 1 |
| Díaz-Rubio, E | 2 |
| Conde, V | 1 |
| Cano, MT | 1 |
| Pachón, V | 1 |
| Aranda, E | 1 |
| Wu, P | 2 |
| Gao, S | 1 |
| Tan, BH | 1 |
| Brammer, K | 1 |
| Randhawa, N | 1 |
| Welch, NT | 1 |
| James, EJ | 1 |
| Catton, JA | 1 |
| Namikawa, T | 3 |
| Munekage, E | 1 |
| Maeda, H | 2 |
| Kitagawa, H | 3 |
| Kobayashi, M | 15 |
| Hanazaki, K | 3 |
| Cinar, P | 1 |
| Calkins, SM | 1 |
| Kelley, RK | 1 |
| Cai, J | 2 |
| Stashkevych, M | 1 |
| Khomutov, E | 1 |
| Dumanskiy, Y | 1 |
| Matviyenko, A | 1 |
| Zinkovych, I | 1 |
| Geng, R | 2 |
| Liu, R | 3 |
| He, G | 4 |
| Xu, CD | 1 |
| Yu, YJ | 1 |
| Sun, WJ | 1 |
| Lu, MD | 1 |
| Qi, DS | 1 |
| Li, PH | 1 |
| Cai, LJ | 1 |
| Song, SP | 2 |
| Meng, LN | 1 |
| Tanriverdi, O | 1 |
| Ogunc, H | 1 |
| Kawasaki, Y | 1 |
| Ishigami, S | 1 |
| Arigami, T | 1 |
| Uenosono, Y | 1 |
| Yanagita, S | 1 |
| Uchikado, Y | 1 |
| Kita, Y | 1 |
| Nishizono, Y | 1 |
| Okumura, H | 3 |
| Nakajo, A | 1 |
| Kijima, Y | 1 |
| Maemura, K | 1 |
| Natsugoe, S | 1 |
| Wu, FL | 2 |
| Li, RT | 1 |
| Yue, GF | 1 |
| Cui, FB | 1 |
| Wu, PY | 1 |
| Yu, LX | 4 |
| Qian, XP | 4 |
| Liu, BR | 4 |
| Ma, D | 1 |
| Song, GW | 1 |
| Sheen, SS | 2 |
| Xiao, J | 2 |
| Lan, P | 1 |
| Shen, Y | 1 |
| Qiu, M | 3 |
| Gou, H | 1 |
| Liao, Z | 2 |
| Xu, F | 4 |
| Choi, YY | 1 |
| Shin, HB | 1 |
| Jo, A | 1 |
| Seo, SH | 2 |
| Bang, HJ | 1 |
| Yang, X | 2 |
| Si, R | 1 |
| Qu, K | 1 |
| Ma, B | 2 |
| Miao, C | 1 |
| Leong, M | 1 |
| Shi, H | 3 |
| Cai, Q | 2 |
| Hua, B | 2 |
| Xi, X | 1 |
| Song, S | 1 |
| Song, EK | 4 |
| Xu, ZY | 1 |
| Tang, JN | 1 |
| Xie, HX | 1 |
| Du, YA | 1 |
| Yu, PF | 1 |
| Cheng, XD | 1 |
| Liang, N | 1 |
| Qiao, L | 1 |
| Luo, H | 1 |
| Zhang, JX | 1 |
| Riera Knorrenschild, J | 1 |
| Pohl, M | 1 |
| Bassermann, F | 2 |
| Helbig, U | 1 |
| Weißinger, F | 2 |
| Schnoy, E | 1 |
| Becker, K | 11 |
| Rüschoff, J | 2 |
| Eisenmenger, A | 1 |
| Karapanagiotou-Schenkel, I | 1 |
| Scheulen, ME | 1 |
| Jassem, J | 1 |
| Vynnychenko, I | 2 |
| Prausová, J | 1 |
| Van Laethem, JL | 2 |
| Wang, JB | 1 |
| Lu, K | 2 |
| Nushijima, Y | 1 |
| Nakano, K | 4 |
| Sugimoto, K | 2 |
| Nakaguchi, K | 2 |
| Kan, K | 2 |
| Maruyama, H | 3 |
| Doi, S | 1 |
| Okamura, S | 2 |
| Murata, K | 2 |
| Hokonohara, K | 1 |
| Takata, A | 1 |
| Noda, T | 1 |
| Hirota, M | 2 |
| Oshima, K | 1 |
| Tanida, T | 1 |
| Hatano, H | 1 |
| Komori, T | 1 |
| Iwazawa, T | 3 |
| Akagi, K | 1 |
| Adachi, S | 1 |
| Dono, K | 2 |
| Jeongho, M | 1 |
| Hatanaka, N | 2 |
| Odagiri, K | 1 |
| Kurokawa, T | 1 |
| Honmyo, N | 1 |
| Yamashita, S | 4 |
| Inoue, M | 6 |
| Irei, T | 2 |
| Tanemura, M | 1 |
| Tominaga, H | 2 |
| Yamamoto, K | 9 |
| Tsujinaka, T | 13 |
| Fukuda, Y | 2 |
| Asaoka, T | 2 |
| Miyamoto, A | 2 |
| Omiya, H | 1 |
| Ikeda, M | 3 |
| Takami, K | 1 |
| Nakamori, S | 4 |
| Sekimoto, M | 1 |
| Asao, Y | 1 |
| Aisu, Y | 1 |
| Ando, Y | 1 |
| Nishiuchi, A | 1 |
| Kadokawa, Y | 1 |
| Machimoto, T | 1 |
| Furuyama, H | 1 |
| Yoshimura, T | 1 |
| Mihara, K | 1 |
| Yamashiro, N | 1 |
| Nishiya, S | 1 |
| Kemmochi, T | 1 |
| Egawa, T | 1 |
| Nagashima, A | 2 |
| Tanaka, R | 2 |
| Kameyama, H | 1 |
| Ichikawa, H | 1 |
| Hanyu, T | 2 |
| Ishikawa, T | 6 |
| Sakata, J | 1 |
| Kosugi, S | 2 |
| Minagawa, M | 1 |
| Koyama, Y | 5 |
| Wakai, T | 1 |
| Turkeli, M | 1 |
| Aldemir, MN | 1 |
| Cayir, K | 3 |
| Simsek, M | 1 |
| Bilici, M | 3 |
| Tekin, SB | 3 |
| Yildirim, N | 1 |
| Bilen, N | 1 |
| Makas, I | 1 |
| Fujikawa, Y | 1 |
| Sato, T | 5 |
| Rino, Y | 6 |
| Uchiyama, M | 1 |
| Atsumi, Y | 1 |
| Kanazawa, A | 1 |
| Hayashi, T | 3 |
| Tsuchida, K | 1 |
| Yamamoto, N | 2 |
| Oshima, T | 5 |
| Yukawa, N | 1 |
| Yoshikawa, T | 5 |
| Masuda, M | 1 |
| Francini, E | 4 |
| Marrelli, D | 2 |
| Fiaschi, AI | 3 |
| Laera, L | 2 |
| Rossi, G | 1 |
| Bianco, V | 1 |
| Brozzetti, S | 1 |
| Soularue, É | 1 |
| de Gramont, A | 4 |
| Nukatsuka, M | 1 |
| Nakagawa, F | 1 |
| Saito, H | 21 |
| Sakata, M | 1 |
| Uchida, J | 2 |
| Lian, G | 1 |
| Ou, G | 1 |
| Zeng, L | 1 |
| Xu, HB | 1 |
| Huang, F | 1 |
| Su, R | 1 |
| Shen, FM | 1 |
| Lv, QZ | 1 |
| Du, N | 1 |
| Tao, G | 1 |
| Hiraoka, K | 2 |
| Nakagawa, T | 4 |
| Ueda, Y | 4 |
| Matsumoto, K | 6 |
| Nishijima, J | 3 |
| Fan, L | 1 |
| Che, XM | 3 |
| Treese, C | 1 |
| von Winterfeld, M | 1 |
| Dogan, Y | 2 |
| Schmidt, SC | 1 |
| Hacibekiroglu, I | 1 |
| Kodaz, H | 1 |
| Erdogan, B | 1 |
| Turkmen, E | 1 |
| Esenkaya, A | 1 |
| Uzunoglu, S | 1 |
| Cicin, I | 1 |
| Ramachandran, L | 2 |
| Chinnathambi, A | 1 |
| Zayed, ME | 1 |
| Alharbi, SA | 1 |
| Arfuso, F | 1 |
| Kurokawa, Y | 5 |
| Miyazaki, Y | 2 |
| Takahashi, T | 28 |
| Yamasaki, M | 4 |
| Miyata, H | 7 |
| Nakajima, K | 8 |
| Gaduputi, V | 1 |
| Tariq, H | 1 |
| Ihimoyan, A | 1 |
| Bodini, FC | 1 |
| Stroppa, EM | 1 |
| Banchini, F | 1 |
| Michieletti, E | 1 |
| Capelli, P | 1 |
| Zangrandi, A | 1 |
| Anselmi, E | 1 |
| Takahama, T | 1 |
| Takeda, M | 1 |
| Nishina, S | 1 |
| Nakagawa, K | 3 |
| Qian, LJ | 1 |
| Su, XY | 1 |
| He, KF | 1 |
| Jin, KT | 1 |
| Gu, LH | 1 |
| Feng, JG | 1 |
| Li, GL | 3 |
| Xu, ZZ | 1 |
| Wang, HH | 1 |
| Teng, LS | 1 |
| Luo, F | 1 |
| Zheng, X | 2 |
| Lu, DC | 1 |
| Ying, YP | 1 |
| Huang, JJ | 1 |
| Zhou, AM | 1 |
| Jiang, DK | 1 |
| Chen, MW | 1 |
| Huang, HQ | 1 |
| Zeng, HY | 2 |
| Qiu, ZQ | 1 |
| Qiu, ZR | 1 |
| Yanai, H | 1 |
| Yahara, N | 1 |
| Furuya, T | 1 |
| Hayashi, H | 5 |
| Murakami, T | 4 |
| Shimokawa, Y | 1 |
| Sugihara, S | 1 |
| Qiao, X | 1 |
| Tan, B | 1 |
| Shi, G | 2 |
| Xu, Q | 4 |
| Yang, P | 1 |
| Mingol, F | 1 |
| Gallego, J | 1 |
| Orduña, A | 1 |
| Martinez-Blasco, A | 1 |
| Sola-Vera, J | 1 |
| Moya, P | 1 |
| Morcillo, MA | 1 |
| Ruiz, JA | 1 |
| Calpena, R | 1 |
| Lacueva, FJ | 1 |
| Springfeld, C | 1 |
| Wiecha, C | 1 |
| Kunzmann, R | 1 |
| Heger, U | 1 |
| Weichert, W | 1 |
| Langer, R | 5 |
| Stange, A | 1 |
| Blank, S | 2 |
| Grenacher, L | 2 |
| Ott, K | 12 |
| Badgwell, B | 1 |
| Estrella, J | 1 |
| Chiang, YJ | 1 |
| Matamoros, A | 1 |
| Fournier, K | 1 |
| Mansfield, P | 1 |
| Peng, XC | 1 |
| Li, ZP | 2 |
| Shen, YL | 2 |
| Liu, JY | 2 |
| Zhao, YQ | 1 |
| Gou, HF | 3 |
| Wei, Z | 1 |
| Junsong, L | 1 |
| Rui, C | 1 |
| Shuai, C | 1 |
| Guanglin, Q | 1 |
| Shicai, H | 1 |
| Zexing, W | 1 |
| Jin, W | 1 |
| Xiangming, C | 1 |
| Shufeng, W | 1 |
| Qu, CY | 1 |
| Chen, YW | 1 |
| Chen, MM | 1 |
| Shen, F | 1 |
| Xu, LM | 2 |
| Ji, R | 1 |
| Xue, J | 1 |
| Qian, H | 2 |
| Lee, HS | 3 |
| Kim, JY | 2 |
| Martínez-Lago, N | 1 |
| Vieito-Villar, M | 1 |
| Vidal-Insua, Y | 1 |
| Padin-Iruegas, ME | 1 |
| Vazquez-Rivera, F | 1 |
| Candamio-Folgar, S | 1 |
| Lopez-Lopez, R | 1 |
| Choi, IJ | 11 |
| Chun, KH | 3 |
| Chen, WY | 1 |
| Huang, CY | 1 |
| Cheng, WL | 1 |
| Hung, CS | 1 |
| Huang, MT | 1 |
| Liu, YN | 1 |
| Chen, CL | 2 |
| Chang, YJ | 1 |
| Jing, S | 1 |
| Deng, Q | 1 |
| Müller, H | 2 |
| Hotopp, T | 1 |
| Tofeili, A | 1 |
| Wutke, K | 1 |
| Park, MI | 1 |
| Moon, W | 1 |
| Kim, SE | 1 |
| Choi, YJ | 3 |
| Shang, ZM | 1 |
| Tang, JD | 1 |
| Jiang, QQ | 1 |
| Guo, A | 1 |
| Ji, WS | 1 |
| Miano, ST | 1 |
| Bellini, MA | 1 |
| Haijun, Y | 1 |
| Qiuji, W | 1 |
| Zhenming, F | 1 |
| Yong, H | 1 |
| Zhengkai, L | 1 |
| Conghua, X | 1 |
| Yunfeng, Z | 1 |
| Yahua, Z | 1 |
| Skoropad, VY | 1 |
| Xie, WJ | 1 |
| Bronsert, P | 1 |
| Schäfer, M | 1 |
| Kulemann, B | 1 |
| Marjanovic, G | 1 |
| Sick, O | 1 |
| Hopt, UT | 1 |
| Zirlik, K | 1 |
| Osumi, H | 1 |
| Yoshio, T | 1 |
| Kumekawa, Y | 1 |
| Suenaga, M | 1 |
| Matsusaka, S | 2 |
| Shinozaki, E | 1 |
| Miyamoto, Y | 3 |
| Morishige, K | 1 |
| Ishiyama, A | 1 |
| Hirasawa, T | 1 |
| Tsuchida, T | 1 |
| Fujisaki, J | 1 |
| Igarashi, M | 1 |
| Liu, SF | 1 |
| Lu, CR | 1 |
| Cheng, HD | 1 |
| Xi, HQ | 1 |
| Cui, JX | 1 |
| Li, JY | 3 |
| Shen, WS | 1 |
| Lim, T | 3 |
| Lee, I | 2 |
| Schneider, CC | 1 |
| Fischer, N | 1 |
| Bühler, S | 1 |
| Venturelli, S | 1 |
| Berger, A | 3 |
| Burkard, M | 1 |
| Kirschniak, A | 1 |
| Bachmann, R | 1 |
| Glatzle, J | 1 |
| Booka, E | 1 |
| Imamura, CK | 1 |
| Takeuchi, H | 5 |
| Gomi, D | 1 |
| Mizukami, T | 1 |
| Ichiyama, T | 1 |
| Tateishi, K | 1 |
| Kawakubo, H | 3 |
| Soejima, K | 1 |
| Tanigawara, Y | 1 |
| Zhu, B | 1 |
| Wu, JR | 1 |
| Zhou, XP | 1 |
| Yue, X | 1 |
| Maruo, H | 4 |
| Ishikawa, S | 1 |
| Higashi, Y | 1 |
| Shoji, T | 1 |
| Nishiyama, R | 2 |
| Kubota, H | 4 |
| Seki, H | 2 |
| Ohi, H | 1 |
| Ozaki, T | 2 |
| Yabusaki, H | 9 |
| Mazani, M | 1 |
| Abbasi, A | 1 |
| Farassati, F | 1 |
| Amani, M | 1 |
| Ochenduszko, S | 1 |
| Puskulluoglu, M | 1 |
| Konopka, K | 1 |
| Fijorek, K | 1 |
| Urbanczyk, K | 1 |
| Budzynski, A | 1 |
| Matlok, M | 1 |
| Lazar, A | 1 |
| Sinczak-Kuta, A | 1 |
| Pedziwiatr, M | 1 |
| Krzemieniecki, K | 1 |
| Ayadi, M | 1 |
| Bahloul, R | 1 |
| Guesmi, S | 1 |
| Allani, B | 1 |
| Chrait, N | 1 |
| Rifi, H | 1 |
| Rais, H | 1 |
| Tanigawa, N | 5 |
| Yamaue, H | 2 |
| Ohyama, S | 3 |
| Sakuramoto, S | 1 |
| Inada, T | 7 |
| Kodera, Y | 9 |
| Omura, K | 7 |
| Nashimoto, A | 14 |
| Nomura, E | 1 |
| Takeuchi, M | 1 |
| Fujii, M | 17 |
| Nakajima, T | 22 |
| Gotoh, M | 4 |
| Nakayama, N | 9 |
| Nong, Z | 1 |
| Lu, G | 1 |
| Park, SC | 1 |
| Chun, HJ | 2 |
| Jiang, D | 2 |
| Zhao, C | 3 |
| Kan, Q | 2 |
| Stoller, R | 1 |
| Shibata, S | 2 |
| Kemeny, M | 1 |
| Krishnamurthi, S | 1 |
| Su, YB | 1 |
| Ocean, A | 1 |
| Mehrotra, B | 1 |
| Ritch, P | 2 |
| Henderson, C | 1 |
| Sun, GP | 1 |
| Lu, HS | 2 |
| Zhong, MZ | 2 |
| Zhang, HL | 2 |
| Hu, XH | 1 |
| Zhou, JT | 1 |
| Guan, ZG | 1 |
| Zhang, K | 2 |
| Gou, Y | 1 |
| Altan, B | 1 |
| Mochiki, E | 1 |
| Toyomasu, Y | 1 |
| Kogure, N | 1 |
| Kimura, A | 2 |
| Bai, T | 1 |
| Bao, P | 1 |
| Suzuki, M | 8 |
| Ogata, K | 1 |
| Asao, T | 1 |
| Nishiyama, M | 13 |
| Kuwano, H | 1 |
| Pandey, A | 1 |
| Vishnoi, K | 1 |
| Mahata, S | 1 |
| Tripathi, SC | 1 |
| Misra, SP | 1 |
| Misra, V | 1 |
| Mehrotra, R | 1 |
| Dwivedi, M | 1 |
| Bharti, AC | 1 |
| Lee, IH | 1 |
| Byeon, SW | 1 |
| Huo, SM | 1 |
| Yoon, SB | 1 |
| Kim, JS | 13 |
| Roh, SY | 2 |
| Qi, Y | 2 |
| Lv, X | 2 |
| Brower, V | 1 |
| Zhu, P | 1 |
| Zhu, Q | 1 |
| Vargas, A | 1 |
| Pagés, M | 1 |
| Buxó, E | 1 |
| Xi, H | 2 |
| Bian, S | 1 |
| Wei, B | 2 |
| Liu, SL | 1 |
| Zhang, XX | 1 |
| Zou, X | 1 |
| Fan, X | 1 |
| Luo, G | 2 |
| Teng, R | 1 |
| Seifer, B | 1 |
| Zhong, G | 1 |
| Li, HK | 1 |
| Wydmanski, J | 2 |
| Polanowski, P | 1 |
| Tukiendorf, A | 1 |
| Maslyk, B | 1 |
| Fazio, N | 7 |
| Biffi, R | 3 |
| Maibach, R | 3 |
| Hayoz, S | 1 |
| Thierstein, S | 1 |
| Brauchli, P | 1 |
| Bernhard, J | 2 |
| Stupp, R | 3 |
| Andreoni, B | 2 |
| Renne, G | 1 |
| Crosta, C | 2 |
| Morant, R | 2 |
| Chiappa, A | 3 |
| Luca, F | 2 |
| Zampino, MG | 4 |
| Huber, O | 4 |
| Goldhirsch, A | 4 |
| de Braud, F | 5 |
| Roth, AD | 6 |
| Du, C | 1 |
| Guo, C | 1 |
| Zhou, A | 1 |
| Li, TT | 1 |
| Li, FP | 1 |
| Hu, YF | 2 |
| Mou, TY | 1 |
| Lin, T | 2 |
| Mansoori, M | 1 |
| Golalipour, M | 1 |
| Alizadeh, S | 1 |
| Jahangirerad, A | 1 |
| Khandozi, SR | 1 |
| Fakharai, H | 1 |
| Shahbazi, M | 1 |
| Jian, B | 1 |
| Xiao, D | 1 |
| Brieau, B | 2 |
| Auzolle, C | 1 |
| Pozet, A | 1 |
| Soibinet, P | 1 |
| Prieux, C | 1 |
| Goujon, G | 1 |
| Marthey, L | 1 |
| Bonnetain, F | 4 |
| Maccaroni, E | 1 |
| Mandolesi, A | 1 |
| Del Prete, M | 1 |
| Andrikou, K | 1 |
| Faloppi, L | 1 |
| Bittoni, A | 1 |
| Bianconi, M | 1 |
| Scarpelli, M | 1 |
| Bracci, R | 2 |
| Tu, Y | 1 |
| Tanigawa, T | 3 |
| Hasuike, Y | 4 |
| Akiyama, Y | 1 |
| Higuchi, I | 1 |
| Ishikawa, A | 2 |
| Okada, A | 1 |
| Miyamoto, M | 1 |
| Ito, K | 9 |
| Mitsunaga, M | 1 |
| Arihiro, S | 1 |
| Saruta, M | 1 |
| Matsuoka, M | 1 |
| Kobayashi, H | 3 |
| Tajiri, H | 4 |
| Alizadeh-Navaei, R | 1 |
| Rafiei, A | 1 |
| Abedian-Kenari, S | 1 |
| Asgarian-Omran, H | 1 |
| Valadan, R | 1 |
| Hedayatizadeh-Omran, A | 1 |
| Ao, L | 1 |
| Hong, G | 1 |
| Guan, Q | 1 |
| Yang, D | 1 |
| Hu, W | 1 |
| Luo, B | 1 |
| Tebbutt, NC | 7 |
| Price, TJ | 1 |
| Ferraro, DA | 1 |
| Veillard, AS | 1 |
| Hall, M | 2 |
| Sjoquist, KM | 1 |
| Pavlakis, N | 1 |
| Strickland, A | 2 |
| Varma, SC | 1 |
| Cooray, P | 1 |
| Young, R | 1 |
| Underhill, C | 2 |
| Shannon, JA | 1 |
| Ganju, V | 2 |
| Bi, T | 1 |
| Dai, W | 1 |
| Qian, L | 1 |
| Blum Murphy, MA | 1 |
| Qiao, W | 1 |
| Mewada, N | 1 |
| Wadhwa, R | 1 |
| Takashi, T | 1 |
| Ho, L | 3 |
| Phan, A | 2 |
| Baker, J | 2 |
| Geetha, P | 1 |
| Sivaram, AJ | 1 |
| Jayakumar, R | 1 |
| Gopi Mohan, C | 1 |
| Gao, K | 1 |
| Liang, Q | 1 |
| Zhao, ZH | 1 |
| Li, YF | 4 |
| Wang, SF | 2 |
| Shao, S | 1 |
| Sun, PH | 1 |
| Satherley, LK | 1 |
| Ji, KE | 1 |
| Feng, YI | 1 |
| Kishi, K | 2 |
| Motoori, M | 2 |
| Sugimura, K | 1 |
| Ohue, M | 1 |
| Sakon, M | 2 |
| Bae, YS | 1 |
| Yu, X | 1 |
| Zhang, JL | 2 |
| Liu, XZ | 1 |
| Wang, PY | 1 |
| Chen, GW | 1 |
| Qiao, SK | 1 |
| Pan, YS | 1 |
| Liu, YC | 1 |
| Aoki, K | 1 |
| Mitsuhashi, Y | 2 |
| Tomiura, S | 1 |
| Suto, A | 3 |
| Miura, T | 6 |
| Ikenaga, S | 1 |
| Shibasaki, I | 1 |
| Endo, M | 9 |
| Smid, D | 1 |
| Kulda, V | 1 |
| Srbecka, K | 1 |
| Kubackova, D | 1 |
| Dolezal, J | 1 |
| Daum, O | 1 |
| Kucera, R | 1 |
| Topolcan, O | 1 |
| Treska, V | 1 |
| Skalicky, T | 1 |
| Pesta, M | 1 |
| Frankel, P | 1 |
| Lim, D | 1 |
| Yeon, C | 1 |
| Leong, L | 1 |
| Chao, J | 1 |
| Ruel, N | 1 |
| Luevanos, E | 1 |
| Koehler, S | 1 |
| Chung, S | 1 |
| Lau, SC | 2 |
| Fakih, MG | 1 |
| Yang, XL | 1 |
| Zhan, YQ | 5 |
| Ji, X | 1 |
| Sukumaran, S | 1 |
| Patel, HJ | 1 |
| Patel, BM | 1 |
| Lan, WG | 1 |
| Xu, DH | 1 |
| Ding, CL | 1 |
| Zhou, YL | 1 |
| Ma, LB | 1 |
| Liu, CM | 1 |
| Sinclair, R | 1 |
| Navidi, M | 1 |
| Griffin, SM | 1 |
| Sumpter, K | 3 |
| Shin, A | 1 |
| Kim, SG | 4 |
| Hwang, JA | 2 |
| Hong, SH | 3 |
| Lee, YS | 4 |
| Kwon, HC | 12 |
| Duan, W | 1 |
| Xin, X | 1 |
| Shan, G | 1 |
| Dong, F | 1 |
| Gao, W | 1 |
| Chaudhry, NA | 1 |
| Coman, R | 1 |
| Al-Fakeeh, A | 1 |
| Mulla, N | 1 |
| Doerksen, T | 1 |
| Al-Ruzug, I | 1 |
| Santos, F | 1 |
| Tanz, R | 1 |
| El Mhadi, C | 1 |
| Toreis, M | 1 |
| Khmamouch, MR | 1 |
| Mahfoud, T | 1 |
| Ali, AA | 2 |
| Errihani, H | 2 |
| Ichou, M | 2 |
| Smyth, EC | 2 |
| Fassan, M | 2 |
| Lampis, A | 1 |
| Hahne, JC | 1 |
| Rugge, M | 2 |
| Nankivell, M | 2 |
| Langley, R | 2 |
| Ghidini, M | 2 |
| Braconi, C | 1 |
| Valeri, N | 2 |
| Chen, XD | 1 |
| He, FQ | 1 |
| Tang, LC | 1 |
| Tang, XL | 1 |
| Song, XL | 1 |
| Kang, HK | 1 |
| Jeong, GW | 1 |
| Ahn, KY | 1 |
| Jeong, YY | 1 |
| Kang, YJ | 1 |
| Cho, HJ | 1 |
| Moon, CM | 1 |
| Kim, HY | 1 |
| Cho, Y | 1 |
| Yim, YS | 1 |
| Pang, X | 1 |
| Cho, JY | 6 |
| Kang, A | 1 |
| Shames, DS | 2 |
| Paget-Bailly, S | 1 |
| Nguyen, T | 2 |
| Mathieu, P | 1 |
| Lamfichekh, N | 1 |
| Fein, F | 1 |
| Fratté, S | 1 |
| Cléau, D | 1 |
| Lakkis, Z | 1 |
| Jary, M | 1 |
| Sakek, N | 1 |
| Jacquin, M | 1 |
| Foubert, A | 1 |
| Fiteni, F | 1 |
| Zhao, T | 1 |
| Huo, X | 1 |
| Tang, Y | 1 |
| He, ML | 1 |
| Shan, F | 3 |
| Xiao, A | 1 |
| Xue, K | 1 |
| Miao, R | 1 |
| Bu, Z | 1 |
| Haghighi, S | 1 |
| Kasbkar, H | 1 |
| Esmaeilpour, K | 1 |
| Yasaei, M | 1 |
| Martin-Romano, P | 1 |
| Sola, JJ | 1 |
| Diaz-Gonzalez, JA | 1 |
| Chopitea, A | 1 |
| Iragorri, Y | 1 |
| Martínez-Regueira, F | 1 |
| Ponz-Sarvise, M | 1 |
| Arbea, L | 1 |
| Subtil, JC | 1 |
| Cano, D | 1 |
| Ceniceros, L | 1 |
| Legaspi, J | 1 |
| Hernandez, JL | 1 |
| Rodríguez, J | 1 |
| Haj Mohammad, N | 1 |
| van Valkenhoef, G | 1 |
| Mali, RMA | 1 |
| Anderegg, MC | 1 |
| Gepfner-Tuma, I | 1 |
| Ruessel, J | 1 |
| Wilke, H | 17 |
| Rafiyan, MR | 1 |
| von Weikersthal, LF | 1 |
| Weusmann, J | 1 |
| Kanzler, S | 3 |
| Schimanski, CC | 1 |
| Otte, M | 1 |
| Schollenberger, L | 1 |
| Koenig, J | 1 |
| Lee, MA | 3 |
| Zhuang, RY | 2 |
| Zhao, NQ | 1 |
| Xia, LL | 1 |
| Tang, YB | 1 |
| Song, FF | 1 |
| Ji, P | 1 |
| Wang, SJ | 1 |
| Zhu, JM | 1 |
| Zhao, GP | 1 |
| Liu, TT | 1 |
| Zhuo, C | 1 |
| Shao, M | 1 |
| Tian, H | 1 |
| Boige, V | 3 |
| Artru, P | 2 |
| Boubaya, M | 1 |
| Benallaoua, M | 1 |
| Locher, C | 1 |
| Baumgaertner, I | 1 |
| Lecaille, C | 1 |
| des Guetz, G | 2 |
| Kim, EY | 1 |
| Jun, KH | 1 |
| Jung, JH | 1 |
| Jo, YS | 1 |
| Chin, HM | 1 |
| Mahlberg, R | 2 |
| Xi, Y | 1 |
| Taki, T | 1 |
| Hoya, Y | 1 |
| Watanabe, A | 6 |
| Okamoto, T | 4 |
| Sekine, H | 1 |
| Mitsumori, N | 1 |
| Yanaga, K | 3 |
| Dai, J | 1 |
| Xie, C | 1 |
| Xiong, B | 1 |
| Pasquini, G | 1 |
| Caparello, C | 1 |
| Musettini, G | 1 |
| Petrini, I | 1 |
| Borro, M | 1 |
| Botticelli, A | 1 |
| Mazzuca, F | 1 |
| Onesti, EC | 1 |
| Gentile, G | 1 |
| Romiti, A | 2 |
| Cerbelli, B | 1 |
| Mazzotti, E | 1 |
| Marchetti, L | 1 |
| Lionetto, L | 1 |
| Simmaco, M | 1 |
| Marchetti, P | 1 |
| Feng, S | 1 |
| Feng, L | 1 |
| Petrelli, F | 1 |
| Yoon, HH | 1 |
| Braiteh, FS | 1 |
| Firdaus, I | 1 |
| Philip, PA | 2 |
| Cohn, AL | 1 |
| Lewis, N | 1 |
| Anderson, DM | 1 |
| Arrowsmith, E | 1 |
| Schwartz, JD | 1 |
| Hsu, Y | 1 |
| Yawata, K | 2 |
| Osada, S | 1 |
| Matsui, S | 3 |
| Okumura, N | 2 |
| Chu, J | 1 |
| Cai, A | 1 |
| Yuan, SQ | 2 |
| Chen, DL | 1 |
| He, YY | 1 |
| Hao, YT | 1 |
| Guo, P | 1 |
| Zeng, YX | 1 |
| Hack, SP | 1 |
| Bruey, JM | 1 |
| McCaffery, I | 1 |
| Phan, S | 1 |
| Chan, DY | 1 |
| Yap, R | 1 |
| Phua, JN | 1 |
| Soh, TI | 1 |
| Chee, CE | 1 |
| Nga, ME | 1 |
| Kanda, M | 1 |
| Shimizu, D | 1 |
| Tanaka, C | 1 |
| Kobayashi, D | 2 |
| Hayashi, M | 1 |
| Iwata, N | 1 |
| Niwa, Y | 2 |
| Yamada, S | 9 |
| Fujii, T | 4 |
| Sugimoto, H | 1 |
| Murotani, K | 1 |
| Fujiwara, M | 4 |
| Ren, HY | 1 |
| Huang, GL | 1 |
| Shen, JX | 1 |
| Zhou, P | 1 |
| Liu, WM | 1 |
| Shen, DY | 1 |
| Ying, X | 1 |
| Xiang, X | 1 |
| Duo-Ji, MM | 1 |
| Ci-Ren, BS | 1 |
| Long, ZW | 1 |
| Luo, DL | 1 |
| Park, BS | 1 |
| Nishino, M | 1 |
| Hosoda, Y | 2 |
| Hoshino, H | 1 |
| Okano, M | 1 |
| Nagai, K | 5 |
| Kim, Y | 2 |
| Takeda, S | 3 |
| Kanekiyo, S | 1 |
| Iida, M | 2 |
| Kitahara, M | 1 |
| Tokumitsu, Y | 1 |
| Tomochika, S | 1 |
| Tokuhisa, Y | 1 |
| Suzuki, N | 3 |
| Ueno, T | 3 |
| Yamamoto, S | 11 |
| Yoshino, S | 2 |
| Hazama, S | 2 |
| Nagano, H | 4 |
| Fernandez, E | 2 |
| Cacheux, W | 1 |
| Frossard, JL | 1 |
| Koessler, T | 1 |
| Abou, M | 1 |
| Moniez, M | 1 |
| Puppa, G | 1 |
| Kaito, A | 1 |
| Shibasaki, H | 1 |
| Kim, KP | 1 |
| Oh, HS | 1 |
| Kang, HJ | 8 |
| Lee, KT | 2 |
| Kim, TW | 20 |
| Liang, X | 1 |
| Qiu, C | 1 |
| Lin, S | 2 |
| Zhao, A | 1 |
| Wen, Z | 2 |
| Xue, Y | 2 |
| Hulkki-Wilson, S | 1 |
| Eltahir, Z | 2 |
| Okines, A | 4 |
| Hewish, M | 1 |
| Allum, W | 2 |
| Stenning, S | 2 |
| Yu, D | 1 |
| Saunders, JH | 1 |
| Bowman, CR | 1 |
| Pang, V | 1 |
| Dorrington, MS | 1 |
| Mumtaz, E | 1 |
| Soomro, I | 1 |
| Kaye, P | 2 |
| Tamaki, R | 1 |
| Kanai-Mori, A | 1 |
| Morishige, Y | 1 |
| Koike, A | 9 |
| Amano, F | 1 |
| Zhang, T | 1 |
| Yan, G | 1 |
| Tu, W | 1 |
| Hu, Z | 1 |
| Doğan, M | 1 |
| Zhou, KR | 1 |
| Cheng, A | 1 |
| Ng, WT | 1 |
| Kwok, TY | 1 |
| Yip, EY | 1 |
| Yao, R | 1 |
| Leung, PY | 1 |
| Lee, VW | 1 |
| Yue, J | 1 |
| Xue, X | 1 |
| Xue, L | 1 |
| Hwang, WS | 1 |
| Chao, TY | 2 |
| Lin, SF | 1 |
| Chung, CY | 2 |
| Chiu, CF | 1 |
| Chang, YF | 1 |
| Chen, PM | 3 |
| Chiou, TJ | 3 |
| Yamamichi, N | 2 |
| Honma, H | 2 |
| Mukai, T | 1 |
| Yoshida, S | 24 |
| Bang, S | 1 |
| Choi, SH | 6 |
| Liu, ZF | 2 |
| Guo, QS | 1 |
| Yang, XG | 1 |
| Guan, F | 1 |
| Fu, Z | 1 |
| Wang, MY | 2 |
| Lukan, N | 1 |
| Mai, S | 1 |
| Staiger, W | 1 |
| Schwarzbach, M | 1 |
| Willeke, F | 2 |
| Shin, SJ | 4 |
| Jeung, HC | 16 |
| Ahn, JB | 4 |
| Yoo, NC | 5 |
| Roh, JK | 14 |
| Dank, M | 2 |
| Zaluski, J | 3 |
| Barone, C | 8 |
| Valvere, V | 3 |
| Peschel, C | 10 |
| Wenczl, M | 2 |
| Goker, E | 2 |
| Cisar, L | 1 |
| Bugat, R | 4 |
| Shi, YX | 2 |
| Lin, TY | 2 |
| Han, B | 3 |
| He, YJ | 3 |
| Shen, XZ | 1 |
| Wu, LL | 1 |
| Weger, W | 1 |
| Kränke, B | 1 |
| Gerger, A | 1 |
| Salmhofer, W | 1 |
| Aberer, E | 1 |
| Matsubara, J | 2 |
| Hirashima, Y | 4 |
| Okita, NT | 2 |
| Lee, JL | 14 |
| Chang, HM | 20 |
| Min, YJ | 2 |
| Rethwisch, V | 2 |
| Clemens, MR | 3 |
| Fritz, M | 2 |
| Seipelt, G | 3 |
| Sievert, M | 1 |
| Atmaca, A | 6 |
| Brell, JM | 1 |
| Krishnamurthi, SS | 1 |
| Javle, M | 2 |
| Saltzman, J | 1 |
| Wollner, I | 1 |
| Pelley, R | 1 |
| Dowlati, A | 1 |
| Kantharaj, BN | 1 |
| Schluchter, MD | 1 |
| Rath, L | 1 |
| Ivy, SP | 1 |
| Remick, SC | 1 |
| Hizawa, K | 1 |
| Nagata, Y | 2 |
| Taniguchi, M | 2 |
| Nakamori, M | 1 |
| Okayasu, I | 1 |
| Kojima, H | 6 |
| Hang, X | 3 |
| Zhong, B | 3 |
| Huang, ZH | 3 |
| Hua, D | 4 |
| Li, LH | 2 |
| Mizoshita, T | 1 |
| Kataoka, H | 1 |
| Kubota, E | 1 |
| Okamoto, Y | 1 |
| Shimura, T | 3 |
| Mori, Y | 4 |
| Wada, T | 5 |
| Ogasawara, N | 1 |
| Sasaki, M | 3 |
| Kamiya, T | 1 |
| Joh, T | 1 |
| Long, YM | 1 |
| Rong, J | 2 |
| Xie, WR | 1 |
| Hwang, J | 2 |
| Lee, SR | 2 |
| Yang, DH | 1 |
| Kim, YK | 2 |
| Lee, JJ | 2 |
| Seo, MD | 1 |
| Lim, JH | 1 |
| Yi, HG | 1 |
| Kim, DY | 5 |
| Zhai, LZ | 1 |
| Oechsle, K | 2 |
| Budach, W | 3 |
| Trarbach, T | 4 |
| Boehlke, I | 2 |
| Kollmannsberger, C | 7 |
| Zhong, H | 1 |
| Ying, JE | 1 |
| Yong, D | 1 |
| Kunoki, N | 1 |
| Ryuzaki, H | 1 |
| Oonishi, M | 1 |
| Yamamoto, T | 4 |
| Uno, A | 1 |
| Ogawa, M | 20 |
| Ogihara, A | 1 |
| Tanaka, N | 10 |
| Moriyama, M | 2 |
| Sou, K | 1 |
| Kinukawa, N | 1 |
| Li, XY | 2 |
| Bai, CM | 2 |
| Chen, SC | 2 |
| Haghighat, P | 1 |
| Bekaii-Saab, T | 1 |
| Masumura, K | 1 |
| Nishizaki, M | 3 |
| Ohno, S | 5 |
| Takakura, N | 4 |
| Takata, S | 1 |
| Bustos, M | 1 |
| Orellana, E | 2 |
| Madrid, J | 3 |
| Galindo, H | 2 |
| Sánchez, C | 2 |
| Pimentel, F | 1 |
| Guzmán, S | 1 |
| Ibáñez, L | 1 |
| Butte, JM | 1 |
| Alvarez, M | 2 |
| Besa, P | 1 |
| Li, CZ | 1 |
| Sheng, LJ | 1 |
| Zhou, DG | 1 |
| Wang, QC | 1 |
| Zhang, EN | 1 |
| Yang, JL | 1 |
| Dai, GH | 1 |
| Niu, RG | 1 |
| Xie, XD | 1 |
| Zhang, FC | 2 |
| Catalano, V | 11 |
| Graziano, F | 12 |
| D'Emidio, S | 3 |
| Baldelli, AM | 6 |
| Rossi, D | 3 |
| Vincenzi, B | 4 |
| Giordani, P | 8 |
| Alessandroni, P | 3 |
| Testa, E | 4 |
| Tonini, G | 6 |
| Catalano, G | 17 |
| Lee, YC | 2 |
| Seol, YM | 1 |
| Song, MK | 1 |
| Kim, GH | 1 |
| Shin, HJ | 3 |
| Song, GA | 1 |
| Chung, JS | 2 |
| Cho, GJ | 2 |
| Feng, CN | 1 |
| Yasuda, K | 2 |
| Kimura, T | 6 |
| Seita, M | 1 |
| Takahata, T | 3 |
| Akazai, Y | 1 |
| Sirak, I | 1 |
| Petera, J | 1 |
| Hatlova, J | 1 |
| Vosmik, M | 1 |
| Melichar, B | 1 |
| Dvorak, J | 1 |
| Zoul, Z | 1 |
| Tycova, V | 1 |
| Lesko, M | 1 |
| Hajduch, M | 1 |
| Tsutani, Y | 3 |
| Sanada, Y | 3 |
| Wada, Y | 7 |
| Fukushima, M | 14 |
| Okada, M | 3 |
| Lorizzo, K | 2 |
| Radice, D | 1 |
| Boselli, S | 1 |
| Ariu, L | 1 |
| Nolè, F | 1 |
| Magni, E | 1 |
| Ardito, R | 1 |
| Minchella, I | 1 |
| Rocca, A | 1 |
| Di Meglio, G | 1 |
| Squadroni, M | 1 |
| Saif, MW | 3 |
| Sandoval, A | 1 |
| Ota, K | 13 |
| Kurita, S | 1 |
| Nishimura, M | 4 |
| Kamei, Y | 1 |
| Imai, K | 3 |
| Ariyoshi, Y | 4 |
| Kataoka, K | 2 |
| Murakami, M | 9 |
| Oyama, A | 1 |
| Hoshino, A | 3 |
| Amo, H | 1 |
| Kato, T | 10 |
| Shao, ZY | 1 |
| Lu, N | 1 |
| Nei, FF | 1 |
| Rong, JJ | 2 |
| You, QD | 2 |
| Guo, QL | 2 |
| Fareed, KR | 2 |
| Soomro, IN | 2 |
| Ilyas, M | 2 |
| Martin, S | 1 |
| Arai, W | 2 |
| Hosoya, Y | 4 |
| Haruta, H | 1 |
| Kurashina, K | 1 |
| Saito, S | 2 |
| Yokoyama, T | 6 |
| Zuiki, T | 1 |
| Sakuma, K | 1 |
| Hyodo, M | 2 |
| Yasuda, Y | 3 |
| Nagai, H | 3 |
| Shirasaka, T | 19 |
| Zou, ZY | 2 |
| Wang, LF | 1 |
| Xavier, MH | 1 |
| Vergueiro, Tde R | 1 |
| Vilar, EG | 1 |
| Pinto, JM | 1 |
| Issa, MC | 1 |
| Pereira, GB | 1 |
| Carocha, AP | 1 |
| Wang, TT | 2 |
| Maruyama, M | 14 |
| Nagahama, T | 8 |
| Sato, E | 1 |
| Maruyama, S | 5 |
| Sanada, T | 1 |
| Koide, A | 3 |
| Ohhinata, R | 1 |
| Ebana, H | 1 |
| Masuzawa, T | 1 |
| Yamazaki, M | 2 |
| Ando, K | 2 |
| Oki, E | 2 |
| Kakeji, Y | 6 |
| Sugiyama, M | 1 |
| Endo, K | 4 |
| Morita, M | 2 |
| Emi, Y | 6 |
| Maehara, Y | 21 |
| Baize, N | 1 |
| Abakar-Mahamat, A | 1 |
| Mounier, N | 1 |
| Berthier, F | 1 |
| Caroli-Bosc, FX | 2 |
| Song, HS | 2 |
| Lee, NS | 2 |
| Lee, MH | 5 |
| Kim, MA | 6 |
| Lin, RB | 1 |
| Fan, NF | 2 |
| Wang, XJ | 1 |
| Jung, JY | 2 |
| Kwon, JH | 2 |
| Song, HH | 1 |
| Kim, I | 1 |
| Lee, JA | 1 |
| Gennatas, C | 1 |
| Michalaki, V | 1 |
| Gennatas, S | 1 |
| Nannini, M | 1 |
| Nobili, E | 1 |
| Di Cicilia, R | 1 |
| Brandi, G | 1 |
| Maleddu, A | 1 |
| Pantaleo, MA | 1 |
| Biasco, G | 1 |
| Guan, Z | 1 |
| Khasanov, R | 1 |
| Philco-Salas, M | 1 |
| Suarez, T | 1 |
| Santamaria, J | 1 |
| Forster, G | 1 |
| McCloud, PI | 1 |
| Norman, AR | 8 |
| Oates, J | 12 |
| Hawkins, R | 2 |
| Nicolson, M | 11 |
| Harper, P | 5 |
| Seymour, M | 5 |
| Hickish, T | 7 |
| Liu, XL | 1 |
| Han, CZ | 1 |
| Qiao, LJ | 1 |
| Yu, JR | 1 |
| Wen, ZZ | 1 |
| Shu, YQ | 2 |
| Wang, BC | 1 |
| Yin, HR | 4 |
| Bai, YX | 1 |
| Zhang, HG | 2 |
| Wan, DS | 1 |
| Jia, TZ | 1 |
| Jin, ML | 4 |
| Lou, G | 1 |
| Comella, P | 2 |
| Lorusso, V | 1 |
| Maiorino, L | 1 |
| Cannone, M | 1 |
| Massidda, B | 3 |
| Putzu, C | 1 |
| Leo, S | 3 |
| Roselli, M | 1 |
| Mancarella, S | 1 |
| Palmeri, S | 1 |
| Greco, E | 2 |
| Vessia, G | 1 |
| Sandomenico, C | 1 |
| Franco, L | 2 |
| Berglund, A | 2 |
| Byström, P | 1 |
| Johansson, B | 1 |
| Nygren, P | 1 |
| Frödin, JE | 1 |
| Pedersen, D | 1 |
| Letocha, H | 1 |
| O'Reilly, EM | 1 |
| Saltz, LB | 1 |
| Maki, RG | 1 |
| Schønnemann, KR | 3 |
| Jensen, HA | 3 |
| Yilmaz, M | 3 |
| Jensen, BY | 1 |
| Larsen, O | 1 |
| Benson, M | 2 |
| Lüpfert, C | 2 |
| Kurek, R | 2 |
| Baselga, J | 1 |
| Hill, A | 4 |
| Liu, JF | 2 |
| Jamieson, GG | 4 |
| Wu, TC | 1 |
| Zhu, GJ | 1 |
| Drew, PA | 1 |
| Dittmar, Y | 1 |
| Voigt, R | 1 |
| Heise, M | 1 |
| Rabsch, A | 1 |
| Jandt, K | 1 |
| Settmacher, U | 2 |
| Zhao, JG | 3 |
| Qiu, F | 4 |
| Xiang, XJ | 5 |
| Yu, F | 4 |
| Zhan, ZY | 3 |
| Feng, M | 3 |
| de Portu, S | 1 |
| Menditto, E | 1 |
| Kim, DW | 5 |
| Heo, DS | 7 |
| Lee, KU | 3 |
| Choe, KJ | 3 |
| Kim, NK | 8 |
| Garrido-Laguna, I | 1 |
| Amador, ML | 1 |
| Ruiz, J | 1 |
| Cortés-Funes, H | 2 |
| Tsukasa, K | 1 |
| Fujimoto, C | 1 |
| Murakawa, M | 1 |
| Syoji, T | 1 |
| Hiranuma, S | 1 |
| Ono, A | 1 |
| Onozawa, Y | 5 |
| Taku, K | 4 |
| Mogck, U | 1 |
| Schuch, G | 2 |
| Jaeger, E | 2 |
| Vallböhmer, D | 2 |
| Drebber, U | 1 |
| Schneider, PM | 2 |
| Baldus, S | 2 |
| Bollschweiler, E | 2 |
| Brabender, J | 2 |
| Warnecke-Eberz, U | 1 |
| Hölscher, AH | 2 |
| Metzger, R | 3 |
| Ji, SH | 1 |
| Yi, SY | 1 |
| Jun, HJ | 1 |
| Chang, MH | 1 |
| Park, MJ | 1 |
| Uhm, JE | 1 |
| Jhawer, M | 2 |
| Coit, D | 1 |
| Brennan, M | 4 |
| Qin, LX | 1 |
| Gonen, M | 2 |
| Klimstra, D | 2 |
| Bao, WQ | 1 |
| Sheng, WQ | 1 |
| Wu, LH | 1 |
| Wu, XZ | 1 |
| Salah-Eldin, MA | 1 |
| Ebrahim, MA | 1 |
| AL-Ashry, MS | 1 |
| Daniel, F | 2 |
| Shibata, SI | 1 |
| Mennemeyer, P | 1 |
| Mai, SK | 1 |
| Hermes, P | 1 |
| Massner, B | 2 |
| Hieber, U | 1 |
| Salepci, T | 1 |
| Seker, M | 2 |
| Uyarel, H | 1 |
| Ustaalioğlu, BB | 2 |
| Oztürk, A | 1 |
| Sonmez, B | 1 |
| Orcun, A | 2 |
| Ozates, M | 1 |
| Irmak, R | 1 |
| Yaylaci, M | 1 |
| Chung, WH | 1 |
| Sung, BH | 1 |
| Kim, SS | 1 |
| Rhim, H | 1 |
| Kuh, HJ | 2 |
| Thompson, J | 1 |
| Brown, G | 3 |
| Riddell, A | 1 |
| Stavridi, F | 1 |
| Ashley, S | 3 |
| Takagi, T | 1 |
| Iio, A | 1 |
| Nakagawa, Y | 2 |
| Naoe, T | 1 |
| Akao, Y | 1 |
| Korbakis, D | 2 |
| Scorilas, A | 2 |
| Oh, KJ | 1 |
| Okines, AFC | 1 |
| McCloud, P | 1 |
| Shiina, M | 1 |
| You, MH | 1 |
| Kim, WJ | 1 |
| Choi, S | 1 |
| Kim, YM | 1 |
| Seo, BG | 2 |
| Han, H | 1 |
| Ferrara, D | 1 |
| Manzione, L | 5 |
| Amstutz, U | 1 |
| Farese, S | 1 |
| Aebi, S | 1 |
| Largiadèr, CR | 1 |
| Lou, F | 1 |
| Zhu, YH | 1 |
| Pan, HM | 1 |
| Strauss, J | 1 |
| Hershman, DL | 1 |
| Buono, D | 1 |
| McBride, R | 1 |
| Clark-Garvey, S | 1 |
| Woodhouse, SA | 1 |
| Abrams, JA | 1 |
| Neugut, AI | 1 |
| Yoshida, R | 1 |
| Masuda, T | 2 |
| Ohgaki, K | 2 |
| Curran, D | 1 |
| Dong, N | 1 |
| Jiang, W | 1 |
| Tanabe, S | 8 |
| Azuma, M | 2 |
| Ishido, K | 2 |
| Nishimura, K | 4 |
| Nakatani, K | 7 |
| Katada, C | 2 |
| Yashiro, M | 7 |
| Inoue, T | 9 |
| Nishioka, N | 1 |
| Matsuoka, T | 8 |
| Boland, CR | 1 |
| Raedle, J | 1 |
| Ebert, MP | 3 |
| Flieger, D | 2 |
| Hoehler, T | 2 |
| Dai, H | 1 |
| Kaneda, I | 1 |
| Furuta, A | 1 |
| Shoji, M | 5 |
| Ishibashi, S | 1 |
| Hatsugai, K | 1 |
| Ohara, M | 1 |
| Sarashina, H | 2 |
| Masuoka, H | 1 |
| Sekine, Y | 1 |
| Watanabe, G | 3 |
| Shinto, O | 1 |
| Tendo, M | 2 |
| Matsuzaki, T | 2 |
| Kaizaki, R | 2 |
| Miwa, A | 1 |
| Liang, YJ | 1 |
| Fu, LW | 1 |
| Keshari, RP | 1 |
| Dong, NN | 1 |
| Budakoglu, B | 4 |
| Güler, T | 1 |
| Odabaşi, H | 1 |
| Gang, Y | 1 |
| Tie, J | 1 |
| Qiao, T | 2 |
| Farhat, FS | 2 |
| Kattan, J | 2 |
| Chahine, GY | 2 |
| Younes, FC | 1 |
| Nasr, FL | 2 |
| Mroue, RM | 1 |
| Ghosn, MG | 3 |
| Adelstein, DJ | 2 |
| Rice, TW | 2 |
| Rybicki, LA | 2 |
| Saxton, JP | 2 |
| Videtic, GM | 2 |
| Murthy, SC | 1 |
| Mason, DP | 1 |
| Rodriguez, CP | 2 |
| Ives, DI | 2 |
| Jansen, EPM | 1 |
| Dubbelman, R | 5 |
| Ge, J | 1 |
| Wesolowski, R | 1 |
| Kim, R | 9 |
| Nakamura, J | 3 |
| Kitajima, Y | 6 |
| Kai, K | 5 |
| Mitsuno, M | 2 |
| Ide, T | 2 |
| Hashiguchi, K | 3 |
| Hiraki, M | 4 |
| Miyazaki, K | 5 |
| Raab, R | 1 |
| Sparano, JA | 1 |
| Ocean, AJ | 1 |
| Christos, P | 1 |
| Ramirez, M | 1 |
| Vinciguerra, V | 2 |
| Kaubisch, A | 2 |
| Tucker, S | 1 |
| Cheng, J | 1 |
| Cao, C | 1 |
| Wang, GR | 1 |
| Zhao, JH | 1 |
| Wu, KJ | 1 |
| Zeng, J | 2 |
| Pan, CE | 1 |
| He, DL | 1 |
| Shi, N | 1 |
| Zelt, S | 1 |
| Doi, Y | 1 |
| Ohira, M | 4 |
| Chansky, K | 1 |
| Christman, KL | 1 |
| Hundahl, SA | 4 |
| Issell, BF | 2 |
| Van Veldhuizen, PJ | 1 |
| Budd, GT | 2 |
| Abbruzzese, JL | 4 |
| Kim, BG | 1 |
| Lee, DM | 2 |
| Kim, DK | 1 |
| Jang, JS | 4 |
| Hang, M | 1 |
| Mao, W | 2 |
| Teng, KY | 2 |
| Kaye, PV | 1 |
| Lobo, DN | 1 |
| Takiuchi, H | 9 |
| Henningsen, N | 1 |
| Hapfelmeier, A | 3 |
| Hois, S | 1 |
| Plaschke, S | 1 |
| Höfler, H | 7 |
| Keller, G | 8 |
| Yildiz, R | 2 |
| Kalender, ME | 1 |
| Sevinc, A | 1 |
| Camci, C | 1 |
| Kaya, AO | 2 |
| Yaman, E | 1 |
| Ozturk, B | 2 |
| Coskun, U | 3 |
| Qin, H | 1 |
| Loupakis, F | 2 |
| Caponi, S | 1 |
| Ginocchi, L | 1 |
| Imazawa, M | 1 |
| Wang, TS | 2 |
| Ding, QQ | 1 |
| Guo, RH | 1 |
| Lu, KH | 1 |
| You, SH | 2 |
| Ge, HM | 2 |
| Kochi, M | 11 |
| Kanamori, N | 8 |
| Kaiga, T | 7 |
| Funada, T | 2 |
| Sym, SJ | 5 |
| Oh, ST | 9 |
| Kim, BS | 26 |
| Robles-Jara, C | 1 |
| Robles-Medranda, C | 1 |
| Bati, Y | 1 |
| Akboru, H | 1 |
| Unsal, M | 1 |
| Matsunaga, T | 1 |
| Kaai, K | 1 |
| Kohno, S | 2 |
| Hirayama, R | 2 |
| Alpers, DH | 1 |
| Komoda, T | 1 |
| Hara, A | 1 |
| Zhang, LH | 3 |
| Bu, ZD | 3 |
| Wu, AW | 3 |
| Wu, XJ | 3 |
| Zong, XL | 3 |
| Li, SX | 1 |
| Zhang, XP | 3 |
| Ji, JF | 3 |
| Tsuchiya, T | 1 |
| Hiramatsu, K | 2 |
| Machiki, Y | 1 |
| Sakuragawa, T | 1 |
| Otsuji, H | 1 |
| Hara, T | 5 |
| Hosoya, J | 1 |
| Yeh, CN | 1 |
| Jung, SM | 1 |
| Chen, TW | 1 |
| Hwang, TL | 1 |
| Jan, YY | 1 |
| Chen, MF | 1 |
| Noshiro, H | 3 |
| Fan, CG | 1 |
| Bao, Y | 2 |
| Li, JS | 3 |
| Won, HJ | 1 |
| Ha, TK | 1 |
| Kwon, SJ | 1 |
| Cho, HY | 1 |
| Hur, SJ | 1 |
| Baik, HH | 1 |
| Suh, SI | 2 |
| Ha, E | 1 |
| Kim, YH | 8 |
| Kerkar, SP | 1 |
| Kemp, CD | 1 |
| Duffy, A | 1 |
| Kammula, US | 1 |
| Schrump, DS | 1 |
| Kwong, KF | 1 |
| Quezado, M | 1 |
| Goldspiel, BR | 1 |
| Venkatesan, A | 1 |
| Giaccone, G | 1 |
| Rosenberg, SA | 1 |
| Ota, T | 1 |
| Shuto, K | 1 |
| Ohira, G | 1 |
| Natsume, T | 1 |
| Sato, A | 5 |
| Kawahira, H | 1 |
| Nabeya, Y | 3 |
| Matsubara, H | 4 |
| Kita, K | 1 |
| Takahashi, M | 15 |
| Nakano, S | 8 |
| Akabane, H | 1 |
| Yanagida, N | 1 |
| Shomura, H | 3 |
| Hanamoto, T | 1 |
| Kuji, M | 1 |
| Oikawa, F | 1 |
| Miyagi, H | 1 |
| Takada, J | 3 |
| Kenno, S | 1 |
| Aoki, T | 7 |
| Hamada, H | 8 |
| Katsuki, Y | 5 |
| Morimoto, J | 1 |
| Oohira, M | 1 |
| Kubo, N | 2 |
| Dan, N | 1 |
| Muguruma, K | 5 |
| Yamashita, Y | 10 |
| Tomiyama, N | 1 |
| Hidaka, M | 1 |
| Hidaka, H | 1 |
| Kawano, Y | 1 |
| Hanada, N | 1 |
| Kawaguchi, H | 2 |
| Arimori, K | 1 |
| Nakamura, C | 1 |
| Lee, GW | 1 |
| Go, SI | 1 |
| Kim, HG | 1 |
| Shimoyama, R | 1 |
| Todaka, A | 2 |
| Tomita, H | 1 |
| Cummins, MM | 1 |
| Sourjina, T | 1 |
| Van Hazel, G | 1 |
| Gibbs, D | 1 |
| Stockler, M | 1 |
| Luber, B | 4 |
| Folprecht, G | 2 |
| Wöll, E | 2 |
| Decker, T | 2 |
| Endlicher, E | 2 |
| Röthling, N | 1 |
| Fend, F | 2 |
| Kang, SH | 2 |
| Moon, HS | 3 |
| Sung, JK | 2 |
| Lee, BS | 3 |
| Fukunaga, M | 2 |
| Ohzato, H | 1 |
| Tatsuta, M | 5 |
| Furukawa, H | 11 |
| Overman, MJ | 1 |
| Kazmi, SM | 1 |
| Jhamb, J | 1 |
| Lin, E | 1 |
| Yao, JC | 2 |
| Zhu, FS | 2 |
| Chen, XM | 2 |
| Huang, ZG | 1 |
| Wang, ZR | 1 |
| Zhang, DW | 1 |
| Koukourakis, MI | 1 |
| Giatromanolaki, A | 1 |
| Pitiakoudis, M | 1 |
| Kouklakis, G | 1 |
| Tsoutsou, P | 1 |
| Abatzoglou, I | 1 |
| Panteliadou, M | 1 |
| Sismanidou, K | 1 |
| Sivridis, E | 1 |
| Boulikas, T | 1 |
| Schuller, JC | 1 |
| Fiori, G | 2 |
| Orsi, F | 1 |
| Bonomo, G | 1 |
| Kanagavel, D | 1 |
| Pokataev, IA | 1 |
| Fedyanin, MY | 1 |
| Tryakin, AA | 1 |
| Bazin, IS | 1 |
| Narimanov, MN | 1 |
| Yakovleva, ES | 1 |
| Garin, AM | 4 |
| Tjulandin, SA | 2 |
| Yanagisawa, S | 1 |
| Tsuchiya, S | 6 |
| Kaiho, T | 1 |
| Togawa, A | 1 |
| Shinmura, K | 1 |
| Okamoto, R | 3 |
| Nomura, S | 2 |
| Nobumoto, D | 1 |
| Miyazaki, M | 9 |
| Rodriguez, W | 1 |
| Garin, A | 1 |
| Falcon, S | 1 |
| Sato, S | 10 |
| Mukai, M | 8 |
| Jørgensen, JT | 1 |
| Chen, WC | 1 |
| Wang, WP | 1 |
| Tian, WY | 1 |
| Zhang, XG | 1 |
| Dalla Chiesa, M | 1 |
| Buti, S | 1 |
| Rovere, RK | 1 |
| Aneiros-Fernandez, J | 1 |
| Husein-ElAhmed, H | 1 |
| Arias-Santiago, S | 1 |
| Escobar Gómez-Villalva, F | 1 |
| Nicolae, A | 1 |
| O'Valle Ravassa, F | 1 |
| Aneiros-Cachaza, J | 1 |
| Yu, JC | 2 |
| Kang, WM | 2 |
| Guo, WD | 1 |
| Allegrini, G | 2 |
| Fontana, E | 1 |
| Granetto, C | 1 |
| Salvatore, L | 1 |
| Mentuccia, L | 1 |
| Andreuccetti, M | 1 |
| Cortesi, E | 3 |
| Merlano, M | 2 |
| Kleber, G | 2 |
| Grothey, A | 2 |
| Haerting, J | 2 |
| Fleig, WE | 2 |
| Disel, U | 1 |
| Gürkut, O | 1 |
| Kaleağasi, H | 1 |
| Mertsoylu, H | 1 |
| Ozyilkan, O | 2 |
| Min, N | 1 |
| He, BF | 1 |
| Liao, H | 1 |
| Jia, YZ | 1 |
| Ye, ZB | 2 |
| Li, FH | 1 |
| Chen, XQ | 1 |
| Zhang, BL | 1 |
| Xu, RL | 1 |
| Qin, YW | 1 |
| Dikken, JL | 2 |
| Bakker, B | 1 |
| Hartgrink, HH | 2 |
| Kranenbarg, EM | 1 |
| Putter, H | 3 |
| Peeters, KC | 1 |
| van de Velde, CJ | 5 |
| Matsushita, S | 1 |
| Ikeda, R | 1 |
| Nishizawa, Y | 1 |
| Che, XF | 1 |
| Furukawa, T | 7 |
| Miyadera, K | 2 |
| Tabata, S | 1 |
| Ushiyama, M | 1 |
| Tajitsu, Y | 1 |
| Takeda, Y | 5 |
| Minami, K | 2 |
| Mataki, H | 1 |
| Kanzaki, T | 2 |
| Yamada, K | 3 |
| Kanekura, T | 1 |
| Akiyama, S | 8 |
| Khorana, AA | 1 |
| Simon, S | 1 |
| Kiefer, G | 1 |
| Rajasenan, K | 1 |
| Hantel, A | 1 |
| Shayne, M | 1 |
| Schmotzer, A | 1 |
| Ramanathan, RK | 1 |
| Ba, MC | 2 |
| Cui, SZ | 2 |
| Lin, SQ | 1 |
| Tang, YQ | 2 |
| Wu, YB | 1 |
| Zhang, XL | 2 |
| Tanizaki, J | 1 |
| Takezawa, K | 1 |
| Tsukioka, S | 1 |
| Kiniwa, M | 1 |
| Fukuoka, M | 1 |
| Andersen, M | 2 |
| Vestermark, LW | 1 |
| Seminara, P | 1 |
| Losanno, T | 1 |
| Emiliani, A | 1 |
| Manna, G | 1 |
| Ni, XF | 1 |
| Dong, M | 1 |
| Xing, PY | 1 |
| Shi, YK | 2 |
| Joon, DL | 1 |
| Jayamoham, J | 1 |
| Spry, N | 1 |
| Harvey, J | 1 |
| Di Iulio, J | 1 |
| Milner, A | 1 |
| Mann, GB | 1 |
| Park, J | 4 |
| Panzram, B | 2 |
| Rosenberg, R | 1 |
| Nekarda, H | 1 |
| Schenk, U | 1 |
| Siewert, JR | 10 |
| Gilligan, D | 1 |
| Ruhstaller, T | 1 |
| Archer, C | 1 |
| Beadman, C | 1 |
| Hwang, YH | 1 |
| Li, QF | 2 |
| Yao, RY | 2 |
| Liu, KW | 1 |
| Lv, HY | 1 |
| Jiang, T | 2 |
| Aftimos, PG | 1 |
| Nasr, EA | 1 |
| Nasr, DI | 1 |
| Noun, RJ | 1 |
| El Helou, JA | 1 |
| Goel, G | 1 |
| Jauhri, M | 1 |
| Negi, A | 1 |
| Aggarwal, S | 1 |
| Smyth, E | 1 |
| Abou-Alfa, GK | 1 |
| Lowery, M | 1 |
| Shamseddine, A | 1 |
| Al-Olayan, A | 1 |
| Naghy, M | 1 |
| Saliba, T | 1 |
| Kelsen, D | 5 |
| Liao, C | 1 |
| Schultheis, B | 1 |
| Riebeling, J | 1 |
| Allali, M | 1 |
| Bergmann, U | 1 |
| Kummer, G | 1 |
| Sendler, U | 1 |
| Tannapfel, A | 1 |
| Sendler, A | 3 |
| Tanaka, K | 5 |
| Toyokawa, A | 2 |
| Kanemitsu, K | 1 |
| Okuda, T | 3 |
| Iwasaki, T | 2 |
| Ishida, T | 4 |
| Zou, MJ | 1 |
| Hu, R | 1 |
| Mutze, K | 2 |
| Novotny, A | 1 |
| Göttlicher, M | 1 |
| Li, XL | 2 |
| Yi, SQ | 1 |
| Song, ST | 1 |
| Zhou, XX | 1 |
| Ji, F | 2 |
| Zhao, JL | 1 |
| Cheng, LF | 1 |
| Xu, CF | 1 |
| Tokunaga, O | 2 |
| Imano, M | 1 |
| Itoh, T | 6 |
| Satou, T | 1 |
| Sogo, Y | 1 |
| Hirai, H | 1 |
| Kato, H | 2 |
| Yasuda, A | 1 |
| Peng, YF | 1 |
| Shinkai, M | 1 |
| Yasuda, T | 10 |
| Imamoto, H | 2 |
| Okuno, K | 1 |
| Shiozaki, H | 7 |
| Ohyanagi, H | 2 |
| Schmidt, M | 1 |
| Dietlein, M | 1 |
| Alakus, H | 1 |
| Mönig, SP | 1 |
| Tham, CK | 1 |
| Choo, SP | 2 |
| Poon, DY | 1 |
| Toh, HC | 3 |
| Ong, SY | 1 |
| Tan, SH | 2 |
| Foo, KF | 2 |
| Ashley, SE | 1 |
| Turner, A | 1 |
| Webb, J | 1 |
| Chua, YJ | 3 |
| Shin, JY | 2 |
| Kim, JO | 1 |
| Chae, HS | 1 |
| Rohwer, N | 1 |
| Dame, C | 1 |
| Haugstetter, A | 1 |
| Wiedenmann, B | 1 |
| Detjen, K | 1 |
| Schmitt, CA | 1 |
| Cramer, T | 1 |
| Kim, SR | 1 |
| Park, CH | 5 |
| Röcken, C | 2 |
| Ebert, M | 1 |
| Hur, HS | 1 |
| Yoon, YK | 2 |
| Song, SH | 2 |
| Konings, IR | 1 |
| van der Gaast, A | 3 |
| van der Wijk, LJ | 1 |
| de Jongh, FE | 1 |
| Eskens, FA | 2 |
| Sleijfer, S | 1 |
| Feyereislova, A | 1 |
| Kulikov, E | 1 |
| Ahn, JY | 1 |
| Johnsson, A | 1 |
| Fernebro, E | 1 |
| Kadar, L | 1 |
| Karlberg, I | 1 |
| Flygare, P | 1 |
| Galizia, E | 1 |
| Ferraù, F | 1 |
| Pucci, F | 3 |
| Silva, RR | 4 |
| Luppi, G | 3 |
| Beretta, GD | 5 |
| Berardi, R | 3 |
| Chen, YB | 3 |
| Sun, XW | 4 |
| Xu, DZ | 4 |
| Guan, YX | 3 |
| Feng, XY | 2 |
| Choi, YH | 2 |
| Malik, I | 1 |
| Bernal, P | 1 |
| Byrd, J | 1 |
| Matsuo, K | 5 |
| Ito, S | 6 |
| Yokota, T | 4 |
| Shibata, T | 2 |
| Ito, H | 3 |
| Hosono, S | 1 |
| Kawase, T | 1 |
| Tajima, K | 3 |
| Yatabe, Y | 1 |
| Miyazaki, I | 5 |
| Kawai, T | 1 |
| Harada, Y | 1 |
| Moriyasu, F | 1 |
| Guan, M | 1 |
| Lo Nigro, C | 1 |
| Monteverde, M | 1 |
| Riba, M | 1 |
| Lattanzio, L | 1 |
| Tonissi, F | 1 |
| Garrone, O | 1 |
| Heouaine, A | 1 |
| Gallo, F | 1 |
| Ceppi, M | 1 |
| Borghi, F | 1 |
| Comino, A | 1 |
| Kim, JA | 1 |
| Liu, FR | 1 |
| Ma, FY | 1 |
| Jang, YJ | 1 |
| Kim, CS | 3 |
| Mok, YJ | 4 |
| Kato, J | 6 |
| Nagahara, A | 1 |
| Iijima, K | 1 |
| Kodani, T | 1 |
| Higashihara, Y | 1 |
| Yoshimura, M | 1 |
| Serizawa, N | 1 |
| Osada, T | 2 |
| Yoshizawa, T | 1 |
| Otaka, M | 1 |
| Watanabe, S | 9 |
| Suzuki, S | 5 |
| Matsushita, A | 2 |
| Hirakata, A | 2 |
| Kawamoto, M | 1 |
| Umakoshi, M | 2 |
| Wakabayashi, H | 2 |
| Sasajima, K | 2 |
| Yu, HB | 1 |
| Xian, HB | 1 |
| Deng, YM | 1 |
| Li, LL | 1 |
| Kwon, JM | 2 |
| Lü, HY | 1 |
| Sun, YY | 1 |
| Song, SA | 1 |
| Norman, G | 2 |
| Soares, M | 1 |
| Peura, P | 1 |
| Rice, S | 2 |
| Suh, D | 2 |
| Wright, K | 2 |
| Sculpher, M | 1 |
| Eastwood, A | 2 |
| Cetin, B | 3 |
| Sentürk, S | 1 |
| Güzel, E | 1 |
| Furukawa, K | 2 |
| Yokoi, K | 1 |
| Mamada, Y | 1 |
| Hasegawa, H | 2 |
| Nakazuru, S | 1 |
| Mita, E | 1 |
| Fujita, T | 3 |
| Lang, M | 1 |
| Tang, X | 1 |
| Shen, X | 2 |
| Kang, MF | 1 |
| Luo, MQ | 1 |
| Dong, CM | 1 |
| Kwon, KA | 2 |
| Gao, H | 2 |
| He, B | 1 |
| Luo, DY | 1 |
| Liao, ZY | 1 |
| Mueller, A | 1 |
| Kubicka, S | 1 |
| Geißler, M | 1 |
| Schwarz, S | 1 |
| Maejima, K | 1 |
| Tokunaga, A | 1 |
| Kiyama, T | 1 |
| Kanno, H | 2 |
| Bou, H | 1 |
| Penault-Llorca, F | 1 |
| Chi, KC | 1 |
| Lefkowitz, RA | 1 |
| Robinson, E | 4 |
| Hirai, S | 1 |
| Fukuda, K | 3 |
| Abei, M | 1 |
| Nakagawa, I | 1 |
| Kawaoka, T | 1 |
| Matsukuma, S | 1 |
| Hiraki, S | 1 |
| Aoyagi, H | 1 |
| Kaneko, J | 1 |
| Ono, H | 2 |
| Isogai, J | 1 |
| Yoshida, M | 6 |
| Someno, Y | 1 |
| Katsuta, E | 1 |
| Saguchi, M | 1 |
| Hasegawa, K | 7 |
| Hamada, S | 1 |
| Sugihara, K | 3 |
| Maejima, S | 1 |
| Hong, L | 2 |
| Niu, L | 1 |
| Niu, D | 1 |
| Spych, M | 1 |
| Serbiak, B | 1 |
| Rychter, A | 1 |
| Jesien-Lewandowicz, E | 1 |
| Gottwald, L | 1 |
| Fijuth, J | 1 |
| Miyashiro, I | 1 |
| Kobayashi, O | 7 |
| Arai, K | 24 |
| Oksuzoglu, BC | 1 |
| Aslan, N | 1 |
| Mizota, A | 2 |
| Orhan, O | 1 |
| Eroglu, C | 3 |
| Kaplan, B | 1 |
| Ucar, K | 1 |
| Altinbas, M | 1 |
| Unal, D | 1 |
| Yildiz, OG | 1 |
| Soyuer, S | 1 |
| Rachakonda, PS | 1 |
| Buechler, M | 1 |
| Hemminki, K | 1 |
| Yan, SK | 1 |
| Dai, WX | 1 |
| Liu, XR | 1 |
| Zhang, WD | 1 |
| Kim, CG | 5 |
| Oshima, A | 1 |
| Michalowski, A | 1 |
| Green, JE | 2 |
| Beliak, NP | 1 |
| Antimonik, NIu | 1 |
| Reberšek, M | 1 |
| Skof, E | 1 |
| Hlebanja, Z | 1 |
| Boc, M | 1 |
| Shimada, K | 3 |
| Ohno, Y | 1 |
| Toshima, H | 1 |
| Miyashita, K | 8 |
| Takinishi, Y | 1 |
| Miyokawa, A | 1 |
| Sakashita, A | 1 |
| Shigaki, N | 1 |
| Yamashita, H | 1 |
| Sugita, H | 1 |
| Arima, N | 1 |
| Shi, HJ | 1 |
| Cassidy, J | 1 |
| Saltz, L | 4 |
| Twelves, C | 1 |
| Hoff, P | 1 |
| Kang, Y | 2 |
| Saini, JP | 1 |
| Gilberg, F | 1 |
| Pignon, JP | 3 |
| Conroy, T | 5 |
| Lebreton, G | 2 |
| Ducourtieux, M | 1 |
| Fabre, JM | 2 |
| Saint-Aubert, B | 2 |
| Genève, J | 1 |
| Lasser, P | 5 |
| Sakatoku, M | 3 |
| Oba, K | 3 |
| Takeuchi, N | 1 |
| Nakayama, A | 1 |
| Ogiwara, H | 1 |
| Tsujimoto, K | 1 |
| Ito, N | 1 |
| Koiwai, K | 1 |
| Arai, Y | 9 |
| Fujii, H | 2 |
| Iwase, H | 4 |
| Ohkuma, M | 1 |
| Mimori, K | 1 |
| Tanaka, F | 1 |
| Kim, HM | 1 |
| Shimomura, M | 1 |
| Koucky, K | 1 |
| Wein, A | 2 |
| Konturek, PC | 1 |
| Albrecht, H | 1 |
| Reulbach, U | 1 |
| Männlein, G | 1 |
| Wolff, K | 1 |
| Ostermeier, N | 1 |
| Busse, D | 1 |
| Golcher, H | 1 |
| Schildberg, C | 1 |
| Janka, R | 1 |
| Hohenberger, W | 1 |
| Hahn, EG | 1 |
| Siebler, J | 3 |
| Neurath, MF | 1 |
| Boxberger, F | 1 |
| Lee, DJ | 1 |
| Baek, KK | 1 |
| Ahn, HK | 1 |
| Herrmann, K | 2 |
| Wieder, HA | 1 |
| Wester, HJ | 1 |
| zum Büschenfelde, CM | 1 |
| Buck, AK | 1 |
| Wilhelm, D | 1 |
| Schwaiger, M | 3 |
| Krause, BJ | 1 |
| Seo, JS | 1 |
| Kim, TG | 1 |
| Chen, JY | 1 |
| Suzuki, T | 13 |
| Furuya, A | 1 |
| Koide, N | 2 |
| Ohkoshi, M | 1 |
| Takiguchi, M | 1 |
| Ochiai, T | 8 |
| Hiwasa, T | 1 |
| Negri, FV | 1 |
| Bozzetti, C | 1 |
| Ardizzoni, A | 2 |
| Lagrasta, C | 1 |
| Crafa, P | 1 |
| Silini, EM | 1 |
| Lim, SJ | 1 |
| Zhao, WY | 1 |
| Chen, DY | 1 |
| Li, JH | 1 |
| Li, B | 2 |
| Jiang, HR | 1 |
| Okada, K | 10 |
| Li, YY | 1 |
| Kos, FT | 1 |
| Odabaş, H | 1 |
| Tseng, CW | 1 |
| Huang, HC | 1 |
| Chuang, KN | 1 |
| Lin, CC | 1 |
| Lai, HS | 1 |
| Lee, PH | 3 |
| Chang, KJ | 2 |
| Juan, HF | 1 |
| Spackman, E | 1 |
| Stirk, L | 1 |
| Danso-Appiah, A | 1 |
| Palmer, S | 1 |
| Werner Kraus, T | 1 |
| Bruch, HP | 1 |
| Noack, F | 1 |
| Altmannsberger, HM | 2 |
| Abbas, F | 1 |
| Romano, O | 2 |
| Bécouarn, Y | 2 |
| Desseigne, F | 1 |
| Edeline, J | 1 |
| Dorval, E | 1 |
| Kramar, A | 1 |
| Pera, M | 1 |
| Montagut, C | 2 |
| Iglesias, M | 1 |
| Conill, C | 1 |
| Reig, A | 1 |
| Balagué, C | 1 |
| Pétriz, L | 1 |
| Momblan, D | 1 |
| Bellmunt, J | 3 |
| Takai, H | 1 |
| Kondoh, E | 1 |
| Sato, Y | 10 |
| Kakui, K | 1 |
| Tatsumi, K | 1 |
| Konishi, I | 2 |
| Yamagiwa, T | 1 |
| Maejima, R | 1 |
| Shimada, N | 1 |
| Dairaku, N | 1 |
| Narisawa, A | 1 |
| Iwahashi, S | 1 |
| Markelis, R | 1 |
| Endzinas, Z | 1 |
| Grižas, S | 1 |
| Pundzius, J | 1 |
| Saladžinskas, Z | 1 |
| Juozaitytė, E | 1 |
| Inčiūra, A | 1 |
| Pranys, D | 1 |
| Maleckas, A | 1 |
| Ong, CW | 1 |
| Wong, WK | 1 |
| Yeoh, KG | 1 |
| So, J | 1 |
| Tsuburaya, A | 5 |
| Grabsch, H | 1 |
| Rozen, S | 1 |
| Wan, WK | 1 |
| Tellez, MS | 1 |
| Wei, ZG | 1 |
| Wang, YN | 1 |
| Wang, ZM | 4 |
| Yoshida, N | 1 |
| Mihara, Y | 1 |
| Tamegai, H | 1 |
| Bojic, M | 1 |
| Thallinger, CM | 1 |
| Maresch, J | 1 |
| Chuai, S | 1 |
| Zheng, D | 2 |
| Bi, TQ | 1 |
| Liao, XH | 1 |
| Zhang, DJ | 1 |
| Long, HL | 1 |
| Li, HJ | 1 |
| Cheong, TC | 1 |
| Zhuo, LJ | 1 |
| Gao, MQ | 1 |
| Huang, AM | 1 |
| Newman, E | 2 |
| Chang, RY | 1 |
| Potmesil, M | 1 |
| Ryan, T | 2 |
| Donahue, B | 1 |
| Chandra, A | 1 |
| Utate, M | 1 |
| Hiotis, S | 1 |
| Pachter, LH | 1 |
| Hochster, H | 1 |
| Muggia, F | 3 |
| Kabeya, M | 1 |
| Yuasa, S | 1 |
| Kikuchi, F | 1 |
| Tajiri, C | 1 |
| Hibi, S | 1 |
| Minagawa, Y | 1 |
| Kayukawa, S | 1 |
| Kataoka, T | 1 |
| Kawai, M | 3 |
| Zhou, N | 1 |
| An, X | 1 |
| Rothmann, F | 1 |
| Blau, I | 1 |
| Schwaner, I | 1 |
| Grothoff, M | 1 |
| Grieser, C | 1 |
| Maurits Swellengrebel, HA | 1 |
| van Grieken, NC | 1 |
| Amarantidis, K | 2 |
| Xenidis, N | 1 |
| Chelis, L | 1 |
| Chamalidou, E | 1 |
| Dimopoulos, P | 1 |
| Michailidis, P | 1 |
| Tentes, A | 2 |
| Deftereos, S | 1 |
| Karanikas, M | 1 |
| Karayiannakis, A | 1 |
| Kakolyris, S | 2 |
| Amini, A | 1 |
| Sanati, H | 1 |
| Langer, B | 3 |
| Starnawski, M | 1 |
| Piacentini, P | 1 |
| Durante, E | 1 |
| Trolese, A | 1 |
| Mercanti, A | 1 |
| Bonetti, A | 1 |
| Shi, X | 1 |
| Brown, KH | 1 |
| Maheshwari, M | 1 |
| Pan, SY | 1 |
| Chen, QQ | 1 |
| Gao, XP | 1 |
| Fonck, M | 1 |
| Brunet, R | 4 |
| Legoux, JL | 1 |
| Dauba, J | 1 |
| Cany, L | 1 |
| Auby, D | 1 |
| Traissac, L | 1 |
| Mertens, C | 1 |
| Soubeyran, P | 1 |
| Bellera, C | 1 |
| Rainfray, M | 1 |
| Mathoulin-Pélissier, S | 1 |
| Oda, H | 1 |
| Mizuno, T | 1 |
| Nomura, H | 2 |
| Saito, K | 13 |
| Tamaru, S | 1 |
| Kageyama, S | 1 |
| Katayama, N | 1 |
| Rollins, KE | 1 |
| Peters, CJ | 1 |
| Safranek, PM | 1 |
| Ford, H | 2 |
| Baglin, TP | 1 |
| Hardwick, RH | 1 |
| Wang, HX | 1 |
| Sbitti, Y | 1 |
| Essaidi, I | 1 |
| Debbagh, A | 1 |
| Kadiri, H | 1 |
| Oukabli, M | 1 |
| Moussaid, Y | 1 |
| Slimani, K | 1 |
| Fetohi, M | 1 |
| Elkaoui, H | 1 |
| Albouzidi, A | 1 |
| Mahi, M | 1 |
| Kundel, Y | 3 |
| Purim, O | 3 |
| Idelevich, E | 2 |
| Lavrenkov, K | 1 |
| Man, S | 1 |
| Kovel, S | 1 |
| Karminsky, N | 1 |
| Pfeffer, RM | 1 |
| Nisenbaum, B | 1 |
| Fenig, E | 1 |
| Sulkes, A | 6 |
| Brenner, B | 4 |
| Weissinger, F | 1 |
| Reymond, M | 1 |
| Dumke, K | 1 |
| Krüger, M | 1 |
| Zhi, QM | 1 |
| Chen, XH | 1 |
| Zhang, JN | 1 |
| Li, JF | 1 |
| Liu, BY | 4 |
| Gu, QL | 2 |
| Bayraktar, UD | 1 |
| Bayraktar, S | 1 |
| Hosein, P | 1 |
| Chen, E | 1 |
| Koniaris, LG | 1 |
| Rocha-Lima, CM | 1 |
| Montero, AJ | 1 |
| Ferri, LE | 2 |
| Chasen, M | 2 |
| Marcus, V | 2 |
| Hickeson, M | 2 |
| Artho, G | 2 |
| Thirlwell, MP | 3 |
| Ren, JH | 1 |
| Cui, CX | 1 |
| Li, JL | 1 |
| Wang, JW | 1 |
| Chang, YR | 1 |
| Han, DS | 1 |
| Quero, L | 1 |
| Bouchbika, Z | 1 |
| Kouto, H | 1 |
| Baruch-Hennequin, V | 1 |
| Munoz, N | 1 |
| Cojean-Zelek, I | 1 |
| Houdart, R | 1 |
| Panis, Y | 1 |
| Valleur, P | 1 |
| Maylin, C | 1 |
| Hennequin, C | 1 |
| Ruan, DY | 1 |
| Kim, CH | 1 |
| Rettig, RL | 1 |
| Lee, ET | 1 |
| Aprelikova, O | 1 |
| Munroe, DJ | 1 |
| Wirtz, R | 1 |
| Werner, D | 1 |
| Nagai, Y | 1 |
| Takagi, S | 2 |
| Yoshioka, A | 1 |
| Chakravarty, T | 1 |
| Crane, CH | 2 |
| Briere, TM | 1 |
| Beddar, AS | 1 |
| Mok, H | 1 |
| Reed, VK | 1 |
| Krishnan, S | 2 |
| Delclos, ME | 2 |
| Saikawa, Y | 5 |
| Wada, N | 2 |
| Deplazes, J | 1 |
| Walch, A | 1 |
| Rauser, S | 2 |
| Eichmann, M | 1 |
| Tey, J | 1 |
| Jiang, R | 1 |
| Fu, S | 1 |
| Lu, JJ | 1 |
| Ohashi, Y | 3 |
| Miyata, Y | 7 |
| Satoh, A | 1 |
| Abe, T | 8 |
| Hatake, K | 1 |
| Noh, JH | 5 |
| Ahn, YC | 2 |
| Sohn, I | 1 |
| Koh, CE | 1 |
| Goh, PG | 2 |
| Kim, ES | 1 |
| Lee, ES | 1 |
| Lei, X | 1 |
| Dong, W | 1 |
| Zanow, J | 1 |
| Leistner, Y | 1 |
| Ludewig, S | 1 |
| Rauchfuss, F | 1 |
| Kim, YW | 5 |
| Noh, SI | 1 |
| Button, P | 1 |
| Sirzén, F | 1 |
| Ferte, C | 1 |
| Bourgeois, V | 1 |
| Peugniez, C | 1 |
| Lindet, C | 1 |
| Ladrat, L | 1 |
| Triboulet, JP | 1 |
| Hebbar, M | 1 |
| Cho, YH | 2 |
| Hong Lee, M | 1 |
| Yoo, MW | 1 |
| Bang, HY | 1 |
| Lee, KY | 1 |
| Yoon, SY | 3 |
| Schiavon, G | 1 |
| Casadei, V | 2 |
| Luzi Fedeli, S | 2 |
| Fiorentini, G | 2 |
| Ben Aharon, I | 1 |
| Brenner, R | 1 |
| Gordon, N | 1 |
| Kim, GM | 1 |
| Jung, I | 1 |
| Inal, A | 5 |
| Kaplan, MA | 4 |
| Kucukoner, M | 4 |
| Isikdogan, A | 5 |
| Zheng, JY | 1 |
| Wang, WZ | 1 |
| Rasouli, HA | 1 |
| Moghadam, MM | 1 |
| Tabatabaiefar, M | 1 |
| Taslimi, F | 1 |
| Sheybani, KM | 1 |
| Alidoosti, A | 1 |
| Ameri, A | 1 |
| Fadavi, P | 1 |
| Aref, S | 1 |
| Matsui, T | 5 |
| Takahashi, I | 7 |
| Miyashita, Y | 4 |
| Baba, H | 15 |
| Zhou, CF | 1 |
| Su, Y | 1 |
| Zheng, YB | 1 |
| Cao, FY | 1 |
| Liu, KJ | 1 |
| Gan, HF | 1 |
| He, XB | 1 |
| Tong, SL | 1 |
| Sun, XC | 1 |
| Ju, AH | 1 |
| Wu, ZM | 1 |
| Teng, RY | 1 |
| Shen, JG | 1 |
| Xie, SD | 1 |
| Xu, CY | 1 |
| Wang, LB | 1 |
| Heindl, S | 1 |
| Eggenstein, E | 1 |
| Keller, S | 1 |
| Kneissl, J | 1 |
| Gasteiger, G | 1 |
| Drexler, I | 1 |
| Kim, SN | 2 |
| Oh, JS | 1 |
| Moretones, C | 1 |
| León, D | 1 |
| Navarro, A | 1 |
| Santacruz, O | 1 |
| Boladeras, AM | 1 |
| Macià, M | 1 |
| Cambray, M | 1 |
| Navarro, V | 1 |
| Modolell, I | 1 |
| Guedea, F | 1 |
| Ma, ZQ | 1 |
| Akram, M | 1 |
| Balasubramanian, I | 1 |
| Tam, KK | 1 |
| Yee, MQ | 1 |
| Liu, JZ | 1 |
| Lin, L | 2 |
| Ge, FJ | 1 |
| Li, SS | 1 |
| Liu, LJ | 1 |
| Zhao, CH | 1 |
| Yoon, DH | 1 |
| MacLellan, SJ | 1 |
| MacKay, HJ | 1 |
| Jacks, L | 1 |
| Kassam, Z | 2 |
| Conrad, T | 1 |
| Khalili, I | 1 |
| Okrainec, A | 1 |
| Fong, CW | 1 |
| DU, JP | 1 |
| Li, SJ | 2 |
| Zhai, LP | 1 |
| Yang, XY | 1 |
| Wu, ZT | 1 |
| Ji, MY | 1 |
| Fang, C | 1 |
| Du, H | 2 |
| Yuan, P | 1 |
| Inane, M | 1 |
| Yetisyigit, T | 2 |
| Turhal, S | 2 |
| Levinson, B | 1 |
| Jeong, JH | 1 |
| Cho, KS | 2 |
| Yoon, HJ | 2 |
| Ferrand, FR | 1 |
| Gontier, E | 1 |
| Guymar, S | 1 |
| Fagot, T | 1 |
| Ceccaldi, B | 1 |
| Malfuson, JV | 1 |
| de Revel, T | 1 |
| Papadimitriou, K | 1 |
| Vassiliou, V | 1 |
| Kountourakis, P | 1 |
| Polyviou, P | 1 |
| Andreopoulos, D | 1 |
| Papamichael, D | 2 |
| Ishiguro, A | 1 |
| Matsumoto, Y | 2 |
| Tanaka, S | 7 |
| Itoh, J | 2 |
| Kawasaki, H | 2 |
| Kudoh, Y | 1 |
| Kijima, H | 1 |
| Shimaya, S | 1 |
| Saijo, Y | 1 |
| Fukudome, I | 1 |
| Okabayashi, T | 2 |
| Qiang, F | 3 |
| Bai, J | 1 |
| Gong, Z | 1 |
| Li, A | 2 |
| Røe, OD | 3 |
| Yi, JH | 1 |
| Mutyala, V | 1 |
| Bains, S | 1 |
| Patil, C | 1 |
| Madhavarao, B | 1 |
| Bai, ZB | 1 |
| Chen, BA | 1 |
| Zhong, YJ | 1 |
| Wu, JZ | 4 |
| Xu, PP | 1 |
| Peng, MX | 1 |
| Cao, JM | 1 |
| Osti, MF | 1 |
| Agolli, L | 1 |
| Bracci, S | 1 |
| Monaco, F | 1 |
| Tubin, S | 1 |
| Minniti, G | 1 |
| De Sanctis, V | 1 |
| Enrici, RM | 1 |
| Cha, Y | 1 |
| Keam, B | 2 |
| Takao, Y | 1 |
| Hayakawa, T | 2 |
| Hosone, M | 1 |
| Smalley, SR | 2 |
| Benedetti, JK | 1 |
| Estes, NC | 2 |
| Goldman, B | 1 |
| Martenson, JA | 3 |
| Jessup, JM | 3 |
| Stemmermann, GN | 2 |
| Tomioka, H | 1 |
| Mukohara, T | 1 |
| Kataoka, Y | 1 |
| Ekyalongo, RC | 1 |
| Funakoshi, Y | 1 |
| Gómez-Martín, C | 2 |
| Salazar, R | 1 |
| Gil-Martín, M | 1 |
| Núñez, JA | 1 |
| Puig, M | 1 |
| Tursi, JM | 1 |
| Peng, TL | 1 |
| Yin, XF | 1 |
| Chen, LZ | 1 |
| Luo, XR | 1 |
| Niu, Y | 1 |
| Miao, L | 1 |
| Frustaci, S | 2 |
| Buonadonna, A | 1 |
| Turchet, E | 1 |
| Corona, G | 1 |
| Tabaro, G | 1 |
| Miolo, G | 1 |
| Torrisi, E | 1 |
| Lo Re, G | 2 |
| Tumolo, S | 2 |
| Toffoli, G | 2 |
| Michaelson, JS | 1 |
| Kelly, R | 1 |
| Wortham, K | 1 |
| Joseph, IB | 1 |
| Phillips, BE | 1 |
| Tubbs, RR | 1 |
| Plesec, T | 1 |
| Vigliar, E | 1 |
| Marino, G | 1 |
| Imbimbo, C | 1 |
| Rossella, de C | 1 |
| Insabato, L | 1 |
| Tsuji, K | 2 |
| Doyama, H | 1 |
| Florschütz, A | 1 |
| Mantovani-Löffler, L | 1 |
| Kneba, M | 1 |
| Glanemann, M | 1 |
| Schlattmann, P | 1 |
| Gahn, B | 1 |
| Sung, EZ | 1 |
| Arasaradnam, RP | 1 |
| Jarvie, EM | 1 |
| James, S | 1 |
| Goodyear, SJ | 1 |
| Borman, RA | 1 |
| Snead, D | 1 |
| Sanger, GJ | 1 |
| Nwokolo, CU | 1 |
| Przyborek, M | 1 |
| Schleucher, N | 3 |
| Heeger, S | 1 |
| Vanhoefer, U | 7 |
| Roy, A | 1 |
| Sörbye, H | 1 |
| Barcelo, JR | 1 |
| Lopez-Vivanco, G | 2 |
| Adler, G | 1 |
| Canon, JL | 1 |
| Lofts, F | 2 |
| Castanon, C | 1 |
| Fonseca, E | 2 |
| Rixe, O | 1 |
| Aparicio, J | 2 |
| Cassinello, J | 1 |
| Mousseau, M | 1 |
| Schalhorn, A | 1 |
| D'Hondt, L | 1 |
| Kerger, J | 1 |
| Hossfeld, DK | 6 |
| Garcia Giron, C | 1 |
| Rodriguez, R | 2 |
| Schoffski, P | 2 |
| Misset, JL | 6 |
| Sonnenblick, A | 1 |
| Rottenberg, Y | 1 |
| Kadouri, L | 1 |
| Wygoda, M | 1 |
| Rivkind, A | 1 |
| Vainer, GW | 1 |
| Peretz, T | 2 |
| Hubert, A | 1 |
| Yin, GJ | 1 |
| Lan, KH | 3 |
| Hu, CY | 1 |
| Lu, Q | 1 |
| Tang, W | 3 |
| Wu, T | 1 |
| Lu, SX | 1 |
| Komatsu, Y | 4 |
| Saji, S | 18 |
| Taira, K | 1 |
| Shimoishi, K | 1 |
| Muto, Y | 1 |
| Asakage, M | 1 |
| Zhou, LK | 1 |
| Bai, M | 1 |
| Unek, IT | 2 |
| Unek, T | 1 |
| Oztop, I | 3 |
| Akman, T | 2 |
| Atilla, K | 1 |
| Ellidokuz, H | 1 |
| Bora, S | 1 |
| Sarioglu, S | 1 |
| Yilmaz, U | 3 |
| Kanetaka, K | 1 |
| Enjoji, A | 1 |
| Furui, J | 1 |
| Fujioka, H | 1 |
| Shiogama, T | 1 |
| Miyata, A | 1 |
| Kishikawa, H | 1 |
| Matsuo, S | 2 |
| Iwata, T | 2 |
| Kanematsu, T | 1 |
| Eguchi, S | 1 |
| Sánchez, A | 2 |
| Irigoyen, A | 1 |
| Llorente, B | 1 |
| Pérez, B | 1 |
| Safont, MJ | 1 |
| Falcó, E | 1 |
| Lacasta, A | 1 |
| Dueñas, R | 1 |
| Muñoz, ML | 1 |
| Regueiro, P | 1 |
| Sanchez-Viñes, E | 1 |
| López, RL | 1 |
| Prochilo, T | 1 |
| Abeni, C | 1 |
| Bertocchi, P | 1 |
| Chen, RX | 1 |
| Meng, H | 2 |
| Wu, GC | 1 |
| Zhang, ZT | 1 |
| Wang, KL | 1 |
| Chu, KM | 1 |
| Sanchez, T | 1 |
| DelaCruz, C | 1 |
| Mukhopadhyay, P | 1 |
| Lainas, I | 1 |
| Ercan, S | 1 |
| Yilmaz, BE | 1 |
| Fan, C | 1 |
| Chiba, T | 2 |
| Matsuo, T | 1 |
| Noda, H | 1 |
| Yamada, N | 5 |
| Itabashi, T | 1 |
| Uesugi, N | 1 |
| Maesawa, C | 4 |
| Tamura, G | 1 |
| Sugai, T | 1 |
| Otsuka, K | 1 |
| Shen, M | 1 |
| Wan, Z | 1 |
| Nam, SH | 2 |
| Yim, CY | 1 |
| Yang, SH | 3 |
| Sui, X | 1 |
| Rong, R | 1 |
| Shi, Q | 1 |
| Mo, L | 1 |
| Shu, X | 1 |
| Kuang, Y | 1 |
| Tao, Q | 1 |
| Zuo, Q | 1 |
| Wang, N | 2 |
| Kucukzeybek, Y | 1 |
| Dirican, A | 1 |
| Erten, C | 1 |
| Somali, I | 2 |
| Can, A | 1 |
| Demir, L | 1 |
| Bayoglu, IV | 1 |
| Akyol, M | 1 |
| Medeni, M | 1 |
| Tarhan, MO | 1 |
| Ryu, KW | 3 |
| Felekouras, E | 1 |
| Karatzas, T | 1 |
| Griniatsos, J | 1 |
| Dimitroulis, D | 1 |
| Polyzos, K | 1 |
| Kontzoglou, K | 1 |
| Mantas, D | 1 |
| Karavokyros, J | 1 |
| Nikiteas, N | 1 |
| Tsavaris, N | 1 |
| Syrigos, K | 2 |
| Vafiadis, I | 1 |
| Chang, EY | 1 |
| Tsai, SH | 1 |
| Shun, CT | 2 |
| Hee, SW | 1 |
| Chang, YC | 2 |
| Tsai, YC | 1 |
| Tsai, JS | 1 |
| Chen, HJ | 1 |
| Chou, JW | 1 |
| Lin, SY | 1 |
| Chuang, LM | 1 |
| Hozaeel, W | 1 |
| Ying, LS | 1 |
| Yu, JL | 1 |
| Lu, XX | 1 |
| Ling, ZQ | 1 |
| Chen, JQ | 1 |
| Qin, XG | 1 |
| Nia, AM | 1 |
| Isensee, H | 1 |
| Gassanov, N | 1 |
| Er, F | 1 |
| Kim, KC | 1 |
| Eisenbraun, J | 1 |
| Huber, R | 1 |
| Yumuk, F | 1 |
| Berk, V | 1 |
| Nakamura, Y | 9 |
| Aydogan, F | 1 |
| Disci, R | 1 |
| Cha, BH | 1 |
| Yoo, JY | 1 |
| Kim, N | 1 |
| Hwang, JH | 1 |
| Weinreich, J | 1 |
| Schott, TC | 1 |
| Königsrainer, I | 1 |
| Küper, M | 1 |
| Schott, H | 1 |
| Nakashima, S | 1 |
| Yoshikawa, Y | 1 |
| Sunada, S | 1 |
| Nishitani, A | 1 |
| Boku, M | 1 |
| Wakahara, M | 1 |
| Kamiike, W | 1 |
| Taniyama, K | 1 |
| Goto, A | 1 |
| Itoh, M | 1 |
| Wakasugi, H | 1 |
| Kanno, S | 1 |
| Yabana, T | 1 |
| Mitsuhashi, K | 1 |
| Adachi, T | 2 |
| Kondo, Y | 6 |
| Shinomura, Y | 2 |
| Bisonni, R | 2 |
| Fedeli, SL | 1 |
| Giustini, L | 2 |
| Inanc, M | 1 |
| Waseda, Y | 1 |
| Komai, Y | 1 |
| Yano, A | 1 |
| Fujii, Y | 2 |
| Noguchi, N | 1 |
| Kihara, K | 2 |
| Chi, B | 1 |
| Unal, OU | 1 |
| Salman, T | 1 |
| Urakci, Z | 1 |
| Guven, M | 1 |
| Nas, N | 1 |
| Yunce, M | 1 |
| Rostom, Y | 1 |
| Zaghloul, H | 1 |
| Khedr, G | 1 |
| El-Shazly, W | 1 |
| Abd-Allah, D | 1 |
| Langley, RE | 3 |
| Thompson, LC | 2 |
| Stenning, SP | 2 |
| Stevenson, L | 1 |
| Middleton, GW | 1 |
| Evans, L | 1 |
| Ford, D | 1 |
| Iveson, TJ | 2 |
| Petty, RD | 1 |
| Plummer, C | 1 |
| Blazeby, JM | 1 |
| Griffin, M | 1 |
| Eatock, MM | 2 |
| Bampton, CL | 1 |
| Strickland, AH | 2 |
| Swieboda-Sadlej, A | 1 |
| Nanayakkara, N | 1 |
| Sun, YN | 1 |
| Zhong, ZD | 1 |
| Bass, MB | 1 |
| Adewoye, AH | 1 |
| Dai, C | 1 |
| Roussel, H | 2 |
| Markoutsaki, T | 1 |
| Trouilloud, I | 1 |
| Elvin, P | 1 |
| Sacconi, A | 1 |
| Biagioni, F | 2 |
| Canu, V | 1 |
| Mori, F | 2 |
| Di Benedetto, A | 1 |
| Lorenzon, L | 1 |
| Ercolani, C | 1 |
| Di Agostino, S | 1 |
| Cambria, AM | 1 |
| Germoni, S | 1 |
| Grasso, G | 1 |
| Blandino, R | 1 |
| Panebianco, V | 1 |
| Ziparo, V | 1 |
| Federici, O | 1 |
| Muti, P | 1 |
| Strano, S | 1 |
| Carboni, F | 1 |
| Mottolese, M | 1 |
| Diodoro, M | 1 |
| Pescarmona, E | 1 |
| Garofalo, A | 1 |
| Blandino, G | 1 |
| Matsumoto, H | 5 |
| Higashida, M | 3 |
| Murakami, H | 3 |
| Tsutsumi, K | 2 |
| Nakashima, H | 3 |
| Oka, Y | 3 |
| Hirai, T | 4 |
| Kourie, HR | 1 |
| Markoutsaki, N | 1 |
| Rahmi, G | 1 |
| Van der Stiegel, M | 1 |
| Palazzo, L | 1 |
| Fabre, M | 1 |
| Cuenod, CA | 1 |
| Jingu, K | 1 |
| Umezawa, R | 1 |
| Takahashi, C | 1 |
| Sugawara, T | 1 |
| Kubozono, M | 1 |
| Abe, K | 9 |
| Tanabe, T | 4 |
| Shirata, Y | 1 |
| Ishikawa, Y | 2 |
| Nemoto, K | 1 |
| Martella, B | 1 |
| Cardin, F | 1 |
| Lorenzetti, R | 1 |
| Terranova, C | 1 |
| Amato, B | 1 |
| Militello, C | 1 |
| Park, JL | 1 |
| Baek, SJ | 1 |
| Noh, SM | 1 |
| Song, KS | 1 |
| Cho, EK | 9 |
| Park, YH | 8 |
| Lee, WK | 6 |
| Chung, M | 5 |
| Kawabe, Y | 2 |
| Mayr, M | 1 |
| Schulte, N | 1 |
| Belle, S | 1 |
| Krause, A | 1 |
| Schmid, RM | 1 |
| Sasada, S | 1 |
| Tsuyama, N | 1 |
| Masujima, T | 1 |
| Hihara, J | 1 |
| Reis-Filho, JS | 1 |
| Waddell, TS | 1 |
| Noor, D | 1 |
| Nishi, T | 2 |
| Uemoto, J | 1 |
| Onodera, K | 1 |
| Warita, E | 1 |
| Yamanaka, Y | 1 |
| Zhan, YP | 1 |
| Lu, YY | 1 |
| Wu, XY | 1 |
| Ye, LH | 1 |
| Ozturk, MA | 1 |
| Ozveren, O | 1 |
| Cinar, V | 1 |
| Erdik, B | 1 |
| Oyan, B | 1 |
| Mao, Y | 3 |
| Kang, EJ | 1 |
| Andalib, A | 1 |
| Yao, F | 1 |
| Yang, AM | 1 |
| Zhong, DR | 1 |
| Wu, DS | 1 |
| Lu, XH | 1 |
| Liu, HY | 1 |
| Ding, L | 2 |
| Graves, CA | 2 |
| Camphausen, K | 2 |
| Hou, MF | 1 |
| Umeda, S | 1 |
| Fushimi, H | 1 |
| Xia, X | 2 |
| Anter, AH | 1 |
| Abdel-Latif, RM | 1 |
| Sekikawa, A | 1 |
| Fukui, H | 3 |
| Maruo, T | 1 |
| Okabe, Y | 1 |
| Wakasa, T | 1 |
| Osaki, Y | 1 |
| Tomita, T | 1 |
| Watari, J | 1 |
| Miwa, H | 2 |
| Ang, J | 2 |
| Huang, PT | 1 |
| Huang, LN | 1 |
| Cao, CH | 1 |
| Zheng, YX | 1 |
| Wang, HJ | 1 |
| Yin, D | 1 |
| Lei, C | 1 |
| Zhu, JF | 1 |
| Cai, XH | 1 |
| Zhang, GQ | 1 |
| Fragoulis, EG | 1 |
| Chen, YN | 1 |
| Chang, SL | 1 |
| Miao, S | 1 |
| An, SH | 1 |
| Lee, HG | 2 |
| Ritchim, P | 1 |
| Charkrabandhu, T | 1 |
| Jongraksat, W | 1 |
| Hartung, G | 1 |
| Samel, S | 1 |
| Pichlmeier, U | 1 |
| Hehlmann, R | 3 |
| Queisser, W | 10 |
| Iwata, S | 3 |
| Takabayashi, A | 3 |
| Yamaoka, Y | 1 |
| Iizuka, R | 1 |
| Takahashi, S | 5 |
| Kakihara, N | 2 |
| Matsumura, H | 1 |
| Takenaka, A | 2 |
| Shimoyama, S | 1 |
| Kusada, O | 2 |
| Kaminishi, M | 3 |
| Ahn, JH | 2 |
| Bahng, H | 1 |
| Kang, WC | 1 |
| Kim, WK | 3 |
| Lee, KD | 2 |
| Liu, TW | 4 |
| Tiu, CM | 1 |
| Liu, JM | 3 |
| Chung, TR | 3 |
| Chang, JY | 5 |
| Whang-Peng, J | 3 |
| Elomaa, I | 1 |
| Kouri, M | 2 |
| Kiviluoto, T | 1 |
| Evans, TR | 1 |
| Pentheroudakis, G | 2 |
| Paul, J | 1 |
| McInnes, A | 1 |
| Blackie, R | 1 |
| Raby, N | 1 |
| Morrison, R | 1 |
| Fullarton, GM | 1 |
| Soukop, M | 6 |
| McDonald, AC | 1 |
| Monden, M | 7 |
| Kerr, C | 1 |
| Mochizuki, F | 8 |
| Kasakura, Y | 7 |
| Yamagata, M | 3 |
| Wakabayashi, K | 3 |
| Kliche, KO | 1 |
| Kubsch, K | 1 |
| Raida, M | 2 |
| Masri-Zada, R | 1 |
| Höffken, K | 3 |
| Leonard, GD | 1 |
| Zhuang, SH | 1 |
| Grem, JL | 4 |
| Ishio, T | 1 |
| Kohnoe, S | 7 |
| Ikeda, Y | 5 |
| Toh, Y | 2 |
| Okamura, T | 6 |
| Kawamoto, K | 1 |
| Tasaka, K | 1 |
| Okada, Y | 5 |
| Tomofuji, Y | 1 |
| Chinzei, T | 1 |
| Shimokawa, H | 1 |
| Nose, N | 1 |
| Ikegami, T | 1 |
| Itoh, H | 2 |
| Kido, A | 1 |
| Ezaki, T | 5 |
| Takizawa, M | 1 |
| Hirano, M | 5 |
| Murakami, N | 7 |
| Uno, Y | 1 |
| Kikuchi, T | 3 |
| Nozawa, H | 2 |
| Asaumi, Y | 1 |
| Kikkawa, H | 1 |
| Norman, A | 9 |
| Mochlinski, K | 2 |
| Prior, Y | 1 |
| Constenla, M | 4 |
| Garcia-Arroyo, R | 1 |
| Lorenzo, I | 1 |
| Carrete, N | 1 |
| Campos, B | 1 |
| Palacios, P | 1 |
| Shiah, HS | 2 |
| Jan, CM | 1 |
| Sugita, M | 1 |
| Togo, S | 1 |
| Miura, Y | 3 |
| Akiyama, H | 9 |
| Kunisaki, C | 2 |
| Shimada, H | 3 |
| Jung, ID | 1 |
| Yang, SY | 1 |
| Park, CG | 1 |
| Lee, KB | 9 |
| Han, JW | 1 |
| Jung, KH | 2 |
| Kim, WS | 6 |
| Brown, TA | 1 |
| Ridge, JA | 1 |
| Goldberg, M | 1 |
| Fu, QG | 1 |
| Meng, FD | 1 |
| Shen, XD | 1 |
| Guo, RX | 1 |
| Lin, AD | 1 |
| Sun, HY | 1 |
| Qu, MW | 1 |
| Wang, FJ | 1 |
| Tigaud, JM | 3 |
| Gamelin, E | 2 |
| Jacob, JH | 1 |
| Levoir, D | 1 |
| Taamma, A | 1 |
| Cvitkovic, E | 2 |
| Kagawa, R | 1 |
| Sakata, S | 1 |
| Tada, M | 2 |
| Aoyagi, K | 7 |
| Koufuji, K | 6 |
| Yano, S | 5 |
| Miyagi, M | 3 |
| Koga, A | 1 |
| Takeda, J | 8 |
| Shirouzu, K | 8 |
| Káposztás, Z | 2 |
| Cseke, L | 3 |
| Kalmár, K | 4 |
| Horváth, OP | 2 |
| Topuz, E | 1 |
| Basaran, M | 1 |
| Saip, P | 1 |
| Aydiner, A | 1 |
| Argon, A | 1 |
| Tas, F | 2 |
| Uygun, K | 1 |
| Aykan, NF | 2 |
| Ji, SR | 1 |
| Lin, YZ | 4 |
| Tono, T | 2 |
| Kinuta, M | 3 |
| Yano, H | 3 |
| Nakano, Y | 12 |
| Kanoh, T | 1 |
| Imasato, M | 1 |
| Okamura, J | 2 |
| Monden, T | 2 |
| Shizawa, R | 1 |
| Nagahori, Y | 1 |
| Kumamoto, N | 1 |
| Hamaguchi, Y | 1 |
| Fukushima, T | 2 |
| Mogaki, M | 1 |
| Fukasawa, S | 1 |
| Eguchi, K | 1 |
| Kawahara, M | 5 |
| Nagahori, K | 1 |
| Hosoi, H | 2 |
| Ohara, T | 2 |
| Akamo, Y | 5 |
| Takeyama, H | 5 |
| Funahashi, H | 2 |
| Yamamori, Y | 1 |
| Teranishi, F | 4 |
| Manabe, T | 6 |
| Takagane, A | 10 |
| Irinoda, T | 6 |
| Yonezawa, H | 5 |
| Nakaya, T | 5 |
| Irie, T | 3 |
| Tokairin, Y | 2 |
| Takemoto, H | 1 |
| Tsujino, T | 1 |
| Ota, H | 1 |
| Umeshita, K | 1 |
| Osuga, K | 1 |
| Nakamura, H | 1 |
| Nakajima, N | 2 |
| Matsuoka, S | 2 |
| Sano, F | 1 |
| Kashiwaba, M | 1 |
| Toge, T | 18 |
| Kurosu, Y | 2 |
| Gochi, A | 3 |
| Tominaga, S | 2 |
| Inokuchi, K | 15 |
| Peng, B | 1 |
| Lai, Y | 1 |
| Kawabe, S | 3 |
| Ohta, S | 3 |
| Katsu, K | 5 |
| Ito, T | 6 |
| Nakai, S | 1 |
| Morimoto, Y | 1 |
| Kitagawa, T | 3 |
| Kurihara, Y | 1 |
| Nishimura, J | 2 |
| Niki, T | 1 |
| Matsumoto, I | 1 |
| Inoue, H | 4 |
| Hamano, K | 4 |
| Maeda, T | 1 |
| Okutani, T | 1 |
| Hirohata, S | 1 |
| Nakashima, T | 1 |
| Yasutake, K | 3 |
| Sashikata, T | 1 |
| Cai, GR | 1 |
| Li, PW | 1 |
| Jiao, LP | 1 |
| Bar Sela, G | 1 |
| Tsalic, M | 1 |
| Gaitini, D | 1 |
| Steiner, M | 1 |
| Haim, N | 4 |
| Yu, RC | 1 |
| Tang, WJ | 1 |
| Duan, P | 1 |
| Inaba, S | 3 |
| Nakata, M | 1 |
| Matsushita, Y | 1 |
| Araki, Y | 1 |
| Koyama, H | 4 |
| Ogino, A | 2 |
| Yamada, E | 4 |
| Matsuyama, T | 1 |
| Krenn, V | 1 |
| Dörken, B | 3 |
| Carrat, F | 1 |
| Mal, F | 1 |
| Mabro, M | 1 |
| Beerblock, K | 1 |
| Vaillant, JC | 1 |
| Cady, J | 1 |
| Aihara, H | 1 |
| Maruoka, H | 1 |
| Kiyozaki, H | 1 |
| Konishi, F | 1 |
| Koinuma, K | 1 |
| Kaneko, Y | 1 |
| Saigenji, K | 6 |
| Ujiie, S | 1 |
| Taguchi, T | 32 |
| Sohn, JH | 2 |
| Jang, WI | 2 |
| Yan, L | 1 |
| Zou, L | 1 |
| Sakurai, M | 2 |
| Yonemura, Y | 10 |
| Usuki, H | 3 |
| Ishimura, K | 1 |
| Yachida, S | 1 |
| Hagiike, M | 1 |
| Okano, K | 2 |
| Izuishi, K | 1 |
| Karasawa, Y | 2 |
| Goda, F | 2 |
| Maeta, H | 2 |
| Naoi, Y | 2 |
| Kanzaki, N | 1 |
| Ohtani, S | 3 |
| Nemoto, T | 1 |
| Hoshino, Y | 1 |
| Kogure, M | 1 |
| Jeong, YW | 1 |
| Kim, KS | 1 |
| Oh, JY | 1 |
| Baek, WK | 1 |
| Suh, MH | 1 |
| Lee, JC | 1 |
| Cho, JW | 1 |
| Cheng, FQ | 1 |
| Yang, YF | 1 |
| Kelleher, M | 1 |
| Andreyev, J | 1 |
| Allen, M | 1 |
| Kitamura, M | 25 |
| Yamamura, Y | 11 |
| Kunii, Y | 7 |
| Motohashi, H | 6 |
| Wilke, HJ | 2 |
| Suganuma, K | 1 |
| Abe, S | 5 |
| Otani, Y | 5 |
| Kumai, K | 6 |
| Kitajima, M | 12 |
| Nakayama, H | 1 |
| Okabe, H | 2 |
| Segura Huerta, A | 1 |
| Pérez-Fidalgo, JA | 1 |
| López-Tendero, P | 1 |
| Gironés Sarrió, R | 1 |
| Aparicio Urtasun, J | 1 |
| Sawabu, N | 1 |
| Menges, M | 2 |
| Schmidt, C | 2 |
| Lindemann, W | 1 |
| Ridwelski, K | 1 |
| Pueschel, W | 1 |
| Jüngling, B | 1 |
| Feifel, G | 1 |
| Schilling, M | 1 |
| Stallmach, A | 1 |
| Zeitz, M | 1 |
| Yang, BQ | 1 |
| Kawabata, H | 2 |
| Takase, I | 1 |
| Murata, A | 4 |
| Nakajima, H | 1 |
| Bamias, A | 4 |
| Pavlidis, N | 2 |
| Cocconi, G | 6 |
| Carlini, P | 4 |
| Gamboni, A | 2 |
| Gasperoni, S | 2 |
| Rodinò, C | 4 |
| Zironi, S | 3 |
| Bisagni, G | 2 |
| Porrozzi, S | 2 |
| Cognetti, F | 4 |
| Canaletti, R | 2 |
| Ruggeri, EM | 2 |
| Camisa, R | 2 |
| Rich, TA | 2 |
| Shepard, R | 1 |
| Penna, Ch | 1 |
| Zhou, NN | 1 |
| Zhou, ZM | 2 |
| Liu, MZ | 2 |
| Teng, XY | 1 |
| Tian, WH | 1 |
| Liu, DG | 1 |
| Hu, PL | 1 |
| Qiu, HJ | 1 |
| Qian, SY | 1 |
| Nomura, K | 1 |
| Baba, Y | 1 |
| Hayashi, S | 4 |
| Oota, H | 2 |
| Kamimura, T | 3 |
| Kokufu, I | 2 |
| Kimura, F | 1 |
| Tanei, T | 1 |
| Yano, T | 4 |
| Uetsuka, H | 1 |
| Haisa, M | 1 |
| Kimura, M | 3 |
| Gunduz, M | 1 |
| Kaneda, Y | 1 |
| Ohkawa, T | 1 |
| Takaoka, M | 1 |
| Nobuhisa, T | 1 |
| Yamatsuji, T | 1 |
| Matsuoka, J | 3 |
| Naomoto, Y | 1 |
| Heo, JS | 4 |
| Kim, YI | 3 |
| Kim, K | 5 |
| Jung, CW | 4 |
| Im, YH | 5 |
| Park, K | 5 |
| Lin, YC | 3 |
| Liau, CT | 2 |
| Wang, CH | 4 |
| Liaw, CC | 2 |
| WILSON, WL | 1 |
| BOTIGLIERI, NG | 1 |
| SULLIVAN, RD | 2 |
| NORCROSS, JW | 1 |
| WATKINS, E | 1 |
| LANGDON, EA | 1 |
| OTTOMAN, RE | 1 |
| ROCHLIN, DB | 2 |
| SMART, CR | 2 |
| FIELD, JB | 1 |
| REITEMEIER, RJ | 8 |
| MOERTEL, CG | 23 |
| BLACKBURN, CM | 1 |
| DALMAUCIRIA, M | 1 |
| MARSHALL, SF | 1 |
| SHERLOCK, P | 2 |
| HAHN, RG | 3 |
| HURLEY, JD | 1 |
| DOWD, JE | 1 |
| DIPAOLO, JA | 1 |
| WATNE, AL | 1 |
| FALKSON, G | 4 |
| SNYMAN, HJ | 1 |
| HART, GD | 1 |
| MYHRE, K | 1 |
| FJAERLI, J | 1 |
| ZUREK, WZ | 1 |
| HELSPER, JT | 1 |
| DEMOSS, EV | 1 |
| MCCAFFERY, JF | 1 |
| KOVEN, BJ | 1 |
| SILVA, A | 1 |
| CHILDS, DS | 4 |
| HOLBROOK, MA | 5 |
| COLBY, MY | 2 |
| Haas, U | 1 |
| Schimanski, C | 1 |
| Hertkorn, C | 1 |
| Heike, M | 2 |
| Yang, JK | 3 |
| Zhen, J | 1 |
| Shen, KP | 1 |
| Leichman, L | 7 |
| Pendyala, L | 1 |
| Leichman, CG | 6 |
| Nagaba, S | 1 |
| Kitamura, T | 1 |
| Dittler, HJ | 2 |
| Helmberger, H | 1 |
| Busch, R | 3 |
| Fink, U | 8 |
| Lai, V | 1 |
| Foo, K | 1 |
| Thompson, A | 1 |
| Lim Joon, D | 1 |
| Weih, L | 1 |
| Ngan, S | 1 |
| Thomas, R | 1 |
| Tajima, Y | 1 |
| Nakanishi, Y | 6 |
| Yokoyama, N | 4 |
| Shimizu, K | 2 |
| Kawamura, M | 1 |
| Kusano, M | 1 |
| Kim, SA | 1 |
| Chung, JH | 1 |
| Takeno, A | 1 |
| Kashiwazaki, M | 1 |
| Ikenaga, M | 3 |
| Sawamura, T | 1 |
| Maruyama, N | 1 |
| Maruyama, K | 4 |
| Furukawa, J | 1 |
| Tanaka, J | 1 |
| Katsumoto, Y | 1 |
| Yokouchi, H | 1 |
| Sue, F | 1 |
| Nishioka, K | 1 |
| Katayanagi, S | 3 |
| Takahashi, K | 8 |
| Miyamoto, H | 4 |
| Horiguchi, S | 1 |
| Takada, T | 4 |
| Saito, E | 2 |
| Hiraide, Y | 1 |
| Funakoshi, K | 1 |
| Tasaki, A | 1 |
| Inayoshi, J | 1 |
| Arai, F | 1 |
| Motoyama, H | 1 |
| Akiyama, N | 2 |
| Mezawa, S | 1 |
| Homma, H | 1 |
| Akiyama, T | 8 |
| Murakami, K | 4 |
| Kogawa, K | 1 |
| Kida, M | 1 |
| Murase, K | 1 |
| Iyama, S | 2 |
| Inagaki, H | 3 |
| Fujimitsu, Y | 3 |
| Tahara, M | 3 |
| Fujimoto, J | 1 |
| Tahara, E | 1 |
| Konishi, N | 1 |
| Ohmori, Y | 3 |
| Mohri, Y | 1 |
| Tonouchi, H | 2 |
| Kusunoki, M | 3 |
| Stahl, A | 1 |
| Stein, H | 1 |
| Link, T | 1 |
| Weber, WA | 2 |
| Assersohn, L | 1 |
| Ward, C | 2 |
| Waters, JS | 2 |
| Hill, ME | 5 |
| Di Cosimo, S | 1 |
| Ferretti, G | 1 |
| Alimonti, A | 1 |
| Gelibter, A | 2 |
| Felici, A | 2 |
| Papaldo, P | 3 |
| Zhang, WM | 1 |
| Xu, GH | 1 |
| Ju, AP | 1 |
| Zheng, YT | 1 |
| Jiang, Q | 1 |
| Yoo, BC | 2 |
| Ku, JL | 2 |
| Shin, YK | 1 |
| Kaleya, R | 3 |
| Haynes, H | 3 |
| Rozenblit, A | 2 |
| Wadler, S | 4 |
| Morimoto, S | 1 |
| Shono, Y | 1 |
| Tsuji, T | 1 |
| Makihara, K | 1 |
| Kawato, N | 1 |
| Hachino, Y | 1 |
| Tabuse, K | 1 |
| Imamura, M | 1 |
| Yamaki, T | 2 |
| Yasuda, M | 3 |
| Ji, YB | 2 |
| Kang, HC | 2 |
| Kim, IJ | 2 |
| Shin, Y | 1 |
| Jung, MS | 1 |
| Di Marsico, R | 1 |
| Galli, C | 1 |
| Cupini, S | 1 |
| Pfanner, E | 1 |
| Marcucci, L | 1 |
| Conte, PF | 2 |
| Jaeger, D | 1 |
| Hahnfeld, S | 1 |
| Rummel, MJ | 1 |
| Rost, A | 1 |
| Orth, J | 1 |
| Knuth, A | 3 |
| Ushijima, T | 1 |
| Chipponi, J | 1 |
| Huguier, M | 2 |
| Basso, N | 1 |
| Hay, JM | 1 |
| Quandalle, P | 1 |
| Jaeck, D | 1 |
| Fagniez, PL | 1 |
| Gainant, A | 1 |
| Nakata, B | 11 |
| Mitachi, Y | 1 |
| Yamamitsu, S | 6 |
| Horváth, G | 1 |
| Varga, E | 1 |
| Kim, E | 1 |
| Park, IS | 2 |
| Chun, JH | 3 |
| Hirata, I | 1 |
| Hongo, H | 1 |
| Fujita, K | 1 |
| Tsuchida, A | 3 |
| Hayashida, Y | 1 |
| Tamura, K | 1 |
| Kawakita, H | 1 |
| Kubouchi, T | 1 |
| Kinoshita, M | 1 |
| Kataba, Y | 2 |
| Choi, SJ | 2 |
| Kim, HT | 2 |
| D'Angelo, A | 1 |
| Salvagni, S | 2 |
| Martignoni, G | 1 |
| Franciosi, V | 1 |
| Soung, YH | 1 |
| Lee, JW | 1 |
| Park, WS | 1 |
| Cho, YG | 1 |
| Kim, CJ | 1 |
| Nam, SW | 1 |
| Yoo, NJ | 1 |
| Sessa, C | 1 |
| Herrmann, R | 4 |
| Borner, MM | 2 |
| Willer, A | 2 |
| Weisser, A | 1 |
| Gnad, U | 1 |
| Saussele, S | 2 |
| Kreil, S | 2 |
| Ceyhan, C | 1 |
| Meydan, N | 1 |
| Barutca, S | 1 |
| Tekten, T | 1 |
| Onbasili, AO | 1 |
| Unal, S | 1 |
| Bayrak, I | 1 |
| Kang, MK | 1 |
| Joh, JW | 1 |
| Park, YJ | 2 |
| Nam, HR | 1 |
| Park, W | 1 |
| Huh, SJ | 1 |
| Kawata, K | 2 |
| Kanai, M | 2 |
| Sasada, T | 1 |
| Dickson, JL | 1 |
| Bang, SJ | 1 |
| Shin, JW | 1 |
| Kim, DH | 4 |
| Kim, GY | 2 |
| Ko, BK | 1 |
| Choi, DH | 1 |
| Cho, HR | 1 |
| Okita, Y | 1 |
| Matsuda, S | 1 |
| Ema, T | 1 |
| Uemura, T | 2 |
| Tanehiro, K | 1 |
| Sakurai, Y | 8 |
| Uraguchi, T | 1 |
| Imazu, H | 1 |
| Ochiai, M | 5 |
| Funabiki, T | 1 |
| Chang, CJ | 1 |
| Wu, MF | 1 |
| Chang, CS | 1 |
| Kao, WY | 1 |
| Hsieh, RK | 3 |
| Yamagishi, H | 4 |
| Yamashita, T | 1 |
| Itoh, N | 1 |
| Itoi, H | 1 |
| Tanimoto, K | 1 |
| Otani, K | 1 |
| Satoh, K | 1 |
| Ohtaki, M | 1 |
| Yahata, H | 1 |
| Chayama, K | 1 |
| Okazaki, Y | 1 |
| Hayashizaki, Y | 1 |
| Hiyama, K | 1 |
| Fackler-Schwalbe, I | 1 |
| Schwalbe, B | 1 |
| Epple, M | 1 |
| Becker, A | 1 |
| Prügl, L | 1 |
| Gassel, WD | 1 |
| Stoffels, D | 1 |
| Südhoff, T | 1 |
| Janjan, N | 2 |
| Morris, J | 1 |
| Pisters, PW | 4 |
| Lynch, PM | 4 |
| Feig, B | 2 |
| Myerson, R | 1 |
| Nivers, R | 1 |
| Cohen, DS | 1 |
| Songun, I | 2 |
| Tesselaar, ME | 1 |
| Kranenbarg, EK | 1 |
| de Vries, JE | 2 |
| Wils, JA | 5 |
| van der Bijl, J | 2 |
| van Krieken, JH | 2 |
| Delaunoit, T | 1 |
| Maréchal, R | 1 |
| Hendlisz, A | 2 |
| Eisendrath, P | 1 |
| Legendre, H | 1 |
| Pector, JC | 2 |
| De Becker, D | 1 |
| Bleiberg, H | 9 |
| Camp, ER | 1 |
| Minnich, DJ | 1 |
| Brank, A | 1 |
| Moldawer, LL | 1 |
| MacKay, SL | 1 |
| Hochwald, SN | 1 |
| Kurihara, M | 18 |
| Chonan, A | 1 |
| Kubo, Y | 3 |
| Maekawa, R | 1 |
| Iwasaki, R | 1 |
| Sasai, T | 1 |
| Fukuyama, Y | 1 |
| Ishikawa, K | 2 |
| Miyoshi, K | 1 |
| Hayakawa, M | 4 |
| Emura, T | 1 |
| Ohshimo, H | 1 |
| Koo, JY | 1 |
| Jung, KO | 1 |
| Park, KY | 1 |
| Harting, MT | 1 |
| Blakely, ML | 1 |
| Herzog, CE | 1 |
| Lally, KP | 1 |
| Andrassy, RJ | 1 |
| Gao, CM | 3 |
| Sun, XF | 2 |
| Wei, ZP | 1 |
| Zuo, Y | 1 |
| Lu, WD | 1 |
| Lu, JF | 1 |
| Park, JN | 1 |
| Han, JY | 1 |
| Young Yoon, S | 1 |
| Kim, JM | 1 |
| Yeom, YI | 1 |
| Kim, NS | 1 |
| Tominaga, K | 2 |
| Okazaki, H | 1 |
| Suto, R | 1 |
| Hamaguchi, M | 1 |
| Sasaki, E | 6 |
| Shiba, M | 1 |
| Oshitani, N | 2 |
| Arakawa, T | 2 |
| Yamao, T | 3 |
| Wilson, D | 2 |
| Hiller, L | 1 |
| Geh, I | 1 |
| Woo, IS | 1 |
| Shim, KH | 1 |
| Fujio, N | 1 |
| Ihara, T | 1 |
| Terakura, M | 1 |
| Takatori, H | 1 |
| Tsukazaki, T | 1 |
| Koyama, I | 1 |
| Tsukazaki, Y | 1 |
| Osugi, H | 1 |
| Morishita, Y | 4 |
| Yamagata, S | 3 |
| Park, JK | 2 |
| Nishio, K | 2 |
| Saijo, N | 2 |
| Raoul, JL | 2 |
| Giovannini, M | 2 |
| Lledo, G | 2 |
| Arsène, D | 1 |
| Paitel, JF | 1 |
| Guérin-Meyer, V | 1 |
| Buecher, B | 1 |
| Kaminsky, MC | 1 |
| Milan, C | 2 |
| Wöhrer, SS | 1 |
| Raderer, M | 2 |
| Szanto, J | 1 |
| Padi, E | 1 |
| Bükki, J | 1 |
| Biakhov, M | 1 |
| Zuber, E | 1 |
| Jacques, C | 1 |
| Imaizumi, T | 2 |
| Tsujie, M | 1 |
| Ohshima, S | 1 |
| Handa, R | 1 |
| Niinobu, T | 1 |
| Kotobuki, T | 1 |
| Fukunaga, K | 1 |
| Ebuchi, M | 8 |
| Takashima, K | 1 |
| Ohbe, M | 1 |
| Shinoura, Y | 1 |
| Katoh, K | 2 |
| Kosaka, T | 10 |
| Imaizumi, H | 1 |
| Kamei, K | 1 |
| Usami, K | 1 |
| Ueno, K | 2 |
| Takashima, S | 12 |
| Sonoyama, T | 1 |
| Kikuchi, S | 2 |
| Ichikawa, D | 1 |
| Sakakura, C | 1 |
| Hagiwara, A | 2 |
| Wu, XQ | 1 |
| Cui, HJ | 1 |
| Tan, HY | 1 |
| Kandaba-shi, K | 1 |
| Ono, M | 3 |
| Narahara, H | 2 |
| Iishi, H | 1 |
| Chung, CW | 1 |
| Popiela, T | 5 |
| Kulig, J | 4 |
| Czupryna, A | 1 |
| Szczepanik, AM | 1 |
| Zembala, M | 3 |
| Liu, BW | 1 |
| DU, WL | 1 |
| Song, ZC | 1 |
| Yang, JQ | 1 |
| Li, QJ | 1 |
| Wang, MX | 1 |
| Li, AF | 1 |
| Lan, C | 1 |
| Nagareda, T | 1 |
| Yamasaki, H | 1 |
| Sohn, HJ | 2 |
| Repp, M | 1 |
| Kingreen, D | 1 |
| Hennesser, D | 1 |
| Micheel, S | 1 |
| Scholz, C | 1 |
| Sugiyama, S | 2 |
| Miyade, Y | 2 |
| Hirohashi, Y | 1 |
| Sumi, K | 1 |
| Matsuyama, S | 1 |
| Gohongi, T | 2 |
| Tokuuye, K | 1 |
| Iida, H | 2 |
| Nakai, R | 2 |
| Gunji, N | 2 |
| Akine, Y | 2 |
| Orii, K | 3 |
| Park, KH | 2 |
| Choi, IK | 4 |
| Choi, CW | 2 |
| Shin, SW | 4 |
| Persiani, R | 1 |
| D'Ugo, D | 1 |
| Rausei, S | 1 |
| Sermoneta, D | 1 |
| Ricci, R | 1 |
| La Torre, G | 1 |
| Picciocchi, A | 1 |
| Lu, CD | 1 |
| Dai, DJ | 1 |
| Sun, YL | 1 |
| Li, YS | 1 |
| Yu, LF | 1 |
| Qiao, MM | 2 |
| Xu, XQ | 1 |
| Zhao, YR | 1 |
| Mei, JF | 1 |
| Shao, ZJ | 1 |
| He, ZM | 1 |
| Atlan, D | 1 |
| Richard, K | 1 |
| Gnad-Vogt, SU | 1 |
| Pilz, L | 1 |
| Kanou, Y | 1 |
| Ooshima, H | 1 |
| Kawase, J | 1 |
| Kudou, J | 2 |
| Mizuno, Y | 3 |
| Todo, T | 1 |
| Kuroki, S | 1 |
| Cohen, JB | 1 |
| Glorioso, JC | 1 |
| Toshiro, T | 1 |
| Cao, HX | 2 |
| Chen, HQ | 1 |
| Kazuo, T | 1 |
| Rudi, J | 2 |
| Werle, S | 1 |
| Bergtholdt, D | 1 |
| Emi, M | 1 |
| Arihiro, K | 1 |
| Uchida, Y | 4 |
| Honnma, S | 1 |
| Kohashi, S | 1 |
| Shinohara, T | 3 |
| Todo, S | 2 |
| Momokawa, K | 1 |
| Sakayauchi, T | 1 |
| Choi, JY | 1 |
| Hwangbo, B | 1 |
| Shen, XJ | 1 |
| Hua, JD | 1 |
| Chong, G | 1 |
| Khaksart, SJ | 1 |
| Oza, A | 2 |
| Couture, J | 1 |
| Japp, B | 1 |
| Moore, M | 2 |
| Siu, LL | 1 |
| Hedley, D | 2 |
| Wong, S | 1 |
| Cummings, B | 2 |
| Napieralski, R | 2 |
| Kremer, M | 2 |
| Specht, K | 1 |
| Vogelsang, H | 1 |
| Müller, M | 1 |
| Rüdiger Siewert, J | 1 |
| Colucci, G | 6 |
| Thaler, W | 1 |
| Dejaco, H | 1 |
| Marsoner, H | 1 |
| Grones, A | 1 |
| Du, J | 1 |
| Behl, S | 1 |
| Mizuno, K | 2 |
| Togashi, T | 2 |
| Watanabe, K | 4 |
| Seki, K | 2 |
| Ohta, H | 4 |
| Bianco, R | 1 |
| Infusino, S | 2 |
| Damiano, V | 1 |
| Simeone, E | 1 |
| Diadema, MR | 1 |
| Castellano, P | 1 |
| Pepe, S | 1 |
| De Placido, S | 2 |
| Bianco, AR | 2 |
| Saio, M | 2 |
| Matsuo, A | 3 |
| Sugiyama, Y | 9 |
| Ryu, BY | 1 |
| Silberman, H | 5 |
| Hu, MJ | 1 |
| Fu, H | 1 |
| Hehr, T | 3 |
| Schleicher, J | 1 |
| Jehle, EC | 1 |
| Kanz, L | 6 |
| Mauer, AM | 1 |
| Kraut, EH | 1 |
| Krauss, SA | 1 |
| Ansari, RH | 1 |
| Kasza, K | 1 |
| Szeto, L | 1 |
| Vokes, EE | 1 |
| Harper-Wynne, C | 1 |
| Tebbutt, N | 1 |
| Choi, EY | 1 |
| Ki Lee, W | 1 |
| Bugalho, P | 1 |
| Chorão, M | 1 |
| Fontoura, P | 1 |
| Burtin, P | 1 |
| Baulieux, J | 1 |
| Nordlinger, B | 3 |
| Martin, C | 1 |
| Echinard, E | 1 |
| Stremsdoerfer, N | 1 |
| Eimermacher, A | 1 |
| Höhler, T | 1 |
| Junginger, T | 1 |
| Geer, T | 1 |
| Gracien, E | 1 |
| Kondo, K | 11 |
| Hirabayashi, N | 8 |
| Kataoka, M | 1 |
| Araki, K | 1 |
| Takiyama, W | 5 |
| Nakazato, H | 16 |
| Nakao, A | 2 |
| Joh, Y | 1 |
| Fujita, S | 2 |
| Ooka, M | 1 |
| Okajima, S | 1 |
| Gamucci, T | 1 |
| Pollera, CF | 1 |
| De Marco, S | 1 |
| Fariello, AM | 1 |
| Moscetti, L | 1 |
| Adami, E | 1 |
| Sperduti, I | 1 |
| Sohn, SK | 3 |
| Sung, WJ | 1 |
| Kim, TB | 1 |
| Jung, HY | 2 |
| Stollfuss, J | 1 |
| Vehling-Kaiser, U | 1 |
| Hentrich, M | 2 |
| Zumschlinge, R | 1 |
| Dietzfelbinger, H | 1 |
| Thoedtmann, J | 1 |
| Hennig, M | 2 |
| Seroneit, T | 2 |
| Bredenkamp, R | 2 |
| Duyster, J | 1 |
| Lee, SN | 1 |
| Park, DK | 2 |
| Jeong, CK | 1 |
| Hong, SP | 1 |
| Chong, SY | 1 |
| Oh, D | 1 |
| Hwang, SG | 1 |
| Ahn, DH | 1 |
| Correale, P | 1 |
| Fulfaro, F | 1 |
| Marsili, S | 3 |
| Cicero, G | 2 |
| Bajardi, E | 1 |
| Intrivici, C | 1 |
| Vuolo, G | 1 |
| Carli, AF | 1 |
| Caraglia, M | 2 |
| Del Prete, S | 1 |
| Gebbia, N | 2 |
| Francini, G | 3 |
| Sugimoto, Y | 3 |
| Yoshida, I | 5 |
| Masui, T | 2 |
| Tonomura, S | 4 |
| Inaba, K | 6 |
| Uyama, I | 6 |
| Komori, Y | 6 |
| Matsuura, S | 2 |
| Oka, T | 2 |
| Nakazawa, K | 2 |
| Tsai, JY | 1 |
| Iannitti, D | 2 |
| Berkenblit, A | 2 |
| Akerman, P | 3 |
| Nadeem, A | 1 |
| Rathore, R | 1 |
| Harrington, D | 2 |
| Roye, D | 1 |
| Miner, T | 3 |
| Barnett, JM | 1 |
| Maia, C | 1 |
| Stuart, K | 2 |
| Pistevou-Gompaki, K | 1 |
| Kouloulias, V | 1 |
| Papaloukas, C | 1 |
| Eleftheriadis, D | 1 |
| Andronikidis, I | 1 |
| Eleftheriadis, N | 1 |
| Bitzilekis, D | 1 |
| Lu, YS | 1 |
| Hsu, CH | 2 |
| Lin, JF | 1 |
| Kuo, SH | 1 |
| Chan, CH | 1 |
| Fodor, MB | 1 |
| Cabral Filho, S | 1 |
| Majlis, A | 4 |
| Assadourian, S | 1 |
| Mizukami, Y | 1 |
| Momiyama, M | 1 |
| Niimi, K | 2 |
| Nagashima, T | 2 |
| Allal, AS | 1 |
| Zwahlen, D | 1 |
| Bründler, MA | 1 |
| de Peyer, R | 1 |
| Morel, P | 1 |
| Sugitani, M | 1 |
| Noguchi, H | 1 |
| Okada, T | 1 |
| Ouchi, M | 1 |
| Yamada, M | 1 |
| Tsuruoka, Y | 2 |
| Futagawa, S | 1 |
| Müller, C | 1 |
| Köster, W | 2 |
| Naito, H | 1 |
| Hamada, T | 1 |
| Mino, K | 1 |
| Shibazaki, W | 1 |
| Minagawa, N | 1 |
| Orimo, T | 1 |
| Ichimura, W | 1 |
| Wolschke, C | 2 |
| Terada, T | 1 |
| Okuda, M | 1 |
| Inui, K | 1 |
| Tajima, T | 3 |
| Ninomiya, H | 3 |
| Wakui, K | 2 |
| Komatsu, N | 2 |
| Tsuchiya, K | 6 |
| Nakasaki, H | 2 |
| Makuuchi, H | 3 |
| Wils, J | 12 |
| Dos Santos, JG | 3 |
| Fountzilas, G | 3 |
| Sava, C | 1 |
| Tres, A | 2 |
| Coombes, RC | 3 |
| Crivellari, D | 2 |
| Sanchez, E | 1 |
| Bliss, JM | 3 |
| Homewood, J | 1 |
| Couvreur, ML | 2 |
| Hall, E | 1 |
| Baron, B | 2 |
| Woods, E | 1 |
| Emson, M | 1 |
| Lise, M | 4 |
| Casali, A | 1 |
| Tonachella, R | 1 |
| Tropea, F | 1 |
| Verri, C | 1 |
| Gionfra, T | 1 |
| Modugno, G | 1 |
| Gallo Curcio, C | 1 |
| Endou, Y | 2 |
| Tochiori, S | 1 |
| Bando, E | 3 |
| Kawamura, T | 1 |
| Shimada, T | 1 |
| Miyamoto, K | 2 |
| Bamba, T | 1 |
| Kanda, T | 2 |
| Ohashi, M | 5 |
| Makino, S | 1 |
| Hatakeyama, K | 1 |
| Hoehn, S | 1 |
| Wittmer, C | 1 |
| Stueber, C | 1 |
| Chen, YG | 1 |
| Cai, XC | 1 |
| Wu, XA | 1 |
| Xu, S | 1 |
| Zhang, YH | 1 |
| Ouyang, XN | 1 |
| Yamakado, K | 1 |
| Nakatsuka, A | 1 |
| Takaki, H | 1 |
| Kida, H | 4 |
| Gallego-Plazas, J | 1 |
| Guillen-Ponce, C | 1 |
| Lee, Y | 1 |
| Han, SH | 1 |
| Meriggi, F | 2 |
| Zhou, ZF | 1 |
| Yin, BJ | 1 |
| Liu, DL | 1 |
| Zhu, LJ | 1 |
| Kim, YT | 1 |
| Cho, BC | 3 |
| Kim, CB | 2 |
| Choi, HJ | 6 |
| Mimae, T | 1 |
| Sasaki, H | 4 |
| Umeoka, T | 2 |
| Choi, Y | 1 |
| Hur, WJ | 1 |
| Jung, GJ | 1 |
| Giordano, KF | 1 |
| Jatoi, A | 1 |
| Stella, PJ | 2 |
| Foster, N | 1 |
| Tschetter, LK | 2 |
| Dakhil, SR | 1 |
| Mailliard, JA | 3 |
| Flynn, PJ | 1 |
| Nikcevich, DA | 1 |
| Paul, F | 1 |
| Aktas, O | 1 |
| Dieste, FJ | 1 |
| Kreitsch, P | 1 |
| Vogel, HP | 1 |
| Zipp, F | 1 |
| Arveux, P | 1 |
| Girault, C | 1 |
| Tentes, AA | 1 |
| Markakidis, SK | 1 |
| Karanikiotis, C | 1 |
| Fiska, A | 1 |
| Tentes, IK | 1 |
| Manolopoulos, VG | 1 |
| Dimitriou, T | 1 |
| Kamano, T | 4 |
| Kawai, K | 3 |
| Watabe, S | 1 |
| Qin, B | 1 |
| Shibata, Y | 1 |
| Arita, S | 2 |
| Harada, M | 3 |
| Papakostas, P | 1 |
| Tsavdaridis, D | 1 |
| Kosmidis, P | 2 |
| Kalofonos, HP | 2 |
| Sakantamis, A | 1 |
| Janinis, D | 1 |
| Skarlos, D | 1 |
| Bafaloukos, D | 1 |
| Xiros, N | 1 |
| Mizuiri, H | 2 |
| Ukon, K | 1 |
| Hecht, JR | 1 |
| Oortgiesen, M | 1 |
| Eduljee, A | 1 |
| Michaeli, D | 2 |
| Shuai, XM | 1 |
| Han, GX | 1 |
| Wang, GB | 1 |
| Chen, JH | 1 |
| Kamoshida, S | 4 |
| Tsutsumi, Y | 4 |
| Schlag, PM | 1 |
| Forshaw, MJ | 1 |
| Chrystal, K | 1 |
| Cheong, K | 1 |
| Atkinson, S | 1 |
| Botha, A | 1 |
| Harper, PG | 4 |
| Mason, RC | 3 |
| Bandou, E | 1 |
| Sawa, T | 1 |
| Yoshimitsu, Y | 1 |
| Sugarbaker, PH | 2 |
| Ruzzo, A | 1 |
| Canestrari, E | 1 |
| Ficarelli, R | 2 |
| Menichetti, ET | 2 |
| Mari, D | 2 |
| Silva, R | 1 |
| Magnani, M | 1 |
| Burge, ME | 1 |
| Topham, C | 1 |
| Jackson, DP | 1 |
| Anthoney, DA | 1 |
| Halstead, F | 1 |
| Seymour, MT | 1 |
| Lockwood, G | 1 |
| O'brien, C | 1 |
| Siu, L | 1 |
| Jeon, SB | 1 |
| Chae, YS | 1 |
| Hong, YJ | 1 |
| Wals, A | 1 |
| Contreras, J | 1 |
| Macías, J | 1 |
| Fortes, I | 1 |
| Rivas, D | 1 |
| González, P | 2 |
| Herruzo, I | 1 |
| Orel, NF | 1 |
| Borisova, TA | 1 |
| Markovich, AA | 1 |
| Zaguzina, NN | 1 |
| Di Seri, M | 1 |
| La Cesa, A | 1 |
| Spalletta, B | 1 |
| Russo, A | 1 |
| Virzi, V | 1 |
| Ahmad, K | 1 |
| Zhang, YS | 1 |
| Zhu, LF | 1 |
| Weng, XS | 1 |
| Corporaal, S | 1 |
| Smit, WM | 1 |
| Russel, MG | 1 |
| van der Palen, J | 1 |
| Legdeur, MC | 1 |
| Milano, MT | 1 |
| Garofalo, MC | 1 |
| Chmura, SJ | 1 |
| Farrey, K | 1 |
| Rash, C | 1 |
| Heimann, R | 1 |
| Jani, AB | 1 |
| Azria, D | 1 |
| Chateau, MC | 1 |
| Borrelly, C | 1 |
| Quenet, F | 1 |
| Rouanet, P | 2 |
| Ichikawa, W | 2 |
| Suto, K | 1 |
| Shirota, Y | 1 |
| Nihei, Z | 1 |
| Shimizu, M | 2 |
| Murad, AM | 4 |
| Skare, NG | 1 |
| Vinholes, J | 1 |
| Lago, S | 1 |
| Pecego, R | 1 |
| Wu, TT | 1 |
| Swisher, SG | 1 |
| Correa, AM | 1 |
| Etzel, CJ | 1 |
| Amos, CI | 1 |
| Chiang, SS | 1 |
| Milas, L | 1 |
| Hittelman, WN | 1 |
| Karpeh, MS | 1 |
| Brennan, MF | 1 |
| Coit, DG | 1 |
| Klimstra, DS | 1 |
| Tang, LH | 1 |
| Abbrederis, K | 1 |
| Voelter, V | 1 |
| Roethling, N | 2 |
| Cecchin, E | 1 |
| Yamada, R | 1 |
| Hatori, S | 2 |
| Imada, T | 6 |
| Thompson, JN | 1 |
| Scarffe, JH | 4 |
| Lofts, FJ | 1 |
| Falk, SJ | 1 |
| Smith, DB | 1 |
| Verma, M | 1 |
| Weeden, S | 1 |
| Jiang, GM | 1 |
| Tian, F | 1 |
| Doroshow, JH | 1 |
| McCoy, S | 1 |
| Patel, T | 1 |
| Cobb, PW | 1 |
| Yost, KJ | 1 |
| Kanamaru, T | 1 |
| Ren, J | 1 |
| Shirado, A | 1 |
| Uto, H | 1 |
| Kusumoto, K | 1 |
| Kurogi, J | 1 |
| Hasuike, S | 1 |
| Nagata, K | 2 |
| Iwamitsu, A | 1 |
| Hori, T | 1 |
| Ibusuki, K | 1 |
| Ido, A | 1 |
| Tsubouchi, H | 1 |
| Martinelli, E | 2 |
| Aurilio, G | 1 |
| Vecchione, L | 1 |
| Alacacioglu, A | 1 |
| Yaren, A | 1 |
| Tarhan, O | 1 |
| Jiang, XT | 1 |
| Tao, HQ | 1 |
| Zou, SC | 1 |
| Artioli, F | 1 |
| Codignola, C | 1 |
| Lazzaro, A | 1 |
| Rizzi, A | 1 |
| Rota, L | 1 |
| Boni, F | 1 |
| Iop, A | 1 |
| Chen, CY | 1 |
| Jia, JH | 1 |
| Zhang, MX | 1 |
| Zhang, RM | 1 |
| Yu, XP | 1 |
| Kandabashi, K | 1 |
| Kanehara, I | 1 |
| Asada, Y | 1 |
| Munemoto, Y | 3 |
| Ikehara, Y | 1 |
| Niwa, T | 2 |
| Biao, L | 1 |
| Ikehara, SK | 1 |
| Ohashi, N | 2 |
| Kojima, N | 1 |
| Nakanishi, H | 2 |
| Sun, YM | 1 |
| Fu, J | 1 |
| Zheng, ZX | 1 |
| Huang, CZ | 1 |
| Peng, RJ | 1 |
| Dong, QM | 1 |
| Yuan, ZY | 1 |
| Jiang, WQ | 1 |
| Peng, YL | 1 |
| Gong, QF | 1 |
| Wand, ZQ | 1 |
| Honda, I | 3 |
| Kagawa, S | 2 |
| Fujiwara, T | 3 |
| Tokunaga, N | 2 |
| Uno, F | 2 |
| Teraishi, F | 2 |
| Gouchi, A | 1 |
| Park, BB | 1 |
| Han, MJ | 1 |
| Zárate, RN | 1 |
| Arias, F | 1 |
| Bandres, E | 1 |
| Cubedo, E | 1 |
| Malumbres, R | 1 |
| Zhang, ZX | 1 |
| Qi, F | 1 |
| Zhou, DJ | 1 |
| Liang, XY | 1 |
| Zhu, LW | 1 |
| Wang, PZ | 1 |
| Kil, SY | 1 |
| Shin, C | 1 |
| Rodrigues, A | 3 |
| Fodor, M | 5 |
| Voznyi, E | 3 |
| Risse, ML | 1 |
| Oeda, M | 1 |
| Shigematsu, H | 1 |
| Pemberton, L | 1 |
| Coote, J | 1 |
| Perry, L | 1 |
| Khoo, VS | 1 |
| Saunders, MP | 2 |
| Xu, WF | 2 |
| Cui, SX | 2 |
| Yuan, YX | 1 |
| Wang, RH | 1 |
| Gai, RY | 1 |
| Makuuchi, M | 5 |
| Kobayashi, N | 1 |
| Mitomi, H | 1 |
| Fang, Y | 1 |
| Sadighi, S | 1 |
| Mohagheghi, MA | 1 |
| Montazeri, A | 1 |
| Sadighi, Z | 1 |
| Dvory-Sobol, H | 1 |
| Sagiv, E | 1 |
| Liberman, E | 1 |
| Kazanov, D | 1 |
| Arber, N | 1 |
| Anderson, C | 1 |
| Nijagal, A | 1 |
| Ji Jung, E | 1 |
| Mie Lee, Y | 1 |
| Lan Lee, B | 1 |
| Soo Chang, M | 1 |
| Ho Kim, W | 1 |
| Siena, S | 1 |
| Rojas Llimpe, FL | 2 |
| Ceccarelli, C | 1 |
| Mutri, V | 2 |
| Giannetta, L | 1 |
| Giaquinta, S | 2 |
| Funaioli, C | 2 |
| Longobardi, C | 2 |
| Piana, E | 1 |
| Martoni, AA | 2 |
| Li, JT | 1 |
| Chen, XJ | 1 |
| Zhang, RH | 1 |
| Satoh, D | 1 |
| Aoki, H | 1 |
| Onoda, T | 1 |
| Shiozaki, Y | 1 |
| Higaki, K | 1 |
| Horváth Ors, P | 1 |
| Papp, A | 2 |
| Yousuf, AF | 2 |
| Esik, O | 2 |
| Tokar, M | 1 |
| Bobilev, D | 1 |
| Ariad, S | 1 |
| Geffen, DB | 1 |
| Shimamura, T | 1 |
| Ishikubo, T | 1 |
| Fujino, K | 2 |
| Taomoto, J | 1 |
| Tahara, H | 1 |
| Mitani, Y | 1 |
| Matsumura, S | 1 |
| Noguchi, T | 1 |
| Kamata, N | 1 |
| Hwang, SJ | 1 |
| Park, JW | 1 |
| Lee, SD | 2 |
| Kim, GJ | 1 |
| Sin, CH | 1 |
| Oblak, I | 1 |
| Anderluh, F | 1 |
| Strojan, P | 1 |
| Song, JH | 1 |
| Song, JS | 1 |
| Kerber, A | 1 |
| Dechow, C | 1 |
| Reitsamer, E | 1 |
| Schmidt, S | 1 |
| Kolassa, Y | 1 |
| Neumann, A | 1 |
| Weidmann, E | 1 |
| Matsukawa, M | 2 |
| Suwinski, R | 1 |
| Poltorak, S | 1 |
| Maka, B | 1 |
| Miszczyk, L | 1 |
| Wolny, E | 1 |
| Bielaczyc, G | 1 |
| Zajusz, A | 1 |
| Nakayama, G | 1 |
| Koike, M | 3 |
| Scholz, M | 1 |
| Nardi, M | 2 |
| Azzarello, D | 1 |
| Maisano, R | 3 |
| Del Medico, P | 1 |
| Giannicola, R | 1 |
| Raffaele, M | 1 |
| Zavettieri, M | 1 |
| Costarella, S | 1 |
| Falzea, A | 1 |
| Roh, MS | 1 |
| Murakami, D | 1 |
| Tsujitani, S | 4 |
| Osaki, T | 1 |
| Katano, K | 1 |
| Tatebe, S | 1 |
| Ikeguchi, M | 2 |
| Nagata, N | 3 |
| Dhillon, S | 1 |
| Scott, LJ | 2 |
| Ou, SH | 1 |
| Holcombe, RF | 1 |
| Akatsu, Y | 1 |
| Akatsu, T | 1 |
| Vega-Villegas, ME | 1 |
| López-Brea, MF | 1 |
| Fakhrejahani, E | 1 |
| Storey, D | 1 |
| Hargreaves, C | 1 |
| Cullingford, G | 1 |
| Boyer, M | 1 |
| Trotter, J | 1 |
| Archer, S | 1 |
| Davidson, A | 1 |
| Johnston, P | 1 |
| Yuen, J | 1 |
| Dhillon, H | 1 |
| Della-Fiorentina, S | 1 |
| Richardson, G | 1 |
| Truskett, P | 1 |
| Goldstein, D | 1 |
| Fujiyama, Y | 1 |
| Zhang, CX | 1 |
| Huang, S | 1 |
| Fang, JW | 1 |
| Shen, P | 1 |
| Bao, YH | 1 |
| Mou, BH | 1 |
| Shi, MG | 1 |
| Zhong, XL | 1 |
| Xiong, PJ | 1 |
| Recchia, F | 3 |
| Saggio, G | 1 |
| Candeloro, G | 1 |
| Cesta, A | 1 |
| Amiconi, G | 1 |
| Blasio, AD | 1 |
| Necozione, S | 1 |
| Rea, S | 1 |
| Pascucci, A | 2 |
| Sciandivasci, A | 1 |
| Tassi, R | 1 |
| Civitelli, S | 2 |
| Tanzini, G | 2 |
| Lorenzi, M | 2 |
| Takano, S | 1 |
| Oda, K | 2 |
| Koda, K | 2 |
| Seike, K | 1 |
| Takiguchi, N | 3 |
| Ember, A | 1 |
| van Meerten, E | 1 |
| van Gameren, EC | 1 |
| Doorn, L | 1 |
| Ellenberg, SS | 1 |
| Sun, W | 1 |
| Carnaghi, C | 1 |
| Cassano, A | 2 |
| Bertetto, O | 1 |
| Frontini, L | 4 |
| Rota, S | 1 |
| Torri, V | 2 |
| Ardizzoia, A | 2 |
| Foa, P | 2 |
| Rabbi, C | 1 |
| Chiara, S | 1 |
| Gasparini, G | 2 |
| Mansutti, M | 1 |
| Arnoldi, E | 2 |
| Piazza, E | 2 |
| Sobrero, A | 1 |
| Li, YM | 2 |
| Yu, CH | 1 |
| Chen, CX | 1 |
| Dupont, J | 1 |
| Jensen, BV | 1 |
| Viteri, A | 1 |
| Muñoz, A | 1 |
| Rubio, I | 1 |
| Barceló, R | 1 |
| Martínez-Bueno, A | 1 |
| Fernández, R | 1 |
| Carrera, S | 1 |
| Mine, T | 1 |
| Homma, S | 1 |
| Ishihara, Y | 1 |
| Yamada, A | 2 |
| Itoh, K | 5 |
| Pintoffl, JP | 1 |
| Quietzsch, D | 5 |
| Meisinger, I | 1 |
| Horger, M | 1 |
| Nehls, O | 1 |
| Sur, HY | 1 |
| Sung, HJ | 2 |
| Jeen, YT | 1 |
| Houhouli, K | 1 |
| Papatheodorou, K | 1 |
| Miloussis, A | 1 |
| Matthaios, D | 1 |
| Chatzaki, E | 1 |
| Lyrantzopoulos, N | 1 |
| Tsaroucha, A | 1 |
| Chun, YJ | 1 |
| Yuh, YJ | 1 |
| Giuliani, F | 3 |
| Montemurro, F | 1 |
| Cartenì, G | 1 |
| Romito, S | 1 |
| Gebbia, V | 3 |
| Sun, T | 1 |
| Zhang, JR | 1 |
| Jia, HS | 1 |
| Ohi, S | 1 |
| Takahashi, N | 6 |
| Tachibana, T | 1 |
| Hirabayashi, T | 2 |
| Ishikawa, H | 6 |
| Wedding, U | 1 |
| Kuss, O | 1 |
| Hirabayashi, Y | 1 |
| Fuchimoto, M | 1 |
| Fujikura, H | 1 |
| Hato, S | 1 |
| Urakami, A | 1 |
| Tsunoda, T | 5 |
| Rodriguez-Blanco, I | 1 |
| Ginarte Val, M | 1 |
| Peteiro, C | 1 |
| Toribio, J | 1 |
| Wagener, DJ | 5 |
| Jeziorski, K | 1 |
| Balleisen, L | 1 |
| Joossens, E | 1 |
| Jansen, RL | 1 |
| Debois, M | 1 |
| Bethe, U | 1 |
| Praet, M | 1 |
| Germano, D | 2 |
| Dinota, A | 2 |
| Romano, R | 1 |
| Reggiardo, G | 2 |
| Chen, CC | 1 |
| Tsou, TC | 1 |
| Pan, WY | 1 |
| Kuo, CC | 1 |
| Yeh, SC | 1 |
| Tsai, FY | 1 |
| Hsieh, HP | 1 |
| Gupta, N | 1 |
| Aggarwal, N | 1 |
| Moon, YW | 2 |
| Ae, T | 1 |
| Feng, JX | 1 |
| Briasoulis, E | 1 |
| Fatouros, M | 1 |
| Roukos, DH | 1 |
| Haberl, C | 1 |
| Marabotti, C | 1 |
| Awad, L | 1 |
| Saletti, P | 1 |
| Köberle, D | 1 |
| Rufibach, K | 1 |
| Wernli, M | 1 |
| Leslie, M | 1 |
| Glynne-Jones, R | 2 |
| Widmer, L | 1 |
| Sharma, SP | 1 |
| Nagashima, F | 3 |
| Kim, WY | 1 |
| Crosby, TD | 1 |
| Bartelink, H | 2 |
| Nam, E | 2 |
| Aizaki, K | 1 |
| Welz, S | 1 |
| Belka, C | 1 |
| Kolodziejczyk, P | 1 |
| Pituch-Noworolska, A | 1 |
| Drabik, G | 1 |
| Szczepanik, A | 1 |
| Sierzega, M | 1 |
| Gurda, A | 1 |
| Liu, JH | 3 |
| Zhu, ZH | 2 |
| Li, XX | 1 |
| Lu, XP | 1 |
| Zhou, SY | 1 |
| Deeks, ED | 1 |
| Curigliano, G | 1 |
| Evans, D | 2 |
| Millis, R | 1 |
| Jean, M | 1 |
| Kennedy, T | 2 |
| Boulesteix, AL | 1 |
| Sawada, N | 1 |
| Kondoh, K | 1 |
| Blanchard, P | 1 |
| Huguet, F | 1 |
| Szöke, D | 1 |
| Györffy, A | 1 |
| Surowiak, P | 1 |
| Tulassay, Z | 1 |
| Dietel, M | 1 |
| Györffy, B | 1 |
| Suttie, SA | 1 |
| Park, KG | 1 |
| Smith, TA | 1 |
| Wang, LY | 1 |
| Chen, QK | 1 |
| Min, J | 1 |
| Chen, RF | 1 |
| Deng, JZ | 1 |
| Li, CM | 1 |
| Kawamura, S | 1 |
| Musha, N | 1 |
| Konno, H | 2 |
| Buzzoni, R | 2 |
| Mariani, L | 1 |
| Ferrario, E | 2 |
| Katia, D | 1 |
| Gevorgyan, A | 1 |
| Zilembo, N | 1 |
| Bochicchio, AM | 1 |
| Marini, G | 4 |
| Schieppati, G | 2 |
| Palazzo, S | 1 |
| Villa, E | 1 |
| Fagnani, D | 1 |
| Reguzzoni, G | 1 |
| Agostana, B | 1 |
| Oliani, C | 1 |
| Kildani, B | 1 |
| Duro, M | 1 |
| Botta, M | 1 |
| Mozzana, R | 1 |
| Mantovani, G | 1 |
| Kimura, H | 5 |
| Inui, N | 2 |
| Hiyama, S | 2 |
| Sagawa, T | 1 |
| Kuroda, H | 1 |
| Hirakawa, M | 1 |
| Sakamaki, S | 1 |
| Niitsu, Y | 3 |
| Zhao, JM | 1 |
| Wu, AZ | 1 |
| Shi, LR | 1 |
| Cruff, D | 1 |
| Maia-Acuna, C | 1 |
| Habr, F | 1 |
| Chauhan, B | 1 |
| Sears, D | 1 |
| Hwang, SW | 1 |
| Kwon, DS | 1 |
| Nam, KW | 1 |
| Kang, HM | 1 |
| Kang, YS | 1 |
| Seong, JK | 1 |
| Satoh, S | 2 |
| Nakafusa, Y | 1 |
| Cheng, YN | 1 |
| Tian, ZG | 1 |
| Cen, P | 1 |
| Jackson, C | 1 |
| Quek, R | 1 |
| Lim, WT | 1 |
| Koo, WH | 2 |
| A-Manaf, A | 1 |
| Yun, T | 1 |
| Na, II | 1 |
| Shin, H | 1 |
| Fu, de L | 1 |
| Long, J | 1 |
| Jin, C | 1 |
| Yu, XJ | 1 |
| Ni, QX | 1 |
| Tamura, F | 1 |
| Mizushima, T | 1 |
| Makino, K | 1 |
| Oura, K | 1 |
| Sumiyoshi, T | 1 |
| Yoshizaki, N | 1 |
| Kondo, H | 2 |
| Kuwamura, H | 1 |
| Lin, XG | 1 |
| Liu, TH | 1 |
| Zhang, AM | 1 |
| Meric, JB | 1 |
| Yang, YQ | 1 |
| Zhang, LJ | 1 |
| Dong, H | 1 |
| Jiang, CL | 1 |
| Han, JS | 1 |
| Xiao, HS | 1 |
| Gao, HJ | 1 |
| Popov, IP | 1 |
| Jelić, SB | 1 |
| Krivokapić, ZV | 1 |
| Jezdić, SD | 1 |
| Pesko, PM | 1 |
| Micev, MT | 1 |
| Babić, DR | 1 |
| Yin, Q | 1 |
| Wang, HZ | 2 |
| Wang, HB | 1 |
| Ohtaka, K | 1 |
| Im, CK | 2 |
| Hayashi, Y | 3 |
| Akiyama, J | 1 |
| Nozaki, Y | 1 |
| Iwashita, R | 2 |
| Nagaoki, Y | 1 |
| Sakurai, T | 1 |
| Yago, Y | 1 |
| Sako, A | 1 |
| Kobayakawa, M | 1 |
| Tamegai, Y | 1 |
| Masaki, N | 1 |
| Uemura, N | 1 |
| Umeda, N | 1 |
| Battistelli, S | 1 |
| Haines, IE | 1 |
| Xue, YW | 1 |
| Han, JG | 1 |
| Li, BX | 1 |
| Yang, BF | 1 |
| Cordio, S | 1 |
| Caputo, G | 1 |
| Condorelli, S | 1 |
| Mattina, M | 1 |
| Amadio, P | 1 |
| Tomimatsu, H | 1 |
| Nakano, T | 1 |
| Wieder, H | 1 |
| Fanti, S | 1 |
| Castellucci, P | 1 |
| Sperandi, F | 1 |
| Furuta, S | 1 |
| Sunagawa, R | 1 |
| Isogaki, J | 2 |
| Zhao, AG | 1 |
| You, SF | 1 |
| Zhao, HL | 1 |
| Tang, LD | 1 |
| Machover, D | 6 |
| Ulusakarya, A | 1 |
| Goldschmidt, E | 6 |
| Sencan, O | 1 |
| Buyukcelik, A | 1 |
| Boruban, MC | 1 |
| Akbulut, H | 2 |
| Demirkazik, A | 2 |
| Senler, FC | 1 |
| Onur, H | 1 |
| Icli, F | 2 |
| Jeong, JS | 1 |
| Jo, JC | 1 |
| Koutras, AK | 1 |
| Gerolymos, MK | 1 |
| Kontogeorgou, E | 1 |
| Iconomou, G | 1 |
| Vourli, G | 1 |
| Tsiata, E | 1 |
| Makatsoris, T | 1 |
| Chrysanthopoulos, C | 1 |
| Melgoza, G | 1 |
| Nervi, B | 1 |
| Jeong, J | 1 |
| Kook, MC | 1 |
| Lee, JR | 1 |
| Cho, SJ | 1 |
| Oida, Y | 1 |
| Motojuku, M | 1 |
| Morikawa, G | 1 |
| Muñoz Martín, AJ | 1 |
| Martínez Marín, V | 1 |
| Arranz Cózar, JL | 1 |
| Cabezón Gutiérrez, L | 1 |
| González del Val Subirats, R | 1 |
| García Alfonso, P | 1 |
| Paik, YH | 1 |
| Lee, DK | 1 |
| Park, HJ | 1 |
| Yoon, DS | 1 |
| Bravi, S | 1 |
| Arcangeli, A | 1 |
| Tonato, M | 4 |
| Strafiuso, G | 1 |
| Corgna, E | 1 |
| Rondini, E | 1 |
| Giunta, A | 1 |
| Monzio Compagnoni, B | 1 |
| Cesari, M | 1 |
| Fornarini, G | 1 |
| Nelli, F | 1 |
| Carboni, M | 1 |
| Enzo, MR | 1 |
| Piga, A | 1 |
| Olivetti, A | 1 |
| Masoni, L | 1 |
| De Stefanis, M | 1 |
| Dalla Mola, A | 1 |
| Camera, S | 1 |
| De Filippis, S | 1 |
| Scipioni, L | 1 |
| Italia, M | 1 |
| Banducci, S | 1 |
| Pisani Leretti, A | 1 |
| Ionta, MT | 1 |
| Nicolosi, A | 1 |
| Biscottini, B | 2 |
| Grigniani, F | 1 |
| Rovei, R | 1 |
| Croce, E | 1 |
| Carroccio, R | 1 |
| Gilli, G | 2 |
| Cavalli, C | 1 |
| Olgiati, A | 1 |
| Pandolfi, U | 1 |
| Rossetti, R | 1 |
| Natalini, G | 1 |
| Oldani, S | 1 |
| Bruno, L | 2 |
| Lungarotti, F | 1 |
| Farris, A | 1 |
| Sarobba, MG | 1 |
| Trignano, M | 1 |
| Muscogiuri, A | 1 |
| Francavilla, F | 1 |
| Figoli, F | 2 |
| Leoni, M | 1 |
| Papiani, G | 1 |
| Orselli, G | 1 |
| Antimi, M | 1 |
| Bellini, V | 1 |
| Cabassi, A | 1 |
| Contu, A | 1 |
| Pazzola, A | 1 |
| Frignano, M | 1 |
| Lastraioli, E | 1 |
| Saggese, M | 1 |
| Mela, M | 1 |
| Leaw, J | 1 |
| Gu, W | 1 |
| Hollerbach, S | 1 |
| Wilhelm, G | 1 |
| Derigs, HG | 1 |
| Grossmann, J | 1 |
| Zhu, JD | 1 |
| Figer, A | 1 |
| Stemmer, SM | 1 |
| Tichler, T | 1 |
| Sulkes, J | 1 |
| Vaccaro, M | 1 |
| Barbuzza, O | 1 |
| Guarneri, F | 1 |
| Guarneri, B | 1 |
| Yakir, R | 1 |
| Luna, K | 1 |
| Marc, W | 1 |
| Tamar, S | 1 |
| Avraham, R | 1 |
| Ayala, H | 1 |
| Fu, ZJ | 2 |
| Tai, YH | 2 |
| Wei, WQ | 1 |
| Liu, DZ | 1 |
| Yang, LX | 1 |
| Seo, HY | 1 |
| Kim, DS | 1 |
| Choi, YS | 1 |
| Kim, MM | 1 |
| Janjan, NA | 1 |
| Phan, AT | 1 |
| Maru, D | 1 |
| Cho, DY | 2 |
| Bae, SB | 1 |
| Cho, IS | 1 |
| Han, CS | 1 |
| Yun, HJ | 1 |
| Ran, FW | 1 |
| Zhang, XR | 1 |
| Du, R | 1 |
| Bouillet, T | 2 |
| Morere, JF | 1 |
| Takayanagi, H | 1 |
| Karaki, H | 1 |
| Yamamori, H | 1 |
| Sugano, I | 1 |
| Ham, HS | 1 |
| Blokhina, NG | 7 |
| Blokhin, NN | 1 |
| Hornowski, S | 1 |
| Olkowski, L | 1 |
| Yamashita, R | 1 |
| Iwa, T | 3 |
| Ueoka, H | 1 |
| Kuroda, S | 1 |
| Ohnoshi, T | 1 |
| Kimura, I | 1 |
| Numoto, A | 1 |
| Hino, I | 1 |
| Tsuji, M | 2 |
| Jones, BG | 2 |
| Fielding, JW | 3 |
| Newman, CE | 1 |
| Howell, A | 1 |
| Brookes, VS | 4 |
| Lempert, KD | 1 |
| Karlin, DA | 2 |
| Stroehlein, JR | 2 |
| Makowka, L | 1 |
| Falk, RE | 3 |
| Ambus, U | 3 |
| Bugala, R | 1 |
| Landi, S | 3 |
| Lawton, JO | 2 |
| Giles, GR | 3 |
| Hall, R | 2 |
| Bird, GG | 2 |
| Matheson, T | 1 |
| Hartenstein, R | 1 |
| Ehrhart, H | 1 |
| Possinger, K | 1 |
| Gusarov, IuP | 4 |
| Yasue, M | 4 |
| Suchi, T | 1 |
| Bottoni, P | 1 |
| Bobba, L | 1 |
| Ranieri, MG | 1 |
| Croce, M | 1 |
| Zaietta, P | 1 |
| Provera, F | 1 |
| Heim, ME | 6 |
| Suga, S | 8 |
| Kimura, K | 8 |
| Isobe, K | 3 |
| Yoshida, Y | 11 |
| Kuwabara, T | 1 |
| Gisselbrecht, C | 6 |
| Smith, FP | 7 |
| Korsmeyer, SJ | 1 |
| Boiron, M | 5 |
| Woolley, PV | 10 |
| Schein, PS | 13 |
| Waddell, WR | 1 |
| Gerner, RE | 1 |
| Reich, MP | 1 |
| Kikuchi, K | 12 |
| Kusama, S | 2 |
| Furue, H | 13 |
| Muto, T | 8 |
| Toriyama, K | 1 |
| Wakiya, M | 1 |
| Yokota, S | 2 |
| Yoshida, J | 2 |
| Fuse, Y | 2 |
| Nishida, K | 1 |
| Takino, T | 4 |
| Kono, A | 2 |
| Grieco, A | 1 |
| Lasorella, A | 1 |
| Astone, A | 2 |
| Vagliviello, L | 1 |
| Bartoloni, C | 1 |
| Schwarzenberg, L | 5 |
| Tourani, JM | 2 |
| Michalski, B | 2 |
| Hayat, M | 2 |
| Dorval, T | 2 |
| Delouche, C | 1 |
| Brochon, D | 1 |
| Fraioli, JP | 1 |
| Jasmin, C | 2 |
| Maral, R | 2 |
| Mathe, G | 4 |
| Kitade, F | 4 |
| Kawashima, Y | 4 |
| Sakuramoto, K | 4 |
| Okajima, K | 6 |
| Matsuka, Y | 1 |
| Ejiri, T | 1 |
| Asano, K | 1 |
| Futatsuki, K | 6 |
| Kanda, Y | 6 |
| Ishibashi, I | 2 |
| Sendai, H | 1 |
| Akazawa, S | 15 |
| Hattori, M | 1 |
| Kemeny, N | 1 |
| Smith, BJ | 1 |
| Ashford, RF | 1 |
| Bakowski, M | 1 |
| Hellman, K | 1 |
| Newton, K | 1 |
| Phillips, R | 1 |
| Lambert, J | 1 |
| Jones, R | 1 |
| Peters, N | 1 |
| Evans, M | 1 |
| Wakui, A | 19 |
| Yokoyama, M | 5 |
| Kaito, I | 1 |
| Ishikawa, M | 3 |
| Goto, Y | 2 |
| Kikkawa, J | 1 |
| Sugahara, K | 2 |
| Taima, T | 1 |
| Fagg, SL | 1 |
| Ellis, D | 1 |
| Hockey, MS | 2 |
| Minawa, A | 1 |
| Craven, JL | 1 |
| Mason, MC | 1 |
| Timothy, A | 1 |
| Waterhouse, JA | 2 |
| Wrigley, PF | 1 |
| Higgins, GA | 2 |
| Amadeo, JH | 1 |
| Smith, DE | 1 |
| Humphrey, EW | 1 |
| Keehn, RJ | 1 |
| Lopez, M | 4 |
| Perno, CF | 1 |
| Köster, R | 1 |
| Scherer, E | 1 |
| Coates, AS | 1 |
| Tattersall, MH | 3 |
| Swanson, C | 1 |
| Fox, RM | 2 |
| Raghavan, D | 1 |
| Komov, DV | 1 |
| Roshchin, EM | 1 |
| Chernova, MV | 1 |
| Dolgushin, BI | 1 |
| Crocker, J | 1 |
| Jones, EL | 1 |
| Hioki, K | 2 |
| Jolivet, J | 1 |
| Giroux, L | 1 |
| Laurin, S | 1 |
| Gruber, J | 1 |
| Bettez, P | 1 |
| Band, PR | 1 |
| Eichler, G | 1 |
| Habs, M | 3 |
| Schmähl, D | 3 |
| Inagaki, J | 3 |
| Horikoshi, N | 4 |
| Ezaki, K | 3 |
| Inoue, K | 13 |
| Usui, N | 2 |
| Nakada, H | 2 |
| Naito, E | 1 |
| Yorioka, S | 1 |
| Kodama, T | 1 |
| Shimono, M | 1 |
| Machida, T | 2 |
| Ikeuchi, H | 1 |
| Kano, K | 1 |
| Sugata, S | 1 |
| Kito, T | 6 |
| Ishibashi, H | 1 |
| Iguchi, K | 2 |
| Hashimoto, I | 5 |
| Kano, T | 7 |
| Notsuka, T | 5 |
| Hiramoto, Y | 3 |
| Abe, Y | 4 |
| Masuda, H | 5 |
| Kumashiro, R | 6 |
| Kajima, T | 1 |
| Takao, H | 5 |
| Ban, K | 3 |
| Ohashi, H | 3 |
| Kunieda, T | 1 |
| Sakata, K | 4 |
| Arima, S | 6 |
| Futami, K | 6 |
| Kinashi, M | 2 |
| Shigeta, M | 3 |
| Jyozaki, H | 1 |
| Shimura, H | 4 |
| Tamada, R | 8 |
| Yamada, F | 3 |
| Kagami, H | 2 |
| Fukutome, A | 1 |
| Mastumine, T | 1 |
| Kasai, Y | 6 |
| Nishi, H | 1 |
| Nishindai, H | 1 |
| Yoshimoto, M | 2 |
| Sawada, Y | 2 |
| Mikami, J | 2 |
| Bekki, E | 1 |
| Friedman, MA | 1 |
| Carter, SK | 3 |
| Hannigan, J | 1 |
| Nakao, I | 5 |
| Takagi, K | 4 |
| Kuno, K | 3 |
| Kajitani, T | 5 |
| Abe, O | 13 |
| Hattori, T | 27 |
| Kondo, T | 16 |
| Ito, I | 4 |
| Izumi, T | 6 |
| Maruyama, T | 3 |
| Miyasaka, K | 2 |
| Soejima, S | 1 |
| Kako, N | 1 |
| Kawaguchi, T | 2 |
| Soga, S | 1 |
| Okouchi, Y | 1 |
| Johjima, Y | 1 |
| Shimazu, R | 1 |
| Ihara, O | 1 |
| Oohara, T | 1 |
| Naito, K | 2 |
| Imaizumi, M | 6 |
| Kamei, H | 2 |
| Ichihashi, H | 8 |
| Hakuta, Y | 1 |
| Ashizawa, I | 1 |
| Nakazima, K | 1 |
| Reyes, JM | 1 |
| Okazaki, N | 4 |
| Yoshino, M | 3 |
| Fujimoto, S | 14 |
| Kitsukawa, Y | 2 |
| Okui, K | 4 |
| Hosaka, T | 2 |
| Karaki, S | 2 |
| Kawanomoto, S | 2 |
| Sato, H | 11 |
| Yamazaki, Y | 5 |
| Amano, H | 1 |
| Hiura, T | 2 |
| Oda, S | 2 |
| Namiki, S | 3 |
| Nagao, K | 5 |
| Panettiere, FJ | 1 |
| Haas, C | 2 |
| McDonald, B | 1 |
| Costanzi, JJ | 1 |
| Talley, RW | 1 |
| Athens, J | 1 |
| Oishi, N | 2 |
| Heilbrun, LK | 2 |
| Chen, TT | 2 |
| Okuyama, K | 4 |
| Isono, K | 3 |
| Satoh, H | 5 |
| Onoda, S | 4 |
| Tohnosu, N | 2 |
| Ryu, M | 2 |
| Koide, Y | 3 |
| Hanaoka, A | 1 |
| Hanatani, Y | 1 |
| Honda, T | 3 |
| Sampi, K | 2 |
| Fujiki, T | 3 |
| Izuno, O | 2 |
| Suda, Y | 7 |
| Akiyoshi, T | 3 |
| Kawaguchi, M | 2 |
| Arinaga, S | 2 |
| Miyazaki, S | 2 |
| Koba, F | 2 |
| Tsuji, H | 4 |
| Ibayashi, J | 2 |
| Shirakabe, H | 2 |
| Fujita, M | 10 |
| Fujita, F | 5 |
| Nosoh, Y | 5 |
| Yoshinaka, K | 4 |
| Nishimawari, K | 4 |
| Hirono, M | 1 |
| Niimoto, M | 14 |
| Kumazawa, H | 1 |
| Imai, N | 1 |
| Shioya, M | 1 |
| Fukaya, Y | 1 |
| Noguchi, A | 1 |
| Miyahara, M | 2 |
| Orita, K | 6 |
| Ogawa, N | 9 |
| Toda, T | 2 |
| Furusawa, M | 3 |
| Kameda, C | 1 |
| Shiomi, M | 1 |
| Saka, M | 3 |
| Itoh, S | 1 |
| Douglass, HO | 11 |
| Lavin, PT | 4 |
| Goudsmit, A | 1 |
| Klaassen, DJ | 2 |
| Paul, AR | 2 |
| Hirose, S | 3 |
| Mano, K | 1 |
| Tsutsui, N | 1 |
| Hamaya, K | 1 |
| Hanaue, H | 4 |
| Kurosawa, T | 4 |
| Kitano, Y | 4 |
| Miyakawa, S | 3 |
| Horie, F | 3 |
| Nemoto, A | 4 |
| Shikata, J | 4 |
| Miyagawa, S | 1 |
| Asagoe, T | 2 |
| Ohashi, I | 2 |
| Takekoshi, T | 2 |
| Ohashi, K | 2 |
| Kato, Y | 9 |
| Shlemkevich, MP | 4 |
| Shiian, DN | 6 |
| Yoshitake, Y | 1 |
| Yoshikawa, K | 3 |
| O'Fallon, JR | 1 |
| Schutt, AJ | 4 |
| Kubo, K | 2 |
| Aoyama, H | 1 |
| Inukai, N | 1 |
| Horiuchi, T | 1 |
| Sawada, H | 5 |
| Ibuka, T | 2 |
| Sakai, Y | 7 |
| Ishiwata, J | 3 |
| Satomi, T | 2 |
| Martin, F | 2 |
| Mutzner, F | 1 |
| Pérez, JE | 2 |
| Macchiavelli, M | 1 |
| Leone, BA | 2 |
| Romero, A | 1 |
| Rabinovich, MG | 1 |
| Arévalo, E | 1 |
| Strauss, E | 1 |
| Vogl, SE | 1 |
| Engstrom, PF | 4 |
| Fornasiero, A | 3 |
| Cartei, G | 2 |
| Daniele, O | 1 |
| Fosser, V | 1 |
| Fiorentino, MV | 1 |
| Ridolfi, R | 2 |
| Casadei Giunchi, D | 1 |
| Cortesi, C | 1 |
| Maltoni, M | 1 |
| McArdle, CS | 3 |
| Carter, DC | 3 |
| Smyth, JF | 1 |
| Allan, SG | 1 |
| Kaye, SB | 2 |
| Sangster, G | 1 |
| Calman, KC | 1 |
| Hutcheon, AW | 1 |
| Epelbaum, R | 2 |
| Cohen, Y | 3 |
| Waldhorn, RE | 1 |
| Tsou, E | 1 |
| Kerwin, DM | 1 |
| Gill, PG | 3 |
| Jones, AM | 2 |
| Abbott, R | 1 |
| Klein, HO | 6 |
| Wickramanayake, PD | 2 |
| Dieterle, F | 2 |
| Mohr, R | 2 |
| Oerkermann, H | 2 |
| Gross, R | 2 |
| Shah, A | 1 |
| MacDonald, WC | 1 |
| Nishioka, B | 5 |
| Kojima, O | 2 |
| Ohuchi, T | 1 |
| Yahata, K | 2 |
| Muto, F | 2 |
| Umehara, M | 2 |
| Yamane, E | 2 |
| Majima, S | 5 |
| Fraschini, P | 1 |
| Beretta, G | 2 |
| Tedeschi, L | 1 |
| Luporini, G | 3 |
| Haas, CD | 1 |
| Mansfield, CM | 1 |
| Leichman, LP | 1 |
| Considine, B | 1 |
| Bukowski, RM | 2 |
| Hoskins, RB | 1 |
| Cohen, AC | 1 |
| Kaufman, S | 1 |
| Wood, WC | 1 |
| Carey, RW | 1 |
| Bedikian, AY | 3 |
| Khankhanian, N | 2 |
| McBride, CM | 1 |
| McMurtrey, MJ | 1 |
| Bodey, GP | 4 |
| Nishidai, H | 1 |
| Kashi, Y | 1 |
| Kuwayama, H | 1 |
| Eastwood, GL | 1 |
| Kohashi, E | 1 |
| Furuta, K | 1 |
| Shinoda, M | 2 |
| Yasuda, S | 1 |
| Nakazaki, S | 1 |
| Kiyomitsu, Y | 1 |
| Schlag, P | 4 |
| Flentje, D | 1 |
| Schnitzler, G | 2 |
| König, H | 2 |
| Katz, R | 2 |
| Fritze, D | 3 |
| Arnold, H | 4 |
| Henss, H | 3 |
| Trux, F | 2 |
| Ratiani, MS | 1 |
| Gnatyshak, AI | 3 |
| Gupta, S | 2 |
| Ahlgren, JD | 3 |
| Tanneberger, S | 1 |
| Ouchi, T | 1 |
| Nomiyama, S | 1 |
| Sakita, M | 1 |
| Tazawa, T | 1 |
| Hikosaka, T | 1 |
| Gambe, K | 1 |
| Britsis, FA | 2 |
| Zakenfel'd, GK | 1 |
| Krampe, RA | 1 |
| Berzinia, VIu | 2 |
| Purkalne, TS | 2 |
| Omuraliev, A | 1 |
| Shimaji, T | 3 |
| Suzuoki, Y | 1 |
| Loginov, GF | 1 |
| Hoth, DF | 2 |
| Lagarde, C | 3 |
| Maezawa, S | 1 |
| Sakuma, M | 1 |
| Ohira, S | 1 |
| Sorokina, GA | 1 |
| Belpomme, D | 1 |
| Mignot, L | 1 |
| Marty, M | 1 |
| Kanbara, H | 1 |
| Kurokawa, A | 1 |
| Miyagi, N | 4 |
| Shiratori, T | 3 |
| Konishi, Y | 1 |
| Hirono, S | 1 |
| Gropp, C | 1 |
| Havemann, K | 1 |
| Sugawara, K | 2 |
| Nishimura, S | 2 |
| Den, N | 1 |
| Ono, F | 1 |
| Yoshimori, M | 2 |
| Hirota, T | 3 |
| Sugie, S | 2 |
| Hayasaka, A | 2 |
| Itoh, I | 3 |
| Koga, S | 3 |
| Ohya, M | 2 |
| Tomita, M | 4 |
| Kosaki, G | 9 |
| Yura, J | 2 |
| Izuo, M | 3 |
| Takemiya, S | 3 |
| Asakawa, H | 2 |
| Otawa, H | 2 |
| Kaga, F | 2 |
| Seki, M | 2 |
| Yagita, A | 1 |
| Sohma, S | 1 |
| Fukuzumi, N | 2 |
| Kaneko, H | 3 |
| Sekizawa, Y | 1 |
| Ohashi, A | 1 |
| Inuo, T | 1 |
| Ozaki, A | 1 |
| Fukao, K | 1 |
| Takase, Y | 1 |
| Takeshima, T | 1 |
| Todoroki, T | 2 |
| Nagoshi, K | 1 |
| Higi, M | 1 |
| Arndt, D | 1 |
| Schmitt, G | 1 |
| Lerner, H | 1 |
| Marcovitz, E | 1 |
| Zaren, H | 1 |
| Honigman, J | 1 |
| Seeber, S | 5 |
| Oszacki, J | 1 |
| Jedrychowski, W | 1 |
| Valdivieso, M | 3 |
| Vaughn, CB | 2 |
| Chapman, JL | 1 |
| Garland, M | 1 |
| Pederson, B | 1 |
| Demitrish, MM | 1 |
| Chinn, B | 1 |
| Ward, D | 1 |
| Brady, PR | 1 |
| Hazel, JJ | 1 |
| Huggins, M | 1 |
| Maksymiuk, A | 1 |
| MacFarlane, JK | 1 |
| Kisner, DL | 1 |
| Schreml, W | 1 |
| Gaus, W | 1 |
| Herfarth, C | 2 |
| Linder, MM | 1 |
| Trede, M | 1 |
| Weber, W | 1 |
| Obrecht, JP | 3 |
| DeLisi, V | 1 |
| Di Blasio, B | 1 |
| Bennetts, RW | 1 |
| Jones, RD | 1 |
| Heifetz, LJ | 1 |
| Mahal, PS | 1 |
| Shiraishi, M | 3 |
| Inoue, F | 2 |
| Kodama, Y | 2 |
| Brock, J | 1 |
| Beyer, D | 1 |
| Tampier, C | 1 |
| Zamorano, R | 1 |
| Tounosu, N | 1 |
| Chin, F | 1 |
| Kouzu, T | 1 |
| Hirasawa, H | 1 |
| Nomi, S | 1 |
| Shibata, J | 1 |
| Makita, T | 1 |
| Ohki, S | 4 |
| Komita, T | 1 |
| Iketa, T | 1 |
| Arimori, S | 1 |
| Nagao, T | 2 |
| Revazova, ES | 1 |
| Savran, VR | 2 |
| Recchia, G | 1 |
| Tempesti, M | 1 |
| Venditti, A | 1 |
| Bianucci, P | 1 |
| Pastorino, G | 1 |
| Joss, R | 1 |
| Tschopp, L | 1 |
| Brunner, K | 1 |
| Nakazawa, I | 1 |
| Ouchi, E | 1 |
| Ouchi, K | 1 |
| Wagai, K | 1 |
| Garelli, S | 1 |
| Valbonesi, M | 1 |
| Banfi, L | 1 |
| Fukuda, I | 3 |
| Destroyes, JP | 1 |
| Baschet, C | 1 |
| Le Henand, F | 1 |
| Bernard, PF | 1 |
| Orlovskaia, LA | 3 |
| Tiutiunova, AM | 1 |
| Kulikova, ML | 2 |
| Vagner, VP | 1 |
| Chernyĭ, VA | 10 |
| Nio, Y | 3 |
| Nakamoto, K | 1 |
| Tanaka, A | 2 |
| Henmi, K | 1 |
| Matsukura, N | 1 |
| Aoyagi, M | 1 |
| Kawachi, T | 1 |
| Hirashima, T | 1 |
| Takasugi, T | 1 |
| Ushio, K | 1 |
| Sugimura, T | 1 |
| Van der Veer, LD | 1 |
| Balint, JA | 1 |
| Ogorodnikova, LS | 1 |
| Gaĭrabed'iants, NG | 1 |
| Smythe, T | 3 |
| Ueno, W | 3 |
| Hoth, D | 2 |
| Smith, F | 1 |
| Ichiki, AT | 1 |
| Krauss, S | 2 |
| Israelsen, KL | 1 |
| Sonoda, T | 2 |
| Collmann, IR | 1 |
| Knorr, V | 1 |
| Schmitz, R | 1 |
| Tsugawa, K | 1 |
| Kuroda, Y | 6 |
| Demachi, H | 1 |
| Yasumoto, K | 3 |
| Iwamoto, M | 4 |
| Hoshiko, M | 2 |
| Kawabata, S | 4 |
| Morimatsu, M | 1 |
| Kakegawa, T | 5 |
| Testa, A | 2 |
| Valenza, R | 1 |
| Latteri, M | 1 |
| Bajardi, G | 1 |
| Mastrandrea, G | 1 |
| Cipolla, C | 1 |
| Pischedda, G | 1 |
| Curto, G | 1 |
| Cannata, G | 1 |
| Highley, MS | 2 |
| Parnis, FX | 1 |
| Trotter, GA | 1 |
| Houston, SJ | 1 |
| Penson, RT | 1 |
| Pyrhönen, S | 2 |
| Kuitunen, T | 1 |
| Nyandoto, P | 1 |
| Bernhard, H | 1 |
| Klein, O | 1 |
| Wächter, B | 1 |
| Theiss, F | 1 |
| Dippold, W | 1 |
| Meyer zum Büschenfelde, KH | 1 |
| Moriyama, A | 2 |
| Murata, I | 1 |
| Kuroda, T | 3 |
| Yoshikawa, I | 1 |
| Tabaru, A | 1 |
| Ogami, Y | 1 |
| Otsuki, M | 1 |
| Hoshima, M | 1 |
| Mugitani, T | 1 |
| Koishi, K | 1 |
| Masuyama, M | 2 |
| Miyata, K | 2 |
| Koizumi, T | 1 |
| Osaku, M | 1 |
| Watahiki, Y | 1 |
| Hojyo, M | 1 |
| Kosaka, A | 2 |
| Sugaya, J | 7 |
| Takano, Y | 4 |
| Kiriyama, M | 4 |
| Tomita, F | 7 |
| Kita, I | 7 |
| Takamatsu, S | 2 |
| Sugano, N | 3 |
| Katada, M | 1 |
| Kasugai, H | 1 |
| Ishiyama, J | 1 |
| Imai, I | 1 |
| Fukuma, E | 1 |
| Miyajima, N | 1 |
| Kano, N | 1 |
| Yamakawa, T | 1 |
| Goto, S | 4 |
| Kera, J | 1 |
| Takeuchi, S | 2 |
| Itani, K | 1 |
| Hiraoka, M | 1 |
| Noguchi, M | 1 |
| Terada, J | 1 |
| Mizuno, I | 3 |
| Ueda, T | 2 |
| Mohri, N | 4 |
| Nonami, T | 1 |
| Hibi, K | 2 |
| Takagi, H | 7 |
| Sahmoud, T | 2 |
| Duez, N | 7 |
| Fiorentino, M | 1 |
| Aiba, K | 3 |
| Goseki, N | 2 |
| Kando, F | 3 |
| Shimoju, K | 1 |
| Adachi, Y | 3 |
| Matsukuma, A | 1 |
| Sakino, I | 1 |
| Konishi, J | 1 |
| Funahashi, S | 1 |
| Yo, R | 1 |
| Iso, Y | 1 |
| Ayabe, K | 1 |
| Hiraishi, M | 4 |
| Konishi, T | 9 |
| Furuya, Y | 4 |
| Kohno, N | 2 |
| Saitoh, Y | 3 |
| Roth, JA | 2 |
| Putnam, JB | 2 |
| Walsh, G | 2 |
| Roubein, LD | 1 |
| Ryan, MB | 1 |
| Natrajan, G | 1 |
| Gould, P | 1 |
| Usami, M | 2 |
| Zheng, JH | 1 |
| Yasuda, I | 2 |
| Haji, S | 1 |
| Kotani, G | 1 |
| Iso, A | 1 |
| Sun, K | 1 |
| Egami, I | 1 |
| Onda, M | 1 |
| Loganzo, F | 1 |
| Maslak, P | 1 |
| Lai, L | 1 |
| de Oliveira, AR | 1 |
| Schwartz, GK | 2 |
| Blundell, ML | 1 |
| Altorki, NK | 1 |
| Albino, AP | 1 |
| Okabayashi, K | 2 |
| Hiratsuka, M | 5 |
| Uchida, K | 3 |
| Nicolaides, C | 1 |
| Klouvas, G | 1 |
| Briassoulis, E | 1 |
| Tatulli, C | 1 |
| Taveri, R | 1 |
| Campanella, GA | 1 |
| Carrieri, G | 1 |
| Wang, GM | 1 |
| Sun, GZ | 1 |
| Toya, N | 1 |
| Masaoka, N | 1 |
| Houya, Y | 1 |
| Matai, K | 1 |
| Yumisashi, T | 1 |
| Onodera, T | 2 |
| Nakagawara, G | 2 |
| Sano, K | 3 |
| Kaibara, N | 7 |
| Kitamura, S | 2 |
| Ohtani, T | 2 |
| Tokunaga, K | 1 |
| González-Barón, M | 2 |
| Espinosa, E | 3 |
| García-Girón, C | 3 |
| Chacón, I | 2 |
| Garrido, P | 3 |
| Colmenarejo, A | 2 |
| Ordóñez, A | 2 |
| Zamora, P | 2 |
| Yamazaki, S | 1 |
| Shimojyu, K | 1 |
| Ohta, J | 3 |
| Ohno, T | 2 |
| Ogawa, T | 4 |
| Murayama, M | 1 |
| Horii, H | 1 |
| Imai, J | 1 |
| Watanabe, C | 1 |
| Ishiyama, M | 1 |
| Kawano, K | 1 |
| Inokuchi, T | 1 |
| Fujihara, T | 1 |
| Tamura, Y | 7 |
| Kimoto, K | 1 |
| Sakuyama, T | 2 |
| Shimono, S | 1 |
| Takamura, S | 1 |
| Inomata, Y | 2 |
| Isshi, K | 1 |
| Chibai, M | 1 |
| Tadaoka, N | 2 |
| Sawada, K | 1 |
| Tan, M | 2 |
| Kanno, M | 3 |
| Saitou, K | 1 |
| Oikawa, K | 2 |
| Shibuya, S | 1 |
| Fukura, Y | 1 |
| Hatakeyoma, F | 1 |
| Shirotani, N | 1 |
| Seshimo, A | 2 |
| Kameoka, S | 1 |
| Bondar', GV | 1 |
| Zabudkin, AF | 1 |
| Bukhteev, SV | 1 |
| Tomioka, K | 1 |
| Sato, F | 1 |
| Yamagata, T | 1 |
| Nagakawa, Y | 1 |
| Kobari, Y | 1 |
| Iwai, S | 3 |
| Shibata, N | 2 |
| Tamai, M | 3 |
| Chung, YS | 4 |
| Nitta, A | 2 |
| Hirayama, K | 1 |
| Kubo, T | 2 |
| Satoh, Y | 1 |
| Une, Y | 1 |
| Fujisawa, J | 2 |
| Sawaguchi, Y | 2 |
| Muranaga, S | 1 |
| Obara, M | 1 |
| Uchino, J | 2 |
| Weh, HJ | 5 |
| Harstrick, A | 5 |
| Kawasaki, S | 4 |
| Yosizane, K | 1 |
| Morokoshi, Y | 2 |
| Soda, M | 2 |
| Misumi, T | 1 |
| Hisikawa, E | 1 |
| Yaguchi, H | 1 |
| Arima, H | 1 |
| Matsumoto, M | 3 |
| Hachisu, T | 1 |
| Kashiwabara, H | 1 |
| Umehara, Y | 1 |
| Okubo, T | 1 |
| Sano, Y | 2 |
| Sakamoto, R | 1 |
| Tsuchiya, Y | 4 |
| Nagato, Y | 1 |
| Moriyama, R | 1 |
| Mizumoto, K | 1 |
| Furumoto, T | 1 |
| Kawamura, Y | 2 |
| Morise, K | 4 |
| Matsuoka, H | 2 |
| Seo, Y | 2 |
| Ohshiro, T | 1 |
| Adachi, E | 1 |
| Nagamine, S | 1 |
| Miyazaki, N | 2 |
| Shiromizu, A | 1 |
| Kounoe, S | 1 |
| Nicolson, V | 3 |
| O'Brien, M | 2 |
| Webb, A | 5 |
| Johnston, PG | 3 |
| Danenberg, KD | 3 |
| Allegra, CJ | 4 |
| Danenberg, PV | 3 |
| Kusugami, K | 1 |
| Horiuchi, Y | 2 |
| Kuroiwa, A | 1 |
| Tominaga, T | 1 |
| Higashi, H | 1 |
| Kitazaki, M | 1 |
| Ishihara, S | 4 |
| Noma, M | 1 |
| Ota, M | 1 |
| Masuda, K | 1 |
| Shida, H | 1 |
| Shchepotin, IB | 6 |
| Shabahang, M | 1 |
| Nauta, RJ | 1 |
| Buras, RR | 1 |
| Brenner, RV | 1 |
| Evans, SR | 1 |
| Hallissey, MT | 3 |
| Dunn, JA | 2 |
| Ward, LC | 3 |
| Chen, YC | 2 |
| Chen, BR | 1 |
| Lee, WJ | 2 |
| Lin, JT | 2 |
| Wang, TH | 1 |
| Kerr, DJ | 2 |
| O'Gorman, P | 1 |
| Wotherspoon, HA | 1 |
| Warren, H | 1 |
| Watson, D | 1 |
| Vinké, BJ | 1 |
| Dobbie, JW | 1 |
| el Eini, DI | 1 |
| Cao, WX | 2 |
| Xiao, HB | 2 |
| Tomita, K | 1 |
| Inaba, Y | 1 |
| Misuta, K | 1 |
| Masui, H | 1 |
| Ike, H | 1 |
| Tsurumi, M | 1 |
| Oka, M | 2 |
| Tangoku, A | 1 |
| Hamanaka, Y | 1 |
| Sejima, T | 2 |
| Fujita, H | 3 |
| Hasebe, K | 1 |
| Kaji, M | 1 |
| Nakai, M | 1 |
| Sahara, H | 1 |
| Kurita, A | 4 |
| Doihara, H | 3 |
| Hirama, K | 1 |
| Mikami, Y | 1 |
| Konn, M | 1 |
| Loehrer, PJ | 1 |
| Harry, D | 1 |
| Chlebowski, RT | 2 |
| Tamaki, Y | 2 |
| Morita, T | 1 |
| Touno, T | 1 |
| Shin, E | 1 |
| Yagyu, T | 1 |
| Takatsuka, Y | 2 |
| Katai, H | 4 |
| Bella, M | 1 |
| Algeri, R | 1 |
| De Lisi, V | 4 |
| Mazzocchi, B | 1 |
| Soldani, M | 4 |
| Mansi, J | 3 |
| Nash, A | 1 |
| Sacks, N | 1 |
| Mahjoubi, M | 3 |
| Bellefqih, S | 2 |
| Oliveira, J | 2 |
| Bognel, C | 3 |
| Elias, D | 3 |
| Poorter, RL | 2 |
| Bakker, PJ | 2 |
| Taat, CW | 2 |
| Bartelsman, JF | 2 |
| Veenhof, CH | 3 |
| Yue, XF | 1 |
| Han, JX | 1 |
| Dai, ZQ | 1 |
| Yang, WY | 1 |
| Xu, JY | 1 |
| Zhou, JJ | 1 |
| Chen, LJ | 2 |
| Meng, FH | 1 |
| Carrillo Hernández, JF | 1 |
| Ernesto de Obaldía Castillo, G | 1 |
| Ramírez Ortega, C | 1 |
| Frías Mendivil, M | 1 |
| Pardo, M | 1 |
| Sasagawa, T | 1 |
| Ho, N | 1 |
| Endo, T | 6 |
| Sekine, T | 1 |
| Tomidokoro, T | 1 |
| Hatakeyama, S | 1 |
| Togashi, M | 1 |
| Onuki, K | 1 |
| Katagiri, J | 1 |
| Okugawa, T | 2 |
| Onodera, S | 1 |
| Sairenji, M | 5 |
| Sakabe, T | 4 |
| Noro, M | 1 |
| Osawa, T | 1 |
| Kusano, F | 2 |
| Yamamoto, C | 1 |
| Maekawa, N | 2 |
| Sasaki, N | 2 |
| Tajiri, K | 1 |
| Tazawa, J | 2 |
| Aizawa, K | 1 |
| Muto, I | 1 |
| Katayanagi, N | 2 |
| Tanaka, O | 6 |
| Okuyama, T | 1 |
| Kuwano, M | 1 |
| Sugimachi, K | 16 |
| Tsuzuki, H | 1 |
| Niki, M | 1 |
| Ueda, H | 3 |
| Takamoto, Y | 1 |
| Oohara, M | 1 |
| Igarashi, S | 4 |
| Osada, H | 1 |
| Nishimura, G | 4 |
| Ishibiki, K | 6 |
| Zyrianov, BN | 2 |
| Makarkin, NA | 2 |
| Tikhonov, VI | 2 |
| Tuzikov, SA | 2 |
| Oyama, S | 1 |
| Nishi, M | 2 |
| Hamashima, N | 1 |
| Kaga, S | 1 |
| Kano, A | 1 |
| Saitoh, A | 1 |
| Fukuhara, T | 1 |
| Kikuchi, H | 3 |
| Tsushima, K | 6 |
| Kudoh, H | 1 |
| Narita, N | 1 |
| Suematsu, T | 1 |
| Kodama, I | 1 |
| Maruiwa, M | 2 |
| Kumegawa, H | 1 |
| Cullinan, SA | 3 |
| Wieand, HS | 4 |
| O'Connell, MJ | 6 |
| Poon, MA | 1 |
| Krook, JE | 5 |
| Valentini, G | 1 |
| Mai, M | 2 |
| Fujimoto, T | 4 |
| Omote, K | 2 |
| Mio, H | 2 |
| Terabe, K | 2 |
| Oshiro, T | 1 |
| Inutsuka, S | 2 |
| Chilvers, CE | 2 |
| Medi, F | 2 |
| Rauschecker, H | 1 |
| Vassilopoulos, P | 1 |
| Ferreira, EP | 1 |
| Vannozzi, G | 1 |
| Taal, BG | 5 |
| Teller, FG | 2 |
| ten Bokkel Huinink, WW | 3 |
| Beijnen, JH | 2 |
| Paillot, B | 3 |
| Burghouts, JT | 3 |
| Fickers, MM | 1 |
| de Graeff, A | 2 |
| Lalisang, FM | 1 |
| Fedeli, A | 2 |
| Nomura, N | 1 |
| Saitou, F | 1 |
| Tsuzawa, T | 1 |
| Yamashita, I | 1 |
| Sakakibara, T | 1 |
| Karaki, Y | 1 |
| Tazawa, K | 2 |
| Fujishima, H | 1 |
| Mitsugi, K | 1 |
| Yoshimatsu, H | 1 |
| Niho, Y | 2 |
| Ohsako, M | 1 |
| Sakoda, K | 1 |
| Tabata, M | 1 |
| Mizouchi, J | 1 |
| Yamaguchi, A | 3 |
| Misono, T | 1 |
| Uchizono, H | 1 |
| Harada, O | 1 |
| Ku, Y | 1 |
| Hamabe, Y | 1 |
| Murase, M | 3 |
| Kiriyama, K | 1 |
| Ogasawara, H | 2 |
| Moriya, N | 1 |
| Nagata, H | 1 |
| Ohiwa, Y | 1 |
| Miwa, M | 1 |
| Inamura, Y | 2 |
| Suzumura, K | 2 |
| Kanemitsu, T | 2 |
| Naruse, T | 2 |
| Ohkura, H | 2 |
| Kajimura, N | 1 |
| Sakakihara, Y | 1 |
| Tsunekawa, K | 1 |
| Matsuzaka, T | 1 |
| Namatame, K | 4 |
| Ko, Y | 1 |
| Nakano, H | 8 |
| Midorikawa, T | 1 |
| Kumada, K | 2 |
| Cervantes, A | 1 |
| Villar-Grimalt, A | 2 |
| Abad, A | 1 |
| Antón-Torres, A | 1 |
| Belón, J | 2 |
| Dorta, J | 1 |
| Camps, C | 1 |
| Anai, H | 7 |
| Muranaka, T | 1 |
| Takeo, S | 1 |
| Maekawa, S | 1 |
| Ikejiri, K | 1 |
| Yakabe, S | 1 |
| Furuyama, M | 1 |
| Saku, M | 1 |
| Nakagohri, T | 1 |
| Miyoshi, H | 1 |
| Tsunoda, Y | 1 |
| Ueda, K | 2 |
| Mochizuki, R | 1 |
| Miyauchi, H | 1 |
| Yasui, A | 3 |
| Nishida, Y | 2 |
| Yoshitoshi, A | 1 |
| McDonald, A | 1 |
| Harding, M | 1 |
| McNulty, L | 1 |
| Guillemin, F | 1 |
| Malissard, L | 1 |
| Kitano, M | 2 |
| Eda, H | 1 |
| Fujimoto, K | 1 |
| Ura, M | 1 |
| Hino, A | 1 |
| Wada, K | 1 |
| Ishitsuka, H | 1 |
| Kase, S | 2 |
| Teramoto, T | 3 |
| Hashimoto, T | 4 |
| Ishida, F | 3 |
| Watanabe, Y | 8 |
| Roelofs, EJ | 1 |
| Fickers, M | 2 |
| Lalisang, F | 1 |
| Neri, B | 3 |
| Gemelli, MT | 1 |
| Pantalone, D | 1 |
| Andreoli, F | 3 |
| Bruno, S | 1 |
| Fabbroni, S | 2 |
| Leone, V | 1 |
| Valeri, A | 2 |
| Borrelli, D | 2 |
| Kato, M | 4 |
| Kunieda, K | 5 |
| Umemoto, T | 3 |
| Miya, K | 4 |
| Azuma, S | 6 |
| Furuta, T | 6 |
| Koishi, Y | 1 |
| Takeuchi, K | 4 |
| Oguro, A | 2 |
| Hidaka, K | 1 |
| Mashima, H | 1 |
| Katano, M | 3 |
| Kishikawa, T | 1 |
| Hisatsugu, T | 3 |
| Masutani, S | 2 |
| Ohigashi, H | 3 |
| Kameyama, M | 4 |
| Kabuto, T | 4 |
| Ishikawa, O | 3 |
| Takami, M | 2 |
| Kitada, M | 1 |
| Tsukahara, Y | 1 |
| Saito, M | 1 |
| Sakakibara, N | 3 |
| Sugano, H | 1 |
| Miwa, K | 5 |
| Suda, K | 2 |
| Ogata, Y | 6 |
| Kajiyama, Y | 2 |
| Tsurumaru, M | 2 |
| Ono, Y | 3 |
| Udagawa, H | 2 |
| Matsuda, M | 2 |
| Ozawa, I | 1 |
| Hishinuma, S | 2 |
| Kotake, K | 2 |
| Ikeda, T | 3 |
| Seki, T | 2 |
| Sasagawa, M | 2 |
| Tanemura, H | 6 |
| Kuno, T | 1 |
| Dohden, K | 1 |
| Ohmura, K | 2 |
| Ziras, N | 1 |
| Samandas, N | 1 |
| Owen, W | 1 |
| Dussek, J | 1 |
| Barker, S | 1 |
| Inaba, H | 2 |
| Miyata, M | 1 |
| Kido, Y | 6 |
| Atiq, OT | 2 |
| Shiu, MH | 1 |
| Tong, W | 1 |
| Trochanowski, B | 1 |
| Toomasi, F | 1 |
| Tsujimura, T | 1 |
| Kawase, K | 2 |
| Hatanaka, T | 1 |
| Ohara, K | 2 |
| Hobara, R | 1 |
| Okamoto, M | 2 |
| Kornek, G | 1 |
| Schulz, F | 1 |
| Depisch, D | 1 |
| Rosen, H | 1 |
| Kwasny, W | 1 |
| Sebesta, C | 1 |
| Ishida, H | 3 |
| Okabe, M | 1 |
| Gomi, K | 1 |
| Horiuchi, R | 1 |
| Watanabe, H | 4 |
| Miyahara, E | 1 |
| Azuma, T | 1 |
| Ohashi, R | 1 |
| Kirihara, Y | 5 |
| Tanada, M | 3 |
| Soga, H | 2 |
| Schnall, S | 1 |
| Suh, C | 2 |
| Park, KC | 3 |
| Santiago, FF | 1 |
| Petroianu, A | 2 |
| Rocha, PR | 1 |
| Rodrigues, MA | 1 |
| Rausch, M | 1 |
| Kuo, TH | 2 |
| Ota, Y | 1 |
| Shirafuji, T | 1 |
| Adachi, A | 2 |
| Williamson, SK | 1 |
| Tangen, CM | 1 |
| Maddox, AM | 1 |
| Spiridonidis, CH | 1 |
| Giotta, F | 1 |
| Cifarelli, RA | 1 |
| Pezzella, G | 1 |
| Pedicini, A | 1 |
| Valori, V | 1 |
| Leach, SD | 2 |
| Yumoto, Y | 1 |
| Shimizu, S | 2 |
| Groshen, S | 3 |
| Cohen, H | 2 |
| Laine, L | 4 |
| Crookes, P | 3 |
| Baranda, J | 3 |
| Garcia, Y | 1 |
| Yu, QS | 1 |
| Zhang, FZ | 1 |
| Tang, XR | 1 |
| Fleming, TR | 4 |
| Peterson, RF | 1 |
| Berenberg, JL | 2 |
| McClure, S | 1 |
| Chapman, RA | 1 |
| Eyre, HJ | 1 |
| Solanki, D | 1 |
| Cruz, AB | 2 |
| Gagliano, R | 1 |
| Gignoux, M | 2 |
| de Leonardis, V | 1 |
| Romano, S | 2 |
| Pernice, LM | 1 |
| Intini, C | 1 |
| Cini, G | 2 |
| Norum, J | 1 |
| Angelsen, V | 1 |
| Miyake, Y | 4 |
| Kishimoto, S | 1 |
| Inaba, M | 4 |
| Mitsuhashi, J | 1 |
| Miike, N | 1 |
| Naoe, Y | 1 |
| Daimon, A | 1 |
| Koizumi, K | 2 |
| Tsujimoto, H | 1 |
| Pancera, G | 2 |
| Giaccon, G | 1 |
| Signaroldi, A | 1 |
| Legnani, W | 1 |
| Tangen, C | 1 |
| Hutchins, LF | 1 |
| Natale, RB | 1 |
| Guy, JT | 1 |
| Angelini, F | 1 |
| Cavicchi, F | 1 |
| Finardi, C | 1 |
| Kung, SP | 1 |
| Fan, S | 1 |
| Tzeng, CH | 1 |
| Wei, CH | 1 |
| Ahmed, FY | 1 |
| Watson, M | 2 |
| Hill, AS | 1 |
| Nicolson, MC | 1 |
| O'Brien, ME | 1 |
| Evans, TC | 1 |
| Murakami, Y | 1 |
| Shparik, IaV | 1 |
| Karpeh, M | 1 |
| Schwartz, G | 1 |
| Gerdes, H | 1 |
| Lightdale, C | 2 |
| Botet, J | 1 |
| Lauers, G | 1 |
| Quan, V | 1 |
| González Barón, M | 1 |
| Blanco, E | 1 |
| Gómez-Navarro, J | 1 |
| Noutomi, M | 1 |
| Tokuhara, K | 1 |
| Inutsuka, K | 1 |
| Isogai, M | 2 |
| Hori, A | 2 |
| Yamaguchi, R | 2 |
| Maeda, A | 1 |
| Kurimoto, H | 1 |
| Fuku, A | 1 |
| Miyaji, M | 1 |
| Ogoshi, K | 3 |
| Kajiura, Y | 2 |
| Mitomi, T | 2 |
| Horiuchi, H | 1 |
| Sasatomi, T | 1 |
| Nozoe, Y | 1 |
| Hyodo, S | 1 |
| Maeda, K | 3 |
| Sowa, M | 8 |
| Kin, Y | 1 |
| Imaoka, S | 3 |
| Larsson, PA | 1 |
| Carlsson, G | 2 |
| Gustavsson, B | 1 |
| Spears, CP | 4 |
| Osawa, S | 1 |
| Shiroto, H | 2 |
| Miyakawa, K | 1 |
| Oku, T | 1 |
| Nishimura, A | 2 |
| Asanuma, F | 1 |
| Kawamura, E | 3 |
| Xiao, S | 1 |
| Del Ferro, E | 2 |
| Hoshino, K | 1 |
| Unate, H | 1 |
| Nitta, K | 1 |
| Gleissner, B | 1 |
| Hilgenfeld, RU | 1 |
| Thiel, E | 1 |
| Kreuser, ED | 1 |
| Vinnik, IuA | 1 |
| Gorbunov, GF | 1 |
| Fockens, P | 1 |
| Tsavaris, NB | 1 |
| Tentas, K | 1 |
| Mylonakis, N | 1 |
| Sakelaropoulos, N | 1 |
| Kosmas, C | 1 |
| Lisaios, B | 1 |
| Soumilas, A | 1 |
| Mandrekois, D | 1 |
| Tsetis, A | 1 |
| Klonaris, C | 1 |
| Takeshita, K | 1 |
| Saito, N | 1 |
| Kok, TC | 1 |
| Splinter, TA | 1 |
| Sakai, H | 1 |
| Windsor, AC | 1 |
| Somers, SS | 1 |
| Crellin, A | 1 |
| Hassan, S | 1 |
| Macadam, R | 1 |
| Sadek, SA | 1 |
| Guillou, PJ | 1 |
| Gonda, T | 1 |
| Hojo, I | 1 |
| Fukunari, H | 1 |
| Tomikawa, M | 1 |
| Au, E | 1 |
| Tan, EH | 1 |
| Ang, PT | 1 |
| Kanai, F | 2 |
| Shiratori, Y | 2 |
| Okabe, S | 2 |
| Wakimoto, H | 1 |
| Omata, M | 2 |
| Kostandy, G | 1 |
| Katapadi, M | 1 |
| Pullarkat, V | 1 |
| Manzi, G | 1 |
| Salama, S | 1 |
| Sosler, B | 1 |
| Hussain, KM | 1 |
| Rubin, J | 4 |
| Gallagher, JG | 1 |
| Schroeder, G | 3 |
| Dalton, RJ | 2 |
| Kugler, JW | 5 |
| Morton, RF | 1 |
| Burch, PA | 3 |
| Melcher, AA | 1 |
| Mort, D | 1 |
| Maughan, TS | 1 |
| Suga, M | 1 |
| Otani, J | 1 |
| Morisue, S | 1 |
| Yoshizane, K | 1 |
| Astre, C | 1 |
| Domergue, J | 1 |
| Ribard, D | 1 |
| Ciurana, AJ | 1 |
| Janbon, C | 1 |
| Pujol, H | 1 |
| Saeki, T | 6 |
| Muto, A | 1 |
| Ashino, Y | 1 |
| Kanno, A | 2 |
| Hiraga, M | 1 |
| Sugamura, K | 1 |
| Makino, M | 1 |
| Shirai, H | 1 |
| Kimura, O | 1 |
| Maeta, M | 6 |
| Joffe, JK | 2 |
| Hughes, M | 1 |
| Wardley, A | 1 |
| Meehan, M | 1 |
| Noda, N | 2 |
| Tanase, M | 1 |
| Shino, Y | 2 |
| Yamashita, J | 1 |
| Deeb, LS | 1 |
| Yamout, BI | 1 |
| Shamseddine, AI | 1 |
| Shabb, NS | 1 |
| Uthman, SM | 1 |
| Yasuda, C | 1 |
| Kuroda, D | 1 |
| Katsumata, K | 3 |
| Ohno, M | 3 |
| Shibata, K | 1 |
| Moriwaki, R | 1 |
| Kohno, M | 1 |
| Tadatomo, H | 1 |
| Koyanagi, Y | 5 |
| Kinoshita, Y | 1 |
| Kobayashi, F | 1 |
| Yamanouchi, T | 1 |
| Adachi, I | 2 |
| Fujimaki, M | 2 |
| Horikoshi, I | 1 |
| Ekström, K | 1 |
| Hoffman, K | 1 |
| Graf, W | 1 |
| Sjödén, PO | 1 |
| Haglund, U | 1 |
| Svensson, C | 1 |
| Enander, LK | 1 |
| Linné, T | 1 |
| Sellström, H | 1 |
| Heuman, R | 1 |
| Swaminathan, R | 1 |
| Santala, RG | 1 |
| Pitot, HC | 1 |
| Garton, GR | 1 |
| Yoshinaga, K | 1 |
| Mizutani, H | 1 |
| Stain, S | 2 |
| Casagrande, Y | 1 |
| Martino, RL | 1 |
| Morrell, LM | 1 |
| Ardalan, B | 1 |
| Richman, SP | 1 |
| Vaughn, DJ | 1 |
| Meropol, NJ | 2 |
| Holroyde, C | 1 |
| Mintzer, D | 1 |
| Nuamah, I | 1 |
| Armstead, B | 1 |
| Saitoh, S | 4 |
| Hizawa, Y | 1 |
| Munakata, A | 4 |
| Lampe, CS | 2 |
| Forkmann, L | 2 |
| Lin, P | 1 |
| Ichikawa, A | 2 |
| Sasaki, K | 4 |
| Denno, R | 2 |
| Oikawa, I | 2 |
| Mukaiya, M | 2 |
| Hiraike, N | 1 |
| Yagihashi, A | 1 |
| Takasaka, H | 1 |
| Katsuramaki, T | 1 |
| Yamashiro, K | 1 |
| Saito, A | 2 |
| Fukuzawa, K | 1 |
| Nagano, A | 1 |
| Amano, T | 3 |
| Korn, M | 1 |
| Vanhöfer, U | 2 |
| Preusser, P | 6 |
| Köhne, C | 1 |
| Klassen, U | 1 |
| Loeffler, TM | 1 |
| Hausamen, TU | 1 |
| Wada, G | 1 |
| Yamasaki, T | 1 |
| Okudaira, T | 1 |
| You, NC | 1 |
| Iwamoto, S | 4 |
| Kimoto, M | 3 |
| Mure, T | 2 |
| Imai, H | 1 |
| Fujimori, Y | 1 |
| Onuma, E | 2 |
| Iki, K | 2 |
| Tadaoka, Y | 2 |
| Kubozoe, T | 2 |
| Takeo, T | 1 |
| Kawasaki, T | 1 |
| Morimoto, O | 1 |
| Shiozaki, K | 1 |
| Baba, S | 1 |
| Miya, A | 1 |
| Tamamura, H | 1 |
| Ooguchi, M | 1 |
| Hashimoto, M | 1 |
| Tomita, I | 1 |
| Kon, H | 1 |
| Sasaki, R | 1 |
| Kawata, S | 3 |
| Hino, K | 1 |
| Masuyama, K | 1 |
| Saitoh, T | 1 |
| Miki, H | 2 |
| Noguchi, S | 1 |
| Kanayama, T | 1 |
| Tazaki, N | 1 |
| Kida, T | 1 |
| Safi, MA | 1 |
| Cellerino, R | 2 |
| Miyasaka, Y | 1 |
| Yo, S | 1 |
| Nagayama, K | 1 |
| Fukasaku, T | 1 |
| Sakuma, I | 1 |
| Sazaki, N | 1 |
| Rowinsky, EK | 1 |
| Kitaura, K | 1 |
| Choi, JS | 2 |
| Ahn, MJ | 1 |
| Suh, CW | 1 |
| Kim, WG | 1 |
| Kim, JC | 1 |
| Kim, SK | 2 |
| Salonga, D | 1 |
| Konda, B | 1 |
| Sasahara, K | 1 |
| Kamei, M | 1 |
| Matsuda, K | 1 |
| Nishioka, M | 1 |
| Teruya, M | 3 |
| Itoh, A | 1 |
| Asakura, R | 2 |
| Araki, S | 2 |
| Hojo, K | 1 |
| Nouchi, T | 2 |
| Majima, T | 2 |
| Kajihara, K | 1 |
| Akama, F | 1 |
| Shigeta, K | 1 |
| Sano, I | 1 |
| Iwasaki, K | 1 |
| Kobayashi, I | 1 |
| Yokomori, T | 4 |
| Iesato, H | 4 |
| Ouya, T | 1 |
| Ohwada, S | 3 |
| Imai, S | 7 |
| Kasahara, M | 1 |
| Corsi, DC | 1 |
| Fontana, T | 1 |
| Noviello, MR | 1 |
| Landriscina, M | 1 |
| Colloca, G | 1 |
| Kajimoto, N | 1 |
| Yamaizumi, J | 1 |
| Aida, M | 1 |
| Maeda, M | 2 |
| Ueshige, N | 2 |
| Kawamura, H | 2 |
| Takiyama, I | 2 |
| Sato, N | 2 |
| Yoshinari, H | 2 |
| Koike, N | 1 |
| Kawashima, K | 1 |
| Takeyoshi, I | 2 |
| Kamiyama, H | 1 |
| Hosokawa, K | 1 |
| Saito, D | 3 |
| Hasebe, T | 1 |
| Mukai, K | 1 |
| Cardarelli, N | 1 |
| Marcellini, M | 1 |
| Otani, T | 1 |
| Yasutomi, M | 2 |
| Okuno, M | 1 |
| Chung, KH | 2 |
| Chi, KH | 3 |
| Chan, WK | 1 |
| Yen, SH | 2 |
| Chen, KY | 1 |
| Lui, WY | 2 |
| Iba, T | 1 |
| Kidokoro, A | 1 |
| Ishi, K | 1 |
| Koyatsu, J | 1 |
| Sumi, S | 1 |
| Kidouchi, K | 1 |
| Fukui, T | 2 |
| Ogawa, Y | 2 |
| Yanagawa, K | 1 |
| Nagao, N | 1 |
| Takagi, Y | 2 |
| Kawaguchi, Y | 1 |
| Fukada, D | 1 |
| Sasaki, J | 5 |
| Sano, M | 2 |
| Tsutsui, M | 2 |
| Makino, H | 2 |
| Kirihara, M | 1 |
| Kawai, S | 1 |
| Ichikawa, T | 1 |
| Kume, S | 2 |
| Araya, M | 2 |
| Nishizuka, S | 1 |
| Hirao, T | 1 |
| Kikuyama, S | 1 |
| Miyakita, M | 1 |
| Tung, SL | 1 |
| Wang, WS | 1 |
| Yen, CC | 1 |
| Fan, FS | 1 |
| Andreyev, HJ | 1 |
| Markman, M | 1 |
| Hamajima, N | 1 |
| Takasaki, M | 3 |
| Takamatsu, M | 1 |
| Horimi, T | 3 |
| Shimoda, K | 2 |
| Shiraishi, N | 1 |
| Kitano, S | 1 |
| Hsueh, CT | 1 |
| Kuniyasu, T | 1 |
| Tabuchi, Y | 1 |
| Lozac'h, P | 1 |
| Topart, P | 1 |
| Volant, A | 1 |
| Gonzales, A | 1 |
| Formento, JL | 1 |
| Milano, G | 1 |
| Rustum, Y | 1 |
| Lacava, JA | 1 |
| Dominguez, ME | 1 |
| Barbieri, MR | 1 |
| Ortiz, EH | 1 |
| Romero Acuña, LA | 1 |
| Langhi, MJ | 1 |
| Romero Acuña, JM | 1 |
| Vallejo, CT | 1 |
| Machiavelli, MR | 1 |
| Romero, AO | 1 |
| Yunoki T Miwa, K | 1 |
| Iwakuma, N | 1 |
| Maekawa, Y | 1 |
| Kinugasa, T | 1 |
| Fukano, S | 1 |
| Sekimoto, K | 1 |
| Murano, A | 1 |
| Kitamura, K | 1 |
| Misaka, T | 1 |
| Murohashi, T | 2 |
| Sumi, T | 2 |
| Ashizawa, T | 2 |
| Whang, I | 1 |
| Averbach, A | 1 |
| Chang, D | 1 |
| Staccioli, MP | 1 |
| Ligi, M | 1 |
| Carnevali, A | 1 |
| Muretto, P | 1 |
| Sasano, N | 1 |
| Demura, H | 1 |
| Sasano, H | 2 |
| Park, HC | 1 |
| Choi, YM | 1 |
| Kondo, S | 1 |
| Kanayama, S | 1 |
| Higashimoto, Y | 1 |
| Kiyohara, T | 1 |
| Zushi, S | 1 |
| Ueyama, H | 1 |
| Matsuzawa, Y | 1 |
| Kornek, GV | 1 |
| Hejna, MH | 1 |
| Miholic, J | 1 |
| Weinlaender, G | 1 |
| Brodowicz, T | 1 |
| Fiebiger, WC | 1 |
| Valencak, JB | 1 |
| Cripps, C | 1 |
| Goel, R | 1 |
| Fine, S | 1 |
| Oza, AM | 1 |
| Skillings, JR | 1 |
| Kerr, I | 1 |
| Germond, CJ | 1 |
| Moore, MJ | 1 |
| Maroun, JA | 1 |
| Franssen, E | 1 |
| Dulude, H | 1 |
| Uner, A | 1 |
| Firat, D | 1 |
| Aziz, SA | 1 |
| Tramboo, NA | 1 |
| Mohi-ud-Din, K | 1 |
| Iqbal, K | 1 |
| Jalal, S | 1 |
| Ahmad, M | 1 |
| Hudes, GR | 1 |
| Lipsitz, S | 1 |
| Grem, J | 1 |
| Morrisey, M | 1 |
| Weiner, L | 1 |
| Benson, A | 1 |
| Rhyu, HS | 1 |
| Hyun, JH | 1 |
| Shinkai, K | 1 |
| Hisano, H | 1 |
| Shibasaki, S | 1 |
| Adamo, V | 1 |
| Scimone, A | 1 |
| Altavilla, G | 1 |
| Ferraro, G | 1 |
| Laudani, A | 1 |
| Pergolizzi, S | 1 |
| Zanghì, M | 1 |
| Noie, T | 1 |
| Agawa, S | 1 |
| Furushima, K | 1 |
| Mafune, K | 4 |
| Okamura, K | 1 |
| Tanabe, D | 1 |
| Sakaguchi, T | 1 |
| Nagamoto, N | 1 |
| Watson, SA | 1 |
| Grimes, S | 1 |
| Morris, TM | 1 |
| Varro, A | 1 |
| Clarke, PA | 1 |
| Smith, AM | 1 |
| Justin, TA | 1 |
| Hardcastle, JD | 1 |
| Iwatani, Y | 2 |
| Kamigaki, T | 3 |
| Auriemma, A | 1 |
| Taniguchi, K | 2 |
| Michiwa, Y | 1 |
| Lin, ZT | 1 |
| Harte, RJ | 1 |
| Matthews, JC | 1 |
| O'Reilly, SM | 1 |
| Tilsley, DW | 1 |
| Osman, S | 1 |
| Luthra, SJ | 1 |
| Brady, F | 1 |
| Jones, T | 1 |
| Price, PM | 1 |
| Shirin, H | 1 |
| Sordillo, EM | 1 |
| Oh, SH | 1 |
| Delohery, T | 1 |
| Weinstein, IB | 1 |
| Moss, SF | 1 |
| Partyka, S | 1 |
| Dumas, P | 2 |
| Sadata, A | 1 |
| Baek, HJ | 1 |
| Kim, YC | 1 |
| Shim, YM | 1 |
| Kim, CM | 2 |
| Zo, JI | 1 |
| Borsellino, N | 1 |
| Lelli, G | 1 |
| Fortunato, S | 1 |
| Liu, HE | 2 |
| Yang, TS | 2 |
| Wang, HM | 2 |
| Hanaoka, K | 1 |
| Tanzawa, F | 1 |
| Shibayama, T | 1 |
| Iwabuchi, H | 1 |
| Nakagawa, A | 1 |
| Hisaoka, M | 1 |
| Kaneko, M | 2 |
| Tomida, A | 1 |
| Wataya, Y | 1 |
| Matsuda, A | 1 |
| Tsuruo, T | 1 |
| Kurakata, S | 1 |
| Takimoto, CH | 1 |
| Yee, LK | 1 |
| Venzon, DJ | 1 |
| Schuler, B | 1 |
| Grollman, F | 1 |
| Chabuk, C | 1 |
| Hamilton, JM | 1 |
| Chen, AP | 1 |
| Mackean, M | 1 |
| Leahy, M | 1 |
| Ohnuma, S | 1 |
| Takenami, K | 1 |
| Kitoh, Y | 1 |
| Kobayashi, E | 2 |
| Okabe, R | 2 |
| Fujimura, A | 1 |
| Kanazawa, K | 1 |
| Ping, B | 1 |
| Keizer, HJ | 1 |
| Hermans, J | 1 |
| Klementschitsch, P | 1 |
| Oka, S | 3 |
| Kondo, A | 1 |
| Keppen, MD | 1 |
| Gerstner, JB | 1 |
| Jancewicz, MT | 1 |
| Ebbert, LP | 1 |
| Murakami, S | 3 |
| Ohi, Y | 1 |
| Kumada, T | 1 |
| Takayasu, Y | 1 |
| Kato, C | 1 |
| Sakumoto, H | 1 |
| Sumiyoshi, K | 1 |
| Takahahsi, T | 1 |
| Kane, T | 1 |
| Sakoda, M | 1 |
| Hosono, Y | 1 |
| Asano, M | 1 |
| Yamamoto, A | 1 |
| Yamazaki, T | 1 |
| Kasuya, K | 1 |
| Kure, N | 4 |
| Shimooki, O | 1 |
| Inaba, T | 1 |
| Takata, N | 1 |
| Yoshinaka, I | 1 |
| Ohara, E | 1 |
| Kawashima, N | 1 |
| Damle, S | 1 |
| Schechner, R | 1 |
| Berkenblit, R | 1 |
| Ladner, RD | 1 |
| Murgo, A | 1 |
| Evans, DB | 1 |
| Raijman, I | 2 |
| Hargraves, K | 1 |
| Curley, S | 1 |
| Ota, DM | 2 |
| Chollet, P | 4 |
| Ganser, A | 1 |
| Wiese, KH | 1 |
| Rambusch, E | 1 |
| de Vries, MJ | 1 |
| Hanauske, A | 1 |
| Anderson, SH | 1 |
| Hudson-Peacock, M | 1 |
| Muller, AF | 1 |
| Kamoshita, N | 2 |
| Nagaoka, H | 2 |
| Okabe, T | 2 |
| Abe, A | 1 |
| Inada, K | 1 |
| Tsukamoto, T | 1 |
| Yasui, K | 2 |
| Tatematsu, M | 1 |
| Ninomiya, Y | 1 |
| Yanagisawa, A | 1 |
| Guimaraes, RC | 1 |
| Aragao, BC | 1 |
| Cabral, LO | 1 |
| Scalabrini-Neto, AO | 1 |
| Peracchia, A | 1 |
| Bonavina, L | 1 |
| Via, A | 1 |
| Incarbone, R | 1 |
| Ohi, R | 1 |
| Shineha, R | 1 |
| Shibuya, D | 1 |
| Shioya, T | 1 |
| Kuwashima, Y | 1 |
| Nakao, K | 1 |
| Itoh, R | 1 |
| Yamamura, T | 1 |
| Presant, CA | 1 |
| Wolf, W | 1 |
| Waluch, V | 1 |
| Wiseman, CL | 1 |
| Weitz, I | 1 |
| Shani, J | 1 |
| Turker, A | 1 |
| Güler, N | 1 |
| Nagashima, K | 1 |
| Kai, S | 1 |
| Kazami, A | 1 |
| Handa, T | 1 |
| Takemoto, N | 1 |
| Minatoya, T | 1 |
| Ajisaka, H | 1 |
| Suzuki, Y | 2 |
| Sinmaru, H | 1 |
| Takeda, N | 2 |
| Nagawa, H | 1 |
| Wakasugi, J | 1 |
| Takao, T | 1 |
| Nose, Y | 1 |
| Yanagida, T | 1 |
| Yamanaka, N | 2 |
| Morisaki, T | 1 |
| Uchiyama, A | 1 |
| Kuroiwa, T | 1 |
| Chijiiwa, K | 1 |
| Sekikawa, K | 2 |
| Ishihata, R | 2 |
| Saitoh, N | 1 |
| Aki, Z | 1 |
| Kotiloğlu, G | 1 |
| Takii, Y | 1 |
| Teng, HC | 1 |
| Hung, HC | 1 |
| King, KL | 1 |
| Chang, FY | 1 |
| Tachikawa, D | 1 |
| Kawahara, K | 1 |
| Ohya, T | 2 |
| Unno, J | 1 |
| Shirozaki, T | 1 |
| Arai, S | 1 |
| Okuyama, H | 1 |
| Hayashida, N | 1 |
| Kouda, S | 1 |
| Tadokoro, M | 1 |
| Ishikou, T | 1 |
| Touda, J | 1 |
| Kajiwara, M | 1 |
| Miyazaki, O | 1 |
| Nosaka, S | 1 |
| Iida, S | 1 |
| Imanishi, Y | 1 |
| Enomoto, T | 1 |
| Ihara, A | 1 |
| Tanaka, I | 1 |
| Hagiwara, M | 1 |
| Seto, Y | 2 |
| Takenoue, T | 1 |
| Nariko, H | 1 |
| De Vivo, R | 1 |
| Pignata, S | 1 |
| Palaia, R | 1 |
| Parisi, V | 1 |
| Westermann, AM | 1 |
| Swart, M | 1 |
| Craanen, M | 1 |
| Gerritsen, WR | 1 |
| Ducreux, MP | 1 |
| Lacave, AJ | 1 |
| Planker, M | 1 |
| Santos, JG | 1 |
| Piedbois, P | 1 |
| Bodenstein, H | 1 |
| Hohenberger, P | 1 |
| Benter, T | 1 |
| Köhne, CH | 2 |
| Tseng, HS | 1 |
| Shen, KH | 1 |
| Hsieh, MC | 1 |
| Kin, R | 1 |
| Nishimoto, N | 3 |
| Kagawa, Y | 1 |
| Yano, Y | 1 |
| Kamata, T | 2 |
| Morita, A | 1 |
| Nakamoto, A | 1 |
| Onishi, I | 1 |
| Takeda, T | 1 |
| Koyasaki, N | 2 |
| Shinkawa, H | 1 |
| Yasuhara, H | 1 |
| Nojiri, T | 1 |
| Okazaki, K | 1 |
| Murashima, N | 1 |
| Gotoh, K | 1 |
| Matsuno, T | 1 |
| Fabian, A | 1 |
| Arima, M | 1 |
| Hori, S | 1 |
| Takeda, A | 1 |
| Yanagawa, T | 1 |
| Sen, K | 1 |
| Tokuda, C | 1 |
| Miyama, Y | 1 |
| Geh, JI | 1 |
| Kwok, QS | 1 |
| Banerji, U | 1 |
| Livingstone, JI | 1 |
| Townsend, ER | 1 |
| Harrison, RA | 1 |
| Mitchell, IC | 1 |
| Hori, K | 1 |
| Tanda, S | 1 |
| Haag, C | 2 |
| Lingenfelser, T | 1 |
| Schroeder, M | 2 |
| Baronius, W | 2 |
| Hempel, V | 2 |
| Terasaki, Y | 2 |
| Yamasaki, Y | 2 |
| Gomyo, Y | 1 |
| Hirooka, Y | 2 |
| Mizutani, S | 1 |
| Fukutomi, K | 1 |
| Chung, YM | 1 |
| Yoo, YD | 1 |
| Weese, JL | 1 |
| Harbison, SP | 1 |
| Stiller, GD | 1 |
| Henry, DH | 1 |
| Fisher, SA | 1 |
| Tokunaga, Y | 1 |
| Kitaoka, A | 1 |
| Yagi, T | 1 |
| Tokuka, A | 1 |
| Ohsumi, K | 1 |
| Kawai, Y | 2 |
| Taki, Y | 1 |
| Yeh, SH | 1 |
| Wang, TM | 1 |
| Ma, IF | 1 |
| Ross, PJ | 1 |
| Eguchi, T | 4 |
| Tsuneda, Y | 2 |
| Tamamori, Y | 2 |
| Toukairin, Y | 2 |
| Okazumi, S | 1 |
| Washizawa, N | 1 |
| Tokura, N | 1 |
| Kase, H | 1 |
| Hirano, K | 1 |
| Masudo, K | 1 |
| Doi, C | 1 |
| Takanashi, Y | 2 |
| Lewis, NL | 1 |
| Yoo, CH | 1 |
| Shin, DW | 1 |
| Lim, H | 1 |
| Nam, DK | 1 |
| Yi, JW | 2 |
| Kim, HC | 2 |
| Kim, MW | 3 |
| Joo, HJ | 2 |
| Kim, KB | 1 |
| Romano, C | 1 |
| Maeba, T | 1 |
| Mihara, T | 1 |
| Ohkawa, M | 1 |
| Senda, S | 1 |
| Kamiya, N | 1 |
| Asano, S | 1 |
| Shinya, F | 1 |
| Berner, J | 1 |
| Tenderenda, M | 1 |
| Pasz, S | 1 |
| Berner, A | 1 |
| Piekarski, J | 1 |
| Kołodziejczyk, P | 1 |
| Dempke, W | 1 |
| von Poblozki, A | 1 |
| Kellner, O | 1 |
| Wolf, HH | 1 |
| Gerhardt, P | 1 |
| Hisamatsu, T | 1 |
| Aoyagi, S | 1 |
| Motohashi, Y | 1 |
| Ikezawa, T | 1 |
| Tatsuno, S | 1 |
| Nishida, J | 1 |
| Scieszka, M | 1 |
| Zielinski, M | 1 |
| Machalski, M | 2 |
| Herman, ZS | 1 |
| Niiya, F | 1 |
| Ikeda, S | 1 |
| Nagata, S | 1 |
| Raina, V | 1 |
| Gujral, S | 1 |
| Boffi, B | 1 |
| Francesconi, D | 1 |
| Mazzanti, R | 1 |
| Mercatelli, A | 1 |
| Siliani, L | 1 |
| Tarquini, R | 1 |
| Moretti, R | 1 |
| Karapetis, CS | 1 |
| Sekikawa, T | 2 |
| Tsukui, H | 1 |
| Kina, S | 1 |
| Kawahara, T | 1 |
| Kishida, Y | 1 |
| Yakumaru, K | 1 |
| Kamiya, K | 1 |
| Baba, M | 1 |
| Oota, M | 2 |
| Shouji, T | 1 |
| Igarashi, A | 1 |
| Baeza, MR | 1 |
| Giannini T, O | 1 |
| Rivera S, R | 1 |
| González, J | 1 |
| Vergara, E | 1 |
| del Castillo, C | 1 |
| Vinés, E | 1 |
| Hayashi, C | 1 |
| Yamamoto, W | 1 |
| Takebuchi, K | 1 |
| Hiratsuka, N | 1 |
| Tadokoro, K | 1 |
| Ushio, J | 1 |
| Kageyama, T | 1 |
| Toizumi, A | 1 |
| Anzai, K | 1 |
| Kimijima, I | 1 |
| Takenoshita, S | 1 |
| Hino, M | 1 |
| Feig, BW | 1 |
| Komaki, R | 1 |
| Nesbitt, J | 1 |
| Vaporciyan, A | 1 |
| Smythe, R | 1 |
| Lahoti, S | 1 |
| Swisher, S | 1 |
| Martin, FD | 1 |
| Xin, M | 1 |
| Schwabe, W | 1 |
| Häusler, P | 1 |
| Van Kuilenburg, AB | 1 |
| Van Gennip, AH | 1 |
| Behnke, D | 1 |
| Ishii, R | 1 |
| Okada, S | 1 |
| Shinkai, T | 1 |
| Kammori, M | 1 |
| Haniuda, N | 1 |
| Takubo, K | 2 |
| Endo, H | 1 |
| Gay, F | 1 |
| Forget, F | 1 |
| Habara, K | 1 |
| Ajiki, T | 1 |
| Uehara, S | 1 |
| Murabayashi, K | 1 |
| Kusta, T | 1 |
| Onishi, H | 1 |
| Saegusa, S | 1 |
| Okanami, Y | 1 |
| Nakamura, I | 1 |
| Tsukioka, Y | 1 |
| Jia, J | 1 |
| Bae, HS | 1 |
| Hasegawa, M | 1 |
| Tamagaki, S | 1 |
| Yasue, A | 1 |
| Matsushita, M | 1 |
| Hosoki, T | 1 |
| Sai, H | 1 |
| Mitomo, M | 1 |
| Nishihara, T | 1 |
| Varvarigos, N | 1 |
| Kamaradou, H | 1 |
| Kourti, A | 1 |
| Papavasiliou, ED | 1 |
| Papaioannou, H | 1 |
| Migdalis, IN | 1 |
| Galanis, C | 1 |
| Kolodziejcyk, P | 1 |
| Zotter, H | 1 |
| Schwinger, W | 1 |
| Kerbl, R | 1 |
| Urban, C | 1 |
| Smolle Juettner, FM | 1 |
| Hinterleitner, T | 1 |
| Xiong, X | 1 |
| Wang, A | 1 |
| Moritani, M | 1 |
| Shinohara, M | 1 |
| Niido, T | 1 |
| Duffaud, F | 1 |
| Ville, E | 1 |
| Laugier, R | 1 |
| Kimura, J | 1 |
| Kanazumi, N | 1 |
| Ishii, M | 1 |
| Dhar, DK | 1 |
| Yamanoi, A | 2 |
| Ono, T | 1 |
| Yashimura, H | 1 |
| Tachibana, M | 1 |
| Kohno, H | 2 |
| Nagasue, N | 2 |
| Ye, SH | 1 |
| Benson, AB | 1 |
| Rothenberg, ML | 1 |
| Berlin, J | 1 |
| Hsieh, YC | 1 |
| Miller, LL | 1 |
| Manziuk, LV | 1 |
| Artamonova, EV | 1 |
| Sholokhov, VN | 1 |
| Strygina, EA | 1 |
| Konishi, M | 1 |
| Nakagouri, T | 1 |
| Sugitou, M | 1 |
| Mera, K | 1 |
| Madisch, A | 1 |
| Wiedbrauck, F | 1 |
| Marquard, F | 1 |
| Stolte, M | 1 |
| Hotz, J | 1 |
| Shan, H | 1 |
| Lim, KC | 1 |
| Dunlop, DJ | 1 |
| Shimoda, S | 1 |
| Koyama, S | 1 |
| Tsukahara, A | 1 |
| Gomi, T | 1 |
| Ohtoshi, M | 1 |
| Tamaki, N | 1 |
| Momoi, H | 1 |
| Kanaya, S | 1 |
| Katayama, T | 1 |
| Taniwaki, M | 2 |
| Tomikashi, K | 1 |
| Takada, R | 1 |
| Nakao, M | 1 |
| Wakabayashi, N | 1 |
| Mitsufuji, S | 1 |
| Horiike, S | 2 |
| Kashima, K | 1 |
| Curti, C | 1 |
| Liaul, CT | 1 |
| Basaki, Y | 1 |
| Chikahisa, L | 1 |
| Yonekura, K | 1 |
| Hashimoto, A | 1 |
| Wierzba, K | 1 |
| Feng, WH | 1 |
| Israel, B | 1 |
| Raab-Traub, N | 1 |
| Busson, P | 1 |
| Kenney, SC | 1 |
| Melchart, D | 1 |
| Clemm, C | 1 |
| Weber, B | 1 |
| Draczynski, T | 1 |
| Worku, F | 1 |
| Linde, K | 1 |
| Weidenhammer, W | 1 |
| Wagner, H | 1 |
| Saller, R | 1 |
| Ross, P | 1 |
| Valle, J | 1 |
| Price, T | 1 |
| Anderson, H | 2 |
| Adamek, HE | 1 |
| Takemura, N | 2 |
| Osaka, Y | 2 |
| Sako, H | 2 |
| Ioka, Z | 2 |
| Nakane, Y | 2 |
| Matsumura, A | 1 |
| Shiozawa, M | 1 |
| Schulze-Bergkamen, H | 1 |
| Zuna, I | 1 |
| Teufel, A | 1 |
| Misawa, K | 1 |
| Sano, H | 1 |
| Naka, M | 1 |
| Okawa, Y | 1 |
| Yoneyama, S | 1 |
| Takada, A | 1 |
| Yanagida, O | 1 |
| Itou, A | 1 |
| Naganuma, J | 1 |
| Morikawa, A | 1 |
| Miyazawa, K | 1 |
| Ozaki, K | 1 |
| Honecker, F | 1 |
| Spott, C | 1 |
| Ferrari, L | 1 |
| Procopio, G | 1 |
| Catena, L | 1 |
| Celio, L | 1 |
| Vitali, M | 1 |
| Beretta, E | 1 |
| Seregni, E | 1 |
| Bombardieri, E | 1 |
| Kono, K | 2 |
| Ichihara, F | 1 |
| Amemiya, H | 1 |
| Iizuka, H | 1 |
| Lim, DY | 1 |
| Kwon, OS | 1 |
| Choi, DJ | 1 |
| Lee, TH | 1 |
| Takemura, M | 1 |
| Ohta, Y | 1 |
| Shuto, T | 1 |
| Takemura, S | 1 |
| Dent, RG | 1 |
| McColl, I | 1 |
| Abrão, A | 2 |
| Cappellano, RS | 2 |
| Possik, RA | 2 |
| Mayr, AC | 1 |
| Zeitoun, P | 1 |
| Nasca, S | 1 |
| Murphy, GP | 1 |
| Hartmann, M | 1 |
| Körner, F | 1 |
| Dent, DM | 1 |
| Werner, ID | 1 |
| Novis, B | 1 |
| Cheverton, P | 1 |
| Brice, P | 1 |
| Goffin, JC | 2 |
| Engstrom, P | 2 |
| Gelber, RD | 1 |
| Carbone, PP | 1 |
| Mabuchi, A | 1 |
| Osawa, N | 2 |
| Yagi, A | 2 |
| Kita, R | 1 |
| Sumida, T | 1 |
| Kasagawa, O | 1 |
| Zollinger, RM | 1 |
| Martin, EW | 1 |
| Carey, LC | 1 |
| Sparks, J | 1 |
| Minton, JP | 1 |
| Shimosato, Y | 1 |
| Merkle, P | 1 |
| Stephens, FO | 1 |
| Harker, GJ | 1 |
| Dickinson, RT | 1 |
| Roberts, BA | 1 |
| Akao, T | 3 |
| Itoh, B | 2 |
| Koshizuka, I | 1 |
| Koyano, K | 1 |
| Lipatov, AM | 1 |
| Karam, M | 1 |
| Borisov, VI | 2 |
| Shkarenkov, VA | 1 |
| Buracheskaia, NV | 1 |
| Heal, JM | 1 |
| Sawai, K | 1 |
| Sonoda, Y | 1 |
| Ohkuma, S | 1 |
| Misawa, S | 2 |
| Kingston, RD | 2 |
| Ellis, DJ | 2 |
| Powell, J | 1 |
| Hurst, MD | 1 |
| Smith, JA | 1 |
| Korman, DB | 4 |
| Honda, H | 1 |
| Speirs, C | 1 |
| Leonard, J | 1 |
| Dykes, PW | 1 |
| Bunn, PA | 1 |
| Nugent, JL | 1 |
| Ihde, DC | 1 |
| Cohen, MH | 1 |
| Eddy, JL | 1 |
| Minna, JD | 1 |
| Voznyĭ, EK | 3 |
| Perevodchikova, NI | 1 |
| Babaian, LA | 1 |
| Vaarik, KhM | 1 |
| Koh, T | 1 |
| Nakano, A | 1 |
| Oride, M | 1 |
| Schaefer, J | 1 |
| Drings, P | 1 |
| Geldmacher, J | 1 |
| Hartwich, G | 1 |
| Kredel, L | 1 |
| Mayer, M | 1 |
| Neidhardt, B | 1 |
| von Oldershausen, HF | 1 |
| Rösch, W | 1 |
| Wahrendorf, J | 1 |
| Rosenoff, S | 1 |
| Buroker, T | 1 |
| Kim, PN | 1 |
| Groppe, C | 1 |
| McCracken, J | 1 |
| O'Bryan, R | 1 |
| Panettiere, F | 1 |
| Costanzi, J | 1 |
| Bottomley, R | 1 |
| King, GW | 1 |
| Bonnet, J | 1 |
| Thigpen, T | 1 |
| Whitecar, J | 1 |
| Vaitkevicius, VK | 1 |
| Hoogstraten, B | 1 |
| Heilbrun, L | 1 |
| Rake, MO | 1 |
| Mallinson, CN | 1 |
| Cocking, JB | 1 |
| Cwynarski, MT | 1 |
| Fox, CA | 1 |
| Wass, VJ | 1 |
| Diffey, BL | 1 |
| Jackson, GA | 1 |
| Comis, RL | 2 |
| Benjamin, RS | 1 |
| Solomon, A | 1 |
| Sekimoto, T | 1 |
| Hartman, HA | 1 |
| Kessinger, A | 1 |
| Lemon, HM | 1 |
| Foley, JF | 3 |
| Scanni, A | 1 |
| Tomirotti, M | 1 |
| Licciardello, L | 1 |
| Annibali, E | 1 |
| Biraghi, M | 1 |
| Trovato, M | 1 |
| Fittipaldi, M | 1 |
| Adamoli, P | 1 |
| Curtarelli, G | 1 |
| Brutti, A | 1 |
| Liberati, AM | 1 |
| Fatati, G | 1 |
| Sini, S | 1 |
| Barzi, AM | 1 |
| Grignani, F | 1 |
| Minami, T | 1 |
| Ishigami, H | 1 |
| Grinevich, IuA | 2 |
| Alferov, AN | 1 |
| Sen'ko, LN | 1 |
| Marcuello Gaspar, E | 1 |
| Germa Lluch, JR | 1 |
| Abad Esteve, A | 1 |
| Badia Canto, A | 1 |
| Diatchin, IuA | 1 |
| Levi, JA | 2 |
| Dalley, DN | 1 |
| Aroney, RS | 1 |
| Tomomatsu, H | 1 |
| Morita, N | 1 |
| Nagai, T | 1 |
| Shiwaku, Y | 1 |
| Shingami, T | 1 |
| Nakao, Y | 1 |
| Shimokawahara, H | 1 |
| Hashimoto, S | 1 |
| Yunoki, K | 1 |
| Himori, T | 1 |
| Harada, T | 2 |
| Ikeda, H | 1 |
| Nakao, E | 2 |
| Morisawa, K | 1 |
| Hartmann, D | 1 |
| Yamaya, F | 1 |
| Yarita, T | 1 |
| Yamamoto, I | 1 |
| Ariyama, J | 1 |
| Wakabayashi, Y | 2 |
| Onuma, H | 1 |
| van Eden, EB | 1 |
| Mittelman, JA | 1 |
| Bakemeier, RF | 1 |
| Hanley, J | 1 |
| Bullen, BR | 1 |
| Malhotra, A | 1 |
| Bunch, GA | 1 |
| Brown, GJ | 1 |
| MacGregor, AB | 2 |
| Miller, AB | 1 |
| Samuel, ES | 1 |
| Franz, JL | 1 |
| Tsunekawa, H | 1 |
| Washino, M | 1 |
| Makino, N | 1 |
| Tamura, Z | 2 |
| Siering, H | 1 |
| Felsch, G | 1 |
| Barthel, E | 1 |
| De Jager, RL | 1 |
| Magill, GB | 1 |
| Golbey, RB | 1 |
| Krakoff, IH | 2 |
| Kliachkin, BM | 1 |
| Maliuta, VI | 1 |
| Nakarzato, H | 1 |
| Tobita, Y | 1 |
| Kimur, K | 1 |
| Niitani, H | 2 |
| Chikada, C | 1 |
| Shimoyama, M | 1 |
| Håkansson, L | 2 |
| Dahn, I | 1 |
| Huldt, B | 1 |
| Tropé, C | 1 |
| Dencker, H | 1 |
| Podil'chak, EM | 1 |
| Rieche, K | 1 |
| Matthes, ML | 1 |
| Mokka, RE | 1 |
| Larmi, TK | 1 |
| Huttunen, R | 1 |
| Kairaluoma, MI | 1 |
| Nitter, L | 1 |
| Ohtsubo, T | 1 |
| Fujieda, S | 1 |
| Monma, K | 1 |
| Sakaki, N | 1 |
| Tabata, I | 1 |
| Hihara, T | 1 |
| Nishiumi, T | 1 |
| Yoneyama, T | 1 |
| Kiyabu, M | 2 |
| Chandrasoma, P | 1 |
| Ohe, Y | 1 |
| Ohmori, T | 1 |
| Niu, MY | 1 |
| Miyama, T | 3 |
| Sakamoto, S | 1 |
| Hirata, T | 3 |
| Idezuki, Y | 3 |
| Paik, S | 1 |
| Koh, E | 1 |
| Ohiwa, K | 1 |
| Kim, JP | 3 |
| Kwon, OJ | 1 |
| Tanimura, H | 1 |
| Noguchi, K | 1 |
| Hotta, T | 1 |
| Iwahashi, M | 1 |
| Iwakura, S | 1 |
| Kelly, KA | 2 |
| Saini, A | 1 |
| Waxman, J | 1 |
| Umeda, T | 1 |
| Okamura, H | 1 |
| Oshima, Y | 1 |
| Miyakawa, T | 1 |
| Okubo, S | 1 |
| Shiina, E | 1 |
| Tokura, Y | 1 |
| Ohsawa, S | 1 |
| Masuko, H | 1 |
| Kataoka, A | 1 |
| Ohmori, K | 1 |
| Takenaka, H | 1 |
| Sumimura, J | 1 |
| Ishizaka, T | 1 |
| Takagaki, M | 1 |
| Bessho, T | 1 |
| Ohata, T | 1 |
| Homma, T | 1 |
| Sakaue, M | 1 |
| Ray, M | 1 |
| Muggia, FM | 1 |
| Radin, R | 1 |
| Jin, YZ | 1 |
| Shen, ZF | 1 |
| Cai, RM | 1 |
| Jin, XQ | 1 |
| Lu, WQ | 1 |
| Xu, JF | 1 |
| Matsu, T | 1 |
| Oguro, Y | 1 |
| Hosokawa, T | 1 |
| Kajiwara, T | 1 |
| Ohkuma, R | 1 |
| Ohsato, K | 1 |
| Kanamaru, R | 5 |
| Kajikawa, S | 1 |
| Horigome, N | 1 |
| Hanasaki, K | 1 |
| Shiohara, E | 1 |
| Haba, Y | 1 |
| Koike, S | 1 |
| Adachi, W | 1 |
| Kaneko, G | 1 |
| Kirita, T | 2 |
| Mabuchi, G | 1 |
| Yoneyama, K | 1 |
| Oishi, H | 1 |
| Hasegawa, E | 1 |
| Ohmura, G | 1 |
| Hirakawa, S | 1 |
| Momose, K | 1 |
| Niwa, M | 1 |
| Maruyama, Y | 3 |
| Ishizuka, K | 4 |
| Hasegawa, T | 1 |
| Ginn, D | 1 |
| Chapman, D | 1 |
| Heelan, R | 1 |
| Min, YI | 1 |
| Ahn, SH | 1 |
| Meyer, HJ | 4 |
| Achterrath, W | 5 |
| Knipp, H | 1 |
| Köhne-Wömpner, CH | 1 |
| Chu, E | 1 |
| Boarman, D | 1 |
| Balis, FM | 1 |
| Murphy, RF | 1 |
| McAtee, N | 1 |
| Yamauchi, M | 4 |
| Ito, A | 2 |
| Nakahara, H | 1 |
| Nagai, S | 1 |
| Kuzuya, T | 1 |
| Satta, T | 3 |
| Nabeyama, A | 1 |
| Nakashima, A | 1 |
| Endoh, A | 1 |
| Sasahashi, N | 1 |
| Akagi, M | 1 |
| Shimazu, H | 1 |
| Hirano, T | 1 |
| Nakagoe, T | 1 |
| Kusano, H | 1 |
| Ifuku, M | 1 |
| Doden, K | 1 |
| Miyanaga, T | 1 |
| MacVicar, D | 1 |
| Husband, JE | 1 |
| Taylor, R | 1 |
| Menzies-Gow, N | 1 |
| Oogushi, K | 1 |
| Morita, H | 1 |
| Sunaga, T | 1 |
| Matsunaga, H | 1 |
| Warlters, A | 1 |
| Morris, DL | 1 |
| Cameron-Strange, A | 1 |
| Lynch, W | 1 |
| Tsukagoshi, S | 2 |
| Nishina, H | 1 |
| Noto, T | 1 |
| Ueo, H | 1 |
| Drake, JC | 1 |
| Trepel, J | 1 |
| Bailey, H | 1 |
| Wilding, G | 1 |
| Tutsch, KD | 1 |
| Arzoomanian, RZ | 1 |
| Alberti, D | 1 |
| Tombes, MB | 1 |
| Spriggs, DR | 1 |
| Ohchi, T | 1 |
| Ihara, H | 1 |
| Nishiyama, T | 1 |
| Kon, M | 1 |
| Cunliffe, WJ | 1 |
| Aigner, KR | 1 |
| Benthin, F | 1 |
| Mayer, HJ | 1 |
| Lenaz, L | 3 |
| Meyer, J | 2 |
| Gerlings, H | 1 |
| Natali, M | 1 |
| Carpano, S | 1 |
| Conti, EM | 2 |
| Barranco, SC | 3 |
| Townsend, CM | 3 |
| Ho, BY | 1 |
| Reumont, KJ | 1 |
| Koester, SK | 1 |
| Ford, PJ | 1 |
| Denham, J | 1 |
| Devitt, PG | 1 |
| Ahmad, A | 1 |
| Yeoh, E | 1 |
| Henne-Bruns, D | 4 |
| Kremer, B | 4 |
| Tohma, H | 1 |
| Shikama, T | 1 |
| Albanell, J | 1 |
| Gallego, OS | 1 |
| Vicente, P | 1 |
| Pazdur, R | 1 |
| Winn, R | 1 |
| Bearden, J | 1 |
| Belt, RJ | 1 |
| Pilat, S | 1 |
| Hallinan, R | 1 |
| Levin, B | 3 |
| Urushiyama, M | 3 |
| Sakamoto, M | 1 |
| Nishibori, H | 1 |
| Kodaira, S | 2 |
| Sakaguchi, Y | 3 |
| Nawata, H | 1 |
| Nozue, M | 1 |
| Miyamoto, T | 2 |
| Mochinaga, N | 1 |
| Fragu, P | 1 |
| Fabri, MC | 1 |
| Papadopoulos, S | 1 |
| Halpern, S | 1 |
| Prade, M | 1 |
| Ranson, M | 1 |
| Kamthan, AG | 1 |
| Dougal, M | 1 |
| Russell, SA | 1 |
| Wilkinson, MJ | 1 |
| Ostick, DG | 1 |
| Cirillo, F | 1 |
| Mortini, B | 1 |
| Troiano, L | 1 |
| Agarossi, M | 1 |
| Riboldi, O | 1 |
| Okumura, S | 1 |
| Mizuno, S | 1 |
| Toyoda, S | 1 |
| Jinushi, K | 5 |
| Sawamura, A | 1 |
| Aogi, K | 2 |
| Ueshima, Y | 1 |
| Tsukuda, N | 1 |
| Shioaki, Y | 1 |
| Ames, FC | 1 |
| McBride, C | 1 |
| Boddie, A | 1 |
| Jackson, DE | 1 |
| Roh, M | 1 |
| Hohn, D | 1 |
| Matsuura, N | 1 |
| Josui, K | 1 |
| Arisawa, Y | 1 |
| Mabuchi, K | 1 |
| Nakashima, I | 1 |
| Itou, K | 1 |
| Kinoshita, K | 1 |
| Tugawa, K | 1 |
| Endo, Y | 1 |
| Kawata, R | 3 |
| Yokkaichi, H | 1 |
| Plukker, JT | 1 |
| Mulder, NH | 1 |
| Sleijfer, DT | 1 |
| Grond, J | 1 |
| Verschueren, RC | 1 |
| Galligioni, E | 1 |
| Talamini, R | 1 |
| Sorio, R | 1 |
| Saracchini, S | 1 |
| Monfardini, S | 1 |
| Bruckner, HW | 3 |
| Chesser, MR | 1 |
| Wong, H | 1 |
| Mandeli, J | 1 |
| Hamazoe, R | 3 |
| Murakami, A | 3 |
| Hoshino, M | 1 |
| Satou, N | 1 |
| Abe, R | 2 |
| Bonneterre, J | 1 |
| Saeki, S | 1 |
| Kusumoto, T | 3 |
| Shu, YH | 1 |
| Koh, Y | 1 |
| Iwai, H | 1 |
| Raschko, JW | 1 |
| Johnson, EA | 1 |
| Treat, J | 2 |
| Gusarova, LT | 1 |
| Beart, RW | 1 |
| Leigh, JE | 1 |
| Pfeifle, DM | 2 |
| Twito, DI | 2 |
| Reis, H | 1 |
| Korsten, F | 1 |
| Leyvraz, S | 1 |
| Weintraub, B | 1 |
| MacLean, KK | 1 |
| Beasley, EG | 1 |
| Jenkins, VK | 1 |
| Berdinskikh, NK | 1 |
| Sanina, OL | 1 |
| Baraboĭ, VA | 1 |
| Starosel'skiĭ, IV | 1 |
| Korobko, VB | 1 |
| Kamenets, LIa | 2 |
| Iaremenko, LIa | 1 |
| Demuynck, B | 1 |
| Maisani, JE | 1 |
| Lagadec, B | 1 |
| Delfau, S | 1 |
| Varette, C | 1 |
| Gonzalez-Canali, G | 1 |
| Krulik, M | 1 |
| Simoncini, E | 2 |
| Marpicati, P | 2 |
| Arcangeli, G | 1 |
| Garattini, P | 1 |
| Raffaglio, E | 1 |
| Ferragni, A | 1 |
| Walter, TA | 1 |
| Garbrecht, M | 2 |
| Crone-Muenzebrock, LS | 1 |
| Kusuyama, T | 4 |
| Okuyama, Y | 1 |
| Shiraishi, T | 2 |
| Tsubono, M | 1 |
| Morimoto, H | 1 |
| Tseng, CC | 1 |
| Tobe, T | 2 |
| Hong, WS | 1 |
| Kang, TW | 1 |
| Yun, TK | 1 |
| Kim, CY | 1 |
| Zupanc, D | 1 |
| Luetić, J | 1 |
| Kolarić, K | 2 |
| Goshima, H | 1 |
| Kokehara, N | 1 |
| Ishida, N | 1 |
| Itou, F | 1 |
| Awane, Y | 3 |
| Moriwaki, S | 1 |
| Suga, T | 1 |
| Deguchi, Y | 1 |
| Minamoto, T | 1 |
| Asai, T | 1 |
| Sawaguchi, K | 1 |
| Ota, J | 1 |
| Sugimoto, T | 1 |
| Sakamoto, Y | 2 |
| Fukunaga, J | 1 |
| Kitahama, H | 1 |
| Okuyama, A | 1 |
| Tsurui, K | 1 |
| Lepage, E | 1 |
| Ishibashi, O | 1 |
| Takagami, S | 4 |
| Ryuji, K | 1 |
| Yorishima, T | 1 |
| Noso, Y | 2 |
| Auther, C | 1 |
| Nishihira, T | 2 |
| Kawachi, S | 1 |
| Blijham, G | 2 |
| Madajewicz, S | 1 |
| Avvento, L | 1 |
| Palmieri, G | 1 |
| Gridelli, C | 1 |
| Airoma, G | 1 |
| Balestrino, M | 1 |
| Bisogno, A | 1 |
| Incoronato, P | 1 |
| Kido, C | 7 |
| Hikishima, H | 1 |
| Douden, K | 1 |
| Obrist, R | 1 |
| Haenggi, ST | 1 |
| Heiman, D | 1 |
| Izumi, R | 1 |
| Matsui, O | 1 |
| Kuwahara, A | 1 |
| Hirao, E | 1 |
| Youn, JK | 3 |
| Lee, YB | 3 |
| Lee, DW | 3 |
| Chung, JB | 1 |
| Rutten, A | 1 |
| Windschitl, HE | 2 |
| Laurie, JA | 1 |
| Jeremic, B | 1 |
| Jevremovic, S | 1 |
| Djuric, L | 1 |
| Mijatovic, L | 1 |
| Gröhn, P | 1 |
| Heinonen, E | 1 |
| Kumpulainen, E | 1 |
| Länsimies, H | 1 |
| Lantto, A | 1 |
| Salmi, R | 1 |
| Numminen, S | 1 |
| Shouji, I | 1 |
| Terasima, K | 1 |
| Igari, H | 1 |
| Akuzawa, K | 1 |
| Ueki, Y | 1 |
| Tofan, AV | 2 |
| Zadorozhnyĭ, AA | 1 |
| Gol'dshmid, BIa | 1 |
| Mukaiyama, T | 3 |
| Vestlev, PM | 1 |
| Pedersen, H | 1 |
| Simonetti, G | 1 |
| Franklin, H | 1 |
| McVie, JG | 1 |
| Borzenko, BG | 1 |
| Gorbachev, AA | 1 |
| Dumanskiĭ, IuV | 1 |
| Efimova, IA | 1 |
| Hirsh, A | 1 |
| Alhalel, A | 1 |
| Weiss, A | 1 |
| Brener, H | 1 |
| Avni, I | 1 |
| Chen, JZ | 1 |
| Wang, GT | 2 |
| Porile, JL | 1 |
| Olopade, OI | 1 |
| Hoffman, PC | 1 |
| Nakatsu, T | 2 |
| Yokoyama, I | 1 |
| Tsuyuki, K | 1 |
| Soh, Y | 1 |
| Hanai, G | 1 |
| Kubo, H | 1 |
| Nohga, K | 1 |
| Koyanagi, H | 1 |
| Geerlings, H | 1 |
| Kozaczka, A | 1 |
| Nishiwada, T | 1 |
| Okumura, T | 1 |
| Arbuck, SG | 5 |
| Silk, Y | 1 |
| Nava, H | 2 |
| Rustum, YM | 5 |
| Milliron, S | 2 |
| Schober, C | 1 |
| Link, H | 1 |
| Lucke, B | 1 |
| Lee, JT | 1 |
| Clark, JL | 1 |
| Barcewicz, P | 1 |
| Nava, HR | 2 |
| Goodwin, PS | 1 |
| Saegusa, J | 1 |
| Iugrinov, OG | 1 |
| Eremenko, VN | 1 |
| Galakhin, KA | 1 |
| Fujii, S | 1 |
| Kalninia, IIa | 1 |
| Kato, N | 1 |
| Sugisaki, T | 1 |
| Fujioka, T | 1 |
| Trave, F | 3 |
| Zakrzewski, SF | 1 |
| Petrelli, N | 1 |
| Herrera, L | 1 |
| Mittelman, A | 1 |
| Creaven, PJ | 1 |
| Kitao, T | 1 |
| Furutani, M | 1 |
| Matsushita, T | 1 |
| Asada, I | 1 |
| Shirosaki, H | 1 |
| Komi, N | 1 |
| Kusumoto, H | 4 |
| Korenaga, D | 1 |
| Toriya, H | 1 |
| Sinmyo, K | 1 |
| Suwa, H | 1 |
| Kitagawa, M | 2 |
| Susaki, H | 1 |
| Danno, M | 1 |
| Ogino, T | 2 |
| Awano, T | 1 |
| Ozaki, M | 1 |
| Gunji, Y | 1 |
| Kinoshita, H | 1 |
| Mori, N | 1 |
| Nakajima, I | 1 |
| Furukohori, N | 2 |
| Yoshimura, S | 2 |
| Flechtner, H | 3 |
| Kabelitz, K | 1 |
| Edler, L | 1 |
| Vallejos, C | 1 |
| Payet, C | 1 |
| Nuñez, J | 1 |
| Montalbetti, J | 1 |
| Solidoro, A | 1 |
| Salazar, F | 1 |
| Sánchez, J | 1 |
| Celis, J | 1 |
| Casanova, L | 1 |
| Otero, J | 1 |
| Falchuk, SC | 1 |
| Neefe, JR | 1 |
| Furukohri, N | 1 |
| Baba, T | 2 |
| Sivets, NF | 1 |
| Sukolinskiĭ, VN | 1 |
| Makorov, NV | 1 |
| Aniskevich, VV | 1 |
| Otsuka, S | 1 |
| Tsubuku, Y | 1 |
| Kenmizaki, H | 1 |
| Tatekawa, I | 1 |
| Koike, H | 1 |
| Li, XT | 2 |
| Rubin, JR | 1 |
| Everson, LK | 1 |
| Marschke, RF | 1 |
| Navarrete, E | 1 |
| Rodier, JF | 1 |
| Janser, JC | 1 |
| Haegele, P | 1 |
| Pusel, J | 1 |
| Rodier, D | 1 |
| Platz, D | 1 |
| Crone-Münzebrock, W | 1 |
| Dalesio, O | 3 |
| Roussel, A | 1 |
| Samana, G | 1 |
| Michel, J | 1 |
| Gerard, A | 1 |
| Grandjouan, S | 1 |
| Droz, JP | 2 |
| Biran, H | 1 |
| Biran, S | 1 |
| Toi, M | 1 |
| Yanagawa, E | 1 |
| Goudeau, P | 1 |
| Faintuch, JS | 1 |
| Boman, BM | 1 |
| Kanojia, MD | 1 |
| Dickinson, R | 1 |
| Presgrave, P | 1 |
| Levi, J | 1 |
| Milliken, S | 1 |
| Woods, R | 1 |
| Effenberger, T | 1 |
| Moroz, TD | 3 |
| Zinevich, AK | 3 |
| Kas'ianenko, IV | 3 |
| Moroz, VL | 1 |
| Nyumura, T | 1 |
| Nabeya, K | 1 |
| Hamakubo, S | 1 |
| Higashino, K | 1 |
| Ohkita, T | 2 |
| Nagayo, T | 1 |
| Horiguchi, M | 1 |
| Sonoda, H | 1 |
| Tsukiyama, I | 1 |
| Egawa, S | 1 |
| Hijikata, J | 1 |
| Pan, XY | 2 |
| Li, FQ | 1 |
| Yu, RJ | 1 |
| Xie, GF | 1 |
| Zhao, LY | 1 |
| Shrestha, RD | 3 |
| Endoh, F | 3 |
| Sugasawa, H | 2 |
| Takahashi, O | 2 |
| Ohta, M | 4 |
| Yang, CJ | 1 |
| Jin, SW | 1 |
| Togawa, Y | 1 |
| Shimozuma, K | 3 |
| Taniguchi, T | 1 |
| Kawabe, K | 1 |
| Choong, YS | 1 |
| Lee, SP | 1 |
| Alley, PA | 1 |
| Iizuka, A | 1 |
| Inagaki, T | 1 |
| Nakura, E | 1 |
| Nishikawa, H | 1 |
| Ohno, R | 2 |
| Hayashi, N | 1 |
| Tunekawa, H | 1 |
| Kasuga, Y | 1 |
| Senga, O | 1 |
| Hanamura, N | 1 |
| Iida, F | 1 |
| Katsuyama, T | 1 |
| Yamazaki, H | 1 |
| Imajo, K | 2 |
| Miyaoka, K | 1 |
| Nakazawa, S | 1 |
| Yoshino, J | 1 |
| Yamao, K | 1 |
| Guimaraes dos Santos, J | 1 |
| Gez, E | 2 |
| Weshler, Z | 2 |
| Caballero, JL | 1 |
| Acosta, P | 1 |
| Silk, YN | 1 |
| Baroni, M | 2 |
| Nakaya, K | 1 |
| Kimoto, Y | 2 |
| Kasai, M | 2 |
| Konno, K | 1 |
| Nakai, Y | 1 |
| Koie, H | 1 |
| Morimoto, T | 1 |
| Miyaishi, S | 2 |
| Bjerkeset, T | 1 |
| Fjøsne, HE | 1 |
| Zhero, SV | 1 |
| Ganina, KP | 1 |
| Jakesz, R | 1 |
| Dittrich, C | 1 |
| Funovics, J | 1 |
| Hofbauer, F | 1 |
| Rainer, H | 1 |
| Reiner, G | 1 |
| Schemper, M | 1 |
| Schiessel, R | 1 |
| Starlinger, M | 1 |
| Shimokawa, K | 3 |
| Tsuya, H | 1 |
| Yasuda, H | 1 |
| Villar, A | 1 |
| Asensio, F | 1 |
| Candel, M | 1 |
| Delgado, F | 1 |
| Garcia, J | 1 |
| Lledó, S | 1 |
| Redón, J | 1 |
| Roig, JV | 1 |
| Sanchis, C | 1 |
| Orikasa, H | 1 |
| Usugane, M | 2 |
| Fujimoto, Y | 3 |
| Matsumoto, A | 1 |
| Fritsch, H | 1 |
| Trux, FA | 2 |
| Yashige, H | 1 |
| Inazawa, J | 1 |
| Nishigaki, H | 1 |
| Sadamoto, Y | 1 |
| Haruma, K | 1 |
| Tokumo, K | 1 |
| Teshima, H | 1 |
| Sumii, K | 1 |
| Kajiyama, G | 1 |
| Origasa, H | 1 |
| Fukunaga, H | 1 |
| Katsumi, M | 1 |
| Aoki, Y | 1 |
| Konishi, R | 1 |
| Yukawa, H | 1 |
| Takifuji, K | 1 |
| Yamada, H | 1 |
| Gunge, N | 1 |
| Murei, T | 1 |
| Kiuchi, T | 1 |
| Okada, N | 1 |
| Clark, PI | 1 |
| Slevin, ML | 1 |
| Sakata, A | 1 |
| Ozeki, H | 1 |
| Nagamine, D | 1 |
| Shinagawa, K | 1 |
| Keymling, M | 1 |
| Lübke, HJ | 1 |
| Wörner, W | 1 |
| Blijham, GH | 2 |
| Leonardi, F | 2 |
| Tateishi, S | 1 |
| Sakaida, R | 1 |
| Saitou, T | 1 |
| Nehashi, Y | 1 |
| de Insausti, CL | 1 |
| Gutiérrez, LE | 1 |
| Takeshita, T | 1 |
| Iwasaki, M | 1 |
| Narita, M | 1 |
| Sou, M | 1 |
| Kameya, S | 1 |
| Iigima, N | 1 |
| Tominaga, M | 1 |
| Kim, RH | 1 |
| Lee, YW | 1 |
| Lee, DC | 1 |
| Joo, SK | 1 |
| Uchino, H | 1 |
| Gustavsson, BG | 2 |
| Berne, M | 1 |
| Frösing, R | 2 |
| Bernstein, L | 1 |
| Hayes, AA | 1 |
| Osinskiĭ, SP | 1 |
| Korn, O | 1 |
| Gaínza, V | 1 |
| Csendes, A | 1 |
| Tamura, H | 1 |
| Gohmann, JJ | 1 |
| Oshita, H | 1 |
| Fukata, D | 1 |
| Sakai, N | 1 |
| Kashizuka, T | 1 |
| Hatoh, T | 1 |
| Lacave, A | 1 |
| Coia, LR | 1 |
| Miyata, T | 1 |
| Torisu, M | 1 |
| Sugimasa, Y | 2 |
| Tamai, S | 2 |
| Iimori, K | 2 |
| Shimizu, N | 2 |
| Inoue, Y | 1 |
| Sawata, T | 1 |
| Takeshita, M | 2 |
| Moynihan, T | 1 |
| Hansen, R | 1 |
| Anderson, T | 1 |
| Quebbeman, E | 1 |
| Beatty, P | 1 |
| Ausman, R | 1 |
| Chitambar, C | 1 |
| Vukelich, M | 1 |
| Maeda, C | 1 |
| Ozawa, H | 1 |
| Terasawa, Y | 1 |
| Rao, XQ | 1 |
| Jack, A | 1 |
| McMurdo, DF | 1 |
| Sugiura, I | 1 |
| Ogasawara, T | 1 |
| Onizuka, T | 1 |
| Kamiya, O | 1 |
| Emrich, LJ | 1 |
| Metzger, G | 2 |
| Zittoun, J | 2 |
| Benavides, M | 1 |
| Marquet, J | 2 |
| Vandenbulcke, JM | 2 |
| Potrebica, V | 1 |
| Stanovnik, M | 1 |
| Fourtillan, JB | 1 |
| Cazap, EL | 1 |
| Estevez, RA | 2 |
| Alvarez, CA | 1 |
| Hannois, A | 1 |
| Ahmed, S | 1 |
| Woods, RL | 1 |
| Thomson, D | 1 |
| Gill, G | 1 |
| Satou, H | 1 |
| Cazap, E | 1 |
| Marantz, A | 2 |
| Wilcosky, T | 1 |
| Stein, J | 1 |
| Starzyńska, T | 1 |
| Vidán, JR | 1 |
| Borda, F | 1 |
| Martínez, B | 1 |
| Adrián, A | 1 |
| Frauca, A | 1 |
| Fortún, MT | 1 |
| Neijt, JP | 1 |
| Lokich, JJ | 2 |
| Shea, M | 1 |
| Chaffey, J | 1 |
| Kenis, Y | 2 |
| Koh, EH | 2 |
| Kim, KW | 2 |
| Stein, M | 1 |
| Theobaldy, S | 1 |
| Hofmann-Preiss, K | 1 |
| Walter, M | 1 |
| Lelcuk, S | 1 |
| Klausner, JM | 1 |
| Inbar, M | 1 |
| Kaplan, O | 1 |
| Merhav, A | 1 |
| Rozin, RR | 1 |
| Miyazaki, T | 1 |
| Athlin, L | 1 |
| Domellöf, L | 1 |
| Tamura, J | 1 |
| Azuma, N | 1 |
| Katami, A | 1 |
| Uchida, N | 1 |
| Kanno, T | 1 |
| Kiyatake, I | 1 |
| Kakuhara, T | 1 |
| Swaroop, VS | 1 |
| Raina, A | 1 |
| Ferrante, F | 1 |
| Bisol, A | 1 |
| Galeone, M | 1 |
| Theodors, A | 1 |
| Purvis, JD | 1 |
| Weick, JK | 1 |
| Gahbauer, R | 1 |
| Kuwatsuru, R | 1 |
| Yoon, S | 1 |
| Saifuku, K | 1 |
| Kasanuki, J | 1 |
| Kokubun, M | 1 |
| Ichiki, N | 1 |
| Miyazaki, A | 1 |
| Insler, MS | 1 |
| Helm, CJ | 1 |
| Theodore, C | 1 |
| Piot, G | 1 |
| Herait, P | 1 |
| Ruffie, P | 1 |
| Carde, P | 1 |
| Yablonsky-Peretz, T | 1 |
| Kurihara, H | 1 |
| Ichihashi, S | 1 |
| Tamura, N | 1 |
| Umeda, M | 1 |
| Akimoto, M | 1 |
| Li, PY | 1 |
| Henderson, A | 1 |
| Urabe, T | 3 |
| Muro, H | 1 |
| Acuña, LR | 1 |
| Castagnari, A | 1 |
| Blajman, C | 1 |
| Schmilovich, A | 1 |
| Hidalgo, A | 1 |
| Fiori, H | 1 |
| Bader, M | 1 |
| Faedi, M | 1 |
| Amadori, M | 1 |
| Gentilini, P | 1 |
| Biserni, R | 1 |
| Bonaguri, C | 1 |
| Mulder, N | 1 |
| Planting, A | 1 |
| Splinter, T | 1 |
| Zehner, J | 1 |
| Weber, L | 1 |
| Fischer, M | 1 |
| Gfirtner, H | 1 |
| Breit, A | 1 |
| Timoshenko, IaG | 1 |
| Zambruni, A | 1 |
| Gorni, F | 1 |
| Ragni, F | 1 |
| Ban, JM | 1 |
| Kim, CK | 1 |
| Ryu, KJ | 1 |
| Minaguchi, S | 1 |
| Hagin, GD | 1 |
| Ishiyama, T | 1 |
| Sugimoto, M | 1 |
| Vanden-Bulcke, JM | 1 |
| Brunner, KW | 1 |
| Weiner, JM | 1 |
| Silverberg, I | 1 |
| Glass, A | 1 |
| Bateman, JR | 1 |
| Green, M | 1 |
| Suyama, K | 1 |
| Isomatsu, T | 1 |
| Ikenaga, T | 1 |
| Yamanaka, T | 1 |
| Ryu, S | 1 |
| Ariga, T | 1 |
| Koh, Z | 1 |
| Odaka, M | 1 |
| Hirahara, K | 1 |
| Aoki, S | 1 |
| Nakagawa, H | 1 |
| Hori, M | 1 |
| Udagawa, I | 1 |
| Koyama, K | 1 |
| Otake, S | 1 |
| Sako, T | 1 |
| Takemori, Y | 1 |
| Takayama, S | 1 |
| Takeshita, Y | 1 |
| Tane, S | 1 |
| Kokunai, I | 1 |
| Watase, M | 1 |
| Ikeya, T | 1 |
| Tozuka, S | 1 |
| Usui, R | 1 |
| Eckhardt, S | 1 |
| Kawaura, Y | 1 |
| Hashizume, Y | 1 |
| Takayama, K | 1 |
| MacIntyre, JM | 1 |
| Catton, GE | 1 |
| Wu, YF | 2 |
| Sugizaki, T | 1 |
| Juan, IK | 1 |
| Zhen, ZA | 1 |
| Shao, JK | 1 |
| Zhen, HD | 1 |
| Han, ZH | 1 |
| Hong, SS | 1 |
| Morita, K | 1 |
| Kobayashi, S | 1 |
| Suzuki, R | 1 |
| Yap, SH | 1 |
| Wobbes, T | 1 |
| van Dam, FE | 1 |
| Hillen, HF | 1 |
| Hoogendoorn, GJ | 1 |
| Scheerder, H | 1 |
| van der Vegt, SG | 1 |
| Kvols, LK | 1 |
| Michelson, M | 1 |
| Chiuten, DF | 1 |
| Miller, A | 1 |
| Loo, TL | 1 |
| Bedikian, A | 1 |
| Benvenuto, JA | 1 |
| Freireich, EJ | 1 |
| Starichkov, MS | 1 |
| Sorokina, EA | 1 |
| Oara, H | 1 |
| Lagunova, IG | 1 |
| Cybulskij, BA | 1 |
| Kornev, II | 1 |
| Minaeva, OD | 1 |
| Sackaja, IS | 1 |
| Kitaoka, H | 2 |
| Fain, WR | 1 |
| Conn, JH | 1 |
| Chavez, CM | 1 |
| Navashin, SM | 1 |
| Fomina, IP | 1 |
| Osokina, LI | 1 |
| Zharikov, AA | 1 |
| Griffen, WO | 1 |
| Humphrey, L | 1 |
| Sosin, H | 1 |
| Muller, CJ | 1 |
| Falkson, HC | 1 |
| Papaioannou, AN | 1 |
| Takatani, O | 1 |
| Hattori, N | 1 |
| Ostroverkhov, GE | 1 |
| Bronshteĭn, BL | 1 |
| Alimov, AT | 2 |
| Iusupov, KN | 1 |
| Koliadiuk, IV | 1 |
| Daniel'-Bek, KV | 1 |
| Vinogradov, AL | 1 |
| Fennelly, JJ | 1 |
| Fitzgerald, MX | 1 |
| Davis, HL | 1 |
| Ramirez, G | 2 |
| Ansfield, FJ | 2 |
| Morrow, LB | 1 |
| Burrow, GN | 1 |
| Kaplan, SR | 1 |
| Mulrow, PJ | 1 |
| Bessot, M | 2 |
| Duprez, A | 2 |
| Kühböck, J | 1 |
| Pokorny, D | 1 |
| Steinbach, K | 1 |
| Eggerth, G | 1 |
| Izsak, FC | 1 |
| Eylan, E | 1 |
| Gazith, A | 1 |
| Shapiro, J | 1 |
| Naharin, S | 1 |
| Raanani, C | 1 |
| Man, B | 1 |
| Kraus, L | 1 |
| Pikielny, S | 1 |
| Massey, WH | 1 |
| Dennis, DL | 1 |
| Fletcher, WS | 1 |
| Wood, DC | 1 |
| Moertel, C | 1 |
| Tormey, DC | 1 |
| Gailani, S | 2 |
| Leone, L | 2 |
| Raevskiĭ, IG | 1 |
| Karim, F | 1 |
| Mackman, S | 1 |
| Skarin, AT | 1 |
| Mil'man, MSh | 1 |
| Chirkina, IuM | 1 |
| Shek, BA | 1 |
| Li, MI | 1 |
| Chernyshev, VK | 1 |
| Holland, JF | 1 |
| Burningham, R | 1 |
| Larsen, V | 1 |
| Moroz, LV | 2 |
| Karev, NI | 1 |
| Orlova, RS | 2 |
| Nordman, E | 1 |
| Kauppinen, C | 1 |
| Lapsa, RKh | 1 |
| Dumbadze, ND | 2 |
| Polishchuk, EI | 1 |
| Nomura, Y | 1 |
| Ito, B | 1 |
| Kovach, JS | 1 |
| Kissel, P | 1 |
| Colby, M | 1 |
| Amino, S | 1 |
| Umeda, K | 1 |
| Nishio, H | 1 |
| Nelson, RS | 1 |
| Lanza, FL | 1 |
| Schwartz, GF | 1 |
| Green, HL | 1 |
| Bendon, ML | 1 |
| Graham, WP | 1 |
| Blakemore, WS | 1 |
| al-Sarraf, M | 1 |
| Reed, ML | 1 |
| Vaitkevicious, VK | 1 |
| Vozny, EK | 1 |
| Pershin, MP | 1 |
| Chumakina, SI | 1 |
| Gunka, II | 1 |
| Pantophel, AM | 1 |
| Steklenev, NA | 1 |
| Zirin, MA | 1 |
| Grjaznova, IN | 1 |
| Shain, AA | 1 |
| Pecherskaja, BG | 1 |
| Saveliev, NP | 1 |
| Bashirova, NG | 1 |
| Kuzmin, VP | 1 |
| Budarina, EM | 1 |
| Svedencov, EP | 1 |
| Phateeva, KV | 1 |
| Iunusmetov, IR | 1 |
| Silitrin, NP | 1 |
| Shklovskii, GS | 1 |
| Balas, AN | 1 |
| Ushivceva, AE | 1 |
| Kanko, T | 1 |
| Harashima, S | 1 |
| Hirota, Y | 1 |
| Tsoĭ, AI | 1 |
| Dement'eva, NI | 1 |
| Sulaeva, LS | 1 |
| Ishida, M | 2 |
| Matsui, K | 1 |
| Nagano, T | 1 |
| Ljungdahl, I | 1 |
| Hatano, S | 1 |
| Letiagin, VP | 1 |
| Imamura, K | 1 |
| Kuroyanagi, Y | 1 |
| Shaĭkhiev, USh | 1 |
| Mitchell, MS | 1 |
| DeConti, RC | 1 |
| Eras, P | 1 |
| Watanuki, S | 1 |
| Milonov, BV | 1 |
| Kosarev, VA | 1 |
| Nikiforov, AM | 1 |
| Evseenko, LS | 1 |
| Henderson, IW | 1 |
| Lipowska, B | 1 |
| Lougheed, MN | 1 |
| Nadler, SH | 1 |
| Abasov, IT | 1 |
| Nadzharov, AG | 1 |
| Boffi, L | 1 |
| Favi, P | 1 |
| Sbaragli, F | 1 |
| Nozaki, H | 1 |
| Isono, S | 1 |
| Kurobane, T | 1 |
| Hamaguchi, E | 1 |
| Utsunomiya, J | 1 |
| Hishigi, S | 1 |
| Gasparian, SA | 1 |
| Clarkson, B | 1 |
| O'Connor, A | 1 |
| Nance, FC | 1 |
| MacVaugh, H | 1 |
| Fitts, WT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pazopanib With 5-Fluorouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line Treatment in Advanced Gastric Cancer; a Randomized Phase-II-study of the Arbeitsgemeinschaft Internistische Onkologie[NCT01503372] | Phase 2 | 75 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma: a Multi-center, Open-labeled, Randomized Controlled Trial[NCT01364376] | 583 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
| A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)[NCT04592913] | Phase 3 | 958 participants (Actual) | Interventional | 2020-11-17 | Active, not recruiting | ||
| Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT): A Phase II Study (GASPAR)[NCT04736485] | Phase 2 | 67 participants (Anticipated) | Interventional | 2021-06-28 | Active, not recruiting | ||
| Infusional Fluorouracil and Weekly Docetaxel as First-line Therapy for Gastric Cancer With Bone Marrow Metastasis and Disseminated Intravascular Coagulation: a Multi-center, Phase II Trail[NCT04547153] | Phase 2 | 24 participants (Actual) | Interventional | 2021-01-15 | Completed | ||
| A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomac[NCT01216644] | Phase 2/Phase 3 | 716 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Phase I Study of Sunitinib With FOLFIRI (Irinotecan, 5-Fluorouracil and Leucovorin) for Advanced Gastroesophageal Cancers[NCT00524186] | Phase 1 | 23 participants (Actual) | Interventional | 2007-05-31 | Terminated (stopped due to PI left institute) | ||
| PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma[NCT02366819] | Phase 4 | 36 participants (Anticipated) | Interventional | 2014-12-11 | Recruiting | ||
| Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors[NCT01928290] | Phase 2 | 67 participants (Actual) | Interventional | 2013-11-08 | Completed | ||
| Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in Previously Untreated HER2 Positive Locally Advanced or Metastatic EsophagoGastric Adenocarcinoma[NCT03409848] | Phase 2 | 97 participants (Actual) | Interventional | 2018-03-01 | Completed | ||
| A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esop[NCT02625610] | Phase 3 | 499 participants (Actual) | Interventional | 2015-12-24 | Completed | ||
| Dragon III- Phase 2: The Preliminary Efficacy Study of FLOT Versus SOX Regimen as Neoadjuvant Chemotherapy for Patients With Locally Advanced Gastric Cancer: Open-label, Randomized Controlled Trial[NCT03636893] | Phase 2 | 74 participants (Actual) | Interventional | 2018-08-24 | Completed | ||
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma[NCT02545504] | Phase 3 | 432 participants (Actual) | Interventional | 2015-10-13 | Completed | ||
| Efficacy of Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Nondrinking Women Younger Than 50 Years Who Received Moderately Emetogenic Chemotherapy: A Randomized, Double-blind, Phase Ⅲ Trial[NCT03674294] | Phase 3 | 248 participants (Actual) | Interventional | 2015-08-04 | Completed | ||
| A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment in Participants With HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric Orgastroe[NCT03675737] | Phase 3 | 1,579 participants (Actual) | Interventional | 2018-11-08 | Active, not recruiting | ||
| Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma[NCT00052910] | Phase 3 | 546 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| A Randomized Phase II Trial of Perioperative Chemoimmunotherapy Verses Perioperative Chemoimmunotherapy Plus Preoperative Chemoradiation for Locally Advanced Gastric (G) or Gastroesophageal Junction (GEJ) Adenocarcinoma[NCT05161572] | Phase 2 | 152 participants (Anticipated) | Interventional | 2021-09-28 | Recruiting | ||
| A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Sintilimab in Gastric Cancer With Peritoneal Metastasis[NCT05648487] | Phase 2 | 46 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | ||
| Clinical Study of CT and MR in Staging and Prediction of Response in Patients With Gastric Cancer[NCT04028375] | 400 participants (Anticipated) | Observational | 2019-09-01 | Recruiting | |||
| A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction[NCT00849615] | Phase 2 | 252 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Radiotherapy, Chemotherapy and Anti-PD-1 Immunotherapy Followed by Surgical Resection in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Prospective, Single Arm, Phase II Trial[NCT06121700] | Phase 2 | 55 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) During Laparoscopic Resection in High-risk Gastric Cancer Patients: A Multicentre Phase-I Study (the PIPAC-OPC4 Study)[NCT04047004] | Phase 1 | 20 participants (Actual) | Interventional | 2020-03-11 | Completed | ||
| CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1[NCT04455282] | 100 participants (Anticipated) | Observational | 2021-02-01 | Recruiting | |||
| An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy[NCT01285557] | Phase 3 | 361 participants (Actual) | Interventional | 2011-04-14 | Terminated (stopped due to Due to significant changes in investigational and clinical practice landscape of frontline advanced gastric cancer, which challenged viability of trial and increased use of modified chemotherapeutic triplets led to slow participant accrual in study.) | ||
| A Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Patients With Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma[NCT00515411] | Phase 2 | 111 participants (Actual) | Interventional | 2006-10-23 | Completed | ||
| A Phase 2, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Second/Third-Line Treatment With NAB®-Paclitaxel (ABI-007) In Combination With Epigenetic Modifying Therapy Of CC-486, Or Immunotherapy of Durvalumab (MEDI4736), Or As Monotherapy [NCT02250326] | Phase 2 | 240 participants (Actual) | Interventional | 2015-01-07 | Completed | ||
| A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NS[NCT02027428] | Phase 3 | 427 participants (Actual) | Interventional | 2014-02-11 | Completed | ||
| A Randomized, Phase II, Placebo-controlled Study of Ipatasertib (GDC-0068), an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma[NCT01896531] | Phase 2 | 153 participants (Actual) | Interventional | 2013-08-14 | Completed | ||
| Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer[NCT01191697] | Phase 2 | 37 participants (Actual) | Interventional | 2011-02-28 | Active, not recruiting | ||
| A Phase II/III Study Comparing Simultaneous Integrated Boost (SIB) Intensity Modulated Radiation Therapy (IMRT) With S1 Based SIB-IMRT Followed by Adjuvant Chemotherapy With S1 in Elderly Patients With Esophageal or Esophagogastric Cancer (3JECROG-P01)[NCT02979691] | Phase 2/Phase 3 | 350 participants (Anticipated) | Interventional | 2016-10-31 | Completed | ||
| A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors[NCT02318329] | Phase 1 | 79 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL[NCT02205047] | Phase 2 | 171 participants (Anticipated) | Interventional | 2015-07-15 | Active, not recruiting | ||
| The Effect of Postoperative Supplemental Parenteral Nutrition (SPN) in Gastric Cancer Patients Who Underwent Gastrectomy: A Multicenter Prospective Randomized Controlled Trial[NCT04607057] | Phase 4 | 224 participants (Anticipated) | Interventional | 2020-12-22 | Recruiting | ||
| REAL 3 : A Randomised Open-labelled Multicentre Trial of the Efficacy of Epirubicin, Oxaliplatin and Capecitabine (EOX) With or Without Panitumumab in Previously Untreated Advanced Oesophago-gastric Cancer[NCT00824785] | Phase 3 | 574 participants (Actual) | Interventional | 2008-05-31 | Terminated (stopped due to Lack of efficacy) | ||
| Multicenter Randomized Controlled Trial to Evaluate the Strategy of Primary Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma (ADCI002 Study)[NCT01717924] | 314 participants (Anticipated) | Interventional | 2012-10-31 | Recruiting | |||
| Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| Approximation to the Therapeutic Individualization in Patients With Locally Advanced Gastric and Gastroesophageal Cancer Through Modelling and Generation of Predictive Gene Signatures[NCT02454673] | 121 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease[NCT00400179] | Phase 3 | 1,053 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| A Retrospective Study for Evaluation of Real-world Efficacy and Safety of Ramucirumab Plus Paclitaxel in Patients With Locally-advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma[NCT04192734] | 1,063 participants (Actual) | Observational | 2019-12-18 | Completed | |||
| A Prospective Study for Real-world Data (RWD) of Ramucirumab Plus Paclitaxel in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma[NCT04915807] | 222 participants (Anticipated) | Observational [Patient Registry] | 2021-06-30 | Not yet recruiting | |||
| A Phase I/II Trial of RAD001/Capecitabine in Refractory Gastric Cancer[NCT01099527] | Phase 1/Phase 2 | 59 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Phase 1 Study Of Sunitinib Malate In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer[NCT00555620] | Phase 1 | 76 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.[NCT02736552] | Phase 3 | 0 participants (Actual) | Interventional | 2016-03-31 | Withdrawn | ||
| Maintenance Treatment With S-1 Versus Observation After First-line Chemotherapy in Patients With Advanced Gastric Cancer: a Randomized Phase II Study[NCT03701373] | Phase 2 | 200 participants (Anticipated) | Interventional | 2016-01-01 | Recruiting | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| A Single-arm, Open Phase II Trial of CAPOX Combined With Bevacizumab Combined With Tirelizumab in First-line Treatment of PDL1 CPS < 5 Advanced Gastroesophageal Adenocarcinoma[NCT05299476] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-04-16 | Recruiting | ||
| Randomized Phase III Study of 5-FU Continuous Infusion (5-FUci) Versus CPT-11 Plus CDDP (CP) Versus S-1 Alone (S-1) in Advanced Gastric Cancer (JCOG9912)[NCT00142350] | Phase 3 | 690 participants | Interventional | 2000-11-30 | Completed | ||
| Open Label, Randomised, Multicenter Phase III Study of Adjuvant Chemotherapy in Radically Resected Adenocarcinoma of the Stomach or Gastroesophageal Junction: Comparison of a Sequential Treatment (CPT-11+5-FU/LV --> TXT+CDDP) Versus a 5-FU/LV Regimen[NCT01640782] | Phase 3 | 1,100 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| A Phase Ib/II Trial of Capeox Regimen Combined With Sintilimab and Bevacizumab in First-line Treatment for Recurrent or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma[NCT05640609] | Phase 1/Phase 2 | 57 participants (Anticipated) | Interventional | 2023-03-10 | Recruiting | ||
| A Double-blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-line Therapy in Patients With Advanced Gastric Cancer[NCT00548548] | Phase 3 | 774 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| A Randomized, Open-label Study of the Effect of First-line Herceptin in Combination With a Fluoropyrimidine and Cisplatin Versus Chemotherapy Alone on Overall Survival in Patients With HER2-positive Advanced Gastric Cancer[NCT01041404] | Phase 3 | 584 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects With Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment With Epirubicin, Cisplatin, an[NCT00719550] | Phase 1/Phase 2 | 130 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial[NCT00941655] | Phase 3 | 15 participants (Actual) | Interventional | 2009-07-22 | Completed | ||
| Placebo-controlled, Double-blinded Phase III Trial of XP (Capecitabine/CDDP) Simvastatin in Advanced Gastric Cancer Patients[NCT01099085] | Phase 3 | 207 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal (GEJ) Tumors: A Phase II Study[NCT00515216] | Phase 2 | 26 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers[NCT02296671] | Phase 2 | 0 participants (Actual) | Interventional | 2015-02-28 | Withdrawn (stopped due to Was unable to accrue any patients) | ||
| Docetaxel, Cisplatin and Fluorouracil Combination in the Neoadjuvant Treatment of Locally Advanced Gastric Adenocarcinoma : Phase II Clinical Study[NCT00343239] | Phase 2 | 59 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [NCT00477711] | Phase 2 | 41 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [NCT02870036] | Phase 1 | 243 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | ||
| Strategy Phase III Intergroup Study for Chemotherapy of the Metastatic or Locally Advanced Cancers of the Stomach[NCT00374036] | Phase 3 | 416 participants (Anticipated) | Interventional | 2005-06-30 | Completed | ||
| PET/MR-imaging and Circulating Tumour Cells to Evaluate the Response of Chemotherapy in Patients With Gastroesophageal Junction Cancer[NCT02433301] | 23 participants (Actual) | Observational | 2015-04-30 | Completed | |||
| A Randomized Phase II Study of Docetaxel in Combination With Oxaliplatin With or Without 5-FU or Capecitabine in Metastatic or Locally Recurrent Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease[NCT00382720] | Phase 2 | 275 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Hyperthermic Intraperitoneal Chemotherapy, Intravenous Chemotherapy Combined With Surgery for the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis[NCT02549911] | Phase 2 | 40 participants (Anticipated) | Interventional | 2015-09-30 | Recruiting | ||
| A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin vs Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) Gastric Adenocarcinoma[NCT00411229] | Phase 3 | 1,035 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Prediction of Benefit From Adjuvant Chemotherapy for pT1N1 Gastric Cancer: A Pilot Retrospective Multicenter Cohort Study[NCT03485105] | 1,000 participants (Anticipated) | Observational | 2017-11-01 | Active, not recruiting | |||
| A Randomized Phase III Trial of Postoperative Chemotherapy or Chemo-radiotherapy for Locally Advanced Gastric Cancer After D2 Resection[NCT03601988] | Phase 3 | 408 participants (Anticipated) | Interventional | 2018-07-28 | Recruiting | ||
| Apatinib Plus S-1 for Advanced Gastric Cancer Refractory to Oxaliplatin Plus Capecitabine Combination Therapy: A Single-arm, Phase-2, Home-based Trial[NCT04338438] | Phase 2 | 37 participants (Actual) | Interventional | 2015-05-01 | Completed | ||
| A Validation Study of Relationships Among Genomic Gene Expression Profile, Prognosis and Prediction of Adjuvant Chemotherapy Benefit With Capecitabine and Oxaliplatin in Gastric Cancer Stage II and III (6th AJCC) Patients After D2 Surgery Using a Phase 3 [NCT03403296] | 640 participants (Actual) | Observational | 2016-07-13 | Completed | |||
| Phase III Multicenter Randomized Controlled Trial of Adjuvant Chemoradiotherapy vs Chemotherapy for Radical Resected Advanced Gastric Carcinoma Concurrent With Lymph Node Metastasis and Lymphovascular Invasion[NCT03680261] | Phase 3 | 556 participants (Anticipated) | Interventional | 2018-10-01 | Not yet recruiting | ||
| Phase II Study of Adjusted-dose Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status.[NCT00733616] | Phase 2 | 44 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System[NCT05165602] | 30 participants (Anticipated) | Observational | 2022-01-01 | Not yet recruiting | |||
| Lapatinib Versus Lapatinib With Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A Randomized Phase II Trial[NCT01145404] | Phase 2 | 76 participants (Anticipated) | Interventional | 2010-06-30 | Terminated (stopped due to Changes of SoC for third line therapy resulting in poor recruitment) | ||
| [NCT02445209] | Phase 3 | 56 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Chemosensitivity Test to Evaluate the Effect of Adjuvant Cancer Chemotherapy (S-1) After Gastric Surgery[NCT00287755] | Phase 2 | 300 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer[NCT01198392] | Phase 3 | 270 participants (Anticipated) | Interventional | 2008-09-30 | Recruiting | ||
| A Phase I/II Study of Docetaxel, 5-Fluorouracil and Oxaliplatin (D-FOX) in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction[NCT00526110] | Phase 1/Phase 2 | 98 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Assessment of Cardiorespiratory Fitness and Lung Function in Lung Cancer Patients Undergoing Neoadjuvant Cancer Therapy and Role of Prehabilitation in Preventing Associated Decline[NCT05636969] | 25 participants (Anticipated) | Observational | 2023-02-01 | Not yet recruiting | |||
| A Pilot Study in Gastric Cancer of Assignment to Postoperative Chemoradiation or Chemotherapy Based Upon Surgical Lymph Node Assessment After Preoperative Chemotherapy, With Gene Assay as Correlate of Biologic Response[NCT03515941] | Early Phase 1 | 6 participants (Actual) | Interventional | 2018-06-22 | Terminated (stopped due to The PI has decided to close the study due to the outdated study design.) | ||
| A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMAb) In Combination With 5-Fluorouracil, Folinic Acid, And Oxaliplatin (mFOLFOX6) In Patients With Metastatic HER2-Negative G[NCT01590719] | Phase 2 | 123 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Toripalimab Combined With Docetaxel or Nab-paclitaxel in the Treatment of Advanced Gastric Cancer : a Single-arm, Open Label, Prospective Phase II Clinical Trial[NCT04563975] | Phase 2 | 54 participants (Anticipated) | Interventional | 2020-07-02 | Recruiting | ||
| Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach[NCT01246960] | Phase 2 | 168 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Phase II Study of S-1 Plus Leucovorin (1 Week on and 1 Week Off) as First-line Treatment for Patients With Metastatic and Recurrent Gastric Cancer[NCT02090153] | Phase 2 | 39 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination With 5-Fluorouracil, Folinic Acid, and Oxaliplatin (mFOLFOX6) in Patients With Metastatic HER2-Negative,[NCT01662869] | Phase 3 | 564 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| Phase 1 Study of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel for Peritoneal Carcinomatosis - PIPAC2 Study[NCT05395910] | Phase 1 | 36 participants (Anticipated) | Interventional | 2022-10-31 | Recruiting | ||
| PD-1 Antibody Adjuvant Therapy for Patients With MSI-H Advanced Gastric or Gastroesophageal Junction Cancer After Radical Surgery With D2 Dissection: a Phase II Single-center, Three-arm, Randomized Controlled Clinical Trial[NCT05468138] | Phase 2 | 141 participants (Anticipated) | Interventional | 2022-08-25 | Not yet recruiting | ||
| Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study[NCT02114359] | Phase 3 | 111 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552] | Phase 3 | 870 participants (Anticipated) | Interventional | 2013-08-19 | Recruiting | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| A Multicenter, Randomised Phase II Trial on the Therapy of Advanced Gastric Cancer or Adenocarcinoma of the Esophagogastric Junction in Patients Older Than 65 Years With Specific Regard of Quality of Life and Pharmacogenetic Risk Profile[NCT00737373] | Phase 2 | 143 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Phase I / II Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in the Second-line Treatment of Advanced Gastric Cancer[NCT04286711] | Phase 1/Phase 2 | 52 participants (Anticipated) | Interventional | 2020-03-31 | Not yet recruiting | ||
| Docetaxel and Irinotecan Combination as a Second Line Treatment of Metastatic Gastric Cancer; a Phase II Multicenter Study[NCT04770623] | Phase 2 | 24 participants (Actual) | Interventional | 2021-03-05 | Completed | ||
| A Prospective, Multicenter Clinical Study of Apatinib Plus Irinotecan as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junctional Adenocarcinoma[NCT03116555] | Phase 2 | 37 participants (Anticipated) | Interventional | 2017-04-05 | Recruiting | ||
| Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma[NCT02289547] | Phase 3 | 184 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar®) in Patients With Advanced Gastric Cancer[NCT01187212] | Phase 2 | 195 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer[NCT01396707] | Phase 2 | 55 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Phase I Trial of Irinotecan, Cisplatin, and Fluorouracil in Patients With Advanced Solid Tumor Malignancies[NCT00005791] | Phase 1 | 0 participants | Interventional | 1999-10-31 | Completed | ||
| Venous Thromboembolism and Bleeding Risk in Patients With Esophageal Cancer[NCT03646409] | 542 participants (Actual) | Observational | 2018-06-11 | Completed | |||
| Prospective Observational Study of Patients With Locally Advanced Gastric Cancer Treated With Perioperative Chemotherapy and Surgery[NCT01633203] | 61 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| Randomized, Placebo Controlled, Phase II Trial, on the Effect of an Oral Supplement,TK3 (Tryptophan and Thiamine) on the Quality of Life and Chemotherapy Tolerance in Cancer Patients With Advanced Disease.[NCT03341286] | Phase 2 | 140 participants (Anticipated) | Interventional | 2017-11-30 | Not yet recruiting | ||
| A Multicenter Randomized Phase III Trial of Neo-adjuvant Chemotherapy Followed by Surgery and Chemotherapy or by Surgery and Chemoradiotherapy in Resectable Gastric Cancer (CRITICS Study)[NCT00407186] | Phase 3 | 788 participants (Actual) | Interventional | 2007-01-11 | Active, not recruiting | ||
| A Phase I/II Study of Oblimersen in Combination With Cisplatin and Fluorouracil in Patients With Advanced Esophageal, Gastro-Esophageal Junction and Gastric Cancer[NCT00064259] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2003-06-30 | Terminated (stopped due to Discontinued development of G3139 (oblimersen)) | ||
| Apatinib Plus XELOX Regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With Lymph Node Metastasis[NCT03229096] | Phase 2 | 35 participants (Anticipated) | Interventional | 2017-02-01 | Recruiting | ||
| A Phase 3, Open-Label, Randomized Study to Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxaliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer Patients at Stage IIIB and IV (M0) (Based on AJCC Ed. 6) Who Received Radical Resecti[NCT01935778] | Phase 3 | 286 participants (Anticipated) | Interventional | 2013-10-02 | Recruiting | ||
| A Phase II Study of Lapatinib for the Treatment of Stage IV Melanoma Harboring ERBB4 Mutations[NCT01264081] | Phase 2 | 34 participants (Actual) | Interventional | 2011-05-20 | Terminated (stopped due to Protocol would not be able to reach stated accrual.) | ||
| A Randomized Phase II Study of Combination Chemotherapy With Epirubicin , Cisplatin and Capecitabine (ECX) or Cisplatin and Capecitabine (CX) in Advanced Gastric Cancer[NCT00743964] | Phase 2 | 91 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System[NCT02662348] | Phase 1 | 6 participants (Anticipated) | Interventional | 2016-02-29 | Enrolling by invitation | ||
| Randomized Phase II Open-Label Controlled Study of EMD 72000 (Matuzumab), in Combination With the Chemotherapy Regimen ECX or the Chemotherapy Regimen ECX Alone as First-line Treatment in Subjects With Metastatic Esophago-Gastric Adenocarcinoma[NCT00215644] | Phase 2 | 72 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Development of a Prospective Clinicobiological Database in Metastatic Digestive Cancers[NCT03978078] | 200 participants (Anticipated) | Interventional | 2016-09-12 | Recruiting | |||
| Diagnostic Value of Intraoperative Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases During Staging Laparoscopy for Gastric Adenocarcinoma: a Prospective, Multicentric Study.[NCT05687617] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-12-15 | Recruiting | ||
| Phase II Study of Trastuzumab in Combination With Chemotherapy (Docetaxel Plus Capecitabine) For First Line Treatment of Her2-Positive Advanced Gastric or Gastro-Esophageal Junction Cancer[NCT02004769] | Phase 2 | 67 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks[NCT02852096] | 600 participants (Anticipated) | Interventional | 2015-11-30 | Recruiting | |||
| Trastuzumab Plus XELOX for HER2-positive Stage III Gastric Cancer After D2 Gastrectomy：Prospective Observational Study.[NCT02250209] | Phase 2 | 40 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| A Phase 1B/2 Study of Trastuzumab, Bevacizumab With Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy (TREAZURE)[NCT05640830] | Phase 1/Phase 2 | 47 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| Efficacy and Prognostic Factors of Trastuzumab Based Therapy in HER2 Positive Advanced Gastric Cancer: a Single Center Prospective Observational Study[NCT03024450] | 98 participants (Actual) | Observational [Patient Registry] | 2012-01-31 | Completed | |||
| Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy and Systemic Chemotherapy in Gastric Cancer With Regional Peritoneal Metastasis, a Multicenter and Single-arm Phase III Study[NCT03023436] | Phase 3 | 220 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| A Phase I Study of the Efficacy and Safety of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors[NCT05707910] | Phase 1 | 9 participants (Anticipated) | Interventional | 2023-02-10 | Recruiting | ||
| A Phase II Study of Adjuvant Chemotherapy of S-1 With Oxaliplatin in Gastric Cancer at Stage IIIB/ IV (AJCC 6th) After D2 Resection[NCT02191566] | Phase 2 | 8 participants (Actual) | Interventional | 2015-05-31 | Terminated (stopped due to The patient's study enrollment was too low.) | ||
| Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by Oral Fluorouracil (UFT) in Serosa-positive Gastric Cancer (JCOG9206-2)[NCT00147147] | Phase 3 | 280 participants | Interventional | 1993-01-31 | Completed | ||
| A Study of 18F-FLT Positron Emission Tomography (PET)/Computed Tomography Imaging in Pediatrics With Myeloproliferative Neoplasms[NCT03121599] | 3 participants (Actual) | Interventional | 2017-06-11 | Terminated (stopped due to Delayed study materials, poor recruitment) | |||
| A Study of 18F-FLT Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Cases of Prefibrotic/Early Primary Myelofibrosis (PMF) and Essential Thrombocythemia (ET)[NCT03116542] | 21 participants (Anticipated) | Interventional | 2017-05-07 | Recruiting | |||
| Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903)[NCT04138212] | Phase 3 | 456 participants (Anticipated) | Interventional | 2019-10-22 | Recruiting | ||
| Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by Surgery for Thoracic Esophageal Squamous Cell Cancer: A Prospective, Single Arm, Pilot Study[NCT04776590] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-01-28 | Recruiting | ||
| Neoadjuvant Chemoradiotherapy VS. Neoadjuvant Chemotherapy Followed by Minimally Invasive Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma（cT3-4aN0-1M0):A Multi-center Prospective Randomized Clinical Trial[NCT03001596] | 264 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| A Phase II Trial of Perioperative Chemotherapy With Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Patients With Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma[NCT04999332] | Phase 2 | 58 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial[NCT02604615] | Phase 3 | 60 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| The Exploratory Study of Conversion Surgery for Apatinib in Combination With Oxaliplatin/S-1(SOX) for Patients With Unresectable Gastric Cancer[NCT03007446] | Phase 2 | 20 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| Multicentric Phase II Trial: Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years Old and More Presenting Gastric Cancer Locally Advanced or Metastatic[NCT00210184] | Phase 2 | 42 participants (Actual) | Interventional | 2004-07-21 | Completed | ||
| A Phase II Study of Neoadjuvant Chemotherapy With Modified FOLFOX6 Regimen and Effects of Tumor Regression in Locally Advanced Gastric Cancer[NCT02226380] | Phase 2 | 75 participants (Anticipated) | Interventional | 2013-10-31 | Recruiting | ||
| The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer: A Randomized Controlled Trial[NCT03607656] | Phase 2/Phase 3 | 270 participants (Actual) | Interventional | 2018-06-08 | Completed | ||
| Modified Folinic Acid-Fluorouracil-Oxaliplatin (FOLFOX) Followed by Capecitabine as First-line Chemotherapy for Elderly or Frail Patients With Metastatic or Recurrent Gastric Cancer[NCT02002195] | 47 participants (Anticipated) | Observational | 2013-11-30 | Recruiting | |||
| MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer Patients Previously Treated With Fluoropyrimidine and Platinum Agents MiCADO Study[NCT02007148] | Phase 2 | 51 participants (Anticipated) | Interventional | 2013-11-30 | Recruiting | ||
| Feasibility Study of Intraperitoneal Paclitaxel With Oxaliplatin and Capecitabine in Patients With Advanced Gastric Cancer[NCT01739894] | Phase 2 | 20 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| Neoadjuvant Transcatheter Arterial Chemoinfusion and Embolism (TACiE) for Patients With Locally Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction: a Pilot Study[NCT05396326] | Phase 1 | 20 participants (Anticipated) | Interventional | 2022-06-01 | Not yet recruiting | ||
| Neoadjuvant Transcatheter Arterial Chemoinfusion and Embolism (TACiE) for Patients With Locally Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction: a Prospective, Phase 2, Single Arm Trial.[NCT05346874] | Phase 2 | 37 participants (Anticipated) | Interventional | 2022-06-01 | Not yet recruiting | ||
| Multicenter, Open Lable Phase II Study to Evaluate the Safety and Efficacy of a Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine in Patients With Gastric Adenocarcinoma, Adenocarcinoma of the Gastro-esophageal Junction or the Distal E[NCT00865982] | Phase 2 | 50 participants (Anticipated) | Interventional | 2008-09-30 | Active, not recruiting | ||
| A Randomized Phase II Trial Comparing Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer (XParTS II)[NCT01406249] | Phase 2 | 100 participants (Anticipated) | Interventional | 2011-08-31 | Active, not recruiting | ||
| Retrospective Validation for Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy With S-1[NCT01905969] | 500 participants (Anticipated) | Observational | 2012-10-31 | Active, not recruiting | |||
| Prospective Controlled Randomized Comparative Study About Quality of Life (QoL), Immunomodulation and Safety of Adjuvant Mistletoe Treatment in Patients With Gastric Carcinoma Receiving Chemotherapy After Operation[NCT01401075] | Phase 4 | 32 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in Selected Centres[NCT00450203] | Phase 2/Phase 3 | 1,103 participants (Anticipated) | Interventional | 2007-10-31 | Recruiting | ||
| A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination With AMG 386 or Placebo in Subjects With Metastatic Gastric, Gastroesophageal Junctio[NCT00583674] | Phase 2 | 171 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| A Phase I Study of Capecitabine, Cisplatin and Imatinib in Patients With Unresectable or Metastatic Gastric Cancer.[NCT00601510] | Phase 1 | 38 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Phase 2 Study of Orally Administrated JBM-TC4 for the Prevention of Acute Radiation-induced Dermatitis in Breast Cancer Patients[NCT02289365] | Phase 2 | 120 participants (Actual) | Interventional | 2014-11-30 | Enrolling by invitation | ||
| A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330] | Phase 2 | 60 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Phase I/II Trial of Docetaxel and Oxaliplatin in Patients With Advanced Gastric Cancer[NCT00533533] | Phase 1/Phase 2 | 68 participants (Anticipated) | Interventional | 2006-01-31 | Completed | ||
| A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407] | Phase 1 | 27 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Phase II Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients[NCT01100801] | Phase 2 | 90 participants (Anticipated) | Interventional | 2010-07-31 | Recruiting | ||
| A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer[NCT00531245] | Phase 1/Phase 2 | 77 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma[NCT04059562] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-10-28 | Active, not recruiting | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Phase II Study of Docetaxel and Capecitabine as 1st Line Therapy for Patients With Locally Advanced or Metastatic Gastric Cancer[NCT00142038] | Phase 2 | 80 participants | Interventional | 2004-03-31 | Completed | ||
| A Phase II Study Of Docetaxel And Capecitabine In Patients With Measurable Metastatic Adenocarcinoma Of The Stomach And Gastroesophageal Junction[NCT00054457] | Phase 2 | 46 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| An Open Label, Sequential Multi-Center Multi Dose Study Of G17T Immunogen In Combination With Cisplatin (CDDP) And 5-Fluorouracil (5-FU) In Subjects With Metastatic Or Locally Recurrent Gastric Or Gastroesophageal Cancer Previously Untreated With Chemothe[NCT00020787] | Phase 3 | 8 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| Morbidity In Open Versus Minimally Invasive Hybrid Esophagectomy[NCT03035071] | 26 participants (Actual) | Interventional | 2010-05-01 | Completed | |||
| Assessment of a Robotic Distal Gastrectomy on Non-inferiority of N2 Area Nodal Dissection for Clinical Stage II or III Gastric Cancer[NCT02572050] | Phase 2 | 87 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| The Clinical Efficacy of Patient-derived Organoid-based Drug Sensitive Neoadjuvant Chemotherapy Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer: a Prospective Multi-center Randomized Controlled Study[NCT05351398] | 54 participants (Anticipated) | Observational | 2022-04-30 | Not yet recruiting | |||
| The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma.[NCT00674167] | Phase 2 | 21 participants (Actual) | Interventional | 2007-05-31 | Active, not recruiting | ||
| A RANDOMISED, CONTROLLED TRIAL OF PRE- AND POST-OPERATIVE CHEMOTHERAPY IN PATIENTS WITH OPERABLE GASTRIC CANCER[NCT00002615] | Phase 3 | 500 participants (Anticipated) | Interventional | 1994-06-30 | Completed | ||
| An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination With Epirubicin, Cisplatin and Capecitabine (ECX) Versus ECX Alone in Subjects With Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction.[NCT01234324] | Phase 2 | 171 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Docetaxel-based Chemoradiotherapy Plus Periradiation Chemotherapy in R0 Gastric Cancer[NCT02640898] | 500 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
| A Phase II Study of PN-401, 5-FU and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach[NCT00004233] | Phase 2 | 65 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score Through Registration[NCT02781285] | 1,500 participants (Anticipated) | Observational [Patient Registry] | 2014-12-31 | Recruiting | |||
| Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies[NCT02648711] | Phase 1 | 41 participants (Actual) | Interventional | 2015-10-31 | Terminated (stopped due to Company decision) | ||
| Open Label, Randomized Multicentre Phase II/III Study of Docetaxel in Combination With Cisplatin (CDDP) or Docetaxel in Combination With 5-Fluorouracil (5-FU) and CDDP Compared to the Combination of CDDP and 5-FU in Patients With Metastatic or Locally Rec[NCT00290966] | Phase 2/Phase 3 | 610 participants | Interventional | 1998-10-31 | Completed | ||
| A Clinical Experience Trial to Detect the Plasma Paclitaxel Drug Concentration in Chinese Non -Small Cell Lung Cancer (NSCLC) Patients Treated With a Paclitaxel Plus Carboplatin (TC) Regimens, and Explore Individualized Treatment Using Pharmacokinetically[NCT02737709] | Phase 2 | 51 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to The study have difficulty in recruiting subjectes) | ||
| A Phase I-II Trial of Dovitinib Plus Docetaxel as Second-line Chemotherapy in Patients With Metastatic or Unresectable Gastric Cancer After Failure of First-line Chemotherapy[NCT01921673] | Phase 1/Phase 2 | 14 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Taxotere-Cisplatin-5FU (TCF) Versus Taxotere-Cisplatin (TC) Versus Epirubicin-Cisplatin-5FU (ECF) as Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial[NCT00004873] | Phase 2 | 0 participants | Interventional | 1999-08-31 | Completed | ||
| A Randomized Trial of Irinotecan, Leucovorin, 5-FU (ILF) Versus ILF Plus Cisplatin (PILF) Combination Chemotherapy in Patients With Advanced Gastric Cancer[NCT00320294] | Phase 2 | 86 participants | Interventional | 2005-02-28 | Active, not recruiting | ||
| A Phase II Study of Docetaxel and Epirubicin Combination in Patients With Advanced Gastric Cancer.[NCT00375999] | Phase 2 | 34 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| White Blood Cells Gene Expression Profiles as a Tool for Predicting Metformin Efficacy in Patients With Type 2 Diabetes Mellitus[NCT01334684] | 100 participants (Anticipated) | Interventional | 2011-05-31 | Not yet recruiting | |||
| Randomized Multicenter Controlled Phase III Study of Postoperative Adjuvant Therapy for Stage II/IIIA Gastric Cancer Using TS-1 Alone or TS-1+PSK Combined Therapy[NCT00216034] | Phase 3 | 255 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Phase III Randomized Controlled Study of Postoperative Adjuvant Therapy Using TS-1 or TS-1+PSK for Stage II or III Gastric Cancer Patients[NCT00687843] | Phase 3 | 480 participants (Anticipated) | Interventional | 2008-06-30 | Active, not recruiting | ||
| Randomized Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Unresectable Advanced Gastric Carcinoma and Recurrent Gastric Carcinoma[NCT00503321] | Phase 2/Phase 3 | 13 participants (Actual) | Interventional | 2006-10-31 | Terminated (stopped due to Patients' enrollment was not sufficient.) | ||
| A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer[NCT01685489] | Phase 1 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to funding sequestered) | ||
| A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase[NCT00248404] | Phase 1/Phase 2 | 155 participants (Anticipated) | Interventional | 2005-09-30 | Completed | ||
| Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma[NCT00226473] | Phase 4 | 200 participants | Interventional | 2001-09-30 | Recruiting | ||
| Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.[NCT03562897] | Phase 2 | 40 participants (Actual) | Interventional | 2018-10-25 | Completed | ||
| Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer[NCT00718354] | Phase 3 | 740 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Induction Chemotherapy for Locally Advanced Esophageal Cancer: A Phase II Study[NCT03110926] | Phase 2 | 40 participants (Anticipated) | Interventional | 2017-06-19 | Active, not recruiting | ||
| Evaluation of Antibody-dependent Cell Cytotoxicity (ADCC) Against Gastric Cancer Cells[NCT02078362] | 30 participants (Anticipated) | Observational | 2013-09-30 | Recruiting | |||
| Comparative Study on the Efficacy of Lobaplatin and Paclitaxel in the Treatment of Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy[NCT04808466] | Phase 2 | 231 participants (Anticipated) | Interventional | 2021-09-18 | Recruiting | ||
| A Pilot Study of Immune Checkpoint Inhibition (Durvalumab With or Without Tremelimumab) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer[NCT02311361] | Phase 1/Phase 2 | 65 participants (Actual) | Interventional | 2015-03-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Clinical benefit rate is the percentage of combined patients who have achieved complete response (CR), partial response (PR), and stable disease (SD)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters~SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 33 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 22 |
Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 5.8 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 10.5 |
"Objective response (defined as complete response (CR) + partial response (PR) by RECIST 1.1 criteria)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 25 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 22 |
Overall survival is defined as the time interval from date of diagnosis to date of death from any cause. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 15.5 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 19.6 |
Duration of time from start of treatment to time of progression or death, whichever occurs first. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 8.4 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 13.8 |
Duration of time from start of treatment to time of progression. Progression is defined as At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 8.0 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 13.9 |
(NCT01928290)
Timeframe: 30 days after completion of treatment (estimated to be 5 months)
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia | Febrile neutropenia | Anal Fistula | Diarrhea | Hematemesis | Nausea | Peripheral ischemia | Vomiting | Fatigue | Laparoscopy surgery | Pain | Sepsis | Lung infection | Pneumonia | Hypernatremia | Neutrophil count decreased | Platelet count decreased | Anorexia | Dehydration | Hypokalemia | Back pain | Peripheral sensory neuropathy | Syncope | Dyspnea | Pleural embolism | Skin infection | Thromboembolic event | Abdominal pain | Enterocolitis | Hemorrhoids | G-tube infection | Neutropenic entercolitis | Alkaline phosphatase increased | |
| Arm A: FOLFIRINOX (HER2-negative) | 1 | 2 | 1 | 4 | 1 | 2 | 1 | 3 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 19 | 3 | 3 | 4 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 0 | 0 | 0 | 5 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
ECOG PS score is widely used by doctors and researchers to assess how a participants' disease is progressing, and is used to assess how the disease affects the daily living abilities of the participant, and determine appropriate treatment and prognosis. The score ranges from Grade 0 to Grade 5, where Grade 0 = Fully active, able to carry on all pre-disease performance without restriction, Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (like light house work, office work), Grade 2 = Ambulatory and capable of all self-care but unable to carry out any work activities, Grade 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours and Grade 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair, Grade 5 = Death. Number of participants with shift in ECOG PS Score to 1 or Higher Than 1 were reported. (NCT02625610)
Timeframe: From randomization into maintenance phase up to 1276 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Chemotherapy + Best Supportive Care (BSC) | 140 |
| Avelumab | 144 |
The ORR defined as the percentage of all randomized participants with a confirmed best overall response (BOR) of partial response (PR),or complete response (CR) according to RECIST v1.1 and as per Investigator assessment. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in sum of longest diameter (SLD) of all lesions. (NCT02625610)
Timeframe: From randomization into maintenance phase up to 1276 days
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy + Best Supportive Care (BSC) | 14.4 |
| Avelumab | 13.3 |
Overall Survival was defined as the time from randomization to the date of death due to any cause. For participants who were still alive at the time of data analysis or who were lost to follow-up, OS time was censored at the date of last contact. OS was measured using Kaplan-Meier (KM) estimates. (NCT02625610)
Timeframe: From randomization into maintenance phase up to 1276 days
| Intervention | months (Median) |
|---|---|
| Chemotherapy + Best Supportive Care (BSC) | 10.9 |
| Avelumab | 10.4 |
The PFS time was defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause (whichever occurs first). PFS was assessed as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as per IRC. PD was defined as at least a 20 percent (%) increase in the sum of longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates. (NCT02625610)
Timeframe: From randomization into maintenance phase up to 1276 days
| Intervention | months (Median) |
|---|---|
| Chemotherapy + Best Supportive Care (BSC) | 4.4 |
| Avelumab | 3.2 |
European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnoea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact. The EORTC QLQ-C30 GHS/QoL score ranges from 0 to 100; High score indicates better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL. (NCT02625610)
Timeframe: Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 3/4 | Week 7 | Week 13 | Week 19 | Week 25 | Week 31 | Week 37 | Week 43 | Week 49 | Week 55 | Week 61 | Week 67 | End Of Treatment | Safety Follow-Up | |
| Avelumab | 0.85 | -1.01 | 0.24 | 1.37 | 0.41 | 1.85 | 1.77 | 3.33 | 4.01 | 4.00 | 2.38 | 4.90 | -11.67 | -9.29 |
| Chemotherapy + Best Supportive Care (BSC) | 1.30 | -1.44 | -2.50 | -5.85 | -4.43 | -3.09 | -1.39 | -1.19 | 1.52 | 0.00 | -5.00 | 0.00 | -11.54 | -7.51 |
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22 ) supplements the EORTC QLQ-C30 to assess symptoms and treatment-related side effects commonly reported in participants. There are 22 questions which comprise 5 scales (dysphagia, pain, reflux symptom, dietary restrictions, and anxiety) and 4 single items (dry mouth, hair loss, taste, body image). Most questions use 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms. (NCT02625610)
Timeframe: Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dysphagia: Week 3/4 | Dysphagia Week 7 | Dysphagia Week 13 | Dysphagia Week 19 | Dysphagia Week 25 | Dysphagia Week 31 | Dysphagia Week 37 | Dysphagia Week 43 | Dysphagia Week 49 | Dysphagia Week 55 | Dysphagia Week 61 | Dysphagia Week 67 | Dysphagia End Of Treatment | Dysphagia Safety Follow-Up | Pain Week 3/4 | Pain Week 7 | Pain Week 13 | Pain Week 19 | Pain Week 25 | Pain Week 31 | Pain Week 37 | Pain Week 43 | Pain Week 49 | Pain Week 55 | Pain Week 61 | Pain Week 67 | Pain End Of Treatment | Pain Safety Follow-Up | Reflux Week 3/4 | Reflux Week 7 | Reflux Week 13 | Reflux Week 19 | Reflux Week 25 | Reflux Week 31 | Reflux Week 37 | Reflux Week 43 | Reflux Week 49 | Reflux Week 55 | Reflux Week 61 | Reflux Week 67 | Reflux End of Treatment | Reflux Safety Follow-up | Eating Restrictions Week 3/4 | Eating Restrictions Week 7 | Eating Restrictions Week 13 | Eating Restrictions Week 19 | Eating Restrictions Week 25 | Eating Restrictions Week 31 | Eating Restrictions Week 37 | Eating Restrictions Week 43 | Eating Restrictions Week 49 | Eating Restrictions Week 55 | Eating Restrictions Week 61 | Eating Restrictions Week 67 | Eating Restrictions EOT | Eating Restrictions Safety Follow-up | Anxiety Week 3/4 | Anxiety Week 7 | Anxiety Week 13 | Anxiety Week 19 | Anxiety Week 25 | Anxiety Week 31 | Anxiety Week 37 | Anxiety Week 43 | Anxiety Week 49 | Anxiety Week 55 | Anxiety Week 61 | Anxiety Week 67 | Anxiety End of Treatment | Anxiety Safety Follow-Up | |
| Avelumab | 0.60 | 1.34 | 0.65 | 1.52 | 1.69 | 4.39 | -0.67 | -2.59 | 1.23 | 0.89 | 1.06 | 1.31 | 8.21 | 7.25 | -0.04 | 2.60 | 0.16 | -0.51 | -1.55 | 0.97 | -1.26 | -1.94 | -0.62 | -1.00 | -1.59 | -0.49 | 9.45 | 10.99 | 0.12 | 0.50 | -1.09 | -1.68 | 1.69 | -1.29 | -4.38 | -5.56 | -2.06 | -3.56 | -6.35 | 0.00 | 4.73 | 2.90 | 0.13 | -0.27 | 0.00 | -0.63 | -1.55 | 0.39 | -3.28 | -3.89 | -5.25 | -6.00 | -5.56 | -2.45 | 10.01 | 11.59 | -4.06 | -1.20 | -2.83 | -1.68 | -1.69 | -0.52 | -1.01 | -1.11 | -6.17 | -4.00 | -4.76 | -1.96 | 5.89 | 4.99 |
| Chemotherapy + Best Supportive Care (BSC) | 0.76 | 2.84 | 1.60 | -0.58 | -1.39 | 0.82 | -7.19 | -4.76 | -3.03 | 0.00 | 0.00 | -1.85 | 7.27 | 9.39 | 1.51 | 2.53 | 2.96 | 3.22 | -1.56 | 4.01 | -4.90 | 1.79 | 1.52 | 0.00 | 3.33 | 0.00 | 9.25 | 8.22 | 1.04 | 0.31 | 0.99 | 1.75 | 0.69 | -2.06 | -6.54 | -3.17 | 1.01 | 2.22 | 6.67 | 7.41 | 3.43 | 1.56 | 0.73 | 0.98 | 1.02 | -2.34 | -2.08 | -2.47 | -8.82 | -4.76 | 0.76 | 3.33 | 0.00 | 1.39 | 8.27 | 7.04 | -0.28 | -1.30 | -0.86 | -1.56 | -2.78 | 4.12 | -3.92 | -3.97 | 0.00 | 2.22 | -4.44 | 9.26 | 4.58 | 5.48 |
EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall composite health state index score, with scores ranging from -0.594 to 1. A higher score indicates better health state. (NCT02625610)
Timeframe: Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)
| Intervention | Units on Scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 3/4 | Week 7 | Week 13 | Week 19 | Week 25 | Week 31 | Week 37 | Week 43 | Week 49 | Week 55 | Week 61 | Week 67 | End Of Treatment | Safety Follow-Up | |
| Avelumab | 0.004 | -0.009 | -0.017 | -0.011 | 0.014 | 0.013 | 0.013 | 0.058 | 0.026 | 0.028 | 0.031 | 0.039 | -0.138 | -0.099 |
| Chemotherapy + Best Supportive Care (BSC) | -0.002 | -0.032 | -0.053 | -0.039 | -0.049 | -0.023 | -0.035 | -0.046 | -0.100 | -0.164 | -0.091 | -0.076 | -0.125 | -0.062 |
EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. (NCT02625610)
Timeframe: Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)
| Intervention | Millimeter (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 3/4 | Week 7 | Week 13 | Week 19 | Week 25 | Week 31 | Week 37 | Week 43 | Week 49 | Week 55 | Week 61 | Week 67 | End Of Treatment | Safety Follow-Up | |
| Avelumab | 0.6 | -2.1 | -0.7 | -0.1 | -1.4 | 1.4 | 0.9 | 3.2 | 2.1 | 3.4 | 3.5 | 4.9 | -10.3 | -9.6 |
| Chemotherapy + Best Supportive Care (BSC) | 0.9 | -0.5 | -3.2 | -3.5 | -4.5 | -2.3 | -1.7 | -4.4 | -2.9 | -9.4 | -6.4 | -7.3 | -12.2 | -8.0 |
Blood samples were collected for the analysis of following hematology parameters: lymphocyte count, neutrophil count, white blood cells, platelet count, lipase, serum amylase, creatinine phosphokinase and creatinine. The hematology parameters were graded according to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case (Grade 4) post Baseline is presented. Only those participants with increase to grade 4 have been presented. (NCT02625610)
Timeframe: From baseline up to 1276 days
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| lymphocyte count decreased | neutrophil count decreased | white blood cells decreased | platelet count decreased | lipase increased | serum amylase increased | creatinine phosphokinase increased | creatinine increased | |
| Avelumab | 1 | 1 | 0 | 0 | 8 | 2 | 2 | 1 |
| Chemotherapy + Best Supportive Care (BSC) | 0 | 6 | 2 | 1 | 6 | 3 | 0 | 0 |
Vital signs assessment included Systolic blood pressure (SBP), Diastolic blood pressure (DBP) and Pulse Rate (PR). Number of Participants with any potentially clinically significant abnormalities in vital signs were reported. Clinical significance was determined by the investigator. (NCT02625610)
Timeframe: From randomization into maintenance phase up to 1276 days
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Increased in Systolic blood pressure | Decreased in Systolic blood pressure | Increased in Diastolic blood pressure | Decreased in Diastolic blood pressure | Increased in pulse rate | Decreased in pulse rate | |
| Avelumab | 62 | 69 | 24 | 26 | 48 | 30 |
| Chemotherapy + Best Supportive Care (BSC) | 57 | 43 | 14 | 21 | 46 | 32 |
ECG parameters included heart rate, pulse rate intervals, QRS interval, QT interval corrected based on Fridericia's formula (QTcF) intervals and QTcB intervals. Clinical significance was determined by the investigator. Number of participants with potentially clinically significant ECG abnormalities were reported. (NCT02625610)
Timeframe: From randomization into maintenance phase up to 1276 days
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Decreased heart rate | Increased heart rate | Increased Pulse Rate interval | Increased QRS interval | QTcF interval greater than (>)450milisecond (ms)less than or equal to(<=)480ms | QTcF interval: > 480 ms <= 500 ms | QTcF interval: > 500 ms | QTcB Interval: > 450 msec <= 480 msec | QTcB Interval: > 480 msec <= 500 msec | QTcB Interval: > 500 msec | |
| Avelumab | 1 | 2 | 3 | 8 | 9 | 3 | 1 | 18 | 2 | 3 |
| Chemotherapy + Best Supportive Care (BSC) | 0 | 2 | 1 | 5 | 9 | 2 | 3 | 19 | 2 | 5 |
Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in participant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs. Number of participants with TEAEs and serious TEAEs were reported. (NCT02625610)
Timeframe: From randomization into maintenance phase up to 1276 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any TEAEs | Any Serious TEAE | |
| Avelumab | 223 | 89 |
| Chemotherapy + Best Supportive Care (BSC) | 214 | 75 |
ORR was defined as the percentage of participants who achieve a complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. CR was defined as the disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT02545504)
Timeframe: Up to 135.4 weeks at the time of final analysis
| Intervention | percentage of participants (Number) |
|---|---|
| Andecaliximab + mFOLFOX6 | 50.5 |
| Placebo + mFOLFOX6 | 41.1 |
OS was defined as the time interval from the date of randomization to death from any cause. (NCT02545504)
Timeframe: Andecaliximab + mFOLFOX6 median follow-up at the time of final analysis: 19.43 months; Placebo + mFOLFOX6 median follow-up at the time of the final analysis: 19.45 months
| Intervention | months (Median) |
|---|---|
| Andecaliximab + mFOLFOX6 | 12.52 |
| Placebo + mFOLFOX6 | 11.76 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. TEAEs are events in a given study period that meet any of the following criteria: Any AE with onset date of on or after andecalizimab/placebo start date and no later than 30 days after permanent discontinuation of all study treatment (andecaliximab/placebo and chemotherapy) or Any AEs with onset date of on or after the andecaliximab/placebo start date and no later than 55 days after permanent discontinuation of andecaliximab/placebo or AEs leading to discontinuation of andecaliximab/placebo. (NCT02545504)
Timeframe: First dose date up to the last dose date (maximum:161.7 weeks) plus 30 to 55 days
| Intervention | percentage of participants (Number) |
|---|---|
| Andecaliximab + mFOLFOX6 | 99.1 |
| Placebo + mFOLFOX6 | 99.5 |
PFS was defined as the interval of time from the date of randomization to the earlier of the first documentation of definitive disease progression or death from any cause. (NCT02545504)
Timeframe: Andecaliximab + mFOLFOX6 median follow-up at the time of the final analysis: 18.64 months; Placebo + mFOLFOX6 median follow-up at the time of the final analysis: 18.74 months
| Intervention | months (Median) |
|---|---|
| Andecaliximab + mFOLFOX6 | 7.46 |
| Placebo + mFOLFOX6 | 7.06 |
Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening. Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any post-baseline time point, up to 30 days after the last dose of all study treatment, or 55 days after the last dose of andecaliximab/placebo for participants who permanently discontinued all study treatments. If the relevant baseline laboratory value is missing, then any abnormality of at least Grade 1 was considered treatment-emergent. (NCT02545504)
Timeframe: First dose date up to the last dose date (maximum: 161.7 weeks) plus 30 to 55 days
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Hematology | Serum Chemistry | Coagulation | |
| Andecaliximab + mFOLFOX6 | 94.4 | 91.7 | 7.4 |
| Placebo + mFOLFOX6 | 89.5 | 92.9 | 3.3 |
DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 8.0 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.7 |
DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 8.3 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 |
DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 10.9 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.8 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE is presented. (NCT03675737)
Timeframe: Up to 33.7 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 257 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 204 |
An AE was defined as any untoward medical occurrence, in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one AE is presented. (NCT03675737)
Timeframe: Up to 36.7 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 776 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 771 |
ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 51.3 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 42.0 |
ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 52.1 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 42.6 |
ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 60.6 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 43.0 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 45.9 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 12.9 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 11.5 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 45.9 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 13.0 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 11.4 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 45.9 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 15.7 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 11.8 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 6.9 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 6.9 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 8.1 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 |
Disease free survival is defined as the time from the date of study enrollment to death or documented second primary tumor, or cancer recurrence.The distribution of disease free survival time will be estimated using the method of Kaplan-Meier. (NCT00052910)
Timeframe: From the date of study enrollment until death or documented second primary tumor, or cancer recurrence; up to 4 years
| Intervention | years (Median) |
|---|---|
| Arm I (5-FU/LV) | 2.7 |
| Arm II (ECF) | 2.3 |
Overall survival is defined as the time from study enrollment to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier. (NCT00052910)
Timeframe: From study enrollment until death from any cause; up to 3 years
| Intervention | years (Median) |
|---|---|
| Arm I (5-FU/LV) | 3.6 |
| Arm II (ECF) | 3.5 |
Duration of response was defined as the time (in months) from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to <10 mm. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 5.1 |
| 5FU+Cisplatin | 4.2 |
An AE was any untoward medical condition that occurred in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication [maximum duration: 35.7 months]). (NCT01285557)
Timeframe: From first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| S-1+Cisplatin | 157 |
| 5FU+Cisplatin | 78 |
ORR was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR) based on the Investigator review of the images and application of Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to less than (<) 10 millimeter (mm). PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | percentage of participants (Number) |
|---|---|
| S-1+Cisplatin | 34.7 |
| 5FU+Cisplatin | 19.8 |
OS was defined as the time from randomization to the date of death for the ITT population. Participants who did not die were censored at the date last known to be alive. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From the date of randomization until disease progression or death, cut-off date: 15 August 2014 (approximately 40 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 7.5 |
| 5FU+Cisplatin | 6.6 |
PFS was defined as the time from date of randomization until date of radiological disease progression or death due to any cause. Disease Progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, where any of the 3 criteria have been met: 1) at least 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum on study, including the baseline sum, 2) Progression in no-target lesion(s), 3) appearance of new lesion(s) Participants who were alive with no PD were censored at the date of the last tumor assessment. Participants who received new anticancer therapy before disease progression were censored at the date of the last evaluable tumor assessment before new anticancer therapy was initiated. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of randomization until disease progression or death, cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 4.4 |
| 5FU+Cisplatin | 3.9 |
TTF was defined as the time from date of randomization until date of PD (clinical or radiologic), or permanent discontinuation of study treatment (S-1 or 5-FU), or death due to any cause. Participates who were still on study treatment at the time of the analysis were censored at the last date the participants was known to be on treatment. (NCT01285557)
Timeframe: From date of randomization until disease progression, cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 4.2 |
| 5FU+Cisplatin | 3.8 |
TTR was defined as the time (in months) from the date of randomization to the date of first observation of response (PR or CR) (whichever status was recorded first). TTR was assessed based on investigator assessment utilizing RECIST 1.1. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to <10 mm. PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 1.8 |
| 5FU+Cisplatin | 1.9 |
AE was defined as any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication [maximum duration: 35.7 months]). (NCT01285557)
Timeframe: From first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| TEAE | TESAE | |
| 5FU+Cisplatin | 111 | 31 |
| S-1+Cisplatin | 214 | 63 |
"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, or similar definition as accurate and appropriate" (NCT00515411)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months
| Intervention | percentage of paticipants (Mean) |
|---|---|
| Arm A, - Modified DCF | 63 |
| ARM B - Parent DCF With G-CSF | 53 |
| Arm C - Modified DCF+ Trastuzumab | 73 |
Overall survival measured in months (NCT00515411)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 43 months
| Intervention | months (Median) |
|---|---|
| Arm A, - Modified DCF | 18.8 |
| ARM B - Parent DCF With G-CSF | 12.6 |
| Arm C - Modified DCF+ Trastuzumab | 24.9 |
Dose intensity was the cumulative dose divided by the dosing period in weeks. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | mg/ week (Mean) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 716.66 |
Dose intensity was the cumulative dose divided by the dosing period in weeks). (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | mg/week (Mean) |
|---|---|
| Nab-Paclitaxel + Durvalumab Combination Arm | 279.96 |
Dose intensity was the cumulative dose divided by the dosing period in weeks. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | mg/m^2/week (Mean) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 54.73 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 57.18 |
| Nab-Paclitaxel Alone | 58.61 |
Overall survival was defined as the time in months between randomization/treatment assignment and death from any cause. Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off, whichever was earlier. Participants who were lost to follow-up prior to the end of the study or who were withdrawn from the study were censored at the time of last contact. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; participants were followed for overall survival up to 30 months
| Intervention | Months (Median) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 8.1 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 10.1 |
| Nab-Paclitaxel Alone | 17.0 |
Progression-free survival was defined as the time in months from the date of randomization/assignment to the date of disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria documented by computed tomography (CT) scan, not including symptomatic deterioration, or death (any cause) on or prior to the clinical cut-off date, which ever occurred earlier. Participants who did not have disease progression and had not died, regardless of whether they were discontinued from treatment, were censored at the date of last tumor assessment, on or prior to the clinical cut-off date that the participant was progression free. Progressive Disease was defined as at least a 20% increase in the sum of diameters of target lesions from nadir. (NCT02250326)
Timeframe: From date of first dose of IP to DP; up to data cut-off date of 30 August (Aug) 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 December (Dec) 2017 for Durva + nab-paclitaxel; participants were followed for PFS for up to 18 months
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 3.2 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 4.5 |
| Nab-Paclitaxel Alone | 4.2 |
Overall Response was defined as percentage of participants who achieved a radiologic confirmed complete response or partial response according to RECIST V 1.1 criteria and compared with baseline among all tumor assessments, where baseline was the last CT obtained prior to or on Day 1 of treatment. Per RECIST V 1.1 criteria, a CR is defined as a disappearance of all target lesions; a PR is defined as having at least a 30% decrease in the sum of diameters of target lesions from baseline. Responses were evaluated every 6 weeks. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | percentage of participants (Number) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 13.6 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 27.8 |
| Nab-Paclitaxel Alone | 16.3 |
"Disease control rate was defined as the percentage of participants who had a CR, PR or SD during the course of the study, according to RECIST version 1.1 criteria, as evaluated by the investigator. RECIST Version 1.1 criteria is defined as follows:~Complete Response is the disappearance of all target lesions;~Partial Response is at least a 30% decrease in the sum of diameters of target lesions from baseline;~Stable Disease is neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease. Responses were evaluated every 6 weeks." (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | Percentage of Participants (Number) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 65.4 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 70.9 |
| Nab-Paclitaxel Alone | 67.5 |
The discontinuation rate was defined as the percentage of participants who had study drug discontinued and was assessed throughout the conduct of the study. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | percentage of participants (Number) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 100.0 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 80.8 |
| Nab-Paclitaxel Alone | 96.2 |
TEAEs were defined as any adverse event or serious adverse event that occurred or worsened on or after the day of the first dose of the IP through 28 days after the last dose of IP for Arms A and C or up to 90 days after the last dose for Arm B, and those SAEs made known to the investigator at any time thereafter that are suspected of being related to IP. A serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild l intervention/therapy required Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death. (NCT02250326)
Timeframe: TEAEs were collected up to 4 weeks after receiving last dose of IP for nab-paclitaxel and CC-486 + nab-paclitaxel, and up to 90 days after the last IP dose for Durva + nab-paclitaxel; TEAEs were collected up to 86.1 weeks
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAE | Serious TEAE | Grade (GR) 3/4 TEAE | Grade 3 or Higher | Treatment Related TEAE | Treatment Related Serious TEAE | Treatment Related GR 3 or Higher TEAE | TEAE With Action to Reduce/Interrupt IP | Treatment-Related to Reduce or Interrupt IP | TEAE with Action Taken to Withdraw IP | TEAE with Fatal Outcome | Treatment Related TEAE with Fatal Outcome | |
| Nab-Paclitaxel + CC-486 Combination Arm | 79 | 30 | 48 | 49 | 74 | 11 | 32 | 49 | 36 | 8 | 4 | 0 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 78 | 37 | 53 | 55 | 71 | 17 | 32 | 57 | 32 | 9 | 12 | 4 |
| Nab-Paclitaxel Alone | 78 | 29 | 47 | 47 | 68 | 5 | 25 | 38 | 27 | 8 | 3 | 1 |
A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities. (NCT02250326)
Timeframe: Up to 16 Jan 2017 for CC-486 + nab-paclitaxel and up to 23 Dec 2017 for nab-paclitaxel and Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | Percentage of Participants (Number) |
|---|---|
| Nab-Paclitaxel | |
| Nab-Paclitaxel Alone | 10.1 |
A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities. (NCT02250326)
Timeframe: Up to 16 Jan 2017 for CC-486 + nab-paclitaxel and up to 23 Dec 2017 for nab-paclitaxel and Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Nab-Paclitaxel | CC-486 | |
| Nab-Paclitaxel + CC-486 Combination Arm | 10.1 | 20.3 |
A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities. (NCT02250326)
Timeframe: Up to 16 Jan 2017 for CC-486 + nab-paclitaxel and up to 23 Dec 2017 for nab-paclitaxel and Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Nab-Paclitaxel | Durvalumab (Reductions Not Allowed per Protocol) | |
| Nab-Paclitaxel + Durvalumab Combination Arm | 14.1 | 0.0 |
Duration of overall response was measured from the time criteria were first met for CR/PR until the first date the recurrent or progressive disease (PD) was radiologically documented. Participants who did not have PD after the response were censored on the date of last tumor assessment. If a participant died before PD, the participant was censored on the date of death. (NCT02027428)
Timeframe: Between Day 1 of the Induction Period through to the date of disease progression or death; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study.
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + BSC: Induction + Maintenance | 5.95 |
| BSC: Induction + Maintenance | 4.60 |
Overall survival was defined as the duration in months between randomization and death from any cause. Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off (01 August 2019 whichever was earlier. The last contact date was the date of the last record in the database, or if the subject was lost to follow-up, the last known date that the subject was alive. (NCT02027428)
Timeframe: From the date of randomization to death from any cause; up to 01 August 2019; survival follow up was 55.89 months
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + Best Supportive Care (BSC) | 17.61 |
| Best Supportive Care (BSC) | 12.16 |
Overall survival was defined as the time in months from Day 1 of treatment for the Induction part to death from any cause. Subjects who were alive at the time of analysis had their OS censored at the date or last contact of 01 August 2019, whichever was earlier. The last contact date was the date of the last record in the database, or if the subject was lost to follow-up, the last known date that the subject was alive. (NCT02027428)
Timeframe: Between Day 1 of treatment in the Induction Part to death from any cause; up to 01 August 2019; survival follow up was 55.89 months
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + BSC: Induction + Maintenance | 20.57 |
| BSC: Induction + Maintenance | 15.05 |
Progression-free survival is defined as the time in months from the date of randomization to the date of disease progression based on the investigator's assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by computerized axial tomography [CT scan], not including symptomatic deterioration) or death (any cause) on or prior to 01 Aug 2019. RECIST 1.1 Definition: - Complete response (CR) -disappearance of all target lesions; - Partial response (PR) -at least a 30% decrease in the sum of diameters of target lesions from baseline - Stable disease (SD) -neither sufficient shrinkage to qualify for partial response (PR) nor sufficient increase of lesions to qualify for progressive disease (PD) - Progressive Disease (PD) - At least a 20% increase in the sum of diameters of target lesions from nadir, and/or the appearance of new lesions. (NCT02027428)
Timeframe: From the date of randomization to the date of disease progression or death of any cause; up to data cut off date of 15 September 2017; up to 27.6 months
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + Best Supportive Care (BSC) | 3.12 |
| Best Supportive Care (BSC) | 2.60 |
PFS was defined as the time in months from Day 1 of treatment for the Induction part to the date of disease progression according to RECIST 1.1 criteria (documented by CT-scan, not including symptomatic deterioration) or death (any cause) on or prior to 01 August 2019, whichever occurred earlier. RECIST 1.1 Definition: - Progressive Disease (PD) - At least a 20% increase in the sum of diameters of target lesions from nadir; the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of new lesions is also considered progression. (NCT02027428)
Timeframe: Between Day 1 of the Induction Part through to the date of disease progression or death; up to 01 August 2019; the maximum treatment duration was 234.1 weeks for entire study
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + BSC: Induction + Maintenance | 6.47 |
| BSC: Induction + Maintenance | 5.55 |
Overall response in the maintenance period was defined as the percentage of participants who showed an improvement in best overall response from stable disease (SD) or partial response (PR) during Induction to a Complete Response (CR) or PR during Maintenance according to RECIST 1.1 criteria and confirmed in no less than 28 days. Evaluation takes as reference the lesion measurement or status at the last tumor assessment before randomization to Maintenance. The 95% CI was calculated using Clopper-Pearson method. RECIST 1.1 Definition: - Complete response-disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. - Partial response-at least a 30% decrease in the sum of diameters of target lesions from baseline. - Stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease. (NCT02027428)
Timeframe: For the induction period the maximum treatment was 19 weeks for the maintenance period the maximum treatment was 150 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Nab-Paclitaxel + BSC: Induction + Maintenance | 9.6 |
| BSC: Induction + Maintenance | 3.0 |
Overall response was defined as the percentage of participants with a confirmed assessment of complete response (CR) or partial response (PR) according to RECIST 1.1 criteria and confirmed in no less than 28 days. The 95% confidence interval (CI) was calculated using Clopper-Pearson method. RECIST 1.1 Definition: - Complete response-disappearance of all target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to < 10 mm. - Partial response-at least a 30% decrease in the sum of diameters of target lesions from baseline. (NCT02027428)
Timeframe: Day 1 of treatment in the induction period and subsequent anticancer therapy, death or discontinuation up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study
| Intervention | percentage of participants (Number) |
|---|---|
| Nab-Paclitaxel + BSC: Induction + Maintenance | 69.1 |
| BSC: Induction + Maintenance | 57.6 |
Disease control rate was defined as the percentage of participants who had radiologic CR, PR or SD for >= 6 weeks according to RECIST 1.1 criteria as determined by the investigator. Only participants with a confirmed CR/PR are included in this summary. Two timeframes are offered: - Time to confirmed response within the Induction timeframe. - Time to Confirmed Response Over the Entire Study, i.e. the time from Day 1 of treatment in Induction to the first occurrence of confirmed CR/PR any time during the study. RECIST 1.1 Definition: - CR- disappearance of all target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to < 10 mm. - PR- at least a 30% decrease in the sum of diameters of target lesions from baseline; - SD- neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for PD. The 95% CI was calculated using Clopper-Pearson method. (NCT02027428)
Timeframe: Induction is from Day 1 to a maximum treatment time of 19 weeks; entire study from Day 1 induction through maintenance up to PD; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study
| Intervention | percentage of participants (Number) |
|---|---|
| All Participants - Induction | 47.9 |
| Nab-Paclitaxel + BSC: Induction + Maintenance | 99.3 |
| BSC: Induction + Maintenance | 100.0 |
Time to confirmed complete or partial response (CR/PR) is defined as the time from day 1 of treatment in Induction to the first occurrence of confirmed CR/PR. Two timeframes are offered: - Time to confirmed response within the Induction timeframe. - Time to Confirmed Response Over the Entire Study, i.e. the time from Day 1 of treatment in Induction to the first occurrence of confirmed CR/PR any time during the study. Only participants with a confirmed CR or PR are included in this summary. (NCT02027428)
Timeframe: Induction is from Day 1 to a maximum treatment time of 19 weeks; entire study from Day 1 Induction through Maintenance up to PD; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study
| Intervention | months (Median) |
|---|---|
| All Participants - Induction | 1.446 |
| Nab-Paclitaxel + BSC: Induction + Maintenance | 1.478 |
| BSC: Induction + Maintenance | 1.413 |
TEAE in the Induction part is defined as any adverse event (AE) with an onset on or after Day 1 of treatment for the Induction part, and on or before the day of randomization for subjects who entered into the Maintenance part, or, for subjects who did not enter into the Maintenance part, before the treatment discontinuation date plus 28 days or any serious AE which occurred thereafter but was determined to be related to any study drug by the investigator. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild, Grade 2 = Moderate Grade, 3 = Severe Grade, 4 = Life threatening, Grade 5 = Death. Relation to study drug was determined by the investigator. (NCT02027428)
Timeframe: Day 1 of Induction up to Week 23 (maximum treatment in Induction plus 4 weeks if not continuing into Maintenance)
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAE | Serious TEAE | Severity Grade 3/4 TEAE | Severity Grade 3 or higher TEAE | Treatment-related (trt-related) TEAE | Trt-related serious TEAE | TEAE-study drug dose reduced or interrupted | Trt-related TEAE-dose reduced or interrupted | TEAE-study drug withdrawn | Trt-related TEAE-study drug withdrawn | TEAE-outcome of death | Trt-related TEAE-outcome of death | |
| All Participants - Induction | 419 | 177 | 337 | 340 | 408 | 82 | 341 | 301 | 55 | 35 | 32 | 7 |
| TEAE Specific to Carboplatin | NA | NA | NA | NA | 394 | 73 | 291 | 236 | 53 | 29 | NA | 6 |
| TEAE Specific to Nab-Paclitaxel | NA | NA | NA | NA | 407 | 80 | 340 | 292 | 55 | 34 | NA | 7 |
TEAE over entire study is defined as any adverse event (AE) with an onset on or after Day 1 of treatment for the Induction part, and before the treatment discontinuation date plus 28 days, or any serious AE which occurred thereafter but was determined to be related to any study drug by the investigator. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life threatening, Grade 5 = Death. Relation to study drug was determined by the investigator. (NCT02027428)
Timeframe: From Day 1 up to 01 August 2019; (maximum treatment length plus 28 days); the maximum treatment duration was 234.1 weeks for entire study
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAE | Serious TEAE | Severity Grade 3/4 TEAE | Severity Grade 3 or higher TEAE | Treatment-related (trt-related) TEAE | Trt-related serious TEAE | TEAE-study drug dose reduced or interrupted | Trt-related TEAE-dose reduced or interrupted | TEAE-study drug withdrawn | Trt-related TEAE- study drug withdrawn | TEAE-outcome of death | Trt-related TEAE-outcome of death | |
| BSC: Induction + Maintenance | 62 | 21 | 48 | 48 | 61 | 8 | 52 | 45 | 0 | 1 | 2 | 0 |
| BSC: TEAE Specific to BSC | NA | NA | NA | NA | 1 | 0 | 1 | 0 | 0 | 0 | NA | 0 |
| BSC: TEAE Specific to Carboplatin | NA | NA | NA | NA | 58 | 7 | 45 | 37 | 1 | 0 | NA | 0 |
| BSC: TEAE Specific to Nab-Paclitaxel | NA | NA | NA | NA | 61 | 8 | 52 | 45 | 1 | 0 | NA | 0 |
| Nab-Paclitaxel + BSC: Induction + Maintenance | 130 | 54 | 108 | 109 | 129 | 22 | 115 | 107 | 22 | 18 | 4 | 0 |
| Nab-Paclitaxel + BSC: TEAE Specific to BSC | NA | NA | NA | NA | 18 | 1 | 17 | 0 | 20 | 2 | NA | 0 |
| Nab-Paclitaxel + BSC: TEAE Specific to Carboplatin | NA | NA | NA | NA | 123 | 16 | 95 | 85 | 1 | 1 | NA | 0 |
| Nab-Paclitaxel + BSC: TEAE Specific to Nab-Paclitaxel | NA | NA | NA | NA | 129 | 22 | 113 | 104 | 22 | 18 | NA | 0 |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Death on study was defined as death from any cause within 30 days of the last dose of study treatment regimen. (NCT01896531)
Timeframe: Baseline until end of study (up to approximately 7.5 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Ipatasertib + mFOLFOX6 | 70 |
| Placebo + mFOLFOX6 | 80 |
Duration of objective tumor response in participants with measurable soft tissue disease at baseline was defined as the time from first observation of an objective tumor response until first observation of disease progression, as assessed by the investigator per modified RECIST Version 1.1. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or progression of non-target lesions. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, up to end of study (up to approximately 7.5 years)
| Intervention | months (Median) | ||
|---|---|---|---|
| Randomized | PTEN Loss Tumor | Akt Dx+ | |
| Ipatasertib + mFOLFOX6 | 4.63 | 4.70 | 4.70 |
| Placebo + mFOLFOX6 | 5.85 | 5.98 | 6.80 |
Objective Response Rate was defined as the percentage of participants achieving either a complete response (CR) or a partial response (PR) based on the investigator assessment using RECIST v 1.1. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, up to end of study (up to approximately 7.5 years)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Randomized | PTEN Loss Tumors | Akt Dx+ | |
| Ipatasertib + mFOLFOX6 | 52.1 | 50.0 | 52.2 |
| Placebo + mFOLFOX6 | 57.3 | 73.3 | 56.5 |
OS was defined as the time from the date of randomization to the date of death from any cause. Kaplan-Meier estimates were used for evaluation. (NCT01896531)
Timeframe: Baseline up to end of study (up to approximately 7.5 years)
| Intervention | months (Median) | ||
|---|---|---|---|
| Randomized | PTEN Loss Tumors | Akt Dx+ | |
| Ipatasertib + mFOLFOX6 | 11.96 | 14.82 | 11.66 |
| Placebo + mFOLFOX6 | 15.31 | 21.78 | 17.22 |
PFS was defined as the time from randomization to the first occurrence of disease progression (as determined using RECIST Version 1.1 and assessed by the investigator), or death from any cause on study. Progressive disease (PD): At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or progression of non-target lesions. Death on study was defined as death from any cause within 30 days of the last dose of study treatment regimen. Kaplan-Meier estimates were used for evaluation. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, assessed up to approximately 1.75 years
| Intervention | months (Median) | |
|---|---|---|
| All Randomized Participants | Participants With PTEN Loss Tumors | |
| Ipatasertib + mFOLFOX6 | 6.57 | 7.10 |
| Placebo + mFOLFOX6 | 7.52 | 7.39 |
(NCT01896531)
Timeframe: Day 1 at 1 hour and 4 hours post-dose; Day 5, pre-dose and 2 hours post-dose
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| Day 1: 1 hour post-dose | Day 1: 4 hours post-dose | Day 5: pre-dose | Day 5: 2 hours post-dose | |
| Ipatasertib + mFOLFOX6 | 506 | 389 | 90.7 | 557 |
DOR is defined as the time from date of first documented confirmed objective response to date of first documented progressive disease (PD). Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated. (NCT01191697)
Timeframe: 23.2 months (IQR: 11.0 - 46.9 months ).
| Intervention | months (Median) |
|---|---|
| Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine | 14.9 |
Overall survival based on the Kaplan-Meier method is defined as the time from randomization to death. Participants alive are censored at the last date of contact (including lost-to-follow-up) or at the date of withdrawal of consent, if relevant. (NCT01191697)
Timeframe: 23.2 months (IQR: 11.0 - 46.9 months ).
| Intervention | months (Median) |
|---|---|
| Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine | 23.2 |
PFS is defined as the duration of time from study entry to documented disease progression (PD) requiring removal from the study or death. Participants alive without PD were censored at the earliest of the date of the last disease evaluation or start of new anticancer therapy. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated. (NCT01191697)
Timeframe: Patients received a median of 19 cycles of therapy (Interquartile range (IQR): 8 - 34.5 cycles). Median duration of follow up of 23.2 months (IQR: 11.0 - 46.9 months ).
| Intervention | months (Median) |
|---|---|
| Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine | 14.0 |
ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions. (NCT01191697)
Timeframe: Patients received a median of 19 cycles of therapy (Interquartile range (IQR): 8 - 34.5 cycles). Median duration of follow-up of 23.2 months (IQR: 11.0 - 46.9 months ).
| Intervention | percentage of patients (Number) |
|---|---|
| Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine | 81 |
Duration of complete or partial response with 95% confidence intervals in gastric cancer population. (NCT02318329)
Timeframe: 16 weeks on average
| Intervention | Weeks (Median) |
|---|---|
| Part 1/2: FPA144 Dose Expansion Gastric or Other Solid Tumors | 14.1 |
Number of Participants with AEs and clinical laboratory abnormalities (Parts 1B and 2 only) (NCT02318329)
Timeframe: 16 weeks on average
| Intervention | Participants (Count of Participants) |
|---|---|
| Part 1B: FPA144 Dose Escalation Gastric Cancer 3mg/kg | 1 |
| Part 1B: FPA144 Dose Escalation Gastric Cancer 6 mg/kg | 1 |
| Part 1B: FPA144 Dose Escalation Gastric Cancer 10 mg/kg | 6 |
| Part 2: FPA144 Dose Expansion Gastric or Other Solid Tumors | 48 |
Number of participants with grade 3 and grade 4 adverse events (AE) and clinical laboratory abnormalities defined as dose limiting toxicities (DLTs) (NCT02318329)
Timeframe: 4 weeks on average
| Intervention | Participants (Count of Participants) |
|---|---|
| Part 1A: FPA144 Dose Escalation Solid Tumors 0.3 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 1 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 3 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 6 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 10 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 15 mg/kg | 0 |
| Part 1B: FPA144 Dose Escalation Gastric Cancer 3mg/kg | 0 |
| Part 1B: FPA144 Dose Escalation Gastric Cancer 6 mg/kg | 0 |
| Part 1B: FPA144 Dose Escalation Gastric Cancer 10 mg/kg | 0 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT02318329)
Timeframe: 16 weeks on average
| Intervention | Participants (Count of Participants) |
|---|---|
| Part 1A: FPA144 Dose Escalation Solid Tumors 0.3 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 1.0 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 3.0 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 6.0 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 10 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 15 mg/kg | 0 |
| Part 1B: FPA144 Dose Escalation Gastric Cancer 3mg/kg | 0 |
| Part 1B: FPA144 Dose Escalation Gastric Cancer 6mg/kg | 1 |
| Part 1B: FPA144 Dose Escalation Gastric Cancer 10mg/kg | 1 |
| Part 2: FPA144 Dose Expansion Gastric or Other Solid Tumors | 4 |
"Sampling following the first dose in Part 1, pre and post-dose at selected cycles, and at the end of treatment for both Part 1 and Part 2.~• Summary of area under serum concentration-time curve, maximum serum concentration," (NCT02318329)
Timeframe: 16 weeks on average
| Intervention | ug*day/ml (Mean) |
|---|---|
| Phase 1a Dose Escalation 1 mg/kg | 1.288 |
| Phase 1a Dose Escalation 3 mg/kg | 1.547 |
| Phase 1a Dose Escalation 6 mg/kg | 1.427 |
| Phase 1a Dose Escalation 10 mg/kg | 1.863 |
| Phase 1a Dose Escalation 15 mg/kg | 1.697 |
| Phase 1b Dose Escalation in Gastric Cancer 3 mg/kg | 2.69 |
| Phase 1b Dose Escalation in Gastric Cancer 6 mg/kg | 1.59 |
| Phase 1b Dose Escalation in Gastric Cancer 10 mg/kg | 1.648 |
| Part 2: FPA144 Dose Expansion Gastric or Other Solid Tumors | 1.867 |
"Sampling following the first dose in Part 1, pre and post-dose at selected cycles, and at the end of treatment for both Part 1 and Part 2.~• Summary of area under serum concentration-time curve, maximum serum concentration," (NCT02318329)
Timeframe: 16 weeks on average
| Intervention | ug/ml (Mean) |
|---|---|
| Phase 1a Dose Escalation 1 mg/kg | 0.2483 |
| Phase 1a Dose Escalation 3 mg/kg | 0.3117 |
| Phase 1a Dose Escalation 6 mg/kg | 0.2873 |
| Phase 1a Dose Escalation 10 mg/kg | 0.4097 |
| Phase 1a Dose Escalation 15 mg/kg | 0.3847 |
| Phase 1b Dose Escalation in Gastric Cancer 3 mg/kg | 0.4900 |
| Phase 1b Dose Escalation in Gastric Cancer 6 mg/kg | 0.232 |
| Phase 1b Dose Escalation in Gastric Cancer 10 mg/kg | 0.2990 |
| Part 2: FPA144 Dose Expansion Gastric or Other Solid Tumors | 0.3145 |
Duration of response was defined as the time from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was the disappearance of all target lesions for at least 4 weeks, PR was at least a 30% decrease in the sum of the longest diameter of target lesions, and PD was at least a 20% increase in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient was randomized).
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 6.5 |
| 5-FU/Cisplatin | 5.8 |
Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient. (NCT00400179)
Timeframe: The cutoff date for survival analysis was 07 March 2008 (12 months after last patient randomized).
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 8.6 |
| 5-FU/Cisplatin | 7.9 |
The proportion of patients with objective evidence of complete response (CR) or partial response (PR) based on tumor response assessments. Per the Response Evaluation Criteria in Solid tumors (RECIST), CR was defined as the disappearance of all target lesions for at least 4 weeks, and PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient randomized).
| Intervention | Percentage of patients in each group (Number) |
|---|---|
| S-1/Cisplatin | 29.1 |
| 5-FU/Cisplatin | 31.9 |
The time from randomization to date of first documented PD or date of death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of first documented PD, date of death, or until data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 4.8 |
| 5-FU/Cisplatin | 5.5 |
The time from randomization to date of permanent discontinuation of S-1 or 5-FU, first documented PD, or death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of permanent discontinuation of S-1 or 5-FU, first documented PD, death, or data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 3.8 |
| 5-FU/Cisplatin | 3.8 |
DR defined as time from start of first documented objective tumor response (CR or PR) to first documented objective tumor progression or death due to any cause, whichever occurs first. (NCT00555620)
Timeframe: Baseline up to Month 15
| Intervention | months (Median) |
|---|---|
| SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | 14.1 |
| SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | 6.3 |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 10.5 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 5.9 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 6.3 |
Any DLT event in Cycle 1: Grade (GR) 3/4 nausea, vomiting, or diarrhea despite anti-emetics, anti-diarrheals; GR 3 nonhematological toxicity for greater than or equal to (≥)7 days (except alopecia, skin or hair discoloration, hyperamylasemia, or hyperlipasemia without other clinical evidence of pancreatitis and asymptomatic hyperuricemia); GR 4 nonhematological toxicity; GR 4 neutropenia ≥7 days or thrombocytopenia; GR ≥3 febrile neutropenia or neutropenic infection; GR 3 thrombocytopenia ≥7 days; any treatment-related toxicity having >3 consecutive CAP or SU missed doses per cycle; delayed toxicity recovery >14 days. (NCT00555620)
Timeframe: Baseline up to Day 21
| Intervention | participants (Number) |
|---|---|
| SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | 1 |
| SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | 0 |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 3 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 2 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0 |
Percentage of participants with an objective response-based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all target lesions. PR defined as ≥30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. (NCT00555620)
Timeframe: Baseline, Day 21 of every even-numbered cycle up to 15 months
| Intervention | percentage of participants (Number) |
|---|---|
| SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | 16.7 |
| SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | 42.9 |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 46.7 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 43.5 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 45.5 |
PFS defined as time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. (NCT00555620)
Timeframe: Baseline up to Month 15
| Intervention | months (Median) |
|---|---|
| SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | 3.2 |
| SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | 6.6 |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 6.4 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 8.0 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 2.8 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 5.5 |
Area under the plasma concentration-time curve from time 0 to 24 hours postdose (0-24), also considered the AUC between doses at steady state. (NCT00555620)
Timeframe: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
| Intervention | nanogram hours per milliliter (ng*hr/mL) (Mean) | ||
|---|---|---|---|
| AUC (0-24) SU011248 | AUC (0-24) SU012662 | AUC (0-24) total drug (SU011248+SU012662) | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 844 | 321 | 1163 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 902 | 327 | 1230 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 1420 | 524 | 1944 |
AUC (12) = Area under the plasma concentration versus time curve from time zero (predose) to the extrapolated time 12 hours postdose. It is obtained from AUC (0 - last) plus AUC (last - 12) (NCT00555620)
Timeframe: Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng*hr/mL (Mean) | |||
|---|---|---|---|---|
| CAP (n = 1, 4, 9) | 5'DFCR (n = 1, 7, 10) | 5'DFUR (n = 1, 6, 10) | 5-FU (n = 1, 5, 10) | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 25435 | 15522 | 15522 | 1299 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 8865 | 10091 | 10291 | 842 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2663 | 7087 | 4822 | 353 |
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng*hr/mL (Mean) | |||
|---|---|---|---|---|
| CAP (n = 1, 4, 10) | 5'DFCR (n = 1, 7, 10) | 5'DFUR (n = 1, 6, 10) | 5-FU (n = 1, 5, 9) | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 7480 | 9200 | 7770 | 386 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 8069 | 11467 | 9099 | 489 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2828 | 8853 | 5703 | 285 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)
| Intervention | ng*hr/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 7555 | 13532 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 7373 | 8213 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2899 | 3157 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)
| Intervention | ng*hr/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 355 | 688 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 506 | 854 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 291 | 350 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)
| Intervention | ng*hr/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 12815 | 8614 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 11229 | 9776 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 8028 | 6464 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)
| Intervention | ng*hr/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 8855 | 8500 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 8951 | 10017 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 5658 | 4829 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 176 | 552 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 495 | 866 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 165 | 153 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 4800 | 5500 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 8017 | 8036 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 3352 | 2267 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 4010 | 6259 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 7166 | 10082 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2891 | 2074 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 7000 | 20491 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 11681 | 16276 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2051 | 1989 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 0.0 | 0.0 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.8 | 0.0 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 0.0 | 0.0 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 11.1 | 50.5 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 55.60 | 0.00 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 13.0 | 0.00 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 0.0 | 33.5 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 34.4 | 0.0 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2.4 | 0.0 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 24.8 | 32.0 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.0 | 0.0 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 0.0 | 0.0 |
(NCT00555620)
Timeframe: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
| Intervention | nanograms per milliliter (ng/mL) (Mean) | ||
|---|---|---|---|
| Cmax SU011248 | Cmax SU012662 | Cmax total drug (SU011248+SU012662) | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 40.1 | 14.0 | 53.9 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 46.5 | 16.6 | 62.4 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 69.7 | 23.7 | 93.0 |
(NCT00555620)
Timeframe: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| Cmin SU011248 | Cmin SU012662 | Cmin total drug (SU011248+SU012662) | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 29.0 | 11.9 | 41.6 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 30.2 | 11.1 | 41.8 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 49.2 | 18.7 | 68.5 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | hr (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 0.8 | 0.6 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.6 | 0.6 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 1.2 | 1.1 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | hr (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 0.7 | 0.7 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.8 | 0.8 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 1.0 | 1.1 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | hr (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 0.7 | 0.6 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.7 | 0.7 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 1.0 | 1.0 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | hr (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 0.3 | 0.4 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.4 | 0.4 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 0.3 | 0.5 |
(NCT00555620)
Timeframe: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
| Intervention | hour (hr) (Median) | ||
|---|---|---|---|
| Tmax SU011248 | Tmax SU012662 | Tmax total drug (SU011248+SU012662) | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 4.0 | 9.0 | 4.0 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 8.0 | 6.0 | 6.0 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 8.0 | 8.0 | 8.0 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | hr (Median) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 4.5 | 0.4 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.6 | 0.5 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2.0 | 3.0 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | hr (Median) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 4.3 | 0.4 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.6 | 0.5 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2.0 | 3.0 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | hr (Median) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 4.5 | 0.4 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.8 | 0.5 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2.0 | 3.0 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | hr (Median) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 4.3 | 0.3 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.5 | 0.4 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2.0 | 2.0 |
Duration of response during first line therapy is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first) during first line therapy. This was only be calculated for participants who achieved a best overall response of CR or PR. Participants who did not progress or die after they had a confirmed response were censored at the date of their last tumor measurement or last follow up for progression of disease during first line therapy. Median duration of response was estimated using the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization to the end of study, up to 26 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab | 7.1 |
| Placebo | 5.8 |
The primary efficacy endpoint for this study was overall survival (time to death), defined as the time between randomization and the date of death irrespective of the cause of death. Patients for whom no death was captured on the clinical database were censored at the most recent date they were known to be alive. Median survival was estimated by the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization until death, up to 26 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab | 12.1 |
| Placebo | 10.1 |
Progression-free survival (PFS) is defined as the time between randomization and the date of first documented disease progression or death, whichever occurs first. Patients who neither progressed nor died at the time of study completion or who were lost to follow-up were censored at the date of the last tumor assessment or last follow up for progression of disease. Median PFS was estimated using the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization until disease progression or death, up to 26 months.
| Intervention | months (Median) |
|---|---|
| Bevacizumab | 6.7 |
| Placebo | 5.3 |
Progression-free survival (PFS) during first-line therapy is defined as the time between randomization and the date of first documented disease progression or death, whichever occurs first and only if it occurs no later than 28 days after last confirmed intake of any study medication and only if it occurs before the start of non-study antineoplastic treatment. Participants who did not progress or die in this interval or were lost to follow-up were censored at the date of the last tumor assessment within this time window. Median PFS was estimated using the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization until 28-days after the last study treatment was administered, up to 26 months.
| Intervention | months (Median) |
|---|---|
| Bevacizumab | 6.9 |
| Placebo | 5.4 |
Time to progression is defined as the time from randomization to the first occurrence of progressive disease (PD). PD was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, or appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Patients with no PD at study completion (including those who died before PD) were censored at the date of the last tumor assessment. Median time to PD was estimated using the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization until disease progression; assessed every 6 weeks for the first year and every 12 weeks thereafter, up to 26 months.
| Intervention | months (Median) |
|---|---|
| Bevacizumab | 7.0 |
| Placebo | 5.6 |
Best overall response during first-line therapy is defined as the occurrence of either a confirmed complete (CR) or a partial (PR) best overall response, as determined by the RECIST criteria. CR is defined as the disappearance of all target and non-target lesions and PR is defined as at least a 30% decrease in the sum of the longest diameter of target lesions and no new or progression of non-target lesions, or the disappearance of all target lesions and persistence of one or more non-target lesion(s). (NCT00548548)
Timeframe: From randomization until the end of study, up to 26 months.
| Intervention | participants (Number) | |
|---|---|---|
| Responders | Non-responders | |
| Bevacizumab | 143 | 168 |
| Placebo | 111 | 186 |
The intensity of Adverse Events (AEs) was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0 on a five-point scale from Grade 1 (Mild) to Grade 5 (Death). A serious AE (SAE) was defined as any event that is fatal, life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above. (NCT00548548)
Timeframe: From randomization until 3 months after last dose (up to 26 months)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Any Adverse event | Serious AE | Grade 3/4/5 AE | Grade 5 AE | Deaths not due to Progression | |
| Bevacizumab | 380 | 134 | 293 | 18 | 31 |
| Placebo | 377 | 137 | 294 | 25 | 29 |
Disease control for participants with measurable disease was defined as a complete response (CR), partial response (PR) or stable disease (SD) for 6 weeks or longer, as determined by the RECIST criteria. For participants without measurable disease, disease control was defined as no disease progression for ≥ 6 weeks. (NCT00548548)
Timeframe: From randomization until the end of study, up to 26 months.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with Disease Control | Participants without Disease Control | |
| Bevacizumab | 300 | 87 |
| Placebo | 271 | 116 |
(NCT01041404)
Timeframe: BL
| Intervention | kg (Median) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 60 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 61 |
The median time, in months, of the duration of response. Participants were censored at the date of death, the date of last tumor measurement, the last date in study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | months (Median) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 4.8 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 6.9 |
Duration of response was defined for responders as the time from the date on which the CR or PR was first recorded to the date on which PD is first noted. Participants were censored on the date of death, the date of last tumor measurement, the last date in study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | percentage of participants (Number) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 80.0 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 71.9 |
The median time, in months, from the date of randomization to the date of an OS event. Participants were censored at the last date tumor measurement, the last date in the study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: BL, Days 1, 8, 15, 22, 43, 64, 85, 106, 127, and every 21 days until the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | months (Median) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 11.1 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 13.8 |
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: Baseline (BL), Days 1, 8, 15, 22, 43, 64, 85, 106, 127, and every 21 days until the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | percentage of participants (Number) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 62.8 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 56.8 |
Clinical benefit was defined as stable disease (SD), CR, or PR for 6 weeks or longer as determined by RECIST. For TLs, SD was defined as neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD, taking as a reference the smallest SLD recorded since treatment had started. For NTLs, SD was defined as a persistence of one or more NTLs and/or maintenance of tumor marker levels above the normal limits. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | percentage of participants (Number) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 69.3 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 78.9 |
For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD. For NTLs, a CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | percentage of participants (Number) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 34.5 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 47.3 |
The median time, in months, from the date of randomization to the date of a PFS event. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | months (Median) |
|---|---|
| Fluoropyrimidine, Cisplatin | 5.5 |
| Trastuzumab, Fluoropyrimidine, Cisplatin | 6.7 |
PFS was defined as the time from the date of randomization to the date of the first documentation of progressive disease (PD) or date of death, whichever occurs first. For target lesions (TL), PD was defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD) of TLs, taking as a reference the smallest SLD recorded since the treatment started, or the appearance of one or more lesions. For non-target lesions (NTL), PD was defined as an unequivocal progression of existing NTLs. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | percentage of participants (Number) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 81.0 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 76.9 |
Individual steady state predicted exposure, as assessed by median AUC (measured as mg multiplied by [*] day per liter [L]) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion. Individual steady state AUC was calculated using all available PK samples from all timepoints. (NCT01041404)
Timeframe: Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106
| Intervention | mg*day/L (Median) |
|---|---|
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 1030 |
The median time, in months, from the date of randomized to the date of a TTP event. Participants were censored at the last date of tumor assessment, the last date in the study drug log, or the last date of follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | months (Median) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 5.6 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 7.1 |
TTP was defined as the time from the date of randomization and the date of the first occurrence of PD. Participants were censored at the last date of tumor assessment, the last date in the study drug log, or the last date of follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | percentage of participants (Number) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 74.1 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 70.7 |
Median Cmax (measured as mg/L) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion. (NCT01041404)
Timeframe: Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106
| Intervention | mg/L (Median) |
|---|---|
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 128 |
Median Cmin (measured as milligrams per liter [mg/L]) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion. (NCT01041404)
Timeframe: Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106
| Intervention | mg/L (Median) |
|---|---|
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 23.0 |
The QLQ-STO22 is a gastric cancer quality of life questionnaire. There are 22 questions concerning disease, treatment related symptoms, side effects, dysphagia, nutritional aspects, and questions about the emotional problems of gastric cancer (dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss). The questions are grouped into five scales and 4 single items which are related to the symptoms of the disease. Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms. (NCT01041404)
Timeframe: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | scores on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dysphagia Scale: BL (n=276,287) | Dysphagia Scale: Week 4 (n=234,250) | Dysphagia Scale: Week 7 (n=181,220) | Dysphagia Scale: Week 10 (n=176,203) | Dysphagia Scale: Week 13 (n=152,183) | Dysphagia Scale: Week 16 (n=120,165) | Dysphagia Scale: Week 19 (n=114,143) | Dysphagia Scale: Week 22 (n=79,143) | Dysphagia Scale: Week 25 (n=64,124) | Dysphagia Scale: Week 28 (n=47,111) | Dysphagia Scale: Week 31 (n=45,95) | Dysphagia Scale: Week 34 (n=37,87) | Dysphagia Scale: Week 37 (n=29,64) | Dysphagia Scale: Week 40 (n=24,55) | Dysphagia Scale: Week 43 (n=12,43) | Dysphagia Scale: Week 46 (n=14,42) | Dysphagia Scale: Week 49 (n=10,36) | Dysphagia Scale: Week 52 (n=8,30) | Dysphagia Scale: Week 55 (n=6,24) | Dysphagia Scale: Week 58 (n=6,21) | Dysphagia Scale: Week 61 (n=4,17) | Dysphagia Scale: Week 64 (n=3,20) | Dysphagia Scale: Week 67 (n=4,16) | Dysphagia Scale: Week 70 (n=3,14) | Dysphagia Scale: Week 73 (n=3,12) | Dysphagia Scale: Week 76 (n=3,8) | Dysphagia Scale: Week 79 (n=3,9) | Dysphagia Scale: Week 82 (n=2,6) | Dysphagia Scale: Week 85 (n=2,6) | Dysphagia Scale: Week 88 (n=2,6) | Dysphagia Scale: Week 91 (n=2,4) | Dysphagia Scale: Week 94 (n=2,6) | Dysphagia Scale: Week 97 (n=1,5) | Dysphagia Scale: Week 100 (n=1,4) | Dysphagia Scale: Week 103 (n=1,4) | Dysphagia Scale: Week 106 (n=1,4) | Dysphagia Scale: Week 109 (n=1,4) | Dysphagia Scale: Week 112 (n=1,5) | Dysphagia Scale: Week 115 (n=1,4) | Dysphagia Scale: Week 118 (n=1,5) | Dysphagia Scale: Week 121 (n=1,5) | Dysphagia Scale: Week 124 (n=1,5) | Dysphagia Scale: Week 127 (n=1,3) | Dysphagia Scale: Week 130 (n=0,3) | Dysphagia Scale: Week 133 (n=1,3) | Dysphagia Scale: Week 136 (n=0,2) | Dysphagia Scale: Week 139 (n=0,2) | Dysphagia Scale: Week 142 (n=0,2) | Dysphagia Scale: Week 145 (n=0,1) | Dysphagia Scale: Final Visit (n=157,159 | Pain Scale: BL (n=276,287) | Pain Scale: Week 4 (n=234,250) | Pain Scale: Week 7 (n=181,219) | Pain Scale: Week 10 (n=176,203) | Pain Scale: Week 13 (n=152,183) | Pain Scale: Week 16 (n=120,165) | Pain Scale: Week 19 (n=114,143) | Pain Scale: Week 22 (n=79,143) | Pain Scale: Week 25 (n=64,124) | Pain Scale: Week 28 (n=47,111) | Pain Scale: Week 31 (n=45,95) | Pain Scale: Week 34 (n=37,87) | Pain Scale: Week 37 (n=29,64) | Pain Scale: Week 40 (n=24,55) | Pain Scale: Week 43 (n=12,43) | Pain Scale: Week 46 (n=14,42) | Pain Scale: Week 49 (n=10,36) | Pain Scale: Week 52 (n=8,30) | Pain Scale: Week 55 (n=6,24) | Pain Scale: Week 58 (n=6,21) | Pain Scale: Week 61 (n=4,17) | Pain Scale: Week 64 (n=3,20) | Pain Scale: Week 67 (n=4,16) | Pain Scale: Week 70 (n=3,14) | Pain Scale: Week 73 (n=3,12) | Pain Scale: Week 76 (n=3,8) | Pain Scale: Week 79 (n=3,9) | Pain Scale: Week 82 (n=2,6) | Pain Scale: Week 85 (n=2,6) | Pain Scale: Week 88 (n=2,6) | Pain Scale: Week 91 (n=2,6) | Pain Scale: Week 94 (n=2,6) | Pain Scale: Week 97 (n=1,5) | Pain Scale: Week 100 (n=1,4) | Pain Scale: Week 103 (n=1,4) | Pain Scale: Week 106 (n=1,4) | Pain Scale: Week 109 (n=1,4) | Pain Scale: Week 112 (n=1,5) | Pain Scale: Week 115 (n=1,4) | Pain Scale: Week 118 (n=1,5) | Pain Scale: Week 121 (n=1,5) | Pain Scale: Week 124 (n=1,5) | Pain Scale: Week 127 (n=1,3) | Pain Scale: Week 130 (n=0,3) | Pain Scale: Week 133 (n=1,3) | Pain Scale: Week 136 (n=0,2) | Pain Scale: Week 139 (n=0,2) | Pain Scale: Week 142 (n=0,2) | Pain Scale: Week 145 (n=0,1) | Pain Scale: Final Visit (n=157,160) | Reflux Symptoms Scale: BL (n=275,287) | Reflux Symptoms Scale: Week 4 (n=234,250) | Reflux Symptoms Scale: Week 7 (n=180,220) | Reflux Symptoms Scale: Week 10 (n=176,203) | Reflux Symptoms Scale: Week 13 (n=152,182) | Reflux Symptoms Scale: Week 16 (n=120,165) | Reflux Symptoms Scale: Week 19 (n=114,165) | Reflux Symptoms Scale: Week 22 (n=79,143) | Reflux Symptoms Scale: Week 25 (n=64,124) | Reflux Symptoms Scale: Week 28 (n=47,111) | Reflux Symptoms Scale: Week 31 (n=45,95) | Reflux Symptoms Scale: Week 34 (n=45,95) | Reflux Symptoms Scale: Week 37 (n=29,64) | Reflux Symptoms Scale: Week 40 (n=24,55) | Reflux Symptoms Scale: Week 43 (n=12,42) | Reflux Symptoms Scale: Week 46 (n=14,42) | Reflux Symptoms Scale: Week 49 (n=10,36) | Reflux Symptoms Scale: Week 52 (n=8,30) | Reflux Symptoms Scale: Week 55 (n=6,24) | Reflux Symptoms Scale: Week 58 (n=6,21) | Reflux Symptoms Scale: Week 61 (n=4,17) | Reflux Symptoms Scale: Week 64 (n=3,20) | Reflux Symptoms Scale: Week 67 (n=4,16) | Reflux Symptoms Scale: Week 70 (n=3,13) | Reflux Symptoms Scale: Week 73 (n=3,12) | Reflux Symptoms Scale: Week 76 (n=3,8) | Reflux Symptoms Scale: Week 79 (n=3,9) | Reflux Symptoms Scale: Week 82 (n=2,6) | Reflux Symptoms Scale: Week 85 (n=2,6) | Reflux Symptoms Scale: Week 88 (n=2,6) | Reflux Symptoms Scale: Week 91 (n=2,4) | Reflux Symptoms Scale: Week 94 (n=2,6) | Reflux Symptoms Scale: Week 97 (n=1,5) | Reflux Symptoms Scale: Week 100 (n=1,4) | Reflux Symptoms Scale: Week 103 (n=1,4) | Reflux Symptoms Scale: Week 106 (n=1,4) | Reflux Symptoms Scale: Week 109 (n=1,4) | Reflux Symptoms Scale: Week 112 (n=1,5) | Reflux Symptoms Scale: Week 115 (n=1,4) | Reflux Symptoms Scale: Week 118 (n=1,5) | Reflux Symptoms Scale: Week 121 (n=1,5) | Reflux Symptoms Scale: Week 124 (n=1,5) | Reflux Symptoms Scale: Week 127 (n=1,3) | Reflux Symptoms Scale: Week 130 (n=0,3) | Reflux Symptoms Scale: Week 133 (n=1,3) | Reflux Symptoms Scale: Week 136 (n=0,2) | Reflux Symptoms Scale: Week 139 (n=0,2) | Reflux Symptoms Scale: Week 142 (n=0,2) | Reflux Symptoms Scale: Week 145 (n=0,1) | Reflux Symptoms Scale: Final Visit (n=1,5) | Eating Restrictions (ER) Scale: BL (n=276,287) | ER Scale: Week 4 (n=234,250) | ER Scale: Week 7 (n=181,220) | ER Scale: Week 10 (n=176,203) | ER Scale: Week 13 (n=152,183) | ER Scale: Week 16 (n=120,165) | ER Scale: Week 19 (n=114,143) | ER Scale: Week 22 (n=79,143) | ER Scale: Week 25 (n=64,124) | ER Scale: Week 28 (n=47,111) | ER Scale: Week 31 (n=45,95) | ER Scale: Week 34 (n=37,87) | ER Scale: Week 37 (n=29,64) | ER Scale: Week 40 (n=24,55) | ER Scale: Week 43 (n=12,43) | ER Scale: Week 46 (n=14,42) | ER Scale: Week 49 (n=10,36) | ER Scale: Week 52 (n=8,30) | ER Scale: Week 55 (n=6,24) | ER Scale: Week 58 (n=6,21) | ER Scale: Week 61 (n=4,17) | ER Scale: Week 64 (n=3,20) | ER Scale: Week 67 (n=4,16) | ER Scale: Week 70 (n=3,14) | ER Scale: Week 73 (n=3,12) | ER Scale: Week 76 (n=3,8) | ER Scale: Week 79 (n=3,9) | ER Scale: Week 82 (n=2,6) | ER Scale: Week 85 (n=2,6) | ER Scale: Week 88 (n=2,6) | ER Scale: Week 91 (n=2,4) | ER Scale: Week 94 (n=2,6) | ER Scale: Week 97 (n=1,5) | ER Scale: Week 100 (n=1,4) | ER Scale: Week 103 (n=1,4) | ER Scale: Week 106 (n=1,4) | ER Scale: Week 109 (n=1,4) | ER Scale: Week 112 (n=1,5) | ER Scale: Week 115 (n=1,4) | ER Scale: Week 118 (n=1,5) | ER Scale: Week 121 (n=1,5) | ER Scale: Week 124 (n=1,5) | ER Scale: Week 127 (n=1,3) | ER Scale: Week 130 (n=0,3) | ER Scale: Week 133 (n=1,3) | ER Scale: Week 136 (n=0,2) | ER Scale: Week 139 (n=0,2) | ER Scale: Week 142 (n=0,2) | ER Scale: Week 145 (n=0,1) | ER Scale: Final Visit (n=157,160) | Anxiety Scale: BL (n=276,287) | Anxiety Scale: Week 4 (n=234,250) | Anxiety Scale: Week 7 (n=181,220) | Anxiety Scale: Week 10 (n=176,203) | Anxiety Scale: Week 13 (n=152,183) | Anxiety Scale: Week 16 (n=120,165) | Anxiety Scale: Week 19 (n=114,143) | Anxiety Scale: Week 22 (n=79,143) | Anxiety Scale: Week 25 (n=64,124) | Anxiety Scale: Week 28 (n=47,111) | Anxiety Scale: Week 31 (n=45,95) | Anxiety Scale: Week 34 (n=37,87) | Anxiety Scale: Week 37 (n=29,64) | Anxiety Scale: Week 40 (n=24,55) | Anxiety Scale: Week 43 (n=12,43) | Anxiety Scale: Week 46 (n=14,42) | Anxiety Scale: Week 49 (n=14,42) | Anxiety Scale: Week 52 (n=8,30) | Anxiety Scale: Week 55 (n=6,24) | Anxiety Scale: Week 58 (n=6,21) | Anxiety Scale: Week 61 (n=4,17) | Anxiety Scale: Week 64 (n=3,20) | Anxiety Scale: Week 67 (n=4,16) | Anxiety Scale: Week 70 (n=3,14) | Anxiety Scale: Week 73 (n=3,12) | Anxiety Scale: Week 76 (n=3,8) | Anxiety Scale: Week 79 (n=3,9) | Anxiety Scale: Week 82 (n=2,6) | Anxiety Scale: Week 85 (n=2,6) | Anxiety Scale: Week 88 (n=2,6) | Anxiety Scale: Week 91 (n=2,4) | Anxiety Scale: Week 94 (n=2,6) | Anxiety Scale: Week 97 (n=1,5) | Anxiety Scale: Week 100 (n=1,4) | Anxiety Scale: Week 103 (n=1,4) | Anxiety Scale: Week 106 (n=1,4) | Anxiety Scale: Week 109 (n=1,4) | Anxiety Scale: Week 112 (n=1,5) | Anxiety Scale: Week 115 (n=1,4) | Anxiety Scale: Week 118 (n=1,5) | Anxiety Scale: Week 121 (n=1,5) | Anxiety Scale: Week 124 (n=1,5) | Anxiety Scale: Week 127 (n=1,3) | Anxiety Scale: Week 130 (n=0,3) | Anxiety Scale: Week 133 (n=1,3) | Anxiety Scale: Week 136 (n=0,2) | Anxiety Scale: Week 139 (n=0,2) | Anxiety Scale: Week 142 (n=0,2) | Anxiety Scale: Week 145 (n=0,2) | Anxiety Scale: Final Visit (n=157,160) | Dry Mouth: BL (n=274,287) | Dry Mouth: Week 4 (n=232,249) | Dry Mouth: Week 7 (n=180,219) | Dry Mouth: Week 10 (n=176,203) | Dry Mouth: Week 13 (n=152,183) | Dry Mouth: Week 16 (n=120,165) | Dry Mouth: Week 19 (n=113,143) | Dry Mouth: Week 22 (n=79,143) | Dry Mouth: Week 25 (n=64,124) | Dry Mouth: Week 28 (n=47,111) | Dry Mouth: Week 31 (n=45,95) | Dry Mouth: Week 34 (n=37,87) | Dry Mouth: Week 37 (n=29,64) | Dry Mouth: Week 40 (n=23,55) | Dry Mouth: Week 43 (n=12,43) | Dry Mouth: Week 46 (n=14,42) | Dry Mouth: Week 49 (n=10,36) | Dry Mouth: Week 52 (n=8,30) | Dry Mouth: Week 55 (n=6,24) | Dry Mouth: Week 58 (n=6,21) | Dry Mouth: Week 61 (n=4,17) | Dry Mouth: Week 64 (n=3,20) | Dry Mouth: Week 67 (n=4,16) | Dry Mouth: Week 70 (n=3,14) | Dry Mouth: Week 73 (n=3,12) | Dry Mouth: Week 76 (n=3,8) | Dry Mouth: Week 79 (n=3,9) | Dry Mouth: Week 82 (n=2,6) | Dry Mouth: Week 85 (n=2,6) | Dry Mouth: Week 88 (n=2,6) | Dry Mouth: Week 91 (n=2,4) | Dry Mouth: Week 94 (n=2,6) | Dry Mouth: Week 97 (n=1,5) | Dry Mouth: Week 100 (n=1,4) | Dry Mouth: Week 103 (n=1,4) | Dry Mouth: Week 106 (n=1,4) | Dry Mouth: Week 109 (n=1,4) | Dry Mouth: Week 112 (n=1,5) | Dry Mouth: Week 115 (n=1,4) | Dry Mouth: Week 118 (n=1,5) | Dry Mouth: Week 121 (n=1,5) | Dry Mouth: Week 124 (n=1,5) | Dry Mouth: Week 127 (n=1,3) | Dry Mouth: Week 130 (n=0,3) | Dry Mouth: Week 133 (n=1,3) | Dry Mouth: Week 136 (n=0,2) | Dry Mouth: Week 139 (n=0,2) | Dry Mouth: Week 142 (n=0,2) | Dry Mouth: Week 145 (n=0,1) | Dry Mouth: Final Visit (n=157,157) | Taste: BL (n=275,286) | Taste: Week 4 (n=234,249) | Taste: Week 7 (n=179,217) | Taste: Week 10 (n=176,200) | Taste: Week 13 (n=151,181) | Taste: Week 16 (n=119,165) | Taste: Week 19 (n=113,143) | Taste: Week 22 (n=79,143) | Taste: Week 25 (n=64,124) | Taste: Week 28 (n=47,111) | Taste: Week 31 (n=45,95) | Taste: Week 34 (n=37,87) | Taste: Week 37 (n=28,64) | Taste: Week 40 (n=24,55) | Taste: Week 43 (n=12,43) | Taste: Week 46 (n=14,42) | Taste: Week 49 (n=9,36) | Taste: Week 52 (n=8,30) | Taste: Week 55 (n=6,24) | Taste: Week 58 (n=6,21) | Taste: Week 61 (n=4,17) | Taste: Week 64 (n=3,20) | Taste: Week 67 (n=4,16) | Taste: Week 70 (n=3,14) | Taste: Week 73 (n=3,12) | Taste: Week 76 (n=3,8) | Taste: Week 79 (n=3,9) | Taste: Week 82 (n=2,6) | Taste: Week 85 (n=2, 6) | Taste: Week 88 (n=2,6) | Taste: Week 91 (n=2,4) | Taste: Week 94 (n=2,6) | Taste: Week 97 (n=1,5) | Taste: Week 100 (n=1,4) | Taste: Week 103 (n=1,4) | Taste: Week 106 (n=1,4) | Taste: Week 109 (n=1,4) | Taste: Week 112 (n=1,5) | Taste: Week 115 (n=1,4) | Taste: Week 118 (n=1,5) | Taste: Week 121 (n=1,5) | Taste: Week 124 (n=1,5) | Taste: Week 127 (n=1,3) | Taste: Week 130 (n=0,3) | Taste: Week 133 (n=1,3) | Taste: Week 136 (n=0,2) | Taste: Week 139 (n=0,2) | Taste: Week 142 (n=0,2) | Taste: Week 145 (n=0,1) | Taste: Final Visit (n=157,158) | Body Image: BL (n=272,286) | Body Image: Week 4 (n=233,249) | Body Image: Week 7 (n=180,219) | Body Image: Week 10 (n=175,203) | Body Image: Week 13 (n=152,182) | Body Image: Week 16 (n=119,165) | Body Image: Week 19 (n=114,140) | Body Image: Week 22 (n=79,143) | Body Image: Week 25 (n=64,124) | Body Image: Week 28 (n=47,111) | Body Image: Week 31 (n=45,95) | Body Image: Week 34 (n=37,87) | Body Image: Week 37 (n=29,64) | Body Image: Week 40 (n=24,55) | Body Image: Week 43 (n=12,43) | Body Image: Week 46 (n=14,42) | Body Image: Week 49 (n=10,36) | Body Image: Week 52 (n=8,30) | Body Image: Week 55 (n=6,24) | Body Image: Week 58 (n=6,21) | Body Image: Week 61 (n=4,17) | Body Image: Week 64 (n=3,20) | Body Image: Week 67 (n=4,16) | Body Image: Week 70 (n=4,14) | Body Image: Week 73 (n=3,12) | Body Image: Week 76 (n=3,8) | Body Image: Week 79 (n=3,9) | Body Image: Week 82 (n=2,6) | Body Image: Week 85 (n=2,6) | Body Image: Week 88 (n=2,5) | Body Image: Week 91 (n=2,4) | Body Image: Week 94 (n=2,6) | Body Image: Week 97 (n=1,5) | Body Image: Week 100 (n=1,4) | Body Image: Week 103 (n=1,4) | Body Image: Week 106 (n=1,4) | Body Image: Week 109 (n=1,4) | Body Image: Week 112 (n=1,5) | Body Image: Week 115 (n=1,4) | Body Image: Week 118 (n=1,5) | Body Image: Week 121 (n=1,5) | Body Image: Week 124 (n=1,5) | Body Image: Week 127 (n=1,3) | Body Image: Week 130 (n=0,3) | Body Image: Week 133 (n=1,3) | Body Image: Week 136 (n=0,2) | Body Image: Week 139 (n=0,2) | Body Image: Week 142 (n=0,2) | Body Image: Week 145 (n=0,1) | Body Image: Final Visit (n=157,159) | Hair Loss: BL (n=64,76) | Hair Loss: Week 4 (n=68,71) | Hair Loss: Week 7 (n=65,82) | Hair Loss: Week 10 (n=75,78) | Hair Loss: Week 13 (n=66,80) | Hair Loss: Week 16 (n=53,72) | Hair Loss: Week 19 (n=50,56) | Hair Loss: Week 22 (n=38,54) | Hair Loss: Week 25 (n=24,49) | Hair Loss: Week 28 (n=20,39) | Hair Loss: Week 31 (n=17,26) | Hair Loss: Week 34 (n=13,24) | Hair Loss: Week 37 (n=12,16) | Hair Loss: Week 40 (n=11,13) | Hair Loss: Week 43 (n=5,9) | Hair Loss: Week 46 (n=5,13) | Hair Loss: Week 49 (n=4,7) | Hair Loss: Week 52 (n=3,4) | Hair Loss: Week 55 (n=2,6) | Hair Loss: Week 58 (n=2,3) | Hair Loss: Week 61 (n=1,2) | Hair Loss: Week 64 (n=1,4) | Hair Loss: Week 67 (n=1,4) | Hair Loss: Week 70 (n=1,2) | Hair Loss: Week 73 (n=1,5) | Hair Loss: Week 76 (n=1,3) | Hair Loss: Week 79 (n=1,4) | Hair Loss: Week 82 (n=1,1) | Hair Loss: Week 85 (n=1,1) | Hair Loss: Week 88 (n=1,2) | Hair Loss: Week 91 (n=1,1) | Hair Loss: Week 94 (n=1,2) | Hair Loss: Week 97 (n=1,2) | Hair Loss: Week 100 (n=1,2) | Hair Loss: Week 103 (n=1,1) | Hair Loss: Week 106 (n=1,1) | Hair Loss: Week 109 (n=0,2) | Hair Loss: Week 112 (n=1,3) | Hair Loss: Week 115 (n=1,2) | Hair Loss: Week 118 (n=1,3) | Hair Loss: Week 121 (n=1,2) | Hair Loss: Week 124 (n=1,2) | Hair Loss: Week 127 (n=1,1) | Hair Loss: Week 130 (n=0,1) | Hair Loss: Week 133 (n=1,1) | Hair Loss: Final Visit (n=61,60) | |
| Fluoropyrimidine/Cisplatin (FP) | 18.7 | 11.8 | 10.9 | 8.5 | 8.8 | 10.2 | 9.5 | 10.0 | 6.9 | 6.6 | 6.4 | 3.9 | 5.4 | 3.7 | 4.6 | 2.4 | 4.4 | 1.4 | 0.0 | 3.7 | 2.8 | 0.0 | 2.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 15.4 | 29.7 | 21.6 | 19.4 | 17.0 | 16.0 | 17.0 | 19.2 | 15.8 | 11.3 | 11.2 | 12.6 | 12.2 | 13.8 | 14.9 | 13.0 | 15.5 | 11.7 | 9.4 | 9.7 | 5.6 | 4.2 | 2.8 | 4.2 | 2.8 | 0.0 | 5.6 | 2.8 | 0.0 | 4.2 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 24.7 | 18.3 | 14.8 | 12.8 | 12.6 | 12.8 | 12.0 | 11.3 | 9.0 | 5.6 | 6.6 | 7.4 | 7.2 | 6.1 | 7.9 | 7.4 | 4.8 | 2.2 | 2.8 | 5.6 | 0.0 | 2.8 | 3.7 | 2.8 | 3.7 | 0.0 | 3.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 15.3 | 27.4 | 20.6 | 18.8 | 17.5 | 16.0 | 17.8 | 20.8 | 15.5 | 11.6 | 13.9 | 13.4 | 10.6 | 12.5 | 13.5 | 9.7 | 10.9 | 11.7 | 5.2 | 8.3 | 9.7 | 4.2 | 0.0 | 8.3 | 2.8 | 5.6 | 2.8 | 5.6 | 4.2 | 4.2 | 4.2 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 23.8 | 47.5 | 42.0 | 40.6 | 38.2 | 35.7 | 32.9 | 35.8 | 31.7 | 25.2 | 27.4 | 29.1 | 23.1 | 27.2 | 29.6 | 30.6 | 26.2 | 20.0 | 23.6 | 31.5 | 20.4 | 8.3 | 5.6 | 11.1 | 3.7 | 7.4 | 0.0 | 11.1 | 11.1 | 11.1 | 11.1 | 11.1 | 5.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 41.5 | 24.5 | 24.0 | 24.6 | 23.5 | 23.2 | 23.9 | 22.4 | 19.0 | 16.1 | 10.6 | 12.6 | 9.9 | 12.6 | 8.7 | 11.1 | 9.5 | 16.7 | 12.5 | 5.6 | 11.1 | 8.3 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 24.0 | 17.2 | 20.7 | 20.1 | 21.8 | 19.9 | 20.4 | 24.5 | 19.0 | 10.9 | 12.1 | 8.1 | 6.3 | 8.3 | 8.3 | 5.6 | 4.8 | 7.4 | 4.2 | 11.1 | 11.1 | 8.3 | 11.1 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 25.3 | 30.9 | 32.6 | 30.7 | 30.1 | 28.9 | 29.1 | 30.7 | 28.7 | 22.4 | 23.4 | 25.2 | 18.9 | 23.0 | 20.8 | 27.8 | 21.4 | 16.7 | 16.7 | 16.7 | 11.1 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 31.0 | 15.1 | 20.1 | 25.1 | 21.8 | 22.2 | 28.3 | 23.3 | 20.2 | 13.9 | 26.7 | 15.7 | 7.7 | 8.3 | 12.1 | 6.7 | 26.7 | 0.0 | 11.1 | 16.7 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | 23.0 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 16.6 | 12.5 | 12.8 | 10.6 | 9.0 | 9.1 | 8.8 | 7.8 | 6.8 | 5.3 | 6.8 | 7.5 | 7.3 | 6.5 | 5.2 | 2.9 | 2.2 | 4.4 | 3.7 | 3.2 | 0.7 | 3.3 | 2.8 | 3.2 | 4.6 | 2.8 | 2.5 | 3.7 | 1.9 | 1.9 | 0.0 | 1.9 | 2.2 | 2.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.6 | 5.6 | 0.0 | 17.0 | 27.0 | 21.8 | 20.1 | 17.5 | 16.2 | 15.9 | 16.3 | 15.1 | 14.4 | 14.0 | 14.6 | 12.5 | 13.8 | 11.8 | 9.7 | 10.1 | 9.5 | 8.6 | 4.5 | 6.3 | 5.4 | 9.6 | 8.3 | 6.5 | 9.7 | 5.2 | 7.4 | 6.9 | 5.6 | 5.6 | 2.1 | 5.6 | 8.3 | 6.3 | 8.3 | 6.3 | 4.2 | 10.0 | 4.2 | 8.3 | 10.0 | 8.3 | 8.3 | 11.1 | 13.9 | 12.5 | 8.3 | 8.3 | 0.0 | 26.8 | 16.9 | 16.0 | 15.4 | 13.5 | 12.9 | 14.4 | 10.6 | 10.6 | 9.7 | 9.6 | 10.1 | 9.3 | 10.9 | 9.3 | 9.0 | 6.6 | 6.5 | 8.1 | 6.5 | 5.3 | 2.6 | 3.9 | 6.3 | 4.3 | 7.9 | 1.4 | 3.7 | 5.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.8 | 0.0 | 0.0 | 0.0 | 4.4 | 0.0 | 6.7 | 7.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 18.3 | 23.9 | 21.1 | 19.0 | 17.4 | 17.0 | 15.1 | 15.5 | 13.6 | 12.9 | 11.3 | 12.5 | 10.9 | 9.5 | 9.5 | 7.0 | 6.0 | 8.1 | 9.3 | 5.2 | 6.0 | 5.4 | 8.3 | 10.4 | 6.5 | 9.0 | 5.2 | 5.6 | 2.8 | 4.2 | 4.2 | 4.2 | 4.2 | 6.7 | 6.3 | 6.3 | 4.2 | 4.2 | 3.3 | 4.2 | 6.7 | 5.0 | 1.7 | 0.0 | 8.3 | 5.6 | 0.0 | 4.2 | 0.0 | 0.0 | 22.8 | 48.2 | 43.8 | 39.3 | 38.2 | 37.5 | 37.1 | 34.9 | 32.8 | 29.2 | 26.9 | 28.4 | 27.8 | 28.2 | 26.3 | 25.1 | 23.3 | 25.9 | 27.4 | 28.2 | 21.7 | 25.5 | 23.9 | 18.8 | 27.0 | 28.7 | 27.8 | 33.3 | 25.9 | 24.1 | 14.8 | 22.2 | 22.2 | 31.1 | 16.7 | 22.2 | 19.4 | 16.7 | 22.2 | 19.4 | 20.0 | 15.6 | 17.8 | 22.2 | 18.5 | 18.5 | 16.7 | 11.1 | 16.7 | 0.0 | 40.9 | 23.9 | 23.3 | 26.9 | 25.0 | 21.1 | 23.4 | 20.5 | 16.3 | 12.1 | 10.8 | 11.2 | 9.6 | 9.4 | 7.3 | 6.2 | 4.8 | 6.5 | 10.0 | 8.3 | 14.3 | 11.8 | 6.7 | 8.3 | 11.9 | 13.9 | 20.8 | 11.1 | 5.6 | 0.0 | 5.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 23.6 | 17.9 | 24.8 | 24.0 | 25.3 | 25.2 | 23.8 | 22.6 | 19.6 | 15.9 | 14.7 | 13.0 | 9.6 | 7.8 | 7.9 | 7.0 | 7.9 | 4.6 | 7.8 | 4.2 | 4.8 | 0.0 | 1.7 | 4.2 | 0.0 | 2.8 | 0.0 | 0.0 | 5.6 | 0.0 | 5.6 | 0.0 | 5.6 | 6.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 20.3 | 31.9 | 31.7 | 27.9 | 28.4 | 28.2 | 28.1 | 25.0 | 22.4 | 22.6 | 20.1 | 19.3 | 18.0 | 18.2 | 19.4 | 15.5 | 15.9 | 13.9 | 16.7 | 16.7 | 15.9 | 13.7 | 18.3 | 14.6 | 16.7 | 27.8 | 37.5 | 25.9 | 16.7 | 11.1 | 6.7 | 16.7 | 16.7 | 13.3 | 8.3 | 8.3 | 16.7 | 8.3 | 6.7 | 16.7 | 6.7 | 6.7 | 6.67 | 11.1 | 0.0 | 11.1 | 16.7 | 0.0 | 16.7 | 0.0 | 30.4 | 25.0 | 16.4 | 19.1 | 20.1 | 20.4 | 23.6 | 21.4 | 22.2 | 18.4 | 14.5 | 10.3 | 16.7 | 12.5 | 12.8 | 3.7 | 5.1 | 9.5 | 8.3 | 0.0 | 0.0 | 16.7 | 0.0 | 0.0 | 0.0 | 6.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 19.4 |
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score equals (=) better level of functioning or greater degree of symptoms. (NCT01041404)
Timeframe: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | scores on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Status: BL (n=274,287) | Global Health Status: Week 4 (n=235,249) | Global Health Status: Week 7 (n=180,220) | Global Health Status: Week 10 (n=176,202) | Global Health Status: Week 13 (n=152,182) | Global Health Status: Week 16 (n=121,165) | Global Health Status: Week 19 (n=114,143) | Global Health Status: Week 22 (n=78,143) | Global Health Status: Week 25 (n=64,124) | Global Health Status: Week 28 (n=47,111) | Global Health Status: Week 31 (n=45,95) | Global Health Status: Week 34 (n=36,87) | Global Health Status: Week 37 (n=29,64) | Global Health Status: Week 40 (n=23,55) | Global Health Status: Week 43 (n=12,43) | Global Health Status: Week 46 (n=13,42) | Global Health Status: Week 49 (n=9,36) | Global Health Status: Week 52 (n=7,29) | Global Health Status: Week 55 (n=5,24) | Global Health Status: Week 58 (n=5,21) | Global Health Status: Week 61 (n=4,17) | Global Health Status: Week 64 (n=3,20) | Global Health Status: Week 67 (n=4,17) | Global Health Status: Week 70 (n=3,14) | Global Health Status: Week 73 (n=3,12) | Global Health Status: Week 76 (n=3,8) | Global Health Status: Week 79 (n=3,9) | Global Health Status: Week 82 (n=2,5) | Global Health Status: Week 85 (n=2,6) | Global Health Status: Week 88 (n=2,6) | Global Health Status: Week 91 (n=2,4) | Global Health Status: Week 94 (n=2,6) | Global Health Status: Week 97 (n=1,5) | Global Health Status: Week 100 (n=1,4) | Global Health Status: Week 103 (n=1,3) | Global Health Status: Week 106 (n=1,4) | Global Health Status: Week 109 (n=1,4) | Global Health Status: Week 112 (n=1,5) | Global Health Status: Week 115 (n=1,4) | Global Health Status: Week 118 (n=1,5) | Global Health Status: Week 121 (n=1,5) | Global Health Status: Week 124 (n=1,5) | Global Health Status: Week 127 (n=1,3) | Global Health Status: Week 130 (n=0,3) | Global Health Status: Week 133 (n=1,3) | Global Health Status: Week 136 (n=0,2) | Global Health Status: Week 139 (n=0,2) | Global Health Status: Week 142 (n=0,2) | Global Health Status: Week 145 (n=0,1) | Global Health Status: Final Visit (n=158,160) | Physical Functioning: BL (n=276,287) | Physical Functioning: Week 4 (n=235,250) | Physical Functioning: Week 7 (n=181,220) | Physical Functioning: Week 10 (n=174,201) | Physical Functioning: Week 13 (n=151,183) | Physical Functioning: Week 16 (n=121,165) | Physical Functioning: Week 19 (n=114,143) | Physical Functioning: Week 22 (n=79,143) | Physical Functioning: Week 25 (n=64,124) | Physical Functioning: Week 28 (n=47,110) | Physical Functioning: Week 31 (n=45,95) | Physical Functioning: Week 34 (n=37,87) | Physical Functioning: Week 37 (n=29,64) | Physical Functioning: Week 40 (n=24,55) | Physical Functioning: Week 43 (n=12,43) | Physical Functioning: Week 46 (n=14,42) | Physical Functioning: Week 49 (n=10,36) | Physical Functioning: Week 52 (n=8,30) | Physical Functioning: Week 55 (n=6,24) | Physical Functioning: Week 58 (n=6,21) | Physical Functioning: Week 61 (n=4,17) | Physical Functioning: Week 64 (n=3,20) | Physical Functioning: Week 67 (n=4,17) | Physical Functioning: Week 70 (n=3,14) | Physical Functioning: Week 73 (n=3,12) | Physical Functioning: Week 76 (n=3,8) | Physical Functioning: Week 79 (n=3,9) | Physical Functioning: Week 82 (n=2,6) | Physical Functioning: Week 85 (n=2,6) | Physical Functioning: Week 88 (n=2,6) | Physical Functioning: Week 91 (n=2,4) | Physical Functioning: Week 94 (n=2,6) | Physical Functioning: Week 97 (n=1,5) | Physical Functioning: Week 100 (n=1,4) | Physical Functioning: Week 103 (n=1,4) | Physical Functioning: Week 106 (n=1,4) | Physical Functioning: Week 109 (n=1,4) | Physical Functioning: Week 112 (n=1,5) | Physical Functioning: Week 115 (n=1,4) | Physical Functioning: Week 118 (n=1,5) | Physical Functioning: Week 121 (n=1,5) | Physical Functioning: Week 124 (n=1,5) | Physical Functioning: Week 127 (n=1,3) | Physical Functioning: Week 130 (n=0,3) | Physical Functioning: Week 133 (n=1,3) | Physical Functioning: Week 136 (n=0,2) | Physical Functioning: Week 139 (n=0,2) | Physical Functioning: Week 142 (n=0,2) | Physical Functioning: Week 145 (n=0,1) | Physical Functioning: Final Visit (n=158,161) | Role Functioning: BL (n=276,287) | Role Functioning: Week 4 (n=234,250) | Role Functioning: Week 7 (n=181,220) | Role Functioning: Week 10 (n=176,202) | Role Functioning: Week 13 (n=152,182) | Role Functioning: Week 16 (n=121,165) | Role Functioning: Week 19 (n=114,143) | Role Functioning: Week 22 (n=79,142) | Role Functioning: Week 25 (n=64,124) | Role Functioning: Week 28 (n=47,110) | Role Functioning: Week 31 (n=45,95) | Role Functioning: Week 34 (n=37,87) | Role Functioning: Week 37 (n=29,64) | Role Functioning: Week 40 (n=24,55) | Role Functioning: Week 43 (n=12,43) | Role Functioning: Week 46 (n=14,42) | Role Functioning: Week 49 (n=10,36) | Role Functioning: Week 52 (n=8,30) | Role Functioning: Week 55 (n=6,24) | Role Functioning: Week 58 (n=6,21) | Role Functioning: Week 61 (n=4,17) | Role Functioning: Week 64 (n=3,20) | Role Functioning: Week 67 (n=4,17) | Role Functioning: Week 70 (n=3,14) | Role Functioning: Week 73 (n=3,12) | Role Functioning: Week 76 (n=3,8) | Role Functioning: Week 79 (n=3,9) | Role Functioning: Week 82 (n=2,6) | Role Functioning: Week 85 (n=2,6) | Role Functioning: Week 88 (n=2,6) | Role Functioning: Week 91 (n=2,4) | Role Functioning: Week 94 (n=2,6) | Role Functioning: Week 97 (n=1,5) | Role Functioning: Week 100 (n=1,4) | Role Functioning: Week 103 (n=1,4) | Role Functioning: Week 106 (n=1,4) | Role Functioning: Week 109 (n=1,4) | Role Functioning: Week 112 (n=1,5) | Role Functioning: Week 115 (n=1,4) | Role Functioning: Week 118 (n=1,5) | Role Functioning: Week 121 (n=1,5) | Role Functioning: Week 124 (n=1,5) | Role Functioning: Week 127 (n=1,3) | Role Functioning: Week 130 (n=0,3) | Role Functioning: Week 133 (n=1,3) | Role Functioning: Week 136 (n=0,2) | Role Functioning: Week 139 (n=0,2) | Role Functioning: Week 142 (n=0,2) | Role Functioning: Week 145 (n=0,1) | Role Functioning: Final Visit (n=158,161) | Emotional Functioning: BL (n=276,287) | Emotional Functioning: Week 4 (n=235,250) | Emotional Functioning: Week 7 (n=180,220) | Emotional Functioning: Week 10 (n=176,202) | Emotional Functioning: Week 13 (n=152,183) | Emotional Functioning: Week 16 (n=121,165) | Emotional Functioning: Week 19 (n=114,143) | Emotional Functioning: Week 22 (n=79,143) | Emotional Functioning: Week 25 (n=64,124) | Emotional Functioning: Week 28 (n=47,111) | Emotional Functioning: Week 31 (n=45,95) | Emotional Functioning: Week 34 (n=37,87) | Emotional Functioning: Week 37 (n=29,64) | Emotional Functioning: Week 40 (n=24,55) | Emotional Functioning: Week 43 (n=12,43) | Emotional Functioning: Week 46 (n=14,42) | Emotional Functioning: Week 49 (n=10,36) | Emotional Functioning: Week 52 (n=8,29) | Emotional Functioning: Week 55 (n=6,24) | Emotional Functioning: Week 58 (n=6,21) | Emotional Functioning: Week 61 (n=4,17) | Emotional Functioning: Week 64 (n=3,20) | Emotional Functioning: Week 67 (n=4,17) | Emotional Functioning: Week 70 (n=3,14) | Emotional Functioning: Week 73 (n=3,12) | Emotional Functioning: Week 76 (n=3,8) | Emotional Functioning: Week 79 (n=3,9) | Emotional Functioning: Week 82 (n=2,6) | Emotional Functioning: Week 85 (n=2,6) | Emotional Functioning: Week 88 (n=2,6) | Emotional Functioning: Week 91 (n=2,4) | Emotional Functioning: Week 94 (n=2,6) | Emotional Functioning: Week 97 (n=1,5) | Emotional Functioning: Week 100 (n=1,4) | Emotional Functioning: Week 103 (n=1,4) | Emotional Functioning: Week 106 (n=1,4) | Emotional Functioning: Week 109 (n=1,4) | Emotional Functioning: Week 112 (n=1,5) | Emotional Functioning: Week 115 (n=1,4) | Emotional Functioning: Week 118 (n=1,5) | Emotional Functioning: Week 121 (n=1,5) | Emotional Functioning: Week 124 (n=1,5) | Emotional Functioning: Week 127 (n=1,3) | Emotional Functioning: Week 130 (n=0,3) | Emotional Functioning: Week 133 (n=1,3) | Emotional Functioning: Week 136 (n=0,2) | Emotional Functioning: Week 139 (n=0,2) | Emotional Functioning: Week 142 (n=0,2) | Emotional Functioning: Week 145 (n=0,1) | Emotional Functioning: Final Visit (n=158,161) | Cognitive Functioning: BL (n=276,287) | Cognitive Functioning: Week 4 (n=235,250) | Cognitive Functioning: Week 7 (n=180,220) | Cognitive Functioning: Week 10 (n=176,202) | Cognitive Functioning: Week 13 (n=152,183) | Cognitive Functioning: Week 16 (n=121,165) | Cognitive Functioning: Week 19 (n=114,143) | Cognitive Functioning: Week 22 (n=79,143) | Cognitive Functioning: Week 25 (n=64,124) | Cognitive Functioning: Week 28 (n=47,111) | Cognitive Functioning: Week 31 (n=45,95) | Cognitive Functioning: Week 34 (n=37,87) | Cognitive Functioning: Week 37 (n=29,64) | Cognitive Functioning: Week 40 (n=24,55) | Cognitive Functioning: Week 43 (n=12,43) | Cognitive Functioning: Week 46 (n=14,42) | Cognitive Functioning: Week 49 (n=10,36) | Cognitive Functioning: Week 52 (n=8,29) | Cognitive Functioning: Week 55 (n=6,24) | Cognitive Functioning: Week 58 (n=6,21) | Cognitive Functioning: Week 61 (n=4,17) | Cognitive Functioning: Week 64 (n=3,20) | Cognitive Functioning: Week 67 (n=4,17) | Cognitive Functioning: Week 70 (n=3,14) | Cognitive Functioning: Week 73 (n=3,12) | Cognitive Functioning: Week 76 (n=3,8) | Cognitive Functioning: Week 79 (n=3,9) | Cognitive Functioning: Week 82 (n=2,6) | Cognitive Functioning: Week 85 (n=2,6) | Cognitive Functioning: Week 88 (n=2,6) | Cognitive Functioning: Week 91 (n=2,4) | Cognitive Functioning: Week 94 (n=2,6) | Cognitive Functioning: Week 97 (n=1,5) | Cognitive Functioning: Week 100 (n=1,4) | Cognitive Functioning: Week 103 (n=1,4) | Cognitive Functioning: Week 106 (n=1,4) | Cognitive Functioning: Week 109 (n=1,4) | Cognitive Functioning: Week 112 (n=1,5) | Cognitive Functioning: Week 115 (n=1,4) | Cognitive Functioning: Week 118 (n=1,5) | Cognitive Functioning: Week 121 (n=1,5) | Cognitive Functioning: Week 124 (n=1,5) | Cognitive Functioning: Week 127 (n=1,3) | Cognitive Functioning: Week 130 (n=0,3) | Cognitive Functioning: Week 133 (n=1,3) | Cognitive Functioning: Week 136 (n=0,2) | Cognitive Functioning: Week 139 (n=0,2) | Cognitive Functioning: Week 142 (n=0,2) | Cognitive Functioning: Week 145 (n=0,1) | Cognitive Functioning: Final Visit (n=158,161) | Social Functioning: BL (n=276,286) | Social Functioning: Week 4 (n=235,250) | Social Functioning: Week 7 (n=179,220) | Social Functioning: Week 10 (n=176,202) | Social Functioning: Week 13 (n=152,183) | Social Functioning: Week 16 (n=180,165) | Social Functioning: Week 19 (n=114,143) | Social Functioning: Week 22 (n=79,143) | Social Functioning: Week 25 (n=64,124) | Social Functioning: Week 28 (n=47,111) | Social Functioning: Week 31 (n=45,95) | Social Functioning: Week 34 (n=37,87) | Social Functioning: Week 37 (n=29,64) | Social Functioning: Week 40 (n=24,55) | Social Functioning: Week 43 (n=12,43) | Social Functioning: Week 46 (n=14,42) | Social Functioning: Week 49 (n=10,36) | Social Functioning: Week 52 (n=8,29) | Social Functioning: Week 55 (n=6,24) | Social Functioning: Week 58 (n=6,21) | Social Functioning: Week 61 (n=4,17) | Social Functioning: Week 64 (n=3,20) | Social Functioning: Week 67 (n=4,17) | Social Functioning: Week 70 (n=3,14) | Social Functioning: Week 73 (n=3,12) | Social Functioning: Week 76 (n=3,8) | Social Functioning: Week 79 (n=3,9) | Social Functioning: Wek 82 (n=2,6) | Social Functioning: Week 85 (n=2,6) | Social Functioning: Week 88 (n=2,6) | Social Functioning: Week 91 (n=2,4) | Social Functioning: Week 94 (n=2,6) | Social Functioning: Week 97 (n=1,5) | Social Functioning: Week 100 (n=1,4) | Social Functioning: Week 103 (n=1,4) | Social Functioning: Week 106 (n=1,4) | Social Functioning: Week 109 (n=1,4) | Social Functioning: Week 112 (n=1,5) | Social Functioning: Week 115 (n=1,4) | Social Functioning: Week 118 (n=1,5) | Social Functioning: Week 121 (n=1,5) | Social Functioning: Week 124 (n=1,5) | Social Functioning: Week 127 (n=1,3) | Social Functioning: Week 130 (n=0,3) | Social Functioning: Week 133 (n=1,3) | Social Functioning: Week 136 (n=0,2) | Social Functioning: Week 139 (n=0,2) | Social Functioning: Week 142 (n=0,2) | Social Functioning: Week 145 (n=0,1) | Social Functioning: Final Visit (n=158,161) | Fatigue: BL (n=276,287) | Fatigue: Week 4 (n=235,250) | Fatigue: Week 7 (n=181,220) | Fatigue: Week 10 (n=176,201) | Fatigue: Week 13 (n=152,183) | Fatigue: Week 16 (n=121,165) | Fatigue: Week 19 (n=114,143) | Fatigue: Week 22 (n=79,143) | Fatigue: Week 25 (n=64,124) | Fatigue: Week 28 (n=47,110) | Fatigue: Week 31 (n=45,95) | Fatigue: Week 34 (n=37,87) | Fatigue: Week 37 (n=29,64) | Fatigue: Week 40 (n=24,55) | Fatigue: Week 43 (n=12,43) | Fatigue: Week 46 (n=14,42) | Fatigue: Week 49 (n=10,36) | Fatigue: Week 52 (n=8,30) | Fatigue: Week 55 (n=6,24) | Fatigue: Week 58 (n=6,21) | Fatigue: Week 61 (n=4,17) | Fatigue: Week 64 (n=3,20) | Fatigue: Week 67 (n=4,17) | Fatigue: Week 70 (n=3,14) | Fatigue: Week 73 (n=3,12) | Fatigue: Week 76 (n=3,8) | Fatigue: Week 79 (n=3,9) | Fatigue: Week 82 (n=2,6) | Fatigue: Week 85 (n=2,6) | Fatigue: Week 88 (n=2,6) | Fatigue: Week 91 (n=2,4) | Fatigue: Week 94 (n=2,6) | Fatigue: Week 97 (n=1,5) | Fatigue: Week 100 (n=1,4) | Fatigue: Week 103 (n=1,4) | Fatigue: Week 106 (n=1,4) | Fatigue: Week 109 (n=1,4) | Fatigue: Week 112 (n=1,5) | Fatigue: Week 115 (n=1,4) | Fatigue: Week 118 (n=1,5) | Fatigue: Week 121 (n=1,5) | Fatigue: Week 124 (n=1,5) | Fatigue: Week 127 (n=1,3) | Fatigue: Week 130 (n=0,3) | Fatigue: Week 133 (n=1,3) | Fatigue: Week 136 (n=0,2) | Fatigue: Week 139 (n=0,2) | Fatigue: Week 142 (n=0,2) | Fatigue: Week 145 (n=0,1) | Fatigue: Final Visit (n=158,160) | Nausea & Vomiting: BL (n=276,287) | Nausea & Vomiting: Week 4 (n=235,250) | Nausea & Vomiting: Week 7 (n=181,220) | Nausea & Vomiting: Week 10 (n=176,201) | Nausea & Vomiting: Week 13 (n=121,183) | Nausea & Vomiting: Week 16 (n=121,165) | Nausea & Vomiting: Week 19 (n=114,143) | Nausea & Vomiting: Week 22 (n=79,143) | Nausea & Vomiting: Week 25 (n=64,124) | Nausea & Vomiting: Week 28 (n=47,110) | Nausea & Vomiting: Week 31 (n=45,95) | Nausea & Vomiting: Week 34 (n=37,87) | Nausea & Vomiting: Week 37 (n=29,64) | Nausea & Vomiting: Week 40 (n=24,55) | Nausea & Vomiting: Week 43 (n=12,43) | Nausea & Vomiting: Week 46 (n=14,42) | Nausea & Vomiting: Week 49 (n=10,36) | Nausea & Vomiting: Week 52 (n=8,30) | Nausea & Vomiting: Week 55 (n=6,24) | Nausea & Vomiting: Week 58 (n=6,21) | Nausea & Vomiting: Week 61 (n=4,17) | Nausea & Vomiting: Week 64 (n=3,20) | Nausea & Vomiting: Week 67 (n=4,17) | Nausea & Vomiting: Week 70 (n=3,14) | Nausea & Vomiting: Week 73 (n=3,12) | Nausea & Vomiting: Week 76 (n=3,8) | Nausea & Vomiting: Week 79 (n=3,9) | Nausea & Vomiting: Week 82 (n=2,6) | Nausea & Vomiting: Week 85 (n=2,6) | Nausea & Vomiting: Week 88 (n=2,6) | Nausea & Vomiting: Week 91 (n=2,4) | Nausea & Vomiting: Week 94 (n=2,6) | Nausea & Vomiting: Week 97 (n=1,5) | Nausea & Vomiting: Week 100 (n=1,4) | Nausea & Vomiting: Week 103 (n=1,4) | Nausea & Vomiting: Week 106 (n=1,4) | Nausea & Vomiting: Week 109 (n=1,4) | Nausea & Vomiting: Week 112 (n=1,5) | Nausea & Vomiting: Week 115 (n=1,4) | Nausea & Vomiting: Week 118 (n=1,5) | Nausea & Vomiting: Week 121 (n=1,5) | Nausea & Vomiting: Week 124 (n=1,5) | Nausea & Vomiting: Week 127 (n=1,3) | Nausea & Vomiting: Week 130 (n=0,3) | Nausea & Vomiting: Week 133 (n=1,3) | Nausea & Vomiting: Week 136 (n=0,2) | Nausea & Vomiting: Week 139 (n=0,2) | Nausea & Vomiting: Week 142 (n=0,2) | Nausea & Vomiting: Week 145 (n=0,1) | Nausea & Vomiting: Final Visit (n=158,161) | Pain: BL (n=276,287) | Pain: Week 4 (n=235,250) | Pain: Week 7 (n=181,220) | Pain: Week 10 (n=176,202) | Pain: Week 13 (n=152,183) | Pain: Week 16 (n=121,165) | Pain: Week 19 (n=114,143) | Pain: Week 22 (n=79,143) | Pain: Week 25 (n=64,124) | Pain: Week 28 (n=47,111) | Pain: Week 31 (n=45,95) | Pain: Week 34 (n=37,87) | Pain: Week 37 (n=29,64) | Pain: Week 40 (n=24,55) | Pain: Week 43 (n=12,43) | Pain: Week 46 (n=14,42) | Pain: Week 49 (n=10,36) | Pain: Week 52 (n=8,30) | Pain: Week 55 (n=6,24) | Pain: Week 58 (n=6,21) | Pain: Week 61 (n=4,17) | Pain: Week 64 (n=3,20) | Pain: Week 67 (n=4,17) | Pain: Week 70 (n=3,14) | Pain: Week 73 (n=3,12) | Pain: Week 76 (n=3,8) | Pain: Week 79 (n=3,9) | Pain: Week 82 (n=2,6) | Pain: Week 85 (n=2,6) | Pain: Week 88 (n=2,6) | Pain: Week 91 (n=2,4) | Pain: Week 94 (n=2,6) | Pain: Week 97 (n=1,5) | Pain: Week 100 (n=1,4) | Pain: Week 103 (n=1,4) | Pain: Week 106 (n=1,4) | Pain: Week 109 (n=1,4) | Pain: Week 112 (n=1,5) | Pain: Week 115 (n=1,4) | Pain: Week 118 (n=1,5) | Pain: Week 121 (n=1,5) | Pain: Week 124 (n=1,5) | Pain: Week 127 (n=1,3) | Pain: Week 130 (n=0,3) | Pain: Week 133 (n=1,3) | Pain: Week 136 (n=0,2) | Pain: Week 139 (n=0,2) | Pain: Week 142 (n=0,2) | Pain: Week 145 (n=0,1) | Pain: Final Visit (n=158,161) | Dyspnoea: BL (n=274,281) | Dyspnoea: Week 4 (n=232,249) | Dyspnoea: Week 7 (n=181,217) | Dyspnoea: Week 10 (n=176,198) | Dyspnoea: Week 13 (n=151,182) | Dyspnoea: Week 16 (n=121,165) | Dyspnoea: Week 19 (n=113,143) | Dyspnoea: Week 22 (n=79,143) | Dyspnoea: Week 25 (n=63,124) | Dyspnoea: Week 28 (n=47,110) | Dyspnoea: Week 31 (n=45,95) | Dyspnoea: Week 34 (n=36,87) | Dyspnoea: Week 37 (n=29,64) | Dyspnoea: Week 40 (n=24,55) | Dyspnoea: Week 43 (n=12,43) | Dyspnoea: Week 46 (n=14,42) | Dyspnoea: Week 49 (n=10,36) | Dyspnoea: Week 52 (n=8,30) | Dyspnoea: Week 55 (n=6,24) | Dyspnoea: Week 58 (n=6,21) | Dyspnoea: Week 61 (n=4,17) | Dyspnoea: Week 64 (n=3,20) | Dyspnoea: Week 67 (n=4,17) | Dyspnoea: Week 70 (n=3,14) | Dyspnoea: Week 73 (n=3,12) | Dyspnoea: Week 76 (n=3,8) | Dyspnoea: Week 79 (n=3,9) | Dyspnoea: Week 82 (n=2,6) | Dyspnoea: Week 85 (n=180,6) | Dyspnoea: Week 88 (n=2,6) | Dyspnoea: Week 91 (n=2,4) | Dyspnoea: Week 94 (n=2,6) | Dyspnoea: Week 97 (n=1,5) | Dyspnoea: Week 100 (n=1,4) | Dyspnoea: Week 103 (n=1,4) | Dyspnoea: Week 106 (n=1,4) | Dyspnoea: Week 109 (n=1,4) | Dyspnoea: Week 112 (n=1,5) | Dyspnoea: Week 115 (n=1,4) | Dyspnoea: Week 118 (n=1,5) | Dyspnoea: Week 121 (n=1,5) | Dyspnoea: Week 124 (n=1,5) | Dyspnoea: Week 127 (n=1,3) | Dyspnoea: Week 130 (n=0,3) | Dyspnoea: Week 133 (n=1,3) | Dyspnoea: Week 136 (n=0,2) | Dyspnoea: Week 139 (n=0,2) | Dyspnoea: Week 142 (n=0,2) | Dyspnoea: Week 145 (n=0,1) | Dyspnoea: Final Visit (n=157,160) | Insomnia: BL (n=276,285) | Insomnia: Week 4 (n=234,248) | Insomnia: Week 7 (n=181,219) | Insomnia: Week 10 (n=175,200) | Insomnia: Week 13 (n=152,183) | Insomnia: Week 16 (n=120,164) | Insomnia: Week 19 (n=113,143) | Insomnia: Week 22 (n=79,143) | Insomnia: Week 25 (n=64,124) | Insomnia: Week 28 (n=47,110) | Insomnia: Week 31 (n=45,94) | Insomnia: Week 34 (n=37,87) | Insomnia: Week 37 (n=29,63) | Insomnia: Week 40 (n=24,55) | Insomnia: Week 43 (n=12,43) | Insomnia: Week 46 (n=13,42) | Insomnia: Week 49 (n=10,36) | Insomnia: Week 52 (n=8,30) | Insomnia: Week 55 (n=6,24) | Insomnia: Week 58 (n=6,21) | Insomnia: Week 61 (n=4,17) | Insomnia: Week 64 (n=3,20) | Insomnia: Week 67 (n=4,17) | Insomnia: Week 70 (n=3,14) | Insomnia: Week 73 (n=3,12) | Insomnia: Week 76 (n=3,8) | Insomnia: Week 79 (n=3,9) | Insomnia: Week 82 (n=2,6) | Insomnia: Week 85 (n=2,6) | Insomnia: Week 88 (n=2,6) | Insomnia: Week 91 (n=2,4) | Insomnia: Week 94 (n=2,6) | Insomnia: Week 97 (n=1,5) | Insomnia: Week 100 (n=1,4) | Insomnia: Week 103 (n=1,4) | Insomnia: Week 106 (n=1,4) | Insomnia: Week 109 (n=1,4) | Insomnia: Week 112 (n=1,5) | Insomnia: Week 115 (n=1,4) | Insomnia: Week 118 (n=1,5) | Insomnia: Week 121 (n=1,5) | Insomnia: Week 124 (n=1,5) | Insomnia: Week 127 (n=1,3) | Insomnia: Week 130 (n=0,3) | Insomnia: Week 133 (n=1,3) | Insomnia: Week 136 (n=0,2) | Insomnia: Week 139 (n=0,2) | Insomnia: Week 142 (n=0,2) | Insomnia: Week 145 (n=0,1) | Insomnia: Final Visit (n=157,160) | Appetite Loss: BL (n=275,286) | Appetite Loss: Week 4 (n=235,250) | Appetite Loss: Week 7 (n=180,216) | Appetite Loss: Week 10 (n=176,201) | Appetite Loss: Week 13 (n=151,183) | Appetite Loss: Week 16 (n=121,165) | Appetite Loss: Week 19 (n=114,141) | Appetite Loss: Week 22 (n=79,143) | Appetite Loss: Week 25 (n=64,124) | Appetite Loss: Week 28 (n=47,109) | Appetite Loss: Week 31 (n=45,95) | Appetite Loss: Week 34 (n=37,87) | Appetite Loss: Week 37 (n=29,64) | Appetite Loss: Week 40 (n=24,55) | Appetite Loss: Week 43 (n=12,43) | Appetite Loss: Week 46 (n=14,42) | Appetite Loss: Week 49 (n=9,36) | Appetite Loss: Week 52 (n=8,30) | Appetite Loss: Week 55 (n=6,24) | Appetite Loss: Week 58 (n=6,21) | Appetite Loss: Week 61 (n=4,17) | Appetite Loss: Week 64 (n=3,20) | Appetite Loss: Week 67 (n=4,17) | Appetite Loss: Week 70 (n=3,14) | Appetite Loss: Week 73 (n=3,12) | Appetite Loss: Week 76 (n=3,8) | Appetite Loss: Week 79 (n=3,9) | Appetite Loss: Week 82 (n=2,6) | Appetite Loss: Week 85 (n=2,6) | Appetite Loss: Week 88 (n=2,6) | Appetite Loss: Week 91 (n=2,4) | Appetite Loss: Week 94 (n=2,6) | Appetite Loss: Week 97 (n=1,5) | Appetite Loss: Week 100 (n=1,4) | Appetite Loss: Week 103 (n=1,4) | Appetite Loss: Week 106 (n=1,4) | Appetite Loss: Week 109 (n=1,4) | Appetite Loss: Week 112 (n=1,5) | Appetite Loss: Week 115 (n=1,4) | Appetite Loss: Week 118 (n=1,5) | Appetite Loss: Week 121 (n=1,5) | Appetite Loss: Week 124 (n=1,5) | Appetite Loss: Week 127 (n=1,3) | Appetite Loss: Week 130 (n=0,3) | Appetite Loss: Week 133 (n=1,3) | Appetite Loss: Week 136 (n=0,2) | Appetite Loss: Week 139 (n=0,2) | Appetite Loss: Week 142 (n=0,2) | Appetite Loss: Week 145 (n=0,1) | Appetite Loss: Week Final Visit (n=156,161) | Constipation: BL (n=276,285) | Constipation: Week 4 (n=235,247) | Constipation: Week 7 (n=179,220) | Constipation: Week 10 (n=175,203) | Constipation: Week 13 (n=152,183) | Constipation: Week 16 (n=121,165) | Constipation: Week 19 (n=114,143) | Constipation: Week 22 (n=78,143) | Constipation: Week 25 (n=64,124) | Constipation: Week 28 (n=47,111) | Constipation: Week 31 (n=45,95) | Constipation: Week 34 (n=37,86) | Constipation: Week 37 (n=29,64) | Constipation: Week 40 (n=24,55) | Constipation: Week 43 (n=12,43) | Constipation: Week 46 (n=14,42) | Constipation: Week 49 (n=10,36) | Constipation: Week 52 (n=8,29) | Constipation: Week 55 (n=6,24) | Constipation: Week 58 (n=6,21) | Constipation: Week 61 (n=4,17) | Constipation: Week 64 (n=3,20) | Constipation: Week 67 (n=4,17) | Constipation: Week 70 (n=3,14) | Constipation: Week 73 (n=3,12) | Constipation: Week 76 (n=3,8) | Constipation: Week 79 (n=3,9) | Constipation: Week 82 (n=2,6) | Constipation: Week 85 (n=2,6) | Constipation: Week 88 (n=2,6) | Constipation: Week 91 (n=2,4) | Constipation: Week 94 (n=2,6) | Constipation: Week 97 (n=1,5) | Constipation: Week 100 (n=1,4) | Constipation: Week 103 (n=1,4) | Constipation: Week 106 (n=1,4) | Constipation: Week 109 (n=1,4) | Constipation: Week 112 (n=1,5) | Constipation: Week 115 (n=1,4) | Constipation: Week 118 (n=1,5) | Constipation: Week 121 (n=1,5) | Constipation: Week 124 (n=1,5) | Constipation: Week 127 (n=1,3) | Constipation: Week 130 (n=0,3) | Constipation: Week 133 (n=1,3) | Constipation: Week 136 (n=0,2) | Constipation: Week 139 (n=0,2) | Constipation: Week 142 (n=0,2) | Constipation: Week 145 (n=0,1) | Constipation: Final Visit (n=158,160) | Diarrhoea: BL (n=276,283) | Diarrhoea: Week 4 (n=234,246) | Diarrhoea: Week 7 (n=180,220) | Diarrhoea: Week 10 (n=174,202) | Diarrhoea: Week 13 (n=152,183) | Diarrhoea: Week 16 (n=120,165) | Diarrhoea: Week 19 (n=114,143) | Diarrhoea: Week 22 (n=78,143) | Diarrhoea: Week 25 (n=64,124) | Diarrhoea: Week 28 (n=47,111) | Diarrhoea: Week 31 (n=45,95) | Diarrhoea: Week 34 (n=37,87) | Diarrhoea: Week 37 (n=29,64) | Diarrhoea: Week 40 (n=24,55) | Diarrhoea: Week 43 (n=12,42) | Diarrhoea: Week 46 (n=14,42) | Diarrhoea: Week 49 (n=10,36) | Diarrhoea: Week 52 (n=8,29) | Diarrhoea: Week 55 (n=6,24) | Diarrhoea: Week 58 (n=6,21) | Diarrhoea: Week 61 (n=4,17) | Diarrhoea: Week 64 (n=3,20) | Diarrhoea: Week 67 (n=4,17) | Diarrhoea: Week 70 (n=3,14) | Diarrhoea: Week 73 (n=3,12) | Diarrhoea: Week 76 (n=3,8) | Diarrhoea: Week 79 (n=3,9) | Diarrhoea: Week 82 (n=2,6) | Diarrhoea: Week 85 (n=2,6) | Diarrhoea: Week 88 (n=2,6) | Diarrhoea: Week 91 (n=2,4) | Diarrhoea: Week 94 (n=2,6) | Diarrhoea: Week 97 (n=1,5) | Diarrhoea: Week 100 (n=1,4) | Diarrhoea: Week 103 (n=1,4) | Diarrhoea: Week 106 (n=1,4) | Diarrhoea: Week 109 (n=1,4) | Diarrhoea: Week 112 (n=1,5) | Diarrhoea: Week 115 (n=1,4) | Diarrhoea: Week 118 (n=1,5) | Diarrhoea: Week 121 (n=1,5) | Diarrhoea: Week 124 (n=1,5) | Diarrhoea: Week 127 (n=1,3) | Diarrhoea: Week 130 (n=0,3) | Diarrhoea: Week 133 (n=1,3) | Diarrhoea: Week 136 (n=0,2) | Diarrhoea: Week 139 (n=0,2) | Diarrhoea: Week 142 (n=0,2) | Diarrhoea: Week 145 (n=0,1) | Diarrhoea: Final Visit (n=157,160) | Financial Difficulties: BL (n=274,286) | Financial Difficulties: Week 4 (n=234,249) | Financial Difficulties: Week 7 (n=178,220) | Financial Difficulties: Week 10 (n=175,202) | Financial Difficulties: Week 13 (n=151,181) | Financial Difficulties: Week 16 (n=120,165) | Financial Difficulties: Week 19 (n=113,143) | Financial Difficulties: Week 22 (n=78,142) | Financial Difficulties: Week 25 (n=63,124) | Financial Difficulties: Week 28 (n=45,111) | Financial Difficulties: Week 31 (n=45,94) | Financial Difficulties: Week 34 (n=36,87) | Financial Difficulties: Week 37 (n=29,64) | Financial Difficulties: Week 40 (n=24,55) | Financial Difficulties: Week 43 (n=12,43) | Financial Difficulties: Week 46 (n=14,42) | Financial Difficulties: Week 49 (n=10,35) | Financial Difficulties: Week 52 (n=8,29) | Financial Difficulties: Week 55 (n=6,24) | Financial Difficulties: Week 58 (n=6,21) | Financial Difficulties: Week 61 (n=4,17) | Financial Difficulties: Week 64 (n=3,20) | Financial Difficulties: Week 67 (n=4,17) | Financial Difficulties: Week 70 (n=3,14) | Financial Difficulties: Week 73 (n=3,12) | Financial Difficulties: Week 76 (n=3,8) | Financial Difficulties: Week 79 (n=3,9) | Financial Difficulties: Week 82 (n=2,6) | Financial Difficulties: Week 85 (n=2,6) | Financial Difficulties: Week 88 (n=2,6) | Financial Difficulties: Week 91 (n=2,4) | Financial Difficulties: Week 94 (n=2,6) | Financial Difficulties: Week 97 (n=1,5) | Financial Difficulties: Week 100 (n=1,4) | Financial Difficulties: Week 103 (n=1,4) | Financial Difficulties: Week 106 (n=1,4) | Financial Difficulties: Week 109 (n=1,4) | Financial Difficulties: Week 112 (n=1,5) | Financial Difficulties: Week 115 (n=1,4) | Financial Difficulties: Week 118 (n=1,5) | Financial Difficulties: Week 121 (n=1,5) | Financial Difficulties: Week 124 (n=1,5) | Financial Difficulties: Week 127 (n=1,3) | Financial Difficulties: Week 130 (n=0,3) | Financial Difficulties: Week 133 (n=1,3) | Financial Difficulties: Week 136 (n=0,2) | Financial Difficulties: Week 139 (n=0,2) | Financial Difficulties: Week 142 (n=0,2) | Financial Difficulties: Week 145 (n=0,1) | Financial Difficulties: Final Visit (n=158,160) | |
| Fluoropyrimidine/Cisplatin (FP) | 55.3 | 61.0 | 60.9 | 62.3 | 63.8 | 60.8 | 61.0 | 65.1 | 68.0 | 72.0 | 69.6 | 70.8 | 66.1 | 62.0 | 72.9 | 75.0 | 68.5 | 72.6 | 76.7 | 76.7 | 79.2 | 77.8 | 75.0 | 77.8 | 80.6 | 77.8 | 77.8 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | NA | 83.3 | NA | NA | NA | NA | 53.2 | 78.9 | 76.0 | 79.3 | 78.2 | 80.2 | 79.8 | 78.8 | 80.7 | 85.8 | 86.2 | 85.6 | 86.3 | 85.7 | 84.4 | 85.6 | 87.6 | 88.7 | 88.3 | 85.6 | 86.7 | 91.7 | 95.6 | 93.3 | 97.8 | 97.8 | 95.6 | 95.6 | 93.3 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 93.3 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | NA | 100.0 | NA | NA | NA | NA | 72.1 | 73.2 | 67.4 | 70.9 | 70.2 | 73.4 | 72.0 | 71.1 | 74.7 | 81.3 | 80.5 | 82.2 | 83.3 | 81.6 | 79.9 | 80.6 | 82.1 | 81.7 | 85.4 | 80.6 | 77.8 | 83.3 | 83.3 | 83.3 | 88.9 | 88.9 | 83.3 | 83.3 | 91.7 | 100.0 | 91.7 | 91.7 | 100.0 | 83.3 | 83.3 | 100.0 | 100.0 | 100.0 | 83.3 | 100.0 | 100.0 | 83.3 | 83.3 | 100.0 | NA | 100.0 | NA | NA | NA | NA | 63.5 | 75.4 | 80.5 | 81.3 | 82.9 | 82.6 | 83.1 | 82.2 | 85.9 | 88.2 | 86.0 | 85.7 | 88.5 | 83.9 | 83.6 | 81.9 | 82.1 | 88.3 | 86.5 | 76.4 | 85.6 | 95.8 | 100 | 95.8 | 97.2 | 94.4 | 100.0 | 97.2 | 95.8 | 95.8 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | NA | 100.0 | NA | NA | NA | NA | 75.1 | 86.9 | 86.0 | 85.7 | 85.6 | 88.2 | 82.8 | 84.2 | 85.9 | 85.9 | 86.5 | 87.0 | 88.3 | 88.5 | 83.3 | 88.9 | 89.3 | 85.0 | 91.7 | 94.4 | 91.7 | 91.7 | 100.0 | 91.7 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | NA | 100.0 | NA | NA | NA | NA | 79.5 | 72.4 | 72.1 | 73.1 | 74.5 | 72.7 | 72.7 | 74.4 | 79.3 | 83.3 | 83.0 | 81.5 | 84.7 | 85.1 | 85.4 | 87.5 | 86.9 | 85.0 | 87.5 | 86.1 | 88.9 | 91.7 | 94.4 | 95.8 | 94.4 | 100.0 | 94.4 | 94.4 | 100.0 | 91.7 | 91.7 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | NA | 100.0 | NA | NA | NA | NA | 68.1 | 36.3 | 37.1 | 34.4 | 35.3 | 32.9 | 33.0 | 33.1 | 30.0 | 22.2 | 24.1 | 22.0 | 22.8 | 21.8 | 23.6 | 19.4 | 20.6 | 19.4 | 16.7 | 18.5 | 16.7 | 8.3 | 7.4 | 13.9 | 11.1 | 7.4 | 7.4 | 7.4 | 0.0 | 5.6 | 0.0 | 0.0 | 0.0 | 11.1 | 0.0 | 0.0 | 11.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 40.4 | 15.0 | 16.6 | 16.9 | 16.4 | 12.8 | 14.2 | 14.2 | 10.3 | 8.6 | 3.5 | 3.7 | 4.5 | 2.9 | 4.2 | 2.8 | 1.2 | 3.3 | 2.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 14.9 | 24.9 | 17.8 | 14.5 | 13.4 | 12.0 | 13.6 | 14.2 | 15.0 | 10.7 | 8.2 | 12.2 | 12.2 | 11.5 | 18.8 | 16.7 | 13.1 | 13.3 | 6.3 | 2.8 | 8.3 | 0.0 | 5.6 | 0.0 | 0.0 | 5.6 | 5.6 | 5.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 27.4 | 12.4 | 12.1 | 12.7 | 14.6 | 11.3 | 15.4 | 15.3 | 13.9 | 12.7 | 9.2 | 10.4 | 10.2 | 10.3 | 9.7 | 19.4 | 11.9 | 6.7 | 12.5 | 5.6 | 5.6 | 16.7 | 0.0 | 8.3 | 0.0 | 0.0 | 11.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 20.0 | 27.2 | 22.1 | 21.9 | 19.8 | 14.7 | 15.3 | 17.1 | 14.8 | 15.1 | 9.9 | 10.4 | 9.0 | 8.0 | 13.9 | 13.9 | 7.7 | 10.0 | 12.5 | 16.7 | 11.1 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 21.9 | 35.2 | 31.5 | 27.2 | 26.7 | 24.7 | 24.5 | 26.9 | 19.0 | 12.0 | 14.2 | 11.1 | 11.7 | 12.6 | 13.9 | 5.6 | 4.8 | 3.7 | 0.0 | 0.0 | 5.6 | 8.3 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 35.3 | 22.9 | 20.6 | 19.0 | 19.2 | 16.7 | 14.6 | 13.5 | 12.0 | 7.3 | 7.8 | 10.4 | 5.4 | 11.5 | 8.3 | 8.3 | 4.8 | 3.3 | 4.2 | 5.6 | 11.1 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.7 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 19.0 | 10.9 | 9.1 | 8.7 | 10.5 | 6.6 | 8.1 | 7.3 | 6.0 | 7.3 | 5.7 | 5.9 | 5.4 | 5.7 | 6.9 | 8.3 | 4.8 | 10.0 | 8.3 | 11.1 | 11.1 | 16.7 | 11.1 | 16.7 | 11.1 | 11.1 | 22.2 | 11.1 | 0.0 | 0.0 | 0.0 | 16.7 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 10.0 | 27.3 | 23.6 | 23.6 | 21.5 | 22.5 | 23.1 | 20.6 | 19.7 | 16.4 | 17.0 | 15.6 | 10.2 | 13.8 | 22.2 | 16.7 | 16.7 | 16.7 | 8.3 | 16.7 | 11.1 | 16.7 | 11.1 | 16.7 | 11.1 | 11.1 | 11.1 | 11.1 | 16.7 | 16.7 | 16.7 | 16.7 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 26.6 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 54.9 | 60.9 | 60.5 | 61.9 | 63.6 | 61.9 | 63.8 | 64.9 | 67.8 | 68.5 | 70.0 | 72.0 | 70.6 | 70.6 | 73.6 | 73.8 | 76.6 | 71.3 | 73.8 | 73.8 | 72.5 | 70.0 | 72.5 | 68.5 | 68.1 | 67.7 | 69.4 | 60.0 | 79.2 | 73.6 | 79.2 | 79.2 | 78.3 | 85.4 | 75.0 | 77.1 | 77.1 | 75.0 | 72.9 | 75.0 | 75.0 | 81.7 | 72.2 | 72.2 | 72.2 | 66.7 | 66.7 | 66.7 | 66.7 | 53.1 | 79.6 | 79.5 | 79.3 | 80.2 | 80.5 | 80.7 | 81.5 | 83.6 | 84.8 | 83.7 | 85.4 | 85.1 | 85.8 | 88.2 | 89.9 | 91.9 | 92.0 | 89.2 | 93.1 | 91.4 | 91.0 | 91.0 | 93.3 | 92.9 | 91.1 | 90.0 | 92.6 | 90.0 | 95.6 | 95.6 | 98.3 | 97.8 | 97.3 | 96.7 | 96.7 | 98.3 | 95.0 | 97.3 | 93.3 | 96.0 | 94.7 | 96.0 | 93.3 | 93.3 | 95.6 | 93.3 | 93.3 | 93.3 | 100.0 | 73.8 | 73.9 | 76.1 | 73.3 | 74.3 | 75.1 | 74.6 | 75.8 | 79.7 | 82.4 | 79.7 | 81.1 | 82.2 | 81.5 | 82.1 | 86.8 | 86.5 | 88.0 | 84.4 | 88.2 | 89.7 | 87.3 | 87.5 | 90.2 | 86.9 | 80.6 | 81.3 | 81.5 | 80.6 | 91.7 | 94.4 | 91.7 | 100.0 | 90.0 | 100.0 | 100.0 | 100.0 | 95.8 | 93.3 | 83.3 | 86.7 | 90.0 | 90.0 | 88.9 | 88.9 | 88.9 | 83.3 | 83.3 | 83.3 | 100.0 | 68.7 | 73.1 | 77.9 | 80.2 | 81.2 | 80.5 | 81.9 | 82.4 | 84.0 | 84.8 | 85.5 | 85.7 | 85.4 | 86.3 | 86.7 | 87.8 | 87.5 | 91.4 | 88.2 | 88.5 | 88.9 | 90.7 | 86.3 | 89.2 | 89.3 | 82.9 | 87.5 | 84.3 | 83.3 | 91.7 | 90.3 | 95.8 | 88.9 | 91.7 | 87.5 | 87.5 | 89.6 | 91.7 | 95.0 | 93.8 | 90.0 | 95.0 | 90.0 | 100.0 | 88.9 | 91.7 | 95.8 | 95.8 | 95.8 | 100.0 | 74.3 | 85.7 | 86.3 | 86.5 | 86.8 | 85.7 | 86.8 | 87.6 | 87.4 | 87.4 | 88.0 | 90.0 | 88.7 | 91.4 | 91.5 | 91.5 | 91.7 | 92.6 | 89.7 | 91.0 | 90.5 | 91.2 | 93.3 | 91.2 | 91.7 | 83.3 | 83.3 | 81.5 | 88.9 | 91.7 | 94.4 | 95.8 | 94.4 | 90.0 | 95.8 | 91.7 | 95.8 | 95.8 | 93.3 | 95.8 | 96.7 | 96.7 | 96.7 | 100.0 | 88.9 | 94.4 | 100.0 | 100.0 | 100.0 | 100.0 | 80.0 | 72.0 | 74.1 | 75.1 | 76.7 | 76.3 | 77.5 | 79.5 | 80.1 | 80.2 | 80.2 | 78.9 | 80.7 | 81.8 | 82.7 | 84.1 | 86.9 | 84.7 | 82.2 | 85.4 | 87.3 | 90.2 | 85.8 | 85.3 | 86.9 | 80.6 | 81.3 | 85.2 | 80.6 | 88.9 | 88.9 | 91.7 | 91.7 | 90.0 | 95.8 | 100.0 | 91.7 | 95.8 | 96.7 | 95.8 | 96.7 | 100.0 | 96.7 | 83.3 | 94.4 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 71.4 | 34.2 | 34.5 | 34.1 | 33.2 | 33.7 | 32.8 | 29.4 | 26.7 | 25.1 | 23.2 | 22.2 | 19.7 | 19.8 | 18.6 | 17.1 | 13.8 | 14.5 | 17.2 | 14.4 | 16.4 | 14.4 | 17.2 | 15.0 | 16.7 | 16.7 | 18.1 | 18.5 | 29.6 | 11.1 | 9.3 | 11.1 | 7.4 | 11.1 | 11.1 | 19.4 | 13.9 | 16.7 | 17.8 | 25.0 | 17.8 | 17.8 | 13.3 | 14.8 | 18.5 | 14.8 | 22.2 | 22.2 | 22.2 | 11.1 | 37.6 | 15.7 | 19.7 | 18.9 | 16.4 | 14.7 | 14.5 | 13.9 | 12.2 | 8.2 | 6.5 | 8.8 | 7.5 | 6.8 | 4.8 | 1.2 | 2.8 | 0.9 | 5.0 | 2.1 | 3.2 | 0.0 | 4.2 | 2.9 | 2.4 | 1.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 19.8 | 25.1 | 17.9 | 16.1 | 14.4 | 13.3 | 12.4 | 12.8 | 13.2 | 12.2 | 12.0 | 11.8 | 11.3 | 12.2 | 10.3 | 8.9 | 6.7 | 6.5 | 10.0 | 8.3 | 7.1 | 4.9 | 6.7 | 4.9 | 4.8 | 9.7 | 8.3 | 9.3 | 2.8 | 0.0 | 2.8 | 4.2 | 0.0 | 3.3 | 8.3 | 0.0 | 0.0 | 0.0 | 3.3 | 0.0 | 3.3 | 3.3 | 0.0 | 0.0 | 5.6 | 5.6 | 0.0 | 0.0 | 0.0 | 0.0 | 25.4 | 13.4 | 11.8 | 10.8 | 11.3 | 13.7 | 13.5 | 11.9 | 12.1 | 9.4 | 10.3 | 9.1 | 9.6 | 10.4 | 4.8 | 6.2 | 5.6 | 4.6 | 5.6 | 8.3 | 6.3 | 3.9 | 8.3 | 5.9 | 7.1 | 8.3 | 8.3 | 7.4 | 16.7 | 5.6 | 5.6 | 8.3 | 5.6 | 0.0 | 0.0 | 8.3 | 8.3 | 8.3 | 6.7 | 8.3 | 6.7 | 6.7 | 6.7 | 11.1 | 11.1 | 11.1 | 16.7 | 16.7 | 16.7 | 33.3 | 18.3 | 23.6 | 23.3 | 20.4 | 18.0 | 18.9 | 17.7 | 20.0 | 17.0 | 15.9 | 13.3 | 14.9 | 13.4 | 11.1 | 10.3 | 9.3 | 9.5 | 7.4 | 7.8 | 8.3 | 9.5 | 7.8 | 10.0 | 9.8 | 9.5 | 11.1 | 8.3 | 11.1 | 11.1 | 11.1 | 5.6 | 0.0 | 5.6 | 6.7 | 8.3 | 0.0 | 0.0 | 0.0 | 6.7 | 0.0 | 6.7 | 6.7 | 0.0 | 0.0 | 11.1 | 11.1 | 0.0 | 0.0 | 0.0 | 0.0 | 24.6 | 33.8 | 33.6 | 31.3 | 29.4 | 28.4 | 27.9 | 25.1 | 20.7 | 16.7 | 11.6 | 13.0 | 9.6 | 10.9 | 9.7 | 7.0 | 5.6 | 6.5 | 10.0 | 10.0 | 4.8 | 0.0 | 8.3 | 5.9 | 7.1 | 5.6 | 4.2 | 0.0 | 5.6 | 5.6 | 11.1 | 0.0 | 5.6 | 0.0 | 0.0 | 8.3 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 11.1 | 11.1 | 0.0 | 0.0 | 0.0 | 0.0 | 33.5 | 21.5 | 20.2 | 17.6 | 15.1 | 15.8 | 15.4 | 14.5 | 10.0 | 10.2 | 9.6 | 6.3 | 4.7 | 10.4 | 7.9 | 7.0 | 7.1 | 5.6 | 10.3 | 6.9 | 6.3 | 5.9 | 5.0 | 5.9 | 4.8 | 11.1 | 4.2 | 3.7 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 20.0 | 10.7 | 12.2 | 14.2 | 11.9 | 12.0 | 12.9 | 10.3 | 9.6 | 6.2 | 4.8 | 4.9 | 5.7 | 4.2 | 3.0 | 2.4 | 1.6 | 3.7 | 2.3 | 4.2 | 4.8 | 0.0 | 3.3 | 2.0 | 3.3 | 2.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.7 | 0.0 | 0.0 | 0.0 | 6.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.0 | 29.3 | 27.7 | 23.9 | 23.3 | 22.7 | 24.4 | 22.4 | 24.9 | 22.3 | 21.6 | 23.4 | 24.5 | 23.4 | 23.6 | 19.4 | 18.3 | 20.0 | 20.7 | 18.1 | 22.2 | 23.5 | 16.7 | 17.6 | 19.0 | 19.4 | 25.0 | 25.9 | 22.2 | 16.7 | 16.7 | 25.0 | 16.7 | 20.0 | 16.7 | 8.3 | 16.7 | 16.7 | 13.3 | 16.7 | 13.3 | 13.3 | 13.3 | 11.1 | 11.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 27.9 |
"The participant assessed their pain on a 0 to 100 millimeter (mm) horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as no pain and the right-hand extreme equals 100 mm as unbearable pain. A negative change indicated improvement." (NCT01041404)
Timeframe: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | mm (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BL (n=275,284) | Week 4 (n=234,249) | Week 7 (n=181,219) | Week 10 (n=174, 202) | Week 13 (n=152,181) | Week 16 (n=121,165) | Week 19 (n=114,142) | Week 22 (n=79,141) | Week 25 (n=64,124) | Week 28 (n=47,111) | Week 31 (n=45,95) | Week 34 (n=37,86) | Week 37 (n=29,64) | Week 40 (n=24,54) | Week 43 (n=12,43) | Week 46 (n=14,41) | Week 49 (n=10,36) | Week 52 (n=8,30) | Week 55 (n=6,24) | Week 58 (n=6,20) | Week 61 (n=4,17) | Week 64 (n=3,20) | Week 67 (n=4,17) | Week 70 (n=3,13) | Week 73 (n=3,10) | Week 76 (n=3,8) | Week 79 (n=3,9) | Week 82 (n=2,6) | Week 85 (n=2,6) | Week 88 (n=2,6) | Week 91 (n=2,4) | Week 94 (n=2,6) | Week 97 (n=1,5) | Week 100 (n=1,4) | Week 103 (n=1,4) | Week 106 (n=1,4) | Week 109 (n=1,4) | Week 112 (n=1,5) | Week 115 (n=1,4) | Week 118 (n=1,5) | Week 121 (n=1,5) | Week 124 (n=1,4) | Week 127 (n=1,3) | Week 130 (n=0,3) | Week 133 (n=1,3) | Week 136 (n=0,2) | Week 139 (n=0,2) | Week 142 (n=0,2) | Week 145 (n=0,1) | Final visit/withdrawal (n=157,161) | |
| Fluoropyrimidine/Cisplatin (FP) | 21.1 | 14.6 | 11.1 | 14.5 | 11.3 | 14.0 | 15.4 | 13.3 | 12.7 | 8.6 | 8.7 | 9.4 | 15.5 | 16.4 | 12.6 | 16.1 | 7.2 | 5.8 | 2.3 | 4.7 | 5.3 | 2.0 | 1.5 | 1.3 | 1.0 | 1.7 | 1.0 | 0.0 | 1.0 | 0.5 | 0.5 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 23.8 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 17.9 | 13.3 | 13.8 | 12.9 | 12.2 | 12.8 | 12.0 | 15.1 | 11.0 | 12.3 | 12.5 | 10.7 | 10.9 | 8.8 | 7.2 | 7.4 | 6.5 | 6.9 | 3.3 | 3.8 | 7.2 | 6.8 | 8.9 | 1.3 | 16.5 | 12.9 | 5.9 | 4.8 | 6.3 | 5.7 | 7.5 | 5.8 | 0.2 | 0.3 | 6.5 | 7.8 | 7.3 | 4.2 | 5.8 | 3.8 | 3.2 | 4.5 | 6.3 | 5.7 | 5.0 | 6.0 | 8.0 | 7.5 | 15.0 | 21.9 |
Analgesic medications were recorded throughout the study until disease progression. (NCT01041404)
Timeframe: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Taking any analgesic medication | Discontinued at least 1 medication | Decreased dose of at least 1 medication | No change in any medication | Increased dose or added at least 1 medication | |
| Fluoropyrimidine/Cisplatin (FP) | 29.0 | 5.9 | 0.3 | 5.5 | 17.2 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 29.3 | 1.7 | 0.3 | 7.1 | 20.1 |
Change in body weight was categorized as an increase of greater than (>)5 percent (%), no change (plus or minus [±]5%), decrease of >5-10%, or a decrease of >10% from BL to the end of study. Time windows were applied in order to assign visits to weight measurements, and the lowest post-screening value recorded was used for the analysis. The percentage change in weight from screening was summarized over time. (NCT01041404)
Timeframe: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Increase >5% | No change (±5%) | Decrease >5-10% | Decrease >10% | |
| Fluoropyrimidine/Cisplatin (FP) | 1.5 | 51.6 | 28.2 | 18.7 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 1.1 | 50.5 | 27.2 | 21.2 |
Participants who were alive and disease free at 12 months. DFS was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response was disappearance of all target lesions. Partial response was at least a 30% decrease in target lesions. Progression was at least a 20% increase in target lesions and stable disease is neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. (NCT00941655)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 2 |
| Systemic Chemotherapy Alone | 0 |
Blood loss during surgery is related to complexity of the operation and via that to the stage of disease (more tumor to be cytoreduced, more blood loss). (NCT00941655)
Timeframe: Day 1
| Intervention | ml (Median) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 650 |
Time it takes to perform this complex surgery and HIPEC to reduce tumor burden overall in this disease. (NCT00941655)
Timeframe: up to 12 hours
| Intervention | hours (Median) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 10.1 |
Recuperation period following complex surgery for this disease. (NCT00941655)
Timeframe: 1-10 weeks
| Intervention | Days (Median) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 17 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00941655)
Timeframe: Date treatment consent signed to date off study, approximately, 40.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 8 |
| Systemic Chemotherapy Alone | 5 |
CCR is assessed by Sugarbaker's criteria. CCR-0 is no residual tumor. CCR-1 is no residual nodules greater than 2.5 mm in diameter, CCR-2 is no residual nodules greater than 25 mm, and CCR-3 is residual nodules greater than 25 mm. (NCT00941655)
Timeframe: Day 1
| Intervention | Scores on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | |
| Surgery + HIPEC + Systemic Chemotherapy | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
Gillys stage measures the completeness of the cytoreduction and is recorded before and after surgery. It is used to classify disease burden and determine prognosis. Stage 0 is no macroscopic signs of disease, stage 1 is nodules >5mm in one part of the abdomen, stage 2 is nodules >5 mm throughout the abdomen, stage 3 is nodules 5mm to 2 cm, and stage 4 is nodules < 2 cm. (NCT00941655)
Timeframe: Day 1
| Intervention | Stage (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient 1 Before Surgery | Patient 1 After Surgery | Patient 2 Before Surgery | Patient 2 After Surgery | Patient 3 Before Surgery | Patient 3 After Surgery | Patient 4 Before Surgery | Patient 4 After Surgery | Patient 5 Before Surgery | Patient 5 After Surgery | Patient 6 Before Surgery | Patient 6 After Surgery | Patient 7 Before Surgery | Patient 7 After Surgery | Patient 8 Before Surgery | Paitent 8 After Surgery | |
| Surgery + HIPEC + Systemic Chemotherapy | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 |
Time between the first day of treatment and the date of death. (NCT00941655)
Timeframe: 12 weeks up to 3 years
| Intervention | Months (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Patient #1 | Patient #2 | Patient #4 | Patient #6 | Patient #7 | Patient #9 | Patient #11 | Patient #15 | |
| Surgery + HIPEC + Systemic Chemotherapy | 19 | 11 | 11 | 4 | 14 | 5 | 12 | 0 |
Time between the first day of treatment and the date of death (NCT00941655)
Timeframe: 12 weeks up to 3 years
| Intervention | Months (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Patient #3 | Patient #5 | Patient #8 | Patient #10 | Patient #12 | Patient #13 | Patient #14 | |
| Systemic Chemotherapy Alone | 17 | 6 | 10 | 0 | 0 | 8 | 0 |
"DCR - complete response, partial response, and stable disease~Complete response - disappearance of all target and non-target lesions~Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter~Stable disease - neither sufficient shrinkage to qualify for partial response not sufficient increase to qualify for progressive disease" (NCT00515216)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Oxaliplatin/Leucovorin/5-FU | 95.7 |
"ORR = complete response + partial response~Complete response - disappearance of all target and non-target lesions~Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter" (NCT00515216)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Oxaliplatin/Leucovorin/5-FU | 39.1 |
(NCT00515216)
Timeframe: 4 years
| Intervention | months (Median) |
|---|---|
| Oxaliplatin/Leucovorin/5-FU | 11.4 |
Progressive disease - at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT00515216)
Timeframe: 4 years
| Intervention | months (Median) |
|---|---|
| Oxaliplatin/Leucovorin/5-FU | 6.2 |
This outcome looks at what genotypes of the ERCC1 c.354C>T (rs11615) gene had a partial tumor response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| C/C | C/T | T/T | |
| Oxaliplatin/Leucovorin/5-FU | 2 | 4 | 3 |
This outcome looks at what genotypes of the ERCC2 c.2251A>C (rs13181) gene had a partial response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | A/C | C/C | |
| Oxaliplatin/Leucovorin/5-FU | 5 | 3 | 1 |
This outcome looks at what genotypes of the GSTP1 c.313A>G (rs1695) gene had a partial response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | A/G | G/G | |
| Oxaliplatin/Leucovorin/5-FU | 4 | 3 | 2 |
This outcome looks at what genotypes of the MDR1 c.3435C>T (rs1045642) gene had a partial response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| C/C | C/T | T/T | |
| Oxaliplatin/Leucovorin/5-FU | 0 | 9 | 0 |
This outcome looks at what genotypes of the TYMS 3'-UTR 1494delTTAAAG(6 bp) (rs34489327) gene had a partial tumor response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | |
|---|---|---|
| +6 bp/+6 bp | +6 bp/-6 bp | |
| Oxaliplatin/Leucovorin/5-FU | 5 | 4 |
This outcome looks at what genotypes of the TYMS 5'-UTR TSER + G>C (rs34743033) gene had a partial tumor response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| TYMS, TSER*2/*2 | TYMS, TSER*2/*3 (G) | TYMS, TSER*2/*3 (C) | |
| Oxaliplatin/Leucovorin/5-FU | 5 | 2 | 2 |
This outcome looks at what genotypes of the XRCC1 c.1196G>A (rs25487) gene had a partial response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | G/A | G/G | |
| Oxaliplatin/Leucovorin/5-FU | 1 | 6 | 2 |
This outcome looks at what genotypes of the ERCC1 c.354C>T (rs11615) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| C/C | C/T | T/T | |
| Oxaliplatin/Leucovorin/5-FU | 1 | 8 | 2 |
This outcome looks at what genotypes of the ERCC2 c.2251A>C (rs13181) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | A/C | C/C | |
| Oxaliplatin/Leucovorin/5-FU | 3 | 6 | 2 |
This outcome looks at what genotypes of the GSTP1 c.313A>G (rs1695) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | A/G | G/G | |
| Oxaliplatin/Leucovorin/5-FU | 8 | 2 | 1 |
This outcome looks at what genotypes of the MDR1 c.3435C>T (rs1045642) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| C/C | C/T | T/T | |
| Oxaliplatin/Leucovorin/5-FU | 1 | 6 | 4 |
This outcome looks at what genotypes of the TYMS 3'-UTR 1494delTTAAAG(6 bp) (rs34489327) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | |
|---|---|---|
| +6 bp/+6 bp | +6 bp/-6 bp | |
| Oxaliplatin/Leucovorin/5-FU | 6 | 5 |
This outcome looks at what genotypes of the TYMS 5'-UTR TSER + G>C (rs34743033) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| TYMS, TSER*2/*2 | TYMS, TSER*2/*3 (G) | TYMS, TSER*2/*3 (C) | |
| Oxaliplatin/Leucovorin/5-FU | 1 | 4 | 6 |
This outcome looks at what genotypes of the XRCC1 c.1196G>A (rs25487) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | G/A | G/G | |
| Oxaliplatin/Leucovorin/5-FU | 6 | 5 | 0 |
"Percentage of partial and complete responses, according to WHO criteria:~Complete Response: Disappearance of all known disease, determined by 2 observations not less than 4 weeks apart.~Partial Response: Decrease by at least 50% of the diameters of all measurable lesions, determined by 2 observations not less than 4 weeks apart." (NCT00382720)
Timeframe: every 8 weeks up to a maximum of 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| (TE) Taxotere and Eloxatin | 23.1 |
| (TEF) Taxotere, Eloxatin and 5-fluorouracil | 46.6 |
| (TEX) Taxotere, Eloxatin and Xeloda | 25.6 |
The number of months measured from the date of randomization to the date of death due to any cause. (NCT00382720)
Timeframe: up to a maximum of 36 months
| Intervention | months (Median) |
|---|---|
| (TE) Taxotere and Eloxatin | 8.97 |
| (TEF) Taxotere, Eloxatin and 5-fluorouracil | 14.59 |
| (TEX) Taxotere, Eloxatin and Xeloda | 11.30 |
"The number of months measured from the day of randomization to the first tumor progression according to World Health Organization (WHO) criteria evaluation of cancer response, or death from any cause.~WHO Criteria for Progressive Disease: ≥ 25% increase in the size of at least one bidimensionally or unidimensionally measurable lesion." (NCT00382720)
Timeframe: every 8 weeks up to a maximum of 36 months
| Intervention | Months (Median) |
|---|---|
| (TE) Taxotere and Eloxatin | 4.50 |
| (TEF) Taxotere, Eloxatin and 5-fluorouracil | 7.66 |
| (TEX) Taxotere, Eloxatin and Xeloda | 5.55 |
MTD is the highest dose at which 1 or fewer dose limiting toxicities (DLT's) are observed in 6 patients. DLT defined as any non-hematologic grade III/IV or neutropenia-associated (infection or fever treated in the hospital) toxicity attributable to this therapy. Response evaluated after two 14-day treatments of Docetaxel, 5-Fluorouracil and Oxaliplatin (One cycle = 28 days). (NCT00526110)
Timeframe: 28 days
| Intervention | mg/m^2 (Number) |
|---|---|
| Phase I | 50 |
Overall survival was defined as the time from the start of treatment until death or last follow-up. Kaplan-Meier curve was used to estimate overall survival. (NCT00526110)
Timeframe: Up to 30 months
| Intervention | months (Median) |
|---|---|
| Phase II | 11.1 |
Progression Free Survival (PFS) defined as the time from the first study drug administration until the first day of radiological and/or symptomatic disease progression is documented, or the start of further anticancer therapy or death from any cause, whichever occurs first. Kaplan-Meier curve was used to estimate PFS. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesion. (NCT00526110)
Timeframe: Assessed from baseline to 30 months
| Intervention | months (Median) |
|---|---|
| Phase II | 6.5 |
Disease recurrence will be defined as radiographic tumor evidence detected by surveillance imaging. Confirmation of recurrence by biopsy will be at the discretion of the treating physician. This study closed early on June 18, 2020. It was earlier than one planned because of the lack of accrual. (NCT03515941)
Timeframe: From the end of completion of assigned therapy, subjects undergo follow-up every 3 months for a total of 36 months(planned) after the date of surgery or until the study closure
| Intervention | months (Median) |
|---|---|
| Arm 1: Adjuvant Chemotherapy | NA |
| Arm 2: Adjuvant Chemoradiation | NA |
The number of patients who complete the recommended therapy will be counted for each arm. (NCT03515941)
Timeframe: From date of assigned therapy up to 17 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1: Adjuvant Chemotherapy | 3 |
| Arm 2: Adjuvant Chemoradiation | 2 |
Duration of response was defined using RECIST v. 1.1 criteria as the time from the date criteria were met for the first objectively recorded CR or PR until the first date criteria for PD were met or death from any cause. CR was the disappearance of all lesions and pathological lymph node reduction in the short axis to <10 mm. PR was a ≥30% decrease in the sum of the diameters of target lesions. PD was a ≥20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of ≥5 mm; the appearance of ≥1 new lesions or unequivocal progression of non-target lesions. Participants who were not known to have died and who did not have PD were censored at the date of the last tumor assessment prior to the date of any subsequent systemic anticancer therapy. (NCT01246960)
Timeframe: Time of first response to measured PD (up to Month 23.0)
| Intervention | months (Median) |
|---|---|
| Ramucirumab and mFOLFOX6 | 7.4 |
| Placebo and mFOLFOX6 | 5.8 |
Participants with treatment-emergent anti-ramucirumab antibodies were participants with a 4-fold increase (2 dilution increase) in immunogenicity titer over baseline titer, or participants who tested negative at baseline and positive post-baseline (at titer of ≥1:20). (NCT01246960)
Timeframe: Months 1, 2, 4, 6, and 8
| Intervention | participants (Number) |
|---|---|
| Ramucirumab and mFOLFOX6 | 0 |
| Placebo and mFOLFOX6 | 1 |
OS was defined as the time from randomization to death due to any cause. OS was censored at the date of the last follow-up visit for participants who were alive or lost to follow-up. (NCT01246960)
Timeframe: Randomization to date of death from any cause (up to Month 28.3)
| Intervention | months (Median) |
|---|---|
| Ramucirumab and mFOLFOX6 | 11.7 |
| Placebo and mFOLFOX6 | 11.5 |
The percentage of participants who achieved a best overall response of partial response (PR) or complete response (CR) is reported. Response was defined using RECIST, v. 1.1 criteria. CR was the disappearance of all lesions and pathological lymph node reduction in the short axis to <10 mm. PR was a ≥30% decrease in the sum of the diameters of target lesions. The percentage of participants with objective response=(number of participants whose best overall response achieved was CR or PR/number of participants treated)*100. (NCT01246960)
Timeframe: Randomization to measured PD (up to Month 23.0)
| Intervention | percentage of participants (Number) |
|---|---|
| Ramucirumab and mFOLFOX6 | 45.2 |
| Placebo and mFOLFOX6 | 46.4 |
PFS was defined using Response Evaluation Criteria in Solid Tumors [RECIST version (v.) 1.1] as the time from randomization to the first observation of progressive disease (PD) or death due to any cause, whichever came first. PD was a ≥20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of ≥5 millimeters (mm); the appearance of ≥1 new lesions or unequivocal progression of non-target lesions. If a participant did not have a baseline disease assessment, PFS time was censored at the randomization date, regardless of whether or not PD or death was observed. Participants not known to have died or have objective PD were censored at the last post-baseline radiological assessment date. (NCT01246960)
Timeframe: Randomization to measured PD or date of death from any cause (up to Month 25.0)
| Intervention | months (Median) |
|---|---|
| Ramucirumab and mFOLFOX6 | 6.4 |
| Placebo and mFOLFOX6 | 6.7 |
TTP was defined using RECIST v. 1.1 as the time from study randomization to the first date of PD. PD was a ≥20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of ≥5 mm; the appearance of ≥1 new lesions or unequivocal progression of non-target lesions. TTP was censored at the date of last adequate tumor assessment if death was due to causes other than PD. (NCT01246960)
Timeframe: Randomization to measured PD (up to Month 25.0)
| Intervention | months (Median) |
|---|---|
| Ramucirumab and mFOLFOX6 | 8.7 |
| Placebo and mFOLFOX6 | 7.1 |
Reported are the number of participants who had ramucirumab/placebo-related: AEs, serious AEs (SAEs), AEs based on common terminology criteria for adverse events (CTCAE) ≥Grade 3, AEs = CTCAE Grade 5, as well as, AEs leading to treatment discontinuation and AEs resulting in death. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events module. (NCT01246960)
Timeframe: Baseline through study completion (up to Month 28.3)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any Ramucirumab/Placebo-Related AE | Any Ramucirumab/Placebo-Related SAE | Any Ramucirumab/Placebo-Related ≥Grade 3 AE | Any Ramucirumab/Placebo-Related Grade 5 AE | Any AE Leading to Treatment Discontinuation | Any AE with Outcome of Death | |
| Placebo and mFOLFOX6 | 64 | 12 | 33 | 3 | 5 | 2 |
| Ramucirumab and mFOLFOX6 | 64 | 10 | 36 | 0 | 18 | 5 |
Adverse events were evaluated according to the National Cancer Institute Common Toxicity Criteria (version 2.0). DLT was defined as grade 3 to 4 hematologic toxicity lasting more than 1 week after 5-FU/cisplatin, grade 3 to 4 nausea or vomiting occurring later than 11 days after cisplatin, grade 3 to 4 diarrhea occurring later than 10 days after 5-FU, and grade 3 to 4 mucositis at the beginning of the next cycle. (NCT00064259)
Timeframe: 21 days
| Intervention | mg/kg/d (Number) |
|---|---|
| Oblimersen + Cisplatin + 5-FU | 5 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01264081)
Timeframe: Date treatment consent signed to date off study, approximately, 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Lapatinib | 3 |
The count of participants with a partial response and complete response is defined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. Partial response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progressions. (NCT01264081)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Partial Response | Complete Response | Stable Disease | Progressive Disease | |
| Lapatinib | 0 | 0 | 2 | 0 |
Objective response was defined as having a CR or a PR. Response assessment was performed using modified WHO criteria. CR: disappearance of all index and non-index lesions, without appearance of any new lesion. PR: >50% decrease from baseline in sum of product of diameters of index lesions, without appearance of any new lesion. Duration of objective response was defined as time from first appearance of CR or PR to time of PD (PD: >25% increase in one or more lesions, or appearance new lesions) or death. Duration of objective response was to be assessed using Kaplan-Meier analysis. (NCT00215644)
Timeframe: From first documented objective response to PD or death due to any cause (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | NA |
| ECX Only | NA |
OS was defined as the duration from randomization to death (due to any cause). OS was estimated using Kaplan-Meier analysis. (NCT00215644)
Timeframe: Baseline until death due to any cause (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | 9.4 |
| ECX Only | 12.2 |
Objective response was defined as having a complete response (CR) or a partial response (PR). Response assessment was performed using modified World Health Organization (WHO) criteria. CR: disappearance of all index and non-index lesions, without appearance of any new lesion. PR: greater than (>) 50 percent (%) decrease from baseline in sum of product of diameters of index lesions, without appearance of any new lesion. (NCT00215644)
Timeframe: Baseline up to PD or death due to any cause (up to approximately 3 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | 31 |
| ECX Only | 58 |
PFS was defined as the time from randomization to the first documentation of PD or to death due to any cause, whichever occurred first. PD: >25% increase in one or more lesions, or appearance new lesions. PFS was estimated using Kaplan-Meier analysis. (NCT00215644)
Timeframe: Baseline up to PD or death due to any cause (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | 4.8 |
| ECX Only | 7.1 |
EORTC QLQ-C30 included GHS/QoL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from EORTC QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL was linearly transformed and ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). EORTC QLQ-C30 GHS/QoL score at baseline and best overall change from baseline (throughout study) are reported. (NCT00215644)
Timeframe: Baseline (Day 1), Post Baseline (Up to 3 Years)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Post-Baseline | |
| ECX Only | 67.9 | -10.0 |
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | 53.3 | 0.0 |
"Response rate is defined as the rate of participants with partial or complete responses according to RECIST V1.0.~Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.)." (NCT00210184)
Timeframe: 2 months
| Intervention | percentage of participants (Number) |
|---|---|
| Irinotecan Associated to Fluorouracil and Leucovorin | 25 |
OS was defined as the time from trial inclusion to death due to any cause. Participants without documented death were censored at the date of the last follow-up or last patient contact. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. (NCT00210184)
Timeframe: From date of inclusion until the date of date of death from any cause, assessed up to 12 months.
| Intervention | months (Median) |
|---|---|
| Irinotecan Associated to Fluorouracil and Leucovorin | 10 |
PFS was defined as time since trial inclusion to progression or death from any cause, whichever occurred first, and data from patients progression-free and lost to follow-up before the study end were censored at date of last news. The PFS was calculated using the product-limit (Kaplan-Meier) method for censored data. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00210184)
Timeframe: From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
| Intervention | months (Median) |
|---|---|
| Irinotecan Associated to Fluorouracil and Leucovorin | 7 |
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin | 6.97 |
Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 10.51 |
The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 41.7 |
Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days
| Intervention | participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 56 |
(NCT00375999)
Timeframe: One year
| Intervention | month (Median) |
|---|---|
| Treatment Group | 13.4 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT02311361)
Timeframe: Date treatment consent signed to date off study, approximately 18 months and 4 days for Cohort 1/Dose Level A1, 23 months and 29 days for Cohort 2/Dose Level A2, 32 months and 19 days for Cohort C/Dose Level C1, and 44 months and 18 days for Cohort C/Dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Durvalumab + 8 Gray (Gy) in 1 Fraction | 14 |
| Durvalumab +5 Gy in 5 Fractions | 10 |
| Durvalumab +Tremelimumab + 8 Gy in 1 Fraction | 19 |
| Durvalumab +Tremelimumab +5 Gy in 5 Fractions | 20 |
Amount of time participants survived after therapy. (NCT02311361)
Timeframe: From study entry to death or date of last contact, whichever occurs first, up to 2 years of follow-up
| Intervention | Months (Median) |
|---|---|
| Cohort A Dose Level A1 | 3.3 |
| Cohort A Dose Level A2 | 9.0 |
| Cohort C Dose Level C1 | 2.1 |
| Cohort C Dose Level C2 | 4.2 |
Participants who survived at least 6 months after therapy. (NCT02311361)
Timeframe: 6 month
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort A Dose Level A1 | 26 |
| Cohort A Dose Level A2 | 58 |
| Cohort C Dose Level C1 | 12 |
| Cohort C Dose Level C2 | 40 |
PFS is the defined as the median amount of time subject survives without disease progression after treatment. Progression is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). NOTE: While RECIST Progressive Disease (PD) will be noted and recorded the immune-related (IR) RECIST criteria will be applied to determine discontinuation of study treatment. For modified Immune-Related Response Criteria (irRC), only target and measurable lesions are taken into account. (NCT02311361)
Timeframe: From study entry to disease progression, death or date of last contact, whichever occurs first, an average of 6 months
| Intervention | Months (Median) |
|---|---|
| Cohort A Dose Level A1 | 1.7 |
| Cohort A Dose Level A2 | 2.5 |
| Cohort C Dose Level C1 | 0.9 |
| Cohort C Dose Level C2 | 2.3 |
Adverse Events (AEs) are reported by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Grade 1=Mild, Grade 2= Moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Fatal. (NCT02311361)
Timeframe: Participants were assessed from the start of study treatment at Cycle 1 then after every cycle (1 cycle = 28 days) of protocol treatment until 30 days after they were taken off treatment, approximately 4.0 months.
| Intervention | Adverse events (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1 Abdominal pain | Grade 1 Alanine aminotransferase increased | Grade 1 Alkaline Phosphatase increased | Grade 1 Anemia | Grade 1 Anorexia | Grade 1 Atrial fibrillation | Grade 1 Aspartate aminotransferase increased | Grade 1 Back pain | Grade 1 Blood bilirubin increased | Grade 1 Cough | Grade 1 Creatinine increased | Grade 1 Diarrhea | Grade 1 Dizziness | Grade 1 Dry mouth | Grade 1 Dysgeusia | Grade 1 Endocrine disorders,Other, Elevated T3, T4 | Grade 1 Eye disorders - decr. in near vision,bilat | Grade 1 - Fatigue | Grade 1 Fever | Grade 1 Headache | Grade 1 Hemorrhoidal hemorrhage | Grade 1 Hoarseness | Grade 1 Hyperglycemia | Grade 1 - Hyperkalemia | Grade 1 Hyperuricemia | Grade 1 Hypoalbuminemia | Grade 1 Hypocalcemia | Grade 1 - Hyponatremia | Grade 1 Hypothyroidism | Grade 1 Infusion related reaction | Grade 1 Lymphocyte count decreased | Grade 1 Mucositis | Grade 1 Musculoskeletal & connective tissue | Grade 1 Nausea | Grade 1 Neutrophil count decreased | Grade 1 Pain | Grade 1 Platelet count decreased | Grade 1 Pruritis | Grade 1 Rash maculo-papular | Grade 1 Serum amylase increased | Grade 1 - Skin/subc tissue disorder - Night sweats | Grade 1 Skin/subc tissue disorder - Rash | Grade 1 Skin/subc tissue - Psoriasis | Grade 1 Skin/subc tissue disorder - Itching | Grade 1 Skin/subc tissue disorder-Skinpeeling hand | Grade 1 Vertigo | Grade 1 Vomiting | Grade 1 Weight loss | Grade 1 White blood cell decreased | Grade 2 Abdominal pain | Grade 2 Anemia | Grade 2 Anorexia | Grade 2 Autoimmune disorder | Grade 2 Diarrhea | Grade 2 Dysgeusia | Grade 2 Endocrine disorders - TSH elev-Hypothyroid | Grade 2 Fatigue | Grade 2 Fecal incontinence | Grade 2 Fever | Grade 2 Gastroesophageal reflux disease | Grade 2 Hyperglycemia | Grade 2 Hypoalbuminemia | Grade 2 Hypothyroidism | Grade 2 Hypophosphatemia | Grade 2 Infusion related reaction | Grade 2 Lymphocyte count decreased | Grade 2 Malaise | Grade 2 Nausea | Grade 2 Neutrophil count decreased | Grade 2 Platelet count decreased | Grade 2 Rash maculo-papular | Grade 2 Weight loss | Grade 2 White blood cell count | Grade 3 Anemia | Grade 3 Anorexia | Grade 3 Colitis | Grade 3 Dehydration | Grade 3 Diarrhea | Grade 3 Fatigue | Grade 3 Hyperthyroidism | Grade 3 Lymphocyte count decreased | Grade 3 Nausea | Grade 3 Serum amylase increased | Grade 3 Vomiting | Grade 4 Lymphocyte count decreased | |
| Cohort A Dose Level A1 | 0 | 1 | 0 | 3 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 15 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Cohort A Dose Level A2 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 0 | 3 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 4 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 |
| Cohort C Dose Level C1 | 0 | 0 | 0 | 9 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 17 | 0 | 0 | 3 | 0 | 0 | 7 | 2 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 9 | 0 | 0 | 2 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 15 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 6 | 0 | 1 | 0 | 2 |
| Cohort C Dose Level C2 | 1 | 5 | 2 | 9 | 3 | 1 | 6 | 1 | 1 | 1 | 1 | 7 | 1 | 0 | 0 | 0 | 0 | 7 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 5 | 1 | 4 | 1 | 2 | 26 | 1 | 0 | 2 | 1 | 1 | 13 | 3 | 2 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 7 | 1 | 10 | 2 | 1 | 4 | 1 | 0 | 5 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 30 | 2 | 3 | 1 | 2 | 1 | 2 | 0 | 3 | 1 | 2 | 3 | 3 | 1 | 1 | 18 | 2 | 0 | 2 | 2 |
Progressive disease (PD): >=20% increase in sum of longest diameter (LD) of target lesion(s), taking as reference smallest sum LD recorded since treatment started. Complete response (CR): disappearance of all target lesions. Partial response (PR): >=30% decrease in sum of LD of target lesion(s), taking as reference baseline sum LD. Stable disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD. (NCT02311361)
Timeframe: At screening then every 8 weeks until disease progression or patient is taken off the trial, whichever comes first, approximately 6 months.
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | |
| Cohort A Dose Level A1 | 0 | 1 | 3 | 4 |
| Cohort A Dose Level A2 | 0 | 0 | 4 | 4 |
| Cohort C Dose Level C1 | 0 | 0 | 2 | 6 |
| Cohort C Dose Level C2 | 0 | 1 | 5 | 10 |
257 reviews available for fluorouracil and Cancer of Stomach
| Article | Year |
|---|---|
Synthesis of 8-Fluoroneocryptolepine and Evaluation for Cytotoxic Activity against AGS Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fluorouracil; Humans; Phosph | 2022 |
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Tri | 2022 |
Docetaxel and fluorouracil as first-line therapy for gastric cancer with bone marrow metastasis and disseminated intravascular coagulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Clinical Trials as Topic; Dis | 2022 |
The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Chemotherapy, Adjuvan | 2022 |
Serpentine Supra-venous Hyperpigmentation "Badge of Courage" in Fight Against Cancer: An Brief Review.
Topics: Adult; Courage; Fluorouracil; Humans; Hyperpigmentation; Male; Stomach Neoplasms; Syndrome | 2022 |
Serpentine Supra-venous Hyperpigmentation "Badge of Courage" in Fight Against Cancer: An Brief Review.
Topics: Adult; Courage; Fluorouracil; Humans; Hyperpigmentation; Male; Stomach Neoplasms; Syndrome | 2022 |
Serpentine Supra-venous Hyperpigmentation "Badge of Courage" in Fight Against Cancer: An Brief Review.
Topics: Adult; Courage; Fluorouracil; Humans; Hyperpigmentation; Male; Stomach Neoplasms; Syndrome | 2022 |
Serpentine Supra-venous Hyperpigmentation "Badge of Courage" in Fight Against Cancer: An Brief Review.
Topics: Adult; Courage; Fluorouracil; Humans; Hyperpigmentation; Male; Stomach Neoplasms; Syndrome | 2022 |
Neoadjuvant Management of Adenocarcinoma of the Esophagus and Esophagogastric Junction: Review of Randomized Evidence and Definition of Optimum Treatment Algorithm.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Eso | 2023 |
CircRNA: A new class of targets for gastric cancer drug resistance therapy.
Topics: Cisplatin; Drug Resistance, Neoplasm; Fluorouracil; Humans; RNA, Circular; Stomach Neoplasms | 2023 |
FLOT or CROSS for gastroesophageal junction cancers-is the debate over yet?
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophagogastric Jun | 2023 |
Perioperative immune checkpoint inhibitor therapy for gastric and gastroesophageal junction cancers: a review of current approaches and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Fluo | 2023 |
S-1 and 5-Fluorouracil-related adverse events in patients with advanced gastric cancer: A meta-analysis.
Topics: Fluorouracil; Humans; Hypokalemia; Hypophosphatemia; Inflammation; Stomach Neoplasms; Stomatitis | 2023 |
Missed Gastric Cancer Metastasis to the Appendix: Case Report and Literature Review.
Topics: Adenocarcinoma; Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Appendiceal | 2020 |
[Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?]
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Free Survival; Doce | 2020 |
[Neoadjuvant chemotherapy for gastric cancer. Frequent overtreatment or meaningful concept?]
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Germany; Human | 2020 |
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITA
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Chemotherapy, Adjuvant; Cisplatin; Do | 2020 |
Comparison of Platinum/S-1 and Platinum/5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis Based on Randomized Controlled Trials.
Topics: Antineoplastic Agents; Coordination Complexes; Disease-Free Survival; Drug Combinations; Drug Therap | 2020 |
Maintenance treatment in advanced HER2-negative gastric cancer.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunolog | 2020 |
[Neoadjuvant and perioperative treatment of gastric cancer, current studies and new biomarkers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Esophageal Neoplasms; Esophagogastric Ju | 2021 |
HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; C | 2021 |
The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineop | 2017 |
Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis.
Topics: Administration, Oral; Antineoplastic Agents; Colorectal Neoplasms; Databases, Bibliographic; Disease | 2018 |
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug C | 2017 |
Chemotherapy for advanced gastric cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; | 2017 |
A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cluster Analysis; Disease | 2017 |
The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Esophageal Neoplasms; | 2017 |
A review of capecitabine-based adjuvant therapy for gastric cancer in the Chinese population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Combine | 2018 |
Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2018 |
Which are the best Chinese herbal injections combined with XELOX regimen for gastric cancer?: A PRISMA-compliant network meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; | 2018 |
Gastroesophageal Cancer During Pregnancy: a Case Report and Review of the Literature.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemoradiotherapy; Do | 2019 |
Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Capecitabine; Chemoradiotherapy, Adju | 2018 |
Predicting the Efficacy of 5-Fluorouracil-Based Adjuvant Chemotherapy in Gastric Cancer by Microsatellite Instability: A Meta-Analysis.
Topics: Chemotherapy, Adjuvant; Fluorouracil; Humans; Microsatellite Instability; Proportional Hazards Model | 2019 |
Long-term survival of an elderly patient with advanced gastric cancer after combination therapy: a case report and literature review.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Cr | 2019 |
The role of oxaliplatin in the management of upper gastrointestinal tract malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Esophageal Neopl | 2003 |
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell | 2012 |
Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease Progression; Docetaxel | 2013 |
An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens.
Topics: Alleles; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2013 |
Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Camptothecin; Capecitabine; Chemoradi | 2013 |
Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase III as Topic; Docetaxel; Fluorouracil; H | 2013 |
Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase III as Topic; Docetaxel; Fluorouracil; H | 2013 |
Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase III as Topic; Docetaxel; Fluorouracil; H | 2013 |
Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase III as Topic; Docetaxel; Fluorouracil; H | 2013 |
Post-surgical chemotherapy versus surgery alone for resectable gastric cancer.
Topics: Antineoplastic Agents; Disease-Free Survival; Fluorouracil; Gastrectomy; Humans; Lymph Node Excision | 2013 |
Capecitabine in the treatment of esophageal and gastric cancers.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Chemoradiotherapy; Deoxycytidine; | 2013 |
Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II | 2014 |
S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxy | 2013 |
Treatment of gastric cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy | 2014 |
Treatment options in patients with metastatic gastric cancer: current status and future perspectives.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cisplatin; Clinical Trials | 2014 |
Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Pati | 2014 |
S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorouracil; Humans; Oxonic Acid | 2014 |
[Pharmacogenomics of the first-line treatment for gastric cancer: advances in the identification of genomic biomarkers for clinical response to chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Biomark | 2014 |
Which is the best Chinese herb injection based on the FOLFOX regimen for gastric cancer? A network meta- analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drugs, Chinese Herbal; Fluorouracil; Humans; Injecti | 2014 |
[Disappearance of a gastric lesion following modified FOLFOX6 chemotherapy in a patient with metastatic colorectal cancer: a case report and literature review].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Ma | 2014 |
The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus 5-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progress | 2014 |
Capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOXs) in advanced gastric cancer: meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; | 2015 |
[Adjuvant treatment for esophagogastric junction cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, | 2015 |
A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer.
Topics: Capecitabine; China; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Drug Combinatio | 2015 |
[CURRENT STATE OF ADJUVANT TREATMENT FOR GASTRIC CANCER AFTER RADICAL SURGERY WITH EXTENDED LYMPH NODE DISSECTION].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothec | 2015 |
High/positive expression of 5-fluorouracil metabolic enzymes predicts better response to S-1 in patients with gastric cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combinations; Fluorouracil; | 2016 |
Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Capecitabine; Disease-Free Surv | 2016 |
Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis.
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; Humans; Neoplasm Staging; Oxonic A | 2016 |
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin | 2016 |
New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin.
Topics: Administration, Oral; Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Fluorouracil; Hem | 2017 |
Modified schedules of DCF chemotherapy for advanced gastric cancer: a systematic review of efficacy and toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; | 2017 |
Synchronous quintuple primary gastrointestinal tract malignancies: Case report.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cancer | 2017 |
The Impact of the Expression Level of Intratumoral Dihydropyrimidine Dehydrogenase on Chemotherapy Sensitivity and Survival of Patients in Gastric Cancer: A Meta-Analysis.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Fluo | 2017 |
The Asian Perspective on the Surgical and Adjuvant Management of Esophagogastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Digestive Sys | 2017 |
Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Docetaxel; Esop | 2008 |
[A case of alpha-fetoprotein-producing gastric cancer with hepatic metastasis successfully treated with combination chemotherapy].
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2008 |
Capecitabine in gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fl | 2008 |
An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Ca | 2008 |
Biomarkers of response to therapy in oesophago-gastric cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; DNA Repair; DNA, Neoplasm; Esophageal Neoplasms; | 2009 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms | 2009 |
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2009 |
Emerging role of capecitabine in gastric cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deox | 2009 |
Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Tri | 2009 |
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2009 |
Is there a role for second-line chemotherapy in advanced gastric cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Delivery S | 2009 |
[Progress in chemotherapy for advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
[Therapy in gastric cancer. From an oncological perspective].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 2009 |
Chemotherapy for advanced gastric cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; | 2010 |
Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidin | 2010 |
S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis.
Topics: Antineoplastic Agents; Drug Combinations; Fluorouracil; Humans; Middle Aged; Oxonic Acid; Randomized | 2011 |
[Diagnosis and treatment of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Signet Ring Cell; Cisplatin; Endo | 2010 |
Capecitabine for the treatment of advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; P | 2010 |
[HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2010 |
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Huma | 2011 |
Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Capecitabine; Cisplatin; C | 2011 |
A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cap | 2011 |
Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity.
Topics: Antineoplastic Agents; Asian People; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasm Sta | 2012 |
Capecitabine in gastric cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil | 2011 |
Second-line chemotherapy for advanced gastric cancer in Korea.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clin | 2012 |
Signet-ring-cell carcinoma of stomach metastatic to the bladder: a case report with cytological and histological correlation and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cytodiagnosis; F | 2013 |
Oxaliplatin-induced lung toxicity. Case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Fluorouracil; Humans; Imatinib Mesylate; | 2012 |
Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; DNA-Binding Proteins; Endonuc | 2012 |
Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2013 |
Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Fluorour | 2012 |
Histological complete response after neoadjuvant XELOX in advanced gastric carcinoma.
Topics: Adenocarcinoma; Aged; Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Biopsy | 2013 |
[Neoadjuvant chemotherapy in advanced stomach cancer--a case of complete response].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administrati | 2002 |
[Progress in postoperative adjuvant chemotherapy in gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Drug Administrat | 2002 |
[Weekly administration of paclitaxel with a short course of premedication for advanced or recurrent gastric cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2003 |
Current topics of S-1 at the 74th Japanese Gastric Cancer Congress.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Drug Comb | 2003 |
S-1 in gastric cancer: a comprehensive review.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Drug Combinations; | 2003 |
Irinotecan in the treatment of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Che | 2003 |
Docetaxel-based chemotherapy in the treatment of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinic | 2003 |
Current treatments and future perspectives in colorectal and gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2003 |
[Recent advances in chemotherapy for digestive cancers with special references to gastric and colonic cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Docetaxe | 2003 |
COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2003 |
Definitive and neoadjuvant therapies for esophageal and gastroesophageal junction tumors: a look back and toward the future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Fluo | 2003 |
[Controversial issues in chemotherapy for inoperable gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Fluorour | 2003 |
Docetaxel in advanced gastric cancer--review of the main clinical trials.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinic | 2003 |
Focus on gastric cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cadheri | 2004 |
[Docetaxel and gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doceta | 2004 |
Systemic treatment of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modali | 2004 |
Palliative chemotherapy for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Cisplatin; Cli | 2004 |
[Combination chemotherapy for gastric cancer including LV/5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 2004 |
[Current combination chemotherapy containing paclitaxel for advanced, recurrent gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combin | 2004 |
[CPT-11 combined chemotherapy for metastatic gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cis | 2004 |
[Second-line chemotherapy in gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Doce | 2005 |
[Chemotherapy of advanced stomach cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Drug Ad | 2004 |
Available options in chemotherapy for advanced gastric cancer: the current developments in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Doxorubicin; Fl | 2005 |
Colonic rupture in a patient on combination chemotherapy for metastasized carcinoma of the esophagogastric junction. Case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cecal Diseases; Cisplatin; Colonic D | 2005 |
Chemotherapy for advanced gastric cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Ran | 2005 |
Current status and future prospects of chemotherapy for metastatic gastric cancer: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Fluorouracil; Huma | 2005 |
Perioperative adjunctive treatment in the management of operable gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Com | 2005 |
Eliminating and suppressing local-regional disease in gastric cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Gastrectomy; Humans; Lymph | 2005 |
Role of post-operative chemoradiation in resected gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluoroura | 2005 |
Experience with docetaxel in the treatment of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cis | 2005 |
[Molecular biology in clinical cancer research: the example of digestive cancers].
Topics: Adenocarcinoma; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agen | 2005 |
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Adjuvant therapy of resected gastric cancer is necessary.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil | 2005 |
The emerging role of oxaliplatin in the treatment of gastric cancer.
Topics: Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Fluorouracil; Humans; Organoplatinum Com | 2005 |
[Efficacy of current adjuvant and neoadjuvant therapeutic concepts in gastric cancer?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials a | 2006 |
A review of adjuvant therapy for resected primary gastric cancer with an update on Taegu's phase III trial with intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clini | 2006 |
Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2006 |
Determinants of chemosensitivity in gastric cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dihydrouracil Dehydrogenase (NADP); D | 2006 |
Clinical implications of genetic polymorphisms on stomach cancer drug therapy.
Topics: Antineoplastic Agents; Biotransformation; Fluorouracil; Gene Expression Regulation, Enzymologic; Gen | 2007 |
Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doceta | 2006 |
Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Biomarkers, Tumor; Carcinoma; Dihydrouracil Dehydrog | 2006 |
Docetaxel in the treatment of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clini | 2006 |
Molecular markers for gastric adenocarcinoma: an update.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2006 |
[Progress in the treatment of gastrointestinal cancers due to introduction of neoadjuvant concept].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Ci | 2006 |
[Chemotherapy in advanced gastric cancer--to ensure timely and appropriate switch to subsequent treatment options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III | 2007 |
[Basic strategies on first- and second-line chemotherapy for advanced gastric cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Doce | 2007 |
[Clinical development of chemotherapy for advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Cli | 2007 |
Capecitabine: in advanced gastric or oesophagogastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Eso | 2007 |
Chemotherapy of advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2007 |
Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Flu | 2007 |
Docetaxel: in gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Do | 2007 |
[Gemcitabine and digestive carcinomas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl | 2007 |
The effectiveness of intravenous 5-fluorouracil-containing chemotherapy after curative resection for gastric carcinoma: A systematic review of published randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Female; Fluoro | 2007 |
Medical treatment for advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2007 |
Therapeutic options in gastric cancer: neoadjuvant chemotherapy vs postoperative chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Periopera | 2007 |
Capecitabine in advanced gastric cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Approva | 2007 |
[Angiogenesis targeting in gastro-intestinal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
The role of UFT in advanced gastric cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as | 2008 |
Capecitabine in the treatment of advanced gastric cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials | 2008 |
Chemotherapy in alimentary tract malignomas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Cytarabine; Doxor | 1981 |
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
[Current state and possibilities of radiotherapy in the inter- disciplinary treatment of malignancies of the stomach, pancreas and bile ducts. I. Stomach cancer].
Topics: Cisplatin; Combined Modality Therapy; Doxorubicin; Fluorouracil; Gastrectomy; Humans; Mitomycins; St | 1984 |
[Treatment of metastatic liver tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Emboli | 1984 |
[Chemotherapy of stomach cancer].
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biological Availabi | 1980 |
Systemic chemotherapy for advanced gastrointestinal cancer.
Topics: Antineoplastic Agents; Apudoma; Biliary Tract Neoplasms; Colonic Neoplasms; Drug Therapy, Combinatio | 1980 |
Possibilities and limitations of the cytostatic treatment of gastrointestinal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Es | 1982 |
[Combined chemotherapy with 5-FU+cis-platin or UFT+cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Colorectal Neop | 1995 |
[Biomodulation of 5-fluorouracil by interferon].
Topics: Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combination; | 1995 |
Is the combination of 5-fluorouracil and folinic acid effective in advanced gastric carcinoma? Results of a pilot study and review of the literature.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1994 |
[Progress on chemotherapy in patients with non-resectable stomach cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Controlled Clinical Trials as Topic; Fema | 1994 |
[Recent advances in chemotherapy for advanced gastric cancer: from the standpoint of survival advantages].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Doxorubicin; Fl | 1995 |
Adjuvant postoperative therapy of gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1994 |
[Chemotherapy of scirrhous gastric cancer].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; E | 1994 |
[Overview of clinical trials on adjuvant chemotherapy for curatively resected gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cl | 1994 |
[Meta-analysis of 10 postoperative adjuvant chemotherapies for gastric cancer in CIH].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Fl | 1994 |
[Targeting therapy of gastric and colorectal cancer].
Topics: Colorectal Neoplasms; Drug Delivery Systems; Fat Emulsions, Intravenous; Fluorouracil; Humans; Infus | 1994 |
Mitomycin therapy in gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M | 1993 |
Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Protocols; Clinical Trials a | 1995 |
[Adjuvant chemotherapy of gastric cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 1995 |
The treatment of advanced gastric cancer.
Topics: Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Anti | 1996 |
[Adjuvant chemotherapy for advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Doxorubicin; Dru | 1996 |
[Optimal administration in combination chemotherapy with 5-fluorouracil and cisplatin for gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1996 |
[Sequential methotrexate and 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 1996 |
Meningeal carcinomatosis as the presenting manifestation of gastric adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Car | 1997 |
Arterial infusion chemotherapy for peritoneal and liver metastasis in gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Intra-Arterial; Liv | 1997 |
Chemotherapy for gastric cancer in Japan.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cis | 1997 |
Selection of adjuvant chemotherapy for gastric cancer using objective criteria.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Carcinoembryonic Antigen; Chemotherap | 1997 |
Pre- and/or post-operative immunochemotherapy for advanced digestive cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colorectal Neopla | 1997 |
[Evaluation of clinical trials on adjuvant chemotherapy for curatively resected gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials a | 1997 |
Paclitaxel pharmacology and other tumor types.
Topics: Alkylating Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols | 1997 |
Treatment of patients with upper gastrointestinal carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Therapy, Com | 1997 |
[Treatment of recurrent gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cis | 1998 |
[Chemotherapy of gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Che | 1998 |
Medical management of advanced gastric cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1998 |
Chemotherapy for gastric carcinoma: new and old options.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capeci | 1998 |
[Improving the anti-tumor activity of 5-fluorouracil by methotrexate].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; DNA; Drug Administration Schedule; Drug Syn | 1999 |
[Leucovorin and 5-FU for advanced gastrointestinal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, | 1999 |
[Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trial | 1999 |
Adjuvant/neoadjuvant chemoradiation for gastric and pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Fluorour | 1999 |
[Theoretical basis for low-dose CDDP/5-FU therapy].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla | 1999 |
[Low-dose FP therapy for advanced and recurrent gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1999 |
Adenocarcinoma at the esophageal gastric junction arising in an 11-year-old girl.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Child; Cisplatin; Esophagectomy; Esophagogastric Ju | 1999 |
[New combination therapies for gastrointestinal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal | 2000 |
The role of chemotherapy in the management of gastric cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2000 |
Preoperative therapy for local-regional gastric cancer: rationale and review of trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Doxorubicin; Et | 2000 |
Chemotherapy of metastatic gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Epirubicin; Etoposide; Fluor | 2000 |
[Infusiontherapy with 5-fluorouracil ("infusional" 5-FU) in solid tumors].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2000 |
[Tumor microcirculation and selective enhancement of drug delivery--clinical applications based on pathophysiological experiments].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxorubicin; Drug Administr | 2000 |
[State of the treatment for gastrointestinal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II a | 2000 |
[Significance of neoadjuvant chemotherapy for gastric cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 2000 |
[Recent advance in gastric cancer chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Screening Assays, Antitum | 2000 |
[Current status and problem of adjuvant chemotherapy for curatively resected gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; | 2000 |
[Latest progress on chemotherapy for advanced gastric cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispl | 2000 |
[Analysis of cases of complete response (CR) in esophageal and gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Esophageal | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colo | 2000 |
Developments in the treatment of gastric cancer in Europe.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II a | 2000 |
[Low-dose administration of 5-fluorouracil and cisplatin for advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Fluorouracil; H | 2001 |
[MTX/5FU sequential therapy for advanced and recurrent gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Disseminated Intravascular Co | 2001 |
[Combination therapy of eucovorin and 5-FU for advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Fluorouracil; Hu | 2001 |
[Capecitabine (Ro09-1978) for therapy of advanced and recurrent gastric cancer].
Topics: Administration, Oral; Animals; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dihydrouracil | 2001 |
[Chemosensitivity test for advanced and recurrent gastric cancer].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Screening Assays, Antitumor; Fluorouracil; Human | 2001 |
[Home chemotherapy and/or outpatient chemotherapy for patient with advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedul | 2001 |
[Levofolinate and fluorouracil combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Colorectal Neopl | 2001 |
[A case of gastric cancer with multiple liver metastases that were completely responsive to hepatic arterial infusion chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirub | 2001 |
[A case of AFP producing early gastric cancer successfully treated with small dose CDDP and 5-FU (PF) therapy].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug | 2001 |
Chemotherapy options for gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2002 |
[Chemotherapy of gastrointestinal tumors (review of the literature)].
Topics: Ancitabine; Carcinoma, Hepatocellular; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fl | 1978 |
Management of gastrointestinal cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluor | 1977 |
A recent overview of chemotherapy for advanced stomach cancer in Japan.
Topics: Antineoplastic Agents; Carbazilquinone; Chromomycins; Drug Therapy, Combination; Fluorouracil; Human | 1978 |
Chemotherapy of gastrointestinal cancer.
Topics: Apudoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms; Hum | 1978 |
[Drug treatment of inoperable stomach cancer].
Topics: Administration, Oral; Drug Administration Schedule; Drug Evaluation; Fluorouracil; Humans; Injection | 1976 |
Combined radiotherapy and chemotherapy in the treatment of gastrointestinal malignancies.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neo | 1992 |
Biochemical modulation of 5-fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedu | 1992 |
[Biochemical modulation--the historical background].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1992 |
[High-dose leucovorin and 5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Fluorodeoxyur | 1992 |
[Combined therapy with 5-FU and levamisole].
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; | 1992 |
The rationale for early postoperative intraperitoneal chemotherapy for gastric cancer.
Topics: Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Drug Evaluation; Fluorouracil; Humans; Infusions, Pa | 1991 |
Rationale for the intraperitoneal approach to surgical adjuvant chemotherapy of gastric cancer.
Topics: Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Fluorouracil; Humans; Infusions, Parent | 1991 |
[Dose intensity in cancer chemotherapy in gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Fluo | 1990 |
Clinical trials with 5-fluorouracil, folinic acid and cisplatin in patients with gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Evaluation; Fl | 1990 |
Clinical trial with 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Drug Evaluation; Drug Therapy, Combination; | 1990 |
Emulsion and activated carbon in cancer chemotherapy.
Topics: Administration, Oral; Adult; Aged; Animals; Bleomycin; Breast Neoplasms; Carbon; Clinical Trials as | 1986 |
[Present status of surgical adjuvant chemotherapy of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Mit | 1989 |
[Combined chemotherapy with the FEM protocol in advanced gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; | 1989 |
[A current overview of chemotherapy in advanced gastric cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Fluor | 1989 |
[Gastric metastases of cancer of the breast. Apropos of a case. Review of the literature].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoembryonic Antigen; Combined | 1989 |
5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1989 |
[Neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma. Preliminary results].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; | 1989 |
[Gastric cancer in adults. A decade's experience at the Hospital Dr. Rafael Hernández L].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Femal | 1988 |
Chemotherapy for stomach cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fluorouracil; Humans; Rand | 1987 |
[Biochemical modulation of 5-fluorouracil by high-dose leucovorin].
Topics: Chemical Phenomena; Chemistry; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Leu | 1988 |
[Current studies of sequential methotrexate and 5-fluorouracil treatment in cancer chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedule; Dru | 1988 |
Chemotherapy of advanced gastric cancer: present status, future prospects.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Fluorouracil; Humans; Mitomy | 1988 |
[A case of an exogastric developing-type carcinoma of the stomach and a review of thirty nine cases reported in Japan].
Topics: Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy P | 1988 |
[Treatment of advanced stomach cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Doxorubicin; Fl | 1986 |
The role of anthracyclines in the treatment of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Drug Administ | 1985 |
The role of chemotherapy in the management of gastric and pancreatic carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1985 |
Potentiation of antimetabolite action by alkylating agents.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brea | 1985 |
[Tumors].
Topics: Antigens; Bleomycin; Daunorubicin; Fetal Proteins; Fluorouracil; Glycolipids; Glycoproteins; Humans; | 1972 |
The prognosis and management of recurrent abdominal malignancies.
Topics: Abdominal Neoplasms; Adolescent; Adult; Antineoplastic Agents; Bile Duct Neoplasms; Chemotherapy, Ca | 1969 |
A review of chemotherapy in gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carmustine; Chlorambucil; Chromomycins; Cyclophosphamide; Cyt | 1974 |
Chemotherapy of residual disease in solid tumours.
Topics: Colonic Neoplasms; Cyclophosphamide; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; Lun | 1971 |
Newer concepts in chemotherapy of cancer.
Topics: Breast Neoplasms; Colonic Neoplasms; Dysgerminoma; Female; Fluorouracil; Humans; Injections, Intra-A | 1972 |
[A review of clinical tumor immunology. An approach to immunochemotherapy].
Topics: Animals; Antibiotics, Antineoplastic; BCG Vaccine; Cytarabine; Drug Therapy, Combination; Fluorourac | 1974 |
941 trials available for fluorouracil and Cancer of Stomach
| Article | Year |
|---|---|
Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Fluorour | 2021 |
Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junction; Fema | 2022 |
Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Male; Midd | 2022 |
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Docetaxel; Epirubicin; Fluorouracil; H | 2022 |
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; D | 2022 |
Safety and efficacy of the FLOT regimen in the Polish population - an analysis of the prospective trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric J | 2022 |
Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Do | 2022 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer: S Pyrhönen, T Kuitunen, P Nyandoto & M Kouri.
Topics: Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Humans; Methotrexate; Stom | 2023 |
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri | 2023 |
A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Fluorouracil; Humans; | 2023 |
Study of Efficacy and Toxicity of Capecitabine Maintenance After Response to Docetaxel, Cisplatin, and 5-Fluracil-Based Chemotherapy in Advanced Carcinoma Stomach.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Cisplatin; Docetaxel; Fluor | 2023 |
Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Randomized Control | 2023 |
Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chromatography, Liquid; Cross-Over Studies; | 2019 |
Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 2020 |
Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA-Binding Proteins | 2020 |
Patient-based cost-effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4-year prospective randomised phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Co | 2020 |
Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Follow-U | 2020 |
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2020 |
Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esopha | 2020 |
Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Cell Line, Tumor; Cisplati | 2020 |
A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil | 2020 |
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Esophageal Ne | 2020 |
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Pr | 2020 |
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2021 |
Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2020 |
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Disease-Free S | 2021 |
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2021 |
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2021 |
Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitan | 2021 |
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2021 |
FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Neuroendocrine; Etopos | 2021 |
Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Fluorouracil; Humans; Leucovo | 2021 |
TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherap | 2017 |
Reduction in Peripheral CD19+CD24hCD27+ B Cell Frequency Predicts Favourable Clinical Course in XELOX-Treated Patients with Advanced Gastric Cancer.
Topics: Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; Capecita | 2017 |
Feasibility of Modified FOLFOX in Elderly Patients Aged ≥80 Years with Metastatic Gastric Cancer or Colorectal Cancer.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Disea | 2017 |
Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 2017 |
Randomized Controlled Trial of Adjuvant Chemotherapy with Fluoropyrimidines
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 2017 |
A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2017 |
A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2017 |
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Female; Fluoro | 2017 |
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Neuroendocrine | 2018 |
Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2018 |
Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Antineoplastic Agents; Antineoplastic Combined C | 2018 |
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer.
Topics: Adult; Aged; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; Do | 2018 |
Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; E | 2019 |
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; ErbB Receptors; | 2018 |
miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Pr | 2018 |
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2019 |
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; F | 2019 |
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; F | 2019 |
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; F | 2019 |
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; F | 2019 |
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 2019 |
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2019 |
Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bridged-Ring Compounds; C | 2019 |
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doub | 2019 |
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2019 |
Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, S | 2019 |
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2019 |
Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2020 |
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Clinical Protocols; | 2019 |
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction aden
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Ag | 2019 |
Safety analysis of weekly paclitaxel plus S-1 versus paclitaxel plus 5-fluorouracil/calcium folinate as first-line therapy in advanced gastric cancer: a multicenter open random phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; | 2013 |
Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Fre | 2014 |
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2013 |
A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; F | 2014 |
Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxyc | 2013 |
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2013 |
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2013 |
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antin | 2013 |
Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Acetylation; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; D | 2014 |
Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADCI002.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; | 2013 |
Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; China; Cisplatin; DN | 2013 |
A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protoc | 2013 |
A phase II study of preoperative chemotherapy with modified FOLFOX6 followed by surgery and postoperative chemoradiation in patients with localized gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2013 |
Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2013 |
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
5-Fluorouracil, mitomycin-c, and polysaccharide-k versus uracil-ftorafur and polysaccharide-K as adjuvant chemoimmunotherapy for patients with locally advanced gastric cancer with curative resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Su | 2013 |
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2013 |
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resis | 2013 |
Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Fr | 2014 |
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2013 |
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2013 |
Image-guided intensity-modulated radiotherapy for patients with locally advanced gastric cancer: a clinical feasibility study.
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Feasibility Studies; Female; Fluoroura | 2014 |
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothera | 2013 |
Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docet | 2014 |
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2014 |
[Effects of XELOX regimen as neoadjuvant chemotherapy on radical resection rate and prognosis in patients with advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Cell Cycle; Ch | 2013 |
Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradi | 2014 |
The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Di | 2014 |
A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2013 |
Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2014 |
[Efficacy of albumin-bound paclitaxel in advanced gastric cancer patients].
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2014 |
Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2014 |
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2015 |
Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuv | 2014 |
Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin).
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Docetaxel; Female; Fluorouracil; Humans; Irinoteca | 2014 |
Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; | 2014 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidin | 2014 |
Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docet | 2014 |
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Com | 2014 |
A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; D | 2014 |
[Prospective multicentric phase III study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Fluorouraci | 2014 |
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum | 2014 |
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum | 2014 |
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum | 2014 |
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum | 2014 |
CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance.
Topics: Adenocarcinoma; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotti | 2014 |
Quality of life in the trastuzumab for gastric cancer trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cis | 2014 |
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2014 |
A phase 2 study of fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as a salvage treatment in patients with refractory or relapsed advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Fluorour | 2015 |
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2014 |
VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophagog | 2014 |
Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Dose- | 2014 |
S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2014 |
Epirubicin combined with oxaliplatin and 5-day continuous infusion of 5-fluorouracil as a first-line treatment for metastatic gastric cancer: treatment outcomes and analysis of prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fluorou | 2015 |
Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian Peo | 2014 |
Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2014 |
S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Drug Combinati | 2014 |
Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols | 2017 |
Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docet | 2014 |
Adjuvant chemoradiotherapy after D2 resection in gastric cancer: a single-center observational study.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Effect of neoadjuvant chemotherapy on postoperative morbidity and mortality in patients with locally advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans | 2014 |
Comparison between better and poorly differentiated locally advanced gastric cancer in preoperative chemotherapy: a retrospective, comparative study at a single tertiary care institute.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Differentiation; Chemotherapy, Ad | 2014 |
Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study.
Topics: Acyl Coenzyme A; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplati | 2014 |
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2014 |
Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2014 |
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplati | 2014 |
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplati | 2014 |
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplati | 2014 |
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplati | 2014 |
Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Disea | 2014 |
Adjuvant radiotherapy for gastric carcinoma: 10 years follow-up of 244 cases from a single institution.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2015 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2014 |
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2015 |
Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
Topics: Acetamides; Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic | 2014 |
Clinical study of nimotuzumab combined with chemotherapy in the treatment of late stage gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Efficacy of docetaxel combined with oxaliplatin and fluorouracil against stage III/IV gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diagnostic Imaging; Do | 2014 |
Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel | 2016 |
Dose-dense biweekly docetaxel combined with 5-fluorouracil as first-line treatment in advanced gastric cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2015 |
A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemoradiotherapy, A | 2016 |
Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cape | 2015 |
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2015 |
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2015 |
Effects of high-intensity focused ultrasound for treatment of abdominal lymph node metastasis from gastric cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modal | 2015 |
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2015 |
Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2015 |
Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemor | 2015 |
TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Epirubicin; | 2015 |
A new approach to delineating lymph node target volumes for post-operative radiotherapy in gastric cancer: A phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Fluorouracil | 2015 |
Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; | 2016 |
Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Fre | 2015 |
Exploratory phase II trial in a multicenter setting to evaluate the clinical value of a chemosensitivity test in patients with gastric cancer (JACCRO-GC 04, Kubota memorial trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combination | 2016 |
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combin | 2016 |
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Dis | 2015 |
S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2015 |
Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2016 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophagogast | 2018 |
Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2016 |
The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; China; Femal | 2016 |
A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovori | 2016 |
A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 2016 |
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 2016 |
Effects of paclitaxel liposome and capecitabine in the treatment of advanced gastric cancer by clinical observation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Free S | 2016 |
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chem | 2016 |
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2016 |
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2016 |
Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 CYP | 2017 |
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2017 |
Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study.
Topics: Adult; Aged; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metast | 2017 |
Phase II Study of Adjuvant Chemoradiotherapy Using Docetaxel/Cisplatin/5-Fluorouracil Before and After Intensity-modulated Radiotherapy With Concurrent Docetaxel in Patients With Completely (R0) Resected Gastric Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemoradiotherapy, A | 2018 |
Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dr | 2008 |
A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Drug Administration Schedule; F | 2008 |
Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 2008 |
Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxy | 2009 |
Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2008 |
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2008 |
A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovori | 2008 |
A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2009 |
Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
Topics: Adult; Aged; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; D | 2008 |
Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2008 |
Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2008 |
Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug-Related Side Effects | 2008 |
A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; C | 2009 |
[Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2008 |
[Curative effects of FTQ combined with cisplatin in treatment of advanced gastric cancer: a multicenter study].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorour | 2008 |
Combination therapy with mitomycin C (NSC-26980), 5-fluorouracil (NSC-19893), and cytosine arabinoside (NSC-63878) for advanced cancer in man.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Colorectal | 1972 |
[Efficacy of oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy for local advanced gastric cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2008 |
Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2009 |
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
A phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as first-line treatment for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 2008 |
Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2009 |
[Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Fema | 2009 |
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineop | 2009 |
An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Dige | 2009 |
Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2008 |
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2008 |
A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Carcinoma, Squamous C | 2009 |
A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progre | 2009 |
Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2009 |
Phase II study of capecitabine plus cisplatin in patients with gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; C | 2009 |
Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Anticoagulants; Antimetabolites, Antine | 2009 |
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2009 |
A phase II trial of epirubicin plus oxaliplatin and fluorouracil as first-line chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fluorouracil; Human | 2009 |
Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2009 |
Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diseas | 2009 |
[Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 2009 |
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2009 |
Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capec | 2009 |
Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2010 |
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2010 |
[FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
[Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2009 |
Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2010 |
Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2009 |
Postoperative chemoradiotherapy in gastric cancer--a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma | 2010 |
A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy, Combination; E | 2010 |
A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2009 |
S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fema | 2010 |
A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined | 2010 |
[Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, A | 2009 |
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C | 2009 |
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C | 2009 |
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C | 2009 |
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C | 2009 |
CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Alleles; Antineoplastic Agents; Cell Cycle; Cisplatin; Cyclin D1; DNA R | 2009 |
Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2009 |
Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2010 |
Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2010 |
Endoscopic chemotherapy with 5-fluorouracil in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Endoscopy, Digestive System; Fluorou | 2010 |
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antin | 2011 |
The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouraci | 2009 |
The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouraci | 2009 |
The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouraci | 2009 |
The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouraci | 2009 |
A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Resp | 2010 |
Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2010 |
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2010 |
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Concurrent liposomal cisplatin (Lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 2010 |
Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 2010 |
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring | 2010 |
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2010 |
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2011 |
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2010 |
[Preliminary study of XELOX regimen as the first-line chemotherapy in advanced or recurrent gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fl | 2010 |
[Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2010 |
Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Pr | 2010 |
A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2010 |
A phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) as first-line chemotherapy in advanced gastric cancer: a Chinese single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Deoxycytidi | 2010 |
Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2010 |
[Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity].
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Calcium Gl | 2010 |
[Comparison of the therapeutic effects of paclitaxel liposome-5-Fu versus paclitaxel-5-Fu on 67 patients with advanced gastric cancer].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Pr | 2010 |
Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Grou
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy | 2011 |
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Prospective randomized trial of short-term neoadjuvant chemotherapy for advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chi-Square Distribution; Cispl | 2010 |
[18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2010 |
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherap | 2010 |
The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2012 |
Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2011 |
Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2010 |
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2011 |
No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2011 |
Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Cispla | 2012 |
A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2010 |
Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ci | 2011 |
[A clinical study of paclitaxel combined with FOLFOX4 regimen as neoadjuvant chemotherapy for advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovori | 2010 |
Phase I study of paclitaxel, cisplatin and 5-fluorouracil combination chemotherapy for unresectable / recurrent gastric cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis | 2010 |
[Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; D | 2010 |
Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Chemotherapy, Adjuvant | 2010 |
Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Chemo | 2011 |
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2011 |
Capecitabine "metronomic" chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy.
Topics: Administration, Metronomic; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Deoxycytid | 2012 |
Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group tri
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2011 |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cluster Analysis; Drug Re | 2011 |
[Efficacy and safety of SOX regimen as neoadjuvant chemotherapy for advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorou | 2011 |
Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2012 |
Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Phase II study of weekly paclitaxel, cisplatin, and 5-fluorouracil for advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin | 2011 |
A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Resistanc | 2011 |
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; De | 2011 |
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Campto | 2011 |
Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2012 |
[Pilot study on clinical effects of rebamipide gargle against oral mucositis induced by fluoropyrimidines].
Topics: Alanine; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Mouthwashes; Pilo | 2011 |
Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Female; Fl | 2011 |
Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort St | 2011 |
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin | 2011 |
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin | 2011 |
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin | 2011 |
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin | 2011 |
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin | 2011 |
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin | 2011 |
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin | 2011 |
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin | 2011 |
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin | 2011 |
Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Area Under Curve; Asian Peopl | 2012 |
[Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: a first-line phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluor | 2011 |
Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2012 |
Phase II clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 2011 |
Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2011 |
Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease | 2012 |
Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cis | 2012 |
Phase II study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Fluorour | 2011 |
Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, | 2011 |
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease P | 2011 |
Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Fr | 2012 |
Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docet | 2012 |
Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docet | 2012 |
Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docet | 2012 |
Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docet | 2012 |
The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2012 |
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2012 |
Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2012 |
A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; F | 2012 |
[Value of normalization window of tumor vasculature in neoadjuvant chemotherapy for patients with unresectable gastric cancer].
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
Treatment of Borrmann type IV gastric cancer with a neoadjuvant chemotherapy combination of docetaxel, cisplatin and 5-fluorouracil/leucovorin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl | 2011 |
A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine | 2012 |
Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Drug R | 2012 |
Cisplatin with capecitabine: tolerance and activity in a phase I/II study preferentially enrolling patients with gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2012 |
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetax | 2012 |
Retrospective analysis of 56 patients with advanced gastric cancer treated with combination of intravenous and intra-arterial intensified neoadjuvant chemotherapy.
Topics: Adult; Aged; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusion | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studi | 2013 |
Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; | 2013 |
Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Ant | 2013 |
Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2012 |
Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplasti | 2013 |
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Doce | 2012 |
Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chem | 2012 |
Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capeci | 2013 |
Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Disease-Free Survival; Drug Ad | 2012 |
A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2012 |
Effects of intermittent 5-fluorouracil and low-dose cisplatin therapy on advanced and recurrent gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Male; | 2012 |
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2012 |
A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epothilones; Female; Fluorouracil; Huma | 2012 |
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2012 |
Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2012 |
Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cytokines; Drug Th | 2012 |
A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free S | 2013 |
Docetaxel-based preoperative chemoradiation in localized gastric cancer: impact of pathological complete response on patient outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisp | 2013 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
Whole-body hyperthermia combined with hyperthermic intraperitoneal chemotherapy for the treatment of stage IV advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2012 |
Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Drug Administration Schedul | 2012 |
A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2013 |
Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabin | 2012 |
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Perioperative DCF chemotherapy protocol for patients with gastroesophageal adenocarcinoma: correlation between response to treatment and outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2013 |
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; | 2012 |
Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Enzyme-Linked I | 2012 |
The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2013 |
Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasm | 2013 |
High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do | 2002 |
Modulation of intracellular glutathione concentration alters dehydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cell Survival; Dihydrouracil Dehydrogenase (NADP); Fem | 2002 |
Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2002 |
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2002 |
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2002 |
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2002 |
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2002 |
Promising results in stomach cancer trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cisplatin; Diphtheria Toxoid; Fluor | 2002 |
Combination chemotherapy comprising 5-fluorouracil, leucovorin, etoposide, and cis-diamminedichloroplatinum for the treatment of advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Fluoroura | 2002 |
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Ne | 2002 |
A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2002 |
Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Disease Progress | 2002 |
A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2002 |
A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.
Topics: Adenocarcinoma; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle | 2002 |
Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2002 |
[Pharmacokinetic study of postoperative peritoneal infusion with large bulk heated hypotonic 5-fluorouracil fluid for prevention of recurrence and hepatic metastasis of gastric cancer].
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Infusions, Parenteral; Liver Neoplasms; Posto | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fema | 2002 |
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2003 |
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2003 |
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2003 |
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2003 |
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2003 |
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2003 |
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2003 |
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2003 |
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2003 |
[Interim report of JFMC study no. 23--phase III randomized clinical trial on the effectiveness of low-dose cisplatin plus 5-FU as a postoperative adjuvant chemotherapy for advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise | 2002 |
[Clinical observation of music therapy combined with anti-tumor drugs in treating 116 cases of tumor patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drugs, Chinese Herbal; Etopo | 2001 |
Etoposide, doxorubicin and cisplatin alternating with 5-fluorouracil, doxorubicin and high-dose methotrexate in patients with advanced adenocarcinoma of the stomach or the gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 2002 |
[Influence of combined therapy of guben yiliu III, moxibustion and chemotherapy on immune function and blood coagulation mechanism in patients with mid-late stage malignant tumor].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation; Carboplatin; Cisplatin; Cyclophos | 2002 |
[Clinical study on effect of Astragalus in efficacy enhancing and toxicity reducing of chemotherapy in patients of malignant tumor].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astragalus propinquus; CD4-CD8 Ratio; Cisplatin; Cyc | 2002 |
Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Doc | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
Infusional fluorouracil, etoposide, and cisplatin (FEP) in advanced and relapsed gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Fluoroura | 2003 |
European experience of docetaxel and cisplatin in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease | 2002 |
A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2003 |
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2003 |
Mitomycin C, carboplatin and protracted venous infusion 5-fluorouracil in advanced oesophago-gastric and pancreatic cancer: results of two phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Fema | 2003 |
Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2003 |
Low toxic neoadjuvant cisplatin, 5-fluorouracil and folinic acid in locally advanced gastric cancer yields high R-0 resection rate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fluorouracil; | 2003 |
Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Squar | 2003 |
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Confidence I | 2003 |
Postoperative chemoradiotherapy for gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Follow | 2003 |
Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Hum | 2003 |
[Clinical study on post-operative metastasis prevention of progressive stage of gastric cancer by weichang'an].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drugs, Chinese Herbal; Female; F | 2003 |
Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2003 |
A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cos | 2003 |
Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2003 |
Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Female; Fluorode | 2003 |
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2004 |
[Clinical results of advanced gastric cancer patients treated with oxaliplatin-containing regimen].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouracil; Follow | 2003 |
Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 2004 |
5-fluorouracil administered as a 48-hour semiintermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorour | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dose | 2004 |
Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-R | 2004 |
A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; | 2004 |
High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug | 2004 |
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Docetaxel; Female | 2004 |
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Dox | 2004 |
Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diseas | 2004 |
Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug | 2004 |
Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2004 |
Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; | 2004 |
Sequence-dependence of cisplatin and 5-fluorouracil in advanced and recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2004 |
[Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Tria
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; | 2004 |
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C | 2004 |
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2004 |
Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2004 |
Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Combined Mo | 2004 |
Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Che | 2005 |
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2005 |
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2005 |
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2005 |
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2005 |
Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2005 |
Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fluorouracil; Huma | 2005 |
[Trial of outpatient anti-cancer chemotherapy with infusion of 5-FU and cisplatin for advanced gastric and colorectal cancers].
Topics: Adenocarcinoma; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; C | 2005 |
Infusional 5-fluorouracil and mitomycin C: an effective regimen in the treatment of advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorour | 2005 |
Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; | 2005 |
[Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 2005 |
Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients.
Topics: Adult; Aged; Antigens, Nuclear; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; | 2005 |
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; D | 2005 |
Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2005 |
Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carbo | 2005 |
Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 2005 |
Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2005 |
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 2005 |
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagog | 2005 |
Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relatio | 2005 |
Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoroura | 2005 |
Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2006 |
Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic A | 2005 |
Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 2005 |
A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2005 |
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2005 |
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area | 2005 |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survi | 2005 |
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2005 |
Neoadjuvant radiochemotherapy for locally advanced gastric cancer: long-term results of a phase I trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2005 |
Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoroura | 2005 |
[A randomized controlled trail of taxol-based combination regimens for advanced gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; F | 2005 |
Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2005 |
Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2006 |
Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dis | 2006 |
A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2006 |
Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Progression; Female; | 2006 |
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2006 |
Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2005 |
Intraarterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Female; F | 2006 |
A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2006 |
Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; F | 2006 |
An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cis | 2006 |
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2006 |
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2006 |
[Study on efficacy and toxicity of new combined regimen "taxoter + cisplatin + 5-fluorouracil" in disseminated and locally-spread stomach cancer. Comparative analysis of tolerance and efficacy in patients younger and older than 65 years].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2006 |
Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 2006 |
Use of a combination of computed tomography and endoscopy to assess the response to 5-fluorouracil/cisplatin and predict survival in gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Endoscopy, Gastrointestina | 2006 |
Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: a novel, safe, and active regimen.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2006 |
A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2006 |
Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Anemia; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.
Topics: Acetates; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2006 |
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; D | 2006 |
Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovori | 2006 |
A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ant | 2007 |
A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2006 |
[The prospective study on application of parenteral nutrition with alanyl-glutamine dipeptide in chemotherapy of gastrointestinal neoplasms patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Complement C3; Compl | 2006 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2007 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2007 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2007 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2007 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
[Oxaliplatin in combination with calcium folinate and fluorouracil as neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovori | 2006 |
Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Do | 2006 |
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2007 |
Results of adjuvant radiochemotherapy for gastric adenocarcinoma in Slovenia.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; F | 2007 |
Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose- | 2007 |
The tolerance and efficacy of preoperative chemoradiotherapy followed by gastrectomy in operable gastric cancer, a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Gastrectomy; Hum | 2007 |
Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2007 |
A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group Study 9601.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemother | 2007 |
Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2007 |
Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 2008 |
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose- | 2008 |
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Pr | 2007 |
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Surv | 2007 |
Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Denmark; | 2007 |
A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; D | 2007 |
Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cell Survival; Colorec | 2007 |
Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do | 2007 |
A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2007 |
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla | 2006 |
A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2008 |
Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2008 |
Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2008 |
Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2008 |
Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2008 |
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastroi
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Europe; Female; Fluorouracil; Human | 2007 |
A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach Cancer (TASC).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2007 |
Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2007 |
Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2007 |
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution | 2007 |
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution | 2007 |
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; E | 2007 |
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; E | 2007 |
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; E | 2007 |
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; E | 2007 |
Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2007 |
A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2007 |
A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Blood Cell Count; Endpoint Determination; Eryt | 2008 |
Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinatio | 2007 |
Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemo | 2007 |
The effects of preoperative chemotherapy on isolated tumour cells in the blood and bone marrow of gastric cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chi-Square Distribution; Cisplati | 2007 |
A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squam | 2007 |
Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2007 |
Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy; Chemotherapy, Adjuvant; Female; Fluor | 2007 |
Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease P | 2007 |
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2006 |
[Clinical observation on treatment of advanced gastric cancer by combined use of Shenqi Fuzheng injection, docetaxel, flurouracil and calcium folinate].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Therapy, Combination; Drugs, C | 2007 |
Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carbop | 2007 |
A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2007 |
Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2007 |
[Postoperative abdominal endogenic field hyperthermia combined with FOLFOX regimen in the treatment of 68 cases of advanced gastric cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluorourac | 2007 |
[Weekly dosage of docetaxel combined with cisplatin and 5-fluorouracil in the treatment of advanced gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel | 2007 |
Bimonthly 24 h infusion of high-dose 5-fluorouracil vs EAP regimen in patients with advanced gastric cancer. A randomized phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2008 |
[Clinical observation on treatment of 34 advanced gastric carcinoma patients by chemotherapy of DCF regimen combined with Fuzheng Hewei Decoction].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2007 |
Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cel | 2007 |
A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineop | 2008 |
Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2007 |
[Effects of fractionated low dose Cisplatin on renal functions of patients with gastric carcinoma].
Topics: Acetylglucosaminidase; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitro | 2007 |
Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progre | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Disease-Fre | 2007 |
A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; | 2008 |
[Neoadjuvant chemotherapy for gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; F | 2007 |
Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagea | 2007 |
Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovori | 2008 |
Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo | 2007 |
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva | 2008 |
Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Rel | 2009 |
Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubici | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Administratio | 2009 |
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.
Topics: 3' Untranslated Regions; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols | 2008 |
Adjuvant chemoimmunotherapy for gastric carcinoma.
Topics: Adult; Aged; BCG Vaccine; Clinical Trials as Topic; Female; Fluorouracil; Gastrectomy; Humans; Male; | 1980 |
Chemotherapy following palliative resection of gastric cancer.
Topics: Aged; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Pallia | 1981 |
A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up | 1982 |
A controlled study of maintenance chemoimmunotherapy vs immunotherapy alone immediately following palliative gastrectomy and induction chemoimmunotherapy for advanced gastric cancer. Tokai cooperative study group for adjuvant chemoimmunotherapy of stomach
Topics: Antineoplastic Agents; Biological Products; Cytarabine; Drug Therapy, Combination; Female; Fluoroura | 1981 |
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Doxorubicin; Drug Administration Schedu | 1983 |
[Phase III multi-center study of levamisole (LMS)--a randomized evaluation in advanced gastrointestinal cancer, with special reference to stomach cancer].
Topics: Adult; Aged; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; | 1983 |
An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British Stomach Cancer Group.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; | 1983 |
Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report.
Topics: Adenocarcinoma; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Fluorouracil; Gastrectomy | 1983 |
[Chemotherapy for advanced stomach cancer -- a controlled study of AF and MF].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; | 1983 |
5-fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine | 1984 |
Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical T | 1984 |
Effect of postoperative total parenteral nutrition (TPN) as an adjunct to gastrectomy for advanced gastric carcinoma.
Topics: Adult; Aged; Antibody Formation; Blood Proteins; Body Weight; Fluorouracil; Gastrectomy; Humans; Imm | 1983 |
[Adjuvant immunochemotherapy combined with OK-432 following surgery of stomach cancer].
Topics: Aged; Biological Products; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immunotherapy; M | 1983 |
Chemotherapy of disseminated gastric cancer. A joint effort of the Northern California Oncology Group and the Japanese Gastric Cancer Chemotherapy Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; California; Clinical Tr | 1983 |
[Randomized study on the long-term adjuvant chemotherapy with ftorafur and mitomycin C for stomach cancer: second report].
Topics: Drug Therapy, Combination; Fluorouracil; Humans; Mitomycin; Mitomycins; Postoperative Period; Random | 1983 |
Randomized study of combination chemotherapy in unresectable gastric cancer. The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubici | 1984 |
[Cooperative studies on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Fluorouraci | 1984 |
[Immunological approach and surgical treatment of cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Gastrectomy | 1983 |
Clinical evaluation of prolonged chemotherapy combined with induction of hepatic drug-metabolizing enzymes as an adjuvant for treating patients with gastric cancer.
Topics: Clinical Trials as Topic; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Inductio | 1983 |
[Clinical studies on induced hypertension chemotherapy based on functional characteristics of microcirculation of tumor vessels].
Topics: Angiotensin II; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxorubicin | 1984 |
Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sch | 1984 |
[Joint clinical Phase II study of SF-SP].
Topics: Clinical Trials as Topic; Colonic Neoplasms; Delayed-Action Preparations; Drug Evaluation; Female; F | 1984 |
A trial of adjuvant combination chemoimmunotherapy for stage III carcinoma of stomach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Cholera Vaccines; Clinical | 1984 |
[A randomized study on the long-term adjuvant chemotherapy with ftorafur and mitomycin C for gastric cancer: the second study (III)].
Topics: Clinical Trials as Topic; Drug Administration Schedule; Fluorouracil; Humans; Mitomycin; Mitomycins; | 1984 |
Levamisole in postoperative adjuvant immunochemotherapy for gastric cancer. A randomized controlled study of the MMC + Tegafur regimen with or without levamisole. Report I.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical T | 1984 |
Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1984 |
An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fl | 1984 |
Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma.
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Re | 1984 |
[Prospective randomized study in advanced stomach cancer. Comparison between combinations of 5-fluorouracil and carmustine without and with adriamycin].
Topics: Adult; Aged; Carmustine; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Leukocyte Cou | 1984 |
Treatment of advanced gastric cancer with 5-fluorouracil versus mitomycin C.
Topics: Adenocarcinoma; Adult; Clinical Trials as Topic; Female; Fluorouracil; Humans; Male; Middle Aged; Mi | 1982 |
Current management of advanced and locally unresectable gastric carcinoma.
Topics: Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; | 1982 |
[Antineoplastic chemotherapy in advanced gastric cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dox | 1982 |
[Clinical evaluation of combination chemotherapy of aclacinomycin A (ACM) and 5-fluorouracil (5-FU) for advanced carcinoma of gastrointestinal tract].
Topics: Aclarubicin; Antibiotics, Antineoplastic; Bile Duct Neoplasms; Clinical Trials as Topic; Colonic Neo | 1982 |
[Follow-up study of preoperative oral administration of an antineoplastic agent as an adjuvant chemotherapy in stomach cancer].
Topics: Administration, Oral; Clinical Trials as Topic; Emulsions; Fluorouracil; Follow-Up Studies; Humans; | 1982 |
[Multihospital randomized study on the adjuvant chemotherapy with mitomycin-C and Futraful for gastric cancer V. Estimation of 5-year survival rate].
Topics: Drug Therapy, Combination; Fluorouracil; Gastrectomy; Humans; Lymphatic Metastasis; Mitomycin; Mitom | 1982 |
[Effect of levamisole in postoperative adjuvant immunochemotherapy of stomach cancer--randomized controlled study of MMC-tegafur combination therapy with or without levamisole. 1].
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Tr | 1982 |
[Effect of levamisole in postoperative adjuvant immunochemotherapy of stomach cancer--randomized controlled study of MMC-5-FU combination therapy with or without levamisole. 1].
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Clinical Trials as Topic; Drug Adm | 1982 |
[Effect of postoperative long-term chemotherapy of stomach cancer using mitomycin C and futraful--the secondary study (1)].
Topics: Aged; Antibiotics, Antineoplastic; Blood Cell Count; Body Weight; Clinical Trials as Topic; Drug The | 1982 |
A follow-up study on chemoimmunotherapy (5-fluorouracil and BCG) in advanced gastric cancer.
Topics: BCG Vaccine; Fluorouracil; Follow-Up Studies; Humans; Immunotherapy; Middle Aged; Stomach Neoplasms | 1982 |
The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced gastrointestinal malignancy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Dru | 1981 |
A prospective trial of 5-FU and BCNU in the treatment of advanced gastric cancer.
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; | 1981 |
Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial.
Topics: Adenocarcinoma; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up | 1981 |
Adjuvant chemotherapy in colon and gastric cancer.
Topics: BCG Vaccine; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; F | 1982 |
Adjuvant 5-fluorouracil and BCNU chemotherapy in gastric cancer: 3-year results.
Topics: Carmustine; Clinical Trials as Topic; Drug Administration Schedule; Female; Fluorouracil; Follow-Up | 1982 |
Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Humans; L | 1982 |
Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Drug Therapy, Com | 1982 |
Gastric carcinoma treated by chemotherapy after resection: a controlled study.
Topics: Adult; Aged; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Gastrecto | 1980 |
Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Epir | 1994 |
Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1994 |
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Adminis | 1995 |
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Adminis | 1995 |
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Adminis | 1995 |
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Adminis | 1995 |
Combination 5-fluorouracil (FU), folinic acid (FA), and alpha-interferon 2B in advanced gastric cancer: results of a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1995 |
[Hepatic arterial infusion therapy for gastric liver metastasis using implanted reservoir].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Fluoroura | 1995 |
[Outcomes of effective treatment of cases of metastatic liver tumors by intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 1995 |
[A study of chemotherapy for patients with severely advanced gastric cancer--comparison of chemotherapy and route].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Routes; Drug Administ | 1995 |
[Intraperitoneal infusion therapy of MTX and 5-FU for advanced gastric cancer and its peritoneal metastasis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 1995 |
[A prospective randomized clinical trial comparing intra-arterial chemotherapy alone and when combined with hyperthermia for metastatic liver cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Th | 1995 |
Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod | 1995 |
[Clinical evaluation of leucovorin and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1995 |
[Clinical evaluation of anticancer effect of methionine-depleting total parenteral nutrition with 5-fluorouracil and/or mitomycin C].
Topics: Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Adminis | 1995 |
[Clinical evaluation of sequential MTX/5-FU therapy for gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluorouracil; Humans; | 1995 |
Randomized study with mitomycin C + 5-fluorouracil+cytosine arabinoside (MFC)+5-fluorouracil, MFC+tegafur and uracil (UFT), and MF+UFT in advanced gastric cancer: interinstitutional differences in a multicenter study in Japan.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1995 |
[A pilot study of combined chemotherapy using methotrexate (MTX), 5-fluorouracil (5-FU) and pirarubicin (THP) for advanced or recurrent gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedule; Fem | 1995 |
Is the combination of 5-fluorouracil and folinic acid effective in advanced gastric carcinoma? Results of a pilot study and review of the literature.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1994 |
[Clinical and experimental study in treating gastric cancer with replenishing qi and invigorating spleen oral liquid combined with chemotherapy].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy, Combi | 1994 |
[A controlled study of AO-90, a methionine-free intravenous amino acid solution, in combination with 5-fluorouracil and mitomycin C in advanced gastric cancer patients (surgery group evaluation)].
Topics: Adolescent; Adult; Aged; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Drug Administr | 1995 |
[A controlled study of AO-90, a methionine-free intravenous amino acid solution, in combination with 5-fluorouracil and mitomycin C in advanced gastric cancer patients (internal medicine group evaluation)].
Topics: Adolescent; Adult; Aged; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Drug Administr | 1995 |
Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorour | 1995 |
Synergistic effect of methionine-depleting total parenteral nutrition with 5-fluorouracil on human gastric cancer: a randomized, prospective clinical trial.
Topics: Aged; Amino Acids; Combined Modality Therapy; Fat Emulsions, Intravenous; Female; Fluorouracil; Gast | 1995 |
[A cooperative late phase II trial of l-leucovorin and 5-fluorouracil in the treatment of advanced gastric cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
Topics: Adult; Aged; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intrav | 1995 |
[Quality of life in patients with advanced gastric cancer receiving AO-90, a methionine-free intravenous amino acid solution, with 5-fluorouracil and mitomycin C].
Topics: Adolescent; Adult; Aged; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Drug Administr | 1995 |
[Usefulness of 5-FU high-dose continuous therapy at home in patients with recurrent gastric and colon cancer].
Topics: Adult; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Home Care Services, Ho | 1994 |
[Home chemotherapy for peritoneal carcinomatosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Doxorubi | 1994 |
[Effect of continuous infusion of 5-fluorouracil and daily low-dose cisplatin for inoperable recurrent cancer of the stomach and colon].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasm | 1995 |
Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 1994 |
[Effect of intraperitoneal chemotherapy with implantable reservoir against unresectable gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Etopo | 1995 |
[Pharmacokinetic study of UFT in cancer patients receiving maintenance dialysis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 1995 |
Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1994 |
[Pharmacological study of 5'-DFUR oral administration and the clinical responses against gastrointestinal carcinoma].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Sch | 1995 |
Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1995 |
[Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy].
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 1995 |
[A randomized early phase II study of l-leucovorin and 5-fluorouracil in gastric cancer. l-Leucovorin and 5-FU Study Group].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration | 1995 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Combined Mo | 1994 |
Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma.
Topics: Colorectal Neoplasms; Dextrins; Dialysis Solutions; Drug Administration Schedule; Drug Stability; Fe | 1994 |
[Effects of preoperative parenteral nutritional support with chemotherapy on tumor cell kinetics in gastric cancer patients].
Topics: Adult; Aged; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Chemotherapy, A | 1994 |
[Evaluation of cases of metastatic liver tumors resected following intra-arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colonic Neo | 1994 |
[The value of hepatic arterial infusion chemotherapy for liver metastases--discussion from viewpoints of prevention of hepatic death and QOL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Fl | 1994 |
[A study of regional chemotherapy: hepatic arterial infusion for metastatic liver tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fluorouracil; Hepat | 1994 |
[Methotrexate/5-fluorouracil therapy in gastric cancer with peritoneal metastasis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Administration Sch | 1994 |
[Intraperitoneal chemotherapy for gastric carcinoma combined with peritoneal dissemination by intraperitoneal catheter with a subcutaneous reservoir].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1994 |
5-fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 1994 |
Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Epir | 1994 |
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chi- | 1994 |
Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Femal | 1994 |
Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise | 1994 |
Epirubicin, cisplatin and intermittent continuous infusion of 5-fluorouracil in advanced gastric cancer: an effective regimen?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorour | 1994 |
[Randomized controlled trial of MMC + UFT and MMC + 5-FU therapy in advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Mitomycin; Quality of Life; St | 1994 |
[The optimal period for orally administered fluoropyrimidines as an adjuvant chemotherapy for gastric cancer--a pilot study using 5-FU tablets compared with surgical operation alone].
Topics: Administration, Oral; Adult; Aged; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Flu | 1994 |
Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Fluo | 1994 |
A pilot clinical trial of postoperative adjuvant intraperitoneal cisplatin, 5-fluorouracil, 6S-leucovorin and interferon alpha 2b in patients with resected gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fema | 1993 |
Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study.
Topics: Adult; Aged; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms | 1994 |
Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administrati | 1994 |
[Combination of 5-FU, high dose methotrexate, epirubicin and cisplatin (FEMTX-P protocol) in non surgical or locally recurrent metastatic gastric cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorour | 1993 |
Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1994 |
Bioavailability of oral etoposide in gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availa | 1994 |
[Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy]
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Combined Ch | 1994 |
[Efficacy of FEM (5-fluorouracil, epirubicin, mitomycin C) therapy for resected advanced gastric cancer. Ehime Gastric Cancer Study Meeting].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Sc | 1993 |
[A double-blind comparison of FUra plasma concentration by oral (UFT) vs continuous intravenous infusion (5-FU)].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Fluoroura | 1993 |
5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorour | 1993 |
Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorour | 1993 |
Epidoxorubicin and high dose leucovorin plus 5-fluorouracil in advanced gastric cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug | 1993 |
[Study of pre- and post-operative chemotherapy with oral 5-FU in patients with gastric cancer. Study Group of Pre- and Post-Operative Oral 5-FU in Gastric Cancer].
Topics: Administration, Oral; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; Neoplasm Staging; | 1993 |
High-dose folinic acid with 5-fluorouracil bolus and continuous infusion in the treatment of advanced gastric and oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Dr | 1993 |
Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1993 |
[Phase I study of 5-fluorouracil and l-leucovorin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1993 |
A phase I-II study of epirubicin, 5-fluorouracil, and leucovorin in advanced adenocarcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relations | 1993 |
Mitomycin therapy in gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 1993 |
Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 1993 |
Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 1993 |
Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 1993 |
Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1995 |
Efficacy of the association of folinic acid and 5-fluorouracil alone versus folinic acid and 5-fluorouracil plus 4-epidoxorubicin in the treatment of advanced gastric carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic | 1995 |
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cisplati | 1996 |
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cisplati | 1996 |
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cisplati | 1996 |
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cisplati | 1996 |
[Clinical study on early use of Chinese medicinal herbs and chemotherapy after operation of gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combination; Drugs, Chine | 1995 |
Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 1995 |
Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; | 1995 |
Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Adminis | 1996 |
Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysi | 1995 |
Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Sensitivity and Sp | 1996 |
Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorour | 1995 |
Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Antidotes; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Infusions, Intrave | 1995 |
The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Fema | 1996 |
Treatment of advanced gastric cancer with a modified regimen of etoposide/leucovorin/5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relations | 1996 |
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Anemia; Antidotes; Antimetabolites, Antineoplast | 1996 |
[Administration and dosage of fluorouracil (5-FU) continuous i.v. infusion in patients with non-curative resected/non-resected gastric cancer].
Topics: Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Female | 1996 |
[Randomized controlled study on adjuvant immunochemotherapy with carmofur (HCFU) for noncuratively resected and unresected gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi-Square Distribution; Com | 1996 |
[ACNU and methyl-CCNU in combination chemotherapy for advanced gastric cancer: a randomized comparative study. Shanghai ACNU Collaborative Study Group].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chin | 1996 |
Different doses of granulocyte colony stimulating factor to support a weekly chemotherapeutic regimen in advanced gastric cancer: a randomized study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 1996 |
[Comparative clinical study of adjuvant postoperative chemotherapy (5-FU, Tegafur, 5-FU + MMC) in curatively resected cases of gastric cancer. Study Group on 5-FU Oral Adjuvant Chemotherapy in Gastric Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorou | 1996 |
Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Fluorour | 1996 |
Intermittent continuous infusion of 5-fluorouracil in combination with epirubicin and cisplatin in advanced gastric cancer: the importance of dose intensity.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Respons | 1996 |
5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Epirubicin; Female; Fluorour | 1996 |
[Neoadjuvant chemotherapy in high-grade advanced gastric cancer with protracted infusional 5-fluorouracil and consecutive low-dose cisplatin].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1996 |
Intraperitoneal 5-fluorouracil and mitomycin C as adjuvants to resectable gastric cancer: a status report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Injection | 1996 |
Histopathological response to preoperative chemotherapy including 5-fluorouracil additionally assessed by immunocytochemical and pharmacologic parameters in patients with advanced gastric cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1996 |
[Arterial infusion chemotherapy for advanced gastric cancer by sequential MTX/5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Drug Ad | 1996 |
[A study of arterial infusion chemotherapy for gastric cancer patients with peritoneal metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Routes; Fluorouracil; | 1996 |
Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Calcium; Colorectal Neoplasms; Fem | 1996 |
A phase II trial of etoposide, leucovorin and 5-fluorouracil (ELF) in patients with advanced gastric cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouracil; Hematologic | 1996 |
Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Female; Flu | 1996 |
Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 1996 |
[Evaluation of hepatic arterial infusion chemotherapy for gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administra | 1996 |
A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1996 |
[Chemotherapy for peritoneal dissemination in gastric cancer under ureteral catheterization].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female | 1996 |
Enhanced induction of apoptosis of human gastric carcinoma cells after preoperative treatment with 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma; Female; Fluorouracil; Huma | 1997 |
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; C | 1997 |
[Clinical evaluation of ondansetron suppository].
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1997 |
Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Female; Fluorouracil; | 1996 |
A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antidotes; Antimetaboli | 1997 |
A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Feasibili | 1997 |
[The influence on prognosis of intraoperative chemotherapy for adenocarcinoma of gastric cardia].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cardia; Female; Fluorouracil; Humans; Intraop | 1996 |
Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergi | 1997 |
[Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 1997 |
The French experience with infusional 5-FU in gastric and pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bio | 1996 |
Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 1996 |
High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1996 |
[Preoperative adjuvant chemotherapy with oral anticancer agents for stomach cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, | 1997 |
Scientific basis for the combination of tegafur with uracil.
Topics: Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Combinations; Female; Fluorouracil; G | 1997 |
[Evaluation of intra-arterial infusion chemotherapy for liver metastasis from gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Fema | 1997 |
A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Femal | 1997 |
Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Infusions | 1997 |
A randomized trial comparing cisplatin plus 5-fluorouracil with or without levamisole in operable gastric cancer.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fema | 1997 |
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.
Topics: Adenocarcinoma; Cisplatin; Combined Modality Therapy; DNA-Binding Proteins; Endonucleases; Female; F | 1998 |
[Sequential chemotherapy with methotrexate and 5-fluorouracil for advanced gastric cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 1998 |
Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1998 |
High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug | 1998 |
Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 1998 |
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; Endothelial Growth Fac | 1998 |
Phase II study of paclitaxel in pretreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1998 |
[A cooperative study on concomitant with low-dose divided administration of cisplatin (CDDP) and sustained drip infusion of 5-fluorouracil (5-FU) for unresectable advanced gastric cancer. Osaka Cisplatin Gastric Cancer Study Group].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administratio | 1998 |
Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubici | 1998 |
Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administra | 1998 |
[Clinical evaluation of intermittent hepatic arterial infusion therapy for metastatic liver tumor of gastric and colorectal cancer].
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; C | 1998 |
[Evaluation of hepatic arterial infusion chemotherapy using reservoir for liver metastases from gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubic | 1998 |
Phase II study of 5-fluorouracil, pirarubicin and low-dose consecutive administration of cisplatin for advanced and recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubici | 1998 |
Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Admini | 1998 |
A phase 2 study of weekly high-dose 5-fluorouracil and leucovorin plus biweekly plus biweekly alternating doxorubicin and cisplatin for advanced gastric cancer.
Topics: Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Che | 1998 |
[A randomized controlled trial with methotrexate (MTX), 5-fluorouracil (5-FU) and pirarubicin (THP) vs 5-FU alone in advanced or recurrent gastric carcinoma. Tokai Hokuriku THP Study Group].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 1998 |
Biochemical modulation of 5-fluorouracil by methotrexate in patients with advanced gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Male; Met | 1998 |
[Clinical evaluation as palliative therapy of combination chemotherapy with continuous infusional 5-fluorouracil and consecutive low-dose cisplatin in unresectable gastrointestinal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1998 |
Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Infusi | 1998 |
Potential of the histoculture drug-response assay to contribute to cancer patient survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug | 1995 |
Treatment of advanced gastric cancer with 5-fluorouracil and cisplatin in combination with dipyridamole.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dipyridamole; Female; Fluoro | 1998 |
OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-F | 1998 |
Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; | 1998 |
A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Etop | 1998 |
A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; | 1999 |
Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1999 |
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouracil; Humans | 1999 |
[Biochemical modulation of 5-FU--effect of low dose CDDP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin | 1999 |
A pilot study of adjuvant chemotherapy with double modulation of 5-fluorouracil by methotrexate and leucovorin in gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorou | 1999 |
[Clinical study on effect of kang' aibao oral liquid in treating 103 malignant tumor patients].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1997 |
Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relations | 1999 |
Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1999 |
Epirubicin, folinic acid, fluorouracil, and etoposide in the treatment of advanced gastric cancer: phase II study of the Southern Italy Oncology Group (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Fluorour | 1999 |
[Influence of preoperative on gastric cancer tissues and cells].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1997 |
Weekly 24-h infusion of high-dose 5-flurouracil and leucovorin in patients with advanced gastric cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Drug Administration Schedule; Female; Fluor | 1999 |
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Epirubicin; Esophageal Neopl | 1999 |
[Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
The effects of Chinese drugs for supporting healthy energy and removing blood stasis on postoperative metastasis of gastric carcinoma and ornithine decarboxylase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubic | 1998 |
Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Ant | 1999 |
Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1999 |
North Central Cancer Treatment Group Phase II study of 5-fluorouracil and high-dose levamisole for gastric and gastroesophageal cancer using survival as the primary endpoint of efficacy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Esop | 1999 |
A phase II trial of low dose administration of 5-fluorouracil and cisplatin in patients with advanced and recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, | 1999 |
Phase II study of combined administration of 5-fluorouracil, epirubicin and mitomycin-C by hepatic artery infusion in patients with liver metastases of gastric cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1999 |
[Arterial infusion therapy with implantable port for inoperable hepatobiliary tumors].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 1999 |
[Therapeutic efficacy of intra-peritoneal infusion of cisplatin and continuous intravenous infusion of 5-fluorouracil in gastric cancer patients with peritoneal metastasis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1999 |
Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxyurac | 1999 |
[Effect of combination chemotherapy with multiple drugs (FLMP therapy) based on the circadian rhythms of the human body in advanced recurrent gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Cisplatin; Drug Administrati | 1999 |
Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Analgesics; Antimetabolites, Antineoplastic; Antineoplastic | 1999 |
Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Relationship, Drug | 2000 |
[Interim report of JFMTC study no. 20 on the effectiveness of high dose CDDP plus 5-FU regimen as an adjuvant therapy for far-advanced cancer of the stomach].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Evalua | 2000 |
A phase III randomized study comparing oral doxifluridine and oral 5-fluorouracil after curative resection of gastric cancer.
Topics: Administration, Oral; Adult; Aged; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Floxuridin | 2000 |
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Dr | 2000 |
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Dr | 2000 |
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Dr | 2000 |
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Dr | 2000 |
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Dr | 2000 |
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Dr | 2000 |
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Dr | 2000 |
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Dr | 2000 |
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Dr | 2000 |
Successful initial treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 2000 |
[The effect of combination chemotherapy to adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in patients with gastric or colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administ | 2000 |
Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardia; Doxorubicin; Dr | 2000 |
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the Europe
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 2000 |
Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Human | 2000 |
Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2000 |
Concomitant chemoradiation treatment in the management of patients with extrahepatic biliary tract recurrence of gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrah | 2000 |
[The clinical effect of low-dose FP (5-FU + low-dose CDDP) in patients with far advanced gastric cancer, and their quality of life].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2000 |
[Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2000 |
[Evaluation of nervous system disorders during the course of gastric carcinoma on the basis of clinical electrophysiologic analysis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Ad | 1999 |
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis | 2000 |
Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2000 |
[Neoadjuvant chemotherapy for advanced gastric cancer using FLEP therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2000 |
[Hepatic arterial injection therapy (HAI) for metastatic liver tumor from gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Hepatic Arter | 2000 |
Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 2001 |
A phase II trial of a new 5-fluorouracil derivative, BOF-A2 (Emitefur), for patients with advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Fluorouracil; | 2000 |
The relationship between improved prognosis in gastric cancer patients in the last 25 years and changing methods of surgical and combined treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcino | 2000 |
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2001 |
Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2001 |
Adjuvant chemotherapy for gastro-oesophageal cancer with epirubicin, cisplatin and fluorouracil: a single-centre experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous | 2001 |
Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2001 |
Adjuvant radiochemotherapy in the treatment of completely resected, locally advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; | 2001 |
A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
[Clinical study on Shenqi Fuzheng injection combined with chemotherapy in treating malignant tumor of digestive tract].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Colo | 1998 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Dig | 2001 |
[Neoadjuvant chemotherapy for advanced gastric cancer with para-aortic lymph node metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Cisplatin; Drug Administrati | 2001 |
A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP).
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2001 |
[FLEP therapy for advanced and recurrent gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2001 |
[Twenty-year experience with multimodal treatment of gastric cancer patients in Poland].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combine | 2001 |
[Preliminary clinical comparison of HLF and ELF regimen in the treatment of advanced gastric carcinoma in middle-aged and elderly patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Etoposide; Fe | 2000 |
[Clinical study on treatment of mid-late stage gastric carcinoma by composite xiansu capsule combined with chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Caps | 1999 |
[Clinical study on effect of shenqi fuzheng injection combined with chemotherapy in treating gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drugs, Chinese Herbal | 1999 |
An analysis of the therapeutic efficacy of protracted infusion of low-dose 5-fluorouracil and cisplatin in advanced gastric cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2000 |
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2001 |
Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer.
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; | 2001 |
Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progressio | 2001 |
Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cost-Benefit Anal | 2002 |
Weekly high-dose 5-fluorouracil (5-FU), leucovorin (LV) and bimonthly cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2001 |
Polysaccharides isolated from Echinacea purpurea herba cell cultures to counteract undesired effects of chemotherapy--a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Echinacea; Etoposide; | 2002 |
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Esophageal Neopl | 2002 |
Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting: efficacy of therapy and value of serum tumor markers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Free Surviva | 2002 |
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2002 |
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Epiru | 2002 |
Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial.
Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality The | 2002 |
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorour | 2002 |
[Palliative gastrectomy associated to drug therapy in advanced gastric cancer[].
Topics: Aged; Clinical Trials as Topic; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Fluo | 1977 |
Prospective randomized trial of combined oncological therapy for gastric carcinoma.
Topics: Aged; Bone Marrow; Clinical Trials as Topic; Fluorouracil; Humans; Middle Aged; Quality of Life; Rad | 1979 |
Chemotherapy of gastric and pancreatic carcinoma: a controlled evaluation of combinations of 5-fluorouracil with nitrosoureas and "lactones".
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; N | 1979 |
Protracted oral chemotherapy with fluorinated pyrimidines as an adjuvant to surgical treatment for stomach cancer.
Topics: Administration, Oral; Adult; Aged; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studie | 1977 |
Management of gastrointestinal cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluor | 1977 |
The West Midlands gastric carcinoma chemotherapy trial: planning and results.
Topics: Adenocarcinoma; Aged; Carcinoma; Clinical Trials as Topic; Disability Evaluation; Evaluation Studies | 1978 |
[Survival of 5-fluorouracil-treated stomach cancer patients in the far-advanced stages].
Topics: Clinical Trials as Topic; Drug Evaluation; Fluorouracil; Gastrectomy; Humans; Kinetics; Neoplasm Met | 1978 |
Carcinoembryonic antigen levels in advanced gastric carcinoma.
Topics: Carcinoembryonic Antigen; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; | 1978 |
5-fluorouracil, methyl-CCNU, adriamycin, and mitomycin C in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Drug Eval | 1978 |
[A prospective multi-centre study of the response of metastatic gastrointestinal tumours (author's transl)].
Topics: Adenocarcinoma; Carmustine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Intestinal Neoplasms; | 1979 |
5 FU infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer: a Southwest Oncology Group Study.
Topics: Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Drug Therapy, Combination; Female; Flu | 1979 |
Chemotherapy in advanced gastric cancer: a controlled, prospective, randomised multi-centre study.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; | 1979 |
Gastric cancer: current status of treatment.
Topics: Adenocarcinoma; Aged; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ther | 1977 |
Nitrosoureas: useful agents for the treatment of advanced gastrointestinal cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combin | 1976 |
A controlled clinical trial of fluorouracil plus imidazole carboxamide dimethyl triazeno plus vincristine plus bis-chloroethyl nitrosourea plus radiotherapy in stomach cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazin | 1976 |
Sequential and combination chemotherapy of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedul | 1976 |
Randomized comparison of melphalan and 5-fluorouracil in the treatment of advanced gastrointestinal cancer.
Topics: Adult; Aged; Biliary Tract Diseases; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; F | 1976 |
Combined treatment with BCG and chemotherapy for metastatic gastrointestinal cancer.
Topics: BCG Vaccine; Colonic Neoplasms; Evaluation Studies as Topic; Fluorouracil; Gastrointestinal Neoplasm | 1977 |
Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer.
Topics: Anastomosis, Surgical; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Pr | 1992 |
The selection of cases for randomised trials: a registry survey of concurrent trial and non-trial patients. The British Stomach Cancer Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coh | 1992 |
Schedule-dependent inhibition of thymidylate synthase by 5-fluorouracil in gastric cancer.
Topics: Aged; Animals; Combined Modality Therapy; DNA, Neoplasm; Drug Administration Schedule; Drug Stabilit | 1992 |
[Stomach cancers and angiotensin II induced hypertension chemotherapy].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxorubicin; Drug Ad | 1992 |
Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1992 |
Treatment of elderly advanced gastric cancer patients with 5-fluorouracil and leucovorin combination.
Topics: Adenocarcinoma; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female | 1992 |
FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Combin | 1992 |
Combination of 5-fluorouracil and recombinant interferon alpha-2B in advanced gastric cancer. A phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Evaluation | 1992 |
Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 1992 |
[Methionine-deprived amino acid solution-induced biochemical modulation of 5-FU and augmentation of the antitumor activity].
Topics: Amino Acids; Colonic Neoplasms; Fluorouracil; Humans; Methionine; Parenteral Nutrition, Total; Retin | 1992 |
A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Dose-Response Relationshi | 1992 |
Treatment of adenocarcinoma of the cardia with synchronous chemotherapy and radiotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Combined Modality | 1990 |
[Chemotherapy for advanced and recurrent cancer patients--the effect of combination chemotherapy using cisplatin, peplomycin, mitomycin C, adriamycin, and 5-fluorouracil].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Colorectal Neopla | 1990 |
The concept of locally advanced gastric cancer. Effect of treatment on outcome. The Gastrointestinal Tumor Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Female; Fluo | 1990 |
A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Evaluation; Femal | 1992 |
Cisplatin plus continuous infusion of 5-fluorouracil for 5 days effective for patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1991 |
[5-FU concentration in the tissue of gastric cancer, and evaluation of cancer chemotherapy with angiotensin-II].
Topics: Angiotensin II; Drug Administration Routes; Fluorouracil; Gastric Mucosa; Humans; Infusions, Intra-A | 1991 |
[Randomized controlled trial of induced hypertension chemotherapy (IHC) using angiotensin II human (TY-10721) in advanced gastric carcinoma (TY-10721 IHC Study Group Report)].
Topics: Adult; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Combine | 1991 |
Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1991 |
Evaluation of two consecutive regimens in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Evaluation | 1991 |
Folate biochemical modulation regimen for the treatment of gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 1991 |
A phase II pilot study of the combined application of hyperthermia and intra-hepato-arterial chemotherapy using cisplatinum and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Modality T | 1991 |
Dipyridamole combination chemotherapy can be used safely in treating gastric cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Doxoru | 1991 |
Continuous infusion 5-fluorouracil with bolus adriamycin and mitomycin and low-dose cisplatin (FAMP) in the treatment of metastatic gastric carcinoma: an evaluation of efficacy and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Fluorou | 1991 |
A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1991 |
Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fluorouracil; Huma | 1991 |
Mitomycin-C, adriamycin, 5-fluorouracil and leucovorin (L-FAM2) in the treatment of advanced gastric cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Female; F | 1991 |
An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispla | 1991 |
[Intraperitoneal administration of recombinant interferon-beta for prevention in peritoneal metastasis of gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gastrectomy; Huma | 1990 |
[Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supp
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; F | 1990 |
[Early phase II study of the combined use of AO-90 methionine-free amino acid solution and anticancer agents (5-FU and MMC) in patients with advanced and recurrent gastrointestinal cancer. AO-90 Study group].
Topics: Adult; Aged; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1990 |
[Requirements for the randomized trial of i.a. vs. i.v. administration to reveal the impact of hepatic arterial infusion on survival in the treatment of liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female; Floxuri | 1990 |
[Randomized controlled study on chemotherapy with 5-FD, ADM plus CDDP in advanced gastric carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administra | 1990 |
Adjuvant treatment of operable stomach cancer with polyadenylic.polyuridylic acid in addition to chemotherapeutic agents: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Th | 1990 |
A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Combined Mo | 1990 |
A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer.
Topics: Adult; Aged; Aspartic Acid; Clinical Trials as Topic; Colorectal Neoplasms; Drug Evaluation; Drug Sy | 1990 |
[High-dose leucovorin and 5-fluorouracil in advanced gastric and colorectal cancer. High-Dose Leucovorin and 5-FU Study Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1990 |
Doxorubicin and 5-fluorouracil versus doxorubicin and oral ftorafur in in the treatment of advanced gastric cancer--a phase II and III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Female; F | 1990 |
A phase II trial of sequential MTx and 5-FU alternated with 4-epidoxorubicin and cisplatin in advanced gastric cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Epi | 1990 |
[Treatment of operated late gastric carcinoma with prescription of strengthening the patient's resistance and dispelling the invading evil in combination with chemotherapy: follow-up study of 158 patients and experimental study in animals].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ehrlich Tumor; Comb | 1990 |
Emulsion and activated carbon in cancer chemotherapy.
Topics: Administration, Oral; Adult; Aged; Animals; Bleomycin; Breast Neoplasms; Carbon; Clinical Trials as | 1986 |
Chemotherapy of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1988 |
[Adjuvant chemotherapy for gastric cancer--the third study. First report: central randomization by telephone method and analysis of patients' background factors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Administ | 1989 |
[An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report)--a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with PSK for Gastric Cancer].
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Top | 1989 |
A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Mo | 1989 |
Dose escalation and split course of 4-epidoxorubicin in combination chemotherapy (FEM II) of advanced gastric carcinoma. A phase-II trail of the 'Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Evaluat | 1989 |
Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy | 1989 |
A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Costs and | 1985 |
An EORTC gastrointestinal (GI) group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Europe; F | 1989 |
[Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administ | 1989 |
[The results of a modified FAMeth chemotherapy protocol in metastatic stomach carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modali | 1989 |
Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Human | 1989 |
5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1989 |
Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three-arm randomized trial in metastatic gastric cancer. Gastrointestinal Tumor Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Doxorubicin; Fl | 1988 |
Adjuvant treatments following curative resection for gastric cancer. The Italian Gastrointestinal Tumor Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality T | 1988 |
Clinical efficacy of endoscopic injections of OK-432 in the treatment of gastric cancer.
Topics: Administration, Oral; Administration, Topical; Aged; Biological Products; Clinical Trials as Topic; | 1988 |
Phase-III clinical trial of adjuvant FAM2 (5-FU, adriamycin and mitomycin C) vs control in resectable gastric cancer: a study of the EORTC Gastrointestinal Tract Cancer Cooperative Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1988 |
Combined 5-fluorouracil and radiation therapy following resection of locally advanced gastric carcinoma: a 5-years follow-up.
Topics: Adult; Aged; Clinical Trials as Topic; Combined Modality Therapy; Female; Fluorouracil; Follow-Up St | 1988 |
Immunochemosurgery as a new approach to reasonable treatment of advanced cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Clinical Trials | 1988 |
Mount Sinai clinical experience with leucovorin and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Drug Administra | 1988 |
Progress report on studies of FAM-CF for gastric cancer and intraperitoneal administration of FUra-CF followed by cisplatin (DDP).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Doxorubicin; Dr | 1988 |
[A randomized controlled trial comparing short-term MF chemotherapy with MF and long-term carmofur chemotherapy as an adjuvant to curative resection of stomach cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dru | 1986 |
[Randomized study of lentinan on patients with advanced gastric and colorectal cancer. Tohoku Lentinan Study Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1986 |
[A randomized controlled trial of surgical adjuvant therapy with mitomycin C, 5-fluorouracil and OK-432 in patients with gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Combined Modality Therapy | 1986 |
[A randomized controlled trial of immunochemotherapy using carmofur (HCFU), mitomycin C and immunopotentiators in advanced gastric cancer following noncurative resection and nonresection].
Topics: Adjuvants, Immunologic; Adult; Aged; Clinical Trials as Topic; Drug Administration Schedule; Female; | 1986 |
Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum.
Topics: Actuarial Analysis; Adenocarcinoma; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Mid | 1986 |
[Adjuvant chemotherapy in patients with radical resection of stomach cancer: 5-year results of a prospective randomized study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Fluorou | 1986 |
Chemotherapy of advanced gastric carcinoma (stage IV): a randomized study of FAM versus 5-FU plus BCNU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D | 1987 |
Chemotherapy for stomach cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fluorouracil; Humans; Rand | 1987 |
[Controlled study of MQF-OK therapy with FT and with UFT on various advanced gastrointestinal cancers. Hirosaki Cooperative Study Group of Cancer Chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Clinical Trials as Top | 1988 |
5-Fluorouracil versus a combination of BCNU, adriamycin, 5-FU and mitomycin C in advanced gastric cancer: a prospective randomized study of the Italian Clinical Research Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D | 1988 |
[A randomized controlled trial comparing short-term MF chemotherapy with MF plus long-term HCFU chemotherapy as an adjuvant to a curative resection of stomach cancer: Mifurol Study Group for Stomach Cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as | 1988 |
Advanced gastric carcinoma chemotherapy with cisplatin, mitomycin C, BCNU, and 5-fluorouracil in combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Female; Fluorour | 1987 |
[Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer (the second report)--a randomized controlled study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedu | 1985 |
[The minimization method in a medium size clinical trial. Study of immunochemotherapy with PSK in gastric cancer].
Topics: Clinical Trials as Topic; Fluorouracil; Humans; Middle Aged; Prognosis; Proteoglycans; Random Alloca | 1988 |
An EORTC Gastrointestinal Group phase III evaluation of combinations of methyl-CCNU, 5-fluorouracil, and adriamycin in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1987 |
Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; | 1986 |
Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Doxorubicin; F | 1986 |
Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D | 1986 |
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1986 |
Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; | 1986 |
Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Tr | 1986 |
[Comparative clinical study of MF(mitomycin and 5-fluorouracil) and MF.BH-AC therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1986 |
FAM (5-fluorouracil, doxorubicin, and mitomycin) plus triazinate (FAM-T) in gastric carcinoma: a combined phase II trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1987 |
[Modulation of the anti-tumor effect of BRM under various nutritional or endocrine conditions].
Topics: Animals; Combined Modality Therapy; Endocrine Glands; Female; Fluorouracil; Humans; Lentinan; Mammar | 1986 |
Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fema | 1985 |
Cyclophosphamide plus 5-FU versus 5-FU alone in advanced gastric carcinoma.
Topics: Adenocarcinoma; Aged; Body Weight; Clinical Trials as Topic; Cyclophosphamide; Drug Administration S | 1985 |
FAM therapy for advanced gastric cancer: an ideal standard?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Fluorouracil; | 1985 |
The role of anthracyclines in the treatment of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Drug Administ | 1985 |
[Results of phase III study of lentinan].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1985 |
[A controlled study of surgical adjuvant chemoimmunotherapy with FT-207 and OK-432 for advanced stomach cancer: the fourth study].
Topics: Administration, Oral; Aged; Biological Products; Clinical Trials as Topic; Combined Modality Therapy | 1985 |
[Randomized study of long-term adjuvant chemotherapy with Futraful and mitomycin C in gastric cancer. A second study (fourth report)].
Topics: Clinical Trials as Topic; Drug Administration Schedule; Drug Synergism; Fluorouracil; Humans; Mitomy | 1985 |
[Intra-arterial infusion therapy with angiotensin II in gastric carcinoma].
Topics: Aged; Angiotensin II; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as To | 1985 |
The role of chemotherapy in the management of gastric and pancreatic carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1985 |
Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle A | 1985 |
Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer.
Topics: Adenocarcinoma; Clinical Trials as Topic; Fluorouracil; Gastrointestinal Neoplasms; Humans; Intestin | 1969 |
Adrenal function in patients treated with testosterone and fluorinated pyrimidines.
Topics: 17-Ketosteroids; Adenocarcinoma; Adrenal Cortex Hormones; Adrenal Glands; Adrenocorticotropic Hormon | 1968 |
Combination therapy with 5-fluorouracil (5-FU; NSC-19893) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) for disseminated gastrointestinal carcinoma.
Topics: Adult; Aged; Anemia, Aplastic; Blood Cell Count; Carcinoma; Clinical Trials as Topic; Colonic Neopla | 1972 |
Cancer of the gastrointestinal tract. Radiation therapy.
Topics: Adenocarcinoma; Clinical Trials as Topic; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurr | 1974 |
Comparison of treatment of metastatic gastrointestinal cancer with 5-fluorouracil (5-FU) to a combination of 5-FU with cytosine arabinoside.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Cytarabine; Diabetic Ketoacidosis; Diar | 1972 |
Treatment of unresectable adenocarcinomas of the stomach with a combination of 5-fluorouracil and radiation.
Topics: Adenocarcinoma; Adult; Aged; Cobalt Isotopes; Female; Fluorouracil; Humans; Injections, Intravenous; | 1968 |
2276 other studies available for fluorouracil and Cancer of Stomach
| Article | Year |
|---|---|
Synthesis and molecular docking study of novel coumarin derivatives containing 4,5-dihydropyrazole moiety as potential antitumor agents.
Topics: Antineoplastic Agents; Binding Sites; Catalytic Domain; Cell Line, Tumor; Computer Simulation; Couma | 2010 |
Synthesis, biological evaluation, and molecular docking studies of 2-chloropyridine derivatives possessing 1,3,4-oxadiazole moiety as potential antitumor agents.
Topics: Antineoplastic Agents; Binding Sites; Catalytic Domain; Cell Line, Tumor; Computer Simulation; Enzym | 2010 |
Design and synthesis of new triazoles linked to xanthotoxin for potent and highly selective anti-gastric cancer agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Proliferation; Drug Design; G2 Phase Cell Cycle Ch | 2017 |
Novel 3-(2,6,9-trisubstituted-9H-purine)-8-chalcone derivatives as potent anti-gastric cancer agents: Design, synthesis and structural optimization.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chalcones; Do | 2019 |
Synthesis and anti-gastric cancer activity evaluation of novel triazole nucleobase analogues containing steroidal/coumarin/quinoline moieties.
Topics: Antineoplastic Agents; Cell Proliferation; Coumarins; Dose-Response Relationship, Drug; Drug Screeni | 2019 |
Novel tertiary sulfonamide derivatives containing benzimidazole moiety as potent anti-gastric cancer agents: Design, synthesis and SAR studies.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line, Tumor; Drug Design; Humans; Stomach Neo | 2019 |
Discovery of 1,2,4-triazine-based derivatives as novel neddylation inhibitors and anticancer activity studies against gastric cancer MGC-803 cells.
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Cell Line, Tumor; Cell Proliferation; G2 Phase Cell | 2020 |
Discovery of tertiary amide derivatives incorporating benzothiazole moiety as anti-gastric cancer agents in vitro via inhibiting tubulin polymerization and activating the Hippo signaling pathway.
Topics: Adaptor Proteins, Signal Transducing; Amides; Antineoplastic Agents; Apoptosis; Benzothiazoles; Cell | 2020 |
Discovery of new [1,2,4] Triazolo[1,5-a]Pyrimidine derivatives that Kill gastric cancer cells via the mitochondria pathway.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Drug Design; Huma | 2020 |
A low toxic CRM1 degrader: Synthesis and anti-proliferation on MGC803 and HGC27.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthe | 2020 |
(S)-Erypoegin K, an isoflavone isolated from Erythrina poeppigiana, is a novel inhibitor of topoisomerase IIα: Induction of G2 phase arrest in human gastric cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type II; D | 2021 |
Discovery of 1,2,4-triazine dithiocarbamate derivatives as NEDDylation agonists to inhibit gastric cancers.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Sc | 2021 |
Discovery of a cinnamyl piperidine derivative as new neddylation inhibitor for gastric cancer treatment.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cinnamates; Cullin Proteins; Dose-Response Rel | 2021 |
Isolation, synthesis and bioactivity evaluation of isoquinoline alkaloids from Corydalis hendersonii Hemsl. against gastric cancer in vitro and in vivo.
Topics: Alkaloids; Animals; Apoptosis; Corydalis; Humans; Isoquinolines; Mice; Mice, Nude; Phosphatidylinosi | 2022 |
Design, synthesis and antitumour activity of novel 5(6)-amino-benzimidazolequinones containing a fused morpholine.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Mice; Mice, Nude; Morpholines; Reactive Ox | 2022 |
Rational Design and Optimization of m
Topics: Adenosine; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antineoplastic Agents; Glioblastoma; Human | 2022 |
A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Confidence | 2021 |
Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer.
Topics: CD8-Positive T-Lymphocytes; Chemotherapy, Adjuvant; Cytidine Deaminase; Fluorouracil; Humans; Minor | 2021 |
Results of the observational prospective RealFLOT study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2021 |
[A Case of Advanced Gastric Cancer Successfully Treated with mFOLFOX6 Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Male; Neopla | 2021 |
Intelligent Algorithm-Based CT Imaging for Evaluation of Efficacy of Docetaxel Combined with Fluorouracil on Patients with Gastric Cancer.
Topics: Algorithms; Docetaxel; Fluorouracil; Humans; Stomach Neoplasms; Tomography, X-Ray Computed | 2021 |
Efficacy and safety of traditional Chinese medicine injections combined with FOLFOX4 regimen for gastric cancer: A protocol for systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; China; Combined Modality Therapy; Fem | 2021 |
Bioactive compounds from Lactarius deterrimus interfere with the invasive potential of gastric cancer cells.
Topics: Agaricales; Antineoplastic Agents; Autophagy; Basidiomycota; Cell Line, Tumor; Cell Movement; Cell P | 2021 |
CAF promotes chemoresistance through NRP2 in gastric cancer.
Topics: Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fibr | 2022 |
Cisatracurium besilate enhances the TRAIL-induced apoptosis of gastric cancer cells via p53 signaling.
Topics: Apoptosis; Atracurium; Cell Line, Tumor; Cell Proliferation; Fluorouracil; Humans; Signal Transducti | 2021 |
Exosomal microRNA-107 reverses chemotherapeutic drug resistance of gastric cancer cells through HMGA2/mTOR/P-gp pathway.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Ci | 2021 |
Beyond Front-Line Therapy for Unresectable Gastroesophageal Adenocarcinoma: Are There Differences in Subsequent Therapy Sequencing?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2022 |
Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcin | 2022 |
[Hyperammonemic encephalopathy after treatment with modified FOLFOX6 regimen for recurrent gastric cancer:a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Female; Fluorouracil; Humans; Hypera | 2022 |
Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Esophageal Neoplasms | 2022 |
Development and validation of a prognostic and predictive 32-gene signature for gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Fluorouracil; Gastrectomy; Gene E | 2022 |
Schisandrin B suppresses gastric cancer cell growth and enhances the efficacy of chemotherapy drug 5-FU in vitro and in vivo.
Topics: Apoptosis; Cell Line, Tumor; Cyclooctanes; Fluorouracil; Humans; Lignans; Polycyclic Compounds; Stom | 2022 |
Experimental Research on the Antitumor Effect of Human Gastric Cancer Cells Transplanted in Nude Mice Based on Deep Learning Combined with Spleen-Invigorating Chinese Medicine.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Computational Biology; Dee | 2022 |
Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2022 |
Docetaxel and 5-FU enhanced the inhibitory effects of apatinib and ramucirumab on growth and migration of gastric cancer.
Topics: Angiogenesis Inhibitors; Animals; Animals, Genetically Modified; Antibodies, Monoclonal, Humanized; | 2022 |
The regulation of hsacirc_004413 promotes proliferation and drug resistance of gastric cancer cells by acting as a competing endogenous RNA for miR-145-5p.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fluorouracil; Humans; MicroRNAs; RN | 2022 |
First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophagogastric Jun | 2022 |
Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Fluorouracil; Humans; STAT3 Transcription | 2022 |
Ursolic acid silences CYP19A1/aromatase to suppress gastric cancer growth.
Topics: Animals; Antineoplastic Agents; Aromatase; Ethanol; Fluorouracil; Hedyotis; Humans; Molecular Dockin | 2022 |
Curcumin inhibits the cancer‑associated fibroblast‑derived chemoresistance of gastric cancer through the suppression of the JAK/STAT3 signaling pathway.
Topics: Biological Products; Cancer-Associated Fibroblasts; Chemokines; Curcumin; Drug Resistance, Neoplasm; | 2022 |
Comparative analysis of cancer gene mutations using targeted sequencing in matched primary and recurrent gastric cancers after chemotherapy.
Topics: Fluorouracil; Genes, Neoplasm; Humans; Mutation; Platinum; Stomach Neoplasms | 2022 |
Long noncoding RNA OVAAL enhances nucleotide synthesis through pyruvate carboxylase to promote 5-fluorouracil resistance in gastric cancer.
Topics: Aspartic Acid; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; Nucleotides; Oxalo | 2022 |
Gastric cancer with microsatellite instability displays increased thymidylate synthase expression.
Topics: B7-H1 Antigen; Fluorouracil; Humans; Microsatellite Instability; Microsatellite Repeats; Prognosis; | 2022 |
Plasma thioredoxin reductase: a potential diagnostic biomarker for gastric cancer.
Topics: Biomarkers, Tumor; Fluorouracil; Humans; Platinum; Stomach Neoplasms; Thioredoxin Reductase 1 | 2022 |
Chitosan-Gelatin-EGCG Nanoparticle-Meditated LncRNA TMEM44-AS1 Silencing to Activate the P53 Signaling Pathway for the Synergistic Reversal of 5-FU Resistance in Gastric Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Catechin; Cell Line, Tumor; Chitosa | 2022 |
Albumin Paclitaxel Compared with 5-Penfluorouracil, Lobaplatin, and Albumin Paclitaxel Combined with 5-Penfluorouracil in the Treatment of Human Gastric Cancer Cell AGS Line Autophagy and Apoptosis.
Topics: Albumins; Apoptosis; Autophagy; bcl-2-Associated X Protein; Cell Line, Tumor; Cyclobutanes; Fluorour | 2022 |
Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasm | 2023 |
PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clin | 2022 |
PAK6 promotes homologous-recombination to enhance chemoresistance to oxaliplatin through ATR/CHK1 signaling in gastric cancer.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; H | 2022 |
Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer.
Topics: Chemotherapy, Adjuvant; Fluorouracil; Humans; Immunotherapy; Prognosis; Stomach Neoplasms; Tumor Mic | 2022 |
Intratumoral PD-1
Topics: CD8-Positive T-Lymphocytes; CTLA-4 Antigen; Fluorouracil; Hepatitis A Virus Cellular Receptor 2; Hum | 2022 |
miR-33a-5p Targets RAP2A to Mediate the Sensitivity of Gastric Cancer Cells to 5-FU.
Topics: Cell Line, Tumor; Cell Proliferation; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; | 2022 |
Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies | 2022 |
[Evaluation of the Usefulness of Pharmaceutical Outpatient Clinic for Gastric Cancer Patients Receiving Capecitabine plus Oxaliplatin as Postoperative Adjuvant Chemotherapy].
Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemothera | 2022 |
Evaluation of TS and ENOSF1 Variants as a Biomarker in Response to Neoadjuvant Chemotherapy based on 5FU in Gastric Cancer Patients.
Topics: 5' Untranslated Regions; Biomarkers; Fluorouracil; Formaldehyde; Humans; Hydro-Lyases; Neoadjuvant T | 2022 |
A combined analysis of bulk and single-cell sequencing data reveals that depleted extracellular matrix and enhanced immune processes co-contribute to fluorouracil beneficial responses in gastric cancer.
Topics: Drug Resistance, Neoplasm; Extracellular Matrix; Fluorouracil; Galectin 1; Humans; Immunity; Stomach | 2022 |
Restoration of miR-648 overcomes 5-FU-resistance through targeting ET-1 in gastric cancer cells in-vitro.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Endothelin-1; Fluorouracil; Gene Ex | 2022 |
ATXN2-Mediated PI3K/AKT Activation Confers Gastric Cancer Chemoresistance and Attenuates CD8
Topics: Ataxin-2; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Drug Resistance, Neoplasm; Fl | 2022 |
Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri | 2023 |
SPAG5 Activates PI3K/AKT Pathway and Promotes the Tumor Progression and Chemo-Resistance in Gastric Cancer.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Eukaryotic Initiation Factor-4E; Fluorouracil; Gene E | 2022 |
No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Delayed-Action Preparations; | 2022 |
Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Eso | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer.
Topics: Animals; Calponins; Cancer-Associated Fibroblasts; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluo | 2023 |
Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer.
Topics: Animals; Calponins; Cancer-Associated Fibroblasts; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluo | 2023 |
Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer.
Topics: Animals; Calponins; Cancer-Associated Fibroblasts; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluo | 2023 |
Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer.
Topics: Animals; Calponins; Cancer-Associated Fibroblasts; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluo | 2023 |
Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer.
Topics: Animals; Calponins; Cancer-Associated Fibroblasts; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluo | 2023 |
Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer.
Topics: Animals; Calponins; Cancer-Associated Fibroblasts; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluo | 2023 |
Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer.
Topics: Animals; Calponins; Cancer-Associated Fibroblasts; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluo | 2023 |
Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer.
Topics: Animals; Calponins; Cancer-Associated Fibroblasts; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluo | 2023 |
Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer.
Topics: Animals; Calponins; Cancer-Associated Fibroblasts; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluo | 2023 |
Gene Regulatory Network-Classifier: Gene Regulatory Network-Based Classifier and Its Applications to Gastric Cancer Drug (5-Fluorouracil) Marker Identification.
Topics: Algorithms; Antineoplastic Agents; Computational Biology; Fluorouracil; Gene Regulatory Networks; Hu | 2023 |
Gene Regulatory Network-Classifier: Gene Regulatory Network-Based Classifier and Its Applications to Gastric Cancer Drug (5-Fluorouracil) Marker Identification.
Topics: Algorithms; Antineoplastic Agents; Computational Biology; Fluorouracil; Gene Regulatory Networks; Hu | 2023 |
Gene Regulatory Network-Classifier: Gene Regulatory Network-Based Classifier and Its Applications to Gastric Cancer Drug (5-Fluorouracil) Marker Identification.
Topics: Algorithms; Antineoplastic Agents; Computational Biology; Fluorouracil; Gene Regulatory Networks; Hu | 2023 |
Gene Regulatory Network-Classifier: Gene Regulatory Network-Based Classifier and Its Applications to Gastric Cancer Drug (5-Fluorouracil) Marker Identification.
Topics: Algorithms; Antineoplastic Agents; Computational Biology; Fluorouracil; Gene Regulatory Networks; Hu | 2023 |
HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer.
Topics: Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resis | 2023 |
HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer.
Topics: Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resis | 2023 |
HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer.
Topics: Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resis | 2023 |
HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer.
Topics: Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resis | 2023 |
Synergistic Effects of the Combinational Use of Escitalopram Oxalate and 5-Fluorouracil on the Inhibition of Gastric Cancer SNU-1 Cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Escitalopram; Fluorouracil; Humans; Mice; | 2022 |
A Pilot Study of Peritumor Administration of 5-FU for Preventing Bleeding in Advanced Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hemorrhage; Humans; Pilot Projects; St | 2022 |
Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancer.
Topics: Animals; Carbon-Sulfur Lyases; Fluorouracil; Humans; Methionine; Mice; Recombinant Proteins; Stomach | 2023 |
Reply to "Is it possible that advanced-stage gastric cancer patients can be cured by surgery alone?"
Topics: Fluorouracil; Humans; Neoplasm Staging; Stomach Neoplasms | 2023 |
Is it possible that advanced-stage gastric cancer patients can be cured by surgery alone?
Topics: Fluorouracil; Humans; Neoplasm Staging; Stomach Neoplasms | 2023 |
Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Eso | 2023 |
Tumor Regression Grade and Overall Survival following Gastrectomy with Preoperative Therapy for Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gastrectomy; Humans; Neoadjuvant Thera | 2023 |
Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Fluo | 2023 |
Comprehensive analysis of cuproptosis-related immune biomarker signature to enhance prognostic accuracy in gastric cancer.
Topics: Apoptosis; Biomarkers; Copper; CTLA-4 Antigen; Fluorouracil; Humans; Prognosis; Stomach Neoplasms; T | 2023 |
Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; DNA Mismatch Repair; Fluorouracil; Humans; Neoplasm Stagi | 2023 |
Impact of HER2 on prognosis and benefit from adjuvant chemotherapy in stage II/III gastric cancer patients: a multicenter observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; Fluorouracil | 2023 |
Epigenetically regulated gene expression profiles decipher four molecular subtypes with prognostic and therapeutic implications in gastric cancer.
Topics: Cisplatin; DNA Methylation; Fluorouracil; Humans; Paclitaxel; Prognosis; Stomach Neoplasms; Transcri | 2023 |
ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Deaminase; Cisplatin; DNA-Binding Proteins; Drug Res | 2023 |
MT1M regulates gastric cancer progression and stemness by modulating the Hedgehog pathway protein GLI1.
Topics: Cell Line, Tumor; Cell Proliferation; Fluorouracil; Gene Expression Regulation, Neoplastic; Hedgehog | 2023 |
Baicalin enhances the efficacy of 5-Fluorouracil in gastric cancer by promoting ROS-mediated ferroptosis.
Topics: Cell Line, Tumor; Ferroptosis; Fluorouracil; Humans; Reactive Oxygen Species; Stomach Neoplasms | 2023 |
Dynamic Profiling of the Immune Tumor Microenvironment in Locally Advanced Gastric Cancer Treated with Perioperative Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Fluorouracil; Humans; Leucovorin; Stomach | 2023 |
Anthracycline chemicals with anthracyclinone structure exert antitumor effects by inhibiting angiogenesis and lymphangiogenesis in a xenografted gastric tumor model.
Topics: Anthracyclines; Cell Line, Tumor; Fluorouracil; Humans; Lymphangiogenesis; Stomach Neoplasms | 2023 |
β-Glucan-Mediated Oral Codelivery of 5FU and Bcl2 siRNA Attenuates Stomach Cancer.
Topics: Animals; beta-Glucans; Fluorouracil; Mice; Mice, Inbred C57BL; RNA, Small Interfering; Stomach Neopl | 2023 |
Second-line Chemotherapy in Advanced Gastric Cancer: Taxanes versus 5-FU-Based Treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil | 2023 |
The Antitumor Potential of λ-Carrageenan Oligosaccharides on Gastric Carcinoma by Immunomodulation.
Topics: Animals; Carcinoma; Carrageenan; Fluorouracil; Immunity; Immunomodulation; Mice; Stomach Neoplasms; | 2023 |
Identification and Validation of a Metabolism-Related Prognostic Signature Associated with M2 Macrophage Infiltration in Gastric Cancer.
Topics: Cisplatin; Fluorouracil; Humans; Macrophages; Prognosis; Stomach Neoplasms; Tumor Microenvironment | 2023 |
Clinical implications and chemo-sensitivity of adjuvant chemotherapy in patients with poorly cohesive cells-gastric cancer.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Humans; Oxaliplatin | 2023 |
The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane-derived, and platinum-based drugs.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Cel | 2023 |
Association between Pre-Treatment Biological Indicators and Compliance to Neoadjuvant/Perioperative Chemotherapy in Operable Gastric Cancer.
Topics: Environmental Biomarkers; Fluorouracil; Humans; Neoadjuvant Therapy; Oxaliplatin; Sarcopenia; Stomac | 2023 |
PICH Activates Cyclin A1 Transcription to Drive S-Phase Progression and Chemoresistance in Gastric Cancer.
Topics: Adenosine Triphosphatases; Cyclin A1; DNA Helicases; Drug Resistance, Neoplasm; Fluorouracil; Humans | 2023 |
Topics: Animals; Apoptosis; Cell Proliferation; Fluorouracil; Humans; MicroRNAs; Stomach Neoplasms; Zebrafis | 2023 |
Clinical effectiveness of fluorouracil and cisplatin intraperitoneal perfusion combined with intravenous chemotherapy for peritoneal metastasis in gastric cancer.
Topics: Case-Control Studies; Cisplatin; Fluorouracil; Humans; Perfusion; Peritoneal Neoplasms; Quality of L | 2023 |
Comparison of adjuvant capecitabine plus oxaliplatin (CAPOX) versus S-1 after gastrectomy: a population-based cohort study using a nationwide claims database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies | 2023 |
Chemotherapeutic Drugs Endow Gastric Cancer Mesenchymal Stem Cells with Stronger Tumor-Promoting Ability.
Topics: Cell Line, Tumor; Cell Proliferation; Culture Media, Conditioned; Fluorouracil; Humans; Mesenchymal | 2024 |
Customizing Therapy for Esophageal Cancer: CROSS vs. FLOT.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri | 2024 |
Stem cell landscape aids in tumor microenvironment identification and selection of therapeutic agents in gastric cancer.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Neoplastic Stem Cells; Stomach Neoplasms; Tumor Mic | 2024 |
Oxidative stress and autophagy-mediated immune patterns and tumor microenvironment infiltration characterization in gastric cancer.
Topics: Afatinib; Autophagy; Fluorouracil; Humans; Prognosis; Stomach Neoplasms; Tumor Microenvironment | 2023 |
[Evaluation of the Leftover Capecitabine Tablets in Adjuvant CAPOX Chemotherapy for Gastric Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Fluorouracil; | 2023 |
Glycoengineered nanoparticles enhance the delivery of 5-fluoroucil and paclitaxel to gastric cancer cells of high metastatic potential.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Drug Delivery System | 2019 |
RAB13 as a novel prognosis marker promotes proliferation and chemotherapeutic resistance in gastric cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Computationa | 2019 |
Prognostic value of mismatch repair deficiency in patients with advanced gastric cancer, treated by surgery and adjuvant 5-fluorouracil and leucovorin chemoradiotherapy.
Topics: Adult; Aged; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Mismatch Repair; | 2020 |
Acute reversible left ventricular systolic dysfunction associated with 5-fluorouracil therapy: a rare and increasingly recognised cardiotoxicity of a commonly used drug.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cardiotoxicity; Conservative Treatment; Diagnosis, D | 2019 |
Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Cell Proliferation; Down-Regulation; Dr | 2019 |
CLIC4 abrogation promotes epithelial-mesenchymal transition in gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Prolifer | 2020 |
Metachronous Signet Ring Cell Bladder Metastasis as First Sing of Cancer Recurrence.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Chemotherapy, Adj | 2019 |
Appearance of cutaneous melanoma and subcutaneous metastases in metastatic gastric carcinoma undergoing chemotherapy with oral 5-fluorouracil prodrug.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2019 |
Methylation of drug resistance-related genes in chemotherapy-sensitive Epstein-Barr virus-associated gastric cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line; Cisplatin | 2020 |
Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Analgesics, Opioid; Antiemetics; Antineoplastic Combin | 2020 |
Role of Metastasis-Related Genes in Cisplatin Chemoresistance in Gastric Cancer.
Topics: Aged; Aged, 80 and over; Apoptosis; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; | 2019 |
Perioperative chemotherapy for gastric cancer in FLOT4.
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Ox | 2020 |
Perioperative chemotherapy for gastric cancer in FLOT4.
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Ox | 2020 |
iASPP-Mediated ROS Inhibition Drives 5-Fu Resistance Dependent on Nrf2 Antioxidative Signaling Pathway in Gastric Adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Drug Re | 2020 |
ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer.
Topics: Aldehyde Oxidoreductases; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell | 2020 |
shRNA-mediated inhibition of PhosphoGlycerate Kinase 1 (PGK1) enhances cytotoxicity of intraperitoneal chemotherapy in peritoneal metastasis of gastric origin.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorou | 2020 |
Alteration and prognostic values of collagen gene expression in patients with gastric cancer under different treatments.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Collagen; Female; Flu | 2020 |
Silence of FAM83H-AS1 promotes chemosensitivity of gastric cancer through Wnt/β-catenin signaling pathway.
Topics: Aged; Antineoplastic Agents; beta Catenin; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; F | 2020 |
Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri | 2021 |
Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Fluorouracil; Huma | 2021 |
Plasma microRNA profiles: identification of miR-1229-3p as a novel chemoresistant and prognostic biomarker in gastric cancer.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Survival; Disease-Free Survival; D | 2020 |
Trim14 promotes autophagy and chemotherapy resistance of gastric cancer cells by regulating AMPK/mTOR pathway.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Benzimidazoles; Biphenyl Compounds; Cell Line, Tu | 2020 |
Gene regulatory network analysis with drug sensitivity reveals synergistic effects of combinatory chemotherapy in gastric cancer.
Topics: Aged; Cell Movement; Cisplatin; Databases, Genetic; Docetaxel; Drug Synergism; Female; Fluorouracil; | 2020 |
Drosha-independent miR-6778-5p strengthens gastric cancer stem cell stemness via regulation of cytosolic one-carbon folate metabolism.
Topics: 14-3-3 Proteins; Animals; Carbon; Cell Line, Tumor; Cytosol; Female; Fluorouracil; Folic Acid; Gene | 2020 |
Clinical Significance of Jagged-1 Activated by APEX1 as a Chemoresistance Factor in Advanced Gastric Cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA-(Apurinic or Apyrimidinic S | 2020 |
Overexpression of secretory clusterin (sCLU) induces chemotherapy resistance in human gastric cancer cells by targeting miR-195-5p.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Cell Survival; Clusterin; Female; Fluorouracil; Humans; Ma | 2020 |
Adjuvant chemotherapy for patients with gastric neuroendocrine carcinomas or mixed adenoneuroendocrine carcinomas.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ne | 2020 |
Survival of esophageal and gastric cancer patients with adjuvant and palliative chemotherapy-a retrospective analysis of a register-based patient cohort.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, | 2020 |
[Clinical Efficacy of mFOLFOX6 for Advanced Gastric Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Japan; L | 2020 |
Reversal Effect of Dihydromyricetin on Multiple Drug Resistance in SGC7901/5-FU Cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Drug Resistance, Multiple; Drug Resi | 2020 |
Inhibition of β-glucosidase overcomes gastric cancer chemoresistance through inducing lysosomal dysfunction.
Topics: beta-Glucosidase; Drug Resistance, Neoplasm; Fluorouracil; Humans; Lysosomes; Stomach Neoplasms | 2021 |
Poor Clinical Outcomes and Immunoevasive Contexture in Intratumoral IL-10-Producing Macrophages Enriched Gastric Cancer Patients.
Topics: Fluorouracil; Humans; Interleukin-10; Macrophages; Prognosis; Stomach Neoplasms; Tumor Microenvironm | 2022 |
FLOT Neoadjuvant Chemotherapy Followed by Laparoscopic D2 Gastrectomy in the Treatment of Locally Resectable Advanced Gastric Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 2020 |
Jianpi-yangwei decoction inhibits DNA damage repair in the drug resistance of gastric cancer by reducing FEN1 expression.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; DNA Repair; Drug Resistance, Neoplasm; Drugs, Chi | 2020 |
High levels of tumor-infiltrating lymphocytes showed better clinical outcomes in FOLFOX-treated gastric cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Fluorouracil; Huma | 2020 |
Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Novel Therapeutic Application of Self-Assembly Peptides Targeting the Mitochondria in
Topics: Animals; Catalase; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dipeptides; Drug Synergism; | 2020 |
Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Sectional Stu | 2020 |
Construction of Aptamer-siRNA Chimera/PEI/5-FU/Carbon Nanotube/Collagen Membranes for the Treatment of Peritoneal Dissemination of Drug-Resistant Gastric Cancer.
Topics: Animals; Cell Line, Tumor; Collagen; Fluorouracil; Nanotubes, Carbon; Pharmaceutical Preparations; P | 2020 |
Correlation between microRNA-766 expression in patients with advanced gastric cancer and the efficacy of platinum-containing chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Doce | 2020 |
miR-149 contributes to resistance of 5-FU in gastric cancer via targeting TREM2 and regulating β-catenin pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Line, Tumor; Drug Resistance, Neoplasm | 2020 |
Efficacy of Metformin and Chemotherapeutic Agents on the Inhibition of Colony Formation and Shh/Gli1 Pathway: Metformin/Docetaxel Versus Metformin/5-Fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Synergism; Fluorou | 2021 |
A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Fluo | 2020 |
Comparison of Three Different Data Sources of Adverse Drug Reactions Using Adverse Drug Reaction Data of Fluorouracil for Gastric Cancer as an Example.
Topics: Adverse Drug Reaction Reporting Systems; Antimetabolites, Antineoplastic; Databases, Factual; Drug-R | 2020 |
Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses.
Topics: Aged, 80 and over; Ammonia; Antimetabolites, Antineoplastic; beta-Alanine; Drug Administration Sched | 2020 |
Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell.
Topics: Aged; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; | 2020 |
Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemora | 2021 |
A qualitative classification signature for post-surgery 5-fluorouracil-based adjuvant chemoradiotherapy in gastric cancer.
Topics: Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Disease-Free Survival; Fluorouracil; Humans; Pr | 2021 |
DJ-1 is involved in the multidrug resistance of SGC7901 gastric cancer cells through PTEN/PI3K/Akt/Nrf2 pathway.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Chromones; Cisplatin; Dox | 2020 |
Loganetin and 5-fluorouracil synergistically inhibit the carcinogenesis of gastric cancer cells via down-regulation of the Wnt/β-catenin pathway.
Topics: Animals; Antineoplastic Agents, Phytogenic; beta Catenin; Biomarkers; Cell Line, Tumor; Cell Surviva | 2020 |
Jianpi Yangwei decoction promotes apoptosis and suppresses proliferation of 5-fluorouracil resistant gastric cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Models, Ani | 2020 |
Combined chemotherapy of platinum and fluorouracil promotes T cell-mediated antitumor immunity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T- | 2021 |
GALNT10 promotes the proliferation and metastatic ability of gastric cancer and reduces 5-fluorouracil sensitivity by activating HOXD13.
Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Cells, Cultured; Female; Fluorouracil; Homeodom | 2020 |
M2 Macrophages Mediate the Resistance of Gastric Adenocarcinoma Cells to 5-Fluorouracil through the Expression of Integrin
Topics: Actin Depolymerizing Factors; Cell Line, Tumor; Cell Movement; Cell Polarity; Drug Resistance, Neopl | 2020 |
Intratumoral CD103
Topics: CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Fluorouracil; Humans; Prognosis; Stomach Neo | 2020 |
SNAIL regulates gastric carcinogenesis through CCN3 and NEFL.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neo | 2021 |
A Japanese Patient with Gastric Cancer and Dihydropyrimidine Dehydrogenase Deficiency Presenting with DPYD Variants.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Contraindications, Drug; Dihydropyrimidine Dehydrog | 2020 |
LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM.
Topics: Alternative Splicing; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; | 2021 |
Translational control of Bcl-2 promotes apoptosis of gastric carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Fluorouracil; Gen | 2021 |
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases | 2021 |
Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri | 2021 |
NOTCH3, a crucial target of miR-491-5p/miR-875-5p, promotes gastric carcinogenesis by upregulating PHLDB2 expression and activating Akt pathway.
Topics: Apoptosis; Carcinogenesis; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Ci | 2021 |
5-Fluorouracil enhances the chemosensitivity of gastric cancer to TRAIL via inhibition of the MAPK pathway.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Cell Proliferation; F | 2021 |
JAK2/STAT3 inhibitor reduced 5-FU resistance and autophagy through ATF6-mediated ER stress.
Topics: Activating Transcription Factor 6; Apoptosis; Autophagy; Cell Line, Tumor; Endoplasmic Reticulum Str | 2022 |
Early myelostimulation in patients with locally advanced gastric cancer after fluorouracil plus platinum-based neoadjuvant chemotherapy is related to poor prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Cisplati | 2021 |
Impact of microsatellite status on negative lymph node count and prognostic relevance after curative gastrectomy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2021 |
Yes associated protein 1 promotes resistance to 5-fluorouracil in gastric cancer by regulating GLUT3-dependent glycometabolism reprogramming of tumor-associated macrophages.
Topics: Adaptor Proteins, Signal Transducing; Carcinogenesis; Cell Line, Tumor; Drug Resistance, Neoplasm; F | 2021 |
Predictors and significance of histologic response to neoadjuvant therapy for gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
CROSS or FLOT in Distal Esophageal and Gastroesophageal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Fluo | 2021 |
MDM4 as a Prognostic Factor for Patients With Gastric Cancer With Low Expression of p53.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cell Line, Tumor; Cisplat | 2021 |
Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as a Neoadjuvant Chemotherapy for Non-metastatic Esophageal Cancer (nMEC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fl | 2021 |
Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Mass Index; Combined Modality | 2021 |
Staged laparoscopic management of locally advanced gastric cancer with outlet obstruction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Female; Fluoroura | 2021 |
Drug-exposed cancer-associated fibroblasts facilitate gastric cancer cell progression following chemotherapy.
Topics: Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Movement; Fluorouracil; Gene Expression; Human | 2021 |
SPARC enhances 5-FU chemosensitivity in gastric cancer by modulating epithelial-mesenchymal transition and apoptosis.
Topics: Actins; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Drug Resistance, Neo | 2021 |
Predictive Significance of Ki-67 and Platelet Lymphocyte Ratio in Patients with Gastric Cancer Receiving Neoadjuvant FLOT Chemotherapy.
Topics: Docetaxel; Fluorouracil; Humans; Ki-67 Antigen; Leucovorin; Lymphocytes; Neoadjuvant Therapy; Oxalip | 2021 |
Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil.
Topics: Apoptosis; Catechin; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Glycolysis; Humans; | 2021 |
Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chemoradiotherapy; Cohort Studies; Disease-Free Surviva | 2021 |
Retinoblastoma tumor suppressor gene 1 enhances 5-Fluorouracil chemosensitivity through SDF-1/CXCR4 axis by regulating autophagy in gastric cancer.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Chemokine CXCL12; Drug Resistance, Neoplasm; Fluorouracil; H | 2021 |
Age as a modifier of the effects of chemoradiotherapy with infusional 5-fluorouracil after D2 dissection in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; | 2021 |
Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophagogastric Junction; Female; F | 2022 |
Controlling Nutritional Status (CONUT) Score Is a Prognostic Factor for Patients with Gastric Cancer Treated by Perioperative FLOT.
Topics: Docetaxel; Fluorouracil; Humans; Leucovorin; Nutritional Status; Oxaliplatin; Prognosis; Retrospecti | 2022 |
Enhanced Vasculogenic Capacity Induced by 5-Fluorouracil Chemoresistance in a Gastric Cancer Cell Line.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Endothelial Cells; Fl | 2021 |
The "Dextran-Magnetic Layered Double Hydroxide-Fluorouracil" Drug Delivery System Exerts Its Anti-tumor Effect by Inducing Lysosomal Membrane Permeability in the Process of Cell Death.
Topics: Adenocarcinoma; Antineoplastic Agents; Azure Stains; Blotting, Western; Cell Death; Cell Line, Tumor | 2021 |
Distinctive Prognostic Value and Cellular Functions of Osteopontin Splice Variants in Human Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Alternative Splicing; Amino Acid Sequence; Cell Adhesion; Cell Line, | 2021 |
Synergistic effects of Rapamycin and Fluorouracil to treat a gastric tumor in a PTEN conditional deletion mouse model.
Topics: Animals; Cell Line, Tumor; Fluorouracil; Humans; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogen | 2022 |
Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; | 2021 |
High L-Type Amino Acid Transporter 1 Levels Are Associated with Chemotherapeutic Resistance in Gastric Cancer Patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2021 |
Union is strength: Textbook outcome with perioperative chemotherapy compliance decreases the risk of death in advanced gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2022 |
Development and Validation of a Computed Tomography-Based Radiomics Signature to Predict Response to Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2021 |
Anti-metastatic Efficacy of Traditional Chinese Medicine (TCM) Ginsenoside Conjugated to a VEFGR-3 Antibody on Human Gastric Cancer in an Orthotopic Mouse Model.
Topics: Animals; Antibodies; Antineoplastic Agents; Cell Line, Tumor; Drugs, Chinese Herbal; Female; Fluorou | 2017 |
Induction of apoptotic DNA fragmentation mediated by mitochondrial pathway with caspase-3-dependent BID cleavage in human gastric cancer cells by a new nitroxyl spin-labeled derivative of podophyllotoxin.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspase 9; Cell Line, Tumor; Cytochromes c; | 2017 |
Calycosin Enhances Some Chemotherapeutic Drugs Inhibition of Akt Signaling Pathway in Gastric Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle | 2017 |
Itraconazole induces apoptosis and cell cycle arrest via inhibiting Hedgehog signaling in gastric cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell S | 2017 |
Salvage chemotherapy for advanced gastric cancer: more than a false hope?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Salvage Therapy; St | 2017 |
Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer.
Topics: Aftercare; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Chi | 2017 |
Gastrin induces multidrug resistance via the degradation of p27Kip1 in the gastric carcinoma cell line SGC7901.
Topics: Aged; Camptothecin; Carcinoma; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resista | 2017 |
Troxerutin (TXN) potentiated 5-Fluorouracil (5-Fu) treatment of human gastric cancer through suppressing STAT3/NF-κB and Bcl-2 signaling pathways.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2017 |
Gankyrin promotes the proliferation of gastric cancer and is associated with chemosensitivity.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Fluorouracil; | 2017 |
Prognostic and Predictive Value of p21-activated Kinase 6 Associated Support Vector Machine Classifier in Gastric Cancer Treated by 5-fluorouracil/Oxaliplatin Chemotherapy.
Topics: Cyclin-Dependent Kinase Inhibitor p21; Cyclooxygenase 2; DNA-Binding Proteins; Drug Resistance, Neop | 2017 |
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Organopl | 2017 |
miR‑206 inhibits cancer initiating cells by targeting EHF in gastric cancer.
Topics: 3' Untranslated Regions; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Fluorouracil; Gene E | 2017 |
Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells.
Topics: Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Fluoro | 2017 |
Feasibility and safety of hyperthermic intraperitoneal chemotherapy using 5-fluorouracil combined with cisplatin and mitomycin C in patients undergoing gastrectomy for advanced gastric cancer.
Topics: Adult; Aged; Cisplatin; Combined Modality Therapy; Feasibility Studies; Female; Fluorouracil; Gastre | 2017 |
Regenerating Family Member 4 (Reg4) Enhances 5-Fluorouracil Resistance of Gastric Cancer Through Activating MAPK/Erk/Bim Signaling Pathway.
Topics: Apoptosis; Bcl-2-Like Protein 11; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal- | 2017 |
[Good remission under HER2 blockade in an advanced carcinoma of the oesophagogastric junction with only focal HER2 overexpression].
Topics: Adenocarcinoma; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antine | 2017 |
The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Drug Resistance, Neoplasm | 2017 |
CISD2 enhances the chemosensitivity of gastric cancer through the enhancement of 5-FU-induced apoptosis and the inhibition of autophagy by AKT/mTOR pathway.
Topics: Adult; Aged; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2017 |
[Effects of traditional Tibetan drug Liu Tea on proliferation and chemotherapeutic sensitivity of drug-resistant human gastric cancer cell BGC823/5-FU].
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Caspase 3; Cell Cycle; Cell Line, T | 2016 |
Dual role of carcinoembryonic antigen-related cell adhesion molecule 6 expression in predicting the overall survival of gastric cancer patients.
Topics: Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cell Adhesion Molecules; Cell Differentiat | 2017 |
Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Chemotherapy, Adjuvant; Female; F | 2017 |
Is There Merit for MET-Targeted Therapies in Gastroesophageal Cancer?
Topics: Adenocarcinoma; Antibodies, Monoclonal; Esophageal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxal | 2018 |
Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Chemistry, | 2017 |
5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2018 |
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Downregulation of MicroRNA-147 Inhibits Cell Proliferation and Increases the Chemosensitivity of Gastric Cancer Cells to 5-Fluorouracil by Directly Targeting PTEN.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Dr | 2018 |
A novel vascular-targeting peptide for gastric cancer delivers low-dose TNFα to normalize the blood vessels and improve the anti-cancer efficiency of 5-fluorouracil.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Models, A | 2017 |
Arterioportal shunt incidental to treatment with oxaliplatin that mimics recurrent gastric cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arteriovenous Fistula; Biopsy; Capecitabine; | 2017 |
A novel design of HA-coated nanoparticles co-encapsulating plasmid METase and 5-Fu shows enhanced application in targeting gastric cancer stem cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carbon-Sulfur Lyases; Cell Movement; Cell Proli | 2018 |
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Ci | 2017 |
Successful Treatment with 5-fluorouracil and Levofolinate Calcium in Advanced Gastric Cancer Patient with Disseminated Intravascular Coagulation.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Disseminated Intravascular Co | 2017 |
Co-delivery of hypoxia inducible factor-1α small interfering RNA and 5-fluorouracil to overcome drug resistance in gastric cancer SGC-7901 cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; | 2017 |
[A Case of Advanced Gastric Cancer Responding to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil, Leading to a Pathological Complete Response].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluorouracil; Ga | 2017 |
Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer.
Topics: Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; China; Di | 2017 |
Complete response of metastatic gastric cancer to chemoimmunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Fluorouracil; | 2017 |
GSDME mediates caspase-3-dependent pyroptosis in gastric cancer.
Topics: Antimetabolites, Antineoplastic; Caspase 3; Cell Line, Tumor; Cell Survival; Fluorouracil; Gene Expr | 2018 |
FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Fluo | 2017 |
Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; DNA Mismatch Repair; Female; Flu | 2018 |
Metaplastic Cells in the Stomach Arise, Independently of Stem Cells, via Dedifferentiation or Transdifferentiation of Chief Cells.
Topics: Adenocarcinoma; Animals; Biomarkers, Tumor; Cell Lineage; Cell Proliferation; Cell Transdifferentiat | 2018 |
5-fluorouracil combined with cisplatin and mitomycin C as an optimized regimen for hyperthermic intraperitoneal chemotherapy in gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Cisplatin; | 2018 |
[Gastric Cancer Recurrence in 12 Years after Surgical Resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonoscopy; Fluorouracil; Gastrectomy; Humans; Inte | 2017 |
Quercetin Suppresses CYR61-Mediated Multidrug Resistance in Human Gastric Adenocarcinoma AGS Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2018 |
Predictors of heterogeneity in the first-line treatment of patients with advanced/metastatic gastric cancer in the U.S.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Electronic Health Records; | 2018 |
Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cycli | 2018 |
HOXA13 contributes to gastric carcinogenesis through DHRS2 interacting with MDM2 and confers 5-FU resistance by a p53-dependent pathway.
Topics: Aged; Alcohol Oxidoreductases; Animals; Antimetabolites, Antineoplastic; Carbonyl Reductase (NADPH); | 2018 |
Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycyt | 2018 |
Beau's lines in nails: An indicator of recent Docetaxel and 5-FU use.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetax | 2018 |
MicroRNA-623 Targets Cyclin D1 to Inhibit Cell Proliferation and Enhance the Chemosensitivity of Cells to 5-Fluorouracil in Gastric Cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Resistance, Neoplasm; Fluorouracil; | 2018 |
Autophagy inhibition enhanced 5‑FU‑induced cell death in human gastric carcinoma BGC‑823 cells.
Topics: Autophagosomes; Autophagy; Cell Line, Tumor; Fluorouracil; Gene Expression Regulation, Neoplastic; H | 2018 |
Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva | 2018 |
Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2018 |
Effect of bevacizumab combined with chemotherapy at different sequences in the gastric-cancer-bearing nude mice.
Topics: Animals; Antineoplastic Agents, Immunological; Bevacizumab; Biomarkers; Cisplatin; Disease Models, A | 2018 |
Peri-tumor administration of 5-fluorouracil sol-gel using a hollow microneedle for treatment of gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Delayed-A | 2018 |
Avicularin reversed multidrug-resistance in human gastric cancer through enhancing Bax and BOK expressions.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cisplatin; Drug Resistance, Multip | 2018 |
Autophagy Facilitates Metadherin-Induced Chemotherapy Resistance Through the AMPK/ATG5 Pathway in Gastric Cancer.
Topics: AMP-Activated Protein Kinases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Aut | 2018 |
The Chemotherapeutic Effect of Docetaxel, Cisplatin and Fluorouracil Regimen on Gastric Cancer Stem Cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2017 |
Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Cellul | 2018 |
Comparison of the synergistic anticancer activity of AlPcS4 photodynamic therapy in combination with different low‑dose chemotherapeutic agents on gastric cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; | 2018 |
HSP70/HSP90-Organizing Protein Contributes to Gastric Cancer Progression in an Autocrine Fashion and Predicts Poor Survival in Gastric Cancer.
Topics: Apoptosis; Autocrine Communication; Caspases; Cell Line, Tumor; Cell Proliferation; Databases, Genet | 2018 |
Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Disease-Free Survival; Doc | 2018 |
Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2018 |
Autophagy regulates chemoresistance of gastric cancer stem cells via the Notch signaling pathway.
Topics: Autophagy; Cell Line, Tumor; Cell Survival; Chloroquine; Drug Resistance, Neoplasm; Drug Synergism; | 2018 |
Sensitization of Gastric Cancer Cells to 5-FU by MicroRNA-204 Through Targeting the TGFBR2-Mediated Epithelial to Mesenchymal Transition.
Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fluorouraci | 2018 |
MicroRNA-17 inhibition overcomes chemoresistance and suppresses epithelial-mesenchymal transition through a DEDD-dependent mechanism in gastric cancer.
Topics: Apoptosis; Cell Movement; Cisplatin; Death Domain Receptor Signaling Adaptor Proteins; DNA-Binding P | 2018 |
Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2018 |
miR‑195‑5p regulates multi‑drug resistance of gastric cancer cells via targeting ZNF139.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Case-Control Studies; Ce | 2018 |
Effect of 5-fluorouracil on excision repair cross-complementing 1 expression and consequent cytotoxicity regulation in human gastric cancer cells.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; DNA Repair; | 2018 |
Corosolic acid reduces 5‑FU chemoresistance in human gastric cancer cells by activating AMPK.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents; Cell Cyc | 2018 |
Treatment Patterns Among Patients with Metastatic and/or Unresectable Gastric Cancer in Brazil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brazil; Cisplatin; F | 2019 |
Association of Antioxidative Enzymes Polymorphisms with Efficacy of Platin and Fluorouracil-Based Adjuvant Therapy in Gastric Cancer.
Topics: Alleles; Catalase; Chemotherapy, Adjuvant; Female; Fluorouracil; Genotype; Glutathione Peroxidase; G | 2018 |
[Data review and analysis of 22 cases of gastric cancer associated with pregnancy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2018 |
Increased extracellular matrix density disrupts E-cadherin/β-catenin complex in gastric cancer cells.
Topics: Antigens, CD; Antimetabolites, Antineoplastic; beta Catenin; Cadherins; Cell Line, Tumor; Cell Proli | 2018 |
Retrospective study on efficacy of a paclitaxel combined with a leucovorin and fluorouracil regimen for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2019 |
Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer.
Topics: Adult; Aged; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Diseas | 2018 |
Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamo | 2018 |
The inhibition of thymidine phosphorylase can reverse acquired 5FU-resistance in gastric cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Fluoroura | 2019 |
miR-874 regulates multiple-drug resistance in gastric cancer by targeting ATG16L1.
Topics: 3' Untranslated Regions; Animals; Autophagy; Autophagy-Related Proteins; Cell Line, Tumor; Chloroqui | 2018 |
A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Resist | 2018 |
The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant | 2019 |
Single-chain Antibody Against Reg4 Suppresses Gastric Cancer Cell Growth and Enhances 5-FU-induced Cell Death in vitro.
Topics: Antimetabolites, Antineoplastic; Cell Death; Cell Line, Tumor; Cell Proliferation; Fluorouracil; Hum | 2019 |
Comment on "Microsatellite Instability as a Predictive Biomarker for Adjuvant Chemotherapy in Gastric Cancer": Are we There Yet?
Topics: Apoptosis; Biomarkers; Chemotherapy, Adjuvant; Fluorouracil; Humans; Microsatellite Instability; Pro | 2019 |
Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colonic N | 2019 |
Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2019 |
An Organoid-Based Preclinical Model of Human Gastric Cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Proliferation; Epirubicin; Epithelium; Fluorour | 2019 |
Impact of modified FOLFOX-6 for patients with gastric cancer and a gastrointestinal obstruction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gastrointestinal | 2019 |
Rosmarinic acid reduces the resistance of gastric carcinoma cells to 5-fluorouracil by downregulating FOXO4-targeting miR-6785-5p.
Topics: Antimetabolites, Antineoplastic; Antioxidants; Carcinoma; Cell Cycle Proteins; Cell Line, Tumor; Cin | 2019 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cap | 2019 |
Imatinib‑induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dru | 2019 |
Deep Learning-Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cohort Studies; Fluorou | 2018 |
25-HC decreases the sensitivity of human gastric cancer cells to 5-fluorouracil and promotes cells invasion via the TLR2/NF-κB signaling pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferatio | 2019 |
MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Drug Resistance, Neoplasm; | 2019 |
XRCC4, which is inhibited by PFDA, regulates DNA damage repair and cell chemosensitivity.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cisplatin; Decanoic Acids; DNA Breaks, Do | 2019 |
Tumor Size Improves the Accuracy of the Prognostic Prediction of Lymph Node-Negative Gastric Cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuv | 2019 |
Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer.
Topics: Animals; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Survival; Coculture Techniques; Drug | 2019 |
Perioperative FLOT: new standard for gastric cancer?
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Ox | 2019 |
Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients.
Topics: Adult; Aged; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Plasma | 2019 |
Extract of
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cel | 2019 |
A miR-567-PIK3AP1-PI3K/AKT-c-Myc feedback loop regulates tumour growth and chemoresistance in gastric cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; | 2019 |
Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/β-catenin signal pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, T | 2020 |
Impact of perioperative treatment on survival of resectable gastric cancer patients after D2 lymphadenectomy: a single European centre propensity score matching analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuv | 2019 |
The Cell Death Phenotype of MGC-803 Cells Inducing with "Dextran-Magnetic Layered Double Hydroxide-Fluorouracil" Drug Delivery System and Fluorouracil.
Topics: Apoptosis; Calpain; Caspases; Cell Death; Cell Line, Tumor; Cell Proliferation; Dextrans; Drug Deliv | 2019 |
MiR-195 reverses 5-FU resistance through targeting HMGA1 in gastric cancer cells.
Topics: 3' Untranslated Regions; Antagomirs; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistan | 2019 |
TFAP2E methylation promotes 5‑fluorouracil resistance via exosomal miR‑106a‑5p and miR‑421 in gastric cancer MGC‑803 cells.
Topics: Apoptosis; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; Exosomes; Fluorouracil; Gen | 2019 |
BATF2 reverses multidrug resistance of human gastric cancer cells by suppressing Wnt/β-catenin signaling.
Topics: Antineoplastic Agents; Apoptosis; Basic-Leucine Zipper Transcription Factors; beta Catenin; Cell Lin | 2019 |
Metastatic gastric adenocarcinoma of the tongue with initial symptoms of glossodynia.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gastric Mucosa | 2019 |
Efficacy of XELOX adjuvant chemotherapy for gastric mixed adenoneuroendocrine carcinoma: A case report.
Topics: Adenoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine; Ch | 2019 |
TMEM100 expression suppresses metastasis and enhances sensitivity to chemotherapy in gastric cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Cell Survival; | 2020 |
Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2019 |
Prognostic factors in metastatic gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2019 |
Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; | 2019 |
Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2019 |
The Role of Human Epidermal Growth Factor Receptor (HER2/neu) in the Prognosis of Patients with Gastric Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies | 2019 |
OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Pro | 2013 |
Lymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Card | 2013 |
Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Codon; Female; Fluorouracil; Genes, p53; Humans; Male; Middle A | 2013 |
Correlation between chemosensitivity to anticancer drugs and telomerase reverse transcriptase mRNA expression in gastric cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Antineoplastic Agents; Biomarke | 2013 |
Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy.
Topics: Aldehyde Dehydrogenase; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cisplat | 2013 |
Nobiletin induces apoptosis and potentiates the effects of the anticancer drug 5-fluorouracil in p53-mutated SNU-16 human gastric cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Caspase 9; Ce | 2013 |
Low-dose paclitaxel modulates tumour fibrosis in gastric cancer.
Topics: Actins; Antigens, CD; Antineoplastic Agents, Phytogenic; Cadherins; Cell Line, Tumor; Cell Shape; Ci | 2013 |
The prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stage.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2013 |
[Effects of 5-FU combined compound ginseng and astragalus on biological behavior of human gastric cancer MGC-803 cells].
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Drugs, Chinese Herbal; Fluorouracil; Humans; | 2012 |
Identification of CD44+ cancer stem cells in human gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Flow Cytometry; Fluorouracil; Humans; Hy | 2013 |
Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2013 |
FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; H | 2014 |
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy, | 2013 |
microRNA expression profiling in multidrug resistance of the 5‑Fu‑induced SGC‑7901 human gastric cancer cell line.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Cell S | 2013 |
Tanshinone IIA reverses the malignant phenotype of SGC7901 gastric cancer cells.
Topics: Abietanes; Analysis of Variance; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antin | 2013 |
Impact of adjuvant chemotherapy cycles on prognosis of resectable stomach cancer: a retrospective analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; D | 2013 |
Low-dose docetaxel/cisplatin - leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2013 |
[Clinical study of the predictors to neoadjuvant chemotherapy in patients with advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva | 2013 |
Ring-enhancing lesion associated with radiation-induced liver disease.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2013 |
Overexpression of ECRG4 enhances chemosensitivity to 5-fluorouracil in the human gastric cancer SGC-7901 cell line.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, N | 2013 |
Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; C | 2015 |
Shugoshin1 enhances multidrug resistance of gastric cancer cells by regulating MRP1, Bcl-2, and Bax genes.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Cycle Proteins; Cell Line, Tumor; | 2013 |
New advances in the treatment of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemother | 2004 |
Chemotherapy and resection for gastric cancer with synchronous liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations | 2013 |
[Quality of life of patients with locally advanced operated gastric cancer during the period of chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Gastre | 2012 |
[Regional chemotherapy in locally advanced and metastatic gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Chemotherapy, Adjuva | 2012 |
Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; DNA-Bind | 2013 |
Study of the mechanism of bystander effect of KDR-CDglyTK system mediated by adenovirus for the treatment of gastric cancer.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Antiviral Agents; Apigenin; Bystander Effect; Cell Co | 2013 |
[Isolation of gastric cancer stem cells based on colony morphology and detection of their sensitivity to 5-fluorouracil].
Topics: Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middl | 2013 |
Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi | 2015 |
Acute arterial thrombosis following chemotherapy in a patient with a gastric carcinoma.
Topics: Acute Disease; Adult; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Arterial Occlu | 2013 |
Noninvasive visualization of microRNA-16 in the chemoresistance of gastric cancer using a dual reporter gene imaging system.
Topics: Animals; Cell Count; Cell Line, Tumor; Diagnostic Imaging; Drug Resistance, Neoplasm; Female; Fluoro | 2013 |
The value of expression of M2-PK and VEGF in patients with advanced gastric cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Follow-Up Studies; Gene Expression Regu | 2013 |
Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer.
Topics: Acenaphthenes; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemothera | 2013 |
Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2014 |
Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Do | 2013 |
Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bayes Theorem; Biomarkers, Tumor; Cell Line, Tumor; Clu | 2013 |
Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cost-Benefit A | 2014 |
A tissue-engineered gastric cancer model for mechanistic study of anti-tumor drugs.
Topics: Animals; Antineoplastic Agents; Apoptosis; CD24 Antigen; Cell Survival; Cisplatin; Drug Screening As | 2013 |
Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2013 |
Counteracting immunosuppressive cofactor B7-H1 may enhance the effects of chemotherapy in cancer patients.
Topics: Antibodies, Blocking; B7-H1 Antigen; Chemotherapy, Adjuvant; Drug Therapy; Fluorouracil; Humans; Imm | 2013 |
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophagogastric Jun | 2014 |
Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2013 |
Cannabinoid receptor agonist as an alternative drug in 5-fluorouracil-resistant gastric cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzo | 2013 |
Synergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Confidence Intervals; Diosgenin; Drug | 2013 |
[Indirect comparison of different adjuvant chemotherapies for stage II-III gastric cancer after D2 gastrectomy in Asian patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; | 2013 |
[Results of combined treatment of patients with metastatic gastric cancer. Case study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2013 |
Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data.
Topics: Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic | 2013 |
Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxy | 2013 |
Expression of orphan nuclear receptor NR4A2 in gastric cancer cells confers chemoresistance and predicts an unfavorable postoperative survival of gastric cancer patients with chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Fe | 2013 |
Hepatoid adenocarcinoma of the stomach: an unusual case of elevated alpha-fetoprotein with prior treatment for hepatocellular carcinoma.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2013 |
[A case of mediastinal lymph node gastric cancer recurrence during S-1 adjuvant therapy successfully treated with cisplatin + capecitabine as second-line chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2013 |
Knockdown of PLA2G2A sensitizes gastric cancer cells to 5-FU in vitro.
Topics: Animals; Antimetabolites; Apoptosis; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluoro | 2013 |
[Approximately four years of survival benefits for a case of gastric cancer postoperative carcinomatous peritonitis by combined modality therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; | 2013 |
[A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Knockdown of inhibitor of growth protein 2 inhibits cell invasion and enhances chemosensitivity to 5-FU in human gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Fluorouracil; Gene Ex | 2013 |
Reversal of multidrug resistance in gastric cancer cells by CDX2 downregulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; CDX2 Transcription Factor; Cell Cycle; Cell Line, Tumor; | 2013 |
Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Diseas | 2013 |
Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, A | 2013 |
Expanding the Lauren classification: a new gastric cancer subtype?
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Fluorouracil; Gene Expression Regulation, | 2013 |
Chemotherapy in elderly patients with metastatic gastric cancer; a single Turkish cancer center experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Fluorouracil | 2013 |
miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily | 2014 |
Inhibition of gastric cancer cell growth in vivo by overexpression of adeno-associated virus-mediated survivin mutant C84A.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Dependovirus; | 2013 |
Ziyuglycoside II-induced apoptosis in human gastric carcinoma BGC-823 cells by regulating Bax/Bcl-2 expression and activating caspase-3 pathway.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma; Caspase 3; Caspase Inhibito | 2013 |
Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2013 |
[Curcumin combined FOLFOX induced cell apoptosis of gastric cancer and its mechanism research].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Ce | 2013 |
DNA damage-inducible gene, reprimo functions as a tumor suppressor and is suppressed by promoter methylation in gastric cancer.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Cycle Proteins; Cell Line, Tumo | 2013 |
Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-F | 2014 |
CD49f(high) cells retain sphere-forming and tumor-initiating activities in human gastric tumors.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Floxuridi | 2013 |
Effects of extended lymphadenectomy and postoperative chemotherapy on node-negative gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Interferon-α enhances 5'-deoxy-5-fluorouridine-induced apoptosis by ERK-dependant upregulation of thymidine phosphorylase.
Topics: Apoptosis; Capecitabine; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Fluorouraci | 2013 |
[Effect of RNA interference inhibition to expression of CD133 on tumor cell biological characteristics in KATO-III CD133(+) cells of human gastric cancer].
Topics: AC133 Antigen; Antigens, CD; Cell Line, Tumor; Cell Movement; Cell Proliferation; Fluorouracil; Glyc | 2013 |
Retrospective analysis of docetaxel, oxaliplatin plus fluorouracil compared with epirubicin, cisplatin and fluorouracil as first-line therapy for advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Surviv | 2014 |
Lentivirus-mediated shRNA targeting of cyclin D1 enhances the chemosensitivity of human gastric cancer to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cel | 2013 |
Capecitabine-induced subacute cutaneous lupus erythematosus: report of a case with positive rechallenge test.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lu | 2013 |
Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer.
Topics: Apoptosis; bcl-X Protein; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2013 |
High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.
Topics: Adult; Aged; Alpha-Globulins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cap | 2013 |
Anti-tumor activity of the X-linked inhibitor of apoptosis (XIAP) inhibitor embelin in gastric cancer cells.
Topics: Apoptosis; Benzoquinones; Blotting, Western; Cell Line, Tumor; Flow Cytometry; Fluorouracil; Humans; | 2014 |
Efficacy and safety of docetaxel plus oxaliplatin and capecitabine in the first line treatment of advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetax | 2013 |
The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Can capecitabine be used instead of concurrent bolus 5-FU in postoperative chemoradiotherapy for gastric adenocarcinoma?
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine | 2013 |
Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Drug Res | 2013 |
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispla | 2013 |
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2013 |
Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Capecitabine; Cell Line, Tumor; Cell Proliferation; Deoxycyti | 2014 |
[A "lymph node" of the hepatic hilum].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Intrahepatic; Cholecystectomy; Cisplatin | 2013 |
The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemothera | 2014 |
[Impact of clinicopathological features and extent of lymph node dissection on the prognosis in early gastric cancer patients].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Carcinoma, Signet Ring Cel | 2013 |
[Application of jejunal interposition after radical proximal gastrectomy].
Topics: Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Che | 2013 |
Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy.
Topics: Adenocarcinoma; Adult; Aged; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Caspase 3; | 2014 |
The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adj | 2014 |
Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; DNA Repair; DNA-Binding Proteins; Endon | 2014 |
The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergis | 2013 |
The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cells, | 2013 |
FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Disease P | 2013 |
TWEAK/Fn14 signaling mediates gastric cancer cell resistance to 5-fluorouracil via NF-κB activation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Cytokine TWEAK; D | 2014 |
Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Capecitabine; Chemotherapy, Adjuvant; | 2013 |
Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism.
Topics: Adult; Aged; Cell Hypoxia; Cell Line, Tumor; Dichloroacetic Acid; Down-Regulation; Drug Resistance, | 2014 |
Cbl-b enhances sensitivity to 5-fluorouracil via EGFR- and mitochondria-mediated pathways in gastric cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell | 2013 |
A visualized investigation at the atomic scale of the antitumor effect of magnetic nanomedicine on gastric cancer cells.
Topics: Antineoplastic Agents; Carboxymethylcellulose Sodium; Cell Death; Cell Line, Tumor; Fluorouracil; Hu | 2014 |
Optimal duration of fluorouracil-based adjuvant chemotherapy for patients with resectable gastric cancer.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Cohort Studies; Female; Fluorouracil; Humans; Male; Middle Aged | 2013 |
[A case of HER2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin, and trastuzumab as first-line chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2013 |
[Recurrent gastric cancer treated with fourth-line chemotherapy consisting of capecitabine and cisplatin leading to partial response].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Fluoro | 2013 |
[Multidisciplinary therapy for 3 patients with lymph node recurrence after curative gastrectomy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2013 |
[A case of metastatic breast carcinoma of the cervical muscles].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Lobular; Deoxycytidine; | 2013 |
Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2014 |
Thymidylate synthase polymorphism in sporadic colorectal and gastric cancer in Tunisian population: a predictive role in 5-fluorouracil based chemotherapy treatment.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Case-Contr | 2014 |
Dermatomyositis associated with capecitabine in the setting of malignancy.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biopsy, Needle; Capecit | 2014 |
Multifunctional cationic polymer decorated and drug intercalated layered silicate (NLS) for early gastric cancer prevention.
Topics: Animals; Antimetabolites, Antineoplastic; Bacterial Adhesion; Cations; Cell Line; Chlorocebus aethio | 2014 |
Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2014 |
Regulatory mechanism of ZNF139 in multi-drug resistance of gastric cancer cells.
Topics: bcl-2-Associated X Protein; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistanc | 2014 |
Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2014 |
Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2014 |
Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2014 |
Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2014 |
A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Case-Control Studies; Cell Cycle Proteins; Cell Survival; | 2014 |
Genistein-inhibited cancer stem cell-like properties and reduced chemoresistance of gastric cancer.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding | 2014 |
[Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): Chinese subgroup analysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; | 2014 |
[Relationship between CD133 and chemoresistance in human gastric cancer and its associated mechanism].
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Sub | 2014 |
A compensatory role of NF-κB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Codon; Drug Resistance, Neoplasm; Fluorouracil; G | 2014 |
Increased drug resistance is associated with reduced glucose levels and an enhanced glycolysis phenotype.
Topics: Antineoplastic Agents; Autophagy; Carboplatin; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kina | 2014 |
Basaloid squamous cell carcinoma: a rare tumor at the esophagogastric junction and an unexpected durable complete response to FOLFOX-4.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophagogastric Junc | 2014 |
Proteomic biomarker predicts therapeutical effects of oxaliplatin combining with fluoropyrimidine in metastatic gastric cancer patients by the SELDI-proteinchip platform.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dise | 2013 |
Association between CHFR methylation and chemosensitivity of paclitaxel in advanced gastric cancer.
Topics: Antineoplastic Agents; Biopsy; Capecitabine; Cell Cycle Proteins; China; Cisplatin; Deoxycytidine; D | 2014 |
Capsaicin inhibits cell proliferation by cytochrome c release in gastric cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capsaicin; Cell Line, Tumor; Cell Proliferation; Cel | 2014 |
Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; China; | 2014 |
[Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine | 2013 |
[Correlated analysis of 5 fluorouracil metabolic enzymes with tumor response after SOX regimen neoadjuvant chemotherapy in advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Fem | 2014 |
[Establishment of drug resistant cell line of MGC-803 and analysis of differential secretome].
Topics: Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Fluor | 2014 |
Pluronic-poly[alpha-(4-aminobutyl)-1-glycolic acid] polymeric micelle-like nanoparticles as carrier for drug delivery.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Diffusion; Fluorouracil; Humans; Micelles; Molecu | 2014 |
[Anti-tumor effect of 5-FU-PLLA-CNTs on human gastric carcinoma cell lines in vitro].
Topics: Cell Line, Tumor; Cell Proliferation; Delayed-Action Preparations; Fluorouracil; Humans; Lactic Acid | 2014 |
[Efficacies of neoadjuvant chemotherapy plus nutritional support in advanced gastric cancer complicated with pylori obstruction].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gastric Outlet Ob | 2014 |
[Reversion of multidrug resistance of human gastric cancer SGC7901/DDP cells by E2F-1 gene silencing].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; ATP | 2014 |
Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Cycle; Cell Line, | 2014 |
Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic | 2014 |
Inhibitory effects of 3-bromopyruvate on human gastric cancer implant tumors in nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; | 2014 |
p16 Methylation is associated with chemosensitivity to fluorouracil in patients with advanced gastric cancer.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Asian People; Cadherins; Cycl | 2014 |
Molecular profiling in gastric cancer: examining potential targets for chemotherapy.
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP Bindin | 2014 |
Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2015 |
Histological complete response to a combined docetaxel/cisplatin/fluorouracil neoadjuvant chemotherapy for T4 stage gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoro | 2014 |
Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway.
Topics: Actin Cytoskeleton; Aged; Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Prolife | 2014 |
Secondary gastrectomy for stage IV gastroesophageal adenocarcinoma after induction-chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; | 2014 |
[A case of S-1/CDDP-resistant recurrent gastric cancer responsive to capecitabine/CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality The | 2014 |
Capecitabine induced colitis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Colitis; Deoxycytidine; Fluorouracil; | 2014 |
[Adjuvant chemoradiotherapy in advanced gastric cancer: experience in 168 patients].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Fe | 2014 |
Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabin | 2014 |
Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2015 |
[Clinical observation of abdominal regional fluorouracil implants in advanced gastric cancer patients during operation].
Topics: Abdominal Cavity; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Retrospective Studies; Stom | 2014 |
[Clinical study of autologous cytokine-induced killer cells combined with XELOX regimen in the treatment of senile advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cytokine-Induced Killer Cells; D | 2014 |
Outcomes in elderly patients treated with a single-agent or combination regimen as first-line chemotherapy for recurrent or metastatic gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Combinat | 2015 |
Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and ci
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fe | 2014 |
Neoadjuvant chemotherapy with FOLFOX4 regimen to treat advanced gastric cancer improves survival without increasing adverse events: a retrospective cohort study from a Chinese center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil | 2014 |
Adjuvant chemotherapy by FOLFOX for gastric hepatoid adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2014 |
Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluor | 2014 |
Decreased intratumoral Foxp3 Tregs and increased dendritic cell density by neoadjuvant chemotherapy associated with favorable prognosis in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dendritic Cells | 2014 |
Comparison of 2-dimensional and 3-dimensional conformal treatment plans in gastric cancer radiotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Fluorouracil; Gastrect | 2014 |
O-MAX chemotherapy: high activity in metastatic esophagogastric adenocarcinoma and possible relation to subclinical hemolysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2014 |
Overexpression of CD133 enhances chemoresistance to 5-fluorouracil by activating the PI3K/Akt/p70S6K pathway in gastric cancer cells.
Topics: AC133 Antigen; Antigens, CD; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subf | 2014 |
Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; C | 2014 |
IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cisplatin; Deoxycyt | 2014 |
[Survey of the current status of capecitabine-induced hypertriglyceridemia].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deo | 2014 |
[A case of gastric cancer with peritoneal dissemination successfully treated with low-dose S-1 or capecitabine chemotherapy for five years].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations | 2014 |
Preparation of 5-fluorouracil-loaded nanoparticles and study of interaction with gastric cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Drug Carriers; Drug Delivery Systems | 2014 |
Expression of multidrug resistance-associated proteins and their relation to postoperative individualized chemotherapy in gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 2014 |
Polymorphism of methylenetetrahydrofolate reductase gene is associated with response to fluorouracil-based chemotherapy in Chinese patients with gastric cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Asian People; Female; F | 2014 |
Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway.
Topics: Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; Flavanones; Fluorouracil; Glycolysis; Hum | 2015 |
Modified administration schedule of docetaxel, cisplatin, and fluorouracil for advanced or recurrent gastric cancer with gastrointestinal stenosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluorouracil; Ga | 2014 |
A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2015 |
Synergic effect between 5‑fluorouracil and celecoxib on hypoxic gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Bindi | 2015 |
Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2014 |
Development and characterization of novel site specific hollow floating microspheres bearing 5-Fu for stomach targeting.
Topics: Biological Availability; Drug Delivery Systems; Fluorouracil; Humans; Kinetics; Microspheres; Partic | 2014 |
Effects of 5‑fluorouracil and class III phosphoinositide 3‑kinase small interfering RNA combination therapy on SGC7901 human gastric cancer cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell | 2015 |
[Safety and efficacy of intraperitoneal hyperthermic perfusion chemotherapy following laparoscopic palliative resection for gastric cancer patients with peritoneal metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Laparoscopy; Pallia | 2014 |
[Application of regional arterial infusion chemotherapy in short-term neoadjuvant chemotherapy for advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Humans; Infusions, Intra-A | 2014 |
Synergistic antitumor effect of puerarin combined with 5-fluorouracil on gastric carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Survival; Dis | 2015 |
[Gastric cancer with liver metastasis and peritoneal dissemination treated with conversion surgery to achieve r0 resection after capecitabine, cisplatin, and trastuzumab chemotherapy-a case report].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2014 |
Improving prognosis after surgery for gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; H | 2014 |
Epstein-Barr virus miR-BART20-5p regulates cell proliferation and apoptosis by targeting BAD.
Topics: 3' Untranslated Regions; Antimetabolites, Antineoplastic; Apoptosis; bcl-Associated Death Protein; B | 2015 |
LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition.
Topics: Adult; Aged; Aged, 80 and over; Animals; Base Sequence; Cell Line, Tumor; Cell Movement; Cell Prolif | 2014 |
Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Capecitabine | 2015 |
A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Clinica | 2014 |
The influence of 5-fluorouracil on activity of thymidine phosphorylase in gastric adenocarcinoma and normal adjacent tissue.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Enzyme Activation; | 2014 |
Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Proto | 2014 |
Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy.
Topics: Aged; Alleles; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aryldialkylpho | 2014 |
[Reversal Effect of curcuma wenyujin extract on SGC-7901/VCR induced subcutaneous transplanted tumor in nude mice and its effect on the expression of P-glycoprotein].
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cisplatin; Curcu | 2014 |
A case report of three patients with metastatic gastric cancer on hemodialysis who were treated with cisplatin-fluorouracil regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Male; Middl | 2016 |
Clinicopathological significance of nuclear factor (erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Nucleus; Dru | 2015 |
Gelatinases-stimuli nanoparticles encapsulating 5-fluorouridine and 5-aza-2'-deoxycytidine enhance the sensitivity of gastric cancer cells to chemical therapeutics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proli | 2015 |
Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod | 2015 |
The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses.
Topics: Adult; Aged; Drug Therapy; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Microsatellite | 2015 |
Inhibition of c-Myc by let-7b mimic reverses mutidrug resistance in gastric cancer cells.
Topics: 3' Untranslated Regions; Cell Differentiation; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Re | 2015 |
Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2015 |
Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis.
Topics: Adenocarcinoma; Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antimetabolites, Antin | 2015 |
[Association between ABCB1 G2677T/A polymorphisms and chemosensitivity of paclitaxel in advanced gastric cancer].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Capecitabine; Cisplatin; Deoxy | 2015 |
[Experimental study of human bone marrow mesenchymal stem cells on regulating the biological characteristics of gastric cancer cells].
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cadherins; Cell Line, Tumor; Cell Proliferation | 2015 |
[Screening for predictive biomarkers of bevacizumab treatment in gastric cancer subcutaneous xenografts].
Topics: Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers; Cell Line, Tumor; Fluorouracil; | 2015 |
5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Disease | 2015 |
Concurrent involved-field radiotherapy and XELOX in gastric cancer patients with postoperative oligometastatic recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxyc | 2014 |
Treatment of locally advanced gastric cancer with the XELOX program of neoadjuvantchemotherapy combined with laparoscopic surgery: the experience in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Deoxycy | 2014 |
[A case of metastatic gastric cancer originating from transverse colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon, Transverse; Col | 2014 |
[A case report of neuroendocrine carcinoma of the stomach with liver metastases curatively resected after neoadjuvant chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2014 |
[A case of advanced gastric cancer with liver metastasis involving curative surgery after neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2014 |
[A case of HER2-positive advanced gastric cancer with extensive lymph node metastasis treated via chemotherapy with a trastuzumab-containing regimen followed by conversion surgery].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cis | 2014 |
[A case of advanced gastric cancer successfully treated with trastuzumab, capecitabine, and Cisplatin therapy followed by curative resection].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cis | 2014 |
[A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2014 |
[A case of early gastric cancer completely responding to adjuvant chemotherapy for advanced colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectom | 2014 |
Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisp | 2015 |
[A case of stage IV gastric cancer resected after chemotherapy with capecitabine plus cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; | 2015 |
Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2015 |
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal | 2015 |
Prognostic significance of the concomitant existence of lymphovascular and perineural invasion in locally advanced gastric cancer patients who underwent curative gastrectomy and adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise | 2015 |
Inverse association between Bmi-1 and RKIP affecting clinical outcome of gastric cancer and revealing the potential molecular mechanisms underlying tumor metastasis and chemotherapy resistance.
Topics: Aged; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, | 2016 |
Transcription Factor AP2ε: A Potential Predictor of Chemoresistance in Patients With Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Deoxycyt | 2016 |
[A case of HER2-positive advanced gastric cancer successfully treated via capecitabine, cisplatin, and trastuzumab combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2015 |
High glucose promotes gastric cancer chemoresistance in vivo and in vitro.
Topics: Adult; Aged; Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, | 2015 |
High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fema | 2015 |
Isorhamnetin augments the anti-tumor effect of capecitabine through the negative regulation of NF-κB signaling cascade in gastric cancer.
Topics: Angiogenic Proteins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sit | 2015 |
A rare cause of esophagitis with crystal deposition.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Crystallization; Esoph | 2015 |
Advanced gastric cancer with liver and lymph node metastases successfully resected after induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Gastrectomy; Hum | 2014 |
A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Cisplatin; Fatal Outcome; Fluorouracil; Gene Express | 2015 |
Establishment and characterization of GCSR1, a multi-drug resistant signet ring cell gastric cancer cell line.
Topics: Animals; Carcinoma, Signet Ring Cell; Cell Line, Tumor; Cell Proliferation; China; Drug Resistance, | 2015 |
Low percentage of CD24hiCD27⁺CD19⁺ B cells decelerates gastric cancer progression in XELOX-treated patients.
Topics: Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocyte | 2015 |
Sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 expression.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily | 2015 |
Long-Term Survival of Patient with Epstein-Barr Virus-Positive Gastric Cancer Treated with Chemotherapy: Case Report.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2016 |
miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2.
Topics: Antineoplastic Agents; Autophagy; Autophagy-Related Protein 12; Cell Line, Tumor; Drug Resistance, M | 2015 |
Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Ch | 2015 |
Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2015 |
Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2015 |
Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease-Free Su | 2015 |
The impact of insulin on chemotherapeutic sensitivity to 5-fluorouracil in gastric cancer cell lines SGC7901, MKN45 and MKN28.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Femal | 2015 |
Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Coated Materials, Biocompatible; Drug L | 2015 |
Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Communication; Cell Line, Tumor; Drug Resi | 2015 |
Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; DNA Repair; | 2015 |
Corosolic acid enhances 5-fluorouracil-induced apoptosis against SNU-620 human gastric carcinoma cells by inhibition of mammalian target of rapamycin.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antit | 2015 |
Effects of IGF2BP2, KCNQ1 and GCKR polymorphisms on clinical outcome in metastatic gastric cancer treated with EOF regimen.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D | 2015 |
Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2015 |
Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer.
Topics: Amyloid Precursor Protein Secretases; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, | 2015 |
Alpha 7-nicotinic acetylcholine receptor mediates the sensitivity of gastric cancer cells to 5-fluorouracil.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survi | 2015 |
Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2014 |
PCF Chemotherapy Combined with Surgical Treatment of Late Gastric Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 2014 |
Systemic Chemotherapy using FLOT - Regimen Combined with Cytoreductive Surgery plus HIPEC for Treatment of Peritoneal Metastasized Gastric Cancer. .
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytoreduction S | 2014 |
[Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progressi | 2015 |
Role of Δ133p53 in Tumor Necrosis Factor-induced survival of p53 functions in MKN45 gastric cancer cell line.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Fluorouracil; Genes, p | 2015 |
Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cognition; Cognition Disord | 2015 |
Inhibition of autophagy by bafilomycin A1 promotes chemosensitivity of gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Movement; Cell Proliferation; Ce | 2016 |
Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2015 |
Comparison of Therapeutic Efficacy between Gastrectomy with Transarterial Chemoembolization Plus Systemic Chemotherapy and Systemic Chemotherapy Alone in Gastric Cancer with Synchronous Liver Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therap | 2015 |
Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Chemoradiotherapy; Colorectal Neoplasms; Combined | 2015 |
Metabolic alteration--Overcoming therapy resistance in gastric cancer via PGK-1 inhibition in a combined therapy with standard chemotherapeutics.
Topics: Adenocarcinoma; Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug | 2015 |
Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; H | 2016 |
A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2015 |
Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; DNA-Bi | 2016 |
Infection by Cx43 adenovirus increased chemotherapy sensitivity in human gastric cancer BGC-823 cells: not involving in induction of cell apoptosis.
Topics: Adenocarcinoma; Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, | 2015 |
[Stage IV Gastric Cancer Made Resectable Following a Chemotherapy Regimen That Included Trastuzumab-A Case Report].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2015 |
Hepatic arterial infusion chemotherapy using fluorouracil, epirubicin, and mitomycin C for patients with liver metastases from gastric cancer after treatment failure of systemic S-1 plus cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwellin | 2016 |
Low-dose all-trans retinoic acid enhances cytotoxicity of cisplatin and 5-fluorouracil on CD44(+) cancer stem cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cel | 2015 |
Perioperative chemotherapy in locally advanced gastric cancer. A retrospective study about 25 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2015 |
Correlation Between Nuclear Factor E2-Related Factor 2 Expression and Gastric Cancer Progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antioxidants; Carcinoma; Drug Resistance, Neo | 2015 |
[Efficacy and Safety of FOLFIRI as Second-line Chemotherapy in Advanced Gastric Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Leucovor | 2015 |
Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Blotting, Western; CASP8 and FADD-Like Apo | 2016 |
HNRNPC as a candidate biomarker for chemoresistance in gastric cancer.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Heterogeneous-Nuclear | 2016 |
[Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transpor | 2015 |
Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Biomarke | 2016 |
Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method.
Topics: Annexin A3; Computational Biology; Drug Resistance, Neoplasm; Drug Therapy; ErbB Receptors; Female; | 2015 |
Berberine and Curcumin Target Survivin and STAT3 in Gastric Cancer Cells and Synergize Actions of Standard Chemotherapeutic 5-Fluorouracil.
Topics: Berberine; Cell Line, Tumor; Cell Survival; Curcumin; DNA; Drug Resistance, Neoplasm; Drug Synergism | 2015 |
[A Case of Advanced Gastric Cancer Presenting as Multiple Colonic Lymphoid Hyperplasia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colonoscopy; Female; Fluorouracil | 2015 |
AMPK activator AICAR promotes 5-FU-induced apoptosis in gastric cancer cells.
Topics: Adenylate Kinase; Aminoimidazole Carboxamide; Apoptosis; Cell Line; Enzyme Activation; Fluorouracil; | 2016 |
miR-125b Suppresses Proliferation and Invasion by Targeting MCL1 in Gastric Cancer.
Topics: Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Female; Fl | 2015 |
Modified gastric cancer chemotherapy: more effective, less toxic.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Drug Ad | 2015 |
MiR-429 Induces Gastric Carcinoma Cell Apoptosis Through Bcl-2.
Topics: 3' Untranslated Regions; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; Cell Surviv | 2015 |
Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease-Free Sur | 2015 |
Pneumatosis intestinalis due to 5-fluorouracil chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Fat4 suppression induces Yap translocation accounting for the promoted proliferation and migration of gastric cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Adult; Animals; Cadherins; Cell Line, Tumor; Cell Movement; Ce | 2016 |
[Effect of Jianpi Yangzheng Xiaozheng Recipe on Apoptosis and Autophagy of Subcutaneous Transplanted Tumor in Nude Mice: an Experimental Study on Mechanism].
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tu | 2015 |
The miR27b-CCNG1-P53-miR-508-5p axis regulates multidrug resistance of gastric cancer.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Cyclin G1; Dru | 2016 |
Overexpression of Lin28 Decreases the Chemosensitivity of Gastric Cancer Cells to Oxaliplatin, Paclitaxel, Doxorubicin, and Fluorouracil in Part via microRNA-107.
Topics: Animals; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplasti | 2015 |
The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Flu | 2016 |
Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; DNA Repair; DNA-Binding Proteins; End | 2015 |
Radiation-induced injury of the exocrine pancreas after chemoradiotherapy for gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Exocrine Pancreatic | 2016 |
[Characteristics of recurrence in patients with gastric cancer after radical gastrectomy and adjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Fluorouracil; Gas | 2015 |
Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2015 |
Genetic Variation in the ABCB1 Gene May Lead to mRNA Level Chabge: Application to Gastric Cancer Cases.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; Biomarkers, Tumor; C | 2015 |
Downregulation of microRNA-193-3p inhibits tumor proliferation migration and chemoresistance in human gastric cancer by regulating PTEN gene.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug | 2016 |
Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2016 |
A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Capecitabine; Chemotherapy, Adju | 2016 |
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cis | 2017 |
Curcumin Enhances the Effects of 5-Fluorouracil and Oxaliplatin in Inducing Gastric Cancer Cell Apoptosis Both In Vitro and In Vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Syne | 2016 |
[Pre-Operative Treatment with Transcatheter Arterial Chemoembolization (TACE) and Hepatic Arterial Infusion (HAI) for Liver Metastasis from Gastric Cancer--A Case Report].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, | 2015 |
Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms.
Topics: Animals; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Fluorouracil; Humans; Immunotherapy | 2016 |
Effect of First Line Gastric Cancer Chemotherapy Regime on the AGS Cell Line - MTT Assay Results.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Prolif | 2016 |
An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Stud | 2016 |
Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Fluo | 2016 |
Lupeol enhances inhibitory effect of 5-fluorouracil on human gastric carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2016 |
Integration of in silico modeling, prediction by binding energy and experimental approach to study the amorphous chitin nanocarriers for cancer drug delivery.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chitin; Curcumin; Docetaxel; | 2016 |
Enhancement of Drug Sensitivity by Knockdown of HIF-1α in Gastric Carcinoma Cells.
Topics: Apoptosis; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; | 2016 |
Synergistic anticancer properties of docosahexaenoic acid and 5-fluorouracil through interference with energy metabolism and cell cycle arrest in human gastric cancer cell line AGS cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Line, T | 2016 |
Reduced RanBPM Expression Is Associated with Distant Metastasis in Gastric Cancer and Chemoresistance.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Adhesion | 2016 |
Usefulness of diagnostic laparoscopy with 5-aminolevulinic acid (ALA)-mediated photodynamic diagnosis for the detection of peritoneal micrometastasis in advanced gastric cancer after chemotherapy.
Topics: Adult; Aged; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisp | 2016 |
Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin; Disease-Free S | 2016 |
Targeting HCCR expression resensitizes gastric cancer cells to chemotherapy via down-regulating the activation of STAT3.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line; Cell Line, Tumor; | 2016 |
[A Case of Double Cancer of Initially Unresectable Sigmoid Colon Cancer and Advanced Gastric Cancer Treated with Curative Resection after mFOLFOX6 Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Fluorouracil; Hum | 2016 |
Tissue microRNAs as predictive markers for gastric cancer patients undergoing palliative chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Disease Progression; F | 2016 |
Application of FLEEOX Preoperative Chemotherapy via Intra-arterial and Intravenous Administration in Treatment of Unresectable Locally Advanced Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Epirubicin; Etoposide; Femal | 2016 |
Evaluation of role of telmisartan in combination with 5-fluorouracil in gastric cancer cachexia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Benzoates; Cachexia; Fluoro | 2016 |
Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfami | 2016 |
The impact of neoadjuvant chemotherapy on cardiopulmonary physical fitness in gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anaerobic Threshold; Antineoplastic Combined Chemotherapy Protocols; Cardiores | 2016 |
Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gene Frequency; G | 2016 |
AT101 exerts a synergetic efficacy in gastric cancer patients with 5-FU based treatment through promoting apoptosis and autophagy.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Autophagy; | 2016 |
Jackhammer oesophagus in a case of linitis plastica.
Topics: Cisplatin; Colonoscopy; Diagnosis, Differential; Docetaxel; Esophagus; Fatal Outcome; Female; Fluoro | 2016 |
[Study of introperitoneal hyperthermic perfusion chemotherapy combined with systemic neoadjuvent chemotherapy in treatment of gastric cancer patients with peritoneal carcinomatosis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; | 2016 |
FOLFOX as Perioperative Chemotherapy of localized Gastric Cancer: Efficacy and Tolerance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Digestive System Surgical Procedures; Flu | 2016 |
Intravoxel incoherent motion diffusion-weighted imaging for monitoring chemotherapeutic efficacy in gastric cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Diffusion Magnet | 2016 |
Inhibitory effects of bevacizumab monoclonal antibodies in combination with chemotherapy in different time sequences on a human gastric carcinoma cell line.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Cell | 2017 |
Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell M | 2016 |
Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell | 2016 |
Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2017 |
The effects of genomic polymorphisms in one-carbon metabolism pathways on survival of gastric cancer patients received fluorouracil-based adjuvant therapy.
Topics: Disease-Free Survival; Female; Fluorouracil; Genotype; Humans; Male; Neoplasm Proteins; Polymorphism | 2016 |
ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Genotype; Humans; | 2016 |
Oxaliplatin, 5Fluorouracil and Leucovorin (FOLFOX4) as First Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; F | 2016 |
Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2016 |
Clinical characteristics of young-age onset gastric cancer in Korea.
Topics: Adult; Age of Onset; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; | 2016 |
Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2016 |
DCTPP1 attenuates the sensitivity of human gastric cancer cells to 5-fluorouracil by up-regulating MDR1 expression epigenetically.
Topics: Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; Cell Line, | 2016 |
Chemotherapy Effectiveness and Prognosis of Gastric Cancer Influenced by PTPN11 Polymorphisms.
Topics: Aged; Alleles; Antineoplastic Agents; Case-Control Studies; Cisplatin; Female; Fluorouracil; Gene Ex | 2016 |
Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dige | 2016 |
Laparoscopic Gastrectomy Followed by Chemotherapy for Advanced Gastric Cancer Diagnosed During Pregnancy: A Case Report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gastrectomy; Humans; La | 2016 |
RAD51B as a potential biomarker for early detection and poor prognostic evaluation contributes to tumorigenesis of gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carc | 2016 |
Usefulness of chemoradiotherapy for inoperable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2017 |
Tissue transglutaminase-1 promotes stemness and chemoresistance in gastric cancer cells by regulating Wnt/β-catenin signaling.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2017 |
D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemothera | 2016 |
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2016 |
Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Drug-Related Side Effects and Adverse Reactions; Esophageal N | 2017 |
Proton pump inhibitor pantoprazole inhibits the proliferation, self‑renewal and chemoresistance of gastric cancer stem cells via the EMT/β‑catenin pathways.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; | 2016 |
CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Fem | 2017 |
The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cycli | 2016 |
MiR-30a Decreases Multidrug Resistance (MDR) of Gastric Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cadherins; Cell Line, Tumor; Cell Prolife | 2016 |
Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species.
Topics: Apoptosis; Cell Line, Tumor; Fluorouracil; Humans; Mitochondria; Naphthoquinones; Organoplatinum Com | 2016 |
Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combinations; F | 2017 |
Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cytokine Receptor | 2016 |
Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxy | 2017 |
Platinum-based Doublet Chemotherapy for Advanced Gastric Cancer with Disseminated Intravascular Coagulation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disseminated | 2017 |
Traditional Chinese medicine Jianpi Bushen therapy suppresses the onset of pre-metastatic niche in a murine model of spontaneous lung metastasis.
Topics: Animals; cdc42 GTP-Binding Protein; Cell Line, Tumor; Chemokine CXCL12; Disease Models, Animal; Drug | 2017 |
Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer.
Topics: Animals; Biomarkers, Tumor; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Fluorouracil; Gastrec | 2018 |
Positive feedback loop of IL-1β/Akt/RARα/Akt signaling mediates oncogenic property of RARα in gastric carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Cell Cycle; Cell Cycle Proteins; Cell Line, Tum | 2017 |
Influence of TS and ABCB1 gene polymorphisms on survival outcomes of 5‑FU-based chemotherapy in a Chinese population of advanced gastric cancer patients.
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily B; Biomarkers, Tumor; China; Female; Fluoro | 2017 |
Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis.
Topics: Capecitabine; Drug Combinations; Fluorouracil; Humans; Network Meta-Analysis; Oxonic Acid; Stomach N | 2017 |
[Analysis of 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel in Advanced Gastric Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Female; Fluorouracil; Humans; Leucovo | 2016 |
[A Case of Heterochronic Cervical Esophageal Cancer with a Subcutaneous Abscess Showing a Complete Response to Chemoradiation Therapy].
Topics: Abscess; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ch | 2016 |
Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluo | 2017 |
Timing of initiation of adjuvant chemotherapy for gastric cancer: A case-matched comparison study of laparoscopic vs. open surgery.
Topics: Abdominal Abscess; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemoth | 2017 |
Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2017 |
Inhibition of polypyrimidine tract-binding protein 3 induces apoptosis and cell cycle arrest, and enhances the cytotoxicity of 5- fluorouracil in gastric cancer cells.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Cycle C | 2017 |
MACC1 mediates chemotherapy sensitivity of 5-FU and cisplatin via regulating MCT1 expression in gastric cancer.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Survival; Cisplatin; Female; Fluoro | 2017 |
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; DNA | 2017 |
The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2017 |
Effects of 5-fluorouracil, adriamycin and irinotecan on HSC-39, a human scirrhous gastric cancer cell line.
Topics: Adenocarcinoma, Scirrhous; Apoptosis; Camptothecin; Cell Line; Cell Proliferation; Cell Survival; Do | 2017 |
The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cis | 2017 |
Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cost of Illness; Cost-Ben | 2017 |
Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2017 |
ATP-based chemotherapy response assay in patients with unresectable gastric cancer.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Dox | 2007 |
Preparation of chitosan-polyaspartic acid-5-fluorouracil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; bcl-2-Associated X Protein; Cell Line, Tumor; Chitosan; Dr | 2008 |
Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I | 2008 |
Docetaxel: new indication. Metastatic gastric cancer: keep using fluorouracil-based chemotherapy. No tangible progress.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Drug Approval; Europe; Fluorouracil; Humans; Neoplasm Metast | 2008 |
Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine.
Topics: Acute Disease; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytid | 2008 |
Capecitabine: new indication. Advanced-stage gastric cancer: oral route for some patients. Risk of palmoplantar erythrodysaesthesia.
Topics: Administration, Oral; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Drug Approval | 2008 |
[Case of gastric cancer with isolated brain metastasis successfully managed by gamma knife radiotherapy and chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined | 2008 |
The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; China; Cohort Studies | 2009 |
Gastric phenotype signet-ring cell carcinoma of the stomach with multiple bone metastases effectively treated with sequential methotrexate and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Signet Ring Cell; Female; | 2008 |
Nuclear factor kappa B: a marker of chemotherapy for human stage IV gastric carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Disease-Free Su | 2008 |
Paeoniflorin suppress NF-kappaB activation through modulation of I kappaB alpha and enhances 5-fluorouracil-induced apoptosis in human gastric carcinoma cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Benzoates; Bridged-Ring Compounds; | 2008 |
[FOLFOX versus PLF regimen in treatment of advanced gastric adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 2008 |
Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Com | 2009 |
Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2008 |
[Post-operative adjuvant treatment with oxaliplatin, fluorouracil, and leucovorin for local advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administra | 2008 |
[A case of long survival in Stage IV gastric carcinoma responding to combination treatment with paclitaxel and 5- fluorouracil followed by surgical resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gastrectomy; Humans; Middle Ag | 2008 |
[Postoperative radio-chemotherapy in locally advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2008 |
[Docetaxel-Cisplatin-5-Fu Combination Chemotherapy as a First-line Treatment in Patients with Metastatic or Recurred Gastric Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Humans; Neoplasm | 2007 |
Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 2009 |
The combination of docetaxel and cisplatin plus fluorouracil as neoadjuvant chemotherapy in the treatment of T4 stage gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2010 |
[A case of gastric cancer accompanied by disseminated carcinomatosis of bone marrow with DIC recovered by sequential therapy consisting of MTX and 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Neoplasms; Carcinoembryoni | 2008 |
Epidermal growth factor receptor as a predictor of tumor response to preoperative chemoradiation in locally advanced gastric carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2008 |
Decreased orotate phosphoribosyltransferase activity produces 5-fluorouracil resistance in a human gastric cancer cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; C | 2008 |
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2009 |
Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Black or African American; Capecitabine; Deox | 2008 |
Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma.
Topics: Animals; Annexin A5; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis R | 2009 |
Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Bone Marrow Diseases; Cell Proliferation; Drug | 2008 |
[ERCC1 mRNA expression levels and outcome of gastric cancer patients receiving oxaliplatin-based chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; DNA-Binding Proteins; Drug Therapy, Combination; Endonucleases; | 2008 |
Cutaneous metastasis of gastric adenocarcinoma: an exuberant and unusual clinical presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cachexia; Carcinoma, Signet Ring Cell; Etoposide; Fl | 2008 |
[Differential gene expression of the inhibitor of apoptosis proteins in docetaxel-resistant gastric cancer cells].
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Docetaxel; Dose-Response Relationship | 2008 |
[Study on adjuvant MTX-5-FU intraperitoneal chemotherapy for advanced gastric cancer].
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Infusions, Parent | 2008 |
[A long-term survival case of gastric cancer with liver metastases treated by hepatic arterial infusion chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Doxorubicin; Female; | 2008 |
[Hepatic artery infusion chemotherapy to three liver metastasis cases in which systemic chemotherapy was impossible or ineffective].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoembryonic Antigen; Female; Fluorouracil; Hepa | 2008 |
To widen the setting of cancer patients who could benefit from metronomic capecitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxyc | 2009 |
[Pre- and post-chemotherapy expressions of Th1 and Th2 type cytokines and their clinical significance in gastric cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Female; Flu | 2008 |
[Indications and results of palliative gastric resection in advanced gastric carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chemotherapy, Adjuvant; Female; Flu | 2009 |
Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2009 |
Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Ischemia; Cisplatin; Fluo | 2009 |
[A case of bone marrow carcinosis from gastric cancer that presented hypocalcemia caused by zoledronic acid during the treatment of methotrexate/5-fluorouracil sequential therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Calcinosis; Diphosph | 2009 |
Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinati | 2009 |
Survivin expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; Fluoro | 2009 |
A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camp | 2009 |
Serum 3'-sulfo-Lea indication of gastric cancer metastasis.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Biomarkers, Tumor; Cell Adhesion; Cell Movement | 2009 |
Blepharoptosis following oxaliplatin administration.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineopl | 2009 |
Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Chemotherapy, | 2009 |
5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels.
Topics: Adult; Aged; Angiotensin II; Brachial Artery; Cardiovascular Diseases; Colonic Neoplasms; Female; Fl | 2010 |
Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Assoc | 2009 |
Decreased expression of microRNA-143 and -145 in human gastric cancers.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blotting, Western; Cell Pr | 2009 |
Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene BCL2L12.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Camptothecin; Cell | 2009 |
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; E | 2009 |
Deriving the intrahepatic arteriovenous shunt rate from CT images and biochemical data instead of from arterial perfusion scintigraphy in hepatic arterial infusion chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Catheters, Indwelling; Colorectal Neoplasm | 2009 |
Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model.
Topics: Animals; Antimetabolites, Antineoplastic; Carbocyanines; Cell Line, Tumor; Cell Movement; Cytosine D | 2009 |
New perspectives in the treatment of advanced or metastatic gastric cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoplas | 2009 |
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2009 |
Use of adjuvant 5-fluorouracil and radiation therapy after gastric cancer resection among the elderly and impact on survival.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorourac | 2010 |
Chemosensitivity and survival in gastric cancer patients with microsatellite instability.
Topics: Aged; Antimetabolites, Antineoplastic; Disease Progression; Female; Fluorouracil; Humans; Lymphatic | 2009 |
Allelic imbalance at p53 and microsatellite instability are predictive markers for resistance to chemotherapy in gastric carcinoma.
Topics: Aged; Aged, 80 and over; Allelic Imbalance; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2009 |
[Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2009 |
[A case of advanced gastric and rectal cancer (double cancer) successfully treated with mFOLFOX6 therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma.
Topics: Adenocarcinoma, Scirrhous; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 2010 |
[Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassett | 2009 |
The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2010 |
Identification of GAS1 as an epirubicin resistance-related gene in human gastric cancer cells with a partially randomized small interfering RNA library.
Topics: Antibiotics, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP | 2009 |
Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Multiple | 2009 |
Hypoxia-inducible factor-1alpha expression predicts the response to 5-fluorouracil-based adjuvant chemotherapy in advanced gastric cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Drug | 2009 |
Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2010 |
Upregulation of human DNA binding protein A (dbpA) in gastric cancer cells.
Topics: Adenomatous Polyposis Coli Protein; Antineoplastic Agents; beta Catenin; Cadherins; CCAAT-Enhancer-B | 2009 |
Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Female; Fl | 2009 |
Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer.
Topics: Adenocarcinoma, Scirrhous; Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Combined Chemoth | 2009 |
Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2009 |
Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2010 |
Treatment of gastric cancer in Asia: the missing link.
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2009 |
Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; | 2010 |
Capecitabine after gastrectomy for advanced gastric cancer: have we got the patient right?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trial | 2010 |
Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Disease-Free Survival; Female; | 2009 |
Expression of livin in gastric cancer and induction of apoptosis in SGC-7901 cells by shRNA-mediated silencing of livin gene.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Apoptosis; | 2010 |
[Complete remission with FLEP chemotherapy for multiple liver metastasis from alpha-fetoprotein-producing gastric cancer--report of a case].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 2009 |
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clinical Trials, Phase III | 2009 |
A retrospective comparison of concurrent 5-fluorouracil or oral UFT in postoperative chemoradiation for gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2010 |
Toxicity against gastric cancer cells by combined treatment with 5-fluorouracil and mitomycin c: implication in oxidative stress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, T | 2010 |
Weekly docetaxel and cisplatin plus fluorouracil as a preoperative treatment for gastric cancer patients with synchronous multiple hepatic metastases: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluorouracil; Fo | 2010 |
[A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2009 |
Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Gastrectomy; Humans; Ma | 2010 |
HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Apoptosis; | 2010 |
[Neoadjuvant chemotherapy of FLEEOX regimen for unresectable gastric cancer resulting from advanced abdominal lymph nodes metastases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Epirubicin; Fem | 2009 |
Differential effects of 5-fluorouracil on glucose transport and expressions of glucose transporter proteins in gastric cancer cells.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Carcinoma, Signet Ring Cell; Cell Line, Tumor | 2010 |
[Evaluation of hepatic arterial infusion chemotherapy for liver metastasis from gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intr | 2009 |
[A case of long-term survival of unresectable-advanced gastric cancer due to chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2009 |
[A case in which intra-arterial chemotherapy for simultaneous hepatic metastases markedly improved AFP-producing gastric cancer].
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antimetabolites, Antineoplast | 2009 |
[A case of stage IV advanced esophageal cancer with a long term survival by radiation therapy combined with nedaplatin and 5-FU chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
Safety, efficacy and pharmacokinetics of S-1 in a hemodialysis patient with advanced gastric cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Drug Combinations; Fluorouracil; Humans; Ma | 2010 |
Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asci | 2009 |
[A prospective study of FOLFOX7 scheme as neoadjuvant chemotherapy for stage III gastric adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2009 |
[Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2010 |
Usefulness of staging laparoscopy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ci | 2010 |
Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-F | 2010 |
Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplat | 2010 |
[Histological complete response in a case of primary squamous cell carcinoma of the stomach treated by chemotherapy with docetaxel and cisplatin plus 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; C | 2010 |
Significance of occult neoplastic cells on tumor metastasis: a case report of gastric cancer.
Topics: Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Signet Ring Cell; Cell Differentiation; Chemothe | 2010 |
Targeted HER2 treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2010 |
CD40 signaling activated by agonistic anti-CD40 monoclonal antibody 5C11 has different effects on biological behavior of gastric carcinoma cells.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CD40 Antigens; Ce | 2010 |
[Oxaliplatin-based regimen for the treatment of advanced or metastatic gastric/esophagogastric junction cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junctio | 2009 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; | 2010 |
Cutaneous metastasis as first clinical manifestation of signet ring cell gastric carcinoma.
Topics: Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Signet Ring Cell; Deoxycytidine; Docetaxel; Fl | 2010 |
[Effect of combination of docosahexaenoic acid and fluorouracil on human gastric carcinoma cell strain MGC803].
Topics: Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docosahexaenoic Acids; Drug | 2010 |
Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Atrophy; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehyd | 2010 |
A case with cardiac tamponade as the first sign of primary gastric signet-ring cell carcinoma treated with combination therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cardiac Tamponade; Drug | 2010 |
Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2010 |
The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Dideoxynucleotides; Early Growth Respo | 2010 |
Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites.
Topics: Adult; Aged; Antineoplastic Agents; Ascites; Chemotherapy, Cancer, Regional Perfusion; Female; Fluor | 2010 |
Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2010 |
Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Col | 2010 |
Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Ant | 2010 |
Images in clinical medicine. Multiple Beau's lines.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Humans; Ma | 2010 |
Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 2010 |
Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Biomarkers, | 2011 |
Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; F | 2010 |
Adjuvant chemo-radiation for gastric adenocarcinoma: an institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2010 |
Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer.
Topics: Adenocarcinoma; Adenoma, Villous; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin | 2011 |
Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach - a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2010 |
[A case of gastric carcinoma with lung and liver metastasis successfully treated by mFOLFOX6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colectomy; Colonic Neoplasms; Female; | 2010 |
Wogonin potentiates the antitumor effects of low dose 5-fluorouracil against gastric cancer through induction of apoptosis by down-regulation of NF-kappaB and regulation of its metabolism.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Down-Re | 2010 |
Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as | 2010 |
The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-Fluorouracil or cisplatin on gastric cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothera | 2010 |
A quantitative evaluation of the determinant proteins for S-1 responsiveness in a biopsy specimen assists in patient selection to neoadjuvant therapy in cases of advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmaco | 2010 |
Capecitabine with radiation is an effective adjuvant therapy in gastric cancers.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Thera | 2010 |
LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Cell | 2010 |
Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Fluorouracil; Gene Kn | 2010 |
Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity.
Topics: Antimetabolites, Antineoplastic; Female; Fluorouracil; Genotype; Humans; Male; Middle Aged; Neurotox | 2010 |
RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Everolimus; Fluorouracil; G1 Phase; | 2010 |
Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette | 2010 |
New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; De | 2011 |
A predictive factor for the response to S-1 plus cisplatin in gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cisplatin; Dihydrouracil Dehydrogenase (NADP); Drug Co | 2010 |
[Oxaliplatin plus capecitabine for advanced gastric cancer: report of 38 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2010 |
Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Epirubicin; Fl | 2010 |
Metastatic lymph node targeted chemosensitivity test for gastric cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; An | 2011 |
[A successful resected case of far-advanced cancer at the esophagogastric junction by chemoradiotherapy with docetaxel, nedaplatin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Docetaxel; | 2010 |
Systemic chemotherapy for peritoneal disseminated gastric cancer with inadequate oral intake: a retrospective study.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; In | 2011 |
[Therapeutic effects of FOLFOX6 versus TLF regimen as the first line chemotherapy for advanced gastric cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Fluorou | 2010 |
Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouraci | 2010 |
[Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2010 |
Ischemic colitis after capecitabine plus cisplatin treatment in advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Colitis, Ischemic; Deoxycyt | 2011 |
[Effects of irinotecan and 5-FU combination therapy in gastric cancer--is combination therapy synergic?].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo | 2010 |
Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Fre | 2010 |
Trastuzumab for gastric cancer treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Folate-functionalized nanoparticles for controlled 5-Fluorouracil delivery.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Drug C | 2011 |
Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 2011 |
Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2010 |
Chemosensitivity test for 5-fluorouracil and 5-chloro-2, 4-dihydroxypyridine predicts outcome of gastric cancer patients receiving S-1 postoperatively.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Fem | 2010 |
Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.
Topics: Adult; Aged; Biomarkers; Cisplatin; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Fema | 2011 |
Unresectable gastric cancer with gastric outlet obstruction and distant metastasis responding to intraperitoneal and folfox chemotherapy after palliative laparoscopic gastrojejunostomy: report of a case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluoroura | 2010 |
Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Cyclin | 2011 |
[A case of duodenal invasion due to recurrent gastric cancer with obstructive jaundice treated by chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phyto | 2010 |
[A case of unresectable and multiple advanced primary cancers of the stomach and rectosigmoid colon with hepatic metastases successfully treated with FOLFIRI for local control of a gastric lesion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Leucovorin; Live | 2010 |
Post-operative radiochemotherapy in patients with gastric cancer: one department's experience of 56 patients.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Fluorouracil; Gastrectomy; Human | 2011 |
Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2010 |
Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer.
Topics: Antineoplastic Agents; Camptothecin; Cohort Studies; Female; Fluorouracil; Humans; Irinotecan; Kapla | 2011 |
Whole abdominal field versus standard field radiotherapy plus concomitant and adjuvant chemotherapy for patients with locally advanced gastric cancer.
Topics: Abdomen; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease- | 2011 |
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II | 2011 |
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II | 2011 |
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II | 2011 |
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II | 2011 |
A metabonomic approach to chemosensitivity prediction of cisplatin plus 5-fluorouracil in a human xenograft model of gastric cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplati | 2010 |
Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Feeding and Eating Di | 2010 |
[Improvement of drug therapy for advanced gastric cancer used at a municipal clinical dispensary].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
[5-FU/l-LV therapy is useful for hemodialysis patients with advanced gastric cancer].
Topics: Aged; Biopsy; Fluorouracil; Humans; Kidney Failure, Chronic; Leucovorin; Male; Neoplasm Staging; Ren | 2011 |
[A resected case of gastric regional lymph node metastasis from ascending colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colon, Ascending; Colonic Neoplasms; Combined M | 2011 |
[Successful withdrawal from disseminated intravascular coagulation caused by disseminated carcinomatosis of bone marrow originated from gastric cancer treated by sequential therapy consisting of MTX and 5-FU and palliative radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disseminated Intravascular Coagulati | 2011 |
Absence of CD71 transferrin receptor characterizes human gastric adenosquamous carcinoma stem cells.
Topics: Animals; Antigens, CD; Biomarkers, Tumor; Carcinogenicity Tests; Carcinoma, Adenosquamous; Drug Resi | 2012 |
Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cisplatin; Dideoxyn | 2011 |
Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cisplatin; Dideoxyn | 2011 |
Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cisplatin; Dideoxyn | 2011 |
Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cisplatin; Dideoxyn | 2011 |
Contribution of Epstein-Barr virus infection to chemoresistance of gastric carcinoma cells to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Culture Techniques; Cell Line, T | 2011 |
Calpain regulates thymidylate synthase-5-fluoro-dUMP complex levels associated with response to 5-fluorouracil in gastric cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Calpain; Cell Line, Tumor; Fluorodeoxyuridylate; Fluoroura | 2011 |
HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2011 |
Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Disease-Free Survival; Drug Combina | 2011 |
First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Feasibility Studies; Female; F | 2012 |
[Comparison of two types of digestive tract reconstruction after total gastrectomy in patients with gastric carcinoma].
Topics: Anastomosis, Roux-en-Y; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Capec | 2011 |
[Weekly regimen of paclitaxel liposome combined with cisplatin and 5-fluorouracil continuous infusion in the treatment of advanced gastric carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2011 |
Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doce | 2011 |
Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Ch | 2011 |
Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fema | 2011 |
Identification of 14-3-3β in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker.
Topics: 14-3-3 Proteins; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; | 2011 |
Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2012 |
Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2011 |
Disseminated intravascular coagulation as the presenting sign of gastric cancer during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma, Signet Ring | 2011 |
[A case of gastric cancer accompanied by disseminated carcinomatosis of bone marrow with DIC, and subdural hematoma successfully treated with sequential methotrexate and 5-fluorouracil therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Disseminated Intravasc | 2011 |
[Early postoperative intraperitoneal chemotherapy for the treatment of advanced gastric cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Gastrectomy; Hum | 2011 |
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cadherins; Cisplatin; Female; Fluorouracil; Galec | 2011 |
[Effect of 5-fluorouracil aerosol on the growth of human gastric cancer cell line MKN-45 in vitro].
Topics: Aerosols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Fluorouracil; Humans; Stomach | 2011 |
[Adjuvant chemotherapy for gastric cancer: more drugs do not mean better efficacy].
Topics: Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; | 2011 |
Complete response to chemoradiotherapy in a patient with synchronous double gastric and esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophage | 2011 |
Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: experience at the Medical University of Vienna.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2011 |
Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemother | 2012 |
Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil.
Topics: Acrylamides; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apopto | 2011 |
Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of β-catenin in gastric cancer.
Topics: Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; beta C | 2011 |
[Improved sensitivity of gastric carcinoma cells to fluorouracil-related drugs by transfection of thymidine phosphorylase gene].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; Floxuridine; Fluorou | 2011 |
Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2012 |
Complete pathologic response with combination oxaliplatin and 5-fluorouracil chemotherapy in an older patient with advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouraci | 2011 |
Weekly Taxotere and cisplatin with continuous-infusion 5-fluoruracil for the treatment of advanced gastric and esophageal cancer: a prospective, observational, single-institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetax | 2012 |
Development and evaluation of novel microemulsion based oral formulations of 5-fluorouracil using non-everted rat intestine sac model.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Benzo(a)pyrene; Biological Availabil | 2012 |
Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Fluorouracil; | 2012 |
[Irinotecan as second-line chemotherapy for 5-FU-resistant gastric cancer with disseminated intravascular coagulation: a case report].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Disseminated Intravascular Coagulation; Fatal Outco | 2011 |
Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2011 |
Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2011 |
Postoperative chemoradiation for resected gastric cancer--is the Macdonald Regimen Tolerable? a retrospective multi-institutional study.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Combined Modality Therapy; Disease-Free Survival; | 2011 |
Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T).
Topics: Abdominal Neoplasms; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antibiotics, Antineoplastic; Antimetabolite | 2011 |
Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2012 |
The value of palliative gastrectomy in gastric cancer with distant metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 2012 |
Postoperative chemotherapy followed by conformal concomitant chemoradiotherapy in high-risk gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chem | 2012 |
miRNA signature associated with outcome of gastric cancer patients following chemotherapy.
Topics: Adult; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gastric Muco | 2011 |
The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2012 |
Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2012 |
Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2012 |
Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; F | 2012 |
[Comparison of the toxicities and efficacies of the combination chemotherapy regimens in advanced gastric cancer patients who achieved complete response after chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ci | 2011 |
[A case report of multiple adenocarcinoma in small intestine after total gastrectomy by Roux-en-Y re-construction].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Gastrectomy | 2011 |
Thymoquinone inhibits growth and augments 5-fluorouracil-induced apoptosis in gastric cancer cells both in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzoquinones; Drug Resist | 2012 |
Unusual course of an abdominal aortic aneurysm in a patient treated with chemotherapy for gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm, Abdominal; Aortogra | 2012 |
Survivin knockdown enhances gastric cancer cell sensitivity to radiation and chemotherapy in vitro and in nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Female; | 2012 |
Comparing cystatin C changes as a measure of renal function before and after radiotherapy in patients with stomach cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers; Blood Urea Nitrogen; Capecitabine; Chemoradiother | 2012 |
Cetuximab combined with FOLFOX4 as the first-line treatment for advanced gastric cancer: report of 25 cases from a single institution.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Reduced lymph node harvest after neoadjuvant chemotherapy in gastric cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Demog | 2011 |
Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines.
Topics: Antibodies, Monoclonal, Humanized; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bio | 2012 |
Anti-mitotic potential of 7-diethylamino-3(2'-benzoxazolyl)-coumarin in 5-fluorouracil-resistant human gastric cancer cell line SNU620/5-FU.
Topics: Antimetabolites, Antineoplastic; Antimitotic Agents; Apoptosis; Benzoxazoles; Cell Line, Tumor; Cell | 2012 |
Interobserver variability in target volume delineation in postoperative radiochemotherapy for gastric cancer. A pilot prospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Fluorouracil; Follow-Up S | 2012 |
Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with node-negative gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2012 |
Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line | 2012 |
[HER-2 expression in advanced gastric cancer and its correlation with clinical features, outcome and prognosis].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Laparoscopic gastrectomy for patients with advanced gastric cancer produces oncologic outcomes similar to those for open resection.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Case-Control Studies; Chemoradiotherapy, Adjuvant; Dis | 2012 |
First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Capecitabine; Cel | 2012 |
Octarepeat peptides of prion are essential for multidrug resistance in gastric cancer cells.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Cisplatin; Doxorubici | 2012 |
Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabine; Cisplatin; Deoxy | 2013 |
EBP50 gene transfection promotes 5-fluorouracil-induced apoptosis in gastric cancer cells through Bax- and Bcl-2-triggered mitochondrial pathways.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Drug Resis | 2012 |
Apoptosis index correlates with chemotherapy efficacy and predicts the survival of patients with gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apop | 2012 |
Adjuvant chemoradiation for gastric cancer: multicentric study of the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, A | 2012 |
Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2012 |
Effectiveness and safe use of modified FOLFOX-6 for metastatic gastric cancer with signet ring cell components complicated by disseminated intravascular coagulation and diffuse bone marrow carcinomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma; Carcinoma, Signet | 2012 |
Adjuvant chemoradiotherapy (CRT) for high-risk gastric cancer (GC) patients: single-center experience using infusional 5-fluorouracil (5FU) and radiotherapy (RT).
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Fluorouracil; Humans; Middle Aged; Sto | 2012 |
[A case of gastric cancer treated with modified docetaxel, cisplatin and 5-fluorouracil(mDCF)with ingestion inability].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxe | 2012 |
Plasma diamine oxidase activity is a useful biomarker for evaluating gastrointestinal tract toxicities during chemotherapy with oral fluorouracil anti-cancer drugs in patients with gastric cancer.
Topics: Administration, Oral; Adult; Aged; Amine Oxidase (Copper-Containing); Antimetabolites, Antineoplasti | 2012 |
Enhancement of anticancer efficacy of chemotherapeutics by gambogic acid against gastric cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Docetaxel; Drug Synergi | 2012 |
Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Chi | 2012 |
Bilateral acute ptosis leading to the diagnosis of a presumed metastatic gastric adenocarcinoma.
Topics: Acute Disease; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blepharoptosis; Capec | 2012 |
Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Chemotherapy, Adjuvant; Dihydrouracil Dehy | 2012 |
Adjuvant chemoradiation with 5-fluorouracil or capecitabine in patients with gastric cancer after D2 nodal dissection.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; | 2012 |
The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Fluorouracil; G | 2012 |
[A successful resected case of advanced esophageal cancer with early gastric cancer responding to neoadjuvant chemotherapy of docetaxel, CDDP and 5-FU].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Ce | 2012 |
A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2013 |
Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cel | 2012 |
Downregulation of gastrokine-1 in gastric cancer tissues and restoration of its expression induced gastric cancer cells to apoptosis.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Cell Survival; Epithelium; Female; Fluorouracil; Gastric M | 2012 |
Adenovirus-mediated double suicide gene selectively kills gastric cancer cells.
Topics: Adenoviridae; Animals; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2012 |
The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Co | 2012 |
Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free S | 2012 |
[Impact of AJCC staging system (2010 edition) on the choice of postoperative adjuvant chemotherapy after radical resection of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Femal | 2012 |
Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function.
Topics: Acetylcholinesterase; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2012 |
Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area | 2012 |
[Antitumor effect of sphingosine kinase 1 inhibitor in combination with chemotherapy on SGC7901 gastric cancer cells in vitro].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumo | 2012 |
[Isolation and characterization of side population cells in human gastric cancer cell line BGC-823].
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Colony-Forming Units | 2012 |
[The chemotherapy with mFOLFOX6 for advanced colon cancer was effective for gastric cancer - a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Human | 2012 |
Overexpression of cyclin L2 inhibits growth and enhances chemosensitivity in human gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Prolifer | 2012 |
Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, epirubicin and cisplatin (modified ECF) as adjuvant chemotherapy in resected gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Disease-Free | 2012 |
Efficacy and safety of neoadjuvant chemotherapy with modified FOLFOX7 regimen on the treatment of advanced gastric cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Mal | 2012 |
The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc | 2012 |
Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Routes; Epirubicin; | 2012 |
Molecular marker identification for relapse prediction in 5-FU-based adjuvant chemotherapy in gastric and colorectal cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor | 2012 |
cRGD conjugated mPEG-PLGA-PLL nanoparticles for SGC-7901 gastric cancer cells-targeted Delivery of fluorouracil.
Topics: Antineoplastic Agents; Cell Line, Tumor; Diffusion; Fluorouracil; Humans; Materials Testing; Molecul | 2012 |
Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Autophagy-Related Protein 12; Autoph | 2013 |
Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Fluoroura | 2012 |
Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2012 |
Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Basic-Leucine Zipper Transcription Factors; Blotting | 2013 |
Prostaglandin reductase 2 modulates ROS-mediated cell death and tumor transformation of gastric cancer cells and is associated with higher mortality in gastric cancer patients.
Topics: 15-Oxoprostaglandin 13-Reductase; Alcohol Dehydrogenase; Animals; Caspase 3; Cell Death; Cell Line, | 2012 |
Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Doce | 2012 |
Enhanced RegIV expression predicts the intrinsic 5-fluorouracil (5-FU) resistance in advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2013 |
[64-year-old patient with alterations of the fingernails].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diagnosis, Differential; Esophagogastric | 2012 |
The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dr | 2012 |
Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; | 2013 |
Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel | 2013 |
Endoscopic self-expandable metallic stent placement in malignant pyloric or duodenal obstruction: does chemotherapy affect stent patency?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiopancreatography, Endoscopic Retrograd | 2013 |
Cytostatic activity of a 5-fluoro-2'-deoxyuridine-alendronate conjugate against gastric adenocarcinoma and non-malignant intestinal and fibroblast cell lines.
Topics: Adenocarcinoma; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Cell Line; Cell Line, | 2012 |
[Long-term survival of a case of advanced cancer of the esophagogastric junction with complete response to low-dose 5-fluorouracil and cisplatin chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophagogastric Jun | 2012 |
[A case of recurrent gastric cancer showing partial response to capecitabine/CDDP after treatment with S-1/CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug C | 2012 |
Prognostic analysis of patients with operable gastric cancer and tolerability to adjuvant radio-chemo-therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2013 |
Pathological complete response and two-year disease-free survival in a primary gastric choriocarcinoma patient with advanced liver metastases treated with germ cell tumor-based chemotherapy: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Choriocarcinoma, Non-gestat | 2012 |
Upregulation of periostin prevents P53-mediated apoptosis in SGC-7901 gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Adhesion Molecules; Cell Line, | 2013 |
Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2013 |
Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasm | 2012 |
Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Blotting, Western; | 2013 |
Chemosensitivity in ovarian metastases from gastric cancer: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Female; Fluorouracil | 2013 |
Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Bcl-2-Like P | 2013 |
miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Fluorouracil; Gene Expression Regulation, Neoplast | 2012 |
An immunoassay method for the pharmacokinetics of 5-fluorouracil in patients with gastric cancer administered adjuvant chemotherapy.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Chemotherapy, Adjuvant; Drug Combinations; Female; Fl | 2012 |
Double pancreatic and gastric adenocarcinomas: a rare association.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; | 2013 |
Local recurrence of gastric cancer after total gastrectomy: an unusual presentation.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoth | 2012 |
Aberrant upregulation of ASCL2 by promoter demethylation promotes the growth and resistance to 5-fluorouracil of gastric cancer cells.
Topics: Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; DNA Methylation; Drug Resistance, Ne | 2013 |
Evaluation of 5-FU plasma concentration by 13C breath test in patients treated with oral 5-FU analogs.
Topics: Acetates; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breath Tests; Carbon Isotopes | 2012 |
Metabolomic analysis of dynamic response and drug resistance of gastric cancer cells to 5-fluorouracil.
Topics: Amino Acids; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Drug Resistance, Neop | 2013 |
[A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy].
Topics: Adenocarcinoma, Scirrhous; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy P | 2012 |
Clinical safety and efficacy of Kanglaite® (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control | 2012 |
Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Topics: 3' Untranslated Regions; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; | 2013 |
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brid | 2013 |
Endoscopic ultrasound in restaging and predicting pathological response for advanced gastric cancer patients after neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Endo | 2014 |
[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capsules; Drug Combinations; Fem | 2012 |
A retrospective study of the safety and efficacy of a first-line treatment with modified FOLFOX-4 in unresectable advanced or recurrent gastric cancer patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Ad | 2012 |
[Efficacy of capecitabine/cisplatin chemotherapy after failure of all conventional therapies in patients with advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female | 2013 |
High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Fem | 2013 |
REG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; | 2013 |
Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy.
Topics: Adult; Aged; Contrast Media; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; N | 2012 |
Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Cisplatin; Dopa Decarboxylase; Dose-Response Re | 2013 |
MDM2 is a useful prognostic biomarker for resectable gastric cancer.
Topics: Aged; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemotherapy, Adjuvant | 2013 |
[A pilot study of chemotherapy combined with intraperitoneal perfusion of cytokine-induced killer cells for advanced gastric cancer patients with ascites].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabin | 2013 |
Oxaliplatin-induced Torsades de pointes and long QT syndrome in a patient with gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Long QT Synd | 2013 |
The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chi- | 2013 |
Combination 5-fluoruracil/cisplatinum versus 5-fluoruracil/leucovorin adjuvant chemotherapy efficacy for R0 gastric resection in locally invasive gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; F | 2012 |
[Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Ascitic Fluid; Drug Combinati | 2002 |
Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Cell Division; Cell S | 2002 |
Non-surgical treatment for afferent loop syndrome in recurrent gastric cancer complicated by peritoneal carcinomatosis: percutaneous transhepatic duodenal drainage followed by 24-hour infusion of high-dose fluorouracil and leucovorin.
Topics: Adenocarcinoma; Afferent Loop Syndrome; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2002 |
[Some light for the prognosis of gastric cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality | 2001 |
Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxo | 2002 |
Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2002 |
[A case of advanced gastric cancer responding to combination chemotherapy with low-dose 5-FU plus CDDP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2002 |
[Gastric cancer with multiple liver metastases, which responded significantly to oral administration of TS-1 following intravenous FMP therapy under hospitalization].
Topics: Adenocarcinoma; Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combine | 2002 |
[Effective weekly paclitaxel administration for gastric cancer with malignant ascites--a case report].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinom | 2002 |
[A case of recurrent gastric cancer that responded dramatically to docetaxel and 5'-DFUR combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr | 2002 |
[A case of gastric cancer with multiple liver metastases responding to combined hepatic arterial and aortic infusion chemotherapy with cisplatinum, 5-fluorouracil, and levofolinate calcium].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2002 |
5-Fluorouracil inhibits nitric oxide production through the inactivation of IkappaB kinase in stomach cancer cells.
Topics: Antimetabolites, Antineoplastic; Cytokines; Drug Interactions; Enzyme Activation; Fluorouracil; Huma | 2002 |
Gastrostomy-site tumor recurrence is not always fatal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brachytherapy; Carcinoma, Squamous Cell; Flu | 2003 |
[Postoperative adjuvant immunochemotherapy using Lentinan for advanced gastric carcinoma patients with metastasis in the regional lymph nodes and serosal invasion].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2002 |
A long-term survival case of gastric cancer treated by continuous low-dosage 5-fluorouracil and cisplatin: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Male; Middle Aged; | 2002 |
[In situ gene therapy for murine gastric carcinoma with UPRT/5-FU enzyme/prodrug system mediated by retrovirus].
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; DNA, Neoplasm; Female; Fluorouracil; Gene E | 2002 |
[A case of postoperative hepatic metastasis from gastric cancer responding to hepatic arterial infusion chemotherapy of paclitaxel].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Dru | 2002 |
[Evaluation of intra-arterial infusion chemotherapy for liver metastasis from gastric cancer FEM--combination therapy of 5 FU, Epirubicin and MMC].
Topics: Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Hepatectomy; Humans; Infus | 2002 |
[Effect of hepatic arterial infusion chemotherapy for liver metastasis from gastric cancer].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin | 2002 |
[Efficacy of intraperitoneal chemotherapy for advanced Borrmann type IV gastric carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Infus | 2002 |
[Combination chemotherapy with intra-perioneal infusion of CDDP and continuous intravenous infusion of 5-FU for peritoneal metastasis in gastric cancer--analysis of long-term survivors].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Drug Therapy, Combin | 2002 |
[A case of carcinomatous enterodermal fistula successfully treated with arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Cathe | 2002 |
[A case of pyloric or antral malignant stenosis treated with arterial infusion chemotherapy and palliative therapy--self-expandable metal stents through gastrostomy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2002 |
[A case of postoperative multiple hepatic metastasis from gastric cancer successfully treated by percutaneous microwave coagulation therapy and hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubi | 2002 |
[A case of gastric cancer associated with synchronous liver metastasis successfully treated with combination therapy of systemic and hepatic arterial infusion chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2002 |
Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR.
Topics: Animals; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Male; Mice; Mice, Inbred | 2002 |
[Clinical comparison between intraoperative local arterial infusion chemotherapy and systemic venous chemotherapy of gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxo | 2001 |
[Effectiveness of chemotherapy for outpatients with gastric or colorectal cancer].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplati | 2002 |
[A case of advanced gastric adenocarcinoma with mild elevation of serum SCC that responded remarkably to adjuvant chemotherapy of ADM, CDDP, ETP and 5-FU (ACVF)].
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chemothera | 2003 |
Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combina | 2003 |
[Effect of shenqi fuzheng injection on immune function in gastric carcinoma patients in post-operational and chemotherapeutic period].
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Dr | 2001 |
[A case report--TS-1/CDDP combined chemotherapy found effective for metastatic recurrence after operation for colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colon, Sigmoid; Combined Modality T | 2003 |
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen).
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2003 |
Sclerosing encapsulating peritonitis (SEP) as a delayed complication of continuous hyperthermic peritoneal perfusion (CHPP): report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; | 2003 |
A case of aggressive neuroendocrine carcinoma of the stomach.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2003 |
[Study on the chemosensitivity test of human gastric cancer using the MTT assay].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Drug Screening Assays, Antitumor; Fem | 2001 |
S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug | 2003 |
Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Disease Models, Animal; Drug Combinations; Ea | 2003 |
Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehyd | 2003 |
Exogenous wild-type p16INK4A gene induces delayed cell proliferation and promotes chemosensitivity through decreased pRB and increased E2F-1 expressions.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Cycle Proteins; Cell Divisi | 2003 |
[Oxaliplatin in combination with LV5FU2 for advanced/metastatic gastric cancer-a multicenter study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovori | 2003 |
Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray.
Topics: Antineoplastic Agents; Cell Division; Cisplatin; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neopla | 2003 |
[Thirteen years' survival in a patient with isolated skin metastases of a gastric carcinoma. What kind of disease is that?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cisplatin; Cobalt Radio | 2003 |
[The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Cisplatin; Colore | 2003 |
[A case of advanced gastric cancer with lymphangitis carcinomatosa of the lung, successfully treated with paclitaxel and TS-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Drug Resistance, | 2003 |
[Cancer of the gastric antrum].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy; Combined Modality Therapy; Fluorourac | 2003 |
[Preliminary report of semimonthly 5-fluorouracil/leucovorin combined with paclitaxel in treatment of advanced gastric cancer (AGC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 2003 |
[A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy].
Topics: Adenocarcinoma; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; | 2003 |
[A case of effective weekly paclitaxel administration for metastatic gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cis | 2003 |
Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line.
Topics: Active Transport, Cell Nucleus; Antimetabolites, Antineoplastic; Apoptosis; Binding Sites; Carcinoma | 2003 |
Mitomycin C (MMC) with weekly 24-hour infusions of high-dose 5-fluorouracil and leucovorin in patients with advanced gastric cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2003 |
Carcinoma of the stomach: treatment with 5-fluorouracil.
Topics: Carcinoma; Fluorouracil; Humans; Stomach Neoplasms | 1963 |
CHEMOTHERAPY OF METASTATIC LIVER CANCER BY PROLONGED HEPATIC-ARTERY INFUSION.
Topics: Alkaline Phosphatase; Bile Duct Neoplasms; Bilirubin; Chemotherapy, Cancer, Regional Perfusion; Colo | 1964 |
EARLY RESULTS OF COMBINED RADIATION AND CHEMOTHERAPY IN TREATMENT OF MALIGNANT TUMORS.
Topics: Antineoplastic Agents; Colonic Neoplasms; Dactinomycin; Fluorouracil; Humans; Lung Neoplasms; Mitomy | 1963 |
5-FLUOROURACIL (NSC-19893) TREATMENT OF ADVANCED CANCER IN AMBULATORY PATIENTS.
Topics: Ampulla of Vater; Bile Duct Neoplasms; Breast Neoplasms; Colonic Neoplasms; Fluorouracil; Humans; Ne | 1963 |
VINCRISTINE (NSC-67574) THERAPY OF ADULT PATIENTS WITH SOLID TUMORS.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Bronchogenic; Carcinoma, Squamous | 1964 |
[NEW ANTIBLASTIC AGENTS].
Topics: Antineoplastic Agents; Colonic Neoplasms; Ethoglucid; Fluorouracil; Neoplasm Metastasis; Neoplasms; | 1963 |
PRESENT-DAY MANAGEMENT OF GASTRIC CANCER.
Topics: Fluorouracil; Gastrectomy; Humans; Mitomycin; Mitomycins; Mortality; Neoplasms; Stomach Neoplasms | 1964 |
ACUTE GASTRITIS RESULTING FROM REGIONAL INFUSION OF AN ANTIMETABOLITE.
Topics: Adenocarcinoma; Angiography; Antimetabolites; Chemotherapy, Cancer, Regional Perfusion; Diagnosis, D | 1963 |
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human | 1964 |
TREATMENT OF ADVANCED CANCER WITH 5-FLUOROURACIL.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Humans; Leuko | 1964 |
INDIVIDUALIZED CHEMOTHERAPY BY IN VITRO DRUG SELECTION.
Topics: Antineoplastic Agents; Bone Neoplasms; Dactinomycin; Female; Floxuridine; Fluorouracil; Genital Neop | 1964 |
EXPERIENCE WITH CHEMOTHERAPY OF CANCER AT THE UNIVERSITY OF PRETORIA.
Topics: Antineoplastic Agents; Aziridines; Breast Neoplasms; Cyclophosphamide; Dactinomycin; Fluorouracil; H | 1964 |
PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER.
Topics: Adenocarcinoma; Ascites; Deglutition Disorders; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasms | 1964 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
PROTRACTED AMBULATORY INFUSION CANCER CHEMOTHERAPY BY THE WATKINS CHRONOMETRIC INFUSOR.
Topics: Adenoma; Antineoplastic Agents; Breast Neoplasms; Carcinosarcoma; Colonic Neoplasms; Dermatitis, Exf | 1964 |
REGIONAL INTRA-ARTERIAL INFUSION OF 5-FLUOROURACIL FOR CANCER.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Carcinoma, Squamous Cell; Female; Fluorouracil; Glioblast | 1964 |
STUDIES IN THE TOXICITY AND CLINICAL APPLICATION OF 5-FLUOROURACIL.
Topics: Adenocarcinoma; Agranulocytosis; Biomedical Research; Diarrhea; Diverticulitis; Drug Eruptions; Fluo | 1964 |
CHEMOTHERAPEUTIC AGENTS IN THE MANAGEMENT OF GASTRIC CANCER.
Topics: Antineoplastic Agents; Fluorouracil; Stomach Neoplasms; Toxicology | 1964 |
CHEMOTHERAPY OF MALIGNANCIES OF THE GASTROINTESTINAL TRACT.
Topics: Antineoplastic Agents; Carcinoid Tumor; Colonic Neoplasms; Cyclophosphamide; Fluorouracil; Gastroint | 1965 |
TREATMENT OF MALIGNANT NEOPLASMS OF THE GASTROINTESTINAL TRACT WITH A COMBINATION OF 5-FLUOROURACIL AND RADIATION: A RANDOMIZED DOUBLE-BLIND STUDY.
Topics: Adenocarcinoma; Colonic Neoplasms; Double-Blind Method; Drug Therapy; Fluorouracil; Humans; Neoplasm | 1965 |
Neoadjuvant chemotherapy: a standard treatment for locally advanced gastric cancer in the near future?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 2003 |
Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dihydrouracil Dehydrogena | 2003 |
Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Female; Fluorourac | 2003 |
High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluo | 2003 |
[Evaluation of intraarterial infusion chemotherapy for liver metastasis from gastric cancer FEM: combination therapy of 5-FU, epirubicin and MMC].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Female; Fl | 2003 |
[Evaluation of arterial infusion chemotherapy for liver metastasis from gastric cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administrat | 2003 |
[Pancytopenia and ARDS with high dose hepatic arterial infusion].
Topics: Aged; Antimetabolites, Antineoplastic; Cisplatin; Drug Combinations; Female; Fluorouracil; Gastrecto | 2003 |
[Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Carcinom | 2003 |
[A case of advanced cancer with liver metastasis and paraaortic lymph node metastasis responding remarkably to combination chemotherapy of low-dose CDDP, 5-FU and CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Cisplatin; Drug Administration | 2003 |
[A case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr | 2003 |
[A case of gastric carcinoma with multiple skin, bone, and bilateral ovary metastasis; effective treatment by chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; | 2003 |
[Effective use of combination chemotherapy with paclitaxel and 5-fluorouracil in a case of non-resectable advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluorouracil; Hu | 2003 |
Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2 Homologous Antagonist-Killer Prot | 2004 |
Modified pharmacokinetic modulating chemotherapy using 5-fluorouracil, UFT, and taxotere (docetaxel) for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Docetaxel; Fluorouracil; Humans; Infusion | 2003 |
Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Drug Resistance, Neoplasm; Electr | 2004 |
[Support of TS-1, 5-FU preparation containing potent DPD inhibitor by determination of urinary uracil/serum 5-FU clearance].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; | 2003 |
[A case of advanced gastric cancer with multiple liver metastases responding completely to hepatic arterial infusion and systemic chemotherapies].
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoth | 2003 |
Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Dihydrouracil Dehydrogenase | 2004 |
Docetaxel regimen provides survival benefits in advanced stomach cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorou | 2003 |
[Patient with stomach cancer with metastases. What is the value of chemotherapy?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm | 2003 |
Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays.
Topics: Antineoplastic Agents; Carrier Proteins; Cisplatin; Cytokines; Doxorubicin; Drug Resistance, Multipl | 2004 |
[Neoadjuvant chemotherapy for locally advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2003 |
DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Cluster Analysis; Disease Progression; Down-Re | 2004 |
[A case of advanced gastric cancer with DIC treated by sequential MTX and 5-FU].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disseminated I | 2004 |
[A case of gastric cancer with a synchronous hepatic metastasis responding to postoperative oral administration of UFT and intermittent intrahepatic arterial chemotherapy of 5-FU].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Adm | 2004 |
Inactivating mutation of the pro-apoptotic gene BID in gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Carr | 2004 |
Influence of high-dose leucovorin and 5-fluorouracil chemotherapy regimen on P wave duration and dispersion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Carcinoma; Colorectal Neoplas | 2004 |
Usefulness of 99mTc-sestamibi scintigraphy in suggesting the therapeutic effect of chemotherapy against gastric cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; AT | 2004 |
Combination chemotherapy with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Fluorour | 2004 |
Sensitivity of scirrhous gastric cancer to 5-fluorouracil and the role of cancer cell-stromal fibroblast interaction.
Topics: Antimetabolites, Antineoplastic; Calcium Channel Blockers; Cell Division; Cell Line; Cell Line, Tumo | 2004 |
Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Dr | 2004 |
[A case of curatively resected gastric cancer through an effective response to chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 2004 |
[A case report of unresectable gastric cancer that responded to 5-FU plus paclitaxel (FT) therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; Fluorouracil; | 2004 |
Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU.
Topics: Adenocarcinoma; Animals; Cisplatin; Dihydrouracil Dehydrogenase (NADP); Drug Therapy, Combination; F | 2004 |
S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study.
Topics: Adenocarcinoma, Mucinous; Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2004 |
Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Fluorouracil; Forecasting; Gene Expression P | 2004 |
[Occlusion of central venous port catheters after simultaneous 24 h infusions of 5-FU and calcium-folinic acid in patients with gastrointestinal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Carbonate; Catheterization, Central Ve | 2004 |
Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ci | 2004 |
Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Di | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
Curcumin inhibits the growth of AGS human gastric carcinoma cells in vitro and shows synergism with 5-fluorouracil.
Topics: Cell Division; Curcumin; Dose-Response Relationship, Drug; Drug Synergism; Fluorouracil; G2 Phase; H | 2004 |
Treatment issues in pediatric gastric adenocarcinoma.
Topics: Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Sig | 2004 |
[Relationship of methylenetetrahydrofolate reductase C677T polymorphism and chemosensitivity to 5-fluorouracil in gastric carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Male; Met | 2004 |
[Preparation of the 5-Fu floating sustained release tablet for gastric retention].
Topics: Antimetabolites, Antineoplastic; Delayed-Action Preparations; Drug Compounding; Drug Design; Fluorou | 2004 |
Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Gene Ex | 2004 |
Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Topics: Administration, Oral; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Kidney | 2004 |
ECF in gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Fluorou | 2004 |
Nail changes during docetaxel containing combination chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2004 |
[A case of recurrent stomach cancer treated with 5-fluorouracil responding to weekly paclitaxel therapy].
Topics: Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Resistance, Neoplasm; Fl | 2004 |
Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity.
Topics: Agar; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2004 |
FLEP chemotherapy for alpha-fetoprotein-producing gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Ascites; Dihydrouracil Dehydrogenase | 2004 |
Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Base Pair Mismatch; Carrier Proteins; Cell Division; Cell Line | 2004 |
[Gastric cancer with liver metastasis effectively treated by intra-hepatic arterial infusion].
Topics: Administration, Oral; Adult; Aged; Agmatine; Antineoplastic Combined Chemotherapy Protocols; Cisplat | 2004 |
[A case report of the 8 year survivor--unresectable liver metastases from advanced gastric cancer (Stage IV) were completely responsive, after 4 years from a total sequential gastrectomy, combining docetaxel treatment to regress the recurrence].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Do | 2004 |
[Three successful case reports of advanced gastric cancer with chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2004 |
[MTX/CDDP/5-FU double modulation intra-peritoneal chemotherapy for advanced and metastatic gastric cancer--comparison with intra-aortic route and intra-venous route].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Infus | 2004 |
[A case of gastric cancer patient with liver metastasis treated by radiofrequency ablation therapy combined with intra-arterial chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cisplatin; | 2004 |
[Intrahepatic arterial chemotherapy with 5-fluorouracil and intramuscular interferon-alpha for a patient with diffuse type of hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration | 2004 |
[Cases of postoperative hepatic metastasis from gastric cancer in which hepatic arterial infusion chemotherapy with 5-FU, adriamycin and cisplatin was performed after TS-1 chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Fluorouracil; Hepatic | 2004 |
[Taxol based chemotherapy in the treatment of advanced gastric cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administratio | 2004 |
[Palliative surgery combined with oxaliplatin-based chemotherapy in treatment of patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2004 |
[Biweekly regimen of high dose of leucovorin, 5-fluorouracil, and paclitaxel for patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2004 |
[Drug distribution in gastric cancer and adjacent tissues by preoperative intraperitoneal chemotherapy with Co-fluorouracil liposome].
Topics: Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Gastric Mucosa; Humans; Infusions, Pare | 2004 |
Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, | 2004 |
Does cisplatin (CDDP) function as a modulator of 5-fluorouracil (5-FU) antitumor action? A study based on a clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Female; Fluorouraci | 2005 |
[A case report of recurrent gastric cancer in which combination chemotherapy with paclitaxel and 5-fluorouracil made for successful biliary stenting and improvement in QOL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Biliary Tract; Chemotherapy, Adjuvant; Drug | 2005 |
[Two cases of gastric cancer with multiple liver metastases responding to TS-1 with hepatic arterial infusion of CDDP following low-dose 5-FU and CDDP chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relat | 2005 |
Concurrent proton beam radiotherapy and systemic chemotherapy for the metastatic liver tumor of gastric carcinoma: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2005 |
Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administrati | 2005 |
[Elevated expression level of wild-type survivin in gastric cancer promotes in vitro docetaxel-resistance].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2004 |
[The impact of decreased Stat3 activation on 5-fluorouracil resistance of human gastric cancer cell line].
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; | 2004 |
[Influence of chemotherapy on Th1/Th2 cytokine switching in stomach cancer patients].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; | 2004 |
[Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Admin | 2004 |
Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
Topics: Animals; Antibodies, Viral; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality | 2005 |
[Polymorphism of methylenetetrahydrofolate reductase and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Female; Fluorouracil; Genot | 2004 |
Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Becaplermin; Benzamides; Blottin | 2005 |
[Evaluation of low-dose FP therapy as adjuvant therapy for gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dose | 2005 |
[Effect of steroid on antiemetic for side effect of anticancer chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dexamethasone; Drug Administration S | 2005 |
[Antitumor effects of chemotherapeutic drugs on fresh human gastric cancer cells and their relationships to expressions of P-glycoprotein and glutathione S transferase-pi].
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothe | 2005 |
Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal N | 2005 |
Post-operative radiochemotherapy for gastric cancer: adoption and adaptation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Human | 2005 |
Regulation of multidrug resistance by ribosomal protein l6 in gastric cancer cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
[Modified pharmacokinetic modulating chemotherapy for progressive gastric cancer accompanied by peritoneal dissemination].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiotensin II; Antineoplastic Combined Chemot | 2005 |
[A case of advanced gastric cancer with bone metastasis and severe DIC responding to hypertensive subselective chemotherapy with pharmacokinetic modulating chemotherapy].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Signet Ri | 2005 |
Apoptosis induced by 5-fluorouracil, cisplatin and paclitaxel are associated with p53 gene status in gastric cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; DNA, Neoplasm; Flow Cytometry; Fluoro | 2005 |
Synergistic effects of matrine and 5-fluorouracil on tumor growth of the implanted gastric cancer in nude mice.
Topics: Adenocarcinoma; Alkaloids; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogen | 2005 |
Miliary brain metastases from primary gastric small cell carcinoma: illustrating the seed and soil hypothesis.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Brain Neoplasms; Carcinoma, Neur | 2005 |
[TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Area Under Curve; Drug Administration Schedu | 2005 |
[Clinical significance of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in Korean patients with gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Screening Assays, Antitumor; Female; Fluorouracil; Human | 2005 |
[Establishment of enzyme-linked immunosorbent assay for quantification of orotate phosphoribosyltransferase in gastric carcinoma].
Topics: Animals; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Humans; Mice; Mice, Nud | 2005 |
Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells.
Topics: Adenocarcinoma, Scirrhous; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cycl | 2005 |
The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs.
Topics: Antineoplastic Agents; Apoptosis; Bisbenzimidazole; Cell Line, Tumor; Cisplatin; Drug Resistance, Ne | 2005 |
Is adjuvant therapy with three-dimensional conformal irradiation combined with capecitabine (Xeloda) for gastric cancer effective?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; | 2005 |
Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Disease-Free Survival; Female; Fluorouracil; Hemoglobins; Human | 2006 |
An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluoro | 2005 |
Long-term complete remission of metastatic gastric cancer after weekly docetaxel, 24 h infusion of high-dose 5-FU/leucovorin and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Digestive System Surgical Procedures; Doc | 2005 |
[Stage IV gastric cancer patient who underwent palliative gastrectomy showing complete response to induction therapy with methotrexate plus 5-fluorouracil and secondary treatment with oral TS-1].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2005 |
Impact of orotate phosphoribosyl transferase activity as a predictor of lymph node metastasis in gastric cancer.
Topics: Aged; Antineoplastic Agents; Cell Proliferation; Female; Fluorouracil; Humans; Lymphatic Metastasis; | 2005 |
Just when you thought the fluorouracil debate was over: S-1 and gastric cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2005 |
Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Fe | 2005 |
[Treatment strategy for primary gastric cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Flu | 2005 |
[Feasibility study of weekly paclitaxel as second-line chemotherapy against 5-FU-refractory gastric carcinoma].
Topics: Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibil | 2005 |
[Case report--postoperative continuous intraarterial infusion of small doses of 5-FU successfully controlled residual tumor and liver metastasis of stage IV gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Drug Combi | 2005 |
Pharmacogenetics of extraordinary responses to 5-FU/cisplatin chemotherapy in advanced gastric cancer -- report of 2 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Male; Middl | 2005 |
Regulation of human peptide transporter 1 (PEPT1) in gastric cancer cells by anticancer drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Fluorouracil; Glucose Transporter | 2005 |
Recurrence and 5-FU sensitivity of stage II/III node-positive gastric cancer with occult neoplastic cells in lymph node sinuses.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Immunohis | 2005 |
Treatment of advanced colorectal and gastric cancer with 5-fluorouracil and calcium n-methyltetrahydrofolate.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; F | 1989 |
[Effect of intraperitoneal chemotherapy on experimental peritoneal dissemination of gastric cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Cisplatin; Docetaxel; | 2005 |
[Safety and efficacy of hypotonic CDDP intraperitoneal administration for gastric cancer with peritoneal dissemination].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Drug Therapy, | 2005 |
Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2006 |
Polymorphism in the 3'-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy.
Topics: 3' Untranslated Regions; Adult; Aged; Antineoplastic Agents; Base Sequence; DNA Primers; Female; Flu | 2006 |
[Chronomodulated chemotherapy of oxaliplatin, 5-fluorouracil and folinic acid for advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Drug Adm | 2005 |
[A case of recurrent gastric cancer with improvement of obstructive symptoms caused by carcinomatous peritonitis and prolonged survival by chemotherapy with combined use of Paclitaxel and 5-FU].
Topics: Adenocarcinoma, Scirrhous; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2006 |
Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modal | 2006 |
[Relapsing reversible posterior leukoencephalopathy after chemotherapy with cisplatin and 5-fluorouracil].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug-Related Side Effects and Adve | 2006 |
Recurrence and 5-FU sensitivity of stage I/II node-negative breast, lung, or gastric cancer with occult neoplastic cells in lymph node sinuses.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluor | 2006 |
Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Fluorouracil | 2006 |
In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell L | 2006 |
Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dihydrouracil Dehydrogenase (NADP); Docetaxel; Drug C | 2006 |
Cyclin D1 antisense oligodexoyneucleotides inhibits growth and enhances chemosensitivity in gastric carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chemoreceptor Cells; Ci | 2006 |
[Clinicopathological significance of orotate phosphoribosyltransferase in gastric carcinoma].
Topics: Aged; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Humans; Male; Orotate Phosphoribosylt | 2006 |
Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
Neoadjuvant treatment of gastric cancer with peritoneal dissemination.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Docetaxe | 2006 |
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cisplatin; Female | 2006 |
Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; | 2006 |
Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Dihydropyrimidine De | 2006 |
Damage assessment in gastric cancer treatment with adjuvant radiochemotherapy: calculation of the NTCP's from the differential HDV of the organs at risk.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 2006 |
Benefit of experimental vaccine for gastric cancer?
Topics: Cancer Vaccines; Cisplatin; Combined Modality Therapy; Fluorouracil; Gastrins; Humans; Stomach Neopl | 2006 |
[Clinical observation on treatment of gastric cancer with zhijing granules: a report of 148 cases].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Dru | 2006 |
Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
TS-1 as first-line therapy for gastric linitis plastica: historical control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; F | 2006 |
Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Mo | 2006 |
[Vascular hepatic injury following neoadjuvant treatment for a cardial adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Female; Fluoroura | 2006 |
Orotate phosphoribosyltransferase levels measured by a newly established enzyme-linked immunosorbent assay in gastric carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Ass | 2006 |
Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1.
Topics: Adult; Aged; Drug Combinations; Drug Therapy, Combination; Female; Fluorouracil; Gene Expression; Hu | 2006 |
Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc | 2006 |
Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biological Availability; Drug Combinations; Female; Fl | 2006 |
[Blood supply of pulmonary metastases and its clinical significance].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 2006 |
[Concurrent low-dose cisplatin/5-FU chemotherapy and radiation for the recurrent gastric carcinoma--case reports].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2006 |
[A case of long-term survival of gastric cancer with peritoneal metastasis effectively treated by TS-1 and paclitaxel (PTX) combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Constriction, Pathologic; Drug Administra | 2006 |
Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Proliferation; Deoxycytidine; Drug Resistance, | 2006 |
[A case of gastric endocrine cell carcinoma with liver metastasis showing rapid growth during pregnancy and marked reduction by systemic chemotherapy after delivery].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Delivery, Obstetric; Dr | 2006 |
Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2006 |
[Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice].
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Drug Synergism; Fluorouracil; Humans; | 2006 |
[Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
Topics: beta-Alanine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Fluorouracil; Humans; Infusions | 2006 |
Comparative proteomics of apoptosis initiation induced by 5-fluorouracil in human gastric cancer.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Fluorouracil; Humans; Proteomics; Stomach Neoplasms | 2006 |
[Clinicopathological characteristics of gastric cancer in elderly patients].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2006 |
[Clinical and prognostic significance of protein and gene expression of orotate phosphoribosyltransferase in gastric carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Gastrectomy; Ge | 2006 |
[A case of advanced gastric cancer responding remarkably to paclitaxel + low-dose FP therapy in a neoadjuvant setting].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2006 |
Transplatin, a cisplatin trans-isomer, may enhance the anticancer effect of 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Cisplatin; Drug Synergism; Fluorouracil; Humans; Stereoisomerism; S | 2006 |
A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle.
Topics: Animals; Carbohydrates; Delayed-Action Preparations; Female; Fluorouracil; Genes, Reporter; Green Fl | 2006 |
[Effect of vascular endothelial growth factor antibody Avastin on angiogenesis of human gastric cancer growing orthotopically in nude mice].
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimet | 2006 |
[Effects of hyperthermic chemotherapy on gastrointestinal cancer cells in vitro].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Cispl | 2006 |
[Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dihydrouracil Dehydrogenase ( | 2006 |
[A case of advanced gastric cancer with peritoneal metastasis that responded to paclitaxel plus 5-FU therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dr | 2006 |
[A case of advanced gastric cancer with liver metastasis completely responding to CPT-11+low-dose 5-FU+CDDP chemotherapy].
Topics: Adenocarcinoma; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardi | 2006 |
Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Codon; Combined Modality Therapy; Femal | 2006 |
[Effect of 5-fluorouracil in combination with Astragalus membranaceus on amino acid metabolism in mice model of gastric carcinoma].
Topics: Amino Acids; Animals; Astragalus propinquus; Fluorouracil; Male; Mice; Mice, Inbred BALB C; Mice, Nu | 2006 |
Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2006 |
The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dihydrou | 2006 |
[Perioperative chemotherapy vs. surgery alone in resectable gastroesophageal carcinomas. Results of the MAGIC study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 2006 |
Adjuvant chemoradiotherapy for gastric carcinoma: dosimetric implications of conventional gastric bed irradiation and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 2006 |
Inhibition of human gastric carcinoma cell growth by atofluding derivative N3-o-toluyl-fluorouracil.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Dr | 2006 |
[Successful treatment of an elderly patient with advanced gastric cancer using low-doses of 5-fluorouracil, levofolinate calcium, and cis-platinum with chronomodulation].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aorta; Chronother | 2006 |
[A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fema | 2006 |
Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway.
Topics: Adenoviridae; Antibiotics, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; beta Catenin; B | 2007 |
Ganciclovir augments the lytic induction and apoptosis induced by chemotherapeutic agents in an Epstein-Barr virus-infected gastric carcinoma cell line.
Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Drug | 2007 |
[Influence of neoadjuvant chemotherapy on microsatellite instability in gastric carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; DNA, Neoplasm; Fluorouracil; Humans; Leucovorin; Mic | 2006 |
Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2007 |
[A case of progressive gastric carcinoma accompanied by disseminated carcinomatosis of bone marrow due to bone metastasis with DIC recovery by joint administration of 5-FU and paclitaxel].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bo | 2006 |
Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
[MTX-CDDP-5-FU double modulation intra aortic chemotherapy for advanced and metastatic gastric cancer--a comparison with an intra venous route].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Female; Fluorouracil; Humans; Infu | 2006 |
A case report--The marked response to gemcitabine combined with irinotecan and low-dose cisplatin chemotherapy for advanced gastric cancer with multiple liver metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ant | 2006 |
Disseminated intravascular coagulation at presentation of advanced gastric cancer.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Bone Marrow Neoplasms; Cisplatin; Disease Pro | 2006 |
[A case report of advanced gastric cancer with carcinomatous ascites successfully treated by outpatient chemotherapy].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Cisplatin; | 2007 |
Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-fluorouracil on gastric cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma; Cell Line, Tumor; DNA, Compl | 2006 |
Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; CA-19-9 Antigen; Carci | 2007 |
Capecitabine and oxaliplatin (XELOX) for the treatment of patients with metastatic gastric cancer and severe liver dysfunction.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Fluor | 2006 |
Cutaneous metastasis resembling acute dermatitis in patient with advanced gastric cancer.
Topics: Antineoplastic Agents; Capecitabine; Cisplatin; Deoxycytidine; Dermatitis; Diagnosis, Differential; | 2007 |
Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2007 |
Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Base Sequence; DNA; DNA Primers; Fluorouracil; Gene Expression; Hum | 2007 |
Chemotherapy for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Fluorouracil; Humans | 2007 |
FOLFOX-4 regimen as fist-line chemotherapy in elderly patients with advanced gastric cancer: a safety study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Male | 2007 |
Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; DNA- | 2007 |
Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2007 |
Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Yoon-Koo Kang.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Hu | 2007 |
Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Sai-Hong Ignatius Ou and Randall F. Holcombe.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Es | 2007 |
Predictive value of GADD153, p21 and c-Jun for chemotherapy response in gastric cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Cyclin-Dependent Kinase | 2007 |
Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer.
Topics: Adult; Cell Differentiation; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gene Expressi | 2007 |
A successful treatment for metastatic liver tumors from endocrine carcinoma of the stomach.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Endocrine | 2007 |
Chemoimmunotherapy in the treatment of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineop | 2007 |
[Pathological evaluation of neoadjuvant chemotherapy with low-dose FP therapy for advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
[Complete regression after neoadjuvant chemotherapy in locally advanced gastric cancer causing peritonitis carcinomatosa--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Chemotherapy, Adjuvant; Cisplati | 2006 |
Adjuvant therapy for gastric cancer: how negative results can help patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Fluor | 2007 |
[The association between DPYD gene polymorphism and chemotherapeutic toxicity of 5-FU in gastric carcinoma and colonic carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dihydrouracil Dehydr | 2007 |
Efficacy and safety of cisplatin and capecitabine in combination as first line treatment for unselected patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2007 |
[Comparison the standard therapies of gastric cancer in Japan with those in the West].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administrati | 2007 |
Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2007 |
[Drug sensitivity test and drug-resistance gene assessment for chemotherapy planning for tumors derived from high-passage mouse gastric cancer cells: therapeutic effect observation in mice].
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin | 2007 |
Establishment and characterization of an IGSK-2 cell line derived from ascitic fluid of recurrent hCG and somatostatin secreted adenocarcinoma of the stomach.
Topics: Adenocarcinoma, Mucinous; Adult; Animals; Antigens, Tumor-Associated, Carbohydrate; Ascitic Fluid; B | 2007 |
Docetaxel for advanced gastric cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, P | 2007 |
[Evaluation of combination chemotherapy with 5-FU, CDDP and CPT-11 for human gastric carcinoma transplanted into nude mice - comparative study of in vivo chemosensitivity test].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Screening Ass | 2007 |
[Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinatio | 2007 |
[A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedul | 2007 |
Multiple atypical naevi after systemic 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Back; Biopsy; Diagnosis, Differential; Fluorouracil; Humans; Male; Nevus, Pigm | 2007 |
Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil.
Topics: Antineoplastic Agents; DNA Adducts; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Fluorour | 2007 |
Stomach-specific drug delivery of 5-fluorouracil using floating alginate beads.
Topics: Alginates; Animals; Chemistry, Pharmaceutical; Delayed-Action Preparations; Female; Fluorouracil; Gl | 2007 |
Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
[Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phyt | 2007 |
[Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; | 2007 |
The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 2007 |
Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 2007 |
Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Doce | 2007 |
Capecitabine and irinotecan in advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycyt | 2007 |
Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; beta-Alanine; Drug Combinations; Fluorouracil; | 2007 |
[Biodistribution of (99m)Tc-labeled anti-VEGF mAb 5-FU loaded polylactic acid nanoparticles in human gastric carcinoma xenografts].
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Fluorour | 2007 |
Docetaxel in gastric cancer: a viewpoint by David Wilson.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Humans; Stomach | 2007 |
Docetaxel in gastric cancer: a viewpoint by Andre M. Murad.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Humans; Stomach | 2007 |
Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Femal | 2007 |
Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: relation to therapy response and clinicopathologic and molecular features.
Topics: Adult; Aged; Cisplatin; DNA Methylation; Female; Fluorouracil; Humans; Loss of Heterozygosity; Male; | 2007 |
Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycy | 2007 |
DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Di | 2007 |
Identification of consensus genes and key regulatory elements in 5-fluorouracil resistance in gastric and colon cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil | 2007 |
[18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.
Topics: Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Surviva | 2007 |
[Study of the anti-tumor effect of anti-vascular endothelial growth factor McAb 5-fluorouracil loaded polylactic acid nanoparticles].
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Carriers; F | 2007 |
[The third report from Sapporo Tsukisamu Hospital--chemotherapy for patients with advanced gastric cancer (peritoneal dissemination, peritonitis carcinomatosa)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Femal | 2007 |
[Fifth-line chemotherapy for metastatic gastric cancer--a case responding to modified FOLFOX 6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Male; Organo | 2007 |
[Docetaxel-cisplatin-5-FU combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoroura | 2007 |
Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases i
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Dihydrouracil De | 2007 |
Inhibition of human gastric carcinoma cell growth by treatment of N(3)-o-toluyl-fluorouracil as a precursor of 5-fluorouracil.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Cell P | 2007 |
Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2007 |
Surgery combined with intra-arterial chemotherapy for stage iv advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fl | 2007 |
[The fourth report from Sapporo Tsukisamu Hospital - chemotherapy and its regimen as second choice for patients with early gastric cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2007 |
[Two cases of advanced gastric cancer in which paclitaxel proved effective after resistance to docetaxel].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplas | 2007 |
Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP) | 2007 |
Upregulated expression of S100A6 in human gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Cell Cycle Proteins; Cell Line, Tumor; Dox | 2007 |
Circulating RNA as a novel tumor marker: an in vitro study of the origins and characteristics of extracellular RNA.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Hypoxia; Cell Proliferation; Cisplatin; Cold Temperat | 2008 |
[A case of recurrent gastric cancer with peritoneal dissemination--prolonging life and good QOL by chemotherapy with combined use of paclitaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoembryonic Antigen; Combined M | 2007 |
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxyc | 2008 |
Doubts about whether docetaxel, cisplatin, plus fluorouracil has any benefit in advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Docetaxel; Fluorouracil; H | 2007 |
[Reversal effect and mechanism of arsenic trioxide on multidrug resistance of gastric carcinoma cells SGC7901].
Topics: Adenocarcinoma; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporte | 2007 |
[Evaluation of neoadjuvant chemotherapy with paclitaxel, 5-fluorouracil and cisplatin for advanced gastric cancer with pyloric stenosis].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ant | 2007 |
[Two cases of stage IV gastric cancer who underwent total gastrectomy and achieved long-term survival by sequential chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2007 |
Visualisation of metastatic oesophageal and gastric cancer and prediction of clinical response to palliative chemotherapy using 18FDG PET.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Female; Fluorodeo | 2007 |
The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2007 |
Levels and expressions of orotate phosphoribosyltransferase in gastric carcinoma and normal gastric mucosa tissues.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Female; F | 2007 |
[Difference of gene expression profile in human gastric cancer grafted onto nude mice treated with WCA].
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Cell Line, Tumor; Ce | 2007 |
Modulation of FU with high-dose folinic acid is effective for treatment of patients with gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Stomach Neoplasms; | 2008 |
Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Chem | 2008 |
The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
[Expression of livin in gastric cancer and effect of silencing of the livin gene on apoptosis in gastric cancer cells].
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apopto | 2007 |
Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2007 |
[Treatment of advanced gastric cancer with oxaliplatin plus 5-fluorouracil/ leucovorin (FOLFOX-4 chemotherapy)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Male; Midd | 2007 |
Tumor lysis syndrome after capecitabine plus cisplatin treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2008 |
[A case of advanced gastric cancer effectively treated with combination of weekly paclitaxel and hepatic arterial infusion of 5-FU/LV].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Fluorouracil; Gastr | 2008 |
Oral treatment for gastric cancer: new choices, better choices?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase III as T | 2008 |
First-line treatment of advanced gastric cancer and hepatic dysfunction with oxaliplatin, 5-fluorouracil and cetuximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2008 |
Adjuvant chemotherapy for gastric cancer or not: a dilemma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin | 2008 |
Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Ch | 2008 |
ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA-Binding Proteins | 2008 |
Weekly infusional high-dose 5-fluorouracil and leucovorin and biweekly cisplatin: a convenient treatment option in advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease P | 2008 |
Nail and periungual toxicity following capecitabine therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Nail | 2008 |
Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Sched | 2008 |
The toxicity and outcomes of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected high-risk gastric cancer: results of a single institute.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
[Anti-tumor effects of chemotherapeutic drugs on human gastric cancer cells in vitro and the relationship with expression of hTERT mRNA].
Topics: Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Antibiotics, Antineoplastic; Antim | 2007 |
[Evaluation of efficacy and influence factors of transarterial interventional therapy in patients with liver metastasis from malignancy of alimentary tract].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, T | 2007 |
Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovori | 2009 |
Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2008 |
[FOLFOX4 regimen versus DP(O)F regimen for advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoroura | 2008 |
miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cisplatin; Down-Regulation; D | 2008 |
Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Drug C | 2008 |
[Anti-tumor effect of chemotherapeutic drugs on human gastric cancer cells in vitro and the relationship with Bcl-2 expression].
Topics: Adult; Aged; Antineoplastic Agents; Cell Survival; Cisplatin; Doxorubicin; Drug Screening Assays, An | 2008 |
Tolerance and efficacy of adjuvant chemoradiotherapy with FOLFIRI in adenocarcinoma of stomach and GI junction.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, A | 2008 |
[A case of advanced gastric cancer with peritoneal metastasis successfully treated over 19 months with postoperative chemotherapy after non-curative surgery].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2008 |
Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydroura | 2008 |
5-fluorouracil therapy for cancer of the stomach.
Topics: Animals; Fluorouracil; Hematopoietic System; Humans; Mice; Neoplasm Recurrence, Local; Radiography; | 1967 |
[A case of jaundice caused by 5-fluorouracil].
Topics: Fluorouracil; Humans; Jaundice; Male; Middle Aged; Postoperative Complications; Stomach Neoplasms | 1967 |
[Studies on the new long-acting anti-cancer preparation, 5-fluorouracil-polyglycolic acid composite].
Topics: Aged; Delayed-Action Preparations; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Needl | 1984 |
[Intraarterial Adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma].
Topics: Adult; Aged; Alkaline Phosphatase; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Sched | 1984 |
Intravascular haemolysis and renal impairment after blood transfusion in two patients on long-term 5-fluorouracil and mitomycin-C.
Topics: Adenocarcinoma; Adult; Anemia, Macrocytic; Brain Edema; Disseminated Intravascular Coagulation; Fema | 1980 |
Haemolysis and renal impairment syndrome in patients on 5-fluorouracil and mitomycin-C.
Topics: Aged; Anemia, Hemolytic; Fluorouracil; Humans; Kidney; Kidney Diseases; Male; Mitomycins; Stomach Ne | 1980 |
Rash, nephritis, hypertension, and haemolysis in patient on 5-fluorouracil, doxorubicin, and mitomycin-C.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Doxorubicin; Drug Eruptions; Drug Therapy, Combinati | 1980 |
[Current status of chemotherapy of gastric and colorectal cancer].
Topics: Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasm Invasivene | 1981 |
[Phagocytic activity and cytochemical indices of the neutrophils in stomach cancer treated with 5-fluorouracil].
Topics: Adult; Aged; Female; Fluorouracil; Humans; Male; Middle Aged; Neutrophils; Phagocytosis; Stomach Neo | 1981 |
[Asymptomatic electrocardiographic abnormalities during antiblastic chemotherapy].
Topics: Aged; Antineoplastic Agents; Arrhythmias, Cardiac; Breast Neoplasms; Cardiac Complexes, Premature; C | 1983 |
Studies on the designing of chemotherapy for gastric cancer in man, based on the tumor tissue concentration of anticancer agents.
Topics: Antineoplastic Agents; Floxuridine; Fluorouracil; Gastric Mucosa; Humans; Stomach Neoplasms; Tegafur | 1982 |
The effect of sequential addition of the nitrosourea, chlorozotocin, to the FAM combination in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Therapy, Combination; | 1983 |
Nonsteroid antiinflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Cyclophosphamide; Drug Therapy, Combination; | 1983 |
[Clinical evaluation of neocarzinostatin in digestive system cancer. 1. Administration of neocarzinostatin in advanced and recurrent carcinoma of the stomach].
Topics: Antibiotics, Antineoplastic; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; | 1983 |
[Immunochemotherapy with tegafur and schizophyllan for stomach cancer--report of 2 cases].
Topics: Aged; Drug Therapy, Combination; Female; Fluorouracil; Glycosaminoglycans; Humans; Male; Middle Aged | 1983 |
[Measurement of 5'-deoxy-5-fluorouridine (5'-DFUR) by high-performance liquid chromatography and studies on pharmacokinetics of 5'-DFUR and 5-fluorouracil by oral and intravenous administration].
Topics: Administration, Oral; Aged; Chromatography, High Pressure Liquid; Colonic Neoplasms; Female; Floxuri | 1984 |
[5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues].
Topics: Administration, Oral; Aged; Animals; Antineoplastic Agents; Enzyme Activation; Female; Floxuridine; | 1984 |
[Chemotherapy of gastrointestinal cancer in the advanced stage with a combination of 5-fluorouracil, adriamycin, mitomycin C (FAM). A non-controlled study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Drug Ev | 1984 |
[Treatment of rectocolic and gastric adenocarcinomas with 5-fluorouracil associated with high doses of folinic acid. Results of an experimental study].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Leu | 1982 |
Clinical evaluation of preoperative combined chemotherapy with neocarzinostatin (NCS) and 5-Fluorouracil (combined NF therapy) against gastric cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Antibiotics, Antin | 1981 |
[Chemotherapy of gastrointestinal cancer in elderly patients--evaluation of combination therapy with mitomycin C and 5-fluorouracil].
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Colonic Neoplasms; Drug Synergism; Dru | 1983 |
[Clinical trial on the effect of tegafur (SF-SP)].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Capsules; Carcinoma, Intraductal, Noninfiltrating | 1984 |
[Chemotherapy of metastasizing stomach cancer].
Topics: Doxorubicin; Fluorouracil; Humans; Leucovorin; Methotrexate; Stomach Neoplasms | 1984 |
Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Drug Therapy, Combination; Female; Fluorouracil; Hemolytic | 1983 |
Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema: a chemotherapy-induced syndrome.
Topics: Adenocarcinoma; Adult; Anemia, Hemolytic; Drug Therapy, Combination; Female; Fluorouracil; Humans; K | 1983 |
Chemotherapeutic study on Yoshida sarcoma ascites cells implanted into the glandular stomach of rats. Monotherapy with 5-fluorouracil, methyl-CCNU, mitomycin C, adriamycin, and cytosine arabinoside, and combination therapy with respective two-drug combina
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cytarabine; Disease Models, Animal; Dox | 1983 |
[Single chemotherapy with 5-fluorouracil or ftorafur and combination chemotherapy with mitomycin C and 5-fluorouracil for inoperable elderly gastric cancers].
Topics: Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Mitomycin; Mitomycins; Stomach | 1983 |
[Combination chemotherapy of advanced gastric cancer with adriamycin, mitomycin C, and ftorafur].
Topics: Adenocarcinoma; Adult; Aged; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; M | 1983 |
[Case of Borrmann III stomach cancer effectively treated by UFT therapy (co-administration of uracil and futraful)].
Topics: Adenocarcinoma; Administration, Oral; Aged; Drug Therapy, Combination; Fluorouracil; Humans; Male; S | 1983 |
[Effect of extended chemotherapy using tegafur following surgery of stage III stomach cancer].
Topics: Aged; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle | 1983 |
[Enzymatic conversion of tegafur in human tumor tissue].
Topics: Adult; Female; Fluorouracil; Humans; In Vitro Techniques; Liver Neoplasms; Middle Aged; Stomach Neop | 1983 |
[Chemotherapy of gastric cancer patients with hepatic metastases].
Topics: Administration, Oral; Antibiotics, Antineoplastic; Fluorouracil; Humans; Liver Neoplasms; Mitomycin; | 1983 |
[Adjuvant chemotherapy for aged patients with gastric carcinoma].
Topics: Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Mitomyci | 1983 |
[A study on postoperative long-term continuous immuno-chemotherapy with PSK and 5-FUDS for advanced gastric and colo-rectal cancers].
Topics: Aged; Antibiotics, Antineoplastic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Human | 1983 |
[Study on the correlation between tissue uptake of anticancer agents and prognosis -- with special reference to Tegafur].
Topics: Adult; Aged; Antineoplastic Agents; Female; Fluorouracil; Humans; Lymph Nodes; Male; Middle Aged; Pr | 1983 |
Late results of postoperative long-term cancer chemotherapy for the gastric cancer patients subjected to curative resection.
Topics: Antibiotics, Antineoplastic; Carcinoma; Dose-Response Relationship, Drug; Drug Administration Schedu | 1983 |
[Experience of a combination chemotherapy consisting of 5-FU, MMC, and FT-207--side effects against kidney].
Topics: Aged; Drug Therapy, Combination; Fluorouracil; Humans; Kidney Diseases; Male; Mitomycin; Mitomycins; | 1983 |
[UFT concentration in various tissues from cancer patients].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1983 |
[Conditions suitable for chemotherapy of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fluorouracil; Humans; Mitomycin; Mitomyc | 1983 |
[Conditions suitable for the adjuvant chemotherapy of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fluorouracil; Humans; Mitomycin; Mitomyc | 1983 |
[Analysis of factors affecting clinical cancer chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Fluorouraci | 1983 |
[Chemotherapy of unresectable Borrmann's type IV stomach cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Mitomycin; Mitomy | 1983 |
[Clinical analysis on side effects of long-term oral administration of futraful to out-patients].
Topics: Administration, Oral; Alanine Transaminase; Aspartate Aminotransferases; Blood Proteins; Breast Neop | 1983 |
Duodenal adenoma with atypia following oral administration of tegafur.
Topics: Adenoma; Duodenal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Postoperative Care; Stomach Ne | 1983 |
[Adjuvant chemotherapy for gastric cancer--relation between long-term administration of FT-207 and prognosis].
Topics: Adult; Aged; Female; Fluorouracil; Humans; Male; Middle Aged; Prognosis; Stomach Neoplasms; Tegafur | 1984 |
[Cooperative phase II study of spansule tegafur (SF-SP)].
Topics: Administration, Oral; Aged; Breast Neoplasms; Capsules; Colonic Neoplasms; Delayed-Action Preparatio | 1984 |
[A gastric cancer patient who underwent curative resection by angiotension-induced hypertension cancer chemotherapy].
Topics: Adenocarcinoma; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxo | 1984 |
Phase II study of orally and rectally administered Tegafur in liver metastases from gastric carcinoma.
Topics: Administration, Oral; Adult; Aged; Drug Evaluation; Female; Fluorouracil; Humans; Liver Neoplasms; M | 1984 |
[Preoperative immunochemotherapy for gastric cancer combined with perifocal administration of OK-432].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Female; Fluorourac | 1984 |
[Basic and clinical studies on metastatic cancer--with special reference of multidisciplinary treatment of gastric and colorectal cancer patients with hepatic metastasis].
Topics: Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Infusions, Intra-Ar | 1983 |
[Combination chemotherapy of CIS-diamminedichloroplatinum (II) and fluoropyrimidine derivatives for advanced gastric cancer: a preliminary report].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 1984 |
Combination of hepatic arterial infusion and systemic chemotherapy for gastric cancer with synchronous hepatic metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Hepatic Artery; H | 1984 |
[Cooperative phase II study of releasing tegafur (SF-SP) against advanced digestive cancers].
Topics: Administration, Oral; Adult; Aged; Colonic Neoplasms; Delayed-Action Preparations; Digestive System | 1984 |
[Chemotherapy of unresectable Borrmann type 4 gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Combinations; Fluorouracil; Humans | 1984 |
Combination chemoimmunotherapy for advanced gastric carcinoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Ca | 1984 |
[Experimental chemotherapy of human gastrointestinal and breast cancers in nude mice and its correlation to clinical effect].
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 1984 |
[Sensitivity test of anticancer agents using human tumor xenografts in nude mice with special reference on correlation between clinical effects and chemotherapy].
Topics: Animals; Antineoplastic Agents; Cell Division; Cyclophosphamide; Drug Resistance; Fluorouracil; Gast | 1984 |
[Increased cytotoxic effects of various anticancer drugs by alpha-interferon (HLBI) on human tumor xenografts in nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Syner | 1984 |
[Study on the concentration of FT-207 and 5-FU in serum, lymph nodes and tissues after administration of FT-207 suppositories].
Topics: Adult; Aged; Breast Neoplasms; Female; Fluorouracil; Humans; Lymph Nodes; Lymphoma, Non-Hodgkin; Mal | 1984 |
[Influence of PSK on the metabolism of FT-207].
Topics: Antibiotics, Antineoplastic; Fluorouracil; Humans; Proteoglycans; Stomach Neoplasms; Tegafur | 1984 |
[Evaluation of tegafur encapsulated with slow-releasing granules (SF-SP) for patients with cancer of the digestive organs].
Topics: Administration, Oral; Adult; Aged; Capsules; Colonic Neoplasms; Delayed-Action Preparations; Drug Ev | 1984 |
[Adjuvant chemotherapy after surgery in advanced gastric cancer].
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Drug Administration Schedule; Fluorouracil; | 1984 |
[Postoperative adjuvant chemotherapy with N1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) for gastric cancer patients. Influence of fat emulsification on lymphatic transport].
Topics: Adult; Aged; Fat Emulsions, Intravenous; Fluorouracil; Humans; Lymphatic System; Male; Middle Aged; | 1984 |
Enhancement of lymphatic transport of N1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) by water-in-oil emulsion in postoperative adjuvant chemotherapy for gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Emulsions; Fluorouracil; Humans; Male; Mid | 1984 |
Endoscopic intramural injection of anti-neoplastic emulsion.
Topics: Administration, Oral; Animals; Dogs; Emulsions; Fluorouracil; Gastric Mucosa; Gastroscopy; Lymph Nod | 1984 |
[5-Fluorouracil treatment combined with ascorbic acid in patients with disseminated stomach cancer].
Topics: Adenocarcinoma; Adult; Aged; Ascorbic Acid; Carcinoma; Combined Modality Therapy; Female; Fluorourac | 1984 |
[Blood concentration of HCFU in gastrectomized patients].
Topics: Fluorouracil; Gastrectomy; Humans; Postoperative Period; Stomach Neoplasms | 1984 |
A case of gastric cancer achieving a complete response by chemotherapy.
Topics: Aged; Fluorouracil; Humans; Male; Stomach Neoplasms | 1984 |
[Mode of action of fluoropyrimidines, in relation to their clinical application].
Topics: Animals; DNA Replication; Fluorouracil; Humans; Leukemia L1210; Mice; Neoplasms; Stomach Neoplasms; | 1984 |
[Low-dose methotrexate and sequential 5-FU treatment in advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 1984 |
[Adjuvant chemotherapy in cancers of the stomach, pancreas and intestine].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined M | 1984 |
[Biochemical criteria of 5-fluorouracil sensitivity and resistance of stomach tumors].
Topics: Alkaline Phosphatase; Drug Resistance; Fluorouracil; Humans; In Vitro Techniques; RNA, Neoplasm; Sto | 1984 |
[State of chemotherapy and adjuvant therapies in the treatment of stomach cancer].
Topics: Carmustine; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; Male; Middle Ag | 1984 |
[Treatment of advanced stomach carcinoma with adriamycin and 5-fluorouracil].
Topics: Aged; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Stoma | 1984 |
Cisplatin, doxorubicin, and 5-FU in combination for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 1984 |
FAM2 regimen in disseminated gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 1984 |
A retrospective study of FAM regimen in 38 patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Midd | 1984 |
Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Doxorubicin; D | 1984 |
Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin C (modified FAM).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fl | 1984 |
Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin | 1984 |
Chemotherapy of advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Drug Therapy, Combinat | 1983 |
High-dose MTX/5-FU and adriamycin for gastric cancer.
Topics: Adult; Aged; Ambulatory Care; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Female; Fluor | 1983 |
Chemotherapy of advanced gastric cancer with 72-hour continuous intravenous 5-fluorouracil infusion at 2-week intervals.
Topics: Adenocarcinoma; Adult; Aged; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, | 1983 |
Studies on the effect of oral administration of 5-FU emulsion as an adjuvant to surgical treatment of gastric cancer.
Topics: Administration, Oral; Combined Modality Therapy; Emulsions; Fluorouracil; Humans; Lymphatic Metastas | 1983 |
Confirmed activity of FAM polychemotherapy in advanced gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 1983 |
Combined nonsimultaneous radiation therapy and chemotherapy with 5-FU, doxorubicin, and mitomycin for residual localized gastric adenocarcinoma: a Southwest Oncology Group pilot study.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Therapy, Co | 1983 |
Combined modality treatment of gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Doxorubicin; Drug Therap | 1983 |
The natural history of gastric cancer and prognostic factors influencing survival.
Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Gastrectomy; Humans; Liver Neoplasms; Lymphatic M | 1984 |
[5-Fluorouracil concentration in various tissues from cancer patients after oral administration of 5-fluorouracil].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Breast Neoplasms; Female; Fluorouracil; Humans; M | 1984 |
Endoscopic local injection of early gastric carcinoma with 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Female; Fluorouracil; Follow-Up Studies; Gastroscopy; Humans; Injections; Male | 1984 |
[A case of advanced gastric cancer which disappeared histopathologically after short-time chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyt | 1984 |
Chemosensitivity testing of human neoplasms using the soft agar colony assay.
Topics: Antineoplastic Agents; Biopsy; Breast Neoplasms; Cell Division; Colonic Neoplasms; Colony-Forming Un | 1984 |
[Combined treatment of stomach cancer patients].
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neo | 1984 |
[Results of combined treatment of cancer of the stomach taking into consideration tumor sensitivity to 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Carcinoma; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies | 1984 |
Intensified cancer themotherapy by induction of hepatic drug-metabolizing enzymes as a trial for the treatment for stomach cancer.
Topics: Drug Therapy, Combination; Enzyme Induction; Fluorouracil; Humans; Liver; Mitomycins; Phenobarbital; | 1980 |
[Combined chemoimmunotherapy in stomach cancer and hematosarcoma].
Topics: Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hemangiosarcoma; Humans; Immunotherapy; N | 1980 |
Clinical basis of chemotherapy for gastric cancer with uracil and 1-(2'-tetrahydrofuryl)-5-fluorouracil.
Topics: Female; Fluorouracil; Humans; In Vitro Techniques; Stomach Neoplasms; Tegafur; Time Factors; Uracil | 1980 |
[Preference of chemotherapy over surgery in stomach cancer].
Topics: Aged; Cyclophosphamide; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Fluorouracil | 1980 |
The FAM regimen for gastric cancer: a progress report.
Topics: Adult; Aged; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1981 |
[Educational lecture of cancer chemotherapy: with references to stomach cancer (author's transl)].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Stomach Neoplasms; Tegafur | 1981 |
Correlation between the level of urinary D-glucaric acid and the degree of activation of masked compound (FT-207) in cancer patients.
Topics: Adult; Aged; Biotransformation; Cytochrome P-450 Enzyme System; Esophageal Neoplasms; Female; Fluoro | 1981 |
[Conservative treatment of primary and recurrent malignant stomach neoplasms].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male | 1981 |
Chemotherapy of carcinomas of the digestive tract.
Topics: Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Esop | 1982 |
[Effects of UFT administered preoperatively in cases of gastric cancer (author's transl)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Fluorouracil | 1981 |
[Heterotransplantation of human stomach carcinomas into nude nice. 3. Effects of MMC and 5FU on 7 strains of transplantable human gastric cancer in nude mice].
Topics: Animals; Fluorouracil; Humans; Male; Mice; Mice, Nude; Mitomycin; Mitomycins; Neoplasm Transplantati | 1982 |
[Two cases with microangiopathic hemolytic anemia caused by anti-cancer drugs who improved rapidly after administration of aspirin and dipyridamole].
Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Agents; Aspirin; Chromomycin A3; Dipyridamole; Female | 1982 |
[Antitumor treatment for synchronous hepatic metastasis from stomach cancer].
Topics: Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Liver N | 1982 |
[Chemotherapy of stomach cancer].
Topics: Adenocarcinoma; Antineoplastic Agents; Carmustine; Cisplatin; Doxorubicin; Drug Administration Sched | 1982 |
[MQF-OK therapy in advanced terminal stomach cancer--with special reference to a comparison with MFC therapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Cytara | 1982 |
[Pre-operative chemotherapy of stomach cancer combined with local administration of OK-432--evaluation of macroscopic results].
Topics: Aged; Animals; Antibiotics, Antineoplastic; Biological Products; Carcinoma, Ehrlich Tumor; Drug Ther | 1982 |
[Effect of immunochemotherapy on the cases of advanced gastric cancer stage III].
Topics: Drug Therapy, Combination; Fluorouracil; Gastrectomy; Humans; Levamisole; Lymphatic Metastasis; Mito | 1982 |
[Preoperative OMF therapy for gastric cancer--examination of macroscopical effect in comparison with histological effect].
Topics: Adult; Aged; Biological Products; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Mid | 1982 |
[Two cases of carcinoid tumor of the stomach which responded to oral administration of UFT].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C | 1982 |
[Radiotherapy combined with tegafur for inoperable advanced gastric cancer].
Topics: Aged; Antineoplastic Agents; Female; Fluorouracil; Humans; Male; Middle Aged; Prognosis; Stomach Neo | 1982 |
[Evaluation of pre-operative chemotherapy using FT-207 suppositories combined with glutathione--with special reference to histopathological antitumor effect].
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorour | 1982 |
[Physiological effects and antitumor efficiency of ACNU in postoperative patients with stomach cancer--an evaluation of the treatment combined with FT-207 or 5-FU dry syrup].
Topics: Antineoplastic Agents; Bone Marrow; Carcinoembryonic Antigen; Drug Administration Schedule; Drug The | 1982 |
[Clinical experiences with UFD-1].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combination | 1982 |
[Tissue concentration of 5-FU following pre-operative administration of FT-207].
Topics: Female; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Large; Lymph Nodes; Male; Middle Aged | 1982 |
[Clinical studies of cancer chemotherapy combined with angiotensin-II (ANG-II)].
Topics: Adult; Aged; Angiotensin II; Antibiotics, Antineoplastic; Antineoplastic Agents; Blood Pressure; Bre | 1982 |
[Gastrointestinal tumors: chemotherapeutic preparations].
Topics: Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Gast | 1983 |
[Analysis of morbidity from simultaneous 5-fluorouracil therapy and radiation therapy in advanced gastrointestinal tumors. Report of results].
Topics: Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Neoplasm Metastasis; Radiothera | 1983 |
Gastric cancer-survival at the Pennsylvania Hospital with and without adjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Gas | 1983 |
[Co-administration of adriamycin and 5-fluorouracil for the treatment of advanced stomach cancer].
Topics: Adenocarcinoma; Aged; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Mi | 1983 |
Treatment of advanced gastric carcinoma with 5-fluorouracil adriamycin, and mitomycin C (FAM).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Dru | 1982 |
[Chemotherapy of gastric carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Therapy, Co | 1982 |
Chemotherapy in gastric and oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, Combinat | 1982 |
Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Gastrointesti | 1982 |
[Chemotherapy of advanced stomach cancer].
Topics: Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Mitomycins; Nit | 1981 |
Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sch | 1982 |
[Autoradiographic studies on nucleic acid synthesis of human gastric cancer cells. II. Effects of 5-fluorouracil on nucleic acid synthesis of cancer cells (author's transl)].
Topics: Adenocarcinoma; Aged; Cell Survival; Cells, Cultured; Female; Fluorouracil; Humans; Male; Middle Age | 1982 |
Postoperative long-term cancer chemotherapy (PLCC) extends life-span of non-curatively resected patients with stage IV gastric cancer.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Injections, Intra-Arterial; | 1982 |
[Chemotherapy schedule for the management of metastasizing gastric cancer. Methotrexate, adriamycin and 5-fluorouracil].
Topics: Adult; Aged; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Methotrexat | 1982 |
[Combined therapy of advanced gastric cancer].
Topics: Adenocarcinoma; Female; Fluorouracil; Gastrectomy; Humans; Methotrexate; Middle Aged; Stomach Neopla | 1982 |
[Evaluation of the therapeutic effect of HCFU (1-hexylcarbamoyl-5-fluorouracil) on non-resectable stomach cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; F | 1982 |
[Evaluation of postoperative long-term chemotherapy using FT-207 for the stage III stomach cancer].
Topics: Drug Administration Schedule; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Neoplasm | 1982 |
[Intramural injection of anticancer emulsion by gastroendoscopy].
Topics: Animals; Dogs; Emulsions; Fluorouracil; Gastroscopy; Injections; Male; Mice; Neoplasms, Experimental | 1982 |
[TAC-278. A new 5-FU derivative, by the oral route for its efficacy and safety in 36 patients with advanced cancers].
Topics: Adult; Aged; Blood Platelets; Drug Evaluation; Female; Fluorouracil; Humans; Intestinal Neoplasms; I | 1982 |
[Effect of postoperative long-term cancer chemotherapy (PLCC) on non-curative gastric cancer of stage IV].
Topics: Antineoplastic Agents; Drug Administration Schedule; Fluorouracil; Humans; Mitomycins; Neoplasm Stag | 1982 |
[Phase II study of carmofur (HCFU) fine granules].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Child; Child, Preschool; Colonic N | 1982 |
[Effect of chemotherapy on the growth of human gastrointestinal tumor strains].
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms, Experimental; Mic | 1980 |
[Late results of the combined treatment of stomach cancer in relation to individual tumor sensitivity to 5-fluorouracil].
Topics: Adult; Drug Resistance; Female; Fluorouracil; Gastrectomy; Humans; In Vitro Techniques; Male; Middle | 1981 |
[Indications and technic of percutaneous external biliary drainage].
Topics: Antineoplastic Agents; Bile; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Cholestasis, | 1981 |
[Immunochemotherapeutic treatment of gastrointestinal neoplasms].
Topics: Adjuvants, Immunologic; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Prognos | 1981 |
[Gastrointestinal tumors. Prognostic factors and chemotherapy of today].
Topics: Carmustine; Colonic Neoplasms; Doxorubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans | 1981 |
Sensitivity of anticancer agents of human gastric cancers transplanted into nude mice.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Drug Resistance; Female; Fluorouracil; Humans; Mal | 1981 |
The effect of oral administration of amphotericin B on the incorporation of 5-fluorouracil into human gastric cancer tissue.
Topics: Administration, Oral; Aged; Amphotericin B; Drug Therapy, Combination; Female; Fluorouracil; Humans; | 1981 |
Defective function of granulocytes in patients with cancer.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Femal | 1981 |
[Histological changes of gastric carcinoma by oral administration of anticancer drug (author's transl)].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Female; Fluorouracil; Humans; Male; Middle | 1981 |
[Change in the nonspecific resistance indices in stomach cancer under the influence of preoperative chemotherapy].
Topics: 17-Hydroxycorticosteroids; Aged; Female; Fluorouracil; Free Radicals; Humans; Immunity, Innate; Male | 1980 |
[Comparative evaluation of combined treatment methods in stomach cancer].
Topics: Dinitrochlorobenzene; Fluorouracil; Gastrectomy; Humans; Immunization; Leukocyte Count; Postoperativ | 1980 |
[Clinical evaluation of immunochemotheray on advanced gastric cancer--combination of OK-432 (picibanil), mitomycin C, and 5-fluorouracil (MF-O therapy) (author's transl)].
Topics: Biological Products; Drug Therapy, Combination; Fluorouracil; Humans; Immunotherapy; Mitomycins; Neo | 1980 |
Chemotherapeutic study on canine gastric cancer induced by N-ethyl-N'-nitro-N-nitrosoguanidine.
Topics: Adenocarcinoma; Animals; Dogs; Fluorouracil; Humans; Male; Methylnitronitrosoguanidine; Stomach Neop | 1980 |
Chemotherapy for gastrointestinal malignancy.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Esophageal Neoplasms; Fluoroura | 1980 |
[Morphological evaluation of the effectiveness of preoperative chemotherapy of stomach cancer].
Topics: Drug Evaluation; Fluorouracil; Humans; Preoperative Care; Stomach Neoplasms | 1980 |
[Biochemical characteristics of the individual sensitivity of human stomach cancers to 5-fluorouracil].
Topics: Adult; Cells, Cultured; Drug Evaluation; Drug Resistance; Female; Fluorouracil; Gastric Mucosa; Huma | 1980 |
5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Doxorubicin; Drug Evaluation; Drug Therapy, Comb | 1980 |
Sequential carcinoembryonic antigen levels. A predictor of response and relapse in combination chemotherapy of advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil | 1981 |
[Animal experiments using adjuvant 5-FU and BCNU chemotherapy in stomach cancer].
Topics: Animals; Carmustine; Drug Therapy, Combination; Fluorouracil; Mice; Mice, Inbred BALB C; Mice, Nude; | 1980 |
[A case of gastric cancer responding well to MTX/5-FU (methotrexate/5-fluorouracil) and PMUE (CDDP, MMC, UFT, etoposide) therapies upon lymphnode recurrence].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 1995 |
[A case of unresectable advanced gastric cancer responding remarkably to combined chemotherapy with 5-fluorouracil and low-dose cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Male; Middle Aged; | 1995 |
Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma. The MRC Gastric Cancer Working Party and the British Stomach Cancer Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Esophageal Neoplasms; Fluorou | 1995 |
Pericardiac metastasis from advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Fluorouracil; Heart Neoplasms; Human | 1995 |
[A case of intrahepatic infusion chemotherapy with angiotensin II human for liver metastasis from early gastric cancer].
Topics: Adenocarcinoma; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure | 1995 |
[A case report of far advanced gastric cancer with multiple liver metastasis (H3) treated with transarterial intermittent chemotherapy and intradermal administration of low molecular lipopolysaccharide (LPSp) extracted from Pantoea agglomerans].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Enterobacteriaceae; Epirubicin; Fluorouracil; | 1995 |
[A case of advanced gastric cancer treated effectively with neo-adjuvant chemotherapy using l-leucovorin and 5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Adminis | 1995 |
[A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1995 |
[Advanced gastric carcinoma with extensive lymph node metastases successfully treated by sequential methotrexate/5-fluorouracil therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluoro | 1995 |
[Effect of low dose CDDP/5-fluorouracil therapy on PCNA labeling index and TS inhibition rate of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cisplatin; DNA, Neoplasm; Flow Cytometry | 1995 |
Serum concentrations of 5-fluorouracil achieved with nocturnal constant-rate infusion in patients with disseminated cancer.
Topics: Adult; Aged; Breast Neoplasms; Circadian Rhythm; Colonic Neoplasms; Drug Administration Schedule; Fe | 1995 |
Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1995 |
Utilization of purine and pyrimidine in human gastric cancer cells (KATO III): effect of a nucleotide and nucleosides mixture (OG-VI) solution on proliferation with coadministration of 5-fluorouracil.
Topics: Animals; Cell Division; Cell Line; Fluorouracil; Humans; Kinetics; Male; Purines; Pyrimidines; Rats; | 1994 |
[A case of liver metastasis of gastric cancer with portal vein tumor thrombosis responding to chemotherapy with 5-FU and epirubicin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Huma | 1995 |
The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line; Cisplatin; DNA Damage; Esophageal Neop | 1995 |
[Blood levels of 5-FU and uracil on additional use of uracil in UFT therapy in gastrectomized patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Sched | 1995 |
Dermatological toxicity from chemotherapy containing 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1994 |
[Evaluation of 5-FU, leucovorin, etoposide, and cisplatin (FLEP) chemotherapy by hepatic artery injection in the treatment of multiple liver metastases from gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Fluorouracil; Hepatic | 1995 |
[Effect of 5-FU on the utilization of purine and pyrimidine by human gastric cancer cells (KATO III)].
Topics: Cell Division; Culture Media; Drug Interactions; Fluorouracil; Humans; Purines; Pyrimidines; Stomach | 1995 |
[Effects of 5-fluorouracil in shrinking residual gastric cancer: a case report].
Topics: Adenocarcinoma; Aged; Fluorouracil; Gastrectomy; Humans; Male; Neoplasm, Residual; Remission Inducti | 1995 |
[Home infusion chemotherapy in patients with relapsed or recurred stomach and colorectal cancer].
Topics: Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Home Care Servic | 1994 |
[Home therapy approach in cancer patients-nutrition therapy (case 1-1)--a case of recurrent gastric cancer with home parenteral nutrition].
Topics: Fluorouracil; Home Infusion Therapy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Parenter | 1994 |
[The use of endolymphatic chemotherapy in patients with metastatic stomach cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1994 |
[Two patients with far advanced gastric cancer responding to combination chemotherapy with 5-FU and CDDP].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 1995 |
[Case report of long-term survivor of advanced gastric cancer associated with peritoneal dissemination successfully treated with cancer chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouraci | 1995 |
[Combination therapy of 5-FU and low dose CDDP for advanced and recurrence gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Femal | 1995 |
FLEP (5-fluorouracil, leucovorin, etoposide, cisplatin) in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; | 1994 |
[A case of advanced gastric remnant carcinoma with Virchow's metastasis treated with neoadjuvant chemotherapy (low dose CDDP + 5-FU) followed by surgical resection].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; E | 1995 |
[A case report: postoperative recurrence of peritoneal dissemination of gastric cancer responding to sequential methotrexate and 5-FU (5-fluorouracil)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Admi | 1995 |
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors.
Topics: Actins; Adult; Aged; Base Sequence; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Regu | 1995 |
[A case of multiple liver metastasis from remnant gastric cancer responding to leucovorin.5-FU+UFT therapy].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Adm | 1995 |
Antitumour activity of 5-fluorouracil, verapamil and hyperthermia against human gastric adenocarcinoma cell (AGS) in vitro.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Combined Modality Therap | 1994 |
Five-drug combination chemotherapy (FAPEL) for advanced gastric cancer: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1994 |
[A case report: multiple liver metastasis from gastric cancer responding to intraarterial infusion of sequential low-dose MTX and 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluorouracil; Hu | 1994 |
[Dual arterial infusion chemotherapy, continuous hyperthermic peritoneal perfusion, and total parietal peritonectomy for peritoneal dissemination in gastric cancer--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality The | 1994 |
[A case of gastric cancer with Borrmann type 4 responding to 5-FU-MMC combined chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluoro | 1994 |
[A case of advanced gastric cancer successfully treated with resection after FEP (5-FU, epirubicin, CDDP) combined chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; D | 1994 |
[Characterization of a fluorouracil-resistant human gastric carcinoma cell line and its morphological behavior].
Topics: Animals; Cell Division; DNA, Neoplasm; Drug Resistance; Fluorouracil; Humans; Mice; Mice, Nude; Mito | 1993 |
[Effect of fagopyrum cymosum rootin on clonal formation of four human tumor cells].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drugs, Chinese Herbal; | 1993 |
Gastric carcinoma: curative resection and adjuvant chemotherapy.
Topics: Adenocarcinoma; Aged; Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Chemot | 1994 |
[Effects of combination chemotherapy using 5-FU, leucovorin, and CDDP (FLP therapy) for noncurative resected or recurrent stomach cancer in outpatients].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant | 1994 |
[A case of advanced gastric cancer with multiple liver metastases showing marked response to new combination chemotherapy using 5-FU, THP and MMC (FTM)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administrati | 1994 |
Augmentation of 5-fluorouracil cytotoxicity by epidermal growth factor in a newly established human signet-ring cell carcinoma of the stomach in culture.
Topics: Carcinoma, Signet Ring Cell; Cell Division; Cell Line; Cell Survival; Dose-Response Relationship, Dr | 1994 |
Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin.
Topics: Aclarubicin; Animals; Carbazilquinone; Carcinoma; Cell Nucleus; CHO Cells; Cisplatin; Cricetinae; Cy | 1994 |
[Successful neoadjuvant chemotherapy in a patient with advanced gastric cancer with multiple liver metastases].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 1994 |
Single-cell suspension assay with an MTT end point is useful for evaluating the optimal adjuvant chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Cisplatin; Coloring Agents; Doxorubicin; Drug Screening Assays, | 1994 |
[Intra-arterial regional chemotherapy in the combined treatment of stage-III cancer of the stomach].
Topics: Catheters, Indwelling; Celiac Artery; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusi | 1993 |
[A case of gastric cancer completely responding to sequential methotrexate and 5-fluorouracil therapy].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Admini | 1994 |
[Neoadjuvant chemotherapy for elderly advanced gastric cancer: a case report of MTX/5-FU sequential therapy followed by radical gastrectomy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug A | 1994 |
[Complete response in a case of unresectable gastric cancer treated by combined chemoimmunotherapy of MMC, 5-FU and OK-432].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; | 1994 |
[Neoadjuvant chemotherapy for far-advanced gastric carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Dr | 1994 |
[Postoperative immunochemotherapy for gastric carcinoma with peritoneal dissemination--the effects with the combination of CDDP, 5-FU and lentinan].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cel | 1994 |
Effect of gastrectomy on the pharmacokinetics of tegafur, uracil, and 5-fluorouracil after oral administration of a 1:4 tegafur and uracil combination.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gastrectomy; Hum | 1994 |
[Successful treatment of advanced gastric cancer (Borrmann 1 type) with FTP chemotherapy after reduction surgery].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1994 |
[A case of advanced gastric cancer complicated with multiple liver metastasis successfully treated with l-LV and 5-FU combination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Drug Administrati | 1994 |
[A case of advanced gastric cancer surviving 3 years and 6 months after resection of Krukenberg's tumor].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplati | 1994 |
[Nocturnal infusion of 5-fluorouracil in advanced digestive tract cancer--two case reports].
Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Circadian Rhythm; Drug Administration Schedule; Eso | 1994 |
[The clinical effect of chemotherapy with 5-FU and low-dose CDDP in patients with advanced gastric cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1994 |
[Efficacy of the treatment of gastric cancer as neo-adjuvant chemotherapy of 48 hour continuous intravenous infusion of 5-fluorouracil (5-FU) with leucovorin (LV)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluo | 1993 |
Semiautomated 14C-thymidine incorporation assay for in vitro screening of anticancer drug.
Topics: Adenocarcinoma; Antineoplastic Agents; Carbon Radioisotopes; Carcinoma, Signet Ring Cell; Cell Divis | 1993 |
[A case of nonresectable gastric cancer treated by sequential methotrexate and 5-fluorouracil].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Admi | 1994 |
[A case of Borrmann type 4 gastric cancer responding to sequential methotrexate and 5-fluorouracil combined with CDDP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 1994 |
The significance of preoperative chemotherapy for early gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administra | 1993 |
A pilot study of cisplatin based combination chemotherapy in gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Fluorouracil; Hu | 1993 |
[Efficacy and indication of radiotherapy in cancers of the stomach].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Sto | 1993 |
A standardized method of using nude mice for the in vivo screening of antitumor drugs for human tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Cyclophosphamide; Doxoru | 1993 |
Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine.
Topics: Antineoplastic Agents; Blotting, Northern; Cell Division; Colonic Neoplasms; Cytokines; Depression, | 1993 |
[Modulation by 1-leucovorin of 5-fluorouracil antitumor activity on human gastric carcinoma xenograft in nude mouse: preliminary report].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Leucovorin; Mice; Mice, Nude; | 1993 |
[Clinical efficacy of cis-diamminedichloroplatinum [II] and 5-fluorouracil (UFT) in advanced cancer of the alimentary tract].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1993 |
[Immunological effects of locoregional immunochemotherapy for liver metastases of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytokines; Doxorubicin; Fluorouracil; Humans; Immuno | 1993 |
[Intermittent intra-arterial infusion chemotherapy of 5-FU and carboplatin for unresectable liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Drug Administration | 1993 |
[Clinical study on the effect of continuous transarterial infusion chemotherapy of CDDP for metastatic liver tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Admi | 1993 |
[Pharmacokinetics following intraperitoneal sequential administration of cisplatin and fluorouracil for gastric cancer].
Topics: Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; Cisplatin; Drug Administration Schedul | 1993 |
[Evaluation of subselective intraarterial infusion chemotherapy in far advanced gastric and colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1993 |
[Intraarterial infusion chemotherapy for recurrent or unresectable gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Fluoroura | 1993 |
[Etoposide, doxorubicin, cisplatin and 5-FU (EAP-F) therapy of advanced gastric cancer--its antitumor effect and evaluation of quality of life].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Drug | 1993 |
[Clinical effect and characteristics of low dose leucovorin and high dose 5-FU therapy in patients with recurrent gastric cancer--a new method of biochemical modulation].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 1993 |
A pharmacodynamic and pharmacokinetic study of fluoropyrimidines in a nude mouse system and in postoperative patients with gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Animals; Colonic Neoplasms; Fluorouracil; Gastrectomy; Humans; | 1993 |
Continuous 5-fluorouracil infusion causing acute gastric mucosal lesions.
Topics: Adenocarcinoma; Female; Fluorouracil; Gastritis; Humans; Infusions, Parenteral; Middle Aged; Stomach | 1993 |
[A case of secondary leukemia induced by chemotherapy with a CDDP-based regimen for gastric cancer 5 years following radical resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Gastrectomy; Humans | 1993 |
Ternary complex formation and reduced folate in surgical specimens of human adenocarcinoma tissues.
Topics: Adenocarcinoma; Colorectal Neoplasms; Culture Techniques; Fluorouracil; Folic Acid; Humans; Leucovor | 1993 |
[Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 1993 |
[Effect of preoperative FPL (5-fluorouracil, cisplatin, leucovorin) therapy on patients with primary unresectable advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl | 1993 |
[Experimental and clinical study in vitro chemosensitivity test for succinate dehydrogenase inhibition test].
Topics: Colonic Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Liver Neopla | 1993 |
[Treatment of advanced gastric and colorectal cancer with 5-FU, leucovorin and interferon-alpha].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1993 |
[Effect of medroxyprogesterone acetate on the anticellular activity of 5-fluorouracil against human breast and stomach cancer cells].
Topics: Breast Neoplasms; Cell Division; Drug Synergism; Estrogens; Female; Fluorouracil; Humans; Medroxypro | 1993 |
[Evaluation of long-term administration of oral anti-cancer agent].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 1993 |
[A case of advanced gastric cancer responding to an FAP (5-FU, ADM, platinum compounds) combined chemotherapy].
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplati | 1993 |
Differential chemosensitivity of local and metastatic human gastric cancer after orthotopic transplantation of histologically intact tumor tissue in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Combined Modali | 1993 |
[A case report: multiple liver metastasis of gastric cancer responding to intraarterial infusion of MTX and 5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluoro | 1993 |
[A patient with stage IV gastric cancer responding to combination chemotherapy with 5-FU, leucovorin and CDDP].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administratio | 1993 |
[FAM as a palliative chemotherapy for gastric cancer with bone metastasis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disseminated Intrava | 1996 |
Curing gastric cancer--hone the scalpel with magic?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Fluorouracil; H | 1996 |
[A case of unresectable gastric cancer responding to combined therapy with intraperitoneal cisplatinum administration and continuous intravenous infusion of 5-fluorouracil].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cisplatin; Femal | 1995 |
[Leucovorin.5-FU therapy for advanced gastric cancer as a neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorouracil; | 1995 |
Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells.
Topics: Antimetabolites, Antineoplastic; DNA, Neoplasm; Drug Resistance; Fluorouracil; Genes; Humans; Phosph | 1996 |
[Estimation of pathways of 5-fluorouracil anabolism in human cancer cells in vitro and in vivo].
Topics: Animals; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Lung Neoplasms; Mice; Mice, | 1996 |
[A case of advanced gastric cancer responding to chemotherapy and radiotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cispl | 1996 |
[A case of advanced gastric cancer with lung and liver metastasis treated by CDDP and 5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 1996 |
[A case of advanced gastric cancer with liver metastasis with no recurrence and long survival].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1996 |
[Successful neoadjuvant chemotherapy in a patient with advanced gastric cancer with periaortic lymph node metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Chemotherapy, Adjuvant; Cisplatin; Comb | 1996 |
[Association between p53 expression and chemosensitivity in advanced and recurrent gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Screening Assays, Antitumor; Fluorou | 1996 |
[Study on the combined preoperative treatment with CDDP and HCFU for gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; F | 1996 |
Thymidylate synthase in advanced gastrointestinal and breast cancers.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Colonic Neoplasms; Fem | 1996 |
[Studies on the in vivo and in vitro chemosensitivity tests using human tumor xenografts].
Topics: Animals; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Screening Assays, An | 1995 |
[A case of AFP (alpha-fetoprotein) producing gastric cancer successfully treated with FEP (5-FU, Epirubicin, cisplatin) therapy by continuous venous daily infusion of 5-FU and low-dose CDDP].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration S | 1996 |
Severe acute metabolic acidosis and Wernicke's encephalopathy following chemotherapy with 5-fluorouracil and cisplatin: case report and review of the literature.
Topics: Acidosis; Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; F | 1996 |
[Effectiveness of preoperative intraperitoneal polychemotherapy in patients with stomach cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 1996 |
[Association of cancer and non-Hodgkin's lymphoma of the stomach].
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplast | 1996 |
Monocyte function associated with intermittent lentinan therapy after resection of gastric cancer.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; A | 1996 |
5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Drug Therapy, Combination; | 1996 |
Paradoxical clinical deterioration despite near-complete pathological response to neoadjuvant chemotherapy for locally advanced gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1995 |
[Induced hypertensive chemotherapy with angiotensin-II for liver metastases from gastric cancer].
Topics: Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Female; Fluoro | 1996 |
[A case of Borrmann type 4 gastric cancer successfully treated with MTX and 5-FU therapy through the hepatic artery].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flu | 1996 |
Tumor-specific gene expression in carcinoembryonic antigen--producing gastric cancer cells using adenovirus vectors.
Topics: Adenoviridae; Carcinoembryonic Antigen; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Thera | 1996 |
Skin metastases: an unusual presenting sign of gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Doxorubicin; Female; Fl | 1996 |
[Trial of home anti-cancer chemotherapy with infusion of 5-FU and low-dose cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Colonic Neopla | 1996 |
A case of bone marrow recurrence from gastric carcinoma after a nine-year disease-free interval.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma, Signet Ring Cell; | 1996 |
[Evaluation of combination chemotherapy with 5-FU and CDDP for human gastric carcinoma transplanted into nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Fluorouracil; Hum | 1997 |
Experimental studies on potentiation of the antitumor activity of 5-fluorouracil with 3'-azido-3'-deoxythymidine for the gastric cancer cell line MKN28 in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Drug Synergism; Female; | 1997 |
[Clinical analysis of adjuvant chemotherapy using 5-fluorouracil, leucovorin and cis-diamminedichloroplatinum for patients with advanced and recurrent gastric cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chem | 1997 |
[Clinical effects of postoperative immunochemotherapy with a combination of 5-FU, CDDP and lentinan for stage IVb gastric carcinoma and long-term pharmacokinetic studies on CDDP and 5-FU].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administrat | 1997 |
Relief of jaundice by 5-fluorouracil and folinic acid in patients with recurrent gastric cancer.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents; Bile; Drug Administration Schedule; Drug Synergism; D | 1996 |
Pilot study of continuous-infusion 5-fluorouracil, oral leucovorin, and upper-abdominal radiation therapy in patients with locally advanced residual or recurrent upper gastrointestinal or extrapelvic colon cancer.
Topics: Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therapy; Fluorourac | 1997 |
[A case of recurrent gastric cancer with liver metastasis responding to combination chemotherapy with cisplatin and carmofur].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluor | 1997 |
[Two cases of advanced gastric cancer effectively treated with chemotherapy of 5-fluorouracil, cisplatin and cytarabine].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Administ | 1997 |
[The combined treatment of locally disseminated stomach cancer with intra-arterial regional chemotherapy].
Topics: Antimetabolites, Antineoplastic; Celiac Artery; Combined Modality Therapy; Evaluation Studies as Top | 1996 |
Effect of preoperative 5-fluorouracil on apoptosis of advanced gastric cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Flow Cytometry; Fluorouracil; Humans; In | 1997 |
[A case of postbulbar duodenal ulcer due to adjuvant chemotherapy after gastrectomy for gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Duodenal Ulcer; F | 1997 |
[A case of advanced gastric cancer with carcinomatosa peritonitis effectively treated by 5-FU and low-dose CDDP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Drug Administration | 1997 |
In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; beta-Galactosidase; Carcinoembryonic A | 1997 |
Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplasti | 1997 |
[A case of papillary adenocarcinoma of the stomach with liver metastases and carcinomatous peritonitis treated effectively by methotrexate/5-fluorouracil sequential chemotherapy].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; D | 1997 |
[Hepatic arterial chemotherapy for liver cancer over a period of 8 years].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Epirubicin; Female; | 1997 |
[Radiation therapy for advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Combined Modality Th | 1997 |
[Extra-arterial dislocation of indwelling catheter in hepatic arterial infusion chemotherapy--special reference to tissue destruction by 5-fluorouracil].
Topics: Aged; Aneurysm, False; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 1997 |
[A case of far-advanced gastric cancer treated with continuous 5-fluorouracil injection and intrahepatic arterial infusion of low-dose cisplatin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasm | 1997 |
[Circadian chemotherapy in cancer patients].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Circadian Rhythm; Drug Administration Schedule; Female | 1997 |
[Correlation between anti-tumor effects and serum hepatocyte growth factor level in patients with liver metastases from gastric cancer treated by induced hypertensive chemotherapy with angiotensin II].
Topics: Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Press | 1997 |
[Experimental study on intraperitoneal sequential MTX/5-FU therapy for peritoneal seeding in comparison with intravenous administration].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 1997 |
[A case of stage IVb gastric cancer effectively treated by neoadjuvant chemotherapy and total gastrectomy with no residual tumor (R0)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 1997 |
[Long-term complete response in two cases of liver metastases from rectal and gastric cancer treated with intra-arterial infusion chemotherapy of leucovorin and 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1997 |
[New combination therapy with FTM [5-FU, pirarubicin (THP) and MMC] for treatment of inoperable advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 1997 |
In vitro combination effect of 5-fluorouracil and cisplatin on the proliferation, morphology and expression of Ki-67 antigen in human gastric cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Coloring Agents; DNA, Neop | 1997 |
[A case of advanced gastric cancer with multiple bone metastasis successfully treated by both methotrexate and 5-fluorouracil sequential therapy, and endoscopic intratumoral injection of 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, | 1998 |
[A case of unresectable advanced gastric cancer with severe obstructive jaundice responding to combined chemotherapy with 5-fluorouracil and low-dose cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Cisplatin; Drug Administration Sc | 1998 |
[Effect of preoperative THP-FLPM (pirarubicin, 5-fluorouracil, leucovorin, cisplatin, mitomycin C) therapy on far advanced gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxo | 1998 |
[A case of advanced gastric cancer with virchow's metastasis responding remarkably to combination chemotherapy of low-dose CDDP and 5-FU].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Chemotherapy, Adjuvant; | 1998 |
[A case of multiple liver metastasis of gastric cancer responding to hepatic arterial infusion chronotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Cisplatin; Drug Ad | 1998 |
[Two patients with obstructive jaundice due to intra-abdominal lymph-node metastases of gastric cancer responding to combination chemotherapy with 5-FU and CDDP].
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Cisplatin; Drug Administ | 1998 |
Gastric cancer associated with acute disseminated intravascular coagulation: successful initial treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Disease-Free Survival; Disseminated Intrava | 1998 |
Synthesis of novel dioxane nucleosides having two bases, physico-chemical properties, and their biological activities.
Topics: Antimetabolites, Antineoplastic; Dioxanes; Fluorouracil; Humans; Indicators and Reagents; Molecular | 1997 |
[p53 and Bax protein expression as predictor of chemotherapeutic effect in gastric carcinoma].
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Apo | 1998 |
[Effect of low-dose CDDP/5-FU therapy on thymidylate synthase content].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA, Neop | 1998 |
[Advanced gastric cancer curatively resected following combined neoadjuvant chemotherapy--report of a case].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 1998 |
Changes in tumor marker levels as a predictor of chemotherapeutic effect in patients with gastric carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 1998 |
[The intratumoral levels of thymidylate synthetase and folate in gastric and colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Fluoro | 1998 |
[A case of gastric cancer with decreased dihydropyrimidine dehydrogenase activity].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Female; F | 1998 |
p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Immuno | 1998 |
[Evaluation of intra-arterial infusion chemotherapy for advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Infusion Pumps, Imp | 1998 |
[Intrahepatic arterial infusion chemotherapy with angiotensin II for liver metastasis from gastric cancer].
Topics: Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Drug Administr | 1998 |
[Appearance of extrahepatic lesions in the superior lip and orbit of a patient with liver metastases of gastric cancer following partial response by hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Fluo | 1998 |
[Pharmacokinetic analysis of low-dose intra-peritoneal cis-platinum administration].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Infus | 1998 |
[Pharmaco-dynamic influence under ascites or laparotomy on intraperitoneal sequential MTX/5-FU therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Fluorouracil; Gastrectomy; Humans; In | 1998 |
[Effects of intravenous infusion of 5-FU and intraperitoneal injection of low-dose CDDP on 3 cases with ascites owing to peritonitis carcinomatosa of postoperative gastric carcinoma and debility].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Drug Administration | 1998 |
[Report of case who survived more than five years after repeated intraperitoneal chemotherapy with cisplatin and 5-fluorouracil for treatment of macroscopically negative but microscopically positive peritoneal dissemination of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1998 |
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcino | 1998 |
[Low-dose CDDP and continuous 5-FU treatment of advanced gastric cancer with peritoneal dissemination: a case with long disease-free survival].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 1998 |
Low-dose cisplatin-5-fluorouracil prevents postoperative suppression of natural killer cell activity in patients with gastrointestinal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colectomy; | 1998 |
UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 1998 |
Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies; Antimetabolites, Antineoplastic; Carcino | 1998 |
[Adenocarcinoma of the Barrett esophagus. Apropos of 44 resected cases].
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; | 1997 |
Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Drug Resistanc | 1998 |
[A case of gastric cancer with multiple bone metastasis treated by nocturnal 5-fluorouracil infusion combined with pamidronate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Signet Ring Cell; Diphosp | 1998 |
[Preoperative intra-arterial and venous neoadjuvant chemotherapy for advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Epirubicin; Female; Fl | 1998 |
Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; E | 1998 |
Clinical applications of the histoculture drug response assay.
Topics: Antineoplastic Agents; Cell Culture Techniques; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta | 1995 |
Modulation of apoptosis by endogenous Bcl-xL expression in MKN-45 human gastric cancer cells.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein | 1998 |
Treatment of advanced gastric cancer with oral etoposide, leucovorin and tegafur: experience with an oral modification of the etoposide, leucovorin and 5-fluorouracil (ELF) regimen.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female | 1998 |
[Nursing situation in outpatient chemotherapy following surgery for gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cispla | 1998 |
Supraventricular arrhythmia: a complication of 5-fluorouracil therapy.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atr | 1998 |
[Preliminary evaluation of adjuvant chemotherapy against stage Ib or II gastric cancer].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 1999 |
[Treatment with 5-FU modulated by low-dose CDDP for advanced cancers and recurrent cases of metastasis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic N | 1999 |
[A case of advanced gastric cancer successfully treated by neoadjuvant chemotherapy with CPT-11, CDDP and 5-FU].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Fluorouracil; Gastre | 1999 |
A comparison of an anti-gastrin antibody and cytotoxic drugs in the therapy of human gastric ascites in SCID mice.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cancer Vac | 1999 |
Proliferating cell nuclear antigen as a predictor of therapeutic effect of continuous 5-fluorouracil administration in gastric cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Northern; Cell Cycle; Cell Division; D | 1999 |
[A case report: modified PMUE therapy might be effective for advanced gastric carcinoma with pulmonary carcinomatous lymphangitis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 1999 |
Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Aspartic Acid; Co | 1999 |
Helicobacter pylori inhibits the G1 to S transition in AGS gastric epithelial cells.
Topics: Antigens, Bacterial; Apoptosis; Bacterial Proteins; Cell Cycle Proteins; Culture Media, Serum-Free; | 1999 |
Circumvention of 5-fluorouracil resistance in human stomach cancer cells by uracil phosphoribosyltransferase gene transduction.
Topics: Adenoviridae; Cytosol; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Escherichia coli | 1999 |
Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biotransformatio | 1999 |
High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chronotherapy; Colonic Neoplasms; Digestive System Neo | 1999 |
[A case of type 4 gastric cancer with peritoneal dissemination treated with intra-aortic chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female | 1999 |
Combination effects of tamoxifen plus 5-fluorouracil on gastric cancer cell lines in vitro.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cell Di | 1999 |
[A case of liver metastases from gastric cancer responding to induced hypertensive chemotherapy with angiotensin II].
Topics: Aged; Angiotensin II; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic C | 1999 |
The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 1999 |
[Percutaneous ethanol injection therapy with hepatic arterial infusion chemotherapy for liver metastases from gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Ethanol; Fluorouracil; Hepatic Art | 1999 |
[Efficacy and problems of hepatic arterial chemotherapy with angiotensin II for liver metastasis from gastric cancer].
Topics: Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Drug Administr | 1999 |
[Pharmaco-dynamic study of methotrexate (MTX) during intraperitoneal MTX/5-FU sequential therapy after gastric surgery].
Topics: Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Gastrectomy; Humans; Infusion | 1999 |
[A long-survival case of gastric cancer with multiple liver metastasis: usefulness of intraoperative multimodality therapy and post-operative intra-arterial chemotherapy for liver lesions].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Sche | 1999 |
[An effective case of arterial infusion therapy of low-dose CDDP and continuous 5-FU for isolated hepatic recurrence of gastric carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administrat | 1999 |
Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis | 1999 |
Complete response of a gastric primary after a short but toxic course of 'S-1' EORTC Early Clinical Studies Group.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Fluorouracil; Huma | 1999 |
Malignant acanthosis nigricans: potential role of chemotherapy.
Topics: Acanthosis Nigricans; Aged; Anal Canal; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic | 1999 |
[A case of advanced gastric cancer with abdominal para-aortic lymph node metastasis successfully treated with FLP therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Carcinoma, S | 1999 |
[Effects of low-dose FP therapy for advanced gastric cancer cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Flu | 1999 |
Induction of apoptosis in metastatic foci from human gastric cancer xenografts in nude mice and reduction of circulating tumor cells in blood by 5-FU and 1-hexylcarbamoyl-5-fluorouracil.
Topics: Animals; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; Cell Division; Dose-Response Relations | 1999 |
Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Comb | 1999 |
Current trends in the surgical treatment of esophageal and cardia adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cardia; Chemother | 1999 |
[5-FU sensitivity and thymidylate synthase in gastric cancer].
Topics: Antimetabolites, Antineoplastic; Cell Differentiation; Drug Screening Assays, Antitumor; Female; Flu | 1999 |
[PMC (pharmacokinetic modulating chemotherapy) for advanced gastric cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 1999 |
Therapy related acute myeloid leukemia after exposure to 5-fluorouracil: a case report.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Leukemia, Myeloid; Mid | 1999 |
[Two cases of recurrent gastric cancer for which combination chemotherapy with pirarubicin, cis-platinum and 5-fluorouracil were markedly effective].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2000 |
Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; CA-1 | 1999 |
[A case of stage IVb (H2P0N4T4) gastric cancer successfully treated with neoadjuvant chemotherapy (PMFE therapy)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Fluorour | 2000 |
[A case of gastric cancer with liver metastasis responding to low-dose CDDP/5-FU combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug Admi | 2000 |
[Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antiemetics; Antimetabolites, Antineoplastic; Br | 2000 |
[Seven patients with stage IVb advanced gastric cancer who were treated with preoperative chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Femal | 2000 |
[Staging laparoscopy for a patient with advanced gastric cancer whose serum CA 19-9 level decreased remarkably after 2 courses of F/P therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Drug Adm | 2000 |
[Evaluation of a novel adjuvant chemotherapy for non-resectable advanced gastric cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplati | 1997 |
Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Biopsy; Coloring Agents; Dihydrouracil Dehydrogenase (NADP); Drug R | 2000 |
A patient with a prolonged prothrombin time due to an adverse interaction between 5-fluorouracil and warfarin.
Topics: Adenocarcinoma; Adult; Anticoagulants; Antimetabolites, Antineoplastic; Drug Interactions; Drug Ther | 2000 |
[Current status of "low-dose cisplatin-5-FU therapy" for solid tumors (2nd report)--from a nationwide questionnaire on its adverse effects].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cispla | 2000 |
[A patient with advanced gastric cancer who obtained downstaging and underwent radical surgery by neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 2000 |
[Thymidylate synthase activity after preoperative administration of 5-FU in patients with gastric or colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administ | 2000 |
[A case of AFP-producing gastric cancer after curative operation effectively treated with chemotherapies including hepatic arterial infusion therapy].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 2000 |
[A case study of alpha feto protein (AFP)-producing gastric carcinoma with multiple liver metastases, in which chemotherapy was effective enough to once save a life in rapid decline].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluor | 2000 |
[A case of biloma caused by early complications of hepatic artery infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile; Cisplatin; Fluorouracil; Hepatectomy; He | 2000 |
Influence of gastrectomy on the distribution of intravenously administered 5-fluorouracil to regional lymph nodes in an animal model.
Topics: Animals; Antimetabolites, Antineoplastic; Female; Fluorouracil; Gastrectomy; Lymph Nodes; Stomach Ne | 2000 |
[A case of gastric cancer with multiple liver metastasis responding to combined chemotherapy with low-dose cisplatin and 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2000 |
[A case of nonresectable scirrhous type gastric cancer successfully treated by low-dose cisplatin (CDDP), 5-fluorouracil (5-FU) and pirarubicin (THP)].
Topics: Adenocarcinoma, Scirrhous; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorub | 2000 |
A feasibility study of chemosensitivity assay by adhesive tumor cell culture system using biopsy specimens for gastric cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biopsy; Cisplatin; Doxorubicin; Drug S | 2000 |
[Antitumor activity of 1-hexylcarbamoyluracil which is carmofur substituted fluorine for hydrogen].
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Mice; Mice, Inbred BALB C; | 2000 |
Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; | 2000 |
Unresectable advanced gastric cancer effectively treated by combined chemo-immunotherapy: a report of two cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluorouraci | 2000 |
Expression of thymidylate synthase in relation to survival and chemosensitivity in gastric cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Chemotherapy, A | 2000 |
[A patient with gastric cancer with para-aortic lymph node metastases surviving for 9 years after effective preoperative chemotherapy and radical operation].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aorta; Fluorouracil; Gastrectomy; Humans; Lymph Nod | 2000 |
[Two cases of advanced gastric cancer responding to TS-1: a novel oral formation of 5-fluorouracil].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sche | 2000 |
Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; DNA; Dose-Response Relationship, Drug; Drug Resi | 2000 |
Postsurgical sequential methotrexate, fluorouracil, and leucovorin for stages 3 and 4 gastric carcinoma: A preliminary study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Sc | 2000 |
Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Co | 2000 |
Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Blotting, Northern; Cell Cycle; Dose-Response Relationship, Drug; D | 2000 |
ECF in gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Epirubicin; Fluorouracil; Hu | 2000 |
[Hepatic arterial infusion chemotherapy for unresectable liver metastasis of gastrointestinal cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Fluorouracil; Hepati | 2000 |
[Two cases of chemotherapy related death associated with acute depression of consciousness complicating hepatic arterial infusion chemotherapy (5-FU and CDDP) for liver metastases from gastric cancer].
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Consciousness Disord | 2000 |
[An effective case of intraperitoneal and intra-arterial combined chemotherapy for unresectably advanced Borrmann type IV gastric carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 2000 |
[A case of stage IV gastric cancer responding to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 2000 |
[Combined 5-FU and CDDP in a gastric cancer patient undergoing hemodialysis--pharmacokinetics of 5-FU and CDDP].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fema | 2000 |
Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2001 |
Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Cati | 2001 |
Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Hu | 2001 |
[Outcomes of home anti-cancer chemotherapy--estimation of hepatic arterial infusion chemotherapy for patients with multiple liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Fluorouracil; He | 2000 |
Advanced gastric cancer with liver metastasis effectively treated by intra-hepatic arterial infusion of 5-FU, MMC and peroral administration of 5-FU: a case report.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hepatic Artery; | 2000 |
[A case of advanced gastric cancer with Virchow's and paraaortic lymph node metastases successfully resected after combined chemotherapy of low-dose CDDP and 5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Drug Administratio | 2001 |
[A patient with obstructive jaundice due to recurrence after gastric cancer surgery responding remarkably to FLP combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Cisplatin; Drainage; Drug Adminis | 2001 |
Surgical and combined treatment of gastric cancer--own experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma; Chemotherapy, A | 2000 |
[Hemorrhagic diathesis as initial symptom of stomach carcinoma].
Topics: Algorithms; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplasti | 2000 |
Options for investigative postsurgical therapy for gastric cancer, and case report of using the option for combined immunotherapy and chemotherapy.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Combin | 2001 |
[A case of gastric cancer with liver metastases successfully treated with combination therapy of systemic and hepatic arterial infusion chemotherapy].
Topics: Administration, Oral; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopla | 2001 |
Quality of life in cancer patients treated by chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2000 |
[A case of advanced gastric cancer complicated with liver metastases responding remarkably to combined chemotherapy with 5-fluorouracil and low-dose cisplatin, with UFT and low-dose cisplatin for maintenance on an outpatient basis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil | 2001 |
Undifferentiated leukemia following treatment of gastric cancer with 5 fluorouracil, doxorubicin, mitomycin C chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow; | 2000 |
Gastric cancer with Virchow's and multiple lung metastases showing a remarkable response to preoperative chemotherapy: report of a case.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2001 |
[Effective combination chemotherapy for a recurrent case of carcinoma of the remnant stomach].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 2001 |
[Curative resection of advanced gastric cancer responding to preoperative chemotherapy--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2001 |
Standard chemotherapy for gastric carcinoma: is it a myth?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Epirubicin; Fluor | 2001 |
Node-positive mucosal gastric cancer: a follow-up study.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Female; Fluorourac | 2001 |
[Inhibition of HCFU absorption after resection for gastric cancer--application of hydroxyaluminium gel].
Topics: Adult; Aged; Aluminum Hydroxide; Antineoplastic Agents; Chemotherapy, Adjuvant; Cross-Over Studies; | 2001 |
[Clinical experience of intermittent administration of 5-FU and CDDP to patients with advanced and recurrent gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Femal | 2001 |
Apoptosis and thymidylate synthase inductions by 5-fluorouracil in gastric cancer cells with or without p53 mutation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Survival; DNA Mutational Analysis; DNA, Neoplasm; F | 2001 |
A pilot study of preoperative chemoradiotherapy for resectable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Feasibility Studies; Female; Fluorouracil; Gast | 2001 |
A simple method for classification of cell death by use of thin layer collagen gel for the detection of apoptosis and/or necrosis after cancer chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Bisbenzimidazole; Cisplatin; Collagen; Eosine Yellowish-(YS); Fluo | 2001 |
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
Topics: Adult; Aged; Alternative Splicing; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neopla | 2001 |
Thymidine phosphorylase expression is useful in selecting adjuvant chemotherapy for stage III gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Female; | 2001 |
Transcatheter therapy for liver metastasis from gastric cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorourac | 2000 |
Retrospective study of hyponatremia in gastric cancer patients treated with a combination chemotherapy of 5-fluorouracil and cisplatin: a possible warning sign of severe hematological toxicities?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Female; Fluoro | 2001 |
A case of bone metastasis from gastric carcinoma after a nine-year disease-free interval.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined | 2001 |
High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro.
Topics: Biliary Tract Neoplasms; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relati | 2001 |
Complete response achieved following administration of S-1 in a patient with adrenal gland metastasis of 5-FU-resistant gastric cancer: a case report.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2001 |
Endoscopic Nd:YAG laser therapy combined with local chemotherapy of superficial carcinomas of the oesophagus and gastric cardia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardia; Combined Modality Th | 2001 |
[Efficacy of intraperitoneal chemotherapy for peritoneal recurrence of gastric carcinoma].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 2001 |
[Usefulness of hepatic arterial infusion chemotherapy for liver metastasis in gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Hepatic Arter | 2001 |
[Efficacy of continuous hepatic arterial infusion of high-dose 5-FU for liver metastases of gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Fluorouracil; Hepatic Artery; H | 2001 |
[A case of advanced gastric cancer with multiple liver metastases partially responding to combination intra-arterial chemotherapy via the hepatic artery and abdominal aorta].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Cisplatin; Drug Administration Sch | 2001 |
[Hepatic resection for synchronous liver metastases of gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Hepatectomy; Hepatic Art | 2001 |
[Pharmacokinetics of "subselective" arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Catheters, Indwelling; Drug Administration Sc | 2001 |
Cardiac tamponade as the first manifestation of gastric cancer and remission after chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiac Tamponade; Cisplatin; | 2001 |
[Basic study on the sensitivity test for inhibiting fibroblast proliferation (II)].
Topics: Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; | 2001 |
Management of a 16-year-old boy with adenocarcinoma at the esophageal gastric junction.
Topics: Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diagnosis, Di | 2001 |
[Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Combined Modality | 2001 |
[A complete response after neoadjuvant chemotherapy for advanced gastric cancer with esophageal invasion].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dihydrouracil Dehydrogenase (NADP); | 2002 |
[A patient with advanced gastric cancer surviving for more than 5 years after neoadjuvant chemotherapy and curative resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Duodenal Ne | 2002 |
Selective approaches to gastric cancer patients with liver metastases: role of liver-directed chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluorouracil; Humans; Infusi | 2001 |
Influence of L-methionine-deprived total parenteral nutrition with 5-fluorouracil on gastric cancer and host metabolism.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; DNA, Neoplasm; Fluorouracil; Male; Methionine | 2001 |
[Combination therapy including mutamycin (mitomycin C) in the treatment of advanced colorectal and gastric cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2001 |
Advanced gastric cancer effectively treated by neoadjuvant continuous low-dosage 5-fluorouracil and cisplatin (FP regimen): a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Lymphatic Met | 2001 |
Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X | 2002 |
Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Feasibility Studies; Female; Fluorourac | 2001 |
[5-Fluorouracil-induced colitis--a review based upon consideration of 6 cases].
Topics: Aged; Colitis; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2002 |
[Implanted percutaneous continuous hepatic arterial infusion system for nonresectable liver metastasis].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Female; Fluorouracil; Humans; Infus | 2001 |
[Dormant chemotherapy by low-dose FP and low-dose UFT-E in recurrent gastric cancer with long-term survival--a case report].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administr | 2002 |
[Three cases of advanced gastric cancer treated by TS-1 in combination with low-dose cisplatinum].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2002 |
[Circadian chronotherapy with cisplatin and 5-fluorouracil in three patients with advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Cisplatin; Fluorouracil; Humans | 2002 |
Current status of chemotherapy for gastric cancer in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Neoadjuvant Therapy | 2002 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |
Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carcinoma; Cisplatin; Dru | 2002 |
Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Chil | 2002 |
Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Esophageal Neoplasms; Fluorou | 2002 |
[Value of postoperative radiochemotherapy with 5-fluorouracil plus leucovorin in stage IB-IV M0 stomach carcinoma].
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Gastrectomy; Humans | 2002 |
[A case of gastric cancer with paraaortic lymph node metastasis responding to preoperative chemotherapy and surviving 4 years and 4 months after total gastrectomy].
Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; D | 2002 |
[A case of advanced gastric carcinoma with liver metastasis with no recurrence and long survival by means of surgery and postoperative chemotherapy].
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2002 |
[A case of complete response (CR) persisting for 2 years and 10 months from UFT-E in a patient with liver metastasis of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 2002 |
In-vitro effect of a combination of 5-fluorouracil (5-FU) and cisplatin (CDDP) on human gastric cancer cell lines: timing of cisplatin treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Synerg | 2002 |
[A case treated successfully with low-dose CDDP and 5-FU for the treatment of liver and para-aortic lymph node metastases and second metastasis to anterior mediastinum lymph nodes from gastric cancer after gastrectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Drug Administration Schedule; Fluo | 2002 |
[A case in which TS-1, an orally-administered 5-FU chemotherapeutic agent, showed marked effectiveness against scirrhous type gastric cancer with multiple organ metastases].
Topics: Adenocarcinoma, Scirrhous; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 2002 |
Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transport | 2002 |
[A case of unresectable gastric cancer complicated by a serious hepatic disorder and Virchow lymph node metastasis in which FP therapy and TS-1 administration were effective].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Letter: 5-Fluorouracil and angina.
Topics: Adult; Aged; Angina Pectoris; Female; Fluorouracil; Humans; Infusions, Parenteral; Injections, Intra | 1975 |
Chemotherapy studies in autochthonous rat tumors. Forestomach and bladder cancer.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carcinoma in Situ; Doxorubicin; Drug Combinations; Female | 1977 |
Enhancement of the cancer chemotherapeutic effect by anticancer agents in the form of fat emulsion.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Animals; Bleomycin; Breast Neoplasms; Carcinoma, | 1977 |
[Stomach neoplasms].
Topics: Aftercare; Eosinophilic Granuloma; Fluorouracil; Gastrectomy; Hodgkin Disease; Lymph Nodes; Mitomyci | 1978 |
Chemotherapy studies in autochthonous rat tumors: carcinomas of the forestomach.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carmustine; Dimethylnitrosamine; Drug Evaluation, Preclin | 1979 |
[Therapeutic advances in digestive oncology. III. Chemotherapy of digestive system cancers].
Topics: Adenocarcinoma; Digestive System Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Neoplas | 1979 |
Comparison of intramural 5-fluorouracil and more conventional routes of drug administration on concentrations in gastric regional lymph nodes: a potential for trans-endoscopic adjuvant chemotherapy.
Topics: Animals; Dogs; Fluorouracil; Gastric Mucosa; Gastroscopy; Haplorhini; Humans; Injections; Kinetics; | 1979 |
Results of cytostatic therapy of metastasizing testicular tumors.
Topics: Fluorouracil; Humans; Neoplasm Recurrence, Local; Postoperative Period; Radiotherapy, High-Energy; R | 1978 |
Clinical studies on PSK: combination therapy of PSK with surgery and chemotherapy.
Topics: Animals; Basidiomycota; Dogs; Drug Administration Schedule; Fluorouracil; Haplorhini; Humans; Mice; | 1978 |
Adjuvant therapy of gastric cancer: the 40742 clinical trial of the EORTC Gastro-intestinal Tract Cooperative Group.
Topics: Adenocarcinoma; Drug Administration Schedule; Fluorouracil; Humans; Radiotherapy, High-Energy; Stoma | 1979 |
[Preoperative administration of antineoplastic agents against gastric cancer. V. Clinical evaluation of combined chemotherapy with neocarzinostatin (NCS) and 5-fluorouracil (combined NF therapy) (author's transl)].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Drug Therapy, Combination; Female; Fluorouracil; Humans; L | 1979 |
[Determination of individual sensitivity of gastric cancer to 5-fluorouracil by tumor tissue respiratory and glycolytic indices].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Carcinoma; Fluorouracil; Glycol | 1975 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenoma, Islet Cell; Carcinoma, Hepatocellular; Carmustine; Colonic Neoplasms; Cytarabine; Drug Ther | 1975 |
Walter Hubert lecture Chemotherapy of upper gastrointestinal carcinoma.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Hepatocellular; Carcinoma, S | 1976 |
Observations on the postoperative tumor growth behavior of certain islet cell tumors.
Topics: Adenoma, Islet Cell; Fasting; Fluorouracil; Gastrins; Humans; Liver Neoplasms; Neoplasm Metastasis; | 1976 |
Experimental chemotherapy of carcinoma of the human stomach and colon serially transplanted in nude mice.
Topics: Adenocarcinoma, Mucinous; Animals; Colonic Neoplasms; Female; Fluorouracil; Humans; Mice; Mice, Nude | 1978 |
[New aspects in the concept of adjuvant and after-care therapy for gastric carcinoma?].
Topics: Aftercare; Antineoplastic Agents; Cell Movement; Drug Therapy, Combination; Fluorouracil; Humans; Mi | 1979 |
Preoperative basal chemotherapy in the management of cancer of the stomach: a preliminary report.
Topics: Adult; Aged; Carmustine; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Infus | 1979 |
[Chemotherapy of cancer of the proximal region of the stomach].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Male; Middle Aged; Stomach N | 1977 |
[A combined immuno-chemotherapy with futraful and picibanil for advanced cancer (author's transl)].
Topics: Aged; Biological Products; Drug Therapy, Combination; Female; Fluorouracil; Humans; Intestinal Neopl | 1977 |
[A clinicopathological study on preoperative anticancer chemotherapy for gastric cancer (author's transl)].
Topics: Adult; Aged; Antineoplastic Agents; Cytarabine; Drug Synergism; Drug Therapy, Combination; Female; F | 1978 |
[Comparative assessment of the effectiveness of the preparations CCNU, 5-fluorouracil, ftorafur and their combinations in inoperable stomach cancer].
Topics: Adenocarcinoma; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; Nitrosourea Compounds; S | 1978 |
Post-operative long-term adjuvant immunochemotherapy with mitomycin-C, PSK and FT-207 in gastric cancer patients.
Topics: Adjuvants, Immunologic; Basidiomycota; Drug Therapy, Combination; Fluorouracil; Gastrectomy; Humans; | 1979 |
A phase II trial of ftorafur: adriamycin and mitomycin-C (FAM II) in advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Marrow; Central Nervous System; Digestive S | 1979 |
Chemotherapy for gastric cancer.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Mitomycins; Stomach Neoplasm | 1979 |
Chemotherapy for sarcoma of the stomach.
Topics: Adult; Aged; Asparaginase; Cyclophosphamide; Dacarbazine; Dactinomycin; Doxorubicin; Drug Therapy, C | 1979 |
Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gas | 1979 |
[A comparative study on the preoperative administration of 5-FU DS and FD-1 against gastric cancer--with special reference to histological findings (author's transl)].
Topics: Adult; Aged; Female; Fluorouracil; Furans; Humans; Lymphatic Metastasis; Male; Middle Aged; Preopera | 1979 |
5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Bone Marrow; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1979 |
Five-day continuous infusion of 5-fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infus | 1979 |
Variations in serum copper and ceruloplasmin levels in advanced gastrointestinal cancer treated with polychemotherapy.
Topics: Aged; Antineoplastic Agents; Ceruloplasmin; Colonic Neoplasms; Copper; Cyclophosphamide; Drug Admini | 1979 |
Combination chemotherapy with 5-fluorouracil and methyl-CCNU for the treatment of advanced gastrointestinal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cells; Colonic Neoplasms; Drug Administration Schedule; Dr | 1979 |
Clinical value of immunochemotherapy with OK-432 or PS-K for stomach cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Biological Products; Dinitrochlorobenzene; Drug Therapy, C | 1979 |
[Dynamics of the leukocyte migration inhibition reaction in stomach cancer].
Topics: Cell Migration Inhibition; Fluorouracil; Gastrectomy; Humans; Immunotherapy; Leukocytes; Stomach Neo | 1979 |
[Experience with weekly intravenous 5-fluorouracil in advanced colonic and rectal neoplasms].
Topics: Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Injections, Int | 1979 |
[Chemotherapy of stomach cancer in an oncology office].
Topics: Adult; Aged; Ambulatory Care; Cancer Care Facilities; Female; Fluorouracil; Hospitals, Special; Huma | 1979 |
[Effect of the endolymphatic administration of chemical preparations on the leukocyte motor activity in stomach cancer].
Topics: Adult; Aged; Cell Movement; Drug Therapy, Combination; Female; Fluorouracil; Foot; Humans; Injection | 1979 |
Improved combination chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Carmustine; Doxorubicin; Drug Therapy, Combination; Female; Fluorouraci | 1979 |
[Combination chemotherapy of mitomycin-C, carboquone, 5-fluorouracil and OK-432 for inoperable gastric cancer (author's transl)].
Topics: Aged; Antineoplastic Agents; Carbazilquinone; Drug Therapy, Combination; Female; Fluorouracil; Human | 1979 |
In vitro sensitivity test of stomach cancer tissues by the use of metal grid method.
Topics: Antineoplastic Agents; Cytarabine; Drug Evaluation, Preclinical; Fluorouracil; Humans; In Vitro Tech | 1979 |
[A case with gastric cancer by OK-MF'C therapy (author's transl)].
Topics: Adenocarcinoma; Antineoplastic Agents; Cytarabine; Drug Therapy, Combination; Fluorouracil; Humans; | 1979 |
Combination chemotherapy for solid tumors using 5-fluorouracil, chromomycin-A, and prednisolone.
Topics: Adenocarcinoma; Breast Neoplasms; Chromomycins; Colonic Neoplasms; Drug Therapy, Combination; Evalua | 1977 |
Evaluation of chemotherapeutic effects on gastric cancer in relation to the histological pattern.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Cytarabine; Drug Therapy, Combination; Fluorouracil; Huma | 1978 |
Basic experiments on oral administration of 5-fluorouracil emulsion as adjuvant chemotherapy to surgical treatment for gastric cancer.
Topics: Administration, Oral; Animals; Emulsions; Fluorouracil; Gastrectomy; Rats; Stomach Neoplasms | 1978 |
[Role of chemotherapy in the treatment of stomach cancer].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Drug Evaluation; Female; Fluorouracil; Fo | 1978 |
Histological evaluation of the effect of 5-FU emulsion on lymph node metastasis of stomach cancer.
Topics: Adenocarcinoma; Administration, Oral; Carcinoma; Emulsions; Fluorouracil; Humans; Lymph Nodes; Lymph | 1978 |
[Current state of therapy for gastrointestinal tumors].
Topics: Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms; | 1978 |
Clinical and experimental studies of oral 5-FU emulsion as an adjuvant to the surgical treatment of gastric cancer.
Topics: Administration, Oral; Animals; Emulsions; Fluorouracil; Humans; Rats; Stomach Neoplasms | 1978 |
Combination therapy with mitomycin C, 5-fluorouracil, and cytosine arabinoside for nonresectable malignant tumor in man.
Topics: Adult; Aged; Bone Marrow; Breast Neoplasms; Cytarabine; Drug Therapy, Combination; Female; Fluoroura | 1978 |
[Cancer chemotherapy on gastric cancer (author's transl)].
Topics: Adult; Aged; Animals; Antineoplastic Agents; Dogs; Drug Evaluation; Drug Therapy, Combination; Femal | 1978 |
Chemotherapy for known residual disease after resection of gastric and colorectal cancer.
Topics: Carcinoembryonic Antigen; Carmustine; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; H | 1978 |
The treatment of gastric cancer with combined surgical resection and chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Prognosis | 1977 |
Quadruple chemotherapy for advanced malignant disease.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotr | 1977 |
Treatment of gastric cancer, with special reference to the survivals of the cancer patients treated with multiple combination MFC therapy or immunochemotherapy of MFC plus OK-432 (NSC B116209).
Topics: Adult; Aged; Cytarabine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; | 1977 |
Gastrointestinal cancer. Treatment with fluorouracil-nitrosourea combinations.
Topics: Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neo | 1976 |
[Experiences with cytostatic treatment of malignant tumors].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Cyclophos | 1976 |
Combination chemotherapy with mitomycin C, 5-fluorouracil, and cytosine arabinoside in gastrointestinal cancer.
Topics: Adult; Aged; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoro | 1976 |
Chemotherapy, adjuvant to surgery, for gastrointestinal cancer.
Topics: Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Intestinal Neoplasms; Male; Stomach Neopla | 1976 |
[Immunological status of patients with stomach cancer during chemotherapy].
Topics: Adult; Aged; Blood Bactericidal Activity; Dinitrochlorobenzene; Female; Fluorouracil; Humans; Immuni | 1975 |
[Evaluation of postsurgical chemotherapy in neoplasms].
Topics: Adult; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; | 1975 |
[Digestive tract cancer: planning of chemotherapy].
Topics: Bile Duct Neoplasms; Cytarabine; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Hum | 1975 |
[Modes of cytocidal action of antineoplastic agents and methods of their administration].
Topics: Adult; Animals; Breast Neoplasms; Female; Fluorouracil; Furans; Humans; Male; Middle Aged; Rats; Sto | 1975 |
The effect of cytostatic drugs on the synthesis of DNA in adenocarcinomas of the stomach. An in vitro study.
Topics: Adenocarcinoma; Antineoplastic Agents; Cells, Cultured; Depression, Chemical; DNA, Neoplasm; Fluorou | 1975 |
Heterogeneity of human adenocarcinomas of the colon and the stomach as regards sensitivity to cytostatic drugs.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Cytarabine; Fluorouracil; Humans; Melphala | 1975 |
[Serum phosphoglucomutase activity in stomach cancer patients].
Topics: Clinical Enzyme Tests; Fluorouracil; Humans; Phosphoglucomutase; Stomach Neoplasms | 1975 |
[Clinical evaluation of Ftorafur (author's transl)].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Drug | 1975 |
[Evaluation of adjuvant chemotherapy by 5-FU and mitomycin C for gastric surgery (author's transl)].
Topics: Fluorouracil; Humans; Mitomycins; Stomach Neoplasms | 1975 |
Evaluation of the ligation of the hepatic artery and regional arterial chemotherapy in the treatment of primary and secondary cancer of the liver.
Topics: Adolescent; Adult; Evaluation Studies as Topic; Female; Fluorouracil; Hepatic Artery; Humans; Ligati | 1975 |
Immunostimulation with intraperitoneally administered bacille Calmette Guérin for advanced malignant tumors of the gastrointestinal tract.
Topics: Adult; Aged; BCG Vaccine; Bile Duct Neoplasms; Carcinoma; Colonic Neoplasms; Cyclophosphamide; Femal | 1976 |
[Chemotherapy in gastrointestinal cancer].
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Meth | 1976 |
[Survival of patients with inoperable stomach cancer treated with 5-fluorouracil].
Topics: Drug Evaluation; Fluorouracil; Humans; Stomach Neoplasms; Time Factors | 1976 |
Chemosensitivity of head and neck cancer with the rapid thymidine incorporation assay and its clinical application.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Child; Cisplatin; Colonic Neopl | 1992 |
[Sequential MTX and 5-FU therapy of gastric cancer with systemic bone metastasis and disseminated intravascular coagulation].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1992 |
[A case of metastatic urinary bladder tumor from gastric carcinoma].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fluorouracil; | 1992 |
Effects of preoperative chemotherapy on gastric adenocarcinomas. A morphologic study of 25 cases.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1992 |
In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Survival; Colony-Forming Units Assay; Colorecta | 1992 |
[Effect of combined use of chemotherapeutic agents and hematopor--phyrin derivative (HPD) on human gastric cancer cell line in vitro].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Agents; Drug Synergism; Fluorouracil; Hematoporphyrin Deriv | 1992 |
Activities of thymidylate synthetase and thymidine kinase in gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Linear | 1992 |
Overexpression of erbB-2 protein in gastric adenocarcinoma--a potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adj | 1992 |
Xenotransplantation of alpha-fetoprotein-producing gastric cancers into nude mice. Characteristics and responses to chemotherapy.
Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; Cisplatin; Doxorubicin; Epirubicin; Flow Cytomet | 1992 |
[Experimental study of biochemical modulation of 5-fluorouracil with l-leucovorin against human esophageal cancer].
Topics: Colonic Neoplasms; Drug Screening Assays, Antitumor; Drug Synergism; Esophageal Neoplasms; Fluoroura | 1992 |
Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay.
Topics: Adult; Aged; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; | 1992 |
Chemotherapy for gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Fluorouracil; Hum | 1992 |
[Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 1992 |
[Blood concentrations of futraful, uracil and 5-fluorouracil (5-FU) after UFT administration in the various reconstructions after gastrectomy. Saitama UFT Research Group].
Topics: Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluo | 1992 |
[A study of urinary tegafur, 5-fluorouracil (5-FU) and uracil concentrations in the cases of gastric carcinoma for the confirmation of drug-taking compliance after UFT oral administration].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Compli | 1992 |
[A five-year-survival case in which complete response was recognized after combined chemotherapy using 5-fluorouracil, adriamycin and mitomycin C (FAM) for unresectable gastric cancer].
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluoro | 1992 |
Effects of glutathione depletion using buthionine sulphoximine on the cytotoxicity in mammalian cells and human tumor cells in vitro.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Buthionine Sulfoximine; Cell Hypoxia; | 1992 |
[Case report of a successful stage reduction of gastric carcinoma preoperatively treated by combined chemotherapy of 5-FU(UFT) and cisplatin].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fem | 1992 |
[Trend and problems of chemotherapy of stomach neoplasms with metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Mitomycin; Neoplasm | 1992 |
Complete disappearance of metastatic abdominal tumors from gastric cancer after treatment with irsogladine maleate.
Topics: Abdominal Neoplasms; Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 1992 |
[Serum concentration of HCFU and 5-FU after oral administration of HCFU in postoperative digestive cancer patients].
Topics: Administration, Oral; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Gastrectomy; Humans; S | 1992 |
[Chemotherapy-associated hemolytic uremic syndrome--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1992 |
[Treatment of liver metastases from gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Admini | 1992 |
[Complications related to catheter indwelling in intra-arterial infusion chemotherapy from the standpoint of the route of cannulation].
Topics: Antineoplastic Agents; Aorta; Catheters, Indwelling; Doxorubicin; Femoral Artery; Fluorouracil; Gast | 1992 |
[Evaluation of loco-regional cancer chemotherapy with assistance of home parenteral nutrition].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorouracil; H | 1992 |
[Experimental study of the treatment of carcinomatous peritonitis in gastric cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Infusions, Parente | 1992 |
[Intraperitoneal chemotherapy of metastatic ovarian cancer].
Topics: Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; | 1992 |
[Effective treatment of liver metastasis and peritoneal dissemination of gastric cancer using intra-arterial therapy--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Drug Administration Schedule; Fluoro | 1992 |
[Borrmann 4 gastric cancer treated with l-LV and 5-FU combination--a case report].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; | 1992 |
Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric cancer: an old lesson revisited.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Fluorouracil; Hum | 1992 |
Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations.
Topics: Colonic Neoplasms; Colorectal Neoplasms; Drug Administration Schedule; Drug Interactions; Fluorourac | 1992 |
[Pharmacokinetic studies on fluorinated pyrimidine in cancer cell and tissue].
Topics: Animals; Carcinoma, Ehrlich Tumor; Colonic Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Gl | 1992 |
[Large volume intraperitoneal chemotherapy as treatment for the peritoneal carcinomatosis from gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Screening Assays, Antitumor; Female; | 1992 |
[A case of recurrent liver tumor from gastric cancer responding remarkably to hepatic arterial infusion of large doses of mitomycin C and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gastrectomy; Hepatic Artery; Hum | 1992 |
[Pharmacokinetic study of tegafur in the hepatic tissue obtained from the patients with liver cancer].
Topics: Aged; Colonic Neoplasms; Fluorouracil; Humans; Liver; Liver Neoplasms; Middle Aged; Stomach Neoplasm | 1992 |
[Treatment of advanced cancer of the alimentary tract with cisplatin and 5-fluorouracil (UFT)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Administration Sc | 1992 |
Intra-abdominal panniculitis can mimic recurrent stomach carcinoma.
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Diagnosis, Diff | 1992 |
[Strategy for therapy of malignant ascites using MTT assay].
Topics: Antineoplastic Agents; Ascitic Fluid; Breast Neoplasms; Cisplatin; Clinical Protocols; Doxorubicin; | 1992 |
Effect of electrohydraulic and extracorporeal shock waves on gastrointestinal cancer cells and their response to cytotoxic agents.
Topics: Cell Survival; Colonic Neoplasms; Fluorouracil; Humans; Mitosis; Stomach Neoplasms; Tumor Cells, Cul | 1992 |
[Mechanism of synergism and clinical results of sequential methotrexate and 5-fluorouracil in the treatment of gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Chemo | 1992 |
MMAF for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Methotrexate; Mit | 1992 |
Preliminary evidence that incorporation of 5-fluorouracil into RNA correlates with antitumor response.
Topics: Colonic Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Humans; Liver Neoplasms; Rectal Neoplasms; Re | 1992 |
Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines.
Topics: Antibodies, Monoclonal; Antibody Specificity; Blotting, Western; Breast Neoplasms; Colonic Neoplasms | 1992 |
[Clinical evaluation of intra-arterial infusion of hyperthermo-chemotherapy in gastric cancer].
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 1991 |
Celiac axis infusion (CAI) chemotherapy for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Doxorubicin; Evaluation Studies as To | 1991 |
New developments in the treatment of gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Evaluation Studie | 1991 |
5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Epirubicin; | 1990 |
Schedule dependent potentiation of antitumor drug effects by alpha-difluoromethylornithine in human gastric carcinoma cells in vitro.
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Cell Cycle; Cell Survival; Doxorubicin; Drug Admin | 1990 |
[Initial results of combined surgical-medical therapy for metastatic cancer of the stomach].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fluorouracil; Gast | 1990 |
[Antineoplastic chemotherapy in digestive tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Fluorouracil; Hum | 1991 |
[Preoperative role of angiotensin II induced hypertension chemotherapy (IHC) in advanced gastric carcinoma].
Topics: Adult; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Combine | 1992 |
[Studies on a slow releasing anticancer agent for prevention of peritoneal recurrence of advanced gastrointestinal carcinomas (clinical study)].
Topics: Delayed-Action Preparations; Duodenal Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Lactat | 1992 |
[European School of Oncology (ESO)--gastric cancer treatment strategy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 1992 |
Increased drug resistance of cultured human cancer cell lines in three-dimensional cellular growth assay using collagen gel matrix.
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Collagen; Colonic Neoplasms; Culture Media; Doxoru | 1992 |
Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Fluorouracil; Humans; Leucov | 1991 |
[Evaluation of induced hypertension chemotherapy (IHC) in ambulatory cancer patients].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Breast | 1991 |
[Nutritional support for cancer bearing patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Home Nursing; Humans | 1991 |
A protein-bound polysaccharide immunomodulator, PSK, does not suppress the conversion from 1-(2-tetrahydrofuryl)-5-fluorouracil to 5-fluorouracil in patients with gastric cancer.
Topics: Antibiotics, Antineoplastic; Biotransformation; Depression, Chemical; Female; Fluorouracil; Humans; | 1991 |
[5-fluorouracil concentration in gastroenterological tumor tissues, in adjacent normal tissues, and in serum after preoperative oral administration of 5'-deoxy-5-fluorouridine (5'-DFUR)].
Topics: Administration, Oral; Colonic Neoplasms; Floxuridine; Fluorouracil; Gallbladder Neoplasms; Humans; S | 1991 |
[5-Fluorouracil level and pyrimidine nucleoside phosphorylase activity in cancer patients after oral administration of doxifluridine (5'-DFUR)].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Colonic Neop | 1991 |
In vivo drug intracellular localisation by analytical ion microscopy: preliminary study in gastric adenocarcinomas treated with 5-fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Microscopy, Electron; Stomach Neoplasms | 1991 |
[Organization of chemotherapy for patients with inoperable cancer of the stomach in the oncological unit of an urban polyclinic].
Topics: Cancer Care Facilities; Fluorouracil; Hospital Units; Hospitals, Urban; Humans; Medication Systems, | 1991 |
MMAF for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; | 1991 |
[The surgical treatment of gastric cancer. A review of the results and a comparison with Japanese experience].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1991 |
[Evaluation of effective neo-adjuvant chemotherapy (FLEP therapy) in the treatment of advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1991 |
[Loco-regional cancer therapy for hepatic metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamid | 1991 |
[Superior mesenteric arterial infusion chemotherapy against intestinal obstruction caused by peritoneal carcinomatosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1991 |
Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1991 |
[A pilot study of the combination of 5-FU and epirubicin for gastric cancer as an adjuvant chemotherapy].
Topics: Administration, Oral; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Flu | 1991 |
Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Enzyme Activation; Flu | 1991 |
Establishment of drug resistance in human gastric and colon carcinoma xenograft lines.
Topics: Animals; Blotting, Northern; Cell Line; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Resistance; | 1991 |
Subrenal capsule assay using nude mice as a predictor of the response of the gastric cancer to chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Fluorouracil; Huma | 1991 |
[Pharmacokinetic approach to the improvement of clinical predictability in the preclinical test for antitumor agents].
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Doxorubicin; Drug Screening Assays, | 1991 |
[Chemosensitivity test for gastric cancer by in vitro MTT assay].
Topics: Antineoplastic Agents; Carbazilquinone; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Et | 1991 |
[A long-term survival case of advanced gastric cancer undergoing radical gastrectomy by second-look operation after successful chemotherapy (CDDP, MMC, 5-FU)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1991 |
[Intraperitoneal administration of cis-platin with arterial infusion chemotherapy of advanced and recurrent gastric cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration S | 1991 |
[Hepatic arterial infusion of farmorubicin (FARM) and 5-fluorouracil (5-FU) in a patient with massive hepatic metastasis from gastric cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fluorourac | 1991 |
Chemotherapy in advanced gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Methotrexate; Mit | 1991 |
[Combination of a biscoclaurine alkaloid, cepharanthine, and anticancer agents: effects and mechanism in human gastric and pancreatic carcinoma cell lines].
Topics: Alkaloids; Antineoplastic Agents; Benzylisoquinolines; Cell Division; Doxorubicin; Drug Synergism; F | 1991 |
[Therapeutic effects of 9 antitumor drugs on stomach adenocarcinoma (MKN-28) in nude mice].
Topics: Animals; Antineoplastic Agents; Carcinoma, Intraductal, Noninfiltrating; Cisplatin; Cyclophosphamide | 1990 |
[Evaluation of pre-operative 5-fluorouracil treatment of the patients with gastric cancer--alteration of the inhibition rate of thymidilate synthetase by dose difference].
Topics: Fluorouracil; Humans; Preoperative Care; Stomach Neoplasms; Thymidylate Synthase | 1991 |
[The phagocytic activity and cytochemical indices of the neutrophils in patients with stomach cancer treated with 5-fluorouracil].
Topics: Adult; Aged; Female; Fluorouracil; Histocytochemistry; Humans; Male; Middle Aged; Neoplasm Metastasi | 1991 |
Relationship between glutathione levels and drug or radiation sensitivities in human gastric cancer cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Chlorambucil; Cyclophosphamide; Doxor | 1991 |
[The use of ceruloplasmin in combination with adjuvant polychemotherapy in stomach cancer].
Topics: Adjuvants, Immunologic; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Cerulopl | 1991 |
High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1991 |
Treatment of metastatic gastric carcinoma with a modified FAMTX chemotherapy regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 1990 |
[Experimental studies on subrenal capsule assay using cyclosporin A treated mice--the optimal treatment schedules of CsA and anticancer agents (mitomycin C and 5-fluorouracil)].
Topics: Animals; Body Weight; Breast Neoplasms; Colonic Neoplasms; Cyclosporins; Female; Fluorouracil; Human | 1990 |
Chemosensitivity correlation between the primary tumors and simultaneous metastatic lymph nodes of patients evaluated by DNA synthesis inhibition assay.
Topics: Breast Neoplasms; Carbazilquinone; Cisplatin; Colorectal Neoplasms; DNA, Neoplasm; Doxorubicin; Drug | 1990 |
Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cytotoxicity, Immunologic | 1990 |
Open phase II with 5-fluorouracil, 4-epi-doxorubicin and mitomycin C (FEM) in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1990 |
[A case of unresectable liver metastasis from leiomyosarcoma of the stomach successfully treated by intra hepato-arterial chemotherapy with Infuse-A-Port].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Hepatic Artery; Humans; I | 1990 |
[Macrocytic anemia as a possible adverse effect of fluoropyrimidines].
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Erythrocyte Indices; Female; Flu | 1990 |
[Evaluation of intraperitoneal cancer chemotherapy using an implantable reservoir in patients with peritonitis carcinomatosa].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Colorectal Ne | 1990 |
[Long-term arterial infusion chemotherapy to the cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Doxorubic | 1990 |
[Evaluation of subselective intraarterial infusion chemotherapy in advanced gastric cancer and recurrence case-evaluated on factors other than direct effects].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 1990 |
[Evaluation of the liver and peritoneal metastasis in the treatment of gastric carcinoma with intra-arterial injection in terms of survival period].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Int | 1990 |
[Clinical evaluation and problem of intra-arterial infusion chemotherapy of liver metastasis from digestive organ cancer].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusion Pumps, Implantabl | 1990 |
[An experimental study of anticancer agent sensitivity test in human gastric cancer cell lines by flow cytometry].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bromodeoxyuridine; Cell Cycle; Cisplatin; DNA, Neopla | 1990 |
Acute non-lymphocytic leukemia following FAM combination adjuvant chemotherapy for gastric and lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherap | 1990 |
[Successful treatment of advanced gastric cancer with multiple liver metastasis by combination chemotherapy using mitomycin C, 5-fluorouracil, and high-dose leucovorin: a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; | 1990 |
[Clinical studies of in vitro chemosensitivity test evaluated by ATP assay of gastrointestinal cancer].
Topics: Adenosine Triphosphate; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Scree | 1990 |
An EORTC phase II study of sequential methotrexate-fluorouracil in locally advanced or metastatic gastric cancer. The EORTC Gastrointestinal Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; | 1990 |
[Preoperative chemotherapy and anti-cancer effect of gastric carcinoma].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap | 1990 |
[A study on pre-operative administration of 5'-DFUR in carcinomas of the gastric, breast, thyroid and colon].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; F | 1990 |
Localized skin toxicity from 5-fluorouracil after paravenous infusion of leukovorin calcium.
Topics: Drug Eruptions; Fluorouracil; Humans; Injections, Subcutaneous; Leucovorin; Liver Neoplasms; Male; M | 1990 |
[Intra-hepato-arterial infusion chemotherapy using catheter inserted and placed in hepatic artery via the left radial artery on liver malignancy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1990 |
[A case of nonresectable gastric cancer completely responding to combined chemotherapy according to the mode of progression].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1990 |
Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin.
Topics: Arrhythmias, Cardiac; Carcinoma, Squamous Cell; Chest Pain; Cisplatin; Electrocardiography; Esophage | 1990 |
Oral carmofur in advanced gastrointestinal cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Admini | 1990 |
[A case of early gastric carcinoma which disappeared with treatment of low dose 5-FU].
Topics: Administration, Oral; Colectomy; Colonic Neoplasms; Fluorouracil; Gastroscopy; Humans; Male; Middle | 1990 |
[2 cases of long-term remission after conservative treatment of inoperable cancer of the stomach].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Combined Modality Therapy; | 1990 |
[The dynamics of the enzymatic activity of DNA metabolism during the treatment of stomach cancer patients].
Topics: Clinical Enzyme Tests; Combined Modality Therapy; DNA, Neoplasm; Fluorouracil; Gastrectomy; Humans; | 1990 |
Bilateral total corneal epithelial erosion as a side effect of cytotoxic therapy.
Topics: Aged; Carcinoma; Cornea; Fluorouracil; Humans; Male; Stomach Neoplasms; Visual Acuity | 1990 |
[Clinical effect of chemotherapy combined with Chinese herbs and western drugs on leukocytes of gastric cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drugs, Chinese Herbal; Fema | 1990 |
Gastric adenocarcinoma presenting with soft tissue masses.
Topics: Adenocarcinoma; Aged; Fluorouracil; Humans; Male; Soft Tissue Neoplasms; Stomach Neoplasms; Thigh | 1990 |
[Clinical reevaluation of continuous intravenous infusion of 5-fluorouracil--plasma concentrations and clinical dose by continuous intravenous and 60-min infusions].
Topics: Adult; Aged; Drug Administration Schedule; Evaluation Studies as Topic; Female; Fluorouracil; Humans | 1990 |
New developments in the treatment of gastric carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1990 |
A new chemotherapeutic regimen in the treatment of advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 1990 |
[Dose intensity and clinical response in patients with advanced gastric carcinoma treated by induced hypertension chemotherapy].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxorubicin; Fluorou | 1990 |
[Effect of concomitant use of anticancer drugs and a Ca2+ antagonist, on human gastric cancer transplanted into nude mice].
Topics: Animals; Antineoplastic Agents; Drug Combinations; Fluorouracil; Humans; Male; Mice; Mice, Inbred BA | 1990 |
A phase II trial of 5-fluorouracil, doxorubicin, mitomycin C, and leucovorin in advanced gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Female; F | 1990 |
High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer--a phase II study in elderly patients or patients with cardiac risk.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Female; Fluorourac | 1990 |
Locally advanced unresectable gastric cancer successfully resected after neoadjuvant chemotherapy with FADE regimen.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1990 |
[Sequential methotrexate.5FU chemotherapy for gastric cancer--comparison between intra-aortic infusion therapy and intravenous administration therapy].
Topics: Adult; Aged; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Male; | 1990 |
Adjuvant 5-FU and MeCCNU improves survival following curative gastrectomy for adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemot | 1990 |
[Efficacy of a 48-hour infusion of 5-fluorouracil in patients with stage IV gastric cancer after palliative gastrectomy].
Topics: Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Gastrectomy; Hu | 1990 |
[Long-term arterial infusion chemotherapy in advanced and recurrent gastric cancer patients at home and an interesting autopsy case].
Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; D | 1990 |
[Preoperative superselective intra-arterial polychemotherapy in combined treatment of gastric stomach].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Evaluation Studies as Topic; Flu | 1990 |
[Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancers xenografted in nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; Li | 1990 |
[Intratumoral administration of 5-fluorouracil and bleomycin in inoperable cancer of the cardioesophageal region].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cardia; Combined Modality Th | 1985 |
[Chemotherapy and total body hyperthermia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Colonic Neoplasms; Combined Mo | 1985 |
Loss in cell killing effectiveness of anticancer drugs in human gastric cancer clones due to recovery from potentially lethal damage in vitro.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Bleomycin; Cell Survival; Cells, Cultured; Dactino | 1986 |
[A study of the antineoplastic activity of K18].
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line; Drug Combinations; Drug Synergism; Fluorourac | 1986 |
Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin.
Topics: Animals; Biotransformation; Cell Division; Colonic Neoplasms; DNA; Drug Synergism; Fluorouracil; Fol | 1987 |
[Long-term administration of tegafur in postoperative adjuvant chemotherapy in gastric cancer patients. Serial analysis of serum tegafur and 5-fluorouracil concentrations, and influence from PSK combination].
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Ther | 1989 |
5-Fluorouracil and UFT-sensitive gastric carcinoma has a high level of thymidylate synthase.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Male; Mice; Mice, Inb | 1989 |
The uptake of anticancer drugs by tumor tissues and lymph node and the effectiveness of postoperative adjuvant chemotherapy on survival time.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Lymph Nodes; Prognosis; Stomach Neoplasms; Tegafur; | 1989 |
[Chemotherapeutic effect on metastatic tumors].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxorubicin; Fluorou | 1989 |
[Influence of OK-432 on intratumor 5-fluorouracil concentration in cases given UFT].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Products; Biotransformation; Colonic Neop | 1989 |
[Anti-tumor effect of fluoropyrimidines on human tumor cell lines transplanted in nude mice with CCl4-induced liver dysfunction].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carbon Tetrachloride; Cell Line; Colonic Ne | 1989 |
[Preventive hepatic arterial infusion in high risk cases of liver metastasis from gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Evaluation; Fluorour | 1989 |
[Over two years survival of intra-arterial infusion chemotherapy in gastric cancer with liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Fluoro | 1989 |
[Arterial infusion chemotherapy in patients with gastric cancer in liver metastasis and long-term survival after treatment].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Aorta; Doxorubicin; Fluorouracil; He | 1989 |
[Three cases of effective hepatic arterial infusion with OK-432, mitomycin C and 5-fluorouracil in liver metastasis from gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Hepatic Artery; Humans; | 1989 |
Effect of combination of 5-fluorouracil, epirubicin and mitomycin C (FEM) on advanced gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fluorouracil; Human | 1989 |
Distributions of tegafur in tissues of gastric adenocarcinoma patients: tissue uptakes and concentrations in plasma after oral and rectal administrations.
Topics: Adenocarcinoma; Administration, Oral; Administration, Rectal; Adult; Aged; Female; Fluorouracil; Hum | 1989 |
Therapy of advanced gastric carcinoma. The Georgetown-Lombardi Cancer Center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Fluo | 1989 |
[Two cases of gastrointestinal cancers with major responses to sequential methotrexate 5-FU plus 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Ne | 1989 |
[Effect of human epidermal factor (hEGF) on antitumor activity of 5-fluorouracil (5-FU) in human gastric cancer cell lines].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Cell Division; Cell Line; Cell Survival; Drug Screening As | 1989 |
[Characteristics of the postoperative period in stomach cancer patients undergoing combined treatment].
Topics: Combined Modality Therapy; Fluorouracil; Gastrectomy; Gold Colloid, Radioactive; Humans; Postoperati | 1989 |
[Metastatic liver cancer from the stomach successfully treated by combined immunochemotherapy and transarterial embolization].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabin | 1989 |
[Effect of sequential MTX/5-FU therapy for a case of disseminated intravascular coagulation syndrome associated with recurrence of gastric cancer--a case report].
Topics: Adenocarcinoma, Scirrhous; Adult; Disseminated Intravascular Coagulation; Fluorouracil; Humans; Male | 1989 |
[Chemosensitivity of MGc 80-3 human gastric adenocarcinoma cells and its clinical significance].
Topics: Adenocarcinoma, Mucinous; Amdinocillin; Antineoplastic Agents; Drug Screening Assays, Antitumor; Flu | 1989 |
5-Fluorouracil, doxorubicin (adriamycin) and mitomycin-C (FAM) in advanced gastric cancer: observations on response, patient characteristics, myelosuppression and delivered dosage.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Doxorubicin; Female; Fluor | 1989 |
[Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Sche | 1989 |
Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1989 |
Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fema | 1989 |
Advanced gastric cancer: a new combined surgical and oncological approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 1989 |
[Optimization of chemotherapy of stomach cancer].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; D | 1989 |
[A 5-FU, ADR, MMC combined hepatic arterial infusion therapy in non-resectable liver metastases from colon and gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Drug Evaluation; Flu | 1989 |
[Clinical effectiveness of arterial infusion chemotherapy in advanced and recurrent gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 1989 |
[Effect of indomethacin on the immunological indices of patients with inoperable stomach cancer].
Topics: Adult; Antigen-Antibody Complex; Drug Evaluation; Drug Therapy, Combination; Erythrocytes; Fluoroura | 1989 |
[Treatment methods for scirrhous carcinoma of the stomach--with special reference to total gastrectomy and chemotherapy in early postoperative period].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fluorouracil; | 1988 |
[The role of thymidylate synthetase in sequential dose of MTX and 5-FU in the advanced scirrhous type gastric cancer].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Adminis | 1988 |
[Cancer chemotherapy of scirrhous type gastric cancer and evaluation of chemotherapeutic efficacy].
Topics: Adenocarcinoma, Scirrhous; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cyt | 1988 |
[Therapeutic treatment of Borrmann type 4 (scirrhous) gastric cancer-chemotherapy and histopathological studies].
Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 1988 |
[A gastric cancer showing marked improvement (stage IV) with lentinan immunotherapy and 5-FU, MMC-chemotherapy].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gastroscopy; | 1988 |
Radiation therapy for advanced gastric cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Aged, 80 and over; | 1988 |
[Experimental chemotherapy of human gastric cancer cell lines in vitro and in nude mice].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Allyl Compounds; Animals; Antibiotics, Antineoplastic; Cel | 1988 |
[Anticancer treatment with a combination of antimetabolites of polyamine and pyrimidine].
Topics: Animals; DNA Replication; Drug Therapy, Combination; Eflornithine; Floxuridine; Fluorouracil; Mice; | 1985 |
[Observation on the curative effect postoperatively of late gastric cancer by the fu zheng anti-cancer method combined with chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Medicine | 1985 |
[Observations on 32 cases of advanced carcinoma of the esophagus and the proventriculus treated by the MOF III plan in combination with fu zheng kang ai tang].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cardia; Esoph | 1985 |
Combined therapy of polyamine antimetabolites and antitumor drugs for human gastric cancer xenotransplanted into nude mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcino | 1986 |
[Combination chemotherapy with 3 or 4 drugs on human breast and gastrointestinal cancer xenografts in nude mice (II)].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla | 1987 |
[Postoperative adjuvant chemotherapy using NCS (neocarzinostatin) and 5-FU in the treatment of gastric cancer. First report--A comparison with the 5-year survival rate of patients undergoing combined therapy with MMC and 5-FU].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Admin | 1987 |
Comparison of the pyrimidine nucleoside phosphorylase activity in human tumors and normal tissues.
Topics: Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; In Vitro Techniques; Pentosyltransferases; Pro | 1988 |
The antiproliferative effects of fluoropyrimidine derivatives against human tumor xenografts in a subrenal capsule assay.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Colorectal Neoplasms; Floxuridine; Fluor | 1988 |
[Low-dose intermittent intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dox | 1985 |
[Sequential chemotherapy with low-dose methotrexate and 5-fluorouracil in advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1985 |
[A case of bilateral metastatic breast carcinoma from gastric carcinoma].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined | 1986 |
A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1986 |
[Combination chemotherapy of cis-diamminedichloroplatinum (CDDP) and 5-fluorouracil (5-FU) in gastrointestinal tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; C | 1986 |
Poorly differentiated human gastric carcinoma is more sensitive to antitumor drugs than is well differentiated carcinoma.
Topics: Aclarubicin; Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Antineoplastic Age | 1987 |
[Antineoplastic agent sensitivity of primary and metastatic foci of nude mouse-transplantable human gastric cancer].
Topics: Animals; Colony-Forming Units Assay; Fluorouracil; Humans; Mice; Mice, Nude; Mitomycin; Mitomycins; | 1986 |
N1-(2 tetrahydrofuryl)-5-fluorouracil (FT-207) in the postoperative adjuvant chemotherapy of gastric cancer. Delivery of a fat-emulsified agent to the lymph.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Fat Emulsions, Intravenous; Fluoroura | 1986 |
[Antitumor effect of interferons with chemotherapeutic agents].
Topics: Antineoplastic Agents; Cell Line; Cells, Cultured; Cisplatin; Drug Therapy, Combination; Fluorouraci | 1986 |
[Combined effect of interferons alpha, beta and gamma on tumor growth in vitro].
Topics: Animals; Cell Line; Cells, Cultured; Drug Therapy, Combination; Fluorouracil; Humans; Interferon Typ | 1986 |
[Adjuvant therapy of gastric cancer in the literature from 1980-1984].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Administration Schedule; Fluorouracil; Humans; Mitomyc | 1986 |
[Clinical study of THP-adriamycin in patients with advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fluorouracil; Huma | 1986 |
[5-FU concentration in the blood and tissue of patients with gastric and colorectal cancer after administration of UFT or tegafur].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Male; Rats | 1986 |
Prediction of individual tumor chemosensitivity in subrenal capsule assay.
Topics: Animals; Antineoplastic Agents; Cisplatin; Colony-Forming Units Assay; Cyclophosphamide; Doxorubicin | 1986 |
[Determination of the individual sensitivity of human stomach cancer cells to fluoropyrimidines by the cytomorphological criteria of heterotransplants in diffusion chambers].
Topics: Adenocarcinoma; Animals; Carcinoma; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Fe | 1986 |
[Chemosensitivity testing for 5-FU and 5-FU derivatives using subrenal capsule assay].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colony-Forming Units Assay; Fluor | 1987 |
[A model for the sensitivity determination of anticancer agents against human cancer using nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Cell Line; Cisplatin; Colonic Neoplas | 1987 |
[Successful treatment of advanced gastric cancer by combined cisplatinum, mitomycin C and 5-FU administration. A case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Gas | 1987 |
Anticancer drug distribution in lymph and blood during adjuvant chemotherapy after surgery for gastric carcinoma. A study with a combined preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil.
Topics: Combined Modality Therapy; Drug Combinations; Fluorouracil; Humans; Lymph; Male; Metabolic Clearance | 1987 |
[Subrenal capsule assay for chemosensitivity testing].
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Colony-Forming Units Assay; Cyclophosphamide; Dox | 1987 |
[The effect of gastrectomy on serum 5-FU concentrations of patients administered UFT per os].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil | 1987 |
5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the "chemotherapiegruppe gastrointestinaler tumoren (CGT)".
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Drug E | 1987 |
[Improved quality of life in a patient with Borrmann type 4 gastric cancer treated with combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Methot | 1987 |
[Advanced gastric cancer with DIC and multiple bone metastasis treated with surgical resection and chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Co | 1987 |
[FO-152].
Topics: Absorption; Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Dogs; Drug Evaluation; Female | 1987 |
[Subrenal capsule assay as a chemosensitivity test (III)--Comparison of host reaction, experimental chemotherapy and use of nude mice].
Topics: Animals; Breast Neoplasms; Cell Line; Drug Evaluation, Preclinical; Fluorouracil; Humans; Mice; Mice | 1987 |
[5-FU concentration in tumor tissue and the antitumor effect in patients with gastric cancer after oral administration of UFT].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluoroura | 1987 |
[A case of gastric cancer with marked response to intra-arterial infusion of cisplatinum, mitomycin C and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Infusions, | 1987 |
[Serum concentration of 5-FU and tegafur (FT-207) after administration of tegafur (FT-207) suppository with the colostomy].
Topics: Adult; Aged; Colostomy; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; | 1987 |
[Experience with CDDP therapy in advanced and recurrent gastric cancer cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Doxorubic | 1987 |
[The effect of tegafur suppository and glutathione in patients with gastric and colonic cancer with special reference to the histopathological anticancer effect].
Topics: Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Glutathione; Humans; Stomach Neoplasms; | 1987 |
[A case of gastric cancer with multiple liver metastases responding to combination therapy of recombinant interferon-gamma (KW-2202) and 5-FU].
Topics: Adenocarcinoma; Aged; Drug Therapy, Combination; Fluorouracil; Humans; Interferon-gamma; Liver Neopl | 1987 |
[Subrenal capsule assay as a chemosensitivity test (V)--Experimental chemotherapy of cyclosporin A-treated mice and nude mice].
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Cy | 1988 |
[Combination chemotherapy of 5-fluorouracil (5-FU), adriamycin (ADM), cis-diamminedichloroplatinum (II) (CDDP) and mitomycin C (MMC) (FAP.MMC) in advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Fluorou | 1988 |
Cure of advanced gastric cancer by combined chemotherapy with cisplatinum, mitomycin C, and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorourac | 1988 |
[Chemotherapy and enteral nutrition in stomach cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 1988 |
Background for and progress of an ongoing EORTC phase-II study in metastatic gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Fluorouracil; Humans; | 1988 |
[Uptake of anticancer drugs by target organs and the usefulness of adjuvant chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Gastrectomy; Humans; Ly | 1988 |
[Combined effects of interferon alpha-A/D with fluoropyrimidine derivatives in the subrenal capsule assay].
Topics: Animals; Colonic Neoplasms; Drug Synergism; Fluorouracil; Interferon Type I; Male; Mice; Mice, Nude; | 1988 |
[The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouraci | 1988 |
[Complete response in a case of unresectable gastric cancer with a combination of tegafur, 5-fluorouracil and mitomycin C].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusion | 1988 |
[Hemolytic-uremic syndrome caused by mitomycin C].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hemolytic-Uremic Syndr | 1988 |
[Blood and tumor levels of tegafur, 5-fluorouracil, and uracil].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 1988 |
UFT is more antineoplastic against gastric carcinoma than 5-fluorouracil, 1-(2-tetrahydrofuryl)-5-fluorouracil and 1-hexylcarbamoyl-5-fluorouracil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Male; Mice; Stomach Neoplasms | 1988 |
[A case of variant angina induced by 5-fluorouracil and Tegafur].
Topics: Adenocarcinoma; Angina Pectoris, Variant; Coronary Vasospasm; Electrocardiography; Fluorouracil; Hum | 1988 |
Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.
Topics: Adenocarcinoma; Breast Neoplasms; Colonic Neoplasms; Deoxyuracil Nucleotides; Drug Resistance; Fluor | 1988 |
[Inhibition of thymidylate synthetase and antiproliferative effect by 1-hexylcarbamoyl-5-fluorouracil].
Topics: Animals; Antineoplastic Agents; Cell Division; Esophageal Neoplasms; Fluorouracil; Mice; Mice, Inbre | 1988 |
[The intraperitoneal administration of chemical preparations and taktivin in the combined treatment of stomach cancer].
Topics: Adjuvants, Immunologic; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Combined | 1988 |
[Chemotherapy of gastric cancer using a MAF combination].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; | 1988 |
Pharmacodynamics of 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Animals; Bone Marrow; Colonic Neoplasms; Deoxyuracil Nucleotides; Fluorodeoxyuridyla | 1988 |
Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Eso | 1988 |
[Prevention of immunodeficiency induced by cancer chemotherapy with BCG].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Colonic Neoplasms; Cytarabine; Fe | 1988 |
[Preoperative treatment of lymph node metastases of gastric cancer by local injection of 5-FU adsorbed on activated carbon--clinical study of 5-FU concentration in resected lymph nodes].
Topics: Adsorption; Carbon; Fluorouracil; Humans; Injections; Lymph Node Excision; Lymph Nodes; Lymphatic Me | 1988 |
[Preoperative treatment of lymph node metastasis in cases of gastric cancer by local injection of anticancer drugs--preliminary report].
Topics: Antineoplastic Agents; Charcoal; Fluorouracil; Humans; Lymphatic Metastasis; Preoperative Care; Stom | 1988 |
Effective treatment for adenocarcinoma of the stomach when surgery is contraindicated.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Female; Fluorouracil; Humans; Stomach Neoplasms | 1988 |
[Clinical results and problems of total-body thermochemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined Modality Ther | 1988 |
[End result of preoperative adjuvant chemotherapy with oral 5-FU dry syrup in gastric cancer].
Topics: Administration, Oral; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Gastrectomy; Hum | 1988 |
Continuous 5-fluorouracil infusion in advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Intravenous; | 1988 |
[The significance of endoscopic treatment of early gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil | 1988 |
[5-FU/ADR/MMC combined hepatic infusion in liver metastases from gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Doxorubicin; Drug Evaluation; Fem | 1988 |
Intra-hepato-arterial chemotherapy with CDDP and 5-FU for metastases to the liver from colorectal and gastric cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1988 |
[Long-term chemotherapy and multiple primary cancers subsequent to gastric cancer].
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Male | 1987 |
[Clinical and experimental studies of shengxue tang combined with chemotherapy in the treatment of late-stage gastric cancer].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ehrlich Tumor; Drug | 1987 |
The 6 day subrenal capsule assay is of no value with primary surgical explants from gastric cancer.
Topics: Adenocarcinoma; Animals; Cisplatin; Doxorubicin; Drug Evaluation, Preclinical; Epirubicin; Fluoroura | 1986 |
[Intra-aortic infusion therapy with sequential methotrexate (MTX) and 5-FU in advanced gastric carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Drug Administration Schedule; Fe | 1986 |
[Biochemical modulation with sequential methotrexate (MTX)-5-fluorouracil (5-FU) treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul | 1987 |
[Methotrexate and 5-fluorouracil with leucovorin therapy in advanced gastric cancer: the enhancement of 5-fluorouracil antitumor activity by leucovorin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Syne | 1987 |
A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma.
Topics: Adenocarcinoma; Bone Marrow Diseases; Diarrhea; Drug Evaluation; Erythema; Fluorouracil; Humans; Inj | 1987 |
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Gas | 1987 |
A phase II trial of 5-fluorouracil and high-dose leucovorin in gastric carcinoma and a phase I trial of intraperitoneal 5-fluorouracil and leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dose-Response Relationship, | 1987 |
Chemotherapy of advanced gastric carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality | 1986 |
[Effectiveness of adjuvant monochemotherapy with 5-fluorouracil in patients gastrectomized for gastric cancer].
Topics: Fluorouracil; Gastrectomy; Humans; Postoperative Care; Prognosis; Spain; Stomach Neoplasms | 1987 |
[Cytostatic agents in the treatment of stomach carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; F | 1987 |
Sequential infusional 5-fluorouracil followed by concomitant radiation for tumors of the esophagus and gastroesophageal junction.
Topics: Aged; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Stomach N | 1987 |
[Preliminary results of a phase II study of 5-FU, adriamycin, and mitomycin C (FAM) in combined hepatic infusion in patients with non-resectable metastatic liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Dr | 1987 |
[Medical decision in clinical oncology: the example of drug therapy of gastric cancer in the advanced stage during the last decade].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Fluorouracil; | 1987 |
Adjuvant treatment of operable stomach cancer with polyadenylic.polyuridylic acid in addition to chemotherapeutic agents. Differential effect on natural killer cell and antibody-dependent cellular cytotoxicity.
Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; C | 1987 |
Treatment of advanced gastric cancer with DDP (cisplatin), adriamycin, and 5-fluorouracil (DAF).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1987 |
[Chemotherapy of metastatic gastric cancer--x-ray follow-up].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Follow-Up | 1987 |
Gastrointestinal anastomotic healing during treatment with perioperative 5-fluorouracil.
Topics: Aged; Colonic Neoplasms; Colostomy; Drug Evaluation; Female; Fluorouracil; Gallbladder; Gastrectomy; | 1987 |
[Sequential methotrexate-5-fluorouracil (MTX-5-FU) treatment of patients with advanced gastric and colorectal cancer. Sequential Methotrexate-5-FU Study Group].
Topics: Adult; Aged; Colonic Neoplasms; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Female; | 1987 |
Adjuvant chemotherapy in gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality | 1987 |
Response of human monocyte phagocytosis to FAM (fluorouracil, adriamycin, mitomycin).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fluorouracil; Humans; Mal | 1987 |
[Absorption of 5-FU orally administered in a patient with postoperative gastric cancer under artificial dialysis].
Topics: Administration, Oral; Combined Modality Therapy; Fluorouracil; Gastrectomy; Humans; Kidney Failure, | 1987 |
Chemotherapy of gastric cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Do | 1986 |
Cardiotoxicity during chemotherapy for advanced gastroenteric tumors.
Topics: Adult; Antineoplastic Agents; Doxorubicin; Female; Fluorouracil; Heart; Humans; Liver Neoplasms; Mal | 1987 |
Phase II trial of sequential chemotherapy and low-dose radiotherapy in advanced gastric adenocarcinoma. A Southwest Oncology Group Pilot Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carm | 1987 |
[Phase II study of 590-S (1-phthalidyl-5-fluorouracil) in patients with gastrointestinal cancer. Tokyo Cancer Chemotherapy Cooperative Group].
Topics: Administration, Oral; Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; | 1987 |
[A case of recurrent gastric cancer successfully treated with a combination of cisplatin and carmofur].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administrat | 1987 |
Gastric cancer with synchronous unresectable hepatic metastasis and a positive response to chemotherapy--report of two cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fluorouracil; Humans; In | 1987 |
Ankyloblepharon associated with systemic 5-fluorouracil treatment.
Topics: Adenocarcinoma; Blepharitis; Eyelid Diseases; Fluorouracil; Humans; Male; Middle Aged; Skin Ulcer; S | 1987 |
Phase II trial of combined 5-fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in advanced gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Drug Administrati | 1987 |
Combined 5-fluorouracil (5-FU) and radiation therapy following resection of locally advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle A | 1986 |
[Clinical study of clonogenic assays--with reference to adjuvant cancer chemotherapy after operation].
Topics: Antineoplastic Agents; Colonic Neoplasms; Colony-Forming Units Assay; Combined Modality Therapy; Flu | 1986 |
[Pharmacokinetic studies of a new fluorinated pyrimidine, 590-S (PH-FU), in human patients].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Female; Fluorouracil; Humans; Kinetics; Male; M | 1986 |
[The dose finding of adjuvant carmofur chemotherapy in patients with stomach cancer].
Topics: Drug Administration Schedule; Fluorouracil; Humans; Stomach Neoplasms | 1986 |
[Clinical application of chemotherapy by using activated carbon particle adsorbing 5-fluorouracil].
Topics: Adsorption; Animals; Carbon; Fluorouracil; Humans; Lymph Nodes; Rats; Rats, Inbred Strains; Stomach | 1986 |
[Comparison of in vitro assays for the cytotoxic effect of anticancer drugs].
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Count; Cell Line; Colony-Forming Units Assay; Diterpenes | 1986 |
Chemotherapy for advanced gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Mitomycin; Mitomy | 1986 |
[Experimental and clinical studies on a sensitivity test of anticancer agents by 3H-thymidine autoradiography using a human malignant tumor transplanted to nude mice].
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Autoradiography; Cyclophosphamide; Drug Evalua | 1986 |
Chemotherapy improves pulmonary function in a patient with gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Hum | 1986 |
[Sequential dose of methotrexate and 5-fluorouracil in advanced gastric cancer--response, survival time and toxicity].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 1986 |
Treatment of advanced measurable gastric carcinoma with 5-fluorouracil, adriamycin, and BCNU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Doxorubicin; Female; Fluoro | 1986 |
Sequential methotrexate, 5-fluorouracil (high-dose), and doxorubicin for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fluorouracil; Huma | 1986 |
Chemotherapy of advanced gastric cancer: a study of 43 consecutive cases treated with fluorouracil, adriamycin and mitomycin C (FAM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fluorouracil; Huma | 1986 |
[Use of the polyamine test in the joint administration of 5-fluorouracil and indomethacin in stomach cancer patients].
Topics: Adult; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Indomethacin; Middle Aged; | 1986 |
[Macroscopic changes in primary early gastric cancer after long-term administration of 5-fluorouracil].
Topics: Administration, Oral; Aged; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle | 1986 |
An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Female; F | 1986 |
[Adjuvant chemotherapy in advanced stomach cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1986 |
[Factor analysis of immunologic reactivity indices in patients with inoperable stomach cancer].
Topics: Adult; Aged; Antineoplastic Agents; Factor Analysis, Statistical; Female; Fluorouracil; Humans; Immu | 1986 |
Treatment of advanced colorectal and gastric cancer with cisplatinum and 5-fluorouracil. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Female; F | 1986 |
Distribution of 5-fluorouracil-14C in body tissues after systemic and regional administration in gastric cancer.
Topics: Carbon Radioisotopes; Fluorouracil; Humans; Injections, Intra-Arterial; Injections, Intravenous; Sto | 1986 |
[Clinical application of sequential dose methotrexate and 5-FU as a neoadjuvant chemotherapy in advanced stomach carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Adminis | 1986 |
Gastric cancer: complete chemotherapy response in an elderly woman: current status of treatment.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fema | 1985 |
Preoperative chemotherapy in patients with gastric cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Doxoru | 1985 |
[Chronic myelogenous leukemia following therapy of early gastric cancer].
Topics: Adenocarcinoma; Fluorouracil; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Multiple Prim | 1985 |
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fl | 1985 |
[Intra-arterial infusion chemotherapy using a subcutaneously implanted silicone reservoir--with reference to the chemotherapy protocol].
Topics: Abdominal Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Cytarabi | 1985 |
[A cooperative study of alternating immunochemotherapy with futraful and PSK (second report)--3-year survival rate].
Topics: Adjuvants, Immunologic; Administration, Oral; Drug Administration Schedule; Fluorouracil; Gastrectom | 1985 |
[Effect of intravenous administration of FT-207 for gastric cancer].
Topics: Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Parenteral; Lymph Nodes; Male | 1985 |
[Preoperative combination therapy involving local administration of a non-specific immunoactivated preparation (OK-432) and chemotherapeutic preparations for patients with stomach cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Female; Fluorourac | 1985 |
[A case of complete regression of gastric carcinoma and liver metastases by treatment with tegafur].
Topics: Adenocarcinoma; Aged; Fluorouracil; Humans; Liver Neoplasms; Male; Stomach Neoplasms; Tegafur | 1985 |
[Preoperative cancer chemotherapy for gastric cancer].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fluorou | 1985 |
[Phase II study of sustained released granules of tegafur (SF-SP) on inoperable or recurrent gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Delayed-Action Preparations; Drug Administration Schedule; Drug Evaluat | 1985 |
[Comparison of the cytotoxic effect of fresh garlic, diallyl trisulfide, 5-fluorouracil (5-FU), mitomycin C (MMC) and Cis-DDP on two lines of gastric cancer cells].
Topics: Allyl Compounds; Antibiotics, Antineoplastic; Cell Line; Cisplatin; Disulfides; Dose-Response Relati | 1985 |
[Evaluation of combined radiotherapy of gastric carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1985 |
[Colony assay for clinical application].
Topics: Adult; Agar; Aged; Antineoplastic Agents; Cell Count; Cell Division; Cells, Cultured; Colonic Neopla | 1985 |
[A case of advanced gastric cancer showing complete cure by immunochemotherapy with FT-207 and OK-432 confirmed by thorough histologic examination of total gastrectomy matter].
Topics: Adenocarcinoma; Biological Products; Female; Fluorouracil; Gastrectomy; Humans; Injections, Intrader | 1985 |
[Comparison of human tumor clonogenic and nude mouse-isotope assays in anticancer-agent sensitivity tests].
Topics: Animals; Breast Neoplasms; Colony-Forming Units Assay; Cyclophosphamide; Doxorubicin; Drug Evaluatio | 1985 |
[Clinical application of local hyperthermia combined with antineoplastic agents].
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Agents; Body Temperature; Cis | 1985 |
[Continuous venous infusion of 5-fluorouracil (5-FU) under total parenteral nutrition (TPN) in advanced gastric cancer].
Topics: Animals; Combined Modality Therapy; Fluorouracil; Humans; Infusions, Parenteral; Male; Parenteral Nu | 1985 |
[5-FU concentration in tissues of gastric cancer patients with preoperative administration of UFT--especially in comparison with FT-207].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Levamisole; Stomach Neoplasms; | 1985 |
[Therapeutic effect of sequential doses of methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced gastric cancer: comparison of intermediate-dose MTX with high-dose MTX].
Topics: Adult; Aged; Alopecia; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusio | 1985 |
[Preoperative treatment with 5-fluorouracil (5-FU) in gastric and colorectal cancer].
Topics: Administration, Oral; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Injections, In | 1985 |
Adjuvant chemotherapy of gastric carcinoma: a pilot study of oral administration of injectable 5-fluorouracil.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Female; Fluorouracil; Humans; Liver; Male; Middle | 1985 |
[Effects of combination therapy of carmofur and nicardipine of human gastric cancer in nude mice].
Topics: Animals; Cell Line; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Humans; Male; Mice; Mic | 1985 |
Evaluation of treatment for gastric cancer with liver metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Evaluation Studies as Topic; Female; Fl | 1985 |
Histopathologic effect of preoperative chemotherapy using 5-Fu fat emulsion in gastric cancer.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Stomach Neoplasms | 1985 |
[A case of progressed gastric cardial carcinoma survived for more than 8 years treated with 3000 rad of radiation and peroral 5-FU].
Topics: Aged; Cardia; Combined Modality Therapy; Fluorouracil; Humans; Male; Prognosis; Stomach Neoplasms | 1985 |
[590-S].
Topics: Administration, Oral; Adult; Animals; Anorexia; Antineoplastic Agents; Drug Administration Schedule; | 1985 |
Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; | 1985 |
A pilot study to determine clinical tolerability of intensive combined modality therapy for locally unresectable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Doxorubicin; Female; Fluorouracil; Humans; Lomustine; Male; Middle Aged | 1985 |
[Duration of remission in advanced gastric cancer patients responding to sequential dose of MTX and 5-FU].
Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; | 1985 |
Immunochemosurgery for gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Combined Modali | 1985 |
Adjuvant treatment with chemotherapeutic agents and polyadenylic-polyuridylic acid in operable stomach cancers. I. Enhancement of natural killer cell activity.
Topics: Adult; Aged; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Humans; Killer Cells, Nat | 1985 |
Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinom | 1985 |
[Combined treatment of patients with inoperable stomach cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorourac | 1970 |
Analysis of serum protein changes in patients with advanced gastric cancer with special reference to -globulin fractions.
Topics: Adrenocorticotropic Hormone; Alpha-Globulins; Animals; Blood Protein Electrophoresis; Cytarabine; Dr | 1972 |
[Successive radio therapy using 25 MeV betatron, and chemotherapy using fluoruracil in the therapy of patients with advanced cancer of the upper part of stomach].
Topics: Adult; Aged; Electrons; Female; Fluorouracil; Humans; Male; Middle Aged; Palliative Care; Radiograph | 1972 |
Prolonged intra-aortic infusion therapy with anti-tumor agents for advanced cancer of the stomach, colon and rectum.
Topics: Adult; Aged; Antineoplastic Agents; Aorta; Bleomycin; Catheterization; Colonic Neoplasms; Cytarabine | 1971 |
Continuous arterial infusion chemotherapy. Experience with 44 cases.
Topics: Adenocarcinoma; Arteries; Brain Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Cath | 1967 |
[Study of the action of antitumor compounds on primary explants from human tumors].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Antibiotics, Antineoplastic; An | 1967 |
[Palliative radiotherapy of cancer in the Karl Bremer Hospital, 1963-1968].
Topics: Black People; Cobalt Isotopes; Colonic Neoplasms; Esophageal Neoplasms; Fluorouracil; Humans; Neopla | 1969 |
Fluorouracil and radiotherapy in gastrointesinal cancer.
Topics: Fluorouracil; Gastrointestinal Neoplasms; Humans; Stomach Neoplasms | 1969 |
5-Fluorouracil and radiotherapy for gastrointestinal cancer.
Topics: Adenocarcinoma; Esophagogastric Junction; Fluorouracil; Humans; Male; Stomach Neoplasms | 1970 |
Echographic evaluation of abdominal tumor regression during antineoplastic treatment.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorub | 1974 |
[Intra-arterial chemotherapy in stomach cancer].
Topics: Animals; Benzene Derivatives; Chemotherapy, Cancer, Regional Perfusion; Drug Therapy, Combination; F | 1974 |
[Chemotherapy in inoperable stomach cancer].
Topics: Adult; Drug Therapy, Combination; Female; Fluorouracil; Gamma Rays; Humans; Male; Moscow; Neoplasm M | 1974 |
[Antineoplastic chemotherapy associated with gastric cancer surgery].
Topics: Evaluation Studies as Topic; Fluorouracil; Gastrectomy; Humans; Stomach Neoplasms; Thiotepa | 1974 |
The value of fluorinated pyrimidines in advanced malignancy.
Topics: Adult; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Female; Floxuridine; Fluorouracil; Humans; Leu | 1968 |
Combination chemotherapy in gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Alopecia; Appendiceal Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Gall | 1970 |
Chemotherapy of gastrointestinal cancer.
Topics: Antineoplastic Agents; Colonic Neoplasms; Esophageal Neoplasms; Floxuridine; Fluorouracil; Gastroint | 1972 |
Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Bile Duct Neoplasms; Evaluation Studies as Topic; Floxuridine | 1974 |
[Treatment of cancer of the liver by regional perfusion].
Topics: Adult; Aged; Angiography; Carcinoma, Hepatocellular; Catheterization; Colonic Neoplasms; Fluorouraci | 1968 |
[Polychemotherapy of malignant tumors and hemoblastoses].
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Bronchial Neoplasms; Carcinom | 1968 |
Growth inhibiting effects of cytotoxic agents on human tumor and tumor-bearing normal tissue in vitro.
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Intra | 1971 |
Catheterization of the umbilical vein and its use for hepatography.
Topics: Adenocarcinoma; Adult; Aged; Angiography; Breast Neoplasms; Catheterization; Diatrizoate; Female; Fl | 1971 |
Lactic dehydrogenase isoenzyme alterations in malignant disease of the liver.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Bronchial Neoplasms; Carcinoma, Hepatocellular; C | 1971 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Alkylating Agents; Biliary Tract; Carcinoid Tumor; Carcinoma, Hepatocellular; Fluoro | 1973 |
[Determination of the individual sensitivity of gastric cancerous tumors to 5-fluorouracil according to respiratory and glycolytic indices].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Carcinoma; Drug Evaluation, Pre | 1974 |
Cancer of the gastrointestinal tract. Chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Carmustine; Cyclohexanes; Cyclophosphamide; Drug Therapy, Combi | 1974 |
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc | 1974 |
[Chemotherapy of inoperable cancer of the stomach].
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Evaluation; Female; Fluorouracil; Humans; | 1974 |
[Determination of the sensitivity of cancerous tumors of the stomach to 5-fluorouracil in vitro].
Topics: Adenocarcinoma; Aged; Drug Evaluation, Preclinical; Female; Fluorouracil; Humans; In Vitro Technique | 1974 |
[Treatment of solid tumors with N-1-(2'-tetrahydrofuryl)-5-fluorouracil (FT-207) alone and in combination: comparison of intravenous and oral administration].
Topics: Administration, Oral; Chromomycins; Drug Therapy, Combination; Fluorouracil; Furans; Humans; Injecti | 1974 |
Impressions on 5-fluorouracil in Bangladesh. Prolonged worthwhile survival in gastrointestinal malignancies.
Topics: Bangladesh; Drug Evaluation; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Hemorrhage; G | 1974 |
[Antibodies to sarcolysine and 5-fluorouracil].
Topics: Animals; Antibody Formation; Basophils; Cross Reactions; Dysgerminoma; Erythrocytes; Esophageal Neop | 1974 |
[Preliminary results of the use of 5-fluoruracil to prevent recurrences and metastases following radical surgery for stomach cancer].
Topics: Adenocarcinoma; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Metastasis; N | 1972 |
[Chemotherapy of gastric cancer].
Topics: Demecolcine; Fluorouracil; Humans; Methotrexate; Stomach Neoplasms | 1972 |
The value of megavolt therapy in carcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Cardia; Cell Division; Cobalt Isotopes; Female; Fluorouracil | 1972 |
[The reactivity of the RES in cancer of the gastrointestinal tract and during treatment with fluorofur].
Topics: Achlorhydria; Adult; Aged; Colonic Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Furans; Go | 1972 |
Study on the sensitivity test of carcinostatic agents by acid phosphatase activity.
Topics: Acid Phosphatase; Adult; Aged; Animals; Antineoplastic Agents; Chromomycins; Cyclophosphamide; Femal | 1972 |
[The effect of pyrogenal on the absorptive function of the liver during chemotherapy of patients with cancer of the stomach].
Topics: Fluorouracil; Humans; Liver; Liver Diseases; Pyrogens; Stomach Neoplasms | 1973 |
[Prophylactic course of chemotherapy against the background of hyperthermia following radical surgery for gastric cancer].
Topics: Fluorouracil; Humans; Hyperthermia, Induced; Postoperative Care; Pyrogens; Stomach Neoplasms | 1973 |
Intra-arterial cancer chemotherapy with combined anticancer agents.
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Deoxycytidine; Drug Therapy, Combination | 1973 |
Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer.
Topics: Adenocarcinoma; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leukopenia; Mal | 1974 |
[Attempts at in vivo synchronization of the synthesis of DNA in human malignant cell by 5-fluorouracil. Autohistoradiographic study].
Topics: Autoradiography; Colonic Neoplasms; DNA, Neoplasm; Fluorouracil; Humans; Stomach Neoplasms | 1966 |
[Preoperative irradiation with betatron electron beam in gastric cancer].
Topics: Electrons; Fluorouracil; Humans; Preoperative Care; Radiation-Sensitizing Agents; Radiotherapy, High | 1968 |
[On intra-arterial chemotherapy of stomach cancer].
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Fluorouracil; Hum | 1969 |
Gastroscopic color photography in cancer chemotherapy.
Topics: Adenocarcinoma; Color; Cyclophosphamide; Fluorouracil; Follow-Up Studies; Gastroscopy; Humans; Lymph | 1970 |
[The morphologic composition of peripheral blood following intra-arterial infusion of 5-fluorouracil and alkylating preparations in stomach cancer patients].
Topics: Anemia; Fluorouracil; Humans; Leukopenia; Melphalan; Nitrogen Mustard Compounds; Stomach Neoplasms; | 1970 |
Combined parenteral hyperalimentation and chemotherapy in the treatment of disseminated solid tumors.
Topics: Amino Acids; Analgesics; Appetite; Body Weight; Breast Neoplasms; Carcinoid Tumor; Colonic Neoplasms | 1971 |
Combined 5-fluorouracil and vinblastine therapy for gastrointestinal and other solid tumors.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; | 1972 |
Results of treatment of malignant tumors with ftorafur.
Topics: Antimetabolites; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Colonic Neoplasms; Deoxyr | 1972 |
Treatment with 5-fluorouracil in prophylaxis of relapses and metastases of stomach cancer.
Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Gastrectomy; Humans; Injections, Intravenous; Mal | 1972 |
[Combined application of drugs in cancer chemotherapy with special reference to the combination of mitomycin C, 5-fluorouracil, and cytosine arabinoside].
Topics: Cytarabine; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Mitomycins; Neoplasm | 1972 |
[Chemotherapy of gastric cancer--combination chemotherapy of mitomycin C, 5-fluorouracil and cytosine arabinoside].
Topics: Adult; Aged; Cytarabine; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycins; Stomach Neopla | 1972 |
[Systemic chemotherapy of cancer of the stomach and the intestine].
Topics: Antineoplastic Agents; Cyclophosphamide; Cytarabine; Fluorouracil; Humans; Intestinal Neoplasms; Mit | 1972 |
[The functional state of the liver during conservative treatment of oncologic patients].
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Esophageal Neoplasms; Fluorouracil; H | 1972 |
[Local intra-arterial infusion chemotherapy of malignant tumor--successful treatment by intra-arterial infusion of 5-fluorouracil and mitomycin C in cases of unresectable cancer of the liver, stomach, colon and rectum].
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infant; Injections, Intra-Arterial; Li | 1971 |
[Continuous intra-arterial infusion of antineoplastic agents in cancerous peritonitis, with special reference to cancer].
Topics: Adult; Aged; Cytarabine; Female; Femoral Artery; Fluorouracil; Humans; Injections, Intra-Arterial; M | 1971 |
[Influence of antineoplastic agents on the tissue respiration in transplanted gastric cancer in rabbits, with special reference to the effects on the growth process of transplanted cancer cells].
Topics: Animals; Carcinoma, Brown-Pearce; Cyclophosphamide; Fluorouracil; Glucose; Hydrogen-Ion Concentratio | 1971 |
[Present status of chemotherapy in gastric cancer in the USSR].
Topics: Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Humans; Injections, Intra-Arterial; Melphala | 1971 |
[Selective intra-arterial infusion of anticarcinogenic agents in stomach cancer].
Topics: Catheterization; Fluorouracil; Gastrectomy; Humans; Injections, Intra-Arterial; Laparotomy; Postoper | 1971 |
Combination cancer chemotherapy by regional intra-arterial or intra-aortic infusion of 5-fluorouracil and mitomycin-C with or without irradiation.
Topics: Aorta; Cobalt Radioisotopes; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hea | 1971 |
[Protein forming function of liver in patients with gastric cancer during intravenous and regional intrarterial chemotherapy with 5-fluorouracil].
Topics: Blood Proteins; Fluorouracil; Humans; Infusions, Parenteral; Liver; Stomach Neoplasms | 1969 |
[Possibilities of treating cancer relapse after proximal gastric resection and gastrectomy].
Topics: Esophageal Neoplasms; Fluorouracil; Gastrectomy; Gastroenterostomy; Humans; Stomach Neoplasms | 1969 |
[Clinical use of 5-fluorouracil in surgical field].
Topics: Adult; Aged; Animals; Breast Neoplasms; Dogs; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1969 |
One-shot infusion of non-surgically administered mitomycin C in the celiac artery for liver metastases. Clinical effects.
Topics: Adult; Aged; Angiography; Blood Cell Count; Blood Platelets; Celiac Artery; Colonic Neoplasms; Femal | 1970 |
[Treatment of neglected forms of cancer of the proximal part of the stomach with 5-fluoruracil].
Topics: Adult; Aged; Female; Fluorouracil; Humans; Injections, Intra-Arterial; Injections, Intravenous; Male | 1970 |
Immunosuppression by 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antibody Formation; Antigens; Blood Bactericidal Activity; Blood Platel | 1970 |
Hepatic coma secondary to metastatic liver disease.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Breast Neoplasms; Colonic Neoplasms; Fluorouracil | 1971 |
[Indication for antineoplastic agents (using 3H-thymidine)].
Topics: Antineoplastic Agents; Culture Techniques; Depression, Chemical; DNA, Neoplasm; Fluorouracil; Humans | 1971 |
[Experience with the treatment of patients with malignant tumors with 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Duodenal Neoplasms; Female; Fluorouracil; Humans; In | 1967 |
[On a method of treating patients with cancer of the stomach with 5-fluorouracil].
Topics: Aged; Duodenal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Metastasis; Stomac | 1967 |
Clinical evaluation of combined radiation and chemotherapy in gastrointestinal malignancies.
Topics: Bone Marrow; Bone Marrow Cells; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; | 1968 |
Oral administration of fluorouracil. A preliminary trial.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Bile Duct Neoplasms; Colonic Neoplasms; Diarrhea; Fluorouraci | 1968 |
5-fluorouracil therapy for cancer of the stomaach.
Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; S | 1968 |
5-fluoruracil therapy of cancer of the stomach.
Topics: Aged; Fluorouracil; Humans; Stomach Neoplasms | 1968 |
[Chemotherapy of advanced gastric carcinoma with 5-fluorouracil].
Topics: Carcinoma; Fluorouracil; Humans; Stomach Neoplasms | 1968 |
[Cancer and appendicitis--death due to incidental appendicitis in recurrent stomach cancer with successful chemotherapy].
Topics: Antineoplastic Agents; Appendicitis; Cholestasis; Female; Fluorouracil; Humans; Middle Aged; Mitomyc | 1968 |
[Clinical application of 5-fluorouracil--with special reference to the evaluation of the intravenous administration method].
Topics: Adult; Antineoplastic Agents; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Methods; | 1968 |
[Tolerance of the stomach wall to antineoplastic preparations].
Topics: Animals; Chemotherapy, Cancer, Regional Perfusion; Dogs; Fluorouracil; Melphalan; Stomach Diseases; | 1969 |
Kinetics of proliferation of cancer cells in neoplastic effusions in man.
Topics: Adenocarcinoma; Antineoplastic Agents; Autoradiography; Cell Division; DNA, Neoplasm; Exudates and T | 1965 |
Metastatic tumor to the breast simulating bilateral primary inflammatory carcinoma.
Topics: Breast Neoplasms; Carcinoma; Diagnosis, Differential; Female; Fluorouracil; Humans; In Vitro Techniq | 1966 |